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The purpose of this project was to investigate techniques that may be successfully 
applied to improve the characteristics of a bioprocess relevant mammalian cell line 
such as CHO (Chinese Hamster Ovary). 
 
The first technique explored in this thesis investigates the possibility of gene targeting 
and knockout using an AAV (adeno associated virus) viral vector. A custom vector 
was constructed comprised of an insertion cassette flanked by homologous ‘arm’ 
sequences generated from the region of genomic DNA being targeted. Infecting cells 
with this virus at an MOI of over 2 x 10
5
 particles per cell, we have demonstrated that 
this unique genomic locus can be successfully targeted with foreign DNA through 
homologous recombination in CHO cells, with a targeting frequency of 3.1% 
calculated in this instance. While single allele knockouts were detected using a DHFR 
targeting vector, a number of alternative techniques implemented did not successfully 
isolate homozygous negative mutants, however further work based on the data 
provided in this study could successfully generate null mutants. 
 
The second technique applied is a variation of the directed evolution approach. A 
gene (TBP) was first selected that is known to be involved at a high level in the global 
cellular transcriptional machinery and subjected to random mutagenesis to generate a 
mutant library. When transfected this created a heterogeneous pool of diverse clones 
with a variety of phenotypes. An environmental stress was then applied for a number 
of passages to select for clones with suitable advantageous mutations, which were 
then isolated and characterised.  
Using this technique we successfully isolated a number of mutant clones with average 
maximum viable cell densities 53% greater than a control cell line when placed 
through the same stress selective procedure. This improvement in growth coupled 
with additional benefits to late culture stage viability contributed to an increase in 
accumulated integrated viable cell density (viable cell-hours) of over 44%. A 
transcriptional profiling experiment was also carried out to investigate the underlying 
cellular mechanisms that may have contributed to these advantageous metabolic 
changes. 
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In the last 35 years, genetic engineering technology has advanced from early methods 
used to construct artificial plasmids and generate the first recombinant organisms, to 
modern techniques that allow for the manipulation of a host cells genetic content with 
the aim of producing large amounts of recombinant therapeutic proteins. Modern 
medicine has chiefly relied on small molecule drugs to treat illnesses and disease. 
However, due to the power of protein biopharmaceuticals, the industrial focus is 
beginning to shift from small molecule drugs to more powerful recombinant protein 
therapies. Due to the proliferation of these therapies, there is a constant effort to 
improve production titres as a means of reducing the cost to manufacture these drugs, 
in turn leading to a wider availability of these treatments which have now been proven 
as important tools in dealing with a range of chronic illnesses. 
 
Since the approval of the first recombinant protein therapy to be produced in 
mammalian cells over two decades ago, the industry has seen a drastic increase in the 
yields of batch production processes used to generate protein therapeutics. This 
increase has driven yields from milligrams per litre to titres of the order of grams per 
litre (Zhou et al. 1997). A number of factors have contributed to this rise in 
productivity. These include improvements to the physical formats used to propagate 
cells, optimisation of the culture media components, selection for cell lines/clones that 
show improved production characteristics as well as genetic manipulation of these 
target cell lines in order to increase levels of recombinant protein synthesis. 
Early, basic recombinant proteins could be produced by expressing the requisite 
coding sequence in simple organisms (one of the first commercial applications of this 
technology involved the production of recombinant insulin in E. coli cells). However, 
with the advent of more complex proteins requiring intricate post translational 
modifications and the necessity for more efficacious therapeutic products, a more 




While a variety of mammalian host cells have been or are currently being used to 
commercially produce therapeutic recombinant proteins, CHO (Chinese Hamster 
Ovary) has stood out for many years due to its range of positive traits necessary for 
large scale biopharma production. High growth, productivity and ease of adaptability 
to necessary conditions such as suspension growth make these cells a very attractive 
host cell line, with a majority of biopharmaceuticals currently being produced using 
CHO. With this in mind, it stands to reason that any improvements that could be 
consistently produced in CHO cells would have a positive influence on a wide range 
of commercial processes. Enhancements made to key properties of these cells in areas 
such as growth, density, lifespan and productivity have the impact of making these 
processes more cost effective, allowing new waves of biopharmaceuticals to be 
produced at a lower cost and ultimately reach a wider range of patients for whom 
these treatments may have a drastic positive impact. 
 
This project was carried out as an attempt to explore alternative ways to improve the 
characteristics of these host cells. While a number of traditional techniques have 
proven to be successful in the past (transgene over expression, refinement of target 
gene expression vectors etc), we set out to explore alternative molecular biological 
techniques and apply them in CHO, with the ultimate objective of providing a means 





This thesis consists of two distinct strategies, both with the aim of investigating 
techniques that may be successfully applied in CHO lines as a means of improving 
their industrially relevant characteristics.  
 
The first strategy investigated involved the use of an adenoviral vector (AAV) for 
gene targeting. In industrial cells this approach has a number of potential uses 
including the targeted disruption of a selected gene, as well as the introduction of a 
gene of interest into a region of known transcriptional activity to improve 
productivity.  
To exploit the process of homologous recombination within cells, first we create a 
viral vector with homologous targeting ‘arms’; sequences identical to the genomic 
locus we wish to insert an exogenous gene or expression cassette. When introduced 
into the cell, these homologous arms then allow for targeted recombination to take 
place, and the vector becomes inserted at the intended site. This process has been 
demonstrated using simpler vectors, however the use of AAV has been shown to 
produce targeting rates in excess of those gained with traditional plasmid based 
recombination. While alternative techniques exist for gene knockout and gene 
targeting, AAV currently presents itself as an attractive alternative as being more 
effective than RNAi for the total elimination of an unwanted gene’s effects, as well as 
being relatively inexpensive compared to novel methods such as engineered 
nucleases. 
This study tests the hypothesis that gene targeting using AAV for the purpose of 
homologous recombination is a viable method for introducing exogenous DNA and 
disrupting native gene sequences in CHO cells. This will involve the characterisation 
of transduced cells for both targeted and off-target insertions, as well as screening 
successfully targeted cells for homozygous (-/-) null mutants. 
 
The second technique investigated attempted to replicate a directed evolution 
technique described as ‘global transcriptional machinery engineering’, notably applied 
in bacterial
 
(Alper and Stephanopoulos 2007) and yeast systems (Alper et al. 2006) in 
order to improve relevant phenotypic traits such as tolerance to alcohol. A gene 
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known to be involved at a high level in the transcriptional machinery is selected and 
mutated to create a diverse library. This is subsequently transfected into CHO to 
create a heterogeneous pool of clones, each expressing its own compliment of mutant 
sequences causing a unique transcriptomic shift in each cell.  
The next phase of this technique involves the application of an environmental 
pressure or external stress to the population. In doing this we allow natural selection 
to take place, eliminating cells with detrimental changes and enriching for cells that 
have integrated advantageous mutants. With subsequent rounds of stress, we would 
expect these artificially adapted cells to gradually outgrow their counterparts in 
culture, leading to a population of cells more resistant to the environmental pressure 
and generating a more effective phenotype. 
Natural selection works to select beneficial features from heterogeneous populations. 
Our hypothesis posits that an artificial increase in heterogeneity (in this case, a mutant 
gene library), followed by a suitable selection procedure will allow for the selection of 
individual clones more suited to an industrial growth environment. This study will 
examine the phenotypic effects of both the mutant library and selective stress 
procedure (the two main features of this approach) in transfected CHO cells by 
investigating key characteristics such as growth, viability and productivity. 
Transcriptomic profiling will also be used as a means of investigating the genetic 










1.3 Mammalian Cell Line Engineering 
 
 
Mammalian cell engineering has undergone a considerable amount of progress in the 
past decade as mammalian cell lines have established themselves as the predominant 
method for biopharmaceutical production. CHO cells in particular have been subject 
to a high level of research due to their attractive basic characteristics for protein 
production (fast growth, ability to grow in suspension, ability to apply post-
translational modifications etc). As such, a vast majority of recombinant 
pharmaceuticals (estimates as high as 60-70%) are produced in these cellular 
factories, with titres as high as 5 grams per litre being achieve, orders of magnitude 
greater than those achieved decades ago (Wurm 2004).  
 
Engineering methods undertaken to modify and improve cells such as these have 
themselves evolved from basic optimisation of growth conditions to complex 
modifications of metabolic targets to maximise their potential for productivity. Here 
we will examine this range of techniques for industrial cell line engineering and 
highlight the changes in approaches used; from basic techniques such as gene 
amplification, to the search for relevant gene targets and related regulatory sequences 
with significant impact on behaviour, through to the whole cell ‘directed 
evolutionary’ techniques that are now used to improve cellular fitness on a genome 
wide level.  
 
 
1.3.1 Environmental optimisation 
 
Before the use of any dedicated genetic intervention, media optimisation is an 
essential basic step in any bioprocess. For laboratory scale work, a vast number of 
media formulations exist for different cell lines and purposes, while many companies 
will invest a large amount of effort generating highly specific proprietary media 
formulations by perfecting the concentrations of carbohydrates, peptides and other 
media supplements to ensure maximum cell viability and productivity rates for 
industrial cell lines.  
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Animal derived serum was commonly used as an additive in cell culture media, due to 
the complex spectrum of macromolecules and growth factors present that 
supplemented cell growth. However, serum is commonly removed from most modern 
industrial bioprocesses due to immunogenic and pathological concerns regarding 
possible contaminants, as well as a batch to batch variability that does not afford tight 
regulation over components’ concentrations. This is now overcome using strictly 
defined media additives, with key proteins found in serum such as albumin, insulin 
and transferrin now replaced by purified recombinant forms (Grillberger et al. 2009) 
that have shown to be effective replacements for animal derived products in 
optimisation experiments
 
(Keenan et al. 2006).  
Aside from media formulation, culture method is also a basic environmental factor 
that may be modified. These can range from basic adherent monolayer cell cultures, to 
the common ‘cell suspension’ bioreactor in batch or fed-batch configurations, to even 
more complex systems such as perfusion cultures in which cells grow attached to 
porous scaffolds allowing the removal of media while keeping the cells in place. 
 
While modifications to the cellular environment such as the media or choice of culture 
method can have positive impacts on the overall productivity of the cell, genetic 
engineering of these cells is currently the main focus of the majority of 
experimentation in order to improve protein producing characteristics, as the gains 
made by approaches involved in environmental optimisation begin to plateau. By 
altering the genetic content of the cell, by means of introducing heterologous 
sequences into the cell or altering/eliminating the expression of native genes, we can 




1.3.2 Basic engineering methods 
 
 
1.3.2.1 Plasmid vectors 
The most basic forms of mammalian cell engineering often involve the transfection of 
plasmids, circular DNA molecules encoding a gene or sequence of interest, generally 
driven by a constitutive promoter if the gene of interest is to be expressed. Once 
transfected into a cell (for example using a common lipisomal based delivery system) 
this will allow for expression of the target gene whose gross effect on the cell can then 
measured. This effect can be measured transiently or by generating stably expressing 
cells using a suitable antibiotic selection marker to induce integration into the 
genome.  
Modern plasmids (circular genetic components originally isolated from bacterial cells) 
are generally engineered to contain a number of key features making them attractive 
to use as vectors. These include a constitutive strong promoter to drive transgene 
expression (such as common viral promoters SV40 or CMV), an antibiotic resistance 
marker to promote integration into a host genome, as well as a multiple cloning site 
for digestion and insertion of an experimental transgene or sequence. 
While plasmid transfection is not the only vector used for introducing exogenous 
sequences into cells (viral vectors are also used extensively for different purposes), 
they are generally the most popular due to the relative ease with which they can be 
manipulated, amplified and delivered into cells. This technique of gene delivery has 
been the standard tool for elucidating the function of numerous genes in many 




1.3.2.2 RNAi-based gene knockdown 
Conversely, the effects of gene silencing and the removal of a genes effect from the 
cell can be examined through the use of short interfering (siRNA) molecules. A 
relatively recent discovery in molecular biology, this mode of naturally occurring 
post-transcriptional gene regulation was first described in plant cells (Hamilton and 
Baulcombe 1999) and soon confirmed as present in mammalian cells (Elbashir el al. 
2001).  
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siRNAs are small, double stranded RNA molecules that play an important role in post 
translational silencing of genes via the RNA interference (RNAi) pathway. In this 
mechanism of gene regulation double stranded RNAs are transcribed and then 
subsequently processed by an endoribonuclease known as Dicer into short (21-25 bp 
long) molecules that become incorporated into a protein complex known as the RNAi 
induced silencing complex (RISC). This activated RISC can then recognise mRNA 
sequences based on sequence specific homology with the short RNA sequence 
contained within, and target them for degradation prior to translation, reducing the 
levels of expressed protein in the cell.  
To transiently examine the effects of the knockdown of a particular gene, artificially 
generated siRNAs can be transfected directly into the cell. These can be enzymatically 
generated in vitro using a purified Dicer enzyme and double stranded template oligos 
or, more commonly, they are chemically synthesized and bought commercially. This 
type of transient effect found with transfected siRNA generally lasts for no more than 
3-5 days (Amarzguioui, Rossi, and Kim 2005). In order to overcome the short lifespan 
of single doses of siRNA, constant transcription of these molecules can be artificially 
induced within the cell using vectors stably generating RNAi effector molecules to 
generate  a more consistent and prolonged effect within the cell. Vectors are created in 
a similar fashion to those designed to over express a target protein, using polymerase 
II or III promoters to drive expression of a cassette producing short hairpin RNAs 
(shRNA) that are in turn processed and integrated in the RISC complex to produce a 
reduction in target gene translation (Wu 2009). Selectable antibiotic markers can also 
be used to induce stable vector integration and generate cell lines with persistent gene 
knockdown effects. 
 
These two basic methods of engineering based on the overexpression or repression of 
target genes form the basis of a wide assortment of engineering strategies in 
mammalian cell lines. A range of applications based on these strategies and tools 
exist, allowing for a number of different means to improve cell characteristics. 
Outlined below are some of these various applications and how they are used to 
improve industrial mammalian cell lines. 
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1.3.3 Gene amplification 
 
Many basic engineering strategies to date have focused on increasing the amount of 
cellular transcription as a means of increasing the final protein titre, such as increasing 
gene copy numbers or improvements to expression vectors that improve mRNA 
production. Gene amplification is a well known and relatively easy method of 
increasing the expression levels of a target gene, often a gene encoding a product of 
value to be expressed. This is carried out by first introducing a vector encoding the 
target gene into the genome paired with a selectable marker that can be used to 
subsequently amplify the construct. Once a stably transfected cell line is developed, 
an inducer molecule is added in gradually increasing concentrations, such as an 
antibiotic or other cytotoxic compound. The negative effect of this molecule is 
mitigated by the selectable marker gene, which multiplies in frequency within the 
genome in response to the addition of higher inducer concentrations. Any genetically 
linked sequences such as the target gene are also then multiplied, leading to increased 
target mRNA expression levels and, ultimately, greater product yield (Omasa 2002).  
 
 
1.3.3.1 DHFR amplification 
The most common of these systems is the dhfr gene amplification system, in which a 
DHFR deficient cell line is transfected with the dhfr gene linked to a target cDNA. 
Methotrexate (MTX), a toxic inhibitor of DHFR, is used as an inducer at increasing 
concentrations with amplified copy numbers of over 1000 frequently reported using 
dhfr amplification system (Crouse, McEwan and Pearson 1983; Kaufman and Sharp 
1982). However, relative gene expression levels can vary from little or no increase, up 
to 10-30 times the level prior to amplification. This is due in part to phenomena such 
as variety in chromosomal integration positions, as well as imperfect copies of the 
amplified cassette generating non functional mRNA. Genes maintained at high copy 
numbers may be subject to instability however, with reductions in gene copy number 
observable when the inducer molecule is removed for extended periods (Johnston, 
Beverley and Schimke 1983). This is a reasonably simple technique that can be 
employed to maximise productive output, with little or no optimisation necessary 
beyond the steady increase in the concentrations of inducer molecule. 
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1.3.3.1 GS amplification 
A similar system also commonly used in CHO is the Glutamine Synthetase (GS) 
amplification system. In the same way that MTX is found to inhibit DHFR, the 
compound methionine sulfoximine (MSX) was discovered as an antagonist of GS, 
with natural cellular resistance to its effects achieved through amplification of the 
locus encoding the GS gene (Sanders and Wilson 1984). This was exploited to 
generate the GS amplification system, in which the gene of interest is linked to a 
recombinant GS gene. Addition of MSX causes amplification of the GS gene as well 
as co-amplification of the linked gene of interest, ultimately increasing target product 
expression and titre. This system was also found to have the advantage of requiring 
fewer rounds of selection with increases of MSX inducer for sufficient amplification, 
often gaining maximum benefits after a single round (Brown et al. 1992).While high 
copy numbers similar to the dhfr amplification system are reported (Sanders et al. 
1987), the relative instability of clones generated compared to the dhfr system has 
been cited as a concern (Jun et al. 2006) as well as its status as a proprietary 
technology requiring a license from its owner Lonza.
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1.3.4 Apoptosis prevention 
 
Apoptosis is defined as the mechanism for programmed cell death, a natural process 
in living organisms that has been extensively studied and many of its causes and their 
associated pathways have been well characterised. Therefore, the genes and proteins 
involved have become prime targets for genetic regulation in order to mitigate the 
destructive effects apoptotic stimuli might have on cultured cells in a bioprocess. By 
preventing or reducing the effects of apoptosis in a commercial process, we can 
expect to increase the length of a viable production culture, thus leading to an increase 
in product titre. Its has been shown that in the later stages of batch culture the vast 
majority of cell death is caused by apoptosis rather than the necrotic effects of the 
culture environment (Goswami et al. 1999). This fact has lead to the development of 
novel methods of suppressing cell death via the alteration in the levels of pro- or anti-
apoptotic genes with the aim of maintaining the viability of a batch culture, thus 
leading to an overall increase in final product yield.  
 
 
1.3.4.1 Anti-apoptotic gene expression 
A number of studies have examined the effect of apoptosis related genes. One 
example demonstrated the generation of an apoptosis resistant CHO cell line by stably 
over expressing bcl-2 (Lee and Lee 2003), an anti-apoptotic gene that inhibits the 
apoptotic effects of caspase proteins. This study attempted to overcome the apoptotic 
effect of sodium butyrate (NaBu), a molecule shown to increase expression of foreign 
proteins at the cost of cell viability. It was confirmed that stable over expression of 
bcl-2 could improve total cell viability and mitigate the negative effects of NaBu, 
leading to an increase in recombinant antibody production. 
The Bcl-2 gene family also contains a number of evolutionarily related genes with 
comparable functions that have been targeted for cell engineering purposes. 
Overexpression of Bcl-2 related proteins such as Bcl-xL (Kim et al. 2009; Majors et 
al. 2008) and Mcl-1 (Majors et al. 2009) have shown to repress caspase activity and 
prolong culture viability in recombinant CHO cell lines. An experiment involving the 
synergistic co-expression of Bcl-2 and c-Myc was also carried out. This study showed 
that Bcl-2 could successfully mitigate the apoptotic effects of overexpressed c-Myc, 
while retaining its positive effect on cell proliferation (Ifandi and Al-Rubeai 2005).  
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1.3.4.2 Pro-apoptotic gene knockdown 
In logical contrast, studies have demonstrated that knockdown of genes that assist in 
apoptotic pathways also proves useful in delaying the effects of programmed cell 
death. One such study investigated the downregulation of pro-apoptotic genes Bax 
and Bak using an RNA interference method (Lim et al. 2006). A CHO cell line 
expressing anti Bax and Bak siRNA was generated with a 90% reduction in 
expression of these genes. These cells were then subjected to a number of chemical 
stimuli and physical conditions known to promote apoptosis. These included stimuli 
commonly found in industrial batch conditions such as depletion of nutrients and high 
osmolarity due to waste build-up. In all cases, the knockdown CHO line demonstrated 
greater resistance to apoptosis and higher viable cell densities than the control, leading 
to a longer culture lifespan and ultimately a higher recombinant protein titre. This 
effect has been replicated in a number of other experiments, with different apoptotic 
genes targeted for knockdown. One example used data from a previous gene profiling 
experiment that identified apoptosis signalling genes. 4 of these targets (FADD, 
FAIM, ALG-2 and Requiem) were stably silenced in an Interferon producing CHO 
cell line. This gene silencing led to a reduction in apoptosis in both batch and fed-
batch culture configurations, with a reported increase in Interferon yields of up to 2.5 
times higher (Wong et al. 2006). 
 
A number of disadvantages with the stable siRNA method have been reported. These 
include difficulty in isolating clones with sufficient knockdown, lack of long term 
stability in these clones as well as the possibility for non specific interference effects 
(Lim et al. 2006). Transfection of increasing numbers of vectors to affect multiple 
targets may also place a transcriptional burden on the cell that may otherwise cause 
metabolic bottlenecks or eventual net loss of productivity. This would suggest that 
absolute gene knockout would be preferable for genes known to have a definitive 
positive outcome when their effects are removed from the cell. Evidence of this 
difference in efficacy has been shown in a comparative study involving Sam68, an 
RNA binding protein implicated in a number of cellular processes (Taylor, Resnick 
and Shalloway 2004). A knockout cell line was compared to a constitutive siRNA 
knockdown cell line, with the conclusion drawn that the knockout cell line provided 
more accurate results than the siRNA knockdown cells (Li et al. 2010). 
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1.3.5 Cell cycle arrest 
 
Similar in approach to interventions designed to prevent apoptosis, a commonly used 
strategy in modern industrial processes is the use of cell cycle arrest to promote both 
an increase in specific productivity as well as a delay in the onset of apoptosis. This 
has been demonstrated as a proven method of directing cells energy expenditure from 
metabolic processes involved in growth and cell division to those involved in 
production and secretion of target recombinant products, employing methods such as 
temperature shift and induction of cytostatic proteins (Kaufmann et al. 1999; 
Fussenegger, Mazur and Bailey 1997). 
 
1.3.5.1 Temperature shift 
The most common iteration of this technique is the use of thermal shock in order to 
harness the positive effects of native temperature-inducible proteins. Numerous 
experiments to date have documented the positive effects of temperature shift on cell 
productivity. One illustrative study was carried out on CHO cells in which the 
surrounding media temperature was reduced from 37°C to 30°C after an initial growth 
phase (Kaufmann et al. 1999). Epitomising the effect found at the heart of the 
temperature shift method, this technique demonstrated a halt to the cell cycle in the 
G1 phase prior to mitotic division in a majority of cells, leading to an increase in 
specific productivity as well as a reduction in waste products such as lactate and 
ammonia. This approach demonstrates the biphasic growth pattern, where cell growth 
is allowed to reach high densities then is halted by temperature shift, channelling the 
cells resources towards generation of the target product. This increase in productivity 
has been repeatedly demonstrated as effective in various CHO cell lines. Examples of 
other studies successfully implementing a biphasic culture include Fox et al. 2006 
(90% increase in product titre at 32°C), Fogolín et al. 2004 (3.2 fold increase in 
productivity at 33°C combined with PYC2 overexpression) and Chen et al. 2004 
(47% increase in productivity in a high density perfusion culture system). 
 
While the ultimate effect of this technique is well established, the intracellular 
processes that govern the temperature shift response are as of yet not entirely 
elucidated, but recent studies carried out have begun to uncover a number of 
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differentially expressed protein and RNA molecules that are implicated in the 
resulting change in metabolism during temperature shift (Kumar et al. 2008, Gammell 
et al. 2007). These targets may prove useful for rational engineering efforts to harness 
the positive effects of these temperature inducible molecules. 
 
1.3.5.2 Inducible systems 
Many cell engineering methods describe the use of constitutive expression of 
molecules designed to continuously produce or, in the case of siRNAs, reduce the 
levels of a given protein within the cell. However, in some cases the persistent 
metabolic change may not be the ultimate goal, with temporal control over gene 
expression at an appropriate point in the growth culture existing as an attractive 
alternative in some cases. This is relevant with regard to genes critical to cell growth 
and proliferation for example, that may be detrimental to product formation once a 
suitable cell density has been reached. In instances like these, the use of inducible 
systems is indicated as being an advantageous approach. Temperature shift remains a 
common tool for cell cycle arrest in industry today, however the energy and 
engineering requirements necessary to repeatedly heat or cool large volumes 
(thousands of litres) carry inherent costs and difficulties. That may be alleviated by 
alternative strategies, such as the use of molecule induced expression systems to 
provoke cell cycle arrest. This has been achieved using a number of inducible systems 
with positive results.  
 
An example of a system used in examining the benefits of regulated expression can be 
seen in the ‘tet-off’ tetracycline responsive expression system, a prevalent method of 
controlling gene expression. It is regulated by a fusion protein, the tetracycline 
transactivator (tTA), containing two halves. One half is derived from a tetracycline 
responsive repressor protein found in E. coli, while the other half is an activator of 
transcription derived from the Herpes Simplex VP16 protein. In the ‘tet-off’ 
configuration, this chimeric transactivator protein binds to the ‘tetO’ operator 
sequence in the absence of tetracycline, activating a local promoter sequence and 
driving transcription of any upstream gene. The addition of tetracycline to the cellular 
medium inactivates this switch and prevents transcription.  
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This configuration typifies the construction of most artificial inducible systems, with a 
protein ‘switch’ (responsive to a specific inducer molecule) coupled to a domain 
capable of regulating transcription when the system is activated. 
This system was used in a study (Fussenegger, Mazur and Bailey 1997) to regulate 
the expression of both a reporter gene and one of a number of cytostatic proteins 
involved in the cell cycle such as p21, p27 as well as a mutant version of the p53 gene 
capable of arresting cell cycle progression, but unable to induce apoptosis. Cell 
proliferation was halted upon depletion of tetracycline from the media, leading to 
roughly a fourfold increase in SEAP production relative to a constitutive control 
producer. A greater proportion of substrate converted to desirable product was noted 
within the process, as well as a reduction in the amount of waste product generated 
such as lactate and ammonia. 
Another study investigated the effect of an inducible antisense c-jun gene in murine 
erythroleukemia cells, the effect of which is the down-regulation of c-jun and an 
inhibition of the cell cycle (Kim et al. 2000). It was shown that induction once 
logarithmic growth had begun could prolong protein production at high cell viabilities 
for double the time period of control cells. This strategy also carries the advantage of 
reducing the levels of apoptotic cells releasing destructive enzymes into their 
environment, degrading the product within the surrounding medium and having a 
detrimental effect on the quality and quantity of the recombinant product being 
manufactured. A similar effect was seen in a study in which an inducible CHO cell 
line was generated using a system responsive to the insect hormone ecdysone 
(Figueroa et al. 2007). Induction of the anti-apoptotic proteins E1B-19K and AVEN 
in tandem was carried out 2 days into fed cultures, resulting in increased viability and 
total productivity due to operational times 5 days longer than control cell lines. 
 
The idea of a temporally controllable system (for example, one that can be activated 
once a process reaches a required cell density) is an attractive one. The downside to 
the use of such chemical inducible systems on an industrial scale remains the cost of 
large volumes of inducer molecule if a drug sensitive system is used, and its possible 
complication of downstream processing and purification. However, with the potential 
for further optimisation and reduction in the necessary concentrations of inducer 
molecule techniques such as these may still prove useful in the creation of an 
optimised cell line for industrial scale protein production. 
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1.3.6 Metabolic engineering 
 
Improvements in expression systems have allowed for greater levels of transcription 
and, to an extent, the amount of translated product within the cell. However, 
experiments have shown that secreted protein levels do not improve when mRNA 
reaches a saturation point (Barnes, Bentley and Dickson 2004). Great increases in 
transcription may also lead to diminishing returns, as cellular machinery may struggle 
to process and secrete large amounts of transcribed mRNA leading to translational 
attenuation and protein degradation as a result of the Unfolded Protein Response 
(UPR) (Schroder 2006). This is one of a number of key biological bottlenecks to 
overcome as increasingly higher levels of production are required to satisfy the 
demand likely to be placed on the biopharma industry as protein drugs become more 
prolific. This has lead some research to focus on developing and improving post 
transcriptional processes as well as the cells metabolic ability to cope with the 
synthesis and processing of large amounts of recombinant product.  
 
 
1.3.6.1 Product formation and processing 
Many experiments carried out to date have demonstrated that augmenting the 
machinery of the cell can remove inefficiencies and bottlenecks from the processes, 
therefore boosting the output of the cell. In some cases this has been achieved by 
overexpressing proteins such as chaperones and enzymes that take part in key protein 
processing pathways. For example, a study carried out in IgG producing insect cells 
demonstrated that overexpression of the protein chaperone BiP could generate a 2.5 
fold increase in IgG secretion (Whiteley, Hsu and Betenbaugh 1997). BiP, a protein 
responsible for preventing protein aggregation prior to correct folding and processing 
within the cell, was shown to reduce the levels of improper association and 
aggregation between heavy and light antibody chains within the cell, allowing for a 
greater level of secretion into the medium of properly folded antibody. A similar 
experiment was carried out overexpressing Protein Disulphide Isomerise (PDI) in 
CHO cells producing two different products (Mohan et al. 2007). While one product 
was shown to have a marked increase in expression (15-27%), the other product 
showed no increase. This was possibly caused by a difference in the amount of 
disulphide bonds (the site of PDI’s catalytic action) between products as different 
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proteins will exert different stresses on the cell, or perhaps that the basal level of PDI 
is sufficient for the processing of some products with no bottleneck to be overcome 
with increased expression. 
A related study investigated the effects of both BiP and PDI proteins’ effects in IgG 
producing CHO (Borth et al. 2005). While increases in PDI did indeed allow for less 
retention of IgG heavy chain, and ultimately greater secretion of the active product, 
these results also demonstrated a reduction in product secretion with BiP upregulation 
in contrast to previous results, such as that of the insect derived cell model. Reasons 
for this result have been speculated on based on modelling of cellular pathways, 
including limiting factors such as concentrations of free ATP and other co-chaperones 
(Khan, Schroder 2008). As the elucidation of the functions and interactions of these 
processing pathways are still ongoing, conflicting reports as to the efficacy of 
interventions are to be expected, especially with regards to differing cell lines and 
products being expressed. Also, due to the complex interactions and feedback loops 
that affect these pathways, it is likely that a more coordinated regulation of the 
expression of a selection of metabolic proteins such as chaperones, foldases and 
glycosylation enzymes would be necessary for a reproducible effect on the output of 
mammalian producer cells.  
 
 
1.3.6.2 Waste forming processes 
The targeting of genes involved in the production of waste products has also proven 
successful in reducing the secretion of these detrimental compounds as well as 
improving target protein production. For example, a study was described in which a 
copy of a CHO lactate dehydrogenase gene (LDH-A) was disrupted using 
homologous recombination (Chen et al. 2001). Following a 50% reduction in LDH 
activity, this led to a 2 fold increase in specific antibody production as well as a 30% 
increase in total cell density. A more recent study used siRNA in CHO cells to 
downregulate LDH-A as well as pyruvate dehydrogenase kinases involved in the 
TCA cycle (Zhou et al. 2011). This combined RNAi approach allowed for greater 
reduction in target expression, leading to a 90% reduction in lactate production and a 




1.3.6.3 Targeting of regulatory genes 
Another approach to achieve an improved metabolism that is being explored is to 
modulate the expression of targets that ultimately control activity of a number of 
genes themselves rather than target single, limited function proteins such as those 
involved in protein folding, secretion or waste production. This approach seeks to 
simplify the levels of change that needs to be affected on a biological system by 
targeting the expression of small numbers of regulatory genes responsible in turn for 
the expression of a wider range of useful genes. The metabolic strain that is placed on 
a cell when multiple beneficial genes are overexpressed using strong constitutive 
promoters may ultimately have negative effects on the phenotype. This may limit the 
amount of direct engineering of individual genes possible, with an eventual maximum 
negating any prior benefit due to the hijacking or overloading of the cells 
transcriptional and translational machinery by the same targets intended to improve 
their action. 
This approach of targeting high level regulatory genes was followed in a study 
examining the effects of XBP1. A gene analysis study was carried out comparing 
xbp1 deficient cells with wild type plasma cells (Shaffer et al. 2004). This gene, a 
transcription factor known to be implicated in the regulation of endoplasmic reticulum 
(ER) stress and unfolded protein response (UPR) related genes as well as the cells 
secretory pathway, was shown to have a broad improvement on phenotype including 
increased overall cell size, ER surface area and total protein synthesis, leading to a 
speculation of its role a ‘master regulator’. This effect was confirmed in CHO cells 
(Tigges and Fussenegger 2006), whereby overexpression of transgenic XBP1 
provided a boost to the post translational processing capacity of production CHO 
lines, in some cases up to 5-fold. 
Similarly, a study was carried out in which the serine/threonine kinase mTOR was 
overexpressed in CHO (Dreesen and Fussenegger 2011). The mTOR pathway is 
known to integrate a wide range of intra-cellular signals relating to translation, 
energy, growth, survival and proliferation, and was chosen as an engineering target 
based on its involvement in this myriad of cellular processes. Ultimately the 
overexpression of recombinant human mTOR in CHO was found to have a beneficial 
impact in the areas of specific productivity and secretion, cell size, proliferation and 
viability, increasing productivity four-fold compared to a parental control cell line. 
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Examples such as this demonstrate the benefits of shaping whole pathways and 
systems, rather than modulating the expression of single genes with discreet 
functions. Increasing knowledge of mammalian processes gained through wide 
ranging ‘-omic’ studies, such as transcriptomic, proteomic and next-gen sequencing 
studies, will provide greater knowledge of the complex interactions within cells, 
allowing us to highlight important targets with beneficial downstream metabolic 
effects whilst avoiding those with potentially negative side effects on growth or 
production. 
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1.3.7 Secondary vector elements and epigenetics 
 
The approaches described previously demonstrate the power of regulating elements 
within the cell such as genes and RNA molecules to improve the cells phenotype and 
ultimately generate more of a protein product within a given bioprocess. These trans-
acting elements function in such a manner that shapes the cells metabolism and 
redirects its resources to pathways that allow it to produce and secrete more 
efficiently. 
A complementary approach to these techniques is to further engineer the vectors that 
deliver the product-containing gene and add secondary cis-acting elements; regulatory 
sequences that function to improve the expression of a target gene and ultimately 
allow for greater levels of productivity. These elements can have various functions, 
such as the reorganisation of nuclear chromatin to allow greater access by 
transcriptional machinery or the negation of negative epigenetic factors that repress 
gene expression and avoid the long term gene silencing associated with some 
exogenous sequences such as viral promoters. 
 
Despite high transgene copy numbers and good initial productivity, many cell lines 
are found to be unstable in the absence of an inducer molecule such as methotrexate. 
While genetic instability and loss of gene copies have been implicated as reasons for 
this decrease in productivity (Weidle, Buckel and Wienberg 1988), other causes for 
this drop in productivity include DNA methylation and histone deactylation affecting 
chromatin accessibility, examples of epigenetic modifications leading to inaccessible 
regions of nuclear chromatin that are unable to remain transcriptionally active 
(Barnes, Bentley, and Dickson 2003; Razin 1998). This has been observed in CHO 
cells, with reduction in activity of trans-acting factors eliminated as an issue and, in 
some cases, productivity temporarily restored by the use of a DNA methylation 
inhibitor (5-Aza-2-deoxycytidine) (Yang et al. 2010) or a histone deacetylase inhibitor 
such as sodium butyrate (Davie 2003). However, in an attempt to circumvent the need 
for the persistent use of small molecules in bioprocesses, genetic factors have been 
investigated in order to reduce the effects of transcriptional gene silencing from 
epigenetic factors such as these. 
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1.3.7.1 Scaffold/matrix attachment regions 
The use of ‘scaffold/matrix attachment region’ (S/MAR) sequences has been 
investigated in mammalian cells. These sequences are thought to serve by facilitating 
the binding of the nuclear matrix to DNA, organising nuclear DNA into defined 
functional chromatin loops, promoting position-independent transcription of 
transgenes and reducing negative random position effects and reducing the differences 
between clones with varying random inserts (Kim et al. 2004). A number of different 
S/MAR elements originating from different sources have been examined, with 
positive effects on transgene expression reported from elements such as the chicken 
lysozyme and human β-globin S/MARs (Wang et al. 2012; Zahn-Zabal et al. 2001). 
While the levels of success reported in studies utilising S/MARs seems to vary 
depending on the combination of cell line and elements used, their relatively small 
size (~3 kb) and ability to improve expression even when co-transfected on a separate 
plasmid (Zahn-Zabal et al. 2001) make them an potentially useful tool for generating 
stable, high producing clones with a reduced need for extensive screening. 
 
 
1.3.7.2 Ubiquitous chromatin opening elements 
A class of sequence element retaining a similar function to that of S/MARs are known 
as Ubiquitous Chromatin Opening Elements (UCOE). UCOEs are promoter like 
elements associated with ubiquitously expressed housekeeping genes. They contain 
extended CpG islands found to be resistant to methylation and the effects of 
heterochromatin formation related to transgene silencing.  
A number of studies have been carried out combining the common CMV promoter 
with fragments derived from UCOE-like elements. One study described a vector 
including an 8 kb UCOE fragment, resulting in a far higher number of clones 
expressing high levels of a GFP control when analysed using flow cytometry (Benton 
et al. 2002), drastically reducing the level of screening necessary to find suitably high 
producers. Another study, examining a smaller 4 kb fragment isolated from a human 
genetic locus (driving HNRPA2B1 and CBX3 housekeeping genes’ expression) found 
not only an increase in the number of stable clones generated, but also 2-4 fold higher 
average levels of recombinant protein production (Boscolo et al. 2012).  
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While spare vector space may be a limiting factor for some applications, UCOE 
fragments as small as 1.5 kb isolated from a human locus expressing housekeeping 
genes TBP and RNP were found to confer greater than 20 fold improvements in eGFP 
expression over 100 passages compared to a hCMV promoter alone (Brooks et al. 
2004). Examples such as these make UCOEs, as well as S/MARs, attractive potential 
additions to vectors to improve phenotype in relation to productivity without the need 
for more potentially disruptive genetic interventions. 
 
 
1.3.7.3 Use of endogenous promoter sequences 
Another potential avenue for increasing specific productivity, while avoiding the 
problems associated with some exogenous sequences (for example, gene silencing 
associated with the strong CMV promoter, Brooks et al. 2004) is to use endogenous, 
mammalian derived promoters. One example of this is the successful use of regulatory 
sequences isolated from the CHO EF-1α gene (Running-Deer and Allison 2004). 
While mammalian promoter sequences and their associated regulatory sequences are 
not currently well defined, vectors containing various 5’ and 3’ EF-1α gene flanking 
sequences were found to successfully induce gene expression between 3 and 26 times 
greater than commonly used promoters such as CMV. This effect was also stably 
sustained without substantial gene silencing after 50 passages without inducer 
molecule (MTX). Interestingly, high expression (up to 10 fold increase) was also 
measured in non hamster mammalian cell lines. An obvious drawback to this 
example, however, is the fragment size necessary for expression, with at least 8 kb 
including both upstream and downstream regulatory sequences providing the greatest 
effect, compared to the comparatively small size of constitutive viral promoters. 
 
Another novel use of mammalian promoter sequences is found in a study by 
Thaisuchat et al. (2011), in which a 1.5 kb upstream regulatory region of a CHO gene, 
whose expression was found to correlate strongly with temperature shift, was assayed 
for promoter activity. This approach led not only to successful gene expression at 
regular temperatures, but expression 3 times greater than an SV40 viral promoter 
construct when temperature was shifted to 33°C. This conditional expression confers 
the benefit of reducing unnecessary target gene activity during the 37°C growth 
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phase, and also boosting productivity in tandem with the metabolic advantages gained 
during temperature shift as outlined previously. 
 
Constructs such as this containing secondary sequences that enhance transgene 
expression may be currently ill-suited for implementation in industrial bioprocesses 
due to their cumbersome size and less than distinct sequence characteristics. However, 
as mammalian regulatory sequences become better defined and our understanding of 
core sequences necessary for these elements to function increases, we can expect to 
see such sequences used more often to help improve vectors engineered to deliver 




1.3.8 Viral vectors 
 
By no means a novel technology, viruses have been extensively studied as a means of 
introducing target sequences into mammalian cells due to their innate ability to infect 
cells and deliver DNA in an efficient manner. While lentiviruses and retroviruses have 
been studied and used successfully, adeno associated viruses (AAV) have proven a 
popular vector for the genetic modification of a number of mammalian cells, 
including mouse, hamster and human derived lines. As a gene delivery vector it has a 
number of qualities that make it a good candidate for such a role. It causes no known 
diseases in humans making it safe for laboratory use, it displays an inability to 
replicate independently, necessitating a helper adenovirus to reproduce, as well as 
having the ability to transduce both dividing and non dividing cells giving it a more 




1.3.8.1 Adeno-associated viral vector 
AAV is a small parvovirus with a single stranded DNA genome known to infect a 
number of host organisms. It generally exists as a latent ‘provirus’ due to its ability to 
integrate within a host cells’ genome, but requiring the assistance of a secondary 
helper virus (such as an adenovirus) for lytic replication. These properties marked it 
as a good candidate for development of a safe and effective mammalian transduction 
vector when originally studied. Early experiments with recombinant forms proved 
successful at both transduction and expressing transgenes, with viral rescue and 
reproduction possible with subsequent infection of an appropriate helper virus 
(McLaughlin el al, 1988; Hermonat and Muzyczka, 1984). To date a range of AAV 
serotypes with varying tropisms have been discovered (Mori et al. 2004), however 
AAV serotype-2 remains the most extensively studied and utilised for mammalian 
cell engineering. 
Due to the extensive study carried out on AAV, recombinant AAV generation is now 
relatively straightforward. The wild type AAV genome consists of two open reading 
frames encoding for key replication (rep) and packaging genes (cap), as well as 
flanking inverted terminal repeat (ITR) sequences critical for virus packaging. In 
recombinant vectors used for molecular engineering, these replication and packaging 
genes are removed, allowing for the insertion of any target transgene or DNA 
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sequence of interest (Adachi and Nakai 2011). For viral generation, these replication 
and packaging genes are delivered in trans on a separate plasmid to the cell line to be 
used for replication (human embryonic kidney cells are commonly used) along with a 
‘helper’ virus or plasmid containing the other genes necessary for AAV reproduction. 
 
 
1.3.8.2 AAV capacity 
Adeno associated viruses carry a natural genome capacity of roughly 4.7 kb, of which 
~0.3 kb is utilised by the mandatory ITR sequences. For recombinant vectors an 
optimum total of ~4.9 kb as been reported, with sharp decreases in packaging 
efficiency observed above this total (Dong, Fan and Frizzell 1996). Methods have 
been devised however, in an attempt to circumvent this limit and deliver larger 
constructs than would otherwise be possible using a single vector. One method was to 
simply co-infect with two viruses, each encoding a separate element of the total 
construct. It was found that separate viral genomes could form intermolecular 
concatemers after uptake within infected cells, linking the viral genomic elements 
prior to integration into the host genome. One example demonstrated a 600 fold 
increase in luciferase expression when the primary virus containing a minimal 
promoter was co-infected with a secondary virus containing extra promoter and 
enhancer elements, with circular concatemers confirmed within the cells (Duan et al. 
2000). This demonstrates the ability to successfully transduce cells with modular 
sequences, utilising this concatemer-forming property to reconstruct larger complex 
expression cassettes from its individual components. This concatemerisation feature 
of dual vectors has also been used to reconstruct larger genes that would not otherwise 
be possible to package by introducing splice sites in between constituent exon-like 
elements that could be recognised and reconstructed by the targeted cell lines natural 
splicing machinery (Ghosh et al. 2008). 
 
 
1.3.8.3 Integration site preferences
 
Many studies based on this method of introducing foreign DNA into host cells rely on 
random integration into the host genome, in a similar manner to that of any stable 
transfection using plasmid vectors. Wild type AAV is found to integrate preferentially 
into a location on chromosome 19 in human cells, however the recombinant forms of 
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AAV commonly used are engineered to lack the requisite Rep protein (which is 
instead transfected separately for viral replication). Mapping studies of its integration 
sites demonstrated that AAV preferentially integrated into gene sequences with a 
frequency of 53% (Nakai et al. 2005), with targeted genes often ones currently being 
expressed in the transduced tissue (Nakai et al. 2003). As there is lack of homology 
between recombinant AAV vector sequences and apparent integration sites, it has 
been suggested that random non-homologous recombination is the likely method of 
integration for non-targeted insertion events (Rutledge and Russell 1997). With 
relation to AAV2’s possible use as a means of altering recombinant protein producing 
cells, this trait could allow for random insertion of transgenes into active genomic 
regions with greater frequency and possibly avoid the negative position effects 
associated with transcriptionally inactive heterochromatin. 
 
 
1.3.8.4 Alternative viral vector systems 
The versatility and high efficiency of AAV viral vectors make it a useful tool for the 
alteration of mammalian cells. It allows for a range of genetic alterations, coupled 
with relatively high efficiency and specificity when used in conjunction with 
homologous recombination. However, as it is the chosen vector for the gene knockout 
experiment carried out in this study, it is used here as an example of a successful 
vector, and not the sole method of transduction in mammalian cells. For example 
lentiviral vectors, another well known viral vector for use in mammalian cells, are 
generated in a similar fashion by separating genes necessary for reproduction from the 
functional vector genome (Trono 2000). It has the advantage of a larger capacity 
approaching 10 kb in size, and has been proven as a viable means of generating stably 
recombinant mammalian cells (Gaillet et al. 2010). Retroviral vectors, such as those 
based on recombinant forms of murine leukemia and Rous sarcoma viruses have also 
been investigated for use in mammalian cell lines (for example, Barsov and Hughes 
1996), however these are more commonly associated with in vivo gene therapy 
(Hawley et al. 1994) 
Differences in the transduction profiles and characteristics of various viral vectors 
indicate that vector choice should be most relevant for the purpose at hand. For 
example, in vivo and in vitro investigations of AAV and lentiviral transduction and 
targeting rates have indicated an advantage using AAV in a particular set of tissues 
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tested (de Backer et al. 2010), indicating that the viral vector to be used should be 
chosen carefully based on its application and cell type to be transduced. 
 
1.3.8.5 Gene targeting 
Random integration can be used for integration and expression of a given transgene. 
However, a common engineering application for viral vectors is their use in gene 
targeting via targeted homologous recombination, rather than random insertion. They 
have been routinely used for gene knockouts and to introduce sequence mutations in 
mammalian cells with efficiency many times greater than those achieved with 
standard plasmid based transfection methods. Studies carried out in human cells have 
comprehensively demonstrated this use for a number of different insertion events.  
Successful studies carried out to date using AAV have demonstrated their 
effectiveness using a variety of vector configurations. These include 
 Gene repair of a mutant selection marker in order to restore function (Russell 
and Hirata 1998)
 
 Insertion into a natively expressed gene sequence to disrupt expression 
(Russell and Hirata 1998)
 
 The introduction of a single base pair mutation (Inoue et al. 2001)  
 Targeted insertion of a functional transgene cassette (Hirata et al. 2002) 
 
In all cases relatively high targeting rates were obtained (approaching 1% of cells), a 
vast increase over traditional transfection based methods that could achieve targeting 








1.3.8.6 Potential uses in mammalian cell line engineering 
The usefulness of viral vectors in the engineering of industrially relevant cell lines 
becomes apparent when we consider this ability to accurately target genetic loci with 
such a relatively high frequency.  
The most obvious beneficial use for this technology is the targeting and disruption of 
genes with detrimental effects on producer cell lines. As described previously, gene 
knockout using homologous recombination has shown to provide more effective 
results when compared to gene silencing technology such as siRNA (Li et al. 2010). 
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This ensures low level expression that may not be totally eliminated by RNA 
interference does not impact on phenotype, while removing the need for a 
constitutively expressive siRNA cassette that may be subject to stability problems in 
the long term. While RNAi may prove useful in screening and validation of such 
targets, true elimination of a genes effect on the cell is likely best suited to gene 
knockout facilitated by homologous recombination. As part of this project, such an 
investigation was carried out as to the potential use of an AAV vector for the targeting 
of specific loci within the CHO genome. 
Another potentially useful application of gene targeting for improved recombinant 
protein production is the specific targeting of known transcriptionally active ‘hot-
spots’ within the genome. Theoretically, by attempting to insert target DNA in areas 
of the genome known to contain transcriptionally active genes, one could hope to 
improve the levels of transgene expression by virtue of their location in open 
chromatin.  
One study was carried out involving the use of a randomly integrating viral vector to 
identify and characterise chromosomal loci associated with high transcriptional 
potential (Mielke et al. 1996). Using SEAP or CAT activity to measure expression, a 
number of regions in embryonic mouse cells identified using inverse PCR were found 
to be associated with high transcriptional activity (interestingly, a number of these 
contained S/MAR like characteristics which, as noted previously, are associated with 
active chromatin). A similar experiment in CHO, investigation of existing high 
producing cell lines or bioinformatic analysis of the CHO genome could identify 
regions with similar characteristics that could be targeted to predictably improve 
transgene expression and reduce the lengthy screening necessary to identify clones 
with productivity suitable for industrial bioprocesses. 
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1.3.9 Engineered nucleases 
 
While the methods of gene knockdown and knockout described previously are now 
commonly used and well characterised technologies, a notable and relatively novel 
method of gene targeting exists in the form of engineered nucleases. For example, an 
elegant and precise method has been described for targeted gene knockout using 
specifically engineered zinc finger nuclease (ZFN) enzymes (Santiago et al. 2008). 
This strategy utilises an engineered DNA cleavage enzyme with two functional 
domains; a DNA cleavage domain isolated from the FokI DNA nuclease coupled to a 
highly specific zinc-finger DNA binding domain. Once this enzyme has bound to its 
cognate sequence, the cleavage domain breaks the DNA which is then repaired via 
non-homologous end joining (NHEJ), a natural cellular DNA repair process. NHEJ is 
an inaccurate repair system that frequently introduces mutations, consequently 
disrupting the target gene. It has been shown that the DNA binding domain can be 
engineered to create novel sequence binding capabilities through the modular 
assembly of individual zinc finger domains that recognise specific base pair triplets
 
(Durai et al. 2005). Zinc finger binding sites with recognition sites up to 24 bases 
have been described (Urnov et al. 2005), permitting the generation of ZF nucleases 
that can target precise DNA sequences, thus allowing for the targeted disruption or 
removal of highly specific DNA sequences within the genome.  
 
This technique has been successfully demonstrated in instances of single (Santiago et 
al. 2008) as well as multiple (Liu et al. 2010) gene knockout. Biallelic knockout 
frequencies >1% were observed in each case, making this an attractive prospect for 
gene knockout over techniques such as plasmid transfection or viral targeting where 
such events may be rarer, or may introduce off-target insertion events. This technique 
was also used effectively to achieve an aim similar to that of an siRNA study 
described previously (i.e. to eliminate the effects of the pro-apoptotic genes Bax and 
Bak; Lim et al. 2006). Using two engineered ZFNs, researchers managed to 
successfully disrupt these two genes, creating double knockout cells resistant to 
apoptotic stimuli that could ultimately produce up to 5 fold more IgG than wild type 
cells (Cost et al. 2010).  
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Protocols for their use in the targeted integration (‘knock-in’) of DNA sequences have 
also been described using a ZFN to generate a double stranded break coupled with a 
targeting vector containing homologous sequences (Orlando et al. 2010). This method 
carries the advantages of high targeted integration rates, coupled with lower instances 
of off-target random insertions. 
 
A similar class of nucleases known as TALENs (Transcription Activator-Like 
Nucleases) are also the subject of current research. TALENs employ a similar 
methodology to ZFNs, with a FokI nuclease domain coupled to a DNA binding 
domain isolated from the plant pathogen Xanthomonas. Sequence recognition is 
facilitated by polymorphic dual amino acid residues found in repeat sequences in the 
TAL binding domain, which in turn correspond to DNA base pairs. Effective methods 
have already been described for the construction of custom binding domain arrays to 
recognise novel sequences (Reyon et al. 2012; Cermak et al. 2011), and published 
experiments successfully utilising TALENs for gene disruption are becoming more 
prevalent with examples demonstrated in a range of model species such as human 
(Hockemeyer et al. 2011) and rat (Tesson et al. 2011). Another class of targeted 
nucleases known as meganucleases has also been used for genome editing in 
mammalian cells by inducing double stranded breaks (Arnould et al. 2010). 
Meganucleases recognise larger sequences (up to 45 bp), but suffer from a more 
difficult engineering process compared to the relative ease of their modular 
counterparts such as ZFNs and TALENs (Epinat et al. 2003). 
 
Zinc finger nucleases pose a great future potential due to the specificity of the 
enzymes generated as well as their modular nature, allowing for the targeting of 
almost any genomic sequence with the generation of bespoke nuclease enzymes. 
However, due to the tight intellectual property rights currently exercised by Sangamo 
Biosciences over this technology and the cost of generating novel ZF nucleases, their 
use is relatively uncommon in research laboratories (Scott, 2005) as they do not 
currently offer a cost effective means of gene targeting for common research. 
However, this method of genome editing is likely to become more common and more 
cost effective in the future with the advent of similar competing technologies such as 
TALENs and engineered meganucleases. 
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1.4 Mutagenesis & Directed Evolution 
 
 
The general method around which a portion of this project was modeled is that of 
mutagenesis and directed evolution. Mutagenesis is the altering of the genetic 
sequence of a given genetic component such (for example a gene or regulatory 
sequence), while directed evolution is the subsequent selection for an advantageous 
phenotype generated by advantageous mutations by applying an environmental 
pressure or selection method. It follows the basic experimental principles: 
 
 Diversification: The target DNA sequence is mutated and altered in some way. 
This can be done using a variety of techniques, such as ‘site-specific’ targeted 
mutations or by generating a diverse random mutant library with each element 
containing a differing sequence. Historically, chemicals such as alkylating agents 
or radiation was used to introduce random mutations, however modern techniques 
such as error prone PCR, gene shuffling or point mutation can be specifically used 
to generate controlled libraries of mutant DNA sequences, as well as rational 
directed changes. Applying these techniques can provide a library of considerable 
diversity in terms of their ultimate function, which in turn can be selectively 
screened for advantageous changes or novel functions that provide significant 
benefit. 
 Selection: Once the mutant DNA is introduced to the cell and expressed, a 
selection or screening process is used to select for advantageous changes. For 
example, an environmental pressure or negative selection method can be used to 
eliminate all mutants not possessing the intended phenotype, while a screening 
process allows for the investigation of individual mutants’ or population’s relative 
performance.  
 
Mutagenesis and directed evolution has proven a powerful methodology in molecular 
biology for the improvement of a variety of biological components and products as 
well as their host strains. It follows the basic tenet of evolution by natural selection 
observed by Darwin in the 19
th
 century; within a diverse population the fittest, 
according to environment factors and the pressures applied, will survive. Rather than 
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attempting the improvement of biological components by effecting rational changes 
and examining the results, we can introduce a wide variety of different changes in the 
form of a synthetic library and allow the chosen selection method to present us with 
the advantageous mutants. This high throughput becomes especially powerful when 
the structure/function relationship or activity of these components is poorly 
understood. By examining the differences between functionally superior mutants and 
their wild type counterparts, this also allows us to gain insight into structurally 
important regions that may be subject to further targeted engineering once a number 
of rounds of random mutations have yielded improvements. 
 
Broadly speaking, mutagenesis techniques can be divided into random and non-
random (rational) techniques. Historically, the effects of mutagenesis on a particular 
organism or constituent gene could be studied within the lab by inducing non-specific 
mutations using chemicals and radiation, often to establish basic links between gene 
and function. As technology has advanced in this field, techniques have been 
developed to allow for highly directed rational changes to be made to genomes and 
gene sequences whose properties are understood, as well as permitting vast mutant 
libraries that allow for the screening and selection of novel or improved phenotypes in 
situations where rational improvement may be difficult to implement. Discussed 
below are a range of these techniques, and how they have been successfully 




1.5 Component Engineering 
 
 
Mutation and directed evolution can be a powerful method of improving molecular 
components such as proteins, cis-acting sequences such as promoters as well as whole 
cell phenotypes. First, this section will examine the means by which researchers can 
generate random and targeted mutations in a given sequence in order to create 
diversity, and focus on examples of how these have implemented to improve on 
cellular components and bioprocess products such as enzymes. 
 
 
1.5.1 Mutation Methods 
 
Summarised below are a variety of methods for the introduction of variation to a 




1.5.1.1 Random mutagenesis 
Early work in the field of directed evolution was generally carried out in bacterial 
systems, often directed at improving the activity of biological products such as 
enzymes that are used as components of large scale industrial applications (for 
example enzymes used in food processing or as components of household detergents) 
Biomolecules such as enzymes were among the first biological products to be 
produced and used on a large scale, and attempts to improve them on a genetic basis 
have formed the basis for industrially relevant directed evolution techniques. A 
fundamental approach used for the generation of improved enzymes, and a 
cornerstone of artificial evolutionary techniques, is the use of low fidelity PCR to 
generate random mutations in a given sequence and generate a mutant library. When 
placed into a population of cells this library can then be screened for activity and, if 




Examples of this fundamental approach have been demonstrated, such as a study 
carried out in an attempt to adapt the Subtilisin E protease, an industrial biocatalyst, to 
maintain its activity in an organic solvent (You and Arnold 1996). A modified 
polymerase chain reaction was used in which reaction conditions were suitably 
modified to increase the frequency of mutations in the Subtilisin gene sequence. 3 
rounds of random evolution were undertaken, each in which a library of the mutant 
genes was generated and reintroduced into B. Subtilisin. Clones were screened for 
activity between rounds, after which the clone with the highest performing enzyme 
was then selected for subsequent mutagenesis and screening. Ultimately, an enzyme 
was generated with 10 distinct mutations resulting in roughly the same catalytic 
efficacy in a 60% dimethylformamide solution as the wild type enzyme displayed in 
water. This approach built on previous similar experimental iterations carried out to 
improve Subtilisin activity in the solvent DMF (Chen and Arnold 1993; Chen and 
Arnold 1991).  
Now commonplace, this technique has also been widely employed to improve the 
function of many enzymes, with phenotypes including activity, specificity, stability 
and temperature sensitivity showing improvements over wild-type variants. Examples 
include restriction enzymes with altered recognition sites (Samuelson el al. 2006), 
non-protein ribozymes with improved pH resistance (Miyamoto et al. 2005) and 
dehydrogenases with improved activity at low temperatures (Sasaki et al. 2008). 
 
The examples above describes the most basic form of mutant library generation, in 
which a target DNA sequence is subjected to error prone PCR to generate a library, 
using modified PCR conditions such as increasing magnesium (Mg++) concentrations 
to decrease enzyme fidelity and introduce mutations. Alternative techniques have also 
been developed to achieve a similar goal, with modern commercial solutions 
commonplace. Commonly used are PCR enzymes engineered to reduce copy fidelity 
and remove proof reading ability (such as the one used in this thesis – Genemorph II 
kit, Agilent technologies) with mutant enzymes derived from Pyrococcus furiosus 
(Pfu) proving particularly effective (Biles and Connolly 2004). ‘Mutator strains’ of 
bacteria have also been used to generate mutant plasmid libraries by successive 
rounds of plasmid reproduction in E. coli strains such as XL-1 red lacking in gene 
repair pathways (Muteeb and Sen 2010), with increases in bacterial generations 
leading to larger mutation rates. 
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1.5.1.2 Site saturation mutagenesis 
For enzymes whose structure and/or function is better understood, site saturation 
mutagenesis has proven a successful alternative to whole sequence random mutation. 
Site saturation mutagenesis involves the targeting of a narrow region of DNA (often 
as small as a single amino acid), and employing random mutation to generate a library 
of mutants localised to this previously determined location. This ‘semi-rational’ 
approach has shown that with prior knowledge and targeting of key amino acids in 
and around active sites and external facing structures, the library size necessary and 
thus the amount of screening and rounds of mutation necessary to generate a positive 
change in phenotype can be successfully reduced. This reduction in scale also allows 
for almost all variations in a small sequence space to be explored, with possibly all 20 
amino acids in a given position able to be substituted and tested.  
In one example, β-Fucosidase activity was enhanced in a β-Galactosidase enzyme in 
just one round of site saturation, as opposed to a comparable previous study requiring 
seven rounds of random DNA shuffling (Parikh and Matsumura 2005). Similarly, a 
different study was carried out in which the Cre recombinase enzyme was modified at 
6 target residues known to recognise and interact with wild type loxP sequences. By 
targeting this active site for mutagenesis, they were able to identify a custom mutant 
enzyme capable of recognising a novel loxP site as well as the wild type sequence 
(Santoro and Schultz 2002). 
 
 
1.5.1.3 Site directed (point) mutagenesis 
Site directed mutagenesis, as opposed to the randomised methods above, is a useful 
method for tailoring specific alterations of target genes. It employs techniques in order 
to generate exact changes in DNA without the need for randomised libraries, 
generally based on known structure/function relationship data. It can be carried out to 
combine advantageous point mutations predetermined through random means onto a 
single sequence, or rationally explore the effects of highly specific mutations.  
The most widely used site directed techniques generally involve the use of modified 
oligonucleotide primers containing the mutation of interest. This primer binds its 
target mutation site, and subsequent PCR cycles integrate this mutation into the 
sequence (An et al. 2011). This technique has been modified and refined to increase 
efficiency and reduce the influence of non-mutated template DNA, for example by 
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digesting with DpnI (Li et al. 2008). Rational engineering using the method described 
has been used successfully to synergistically combine target residues previously 
determined as advantageous by random means to generate a more functional laundry 
peroxidise enzyme (Cherry et al. 1999). In another study it was used as an 
intermediate tool to introduce restriction sites in order to link domains to create a 
fusion protein (Japrung et al. 2005). While originally limited by the ability to 
introduce single point mutations at a time, modified protocols have been demonstrated 




1.5.1.4 Gene shuffling 
Other techniques have also been used to successfully engineer stability and activity in 
enzymes. The above methods have proven successful, but are limited by iterative 
additions of small numbers of beneficial mutations. Multiple simultaneous random 
mutations are like to be deleterious, so progress is made in smaller steps, generally 
through multiple rounds of mutation after selecting for beneficial changes and/or 
subsequent site saturation techniques. Gene shuffling was designed as a means to 
overcome this limitation, by allowing the random recombination of beneficial 
mutations after a round of random mutagenesis in order to select for advantageous 
combinations, with reduced need for multiple iterative rounds of mutation on single 
select mutants. 
First, a selection of homologous sequences are pooled and randomly fragmented (for 
example, a mutant library or selection of sequences with known beneficial mutations). 
Primerless PCR is then carried out, with homology between fragments sufficient to 
allow fragments to prime each other. Fragments of different sequences cause 
crossovers, eventually recreating the full length sequence incorporating a mixture of 
mutations. This library of chimeric sequences can then be screened for improved 
phenotype (Stemmer 1994). 
This single gene technique has proven beneficial for the improvement of a number of 
sequences without the need for in-depth prior knowledge of its structure. Examples 
include a mutant GFP generated over 3 cycles of DNA shuffling with a 42-fold 
increase in fluorescence when expressed in CHO cells (Crameri et al. 1996). A plant 
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reporter gene, β-glucuronidase, was also engineered using this technique to gain 
thermostability even when treated to 100°C temperatures (Xiong et al. 2007). 
 
A modified version of the gene shuffling technique known as family gene shuffling 
has also proven successful. Rather than recombine a gene with itself to generate new 
functionality, the functional diversity of homologous genes from within the same 
family or homologous genes from different organisms can be exploited to gain 
improved phenotype when these genes are recombined using shuffling techniques. 
The influence of natural selection to select for functional mutations over millions of 
years is used as the starting point, increasing diversity and the likelihood of screening 
for positive recombinants from a given library (Crameri et al. 1998). 
A clear example of this technique involves the shuffling of yeast lipase enzymes. 
(Suen et al. 2004) Gene fragments are generated from homologous lipases from 3 
separate yeast species. These fragments were then recombined to generate a rich 
library that combined the natural diversity of the organisms used, as well as the 
inherent heterogeneity generated in the gene shuffling technique. A number of clones 
were screened for that produced between 5 and 20 fold increases in activity, as well as 
enhanced thermostability, thereby reducing inactivation as temperatures increased up 
to 45°C. This same process has also been successfully replicated to generate novel 
cytochrome P450 enzymes for dye production (Rosic 2008) and novel promoter 
sequences with increased gene expression activity (Ranjan et al. 2012) amongst other 
examples. One study was also able to identify previously unknown homologous 
sequences from environmental ‘metagenomic’ bacterial samples encompassing a 
heterologous mix of organisms, overcoming a lack of genetic diversity in established 




1.5.2 Genotype-Phenotype Linkage Methods 
 
While enzymatic function is a relatively simple characteristic to assay, a method must 
be established to select for improvements via evolution of more subtle traits of 
proteins that may be more difficult to detect. These include activities that cannot be 
easily assayed on a large scale, such as DNA binding capacity and interactions with 
other proteins that one may want to select from a complex library.  
For this reason, employing a ‘genotype-phenotype’ linkage method is important. As 
proteins are not self replicating, an improved mutant that has successfully been 
screened or selected for must somehow be physically linked to its original DNA or 
RNA sequence. At this time, a number of ‘display’ techniques are commonly used to 
link the protein of interest to its cognate nucleic acid sequence. 
 
 
1.5.2.1 Phage display 
Phage display is a common method of the display technique, generally used to select 
for novel or improved binding specificity, such that it is often used to in conjunction 
with mutagenesis to improve the specificity of antibodies. It is based on the 
filamentous bacteriophage, a virus known to infect gram-negative bacteria. A library 
of varying ligands is first cloned as a fusion protein together with a phage coat 
protein. This library is then transformed into E. coli and the phage generated. The 
target binding molecule is immobilised onto a surface, and exposed to the phage 
library. When the library comes into contact with the target molecule, any phage 
displaying a successfully bound protein will remain bound, with all others then 
washed away. Bound phage can then be eluted and used to generate more phage, 
enriching for the target proteins and their linked genetic sequences. Repeated cycles 
(known as panning) will eventually select for proteins or peptides with the highest 
binding affinity within the library, whose sequence (contained within the phage) can 
then be amplified.  
 
An early example of this technique proved its efficacy in isolating antibodies with 
highly specific variable binding regions (McCafferty et al. 1990). This served to speed 
up the process through which antibodies with enhanced binding capacity could be 
screened, rather than assaying individual clones for improved specificity.  
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Modifications of this protocol have also been employed, such as one study that treated 
affinity tag immobilised protein-phage fusions with a protease. This served to remove 
unstable and poorly folded mutants on display, thus selecting for the more stably 
folded protein variants (Finucane et al. 1999). Examination of these stable proteins 
can also provide an insight into their properties, and increase our understanding of the 
structure-function relationship. This technique has also been effectively used for its 
ability to screen for novel protein-DNA interactions such as early attempts to isolate 
novel zinc finger proteins, a technique that would be later used to generate the novel 




1.5.2.2 mRNA/ribosome display 
Newer methods of display for selection from large libraries have also emerged, such 
as ribosome and mRNA displays. These methods are carried out entirely in vitro, 
removing the limits of library size imposed by transformation efficiencies for in vivo 
methods. Phage display, for example, has an upward limit of the order of ~10
9
, while 
an mRNA library can theoretically contain upwards of 10
13
 different sequences (Gold 
2001). It also avoids bias that may arise from proteins that are too toxic or difficult to 
produce in vivo, increasing variation.  
 
For mRNA display, mRNA is first derived from gene libraries generated though 
mutagenesis. These sequences are then covalently tagged to puromycin, a ribosome 
inhibitor, at the 3’ end. Translation then takes place in vivo, and the nascent peptide 
chain is left with an intact link to its mRNA due to the puromycin molecule 
terminating translation. The peptides are then purified and exposed to the target 
molecule, bound, and the unbound molecules washed away. The mRNA tagged to 
successfully bound proteins can then be used for amplification and further analysis. 
This method is similar to ribosome display, in which a spacer sequence is used in 
place of puromycin to terminate translation, allowing the nascent polypeptide to fold 
and interact with its environment while also retaining the original nucleic acid 
sequence in a complex with the ribosome. ‘Panning’ is then carried out as usual to 
remove non binding proteins and select for improved variants. 
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mRNA display has been used successfully in one instance to detect 16 novel 
interactors with the Jun protein by carrying out mRNA display on a mouse brain 
cDNA library, 10 of which were subsequently confirmed to interact in vitro 
(Horisawa et al. 2004). It has also been used to generate novel proteins with strong 
immunoglobulin-like binding capacity (Xu et al. 2002), as well as application in a  
search for previously unknown protein Bcl-xL binding partners using tissue derived 
mRNA libraries (Hammond et al. 2001). Ribosome display is generally used in a 
similar manner, with a typical study carried out Hanes et al. (2000) involving its use 




1.6 Directed Evolution of Cellular Phenotype 
 
 
The methods described above have proven useful for engineering discreet protein 
interactions, generating increases in activity or specificity in products such as 
enzymes or improving the properties of sequences such as promoters. The success of 
such single element engineering has led research to focus on the directed evolution of 
entire cell lines, especially those utilised in industrial biotech processes. Applying 
these principles to organisms is an attractive proposition for the improvement of 
industrially relevant phenotypes. By helping shape overall cellular processes through 
directed evolutionary techniques, we can hope to develop key cellular attributes such 
as growth and maximum density, specific productivity, as well as resistance to 
apoptotic factors and reduction of waste secretion.  
Rather than engineering component functions such as those outlined previously, the 
idea is to guide the evolution of the entire cell by facilitating the direct or indirect 
manipulation of a number of genes or cellular networks by introducing artificial 
variation through mutation or exploiting naturally occurring heterogeneity. This also 
takes advantage of the cells complex ability to auto-regulate the activity of a range of 
proteins and other regulatory factors in order to achieve a desired phenotype, 
cumulative effects that are hard to predict or implement through rational engineering. 
 
 
1.6.1 Stress Induced Adaptive Evolution 
 
One method of directed evolution for whole organisms is relatively simple as it 
requires no genetic manipulation. Adaptive evolution methods rely on the natural 
variation in a heterogeneous population to provide beneficial mutations that are then 
selected for using an environmental stress dictated by the researcher. This includes 
clonal derivatives that, while initially may be genetically identical, eventually develop 
phenotypic variation (Stockholm et al. 2007). These stresses are generally 
implemented gradually in order to allow for changes to build up over successive 
generations, eventually conferring a level of resistance to the stress, signifying a level 
of adaptation on a genetic level (Roth et al. 2006). 
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Due to their fast generation time and relative simplicity compared to mammalian 
cells, this approach to the improvement of industrial cell lines was first demonstrated 
in bacterial and yeast systems. Ethanol production in genetically engineered E. coli, 
for example, is limited by their tolerance to the product secreted, restricting maximum 
biofuel output of producers. One study managed to select for resistance to ethanol in 
E. coli by steadily increasing ethanol concentrations up to 50g/L, with selection of 
ethanol producing clones on solid medium in between increases to ensure continuing 
production and high growth. These evolved variants displayed high ethanol resistance 
without genetic intervention compared to the parent control, with no changes to other 
factors such as production or osmotic resistance (Yomano, York and Ingram, 1998). 
Further work investigated if such a phenotype could be recreated directly in parental 
cells without the incremental forced evolution stage. This was achieved in an 
experiment regarding isobutanol tolerance in E. coli. Initially, a similar sequential 
transfer method was used as above to gain tolerance and generate a phenotype that 
researchers would then attempt to recreate. Genome sequencing was carried out on the 
most successful clone. While a large number of mutations were detected, 5 were 
determined to have the biggest impact on the improved phenotype through gene 
repair. This genetic relationship to phenotype was then validated via reconstruction in 
a parent strain through systematic inactivation of these loci to re-establish isobutanol 
tolerance (Atsumi et al. 2010). 
 
Similar methodology of stepwise adaptation has proven successful in mammalian cell 
lines as well. Adaption to serum free conditions is a basic adaptation method 
commonly used now in industrial applications to avoid the potential immunogenic 
and variability concerns that come with use of animal derived serums. Historically, 
this required no genetic intervention and could be achieved with a gradual stepwise 
reduction in serum concentration. Such environmental adaptations have also proven 
successful for other factors, demonstrating the elasticity that exists naturally in many 
cultured cell lines. For example, a CHO-K1 strain, previously adapted to serum free 
and suspension growth conditions was passaged at high densities in medium 
containing gradually reducing concentrations of glutamine (Bort, Stern and Borth 
2010). By sorting for viable cells after the inevitable crash in viability after glutamine 
reduction, eventually a cell population was adapted to grow in entirely glutamine free 
media, with metabolism supported by an increase in glutamate and aspartate 
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consumption. A similar technique was applied to mouse hybridoma cell lines to select 
for cells exhibiting resistance to the toxic effects of ammonia accumulation by serial 
spiking of NH4Cl (Matsumura et al. 1991). 
Other experiments have also demonstrated a cell lines ability to evolve and adapt to 
withdrawal of supposedly key components, such as investigations into medium 
supplementation that yielded insulin independent CHO-K1 derivatives (Mendiaz et al. 
1986). Another study successfully attempted to select for cells with a general 
improvement in phenotype related to bioreactor performance, using a method dubbed 
‘bioreactor evolution’ (Prentice, Ehrenfels and Sisk 2007). Cells were iteratively 
passaged under normal bioreactor conditions, with late stage cells rescued after a 
decrease in viability, expanded and then used to reseed another batch. This ‘training’ 
of cells for bioreactor conditions was intended to expose cells to negative batch 
culture conditions such as high waste and low nutrient availability, effectively using 
these as selective pressures. This resulted in a stable population with a total integrated 
cell density 72% higher than its parental line over a 13 day batch culture. This 
confirms that cells can be evolved to a wide range of conditions by simply gradually 
exposing cells to the environment one wishes to adapt them to, effectively mimicking 
natural evolution in vitro. It is this method of exposure to industrially relevant stress 
conditions that helped inform the original aims that were to shape a portion of this 
thesis, with exposure to apoptotic late-culture conditions to select for an improved 
phenotype used as part of this experimental method. 
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1.6.3 Genetic Engineering and Directed Evolution 
 
The methods explored above describe means by which whole organisms can be forced 
to adapt to environmental stresses by taking advantage of ordinary evolutionary 
processes and naturally occurring heterogeneity. However, limitations exist as to the 
complexity of phenotype that can be generated from a parental cell line without more 
drastic external interventions, as well as being limited by the speed at which natural 
mutations can accumulate with no artificial genetic modification.  
This can be overcome by artificially generating diversity in manners such as those 
described previously such as random mutagenesis or sequence shuffling, with the 
methods employed as means to improving a cell lines overall phenotype as opposed to 
a single component and its activity or other such properties. The use of such 
techniques also carry the benefit of being able to produce improved phenotypes 
without the need to fully understand the complex relationships between genotype and 
phenotype, as a good selection method will eventually present such phenotypes 
naturally if an appropriate measure is taken, for example introducing a mutant library 
with a portion of beneficial variations.   
Early attempts involved simpler methods such as radiation (Urlaub et al. 1986) or 
mutagenic chemicals (Urlaub and Chasin 1980) to induce mutations prior to 
screening. Modern techniques have since been developed, providing better means of 
increasing functional diversity or allowing us to target mutations to sequences more 
likely to provide beneficial results. Outlined below are examples of engineering 
methods undertaken to introduce variation in critical genes, pathways and even whole 
genomes as means of improving cellular phenotype. 
 
 
1.6.3.1 Genome shuffling 
As described previously, gene shuffling is a method by which a series of beneficial 
mutations can be randomly recombined in order to uncover complex synergistic 
combinations of mutations that would otherwise prove difficult to discover through 
repeated random or stepwise rational engineering methods. This concept has also been 
applied on a larger genome-wide scale in order to breed new combinations of different 
genotypes (Stephanopoulos 2002). Genomic shuffling methods such as these hold the 
benefit of being able to exploit a combination of advantageous mutations gained after 
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a round of mutagenesis, amplifying the diversity found within a selected population. 
This is in contrast to basic mutation and selection methods, in which the highest 
performing sequence is selected for iterative rounds of mutation, discarding other 
potentially beneficial mutations. In whole cell genomic shuffling, a workflow similar 
to that of gene shuffling is applied; first random mutagenesis is carried out to obtain a 
number of organisms with an improved phenotype. Then, rather than chose one 
specific clone with improved properties for further mutagenesis, a selection of clones 
with beneficial alterations are ‘bred’ together to accelerate the accumulation of 
advantageous mutations.  
 
The key process of whole-genome recombination is based on a protocol known as 
‘protoplast fusion’, previously shown to be successful at combining genetic markers 
in both bacteria (Palleroni 1983) and yeast strains (Wei et al. 2001). Protoplasts are 
cells with their tough outer walls degraded or removed through chemical or enzymatic 
means (such as the use of lysozyme or zymolase enzymes). Cell fusion can then be 
encouraged by incubating in a medium containing compounds such polyethylene 
glycol and CaCl2. Homologous genetic recombination ensures a mix of different 
mutations in each cell, and a mixture of resulting phenotypes which can then be 
selected for using an appropriate environmental pressure. 
 
A number of successful examples of this method have been demonstrated, with strains 
developing phenotypic improvements far quicker than with conventional mutagenesis. 
In one study, bacterial samples with the ability to break down an artificial pesticide 
(PCP) were chemically mutated using nitrosoguanidine (Dai and Copley 2004). 
Colonies with improved PCP degradation and growth rate were shuffled, with 
resulting clones displaying 10 times the activity of the parental cell line. A similar 
study was carried out in Lactobacillus using strains mutated via environmental stress 
as well as nitrosoguanidine. These were successfully shuffled to generate a strain 
resistant to low pH, ultimately able to produce threefold more lactic than its parent 
(Patnaik et al. 2002). The versatility of this method was also highlighted in a genome 
shuffling study carried out in Saccharomyces cerevisiae, with recombinants found to 
possess a number of improved traits such as resistance to elevated heat and ethanol 
concentrations, as well as an increase in ethanol productivity (Shi, Wang and Wang 
2009). 
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1.6.3.2 Pathway engineering 
A more directed use for random engineering methods is found in current attempts to 
combine mutagenesis and rational engineering of cellular pathways to generate 
improved phenotypes. New data is continually generated with regards to genomic and 
transcriptomic profiles of industrially relevant organisms, and a new frontier exists in 
implementing this knowledge for the engineering and fine tuning of particular 
metabolic pathways to improve a cell’s behaviour. 
Engineering methods such as non-discriminate mutagenesis and whole genome 
shuffling techniques outlined previously are powerful at generating phenotypes that 
would be difficult or otherwise impossible with predetermined rational efforts. 
However, it can be theorised that such efforts could be even more effective if 
mutagenesis is targeted to specific genomic loci. These loci can be identified using the 
wealth of knowledge and experience that has been generated previously on the global 
physiology of the cell; data on the genotype/phenotype relationship of thousands of 
genes based on the detailed annotations of genomes, knowledge of gene interactions 
and their involvement in metabolic pathways as well as transcriptomic data that 
details the impact of varying gene expression levels on phenotype. Pathway 
engineering seeks to move away from the relatively crude method of gene 
overexpression or knockdown, but to improve and modify pathways and their 
components in more subtle ways to elicit an improved or novel function. 
 
A typical example of this approach is the rational targeting of key metabolic enzymes 
for improvement via mutagenesis. This can serve to remove rate limiting steps, such 
as the increased synthesis of key metabolites, and allow a pathway to work at an 
optimal level. In one instance, an enzyme known as GSP from well characterised 
carotenoid synthesis pathway in E. coli was found to be the rate limiting step (Wang, 
Oh and Liao 2000). Error prone PCR and staggered extension process PCR (StEP, a 
process similar to gene shuffling) was carried out to generate improved versions of 
this gene, resulting in two fold increases in lycopene product formation in an already 
highly optimised system. Improved activity was also generated in a study examining 
the effects of mutagenesis on the gene aveC, whose activity plays a role in the 
synthesis of the veterinary anti-parasitic drug doramectin (Stutzman-Engwall et al. 
2005). This gene was also known to generate a fraction of undesirable analogue 
compounds, reducing the overall output of target product. In order to reduce this 
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fraction, mutagenesis and shuffling was carried out to generate a mutant with 23 fold 
improved production of its target metabolite.  
Similar approaches have also been undertaken to generate novel enzyme specificity, 
rather than an improvement in existing function. In one study, a microbial enzyme 
(HisA) with a (βα)8-barrel structure resembling a similar enzyme (PRA) was mutated 
and shuffled. This yielded a new enzyme, with modified activity encompassing that of 
both HisA and PRA, allowing it to incorporate separate substrates into the same 
biological pathway (Jürgens et al. 2000). In industrial situations, this dual activity 
could be used potentially to increase the range of substrates available to a cell in 
situations where nutrient depletion may hamper growth or product formation. 
 
A notable technique combining the benefits of pathway mutagenesis with the ability 
to simultaneously alter multiple gene sequences is MAGE (multiplex automated 
genome engineering). In this technique a number of degenerate oligonucleotide pools, 
each with degrees of homology and mismatch to a different corresponding target 
locus, are introduced into the cell. Integration of these mutant alleles is then achieved 
during DNA replication using a DNA binding protein isolated from the bacteriophage 
‘λ-Red’ (Poteete 2001), effectively carrying out random mutagenesis on a number of 
gene sequences at once. This allows for the screening of a vast range of permutations 
of mutant combinations, an attractive prospect compared to the existing power of now 
common mutagenesis and screening techniques. 
A good demonstration of this technique is found in a study examining lycopene 
production in E. coli (Wang et al. 2009). In order to optimise lycopene production, 24 
targets involved in its metabolic pathway were chosen for both tuning of expression 
or inactivation using MAGE mutagenesis. With an average MAGE cycle time of 2-
2.5 hours, up to 15 billion variants were generated after 35 cycles. This resulted in 
strains with up to 5 fold greater lycopene production than parental strains. Factors 
such as oligo sequence diversity and cycle number variation were also demonstrated 
to allow a good degree of control over mutational rates. This technique, if developed 
to operate efficiently in mammalian cells, could prove a powerful tool for the 





1.6.3.3 Global Transcriptional Machinery Engineering 
A successful method known as ‘Global transcription machinery engineering’, or 
gTME, has been successfully employed to generate complex phenotypes in 
prokaryotic cells. It is an applied use of mutagenesis in industrially relevant cell lines, 
however, instead of the objective being improvement in function of a given cellular 
component, gTME seeks to improve the overall fitness of the cell by generating 
functional diversity at the highest levels of a cell’s transcriptional machinery.  
By introducing a variety of subtle perturbations in the mechanisms that control the 
expression of all other genes within the cell via mutant gene library, we can hope to 
fundamentally alter the transcriptomic landscape of the cell and generate a wider 
range of variations in phenotype. This is preferable to the targeting of genes with less 
central roles in cellular metabolism, whose limited range of downstream effects is less 
likely to elicit the phenotypic variation necessary to allow selection of an improved 
phenotype.  
 
A typical example of this approach to cell line engineering is found in a mutagenesis 
experiment carried out in E. coli (Alper, Stephanopoulos 2007). The rpoD gene 
encoding the sigma factor σ70 was first subjected to random mutagenesis and then 
reinserted into cells prior to screening. This gene was chosen due to its role as a key 
transcription factor for a wide range of other genes, with the theory that mutations 
could shift the promoter preference of the native RNA polymerase, thus generating a 
wide range of perturbations in the transcriptional profiles of the transformed cell 
population. Once transformed, cells were subjected to a high concentration of ethanol 
overnight, after which surviving colonies were picked and analysed. The relationship 
of the phenotype to the mutant gene was verified by retransforming into a parental 
host population and testing for tolerance, and then subjected to subsequent rounds of 
mutation and increased ethanol concentrations. 
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A similar study in E. coli documented tolerance to butanol and other alcohols via 
mutation of cellular polymerase (Klein-Marcuschamer et al. 2009).
 
This approach was 
also used successfully in an earlier study by Alper et al. (2006) in S. cerevisiae, a 
eukaryote naturally containing more complex metabolic machinery than bacteria. 
Random mutagenesis was carried out on the SPT15 gene encoding the TATA-Binding 
protein (TBP) in yeast, as well as TAF25, a TBP associated factor. Once again, 
ethanol tolerant strains with improved production characteristics were generated, even 
with starting concentrations of 20% v/v EtOH.  
 
More recent studies have replicated this beneficial effect with the mutagenesis of the 
transcription factor CRP (cAMP receptor protein) by error prone PCR and gene 
shuffling. Implementing a variety of different stresses, strains have been developed 
with phenotypes such as improved osmotolerance to levels of NaCl greater than 1M 
(Zhang et al. 2012a) as well as an increased resistance to the negative effects of 1-
butanol (Zhang et al. 2012b). 
A study examining the effects of sigma factor mutagenesis in Lactobacillus 
plantarum demonstrated the effect of various mutation rates on the levels of diversity 
in phenotype gained and the chances of isolating an improved phenotype using 
resistance to low pH as their example. A number of conclusions were reached 
regarding the effects of gTME-like mutagenesis (Klein-Marcuschamer and 
Stephanopoulos 2008). They found that such alterations to globally acting genes 
increases phenotypic diversity (more effectively than chromosomal mutagenesis), 
improving the chances of selecting for beneficial mutants. Using the wild type gene as 
a control, it was also found that phenotypic divergence increases as higher mutation 
rates are employed. However, as a greater number of misfolded and non-functional 
proteins accumulate, this may ultimately serve to reduce diversity as negative 
phenotypes begin to dominate, suggesting a level of optimisation is necessary. It was 
also concluded that such mutations are pleiotropic, suggesting that such an approach 
is versatile as populations can then be screened under multiple conditions to search for 
benefits with regard to a number of different phenotypic traits. These conclusions 
underline the results from the successful studies highlighted earlier, marking this 
approach as an attractive method of cell line engineering. 
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1.6.3.4 gTME in CHO 
It is the above techniques involving mutation of a key transcriptional regulatory gene 
to enhance directed evolution that we hope to successfully apply in a mammalian cell 
line, namely Chinese Hamster Ovary cells. We have selected the CHO TATA-
Binding protein (TBP) as our target for mutagenesis due to its analogous function in 
mammalian cells to that of the sigma factor and other transcription factors examined 
in previous mutational studies in bacteria and yeast. It holds a wide range of 
interactions with a host of other transcription factors and plays a key role as a subunit 
in Transcription factor IID, a general transcription factor responsible for the 
recruitment of RNA polymerase II to a large portion of genes in mammalian cells 
(Cler et al. 2009), among other transcriptional roles. It is theorised that, in a similar 
fashion to the studies outlined above, one can introduce a wide range of perturbations 
into the transcriptional machinery of a mammalian cell population therefore causing a 
high level of heterogeneity. From there, one can then apply an environmental pressure 
and hopefully select for advantageous mutants that provide a suitably ‘evolved’ 
phenotype, better suited to perform in a bioprocess. 
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1.7 TBP (TATA-binding protein) 
 
 
TATA-binding protein (TBP) is a general transcription factor expressed in 
mammalian cells, and plays an important role in the transcription of virtually all 
expressed genes due to its key function in the initiation of the three RNA polymerases 
(Chasman et al. 1993). It functions as a component of initiation factors for both RNA 
Polymerases I and III. However, it is most commonly associated with its involvement 
in the facilitation of RNA Polymerase II (Pol II), the polymerase involved in the 
expression of protein coding genes. TBP, along with a number of TBP associated 
factors, form a subunit of transcription factor II-D (TFII-D). TFII-D then, along with 
general transcription factors TFII-A, -B, -E, -F and -H form the main structure of the 
Polymerase II pre-initiation complex. This complex, coordinated primarily through 
the direct binding of TBP to a core promoter DNA sequence, allows for the definition 
of the transcriptional start site and the recruitment of RNA polymerase II to an 
expressed gene for its subsequent transcription (Smale and Kadonaga 2003). This 
high level involvement in the transcriptional machinery that makes TBP an attractive 
target for random mutagenesis due to the wide range of potential effects it could have 
on the cells metabolism, and was chosen for this study as the prime candidate 
 
 
1.7.1 TBP Structure  
The TBP orthologue found in CHO consists of 315 amino acids, compared to the 
mouse (316 aa), rat (318 aa) and human (339 aa) sequences. Due to the critical 
transcriptional function of this gene, it is a highly conserved gene in all eukaryotes. 
While many species may contain orthologous sequences shorter than the more highly 
conserved mammalian version, the key TATA binding domain generally remains 
unchanged. 
Structurally, two features are noted as important in the function of this protein, the 
more variable N-terminus sequence and the highly conserved C-terminal binding 
domain.  
The N-terminus’ function is not widely understood, and difficulty in understanding its 
function is compounded by the variety found in different species, with divergence in 
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length and sequence common. A common feature of mammalian TBP N-terminus 
sequences is a polyglutamine domain. Mutation and deletion studies in yeast have 
found it to be important in modulating the effect of TBP, indicating interactions with 
other transcription factors as well as the core of the TBP protein itself. (Friedman et 
al. 2007; Lee and Struhl 2001) 
At the TBP C-terminus is the TATA box binding domain, comprising of ~180 amino 
acids. This portion accounts for the majority of the true functionality of this gene, 
with truncated ‘c-terminal only’ versions functioning sufficiently for cell growth in 
experiments (Cormack et al. 1991). It is also the most highly conserved portion, with 
sequence similarity to the human sequence of over 75% found across almost all 
species (Hampsey 1998). Once correctly folded, this domain takes on a saddle shaped 
structure due to its intramolecular symmetry. Acting as a monomer, this saddle shape 
sits within the minor groove of the target TATA box sequence, unwinding the double 
helix through 120
o 
and compressing the major groove by 80
o
. This sharp bending of 
the DNA template causes a strain on the DNA base pair bonding, allowing separation 




1.7.2 TATA box and other core promoter elements 
The TATA box is a core promoter element found 25-30 bp upstream of the 
transcriptional start site of TATA-containing genes, and the sequence most associated 
with TBP DNA binding capacity. It is this element that assists DNA unwinding due to 
the concentration of thymine-adenine (T-A) bonds found in its sequence. It may be 
impossible to define an exact consensus for all TATA boxes, however a binding site 
analysis identified the sequence 5′-TATATAAG-3′ as preferential for TBP 
recognition (Hampsey 1998). The relaxed specificity of TATA binding is thought not 
to be a result of an exact base order, but is permitted by the relatively weaker 
interactions of T-A bases containing only two hydrogen bonds as well as avoiding the 
C2-NH2 group protruding from G-C bonds, thus facilitating easier unwinding of DNA 
(Juo et al. 1996). 
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TATA dependent promoters are a common feature of transcription initiation and their 
method of action is relatively well understood, however they are by no means the only 
method. For example, in humans the TATA box or TATA-like elements are found in 
approximately 24% of all genes (Yang et al. 2007), ~30% of genes in Drosophila 
(Ohler et al. 2002) and ~19% in yeast (Basehoar, Zanton and Pugh 2004). This means 
that a large portion of genes are regulated by TATA-independent promoter elements. 
Nevertheless, TBP (as a key subunit of the TFIID transcription factor) is still required 
for successful transcription, likely mediated through other DNA-binding transcription 
factors and co-activators (Pugh and Tjian 1991). Other core promoter elements have 
been identified that facilitate the interaction of the pre-initiation complex with DNA. 
Well defined elements with proven function include:  
 The Initiator (Inr) element, a sequence that encompasses the transcriptional 
start site and interacts with TFIID subunits TAFI and TAFII (Chalkley and 
Verrijzer 1999)  
 The downstream promoter element (DPE) found ~30 bp downstream from the 
transcriptional start site that is found to interact with TFIID subunits TAF6 
and TAF9. (Yang et al. 2007).  
 The TFIIB recognition element (BRE). Consisting of 7 nucleotides and 
located immediately upstream of TATA-like elements, it is notable for being 
one of the more well known elements not interacting directly with TFIID. 
 
In these cases, the role of TBP is shifted from direct DNA binding to one facilitating 
the interactions of other transcription factors. Support for this function was described 
in a study in which the DNA binding site of TBP was mutated to remove binding 
activity. Transcription of TATA driven genes was diminished, however genes 
containing the Inr element were largely unaffected. Studies have shown that TATA-
less promoters function via a combination of common elements such as these, as well 
as other more gene specific promoter elements (Anish et al. 2009; Xi et al. 2007) that 
are not as well characterised at this time. From this we can infer that the TFIID 
complex and the subsequent polymerase II holoenzyme is a heterogeneous mix that 
may differ from gene to gene in accordance with the combination of different 
transcription factors and TBP associated factors that interact with cis- regulatory 
elements. 
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Interestingly, there seems to be an apparent difference between genes with and 
without TATA-based transcription in terms of their function. A study of human genes 
using the Gene Ontology database identified that lists of TATA responsive genes 
generally include more highly regulated genes such as those involved in stress 
response or developmental cues, while those responsive to Inr elements and other 
promoters tended to be associated with basic constitutive biological functions such as 
intracellular transport and protein metabolism (Yang et al. 2007). A similar study in 
yeast provided equally interesting results (Basehoar, Zanton, and Pugh 2004). It was 
demonstrated that when subjected to an environmental stress such as a low glucose 
environment or heat shock, genes whose regulation was altered the most to 
accommodate the changes were generally those with TATA boxes. These were also 
genes that tended to have the highest or lowest expression at that time, indicating the 




1.7.3 TBP Interactions 
While TBP is implicated in the direct binding of DNA, such as in the category of 
genes described above, it holds an extensive number of interactions with various other 
proteins. A large category of known and predicted interactions exists, listed below are 
examples of known TBP interactors and the different activities that are mediated by 
TBP 
 
 TFIIA – Subunit of the Pol II holoenzyme, recognises the TBP-DNA interaction 
and is recruited by TBP. Known to stabilise this protein-DNA interaction 
(Weideman et al. 1997) 
 TFIIB – Functions as a molecular bridge between the TFIID complex and RNA 
polymerase II. Can also function in DNA recognition at sites around the TATA 
box, such as the BRE (Tang et al. 1996) 
 TBP associated factors (TAFs) – Along with TBP, TAFs make up the core of 
TFIID. These vary in function, from interaction with other general transcription 
factors and co-activators to modulate transcription, to DNA recognition function as 
noted above (Hampsey 1998) 
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 p53 – A tumour suppressor protein also involved the cell cycle. Interaction with 
TBP serves to repress transcription of a category of genes, acting as a  link between 
TBP activity and the cell cycle (Seto et al. 1992) 
 UBF – Upstream binding factor (UBF) is shown to interact with SL1 (a complex of 
TBP and 3 associated TAFs), ultimately implicating TBP in the machinery 
necessary for rRNA transcription by RNA Pol I (Tuan, Zhai and Comai 1999) 
 TFIIIB – TBP is also a component of Transcription factor IIIB, a protein complex 
involved in the transcription of tRNA and other small RNAs (Hernandez 1993) 
 
While by no means comprehensive, the examples above give an indication of the 
variety of proteins found to interact with TBP, hinting at the potential for a range of 
different downstream perturbations in CHO metabolism that may arise from 
interactions with a mutant TBP library. 
 
 
1.7.4 TBP Mutagenesis 
We can see from the examples above that TBP is a versatile protein, playing a vital 
role at the core of practically all cellular transcriptional mechanisms. By being 
involved in direct DNA binding, as well as recruiting and interacting with a wide 
range of other proteins, we can begin to view this particular transcription factor as an 
attractive candidate for mutagenesis due to the wide range of possible altered 
interactions a mutated TBP molecule may have. 
 
As discussed previously, random mutagenesis of transcription factors and metabolic 
targets involved at a high level in the cells metabolic functions can have a greatly 
beneficial effect on the cell once a suitable screen has been applied to eliminate cells 
with detrimental function. Small alterations in the action of these regulatory 
molecules can have a tremendous knock-on effect to the rest of the cells metabolism. 
With a large enough mutant library to generate a wide number of different 
phenotypes, we can hope to select for clones whose properties allow them to outgrow 
their counterparts in culture, naturally outcompeting less successful mutants and 
gradually filling the environmental space with phenotypically superior cells.
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1.8 Expression Profiling 
 
 
As part of this thesis, a gene expression profiling experiment was carried out on a 
number of successful clones derived from the directed evolution project. Gene 
expression profiling using microarrays offer a means of evaluating the relative 
expression levels of thousands of genes across a number of cell lines and samples. 
This provides a powerful, unbiased tool for evaluating the underlying mechanisms 
that give rise to the various phenotypes that can be found amongst various strains of 
genetically identical cell lines such as CHO. By comparing an interesting cell line 
such as a particularly high producer or apoptotic resistant clone to an appropriate 
control, we can hope to uncover the specific genes that are responsible for these 
phenotypic differences. These genes then become attractive targets for future rational 
engineering of mammalian producer cell lines. 
 
 
1.8.1 Principles of microarray profiling 
A DNA microarray consists of large numbers of short DNA probe sequences, each 
bearing homology to a different gene (for example, the Affymetrix arrays used in the 
course of this experiment contain 25 bp length probes, with at least 11 different 
probes corresponding to each gene to used increase statistical accuracy when 
measuring expression). Reverse transcription is used to generate complimentary 
nucleic acid sequences from an extracted RNA sample. Each sample sequence will 
then bind to its spotted probe and produce a fluorescent signal in a manner 
proportional to the abundance of copies in the original sample. This signal can then be 
compared to equivalent spots on separate chips for experimental and control samples. 
The collection of signals from all these gene spots gives a detailed account of the 
transcriptomic fingerprint of the sample analysed, and can indicate the relative up or 
downregulation of genes when compared to an appropriate control cell line. 
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1.8.2 Expression profiling in CHO  
This technique has been standard for some years, providing a high throughput means 
of assessing large numbers of samples for transcriptomic profiles. Early iterations of 
this technology were costly, and arrays allowed for detection of tens of hundreds of 
transcripts (Shalon, Smith and Brown 1996). Spot selection would generally be 
hypothesis driven in order to target genes relevant to particular pathways or 
applications such as toxicology or cancer screens (DeRisi et al. 1996). Modern chips 
allow for the spotting of tens of thousands of probes spanning entire genomes. An 
example of a current high density chip, the Affymetrix Human Genome U133+ 2.0, 
provides analysis of 47,000 individual transcripts. This is based on extensive 
sequencing, annotation and understanding of the human genome and its expressed 
transcripts. Unfortunately, knowledge such as this relating to CHO cells has been 
unavailable to the public for many years, possibly due to industrial competition and an 
unwillingness to share proprietary data with competitors due to CHOs prolific use in 
industrial biopharma production. Homology with related species such as mouse and 
rat allowed for transcriptomic work to progress despite a lack of CHO specific data, 
however analysis demonstrated that only subsets of cross species probes gave a 
consistently reliable result, with many of the 25 bp probes investigated displaying a 
poorer ability to accurately quantify differential expression than CHO specific probes 
based on known sequences (Yee et al. 2008). 
 
Rapid progress in generating CHO specific data has been made since the foundation 
of the Consortium on Chinese Hamster Ovary Cell Genomics in 2006 (. Recent efforts 
have led to the publication of the CHO genome (Xu et al. 2011), an important 
milestone and invaluable resource for large scale ‘-omic’ experiments such as 
proteomic or transcriptomic microarray experiments. Sequencing, analysis and 
annotation of thousands of CHO expressed sequence tags (ESTs) has allowed for the 
current generation of accurate, CHO-specific microarrays capable of quantifying a 
wide range of thousands of expressed genes (Kantardjieff et al. 2009). 
This new generation of CHO-specific microarrays has been put to use by a number of 




1.8.3 Possibilities for experimental design 
Traditionally, experiments involve comparison of a given cell line possessing an 
advantageous trait or one placed under a specific treatment to a relevant control. A 
typical example carried out by Doolan et al. (2012) involved comparing cell lines with 
sustained productivity to those whose productivity is shown to drop after day 7 of 
culture. This experimental design and cell lines chosen allowed for a hypothesis based 
on comparison of cell lines differing in a specific phenotypic trait, thus allowing 
conclusions to be drawn relating these differentially regulated gene targets to that 
particular phenotypic trait. A similar approach was taken in a study investigating 
clones of fast and slow growth rates (Doolan et al. 2010). In this instance a proteomic 
analysis of all differentially expressed proteins also carried out in parallel was cross 
referenced with the lists of differentially regulated genes generated from micro array 
experimental data. This study identified 21 genes common to both approaches, strong 
contenders for further functional validation and possible engineering experiments. 
This approach addresses one of the drawbacks to transcriptomic profiling, in so far as 
transcription levels do not always correspond to expressed functional protein levels. 
By eliminating genes that are not differentially expressed at the protein level, we can 
disregard genes that may not have a true impact on cell metabolism due to any of the 
post translational regulatory processes (such as RNAi) that prevent mRNA from 
becoming a functional protein and truly impacting a cells metabolism.  
Reactions to environmental pressures or treatments in identical cells can also be 
quantified on the transcriptomic level. For example, CHO cells undergoing sodium 
butyrate (NaBu) treatment and temperature shift were found to improve in 
productivity from 40pg/cell/day to over 100pg/cell/day (Kantardjieff et al. 2010). The 
causes of this effect were assessed, among other techniques, by transcriptional 
profiling. By evaluating the differential expression of a wide range of genes, a number 
of different functional classes were identified as important to the improved protein 
production and secretory abilities such as genes relating to cell cycle and the golgi 
apparatus. 
 
Highlighting the advantages of larger data sets and the advantages of increased 
statistical confidence, a broader profiling experiment was carried out in contrast to the 
narrower trait/treatment-specific studies outlined above. It incorporated 295 
microarrays from over a hundred individual clones, each with a range of relevant 
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characteristics analyzed including growth, viability, specific productivity and waste 
secretion (Clarke et al. 2011). Coupling this large data set with suitable statistical 
analysis, transcriptional patterns for groups of genes (known as modules) rather than 
single genes could be discovered. These modules were found to maintain consistent 
correlation of expression across multiple cell lines and environmental variables, with 
subsequent analysis of these gene groups providing us with a global, holistic overview 
of the CHO metabolism and how groups of genes work in tandem to generate a 
phenotype. This ‘guilt by association’ approach also allows us to predict the function 
of novel genes, by assigning them to functional classes based on their similarly co-
expressed partners, an approach that has also been shown to work successfully in 
yeast (Hughes et al. 2000). Knowledge of these gene networks and functional classes 
provide us with a better opportunity to rationally modify the processes within 
industrially relevant cells. By targeting classes of genes and the regulatory switches 
that control them, we may begin to improve upon the older, single gene oriented 
engineering approaches.  
 
1.8.4 Potential disadvantages 
Of course, despite the power of this technique, there are inherit weaknesses and 
drawbacks to this methodology. Statistical confidence in results values is limited by 
sample number, which may limit the numbers of genes that can be confidently 
identified by smaller scale experiments when an appropriate threshold for fold change 
expression is set. Due to the inherent noise of data generated in such experiments, 
higher statistical limits must be set. This might exclude genes from analysis that have 
profound impacts despite small changes in their expression levels and, conversely, 
highlight genes with little effect despite large fold changes in expression. Also, as 
discussed previously, the effects of some genes may be regulated at the protein level 
rather than the RNA level. This makes the comprehensive proteomic/transcriptomic 
approach a more costly but highly accurate depiction of the cell at a given point in 
time, with both techniques complementing each other by covering the potential 
drawbacks of each. 
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1.8.5 TBP Mutant Profiling 
For the purposes of this thesis, expression profiling was used to investigate the genetic 
basis for the differences in phenotype witnessed in the directed evolution experiment. 
As a number of phenotypically advantageous clones were isolated, we wanted to 
dissect the transcriptomes of these clones and identify gene activity potentially 
responsible for improvements in growth and viability. Samples were selected to give a 
broad indication of the effects of the various stages of the experiment, and how they 
might interact in a synergistic manner to generate an advantageous phenotype. These 
included examining the effects of TBP overexpression and the effects of the stress 
procedure on transfected and control cells. High performing clones were also included 
to gain an insight into their transcriptomic profile, hopefully elucidating some of the 
genetic bases responsible for their advantageous phenotypes and provide us with 











Materials and Methods  
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2.1  Routine Management of cell lines 
 
2.1.1 Safety precautions 
 
All routine cell culture work was carried out in a class II down flow re-circulating 
laminar flow cabinet (Nuiaire Biological Cabinet), while any work involving toxic 
drug compounds was carried out in a cytoguard safety cabinet (Gelman). Strict aseptic 
techniques were adhered to at all times (see NICB SOP No. 000-01). Laminar flow 
cabinets were swabbed with 70% industrial methylated spirits (IMS) prior to and 
following all work, as well as all equipment used during experiments. Only one cell 
line was worked with at a time in a cabinet, with 15 minutes clearance time given 
between work with individual cell lines. Each week cell culture cabinets and any 
incubators used were cleaned with industrial detergents (Virkon) and IMS. A separate 




2.1.2  Subculture of adherent cell lines 
 




 tissue culture flasks and typically 
fed every 2-3 days. These were maintained at an incubation temperature of 37°C, with 
5% atmospheric CO2. During subculturing or harvesting of adherent cell lines for 
experimentation, cells were removed from their vessels by enzymatic detachment. 
 
Cell culture flasks were emptied of waste medium and rinsed with pre-warmed (37°C) 
trypsin/EDTA solution (0.25% trypsin (Gibco, cat. 15090), 0.01% EDTA (Sigma, cat. 
E4884) solution in PBS) in order to remove any naturally occurring trypsin inhibitors 





 flask) and then incubated at 37°C until cells were seen to have detached 
fully (5-10 mins). The trypsin was then inactivated by the addition of growth medium 
(i.e. containing 5% serum). This solution was then transferred to a 20ml sterile 
container (Greiner, cat. 201151) and centrifuged at 1000 rpm (170 x g) for 5 mins. 
The resulting cell pellet was then resuspended in fresh growth medium and counted 
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2.1.3 Subculture of suspension cells 
 
Cell lines adapted to suspension growth were generally grown in either sterile 
disposable 250 ml flasks (Corning, cat. 431144) with a 50ml working media volume 
or a disposable 50 ml spin-tube (Sartorius, cat. DF-050MB-SSH) with a 5ml working 
media volume. These conditions were used as they closely mimic the responses of 
large scale cultures on a smaller magnitude that is manageable in the lab.  
 
First, a 100μl was removed from the flask or tube and counted using trypan blue (see 
2.1.4). The cell suspension was then removed to a 20ml sterile container (Greiner, cat. 
201151) and centrifuged at 1000 rpm (170 x g) for 5 mins. The resulting pellet was 
resuspended in fresh warm growth medium, and an appropriate volume used to seed 
fresh flasks/tubes for further subculture or to seed for planned experiments. 
 
 
2.1.4 Cell counting 
 
Cell counting and viability estimations were carried out using a trypan blue dye 
exclusion technique.  
First a sample was taken from a cell suspension and mixed 1:1 with trypan blue (i.e. 
100μl cell sample mixed with 100μl trypan blue, 0.2% solution in PBS). This was 
incubated for 3 mins at room temperature, after which a sample was applied to a 
haemocytometer over which a glass coverslip has been placed. Cells in the outer four 
corners of the chamber were then counted microscopically using Nikon TS100 
microscope and 10x objective lens. Non-viable cells were stained blue, while viable 
cells remained white. An average number of viable cells in each corner was calculated 
with the dilution factor taken into account and multiplied by 10
4
 to determine the cell 
per ml concentration in the original sample. The volume occupied by the sample 
chamber is 0.1cm x 0.1cm x 0.01cm i.e. 0.0001cm
3
, therefore average cell number 
multiplied by 10
4
 is equivalent to cells per ml. 
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2.1.5 Cell freezing 
 
To allow for long term storage of cell stocks, cells were cryo-preserved in liquid 
nitrogen at temperatures below -180°C, allowing the indefinite storage and 
preservation of cell samples. Dimethyl sulphoxide (DMSO) (Sigma, cat. D8418) was 
used as a cryoprotectant. 
1. Cells to be frozen down were grown until the exponential phase, harvested and 
counted in single cell suspension as per 2.1.3. 
2. Cells were then pelleted by centrifugation at 1000 rpm (170 x g) for 5 mins and 
resuspended in medium to give a concentration of at least 5 x 10
6
 cells/ml. 
3. An equal volume of 2X concentrated freezing medium was then added 
dropwise. Due to the toxicity of the DMSO used this is added slowly to prevent 
shock to the cells, allowing them to adapt to its presence. Two distinct freezing 
media were used; one for cells cultured in the presence of serum (DMSO-10%, 
serum-20%, serum free medium-70%) and one for cells cultured in serum free 
medium (DMSO-15%, serum-40%, serum free medium-45%) 
4. This suspension, containing minimum 2.5 x 106 in freezing medium, was 
aliquoted into cryovials (Greiner, cat. 12279) and quickly placed into a freezer at 
-20°C for 1-2 hours. This was then transferred to a freezer at -80°C overnight 
before finally being placed into storage in liquid nitrogen. 
 
 
2.1.6 Cell thawing 
 
1. Prior to the removal of a cryovial from liquid nitrogen storage for thawing, a 
sterile universal tube containing pre-warmed (37°C) growth medium was 
prepared for the rapid transfer and dilution of thawed cells to reduce their 
exposure to the toxic DMSO present in the freeze medium. 
2. Once removed from liquid nitrogen the cryovial was thawed in warm water. 
3. Once slightly thawed the contents of the cryovial was transferred to the pre-
warmed medium. 
4. This suspension was centrifuged at 1000 rpm (170 x g) for 5 mins. The 
supernatant was then removed and the pellet re-suspended in fresh warm growth 
medium. 
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5. This thawed cell suspension was then placed in an appropriate flask (i.e. 75cm2 
tissue culture flask for attached growth cells or a 5ml spin tube for suspension 
growth) 
6. After 24 hours, the medium was then replaced with fresh growth medium to 
remove any potential traces of DMSO and the cells subcultured if necessary. 
 
 
2.1.7 Sterility checks 
 
Sterility checks were routinely carried out on all media, supplements (serum etc.) and 
trypsin used for cell culture (see NICB SOP 002-01). A 1ml sample of the material 
being examined was inoculated into 9mls of both tryptone soya broth (TSB) and 
thioglycollate broth (Thio) and incubated at 37°C for 7 days. Both samples were then 
checked for turbidity and change in colour, indicating contamination. TSB supports 
the growth of yeasts and aerobes, while Thio mainly allows for the growth of both 
aerobic and anaerobic bacteria. 
 
 
2.1.8 Mycoplasma analysis 
 
Routine Mycoplasma examinations were carried out on all cell lines used in this study 










Ultrapure water was used in the preparation of all solutions used for cell culture. Pre-
treatment, involving activated carbon, pre-filtration and anti-scaling was first carried 
out. This water was then purified by a reverse osmosis system (Millipore Milli-RO 10 
Plus, Elgastat UHP), which is low in organic salts, organic matter, colloids and 





All solutions for use in cell culture and maintenance were prepared and stored in 
sterile glass bottles. Bottles, lids ad all other glassware used for any cell related work 
were prepared as follows: all glassware and lids were soaked in a 2% (v/v) solution of 
RBS-25 (AGB scientific, cat. 83460) for at least 1 hour. This acts as a deproteinising 
agent, which removes proteinous materials from the bottles. Glassware was scrubbed 
and rinsed several times in tap water; the bottles were then washed by machine using 
Neodisher detergent, an organic, phosphate-based acid detergent. The bottles were 






Water, glassware and all thermolabile solutions were sterilised by autoclaving at 
121°C for 20 mins under 15 p.s.i. pressure. Thermolabile solutions were filtered 
through a 0.22µm sterile filter (Millipore, cat. SL6V033RB), with low protein binding 




2.3 DNA Manipulation and analysis 
 
2.3.1 Production of unique plasmid DNA samples 
 
In order to generate the unique plasmids necessary for the subsequent experiments 
detailed in this study, plasmids containing target DNA sequences were generated by 
digesting the target DNA sequence and plasmid with restriction enzymes (see 2.3.5) 
to create the ‘sticky’ ends necessary for a standard ligation reaction (see 2.3.9). These 
target sequences were either created via polymerase chain reaction (PCR) using a 
genomic DNA template (see 2.3.7) or removed by restriction digestion from another 
plasmid containing the fragment and purified by means of gel electrophoresis (see 
2.3.8). 
Once successfully cloned and verified using restriction digest analysis or PCR 
screening (see 2.3.10), plasmid samples were then transformed into bacteria cells 




2.3.2 Transformation of bacterial cells 
 
1. 1 vial (50μl) of competent cells (DH5, Invitrogen, cat. 18263-012) was 
removed from storage at -80°C and thawed on ice. Transformation tubes Falcon, 
cat. 352059) were also chilled on ice during this time. 
2. Once thawed the bacteria was added to a transformation tube along with 2.5μl 
(5% total volume) of plasmid sample or ligation reaction mixture. 
3. This mixture was left on ice for 10-15 mins, heat shocked in a 42°C waterbath 
for 30 seconds then placed back on ice for a further 1.5 mins. 
4. 200μl of SOC medium (Invitrogen, cat. 15544) was then added, and this 
mixture incubated at 37°C for 1 hour at 200 rpm agitation speed. 
5. The sample was then transferred to a fresh 1.5ml tube (Costar, cat. 3620) and 
spun at 3000 rpm in a benchtop microfuge (Hettich Mikro 120) for 2 mins to 
pellet the bacterial cells. 
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6. 160μl of the supernatant was removed and the pellet resuspended in the 
remaining 100μl SOC. This was then spread on LB agar plates (10g Tryptone 
(Sigma, cat. T7293), 5g Yeast Extract (Oxoid, cat. LP0021), 10g NaCl (Sigma, 
cat. S7653), 20g agar select (Sigma, cat. A5054), to 1L with UHP water, 
autoclaved before use) containing Ampicillin (100ng/ml working concentration) 
and incubated overnight at 37°C. 
 
 
2.3.3 Small scale preparation of plasmid DNA (Miniprep) 
 
This technique was employed in order to generate small amounts (10-30g) of 
plasmid DNA for use in restriction digest and ligation reactions. 
 
1. After successful generation of transformed bacterial colonies (see 2.3.2), a single 
colony was picked and grown overnight at 37°C, 130 rpm in a 10ml aliquot of LB 
broth (10g Tryptone (Sigma, cat. T7293), 5g Yeast Extract (Oxoid, cat. LP0021), 
10g NaCl (Sigma, cat. S7653), to 1L with UHP water, autoclaved before use) 
containing Ampicillin (100ng/ml working concentration). 
2. This culture was then processed using a Qiagen QIAprep Spin Miniprep kit (Cat. 
No. 27106, see manufacturers protocol for details), with a final DNA elution step 
carried out using 50μl of TE buffer. 
3. The concentration of this DNA prep was determined using a NanoDrop 1000 
spectrophotometer. This could then be used in subsequent DNA manipulation 






2.3.4 Large scale preparation of plasmid DNA (Maxiprep) 
 
This technique was employed in order to generate large amounts (<200μg) of plasmid 
DNA for use in restriction digest and ligation reactions. 
 
1. After successful generation of transformed bacterial colonies (see 2.3.2), a single 
colony was picked and grown at 37°C for 7-8 hours, 130 rpm in a 10ml aliquot of 
LB broth (10g Tryptone (Sigma, cat. T7293), 5g Yeast Extract (Oxoid, cat. 
LP0021), 10g NaCl (Sigma, cat. S7653), to 1L with UHP water, autoclaved before 
use) containing Ampicillin (100ng/ml working concentration) to generate a starter 
culture. 
2. This starter culture was then added to a further 250ml of LB broth containing 
Ampicillin and incubated overnight at 37°C, 130 rpm. 
3. After incubation this culture was then spun at 6000g for 15 mins, 4°C, and the 
supernatant discarded. 
4. The resulting cell pellet was then processed using a Qiagen Plasmid Maxi kit (Cat. 
No. 12362, see manufacturers protocol for details), with a final DNA resuspension 
step carried out using 500μl of TE buffer. 
5. The concentration of this DNA prep was determined using a NanoDrop 1000 
spectrophotometer. This could then be used in subsequent DNA manipulation 
reactions or stored at -20°C. 
 
 
2.3.5 Restriction digest of DNA samples 
 
Restriction digest is a key technique involved in the manipulation of DNA sequences. 
Once plasmid DNA or PCR sequences have been generated, restriction digest can be 
employed to linearise circular DNA, generate “sticky ends” for cloning reactions or 
confirm sequences and sequence orientation within plasmids based on key restriction 
sites within. 
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NEB Buffer (10x) 2μl 
Bovine Serum Albumin 0.2μl 
Restriction Enzyme* 1μl (5%) 
H20 to 20μl 
Total volume 20μl 
 
* If multiple enzymes are used, they are kept below a final concentration of 5% 
 
 
This reaction was incubated at 37°C for at least 3-4 hours to ensure complete 
digestion. 
 
The volumes of these reagents could be up-scaled in proportion to generate volumes 
larger than 20μl of digested DNA. This was sometimes necessary to create large 
amounts of insert DNA for ligation reactions (see 2.3.9) 
Also, multiple restriction enzymes could be used in single reactions provided a 
suitable NEB buffer was available, while keeping the volume of enzyme below 5% of 




2.3.6 Alkaline Phosphatase treatment of digested plasmid samples 
 
To prevent the re-circularisation of digested plasmid backbone samples and to 
improve the efficiency of ligation reactions, purified backbone samples were treated 
with alkaline phosphatase (AP) 
 
1. After digestion, the reaction was run on a low melting agarose gel (Sigma, A9414) 
and excised using a clean scalpel. 
2. This gel fragment was purified using a Gel Extraction Kit (Qiagen, cat. 20021) 
and eluted in 20μl TE buffer. 
3. To this solution 2.2μl of phosphatase buffer was added, along with 0.8μl (16U) 
alkaline phosphatase (Roche, cat. 11097075001) and incubated for 1hr at 37°C. 
4. To remove any traces of enzyme that may damage DNA or inhibit further 
reactions, this solution was then purified using a MinElute PCR Purification Kit 
(Qiagen, cat. 28006). 
 
This purified and AP treated plasmid DNA could then used in subsequent ligation 





2.3.7 Polymerase Chain Reaction to generate fragments for cloning 
 
In order to construct plasmids for future use in cell engineering or virus propagation, 
PCR was carried out on a suitable template to generate fragments that we’re 
subsequently used for ligation reactions. For this purpose, a high fidelity enzyme 
(KOD Hi-fi) was used to minimise possible mutations or errors during amplification. 
 




















Total Volume 50 
 
1 - KOD Hi-fi Polymerase (Merck, cat. 71085) 
2 - Primer sets designed to generate relevant fragments, usually incorporating 
restriction sites for generation of ‘sticky’ ends prior to ligation 
3 - Template DNA incorporating target sequence (e.g. plasmid, genomic, cDNA etc.) 
 
These reactions were generally run in a 0.2ml thin walled PCR tube in a thermocycler 
(Thermo Scientific Hybaid Px2) under the following conditions; 
 
Stage Temperature Time Cycle Number 
Initial Denaturation 95°C 2 mins  
Denaturation 94°C 30 secs 
25 cycles Annealing (primer specific) 30 secs 
Elongation 72°C 1 min/kb 
Final elongation 72°C 10 mins  
 
 
A 5μl sample of each reaction was then run on an agarose gel to confirm the presence 
of the target band, and determine if any nonspecific contaminating bands are present.
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2.3.8 Analysis of DNA samples using agarose gel electrophoresis 
 
Agarose gel electrophoresis was used to visualise and isolate specific fragments of 
any DNA sequences used in this study. 
 
1. First, a stock of 50x TAE buffer was created (242g Tris Base, 57.1ml Glacial 
Acetic Acid, 100ml 0.5M pH8.0 EDTA, to 1L with UHP water). This was diluted 
to 1x stock with UHP water and Agarose (Sigma, cat. A9539) added to a final 
concentration of 1% w/v. This percentage was chosen to visualise most fragments, 
however this percentage could be increased of decreased to achieve better 
resolution on smaller or larger fragments respectively. 
2. This solution was then heated in a microwave until molten, Ethidium Bromide 
was then added to a final concentration of 0.5 µg/ml and poured into the 
appropriate mould with a comb to allow for sample wells. 
3. Once solidified the gel was placed in an electrophoresis tank filled with 1x TAE 
buffer. DNA samples, mixed with a suitable loading buffer, were then added to 
the wells and current applied to the gel. 90-100V was generally used for 
visualisation; however greater resolution could be achieved at a lower voltage 
applied for a longer period. 
4. A reference DNA ladder sample was also generally run alongside samples to 
measure visualised band sizes. 





2.3.9 Ligation of DNA samples 
 
In order to insert target DNA sequences into a plasmid, both samples (insert and 
plasmid vector) were first restriction digested to generate ‘sticky’ ends (see 2.3.5) and 
treated with alkaline phosphatase (see 2.3.6). These samples could then be ligated 
using a T4 DNA ligase enzyme (see 2.3.9). 
 
1. The default vector:insert ratio chosen was 1:10. First, the correct amount of 




2. A standard ligation reaction was then set up on ice as detailed below, with 
control reactions used to estimate the efficiency of insertions in comparison to 
plasmid self ligation. 
 
 1:10 Insert Ratio Control (No insert) Control (No ligase) 
Ligase Buffer (10x) 1.5 1.5 1.5 
Plasmid Backbone 1 1 1 
Insert DNA variable* 0 0 
Ligase Enzyme 0.5 0.5 0 
H2O to 15l to 15l to 15l 
Total Volume 15 15 15 
 
*Note: The insert DNA volume was variable depending on the sample concentration. 
Volume used was sufficient in each case for a minimum of 1:10 vector:insert ratio. 
 
 
3. This reaction mixture was incubated at 14°C overnight. 
4. The enzyme was inactivated by incubation for 10 mins at 65°C. This mixture was 
then used for bacterial transformation (see 2.3.2). 
                        Insert length (bp) 




2.3.10 Screening of cloned plasmid samples using PCR 
 
After ligation and transformation, screening of colonies was necessary to ensure the 
insertion of the correct sequence into the plasmid backbone before plasmid 
preparation. This was achieved by running a high throughput PCR screen on 
individual colonies, using a small culture of each colony as a source of DNA. 
 
1. After transformation of a ligation mixture (see 2.3.2), colonies were picked using 
a sterile pipette tip into 100μl of LB medium in a 96 well plate with Ampicillin 
and grown overnight at 37°C. 
2. A standard PCR reaction was set up on ice as below. A master mix was created 
with excess volume to allow for pipetting errors. 
 







Reverse Primer (10nM) 
2 
0.5 
Bacterial culture 1 
Total Volume 25 
 
1 – Platinum supermix (Invitrogen, cat. 11306) 
2 – Primers selected to amplify any selected region within the ligated insert sequence 
that would not be otherwise present in the original plasmid backbone. 
 
 
This reaction was performed under standard PCR conditions in a 96 well PCR plate; 
 
Stage Temperature Time Cycle Number 
Initial Denaturation 95°C 2 mins 1 cycle 
Denaturation 94°C 30 secs 
20 cycles Annealing (primer specific) 30 secs 
Elongation 72°C 45 secs 
Final elongation 72°C 10 mins 1 cycle 
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3. A 10μl sample of each PCR reaction was then run on a 1% gel (see 2.3.8). A band 
of the expected size would indicate a positive result, i.e. a plasmid that has been 
successfully ligated with the target insert. 
4. A sample from the 100μl bacterial culture could then be used to generate a 5ml 
starter culture when incubated at 37°C, which in turn could be used for small scale 
or large scale plasmid preparation (see 2.3.3/2.3.4) 
 
 
2.3.11 cDNA generation from RNA for qRT-PCR 
 
The protocol outlined below allows for the isolation of RNA and generation of a 
cDNA library. This can then be used in a subsequent qRT-PCR to measure the 
relative expression of a target gene between cell samples. 
 
1. A flask of cells for each cell line to be analysed via qRT-PCR was cultured til 50-
60% confluence, trypsinised and pelleted. This pellet was then processed using the 
RNeasy Mini kit (QIAgen, cat. 74106) and finally eluted in 40μl of H2O. 
2. A standard RT reaction was then set up as below on ice (Applied Biosystems, cat. 
4387406), with an RT negative control reaction also run for each sample. 
 
 
Component Volume (l) 
 RT+ RT- 
2x RT Buffer 10 10 
20x RT Enzyme Mix
 
1 - 
Nuclease-free H20 - 1 
RNA sample 9 9 






The following thermocycler conditions were programmed for this reaction: 
 
Stage Temperature Time 
1 37°C 60 mins 
2 95°C 5 mins 
3 (storage) 4°C - 
 
 
3. This reaction was then diluted 1:10 with nuclease free H2O and stored at -20°C or 




2.3.12 Quantitative PCR (qPCR) 
 
In order to determine whether a gene is currently over expressed or knocked down in 
a cell line, as well as comparing its relative expression between clones, qPCR is used 
to measure this expression level.  
 
These levels are measured by first isolating the RNA content of the cell, then 
generating a corresponding cDNA library via reverse transcription. qPCR is then 
carried out on this cDNA sample. The differences in expression between cell lines can 
be determined using the expression of a known housekeeping gene as a control, while 
a standard curve of known concentration can be used to measure sequence copy 
number 
 
1. The qPCR reaction detailed below was set up on ice in a MicroAmp optical 96-
well plate (Applied Biosystems, cat. 4346906) using a qPCR mastermix 
containing SYBR green to quantitate the levels of double stranded DNA generated 
(Fast SYBR Green Master Mix, Applied Biosystems, cat 4385612). The table 
outlines the components for this reaction. Samples were run in triplicate, including 
the RT+ and RT- samples.  
This complete sample set was also run using a second set of control primers based 
on a housekeeping gene know to have a relatively constant expression level. 
 
 
Component Volume (l) 













2. This reaction is then carried out on an Applied Biosystems 7500 Fast Real-Time 
PCR System under the following cycling conditions; 
 
Stage Temperature Time Cycle Number 
Enzyme Activation 95°C 20 secs 1 cycle 
Denaturation 95°C 3 secs 
40 cycles 
Annealing/Elongation 60°C 30 secs 
 
 
3. Results are then analysed using Applied Biosystems 7500 software.  
 
If gene expression is measured in comparison to an internal housekeeping gene (qRT-
PCR), the “2(-ΔΔCt)” method is used to calculate relative expression, while standard 
curves are used to determine absolute copy number. 
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2.4 Virus Generation and Purification 
 
2.4.1 Propagation and transfection of HEK-293 cells 
 
For this study a helper free adeno-associated viral system was utilised (Agilent 
Technologies, cat. 240071). This system consists of a number of components 
including: 
 HEK-293 cells used to generate the viral particles 
 Plasmids (pRC and pHelper) coding the genes necessary for viral production 
 pAAV plasmid modified to carry sequences both used for viral packaging as 
well as the homologous targeting cassettes used in this study 
 A pAAV-GFP control plasmid was also used in each transfection to calculate 
transfection and transduction efficiencies. 
 
HEK cells were used in this study as means of generating adeno-associated viruses 
(AAV), which were themselves used in all subsequent gene knockout experiments. 
This protocol describes the method used to grow and transfect HEK-293 cells with the 




1. The HEK-293 cells used in this study were cultured in DMEM medium with 10% 
FCS in T-75 flasks, with minimal passaging between revival and transfection to 
ensure no change in phenotype. 
2. 24 hours before transfection cells were trypsinised and plated on 96mm tissue 
culture dishes at a density of 2 x 10
6
 cells per plate. For high concentration virus 
preparations (for example knockout virus constructs) 10 plates were seeded; 9 
plates for virus generation and 1 plate to act as a transfection control. 
3. Immediately prior to transfection the medium was replaced with 8ml of fresh 
DMEM (10% FCS) per plate. 
4. DNA solutions were made by mixing 10μg of each plasmid (pHelper, pRC and 
pAAV) in a 1.5ml tube (including 1 mixture containing pAAV-GFP for a control 
transfection). 
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5. 30μl FuGene 6 transfection reagent (Roche, cat. 11 814 443 001) was then mixed 
with 500μl OptiMEM (Invitrogen, cat. 11058-021) medium for each plate to be 
transfected. This solution was left to sit at room temperature for 5 mins. 
6. Each DNA mix was then added to a FuGene/OptiMEM solution and mixed well. 
This solution was left to set at room temperature for 20 mins. 
7. Each DNA/FuGene/OptiMEM mixture was then slowly added to each plate of 
HEK-293 cells dropwise. These plates were then returned to the incubator under 
normal growing conditions for 72 hours until harvesting (37°C, 5% CO2). 
8. After 48 hours, the AAV-GFP control plate was also viewed under a fluorescent 




2.4.2 Harvest and purification of viral particles 
 
After successful transfection, HEK cells were lysed using a freeze/thaw method and 
purified using a commercial viral purification kit (ViraBind AAV Purification kit, 
Cell Biolabs, cat. VPK-141) 
 
1. Plates containing successfully transfected virus producing HEK-293 cells were 
first scraped using a sterile scraper and the cells and supernatant collected. 
2. For multiple plates (such as the 9 generated for the targeting construct viruses), 
these were combined and centrifuged at 1500 rpm (380 x g) and the resulting cell 
pellets resuspended in 25ml of supernatant (a prerequisite volume for the 
purification kit used in this experiment) 
3. This cell suspension was then subjected to 4 rounds of freeze thaw lysis. This was 
achieved by submerging the tubes in liquid nitrogen and thawing in a 37°C 
waterbath. 
4. After lysis, this suspension was then spun at 10,0000 x g for 10 mins and the 
supernatant containing viral particles was removed and stored at -20°C prior to 
purification (single GFP virus plates were not subject to purification but used neat 
to estimate transduction efficiency). 
5. Supernatants were subsequently purified as per the protocol from the Virabind 
purification kit. This resulted in a final volume of ~130μl of purified virus. 
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2.4.3 Transduction of CHO-K1 cells 
 
Once purified, AAV viral particles were applied to CHO-K1 cells to allow for 
delivery of the targeting cassette sequence into the nucleus of the cell.  
 
1. CHO-K1 cells in attached culture were trypsinised and seeded in 6 well plate at a 
density of 5 x 10
4
 cell per well with 2ml of fresh medium. These were incubated 
for 24 hours before proceeding. (Assuming a doubling time of roughly 24 hours, 
this would generate 1 x 10
5
 cells per well overnight.) 
2. After 24 hours, the old medium was replaced with fresh medium. In one well, the 
entire stock of purified virus was added (~130μl). To other wells 200μl of control 
GFP virus was added in order to confirm the presence of viable viral particles and 
estimate transduction efficiency. 
3. After 48 hours cells transduced with targeting viruses were trypsinised and seeded 
into a T-75 flask. Appropriate drug selection was also applied to remove the 
background of untransduced cells. 
4. AAV-GFP transduced cells were also trypsinised and removed for analysis of 
fluorescent cell numbers via flow cytometry. 
 
 
2.4.4 Single cell cloning 
 
The protocol detailed below was used to isolate single cell clones from a mixed cell 
population. 
 
1. A T-75 flask of cells was cultured till 50-60% confluence. These were initially re-
fed with fresh warm medium 3-4 hours prior to single cell cloning. 
2. The flask of cells was then trypsinised, and resuspended in 5mls of medium. This 
was pipetted up and down to ensure a single cell suspension. 
3. Another 15ml was added to this suspension and the solution mixed thoroughly. At 
this point a number of separate samples (at least 3) were taken for cell counting. 
4. Once an accurate count had been obtained, serial dilutions were then carried out to 
bring the concentration to a target of 5 cells/ml. 
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For example, an initial dilution in 20mls of medium would bring the concentration 
to 2 x 10
4
 cells/ml. Further dilution steps ranging from 1:50 to 1:100 fold dilutions 
would then bring the concentration to its target of 5 cells/ml, with care taken to 
ensure homogenous mixing in between. 
5. The final dilution step was carried out in fresh medium containing 15% 
conditioned medium (conditioned for 48-72 hours on CHO-K1 cells) to increase 
the survival rate of single cells in isolated wells. 
6. 100μl of this suspension was then added to each well of a 96 well plate. This gives 
a theoretical rate of 0.5 cells per well; high enough to ensure a practical number of 
clones per plate while reducing the number of wells with multiple cells. 
7. Plates of clones were then monitored for growth over the next 8-10 days and 
single cell colonies identified (disregarding wells containing more than one 
colony), re-feeding with fresh medium as necessary. 
 
Once cells had reached near confluence, selected single cell clones were then 
trypsinised and split in duplicate. One plate was then used to isolate genomic DNA 
for PCR screening (see 2.4.6), while its corresponding identical plate was frozen 
down for future revival. 
 
 
2.4.5 Cell freezing (96 well plate format) 
 
Once single cell clones had been isolated, a sample of these cells was usually frozen 
down to enable further study or characterisation to be carried out on any DNA or 
RNA extracted from these cells. The protocol below was used to freeze large numbers 
of these clones in a 96 well format, which were then stored at -80°C. 
 
1. Plates were initially fed with fresh medium a number of hours prior to freezing. 
2. All medium was then removed and wells rinsed twice with sterile DPBS –Cl –Mg 
(Gibco, cat. 14190) 
3. 30μl of trypsin was applied to each well, an incubated for 10 mins at 37°C. 
4. 70μl of chilled medium with 10% serum was then added to inactivate trypsin. 
5. 100μl of chilled 2x freeze medium (DMSO-15%, serum-40%, cell culture 
medium-45%) was then added. 
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6. A 50μl overlay of sterile mineral oil was then added to each well to prevent 
evaporation while frozen, and the plates sealed with parafilm. 
7. Plates were placed in a sealed Styrofoam container and placed in a -20°C freezer 
initially for 2 hours. 
8. This sealed container was then placed in storage at -80°C for longer term storage. 
 
Revival of these clones when necessary was carried out in a similar manner to that of 
regular vials (see 2.1.6), with revived cells being placed in 48 well plates due to their 
reduced cell density. 
 
 
2.4.6 Isolation of genomic DNA via ethanol precipitation 
 
Once a large number of single cell clones had been isolated after viral transduction, an 
extraction of genomic DNA was first carried out to allow for the characterisation of 
homologous recombination events via PCR. The protocol below outlines the high 
throughput method used to isolate genomic DNA from single cell clones propagated 
in a 96 well plate format. 
 
1. First, cells were grown to reach confluence in a 96 well plate. 
2. All medium was removed and each well rinsed twice with PBS. 
3. To each well, 50μl of lysis buffer (10mM Tris, 10mM EDTA salt, 10mM NaCl, 
0.5% w/v SDS, with 1mg/ml Proteinase K (Sigma, cat P-2308) added immediately 
prior to use) was added. 
4. Plates were then incubated at 60°C overnight in a humid atmosphere (achieved by 
placing on top of tissue soaked in water, all in a sealed container) 
5. After incubation, 100μl of an NaCl  and cold ethanol mix was added to each well 
(150μl 5M NaCl mixed with 10ml ice cold ethanol, with constant mixing needed 
to ensure a homogenous solution) 
6. Plates were allowed to stand undisturbed at room temperature for 30 mins to allow 
for the precipitation of genomic DNA. 
7. After precipitation, plates were carefully inverted and the salt/ethanol mixture 
discarded. Excess liquid was blotted on tissue. 
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8. 150μl of 70% ethanol solution was slowly dripped down in order to wash each 
well. This wash was repeated for a total of 3 washes. 
9. Each plate was then blotted and allowed to dry at room temperature, with care 
taken not to over dry (to prevent the difficult resuspension of DNA) 
10. 50μl of TE buffer was then added to each well and allowed to sit for 2 hours to 




2.4.7 PCR screening of genomic DNA 
 
In order to screen large numbers of clones for recombination events subsequent to 
viral transduction, a PCR method was chosen for its ability to characterise different 
insertion events on a large scale using a small number of primer sets. The protocol 
outlines here is the final method optimised to give clear results when used to amplify 
bands from the genomic DNA samples obtained previously (see 2.4.6) 
 
1. First, a standard PCR reaction is set up on ice as detailed below. For each plate 
these volumes were multiplied by 100 to generate a master mix that would allow 
for all samples as well as pipetting error 
 














Genomic DNA 2 
H20 9.5 
Total Volume 25 
 
(1) - DreamTaq PCR Master Mix (Fermentas, cat. K1072) 




2. These reactions were carried out in a 96 well PCR plate (Applied Biosystems, cat. 
4349606) under the following conditions (denaturation times and cycle numbers 
were increased during original optimisation to improve product yield from 
genomic DNA) 
 
Stage Temperature Time Cycle Number 
Initial Denaturation 95°C 10 mins  
Denaturation 94°C 1 min 
35 cycles Annealing (primer specific) 30 secs 
Elongation 72°C 1 min/kb 
Final elongation 72°C 10 mins  
 
 
3. A 10μl sample of each reaction was then run on an agarose gel to determine what 
samples were positive for the criteria being examined (for example the presence or 
absence of a particular band or a difference in band size based on a homologous 
recombination event) 
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2.4.8 qPCR to quantify viral insertion events 
 
In order to estimate the numbers of off-target insertion events in cells having 
undergone viral transduction and integration, qPCR using genomic DNA was carried 
out on targeted samples.  
 
For this reaction genomic DNA samples were isolated and diluted to a suitable 
concentration. An untransduced CHO-K1 sample was used to control for variance in 
concentration due to the difficulty in obtaining absolutely equal concentrations using 
the Nanodrop instrument. Instead, β-actin is used as a reference gene, assuming 2 
intact alleles in each genome assayed. The neomycin resistance gene within the 
targeting cassette is then used as the target to measure insert frequency. Levels of this 
gene were measured against a standard curve generated using serial dilutions of a neo-
containing plasmid. These reference samples were also spiked with an appropriate 
level of control genomic DNA to account for differences in amplification efficiency 
that may arise from the use of a plasmid template alone. 
 
 
1. The RT-PCR reaction detailed below was set up on ice in a MicroAmp optical 96-
well plate (Applied Biosystems, cat. 4346906) using a qPCR mastermix 
containing SYBR green (Fast SYBR Green Master Mix, Applied Biosystems, cat 
4385612). The table outlines the components for this reaction. Samples were run 
in triplicate. For standard curve samples, a plasmid template spiked with CHO-K1 
genomic DNA was used.  
 
Component Volume (l) 







DNA sample 2l (30ng) 
H2O 6 




2. This reaction is then carried out on an Applied Biosystems 7500 Fast Real-Time 
PCR System under the following cycling conditions; 
 
Stage Temperature Time Cycle Number 
Enzyme Activation 95°C 20 secs 1 cycle 
Denaturation 95°C 3 secs 
40 cycles 
Annealing/Elongation 60°C 30 secs 
 
 




2.5 DNA Mutagenesis 
 
2.5.1 Mutagenesis PCR (Megaprimer synthesis) 
 
The first step in the process of generating the library of mutant gene sequences used in 
this study involved a kit based low fidelity PCR enzyme, used to amplify and 
incorporate mutations into the target sequence.  The protocol below details the 
optimised protocol used for the generation and isolation of the gene sequences used to 
generate the mutant library. 
 
1. After successful generation of the plasmid containing the target gene sequence, a 
mutagenesis PCR was carried out using the lo-fi enzyme contained within the 
GeneMorph II EZClone Mutagenesis kit (Agilent Technologies, cat. 200552). 
 
In order to examine a number of mutation rates, three reactions (high, medium and 
low mutation rates) were set up by differing the plasmid concentrations therein. 
Also, a control reaction was set up using a control plasmid and primers contained 
within the kit. These reaction mixtures are detailed below. 
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The reactions below were set up on ice in PCR tubes. 
 
Component Volume (μl) 
 Low Medium High Control 
10x Buffer 5 5 5 5 
Forward Primer
1 




0.5 0.5 0.5 
Plasmid DNA
2 
100ng 20ng 0.1ng 1ng 
dNTP (40mM) 1 1 1 1 
Polymerase (2.5U/l) 1 1 1 1 
H2O to 50μl to 50μl to 50μl to 50μl 
Total Volume 50 
 
1 – Primers selected to amplify region containing target gene sequence. 125ng of each 
target primer used (1μl of control primers used contains primer mix) 
2 – Plasmid DNA amounts added was based on target sequence concentration, not 
total plasmid concentration 
 
The above reactions were run using the cycle program below: 
 
Stage Temperature Time Cycle Number 
Initial Denaturation 95°C 2 mins  
Denaturation 95°C 30 secs 
35 cycles Annealing (primer specific) 30 secs 
Elongation 72°C 1 min/kb 
Final elongation 72°C 10 mins  
 
 
2. A 5μl sample of this reaction was visualised via gel electrophoresis (see 2.3.8) to 
verify that the PCR had worked. 
3. The remainder was electrophoresed on a low melting agarose gel at a low voltage 
(50V) to ensure good resolution, then excised and purified using a Gel Extraction 
Kit (Qiagen, cat. 20021) and eluted in 10μl TE buffer. 
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2.5.2 EZ-Clone reaction 
 
Once the mutant gene sequences had been generated, these were then used as 
“megaprimers” in a secondary PCR reaction used to amplify the target plasmid while 
incorporating the mutant DNA sequences into the plasmid itself. A high fidelity 
enzyme was utilised to prevent any further mutations being incorporated into the 
plasmid sequence. 
 
1. A reaction was prepared on ice as below for each of the high, medium and low 
mutation megaprimer samples generated previously. 
 
Component Volume 









EZClone Solution 3μl 
H20 to 50μl 
Total Volume 50μl 
 
The above reactions were run using the cycle program below: 
Stage Temperature Time Cycle Number 
1 95°C 1 min 1 cycle 
2 
95°C 50 secs 
25 cycles 60°C 50 secs 
68°C 2 min/kb of plasmid length 
 
 
2. Following temperature cycling, these reactions were placed on ice for 2 mins to 
cool the reaction to ≤37°C. 
3. 1μl (10U) of Dpn enzyme was then added to the reaction and gently mixed by 
pipetting. This reaction was then incubated for 2 hours at 37°C in order to digest 
any remaining parental (non-mutated) plasmid DNA. This treated plasmid sample 
could then be used to transform bacterial cells. 
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2.5.3 Estimation of potential library complexity 
 
The experiment below was carried out in order to estimate the number of individual 
plasmids in a sample of transformed bacteria and, in turn, an indication of the 
potential complexity of the mutant library. 
 
1. First, varying amounts of plasmid sample were transformed into 50μl of DH5 as 
per the protocol (see 2.3.2). This transformation was then spread on LB agar plates 
containing Ampicillin. 
2. After 24 hours incubation at 37°C the number of colonies per plate was then 
counted. The transformation that yielded the most colonies was determined to be 
the optimal volume for transformation. 
3. This transformation was then repeated using the optimum volume established 
above. 
4. 10μl (4%) and 40μl (16%) of this transformation was then spread on separate LB 
agar plates containing ampicillin. 
5. After 24 hours incubation at 37°C the number of colonies per plate was then 
counted. This number of colonies, taken as a portion of the entire transformation 
reaction, was used to calculate the number of individual colony forming units 
generated per transformation. This number also indicated a rough indication of 





2.5.4 Large scale preparation of mutant library plasmid  
 
This protocol outlined below was followed in order to generate a large stock of 
mutant plasmid DNA that could be used to generate stably transfected mammalian 
cells. To prevent the introduction of bias in the library due to differences in bacterial 
growth after transformation, a rich medium (Terrific Broth) was used as opposed to 
the LB broth used in standard DNA preps. 
 
Terrific Broth 10x Phosphate Salts 
12g Tryptone 11.56g (KH2PO4)2H2O 
24g Yeast Extract 62.7g (K2HPO4)2H2O 
4ml Glycerol - 
to 1L with UHP water to 500ml with UHP water 
 
Both solutions are autoclaved before use. 30ml of 10x phosphate salt solution was 
then added to 270ml terrific broth to generate the working medium solution. 
 
1. Ten individual transformation reactions were carried out as per the standard 
transformation protocol using the optimum DNA volume determined previously. 
2. After the addition of SOC medium and incubation for 1 hour, 2ml of Terrific 
Broth containing Ampicillin was added to each transformation and these cultures 
incubated for 1 hour at 230 rpm. 
3. All 10 cultures were then added to 280ml of Terrific Broth containing Ampicillin 
and grown overnight at 37°C at 230 rpm. 
4. After incubation this culture was then spun at 6000 x g for 15 mins, 4°C, and the 
supernatant discarded. 
5. The resulting cell pellet was then processed using a Qiagen Plasmid Maxi kit 
(Qiagen, cat. 12362, see manufacturers protocol for details), with a final DNA 
resuspension step carried out using 500μl of TE buffer. 





2.5.5 Stable cell line generation 
 
A transfection followed by selection for cells stably integrating the transfected 
plasmid to generate a mixed population was carried out as detailed below. A lipid 
based transfection reagent (Lipofectamine 2000, Invitrogen cat. 11668) was used for 
this method. 
 
1. Healthy CHO-K1 cells were seeded in 6-well plates at a density of 5 x 105 cells 
per well and incubated overnight in 2mls of fresh medium. A control well was 
also seeded that would not be transfected with plasmid. 
2. Prior to transfection the medium was replaced with fresh medium. 
3. DNA and lipofectamine mixes were created. 2μg of plasmid DNA and 4μl of 
lipofectamine were added to separate 50µl aliquots of serum free medium and left 
to stand for 5 mins. 
4. The DNA and lipofectamine mixes were then combined and left to stand for a 
further 15 mins. 
5. This DNA/lipofectamine solution was then slowly applied dropwise to a well of 
cells. 
6. After 48 hours medium was replaced and the appropriate selective drug applied to 
kill cells that have not successfully taken up the plasmid. 
7. After 4 days cells were then trypsinised and moved to a T-75 flask with 
appropriate medium and selective pressure. Cells were continually monitored and 
maintained until all cells in the control sample were dead, indicating the 
background of untransfected cells was eliminated. 
8. Once a population of stably transfected cells was achieved a stock was frozen 
down and this population then used for further experiments. 
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2.6 Gene Expression Profiling 
 
Gene expression profiling is a powerful technique that allows for the measurement of 
expression levels across a large number of genes. By comparing samples under 
different experimental conditions to a suitable control, one can deduce from the 
differentially expressed genes the genetic basis from which a particular phenotype 
may have arisen and the specific genes responsible for the differences. As with any 
experiment, statistical confidence is increased with a greater number of biological 
replicates, however due to the economic costs triplicate samples are usually run as 
standard. 
 
The protocol followed for this experiment was developed in-house by Dr. Padraig 
Doolan and Dr. Sinead Aherne, a modified version of the original protocol designed 
for use with the commercial GeneChip 3’ IVT Express Kit (Affymetrix, 901229). The 
specific gene chips used for this experiment were ‘Hamster 3a 520384’ chips (Lot no. 
4115243, ref no. 520384), manufactured by Affymetrix with the ability to measure the 
expression of roughly 19,000 CHO gene transcripts generated to measure ~8,000 
genes. Due to the large volume of data generated, suitably powerful statistical analysis 
is then needed to identify gene targets substantially up or downregulated.  
 
Experimental conditions for comparing samples may vary depending on the 
application, for example a single cell line may be subjected to varying conditions such 
as temperature shift or have various genes artificially up or downregulated. In this 
instance a number of cell lines resulting from the TBP mutagenesis project including 
suitable controls were grown under standard growth conditions, with 1 x 10
6
 cells 
pelleted and their RNA extracted for profiling. To understand the genetic mechanisms 
that differentiate the various clones and help discover the differences in gene 
expression that may be responsible for the changes in phenotype, this RNA is then 
processed and analysed on a gene profiling chip. 
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The protocol described below follows the basic workflow of a standard profiling 
experiment such as this: 
 Cell lines to be compared are seeded and grown under standard growth 
conditions 
 Total RNA is extracted from the experimental cell samples at a suitable 
time point and quantified  
 Quality control assesses sample integrity to prevent problems with 
downstream processing. 
 Double stranded cDNA is synthesised from extracted RNA. Exogenous 
spiked prokaryotic RNA is included as an experimental control 
 In Vitro Transcription (IVT) is carried out to generate biotin labelled 
antisense RNA (cRNA). These samples are then purified and QC carried 
out on these samples. 
 cRNA samples are fragmented and hybridised to the gene chip. Suitable 
wash and staining steps are carried out 
 The chips are then placed in the GeneChip Scanner to be scanned and the 
signal detected. The resulting data is then analysed, with suitable statistical 
limits set to select for gene targets with substantial changes in expression 
in relation to a control sample. 
 
All buffers and enzymes are contained within the GeneChip 3’ IVT Express Kit 




2.6.1 RNA extraction 
 
Cell lines were seeded at 2 x 10
5
 in triplicate and allowed to grow under standard 
growth conditions. Cells were measured for density and viability from day 2 onwards, 
with samples taken daily for future processing.  
Samples consisted of 1 x 10
6
 viable cells pelleted, washed in PBS and resuspended in 
0.5ml TRI reagent (Invitrogen, cat. 10296-010). RNA was purified and extracted as 
per the manufacturer’s protocol and resuspended in 20μl nuclease-free H20. The 
concentration of this RNA prep was determined using a NanoDrop 1000 
spectrophotometer, diluted to 100ng/l and stored at -80°C.  
 
Due to the precious nature of the primary RNA samples, particular care was taken 
during this experiment when handling these samples in order to prevent degradation 
from RNAses. This included precautions such as 
 Through cleaning of all work surfaces and tools (pipettes etc.) 
 The use of RNaseZap (Ambion, cat. AM9780) to reduce RNAse 
contamination on surfaces and tools 
 The use of fresh nuclease-free H20 for any required applications 
 The use of filtered pipette tips to prevent any possible cross contamination 
 
 
2.6.2 RNA Quality control  
 
RNA quality control was carried out to ensure sample integrity prior to embarking on 
the profiling protocol. This was carried out using an Agilent 2100 Bioanalyser.  
 
A 1μl aliquot of each sample was diluted 1:1 with nuclease free H20 and run using the 
RNA 6000 Nano Kit (Agilent, cat. 5067-1511) according to the manufacturers 
protocol. 
 
These RNA chips function in a similar fashion to an electrophetic gel, albeit on a 
microscopic scale. The sample is added to a gel matrix, which then passes through a 
number of connected microchannels when a current is applied. This allows for the 
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analysis of RNA fragment sizes and their concentrations. Degradation, if present, is 
measured by the software and sample integrity designated with a RIN (RNA integrity 
number) score between 1 and 10, with RINs approaching 10 proving the highest 
quality. A simulated visual depiction is also generated, similar to that of a traditional 
electrophoretic gel, in which band ‘smearing’ (indicative of sample degradation can 





Figure 2.6.1.1: A simulated visual result from a selection of samples used in this study 
generated using the RNA 6000 Nano Kit. A 1μl aliquot of each RNA sample was 
diluted 1:1 with nuclease free H20, and analysed using the Agilent RNA 6000 Nano 
Kit. All samples in this instance provided RIN scores >9, indicating a sample quality 





2.6.3 cDNA synthesis  
 
First strand synthesis is carried out as the first stage of cDNA generation. Poly A 
primers bind to the RNA transcripts, with a DNA polymerase generating the first and 
second strands of cDNA.  
 
1. 2μl of exogenous control RNA, diluted according to the manufacturer’s 
instructions, is added to 3μl of the experimental RNA sample. This is used as a 
basis to create the first strand synthesis reaction mix 
 
Component Volume (l) 







First-Strand Enzyme Mix 1 
Total Volume 10 
 
2. This is incubated for 2 hours at 42°C in a thermocycler. 
3. After incubation, the reaction is placed on ice. The mix is then made up for 
second strand synthesis, adding in the 10μl first strand synthesis reaction 
immediately before incubation 
 
Component Volume (l) 







First-Strand Reaction Mix 10 
Total Volume 30 
 
4. This second strand mix was incubated for 1 hour at 16 °C followed by 10 
minutes at 65 °C in a thermal cycler. After incubation, the reaction is placed on 
ice, and used directly for the next in vitro transcription reaction. 
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2.6.4 In Vitro Transcription (IVT) to synthesize labelled cRNA 
 
The following reaction is carried out to convert the double stranded cDNA to its 
complementary RNA labelled with biotin. It is this cRNA that is then used for 
subsequent binding to the gene chip. 
 
1. The following reaction mix is made up at room temperature, adding the 
previous 30μl of synthesised cDNA immediately prior to incubation. 
 
Component Volume (l) 







cDNA Reaction Mix 30 
Total Volume 60 
 
 
2. This reaction is then incubated overnight for 16 hours at 40 °C in a thermal 
cycler. Once the reaction is complete, the product was used purified and 





2.6.5 cRNA Purification and fragmentation 
 
Before using the cRNA directly on the chip, it is first purified to remove reaction 
components that would otherwise contaminate the chip. It is then fragmented to break 
up any secondary structures and reduce RNA fragments to an optimal size for binding 
to the gene chip probes (with an average of ~100-120 bp) 
 
1. Purification of the RNA samples was carried out using Affymetrix GeneChip 
Sample Cleanup Spin Columns. The protocol was followed as per the 
manufacturer’s instructions, following a basic binding/wash/elution protocol. 
2. RNA was eluted in 15μl. This eluent was then placed back on the cleanup 
column and spun again at ≤ 25,000 x g for 1 minute to recover as much RNA as 
possible. 
3. The concentration of this RNA was determined using a NanoDrop 1000 
spectrophotometer, and a sample evaluated via Agilent 2100 Bioanalyser 
running a RNA 6000 Nano Kit as above to ensure sample integrity. 
4. The following fragmentation mixture was then assembled using a suitable 
volume of purified cRNA from the previous labelling reaction. 
 
Component Volume (l) 







Total Volume 37.5 
 
5. This reaction is incubated at 94C for 35 minutes in a in a thermal cycler. 
6. After incubation, samples are put on ice and used directly in the following 




2.6.6 Target hybridization and staining  
 
The final stages prior to scanning the chip involve hybridisation of the samples to the 
chip and washing of any unbound or loosely bound non-specific targets that may 
provide a false positive signal. After hybridization, the chip is then stained with 
streptavidin-phycoerythrin (SA-PE), a molecule that binds to the biotin labelled probe 
targets. A subsequent step then employs an anti-streptavidin antibody and biotin 
labelled goat antibody to provide signal amplification via a bound fluorescent 
molecule. A confocal laser is used to excite this fluorophore and provide the ultimate 
signal which is then scanned and interpreted by the analysis software 
 
 
1. The gene chip array is first equilibrated to room temperature prior to use. 
2. The probe is filled with 200μl pre-hybridization mix and incubated at 45°C for 10 
minutes with 60 rpm rotation in a hybridisation oven (Affymetrix Hyb Oven 640) 
3. A hybridisation cocktail for each sample is made up using the 37.5μl of 
successfully fragmented RNA from the previous step. 
 
Component Volume (μl) 




20X Hybridisation Control mix  
(bioB, bioC bioD, cre), 
 12.5 
2X Hybridization Mix 125 
DMSO 25 
Nuclease-Free Water 45.8 
Total Volume 250 
 
4. This hybridisation cocktail is heated to 99C for 5 minutes in a heat block, 
transferred to a 45 C heat block for 5 minutes then spun down for 5 minutes at 
maximum speed in a bench top centrifuge. 
5. The pre-hybridisation mix is removed from gene chip array and 200μl of the 
hybridisation cocktail is then added. 
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6. PVC ‘Tough-spot’ label stickers are placed over the septa on the array to prevent 
sample leakage. 
7. The array is then placed in the hybridization oven) at 45C, 60 rpm for 16 hours 
overnight to hybridise the sample. 
8. Arrays are then placed in the Affymetrix GeneChip Fluidics Station 450. the 
following staining reagents are then placed in the instrument and the appropriate 
fluidics protocol run: 
 600μl of stain cocktail 1 in an amber microcentrifuge tube (light sensitive 
solution, exposure to light should be minimised) 
 600μl of stain cocktail 2 in a 1.5 ml (clear) microcentrifuge tube 
 800μl of array holding buffer in a 1.5 ml (clear) microcentrifuge tube 
9. This staining procedure takes ~70 minutes to process. Processed array chips are 




2.6.7 Scanning of gene chips and data collection 
 
Once all gene chip arrays have been processed and successfully stained, all samples 
are placed simultaneously in the Affymetrix GeneChip Scanner 3000 7G. An 
autoloader and barcode scanner system ensures samples are read sequentially, with a 
single chip being scanned in roughly 20 mins using Affymetrix Operating Software, 
version 1.4) 
Data was subsequently collected and processed with suitable statistical analysis to 
identify statistically relevant up or down-regulated genes. 
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2.7 Protein Quantification Assays 
 
2.7.1 Western Blot 
 
Western blotting is a standard technique that was used in the course of this project. It 
is carried out to identify a target protein within a sample by means of an immunogenic 
reaction between the protein of interest and a specific antibody. This binding can then 






1. Experimental cells are grown and harvested at a suitable time. Cells are pelleted 
and stored at -80°C or used directly for protein extraction. 
2. Lysis buffer is used for cell lysis and sample dilution (Lysis Buffer: 7M Urea, 2M 
Thiourea, 4% CHAPS, 30mM Tris, pH to 8.5 with HCl). An appropriate volume 
of lysis buffer is added to cells (200μl per 10 x 107 cells).  
3. Add Nuclease solution to a final concentration of 1x (100x solution, GE, cat. 80-
6501-42). This is then left at RT for 30 mins, with occasional vortexing. 
4. Spin samples at full speed (13,000 rpm) in a benchtop centrifuge at 4°C. The 
supernatant is the protein fraction, the pellet is discarded. 
 
Bradford assay to determine concentration 
 
Note: This assay has an accurate linear range up to 1mg/ml of protein. Samples 
should be diluted in this range to gain accurate quantification 
 
5. A set of sample dilutions of bovine serum albumin (BSA) is generated to create a 
standard curve by which experimental samples can be read (i.e. 1, 0.75, 0.5, 0.25, 
0.125 and 0 mg/ml) 
6. In a flat bottom 96 well plate, 5μl of each standard concentration and experimental 
samples are added to wells along with 250μl 1x Bradford dye reagent (Biorad, cat. 
500-0205) and mixed well. Samples should be measured in minimum of triplicate. 
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7. Absorbance is then read in a microplate reader at a wavelength of 595nm. Sample 




One Dimensional Gel Electrophoresis  
 
In this experiment, a Bis-Tris gel (Invitrogen, cat. NP0322BOX) was used to separate 
proteins. 
 
8. 10μg of protein per sample is diluted in 5μl lysis buffer. 5μl Laemmli buffer is 
added to this sample, and heated to 95°C for 3 mins to denature protein. 
9. The gel apparatus is constructed. MOPS with added antioxidant is used as a 
cathode buffer, with MOPS used as an anode buffer. 
10. 9μl of each sample is added to separate wells, along with 1 well of a suitable 
molecular size marker. The gel is then run at 200V (constant voltage) 
 
 
Transfer of protein to blot 
 
11. A suitably sized membrane is cut (GE, cat. RPM303F) and immersed in methanol 
for 20secs. 
12. This membrane is then equilibrated in Transfer Buffer (20% Methanol, 10% Tris-
Glycine, 70% H20) for 15 mins. 
13. The gel is removed rinsed in H20 and equilibrated in transfer buffer for 5 mins. 
14. The gel ‘sandwich’ is then constructed in an electro-blot apparatus in the 
following configuration (filter paper is pre-equilibrated in transfer buffer) ; 
(+)Anode – 6x filter paper – Membrane – Gel – 6x filter paper – Cathode(-) 
15. The transfer is run at 0.24A (constant amps) for 35 mins. 
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Blocking and application of Primary Antibody 
 
16. After transferring, the blot is covered in blocking solution (5% Milk Marvel (w/v) 
in Tris Buffered Saline (TBS) with 0.5% Tween) and incubated with gentle 
shaking for 2 hours. 
17. The blot is rinsed twice with TBS + 0.1% Tween, before adding the primary 
antibody solution (TBP + 0.1% Tween, with 1μg/ml antibody). Antibody 
concentration may be varied, depending on the strength of the target band and/or 
other non-specific bands that may be detected. 
18. This is incubated with gentle shaking for overnight at 4°C. 
 
 
Detection of signal 
 
19. The blot is then rinsed 3 times in TBS + 0.5% Tween for 15 mins at RT with 
gentle shaking. 
20. The secondary enzyme linked detection antibody is then added. This is selected 
based on the primary antibody used (i.e. primary mouse antibody requires a 
secondary anti-mouse antibody). 15mls TBS + 0.1% Tween is used containing a 
secondary antibody at a 1:2000 dilution, incubated for 1.5 hours at RT with gentle 
shaking. 
21. The blot is then rinsed 3 times in TBS + 0.5% Tween for 15 mins at RT with 
gentle shaking. 
22. The wash buffer is removed and 2ml ECL substrate added (Thermo, cat. 34075) 
23. After 1 min of incubation the blot is removed from the substrate and the signal 
detected by exposure to a suitable x-ray film (Thermo, cat. 34090) 
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2.7.2 SEAP Assay 
 
SEAP is a commonly used marker protein used to measure expression levels in 
transfection assays. The protocol outlined below is used to detect SEAP levels in the 
supernatant of CHO cells transfected with a SEAP containing plasmid. 
 
1. 2x SEAP buffer is first prepared (10.50g diethanolamine, 50 μl of 1M MgCl2, 226 
mg L-homoarginine brought to 50ml with distilled water) 
2. Samples are collected from SEAP producing cells. These are spun at 1000 rpm 
(170 x g) for 5 mins to pellet cells, and the supernatant removed for analysis. 
3. 50μl of each sample is added to a flat bottom 96 well assay plate along with 50μl 
2x SEAP buffer. This is then pre-warmed to 37°C 
4. Phosphatase substrate solution, p-Nitrophenyl Phosphate (pNPP) (Sigma, cat. 
P4744) is made immediately before use (0.158mg pNPP in 5mls 1x SEAP buffer) 
5. 10μl of this substrate solution is then added to each well 
6. Change in absorbance per minute is then read in a microplate reader at a 
wavelength of 405nm, with the plate ideally incubated at 37°C 
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2.7.3 ELISA assay 
 
An ELISA (Enzyme-linked immunosorbent assay) is a common technique used to 
detect an antigen of interest via an enzyme linked antibody specific to the analyte of 
interest. When non-specific unbound antigens are washed away, the linked enzyme is 
used to generate a colorimetric signal whose signal is proportional to the 
concentration of target analyte in the original sample. 
Buffers used in this protocol: 
 Coating Buffer – 0.05M Carbonate Bicarbonate, pH 9.6 
 Wash Solution – 50mM Tris, 0.14M NaCl, 0.05% Tween20, pH 8.0 
 Blocking Solution – 50mM Tris, 0.14M NaCl, 1% BSA, pH 8.0 
 Sample Diluent – 50mM Tris, 0.14M NaCl, 1% BSA, 0.05% Tween20 
 Stop Solution – 0.18M H2SO4 
 
1. Dilute 1μl coating antibody in 100μl coating buffer for each sample, and add to 
each well 
2. Incubate coated wells at 4°C overnight 
3. After incubation, remove the coating buffer and wash plate 5 times with wash 
buffer 
4. Add 200μl blocking solution to each well and incubate for 1 hour at RT 
5. Remove this solution and wash plate 5 times with wash buffer 
6. Prepare samples and relevant standard curve in sample diluent 
7. Add 100μl sample/standard to their assigned wells and incubate for 1 hour at RT 
8. After incubation, remove the samples and standards and wash plate 5 times with 
wash buffer 
9. Dilute the enzyme (HRP) linked detection antibody in sample diluent at a dilution 
of 1:100,000 and add 100μl to each well and incubate for 1 hour at RT 
10. After incubation, remove the coating buffer and wash plate 5 times with wash 
buffer 
11. Add 100μl HRP substrate solution (TMB - 3,3',5,5'-Tetramethylbenzidine) to each 
well and incubate in darkness for 15 mins 
12. Add 100μl stop solution to each well and tap plate gently to mix 
13. Absorbance can then be read in a microplate reader at a wavelength of 450nm 
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2.8 Southern Blot 
 
In order to detect genomic insertion events, a non-radioactive southern blot detection 
kit was used. This kit was based on a DIG (Digoxigenin) labelled nucleotide base that 
is incorporated into the target probe via PCR. When this probe is bound to its target 
sequence, an enzyme linked anti-DIG antibody is then used to detect this probe, with 
alkaline phosphatase fluorescence used as the signal detection method. The Roche 
DIG-labelled southern blot system was used for this experiment, including reagents 





1. The first step is to carry out the probe generating PCR reaction in which the DIG 
labelled dUTP base is incorporated into the sequence. This is carried out alongside 
an unlabelled control reaction. When visualised on an agarose gel, a slight 
increase in size for the labelled probe band compared to the control is indicative of 





PCR Buffer 5 5 






Primers (F/R) (10pmol/μl) 2 2 
Enzyme Mix 0.75 0.75 
Template DNA (10pg/ul) 2 2 
H20 35.25 35.25 
Total Volume 50 
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2. The following cycling conditions is used for the PCR labelling reaction; 
 
Stage Temperature Time Cycle Number 
Initial Denaturation 95°C 2 mins  
Denaturation 95°C 30 secs 
30 cycles Annealing 52°C 30 secs 
Elongation 72°C 40 secs 
Final elongation 72°C 7 mins  
 
DNA digestion and separation 
3. The following reaction is set up to digest genomic DNA prior to separation on an 
agarose gel. 
Component Volume (μl) 
DNA variable 
NEB Buffer 3 (10x) 8 
BSA 0.8 
BamH1 1.6 
Bgl II 1.6 
Spermidine (0.1M) 2 
H20 to 80μl 
Total volume 80μl 
 
4. These digested samples are then run on a 0.7% agarose gel, run at ~40V to ensure 





5. To depurinate DNA, the gel is submerged in 250mM Hcl for 20 mins and rinsed 
in double distilled H20. 
6. To denature DNA, the gel is then submerged in denaturation solution (0.5 NaOH, 
1.5M NaCl) for 30 mins and rinsed in double distilled H20. 
7. The gel is then equilibrated for 10 mins in 20 x SSC (3M NaCl, 300mM sodium 
citrate, pH 7) 
8. A standard blot transfer is then carried out to transfer DNA onto a nylon 
membrane. A piece of Whatman 3MM paper is placed on a bridge above a 
reservoir of 20xSSC, with its ends used to wick fluid upwards. A blot ‘sandwich’ 
is then constructed on top of this bridge in the following order; agarose gel – 
nylon membrane – Whatman 3MM paper (soaked) – Stack of paper towels – Flat 
weight (~400g). 
9. DNA is allowed to transfer onto the nylon blot overnight, then the apparatus 
disassembled 
10. DNA is then cross linked to the membrane by exposure to 120mJ UV for 1 min. 
 
Hybridisation 
11. The blot is placed in a suitably sized roller bottle, and 15ml (or enough to cover 
the blot) pre-warmed hybridisation solution added (pre-hybridisation step). 
12. This is incubated for 30 mins in a rotating incubator at the appropriate 
hybridisation temperature. This temperature is calculated using the following 
formula, taking into account the sequence GC content (%G+C) and length (L) in 
base pairs:  
 Thyb = [49.82 + 0.41 (% G+C) – 600/L] – (20°C -25°C) 
13. 20μl of the labelled probe is added to 5ml pre warmed hybridisation solution. 
14. The pre-hybridisation buffer is removed, and the probe/hybriisation buffer added. 
15. This is then incubated overnight 
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16. After incubation, the blot is rinsed twice for 5 mins at room temperature with 
shaking in fresh low stringency buffer (2 x SSC, 0.1% SDS) 
17. The blot is then rinsed twice for 15 mins in high stringency buffer (0.5 x SSC, 
0.1% SDS) preheated to 65°C 
 
Detection 
18. The blot is then transferred to a new container and rinsed for 2 mins in washing 
buffer (0.1M maleic acid, 0.15M NaCl, pH 7.5, 0.3% Tween 20) with shaking. 
19. After removing the washing buffer, the blot is incubated for 30 mins in 100ml 
blocking solution (Roche, cat. 11585762001) with shaking. 
20. The blocking solution is then discarded, and replaced with 20ml anti-DIG 
antibody solution (Roche, cat. 11585614910) and incubated for 30 mins 
21. The membrane is then washed twice in 100ml washing solution with shaking. 
22. The blot is then equilibrated for 3 mins in 20ml detection buffer (0.1M Tris-Hcl, 
0.1M NaCl, pH 9.5) 
23. Chemiluminescent substrate (CSPD – Roche, cat. 11858614910) is then added 
dropwise to the blot which is then sealed in a clear envelope and incubated for 5 
mins. 




2.9 Statistical analysis 
 
Throughout the course of this study the appropriate statistical analysis was carried out 
on the data generated in order to successfully interpret its significance in relation to 
the experiment being undertaken. This was done to ensure that reliable conclusions 
could be drawn from the results. 
 
The most common calculations and methods of analysis used to evaluate data 
throughout this thesis include; 
 The standard deviation and coefficient of variance (C.V.) of experimental 
replicates to ensure accuracy of results 
 Student’s t-tests to investigate if significant statistical differences exist 
between groups of experimental results to confirm or deny a given hypothesis 
 Linear regression to generate standard curves of known analyte concentrations 














One of the main techniques employed in the course of this study was an investigation 
into the use of a viral vector for gene targeting in a CHO cell line.  
This study was originally conceived as a method of gene targeting in which an adeno-
associated viral vector would be used to deliver a basic expression cassette to a 
defined genomic locus. This cassette would be flanked by two ‘targeting arms’; 
sequences identical to a specific region of genomic DNA that was to be targeted. This 
would allow for homologous recombination to take place, inserting the expression 
cassette contained within the viral vector into the target homologous region of 
genomic DNA (Rutledge and Russell 1997). 
 
Gene targeting, the insertion of exogenous DNA into a specific site within the 
genome, has the potential to be used successfully for a number of aims within 
industrially relevant mammalian cells such as CHO. Its main obvious potential use in 
industrial CHO cell lines is that of targeted gene knockout, the initial aim of this study 
when it was carried out. In this configuration, a viral vector is constructed containing 
homologous targeting arms specific to a gene of interest whose effect we wish to 
remove from the cell (Russell and Hirata 1998). Insertional disruption of these genes 
(for example, pro-apoptotic genes) then provides a benefit to the cellular phenotype 
when their effect is removed.  
Methods such as RNA interference technology currently exist for controlled 
knockdown of genes, and this method can quickly generate an altered phenotype by 
reducing the levels of a target gene RNA. This can be useful for screening and 
validation of large numbers of potential gene targets, and stable siRNA producers can 
be generated to produce a cell line with persistent altered properties. However, due to 
possible genetic instability from the maintenance of a transcriptionally active shRNA 
expression cassette, as well as the potential for ‘leaky’ low level expression of the 
targeted gene, total gene knockout has been shown to be preferable in instances where 
complete elimination of a gene is the aim (Li et al. 2010). 
 
 118 
This experiment was carried out as a ‘proof of concept’ study exploring the possibility 
of using homologous recombination via a viral vector to successfully target and 
disrupt a pair of model genes in CHO cells (namely DHFR and HPRT). This was 
attempted by utilising a viral vector containing a cassette containing elements 
necessary for homologous recombination, a common strategy for gene targeting. Key 
to this strategy are two sequences homologous to a section of the gene to be 
inactivated, known as the ‘targeting arms’. These flank the central cassette elements 
in the expression vector, in this case a selectable marker to allow for the selection of 
successful integrants. Once the vector is introduced into the cell, these ‘arm’ 
sequences allow for homologous recombination to occur, integrating the targeting 
cassette into the targeted region (Vasileva, Linden and Jessberger 2006). This 
insertion leads to a disruption of the genomic gene sequence, preventing the target 
gene’s transcription and effectively removing its effect from the cell.  
 
Homologous recombination is a key process in eukaryotic cells for the repair of 
double stranded breaks in DNA, as well as the recombination of parental genetic 
material prior to meiosis. For AAV mediated gene targeting via homologous 
recombination, a pre-existing break in the sequence at the point of homology is 
exploited to introduce the exogenous DNA. This break is processed by nucleolytic 
enzymes, and the resulting single strand is bound by the protein RAD51. This protein 
then searches for homology (for example on a sister chromatid or, in this case, is 
found on the homologous arm of the recombinant viral vector), and ‘invades’ this 
sequence. The homologous vector DNA then serves as the template for repair, with a 
polymerase using the invading strand as a primer and the vector sequence as a 
template for new DNA synthesis. This reconstruction at the break site incorporates the 
vector sequence into the genome at this locus, and successful recombination at both 
up and downstream targeting arms permits the integration of the interstitial cassette 
sequence into the target site (Porteus 2007).  
 
The homologous method of DNA repair exploited for AAV recombination is in 
contrast to the other main double stranded break repair pathway known as non-
homologous end joining (NHEJ). This method repairs DNA via ligation of blunt ends, 
and is known to mediate viral integration into random locations in the genome as well 
as eliminating viral genomes through concatemerisation, leading to their subsequent 
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degradation. As such, the knockdown of this pathway is known to increase 
homologous AAV targeting rates and reduce off-target insertions (Bertolini et al. 
2009; Fattah et al. 2008). 
 
The adeno-associated virus serotype 2 (AAV-2) was chosen as a suitable vector for 
this study. It has previously been shown to achieve high targeting rates approaching 
1% (Russell and Hirata 1998), and its broad tropism has allowed it to be used 
successfully to target specific gene sequences in a wide range of mammalian cell lines 
such as mouse, rat, human and other primates. Its genome size of ~4.7 kb is also 
suitable for this purpose, permitting the inclusion of a suitable selection marker (in 
this case neomycin) alongside the targeting arms necessary for homologous 
recombination. Manipulation and generation of AAV is also relatively 
straightforward; due to its popularity as a vector a number of kit-based solutions exist 
for creating custom vectors such as the one used in this experiment. 
 
Described below are the details and results of the experiment, including the generation 
of the recombinant AAV vectors used to target the two model genes, the application 
of the virus and multiplicity of infection (MOI) used to infect the targeted CHO, PCR 
screening carried out to detect correctly targeted inserts as well as experiments carried 




3.1.2 AAV Helper-free system 
 
The strategy used to generate viral particles in this study was a ‘helper-free’ AAV kit-
based system from Agilent Technologies (cat. 240071). In this system a number of 
separate plasmids are transfected into a suitable cell line (in this case human 
embryonic kidney (HEK-293) cells) to generate the final stock of viral particles. 
Wild-type AAV require a secondary ‘helper’ virus for lytic replication. To remove the 
necessity for this secondary virus, the adenoviral-derived genes necessary for lytic 
replication as well as packaging and capsid genes are provided in trans by the 
plasmids pAAV-RC and pHelper. When co-transfected with the plasmid encoding the 
recombinant AAV vector sequence itself into modified HEK-293 cells, this brings 
together all the components necessary for correct viral production and packaging. 
This modularisation of components ensures the integrity of the targeted cell line by 





















Figure 3.1.2.1: Components necessary for successful AAV production and packaging 
are delivered on separate plasmids. pAAV-RC contains AAV rep and cap genes, 
while pHelper encodes adenoviral-derived genes necessary for lytic viral replication. 
The recombinant vector plasmid encodes for the viral sequence and the targeting 
cassette. 
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3.1.3 Selection of genes for targeting 
 
The first step prior to the generation of the targeting viral vectors was to select 
suitable genes. Ideally, the genes selected would provide a phenotype that could be 
easily screened for in the event of a homozygous gene knockout, without having a 
detrimental effect on the cell’s ability to survive. Also, as these vectors were 
constructed prior to the publication of the CHO draft genome (Xu et al. 2011), a 
degree of sequence information regarding these genes would be necessary for their 




The DHFR gene encodes for the Dihydrofolate reductase protein, an enzyme involved 
in the generation of tetrahydrofolate, an important precursor necessary for the 
generation of nucleic acids. Cells lacking in this enzyme can survive using alternative 
metabolic pathways however, with the addition of hypoxanthine and thymidine (HT) 
to its growth medium (Urlaub and Chasin 1980). This provides us with a means to 
easily screen for DHFR -/- knockouts in a targeted CHO cell line (i.e. by placing 
clones in HT deficient medium and screening for cells that do not survive in such an 
environment). 
 
Another advantage to using this gene in CHO was the sequence data available to us 
when generating the DHFR targeting construct. A paper relating to DNA replication 
in this locus (Sasaki et al. 2006) provided a sequenced region of over 67 kb worth of 
data (GenBank accession: AB239764.1), allowing us to confidently identify intron 
and exon regions, as well as generate the primers necessary to amplify homologous 
arm sequences and carry out post-transduction screening of infected cells to identify 
correctly targeted recombinants. 
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- HPRT 
The second model gene chosen for targeting was the HPRT gene encoding the 
Hypoxanthine-guanine phosphoribosyltransferase enzyme. This enzyme is involved in 
a purine salvage pathway, however this pathway is not strictly necessary for growth in 
a supplemented growth medium, therefore knockout of this gene would have no 
detrimental effects on CHO cell growth if targeted.  
One advantage for the use of this gene for knockout screening is the sensitivity it 
confers to the drug 6-Thioguanine (6-TG). If an active version of the HPRT gene 
exists within the cell, this catalyses the transformation of 6-TG into 6-thioguanine 
monophosphate (TGMP). This compound is cytotoxic due to its ability to prevent the 
production of guanine based nucleotides, as well as deleterious effects when further 
TGMP metabolites are incorporated into DNA and RNA. As such, it has been used as 
a selective marker in previous HPRT knockout studies (Russell and Hirata 1998) to 
easily screen for clones that are homozygous for disrupted HPRT alleles. 
 
Unlike DHFR, an ideal amount of sequence data was not initially available for the 
CHO HPRT genomic locus when this targeting vector was constructed. To circumvent 
this problem and generate sufficient sequence data to generate primers and allow us to 
create the necessary targeting arms, existing sequence data from a similar organism 
(Cricetulus longicaudatus, Long-tailed Hamster) was used as a basis to generate 
primers for sequencing experiments that could then be carried out on the CHO 
genome. Using this CHO specific sequence data, we could then create the 
homologous targeting arms necessary to create the HPRT targeting vector.
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3.1.4 Targeting vector design  
 
The first step in creating the plasmid constructs necessary to generate viral stocks 
used for gene targeting was the creation of the targeted knockout cassette. The 
targeting cassette used in this study was based on a cassette generated by Dr. Olga 
Piskareva for use in a similar experiment targeting LINE1 elements, a common 
repetitive sequence within the genome. This cassette (comprising the elements 
between the homologous arm sequences) was copied and used as the basis for the 
DHFR and HPRT targeting vectors used in this study. The configuration of these 
elements can be seen in figure 3.1.4.1. These targeting vectors are comprised of the 
following key functional elements: 
 
- Homologous targeting arms: 
The targeting arms are a key component of the targeting cassette. These sequences are 
generated via PCR directly from CHO genomic DNA, ensuring their sequence is 
identical to the targeted region within the genome. This homology encourages 
recombination at the chosen region, allowing the expression cassette to become 
inserted within this target sequence.  
Although the exact mechanism behind this method of recombination is unknown, 
evidence suggests that double stranded break (DSB) homologous recombination is a 
likely method for its action, with one study demonstrating AAV targeting frequencies 
60-100 fold greater in conjunction with induced DSBs (Miller, Petek and Russell 
2003). Elimination of genes whose activity is involved in homologous recombination 
(such as RAD54) has also been demonstrated to reduce or eliminate site specific 
targeted insertions, furthering the evidence implicating this method of action 
(Vasileva, Linden and Jessberger 2006; Essers et al. 1997). 
 
- Neomycin resistance gene: 
A key feature of the targeting cassette, conferring resistance to the antibiotic G418 
and allowing us to select for cells that have undergone any form of recombination 
having incorporated the viral vector into its genome. 
This variant of the neo resistance is broken into two exons (neo and Δneo), separated 
by a single 146 bp intron. 
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- Intron and LoxP sites: 
A 146 bp intron separates the two exons that constitute the neo resistance gene, with 
LoxP sites contained within this intron and downstream at the 3’ end of the Δneo exon 
(see figure 3.1.4.1). This was designed to allow for inactivation of the neo gene using 
Cre recombinase to excise the Δneo portion of the gene, thus avoiding the negative 
effects of selectable markers on recombinant gene expression (Pham et al. 1996; 
Artelt et al. 1991). 
The single LoxP site and neo fragment that would remain after Cre treatment would 
also facilitate future work, such as an investigation into the transcriptional potential of 
targeted sites by introducing a gene of interest via recombinase-mediated cassette 
exchange (RMCE) (Turan et al. 2011). A correctly pre-targeted cell line would 
ultimately allow for a product gene to be inserted and neo resistance restored at this 
target site and, eliminating the variability in expression inherent in populations with 
random insertions. 
 
- Polyadenylation signal: 
A Polyadenylation (polyA) signal is included at the end of the neo sequence. 
Functioning in a similar method to a ‘gene trap’, the polyA signal works in tandem 
with the splice site at the start of the Δneo exon to prevent correct splicing and 
expression of the target gene transcript (Carlson and Largaespada 2005). This 
generates a truncated, non-functional version of the target gene, removing its effect 
from the cell and generating a ‘knockout’ phenotype. 
 
- CMV Promoter: 
A standard cytomegalovirus promoter (pCMV), a common strong viral promoter, is 
used to drive Neo expression. 
 
- pAAV-MCS Backbone: 
The features described above, once correctly assembled, were in turn ligated into the 
backbone of the pAAV-MCS plasmid. Using the NotI restriction sites provided (see 
figure 3.1.5.1.4), the generic expression cassette is removed from this plasmid and 
replaced with the custom targeting cassettes. A notable feature of this backbone is the 
Inverted Terminal Repeat (ITR) sequences flanking the cassette. These 145 bp 
sequences contain the viral origin of replication, and are critical for viral packaging 





Figure 3.1.4.1: This diagram demonstrates the ultimate planned design of the targeting 
vectors pAAV-DHFR and pAAV-HPRT. The key components are highlighted below 
- 5’/3’ targeting arms: These sequence fragments flank the other cassette 
components and are homologous to a portion of the DHFR gene to be targeted, 
generated by PCR on target genomic DNA. If recombination occurs, these 
recombine with the target site, also integrating the sequence information between 
the arms and ultimately disrupt the target gene 
- Neomycin resistance gene: Allows the selection of successful integrants by 
application of G418 after transduction. Also includes a single intron, which 
contains one of the vectors two loxP sites. A polyadenylation signal at its 3’ end 
also serves as a termination signal for targeted gene transcription 
- L/R-ITR: Inverted terminal repeat sequences necessary for the replication and 
packaging of viral particles 
- LoxP sites: Allows inactivation of Neomycin resistance via Cre recombinase once 
a successful gene knockout cell line has been established, as well as the future 
integration of a target gene at this defined locus 
- CMV promoter: Drives the expression of the resistance gene 
- pAAV-MCS Backbone: The plasmid backbone taken from a generic AAV 
expression vector used as the basis for the targeting vectors used in this study 
These components were generated through subcloning from existing vectors, or 
generated via PCR of native CHO sequences using primers generated from CHO 
sequence data. 
 
         Neo-intron-loxP-Δneo-polyA 
pAAV-MCS plasmid backbone 
5’ Arm 
Pcmv      loxP 
L-ITR R-ITR 
      loxP 
3’ Arm 
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3.1.5 Targeting vector construction 
 
In order to create the final targeting vector, the targeting cassette was first assembled 
in a pBluescript cloning vector. Components such as the neo resistance gene and loxP 
sites were subcloned from a similar targeting vector generated previously, with 
targeting arms generated specifically to the model genes examined in this experiment. 
 
 
3.1.5.1 Targeting arm generation 
 
DHFR 
The DHFR gene itself consists of 6 exons, with variable amounts of intronic DNA 
between each. A large intron (2331 bp) between exons 2 and 3 was chosen as the 
integration site for the targeting cassette. Primers were designed to amplify regions of 
this intron to generate the 5’ and 3’ targeting arms. These were 920 bp (5’ arm, 
contained within the intron) and 1413 bp (3’ arm, contained within the intron and 
overlapping exon 3 by 64 bp) in size respectively (see figure 3.1.5.1.1). These were 
then ligated into the pBluescript vector containing the other cassette elements. This 
completed cassette sequence was then removed using the flanking NotI restriction 
sites and successfully ligated into the pAAV backbone to generate the pAAV-DHFR 
targeting vector (see figure 3.1.5.1.5).  
 
 














Figure 3.1.5.1.1: Details of the primers used to amplify the regions of CHO genomic 
DNA comprising the DHFR targeting arms. Bases in uppercase denote those used in 
direct sequence binding, while lowercase italicised characters indicate overhangs 




A similar rationale to that used to design the DFHR vector was followed for design of 
the HPRT targeting arms. However, due to the lack of reliable sequencing data, work 
was initially based on mRNA sequence data from the long-tailed hamster (Cricetulus 
longicaudatus, GenBank accession: x59652). 
 
From this sequence, primers were designed and used to sequence intronic sections, 
providing further data which was ultimately used to create the primers necessary to 
amplify the HPRT targeting arms (see figure 3.1.5.1.2). These were 935 bp (5’ arm) 
and 922 bp (3’ arm) in size respectively (see figure 3.1.5.1.3). As with the DHFR 
targeting cassette, these were then ligated into the pBluescript vector containing the 
other cassette elements. This completed cassette sequence was then removed using the 
flanking NotI restriction sites and successfully ligated into the pAAV backbone to 





HPRT locus in genome




5' Arm (935 bp) 3' Arm (922 bp)
 
Figure 3.1.5.1.2: Schematic detailing the sequencing experiment carried out on the 
CHO HPRT locus. Initially, sequencing primers were generated using a long-tailed 
hamster mRNA sequence. Using the resulting sequence data, primers were then 
















Figure 3.1.5.1.3: Details of the primers used to amplify the regions of CHO genomic 
DNA comprising the HPRT targeting arms. Bases in uppercase denote those used in 
direct sequence binding, while lowercase italicised characters indicate overhangs 







Figure 3.1.5.1.4: A schematic diagram of the pAAV-MCS vector that provides the 
backbone for the fully constructed targeting cassette. Highlighted in red are the left 
and right inverted terminal repeats (L/R-ITR), sequences critical for the successful 
packaging of viral particles.  
The highlighted NotI restriction sites were used to remove the existing expression 
cassette and insert the completed targeting cassettes once they were excised from the 












Figure 3.1.5.1.5: A scaled representation of the fully constructed pAAV-DHFR 
plasmid. While the total plasmid size is over 7 kb, the size of the viral genome 
between and including the ITR sequences is ~4.5 kb, below the upper limit of ~4.7 kb 
for efficient AAV2 viral packaging. The complete annotated sequence of this plasmid 
can be found in appendix 5.2.1. NotI restriction sites outside of the LTR sequences 
(see figure 3.1.5.1.4) were used to join the pAAV backbone to the targeting vector 





Figure 3.1.5.1.6: A scaled representation of the fully constructed pAAV-HPRT 
plasmid. While the total plasmid size is over 6.6 kb, the size of the viral genome 
between and including the ITR sequences is ~4 kb, below the upper limit of ~4.7 kb 
for efficient AAV2 viral packaging. The complete annotated sequence of this plasmid 
can be found in appendix 5.2.2. NotI restriction sites outside of the LTR sequences 
(see figure 3.1.5.1.4) were used to join the pAAV backbone to the targeting vector 
sequence once fully constructed in a temporary parent vector (pBluescript). 
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3.1.6 Virus generation and purification 
 
 
Once these targeting constructs had been successfully generated, the protocols for 
virus generation and purification (as detailed in materials and methods section 2.4) 
were followed. For both targeting constructs (DHFR and HPRT), 9 x 96mm plates of 
HEK-293 cells were transfected with the plasmids pHelper, pAAV-RC and its 
respective targeting plasmid (pAAV-DHFR and pAAV-HPRT) to generate the 
targeting viral stocks.  
 
A single plate of a GFP-expressing control virus was also generated in each case to 
determine successful generation of viral particles. This control virus was used 
subsequently to ensure the infectivity of the viruses produced and examine their 
potential for infecting CHO cells. Transduction efficiency of CHO with this virus 
could be estimated using flow cytometry to quantify GFP positive cells. 
 
The protocol used for this purpose (section 2.4.1) was adapted to utilise a commercial 
transfection reagent (FuGene, Roche, cat. 11 814 443 001). Optimisation of this 
process was found to provide superior efficiency compared to the default calcium 
chloride transfection protocol suggested by the AAV kit manufacturer. 
Originally, 10μg of each plasmid (pRC, pHelper and pAAV-GFP) was mixed with 
0.3M CaCl2 and 2 x HEPES Buffer solution as per the manufacturers protocol 
(Agilent, cat. 240071). However, after harvest a 200μl sample of viral supernatant 
was found to only transduce 6% of CHO-K1 when applied to a sample of 1 x 10
5
 cells 
(see 2.4.3). Increases in HEK-293 cell concentration and plasmid concentration did 
not improve this result, and a protocol previously successful in a similar viral 
transfection experiment utilising the FuGene reagent was adapted and employed with 
greater initial success. 
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Initially, lower concentrations of plasmid (2μg pRC and pHelper, 4μg pAAV-GFP) 
were mixed with 18μl of transfection reagent, resulting in a viral supernatant with 
33.5% transduction rate when harvested. Further increases in plasmid DNA and 
FuGene concentration were found to achieve greater success, with a maximum 
concentration of 10μg of each plasmid mixed with 30μl FuGene found to produce the 
greatest level of viral production. A 200μl sample of this unpurified virus, produced 




Using this method, 9 plates of both targeting viruses were then produced and 
concentrated. These viral stocks were then concentrated and purified using the 
ViraBind AAV Purification kit (Cell Biolabs, cat. VPK-141). These final 
concentrated viral stocks were eluted in a final volume of ~130μl, which was then 
subsequently used for targeting experiments by applying to an adherent monolayer 
culture of CHO-K1 cells. 
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3.1.7 Estimation of viral titre 
 
MOI (multiplicity of infection) is a term that quantifies the relative number of viral 
particles applied, per cell, to a population (for example, an MOI of 10 would describe 
10 viral particles per cell). For the purposes of this experiment, we aimed to achieve 
an MOI as high as possible, as evidence has shown that increased targeting 
efficiencies relate to an increase in MOI (Russell and Hirata 1998, Porteus et al. 
2003). For this reason, a larger number of transfected HEK-293 plates were combined 
and concentrated, and applied to a relatively small number of cells. 
 
In order to determine an estimate of the MOI, qPCR (as detailed in section 2.4.12) 
was carried out on the control GFP sample to determine the number of viral 
particles/ml of viral stock that were produced per single plate under the transfection 
conditions used for production. 
 
The GFP control AAV plasmid was serially diluted and analysed with samples of the 
GFP virus. Knowing the number of plasmid copies within each control sample then 
allowed us to generate a reference curve. This was achieved using the following 
formula:  
 
Plasmid Copy Number (per µl) 
 = [amount (ng) x 6.022×10
23
] / [plasmid length x 1×10
9
 x 660] 
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Standard curve (pAAV-GFP)















Figure 3.1.7.1: The standard curve used to calculate the number of viral particles 
present per ml of viral stock, generated via qPCR on a plasmid with a pre-determined 





 plasmid copies. 
  
 
From the GFP viral stock that was generated, a minimum of 4.82 x 10
8
 viral particles 
per ml was calculated using the above reference curve. 
 
To calculate the final MOI that would be used when the stock of concentrated DHFR 
virus was applied to cells, the following factors were taken into account; 
 1 plate = ~8mls 
 9 plates of targeting vector were generated 
 These were concentrated with a >60% recovery rate from the purification kit 
 This concentrated stock was applied to 1 x 105 cells (see transduction protocol, 
section 2.4.3) 
 
This leads to a minimum calculated MOI of 2.08 x 10
5
 (~200,000) viral particles per 
cell. 
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To ensure the functionality of the virus and confirm the AAV-2 tropism extended to 
CHO cells, 50μl and 200μl sample volumes of the unpurified GFP control virus 
supernatant were applied to 1 x 10
5 
cells in a 6 well plate. After 48 hours fluorescence 
was measured on a Guava flow cytometer and, by gating with an untransduced control 




Figure 3.1.7.2: An image of CHO-K1 cells 48 hours post-transduction with 200μl 




When fluorescence was measured on the flow cytometer, the following percentage of 
fluorescent cells was measured from application of the 50μl and 200μl GFP samples 
 
Volume AAV-GFP % fluorescent cells Estimated MOI 
200μl 74.8% 9.64 x 102 
50μl 31.5% 2.41 x 102 
 
 
This data suggested the viruses generated were viable and even a relatively small MOI 
(less than 1000 particles per cell) from an unconcentrated sample could successfully 
infect a large number of CHO cells. 
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3.1.8 Transduction and selection of targeted cells 
 
Once the viral stocks had been generated and purified, the entire concentrated volume 
(~130μl) was applied to 1 x 105 cells (an estimated MOI of 2.08 x 105 viral particles 
per cell).  
A 200μl sample of the unconcentrated GFP control virus was also applied to a 
separate cell sample as above. This control transduction provided 74.25% GFP 
positive cells, indicating successful transduction (see figure 3.1.7.2). 
 
After 48 hours, these cells were placed under Neomycin selection at a concentration 
of 0.5mg/ml, a concentration previously determined to successfully eliminate non neo 
resistant cell background. Once this untransduced background population was cleared, 
a stock of the transduced population was frozen for liquid nitrogen storage. Further 
investigations were then carried out to examine efficiency of targeting, as well as 





Pcmv NEO-CassetteAAV-DHFR targeted locus
5'HR Screen 3'HR Screen
5' Arm 3' Arm
Pcmv NEO
AAV-DHFR targeting vector
DHFR locus in genome
5' Arm
LoxP
3' ArmExon 2 Exon 3




Figure 3.1.8.1: This diagram describes the homologous recombination event expected 
to occur post-transduction once the viral DHFR knockout genome containing the 
homologous arms recombines with the CHO genome sequence. The arm sequences 
themselves are homologous to the region between exon 2 and 3 of the CHO DHFR 
gene, with a slight overlap (64 bp) into exon 3 at the 3’ arm. Once homologous 
recombination takes place, we can predict the genomic sequence to resemble the 
lower diagram, having incorporated the targeting vector at the designated locus and 
disrupted the target gene. Regions targeted for PCR screening of targeted 
recombinants are also highlighted. 
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3.1.9 PCR Screening to estimate targeting efficiency 
 
In order to estimate the efficiency of successful gene targeting in comparison to cells 
with randomly inserted cassettes, a number of single cell clones were isolated from 
the DHFR targeted cell population. These were then screened using a series of PCR 
reactions designed to indicate the successful integration of the neo expression 
cassette, as well as targeted recombination events at both the 5’ and 3’ targeting arm 
locations.  
 
To achieve this, 3 reactions with individual sets of primers were used. 
 Neo: Designed to amplify a portion of the neomycin resistance marker. This 
would indicate the presence of the targeting cassette at any position in the 
genome 
 5’/3’ arms: To detect correctly targeted HR events, primer pairs were designed 
featuring one anchored within the targeting cassette, and the other binding just 
outside the arm sequence in genomic DNA. A correctly sized band from this 





Figure 3.1.9.1: The binding positions of primer sets used for screening of insertion 
events. Initially, a set binding internally to the cassette was used [Neo F/R] to screen 
for all clones with any insertion events. These neo positive clones were then screened 
with primers to determine targeted events [5’/3’ F/R]. By placing one primer within 
the cassette and one outside the arm sequence, a positive band of the predicted size 








Initially, over 300 single cell clones were isolated from a G418 selected population of 
DHFR targeted cells. Genomic DNA was extracted using the ethanol precipitation 
method detailed in section 2.4.6.  
PCR was then optimised to run in a high throughput plate format with a genomic 
DNA template. This optimisation included increases in denaturation times and cycle 
numbers which were found to have a positive effect on amplifying the target 
sequences from genomic DNA. 
 
 
3 sets of primers were successfully used; an internal set to detect the Neo gene and 








Forward 5’ – AAGATGGATTGCACGCAGG – 3’ 
300 
Reverse 5’ – GAGATGACAGGAGATCCTG – 3’ 
5’ Arm 
Forward 5’ – TGAATGACCACCACCTCC – 3’ 
1000 
Reverse 5’ – TAACGCGGAACTCCATATATG – 3’ 
3’ Arm 
Forward 5’ – AGCGCATCGCCTTCTATCG  – 3’ 
1880 
Reverse 5’ – GTGCGCGTGCGTGCAC – 3’ 
 
Table 3.1.9.2: Details of the primer sets used for the PCR screening designed to 





Figure 3.1.9.3: This image displays a typical result from a high throughput (96-well) 
PCR screen when visualised via gel electrophoresis. The above image, for example, 
shows the result from a 5’ arm insertion screen, with 2 visible positive results (1000 




Screen Number of positive clones Targeting Efficiency 
Neo 195 - 
5’ Arm 11 5.6% 
3’ Arm 6 3.1% 
 
Table 3.1.9.4: Results of PCR screening for targeted insertions. Targeting efficiency 




Of the ~300 clones isolated, 195 genomic samples gave neo positive results. The 
remaining 100+ neo negative clones were likely a result of poor quality DNA 
extracted. Due to the high-throughput nature of the ethanol extraction method 
employed, not all wells provided adequate concentrations of DNA for PCR.  
While all clones examined were G418 resistant, a lack of an integrated neo gene may 
also be a result of AAVs ability to exist episomally within the cell, thus maintaining 
resistance without the need for genomic integration (Bertran et al. 1996; Penaud-




11 (5.6%) of these neo positive clones proved positive for the 5’ arm insertion event. 
Only 6 (3.1%) proved positive for successful 3’ arm recombination. Interestingly, 
these 6 clones were a subset of the 5’ positive group, meaning no 3’ arm insertion 
events happened independently of 5’ arm recombination events. 
This result compares favourably to the commonly reported targeting frequency of 
~1% using AAV (Hirata et al. 2002; Russell and Hirata 1998) and a vast increase over 
plasmid based methods (Williams et al. 1994), however this figure is also enhanced 
through the use of drug selection to remove untransduced cells. 
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3.1.10 Screening for homozygous (-/-) knockouts 
 
With targeting efficiency established at over 3%, a variety of screens, including 
selective and PCR screens, were carried out to determine if the successfully targeted 
DHFR clones were heterozygous for the disrupted DHFR allele, or true null (-/-) 
mutants.  
 
PCR screening was necessary to indentify DHFR targeted cells due to the lack of a 
suitable negative selective pressure. However, due to the sensitivity of HPRT-
containing cells to the guanine analog 6-TG, this compound could be used directly to 
screen for knockout cells potentially generated by the HPRT targeting vector. Having 
calculated a suitable concentration to eliminate untargeted cells, a negative selection 
screen was carried out on HPRT targeted cells using 6-TG to select for cells having 
potentially undergone a double allele knockout. 
 
 
3.1.10.1 Selective DHFR (-/-) screen 
 
DHFR is necessary for growth under HT deficient conditions to generate critical 
folate derivatives, and as such the inability to survive in HT deficient medium would 
indicate these clones have lost both alleles and are null mutants. 
This was achieved by seeding each of the 6 clones previously identified for correctly 
targeted insertions in hypoxanthine and thymidine (HT) deficient CHO-S-SFM 
medium (Invitrogen, cat. 31033-020), including dialysed serum to ensure no trace 
amounts of these vital compounds.  
 
Result: 
Unfortunately, all 6 cell lines tested retained the ability to grow in this medium, 
suggesting there was still a functional allele of this gene within the cell. 
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3.1.10.2 PCR screen for intact DHFR allele 
 
A PCR screen was also carried out using primers to detect the intact version of the 
DHFR gene (see figure 3.1.10.2.2). Primers were designed to flank the targeting 
cassette insertion point within targeted cells. A predicted band size of 371 bp would 
indicate the presence of an intact DHFR allele. 
 
Forward 5’ – GAAACAGGTCAGCAGAGCAGATGTTG – 3’ 
Reverse 5’ – CACTGTGCACCTGTTTGCACAGG– 3’ 
 
Figure 3.1.10.2.1: PCR primers used to detect the intact DHFR allele 
 
.  
Figure 3.1.10.2.2: The result of the PCR screen to detect intact DHRF alleles in the 
targeted clones. The bands visible at 371 bp in each lane indicate an intact copy of the 
DHFR gene in the CHO genome, while the fainter band at 2224 bp signifies the 
targeted allele containing the inserted targeting cassette. 
 
Result: 
For all 6 correctly targeted clones analysed, an intact copy of the DHFR allele was 
found to be present in each case (i.e. DHFR +/-), confirming the results of the selective 
–HT medium screen. 
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3.1.10.3 qPCR screen for DHFR expression 
 
Finally, qPCR was carried out to detect the levels of DHFR expression in the insertion 
positive cell lines isolated. Primers were designed to generate a 142 bp DHFR 
fragment suitable for qPCR, with PabpnI used as a reference gene for normalisation. 
The protocol for qPCR was followed as per methods section 2.3.12. 
 
Forward 5’ – GAAGCCATGAATCAGCCAGGCC– 3’ 
Reverse 5’ – GGACTTCAGAAAGGACCCCTGG– 3’ 
 

























Figure 3.1.10.3.2: DHFR mRNA expression from DHFR +/- targeted clones. RNA 
was isolated from each cell line and analysed in triplicate via qPCR, error is reported 
as the standard deviation of these technical replicates. Expression is reported relative 




Continued expression is noted at a reduced level (average 59%) in all clones. While 
expression levels were generally lower than an untargeted negative control as 
expected in a single allele knockout cell line, all clones still showed positive DHFR 
expression. 
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3.1.10.4 6-TG negative selection screen for HPRT knockout cells 
 
In order to screen for HPRT targeted cells that had potentially undergone homologous 
recombination at both alleles, a negative selection screen was carried out. While 
HPRT positive cells are sensitive to 6-TG due to its deleterious effects on nucleotide 
metabolism, HPRT negative (-/-) cells are able to survive its effects. This feature can 
be exploited to eliminate untargeted and functionally heterozygotic targeted cells, as 
well as bypassing the need to carry out a PCR screen to identify successful knockout 
cells. 
 
Before applying to virally targeted cells, a kill curve was carried out by seeding 1 x 
10
5
 untargeted CHO cells in 6 well plates containing various concentrations of the 
selective agent. From this experiment, it was determined 3µg/ml 6-TG was sufficient 




Unfortunately, no HPRT targeted cells survived this selective process. This suggests 




3.1.11 Alternative techniques for null mutant selection 
 
The PCR screening carried out on DHFR targeted cells confirmed a relatively high 
number of correctly targeted cells (>3%). However, after subsequent analysis of these 
cell lines they were found to contain a remaining intact copy of the DHFR allele. A 
number of alternative techniques were attempted in an effort to generate null mutants. 
These included exposing homozygous targeted cell lines to a high pulse of selective 
drug in order to stimulate gene conversion at the untargeted allele, as well the 
development of a secondary viral vector containing an alternative selective marker in 
order to disrupt the untargeted allele. 
 
 
3.1.11.1 Increased G418 concentration to select for null mutants 
 
Due to the failure of the initial DHFR targeting virus to successfully generate null 
mutants, we investigated the use of a method in which a high pulse of the selective 
drug used to generate the initial heterozygous mutants is applied. This causes loss of 
heterozygosity, with mechanisms such as chromosomal loss (and subsequent 
duplication), gene conversion as well as mitotic recombination to be responsible for 
this phenomenon. This technique has been demonstrated effectively in mammalian 
embryonic stem cells (Mortensen et al. 1992), as well protozoan eukaryotes such as 
Leishmania (Hwang et al. 1996). 
 
In this attempt a selection of correctly targeted (5’/3’ arm insertion), heterozygotic 
clones isolated from the previous DHFR experiment were seeded at 1 x 10
5
 cells per 
well of a 6 well plate. The 3 clones used were designated 1A9, 1H1 and 3H10, as well 




Increasing concentrations of G418 were applied to these 3 clones. This was carried 
out to find a suitable concentration of selective marker that would inhibit growth and 
stimulate a genetic response such as the chromosomal recombination detailed in 
previous studies resulting in null mutants. Data from a previous example of this 
technique (Mortensen et al. 1992) would suggest a benefit to efficiency by using 
higher concentrations, as well as reducing the numbers of resulting clones to be 
screened. Due to the unknown number of neo insertions in these clones, this 
concentration would also have to overcome the G418 resistance conferred by a 
potentially high number of neo gene copies. 
 
 
Plates were tested under a range of G418 concentrations. 0.5mg/ml is generally used 
to eliminate background levels of untransfected cells, as well as maintain resistance in 
cell lines using neo as a selective marker. In this case, 0.5, 1.5, 2.5, 3 and 5mg/ml 
G418 were tested. 
 
Concentrations as high as 1.5mg/ml were found to have little or no impact on the 
growth of the cell lines tested, suggesting a high level of resistance to the drug. As 
expected, the extremely high concentration of 5mg/ml was found to impact cell 
growth the greatest. This was lethal to two of the cell lines tested, with less than 1 x 
10
4





The cell line 1H1, after exposure to this high concentration treatment, was expanded 
and a population of single cell clones isolated (n=192). These were subsequently 
seeded in HT deficient medium with dialysed serum for a number of passages, 
however all clones maintained their ability to grow in this environment suggesting 




3.1.11.2 Secondary viral knockout construct 
 
A second approach explored a technique more commonly used to generate second 
allele knockouts. This method involves the use of a secondary knockout vector. This 
vector is generally identical to the initial targeting vector, however the selectable 
marker is replaced with a different resistance gene to allow for the specific selection 
of secondary vector integration events. 
This has been successfully employed in CHO cells (albeit using plasmid vectors as 
opposed to the recombinant viral vectors used in this study) to sequentially target both 
alleles of a gene, resulting in homozygous knockout cell lines (Yamane-Ohnuki et al. 
2004; Yamane-Ohnuki, Yamano & Satoh 2008).  
 
 
To generate this secondary DHFR targeting vector, the DHFR vector plasmid (pAAV-
DHFR) was modified. Using the unique restriction sites BamHI and XhoI flanking the 
neo gene, this resistance marker was removed and replaced with a Zeocin (zeo) 
selectable marker. This secondary marker was amplified from pcDNA3.1/Zeo 
plasmid, resulting in a 669 bp fragment which was subsequently ligated into the 












Figure 3.1.11.2.1: Details of the primers used to amplify the regions of plasmid DNA 
comprising the Zeocin resistance gene. Italicised sequences contain restriction sites 
for digestion and ligation purposes. 
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This secondary DHFR/Zeo targeting virus was created as before, with 9 plates 
transfected, purified and concentrated. 
 
For the purposes of transduction the heterozygotic clone 1A9, previously determined 
to contain both a functional and disrupted DHFR allele, was chosen for re-targeting. 
 
Transduction and selection was carried out as detailed previously, using 200µg/ml 
Zeocin (Invitrogen, cat. R250-01). 
After the background of untransduced cells was removed (those not expressing zeocin 
resistance), 4 x 96-well plates of single cell clones were isolated and placed under 




All clones isolated maintained their ability to grow in this environment suggesting this 




3.1.12 Determination of off-target insert frequency 
 
While viral targeting may efficiently generate targeted cells due to the effects of 
homologous recombination, it also suffers from the unintended consequences of 
random off-target insertions. These insertions may be mutagenic, or otherwise place 
an undue transcriptional burden on the cell due to the expression of multiple selective 
marker integrations. 
 
Initially, a southern blot technique was investigated for its use in detecting off-target 
insertions. For this purpose, the Roche DIG (Digoxigenin) system was purchased and 
tested with a number of virally targeted samples (see methods section 2.8). This 
system based on a non-radioactive DIG-labelled probe, with an anti-DIG enzyme 
linked antibody used to produce a chemiluminescent signal. The following primers 
were first used to successfully generate a suitable 306 bp DIG-labelled probe designed 
to bind to the neo selection marker contained within the viral targeting cassette; 
 
Forward 5’ – AAGATGGATTGCACGCAGG– 3’ 
Reverse 5’ – GAGATGACAGGAGATCCTG– 3’ 
 
Following the protocol described in section 2.8, 5g of genomic DNA from each 
sample was digested and transferred onto a nylon blot. However, after hybridisation 
and signal detection no bands were visible in any of the experimental samples. A 
sample of digested plasmid DNA containing the neo target locus at the correct size 
was visible, suggesting the probe was suitable. 
 
A number of optimisations were made to the protocol in order try and achieve a 
positive result; 
 Successively lower hybridisation temperatures were tested 
 Wash stringency was lowered by reducing the wash temperature and 
increasing SSC concentrations 
 Increased and decreased concentrations of target genomic DNA were used 
 Alternative size probes (including a smaller 165 bp and larger 757 bp probe) 
were tested 
 Increases in probe concentration (double and triple concentration) was 
attempted 
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Unfortunately, none of these changes in protocol, either alone or in combination, were 
found to generate a positive band signal in any of the targeted cell lines tested. A limit 
of detection experiment using the standard prescribed conditions was tested using 
dilutions of the control plasmid, the only sample shown to generate a signal. Despite 
the manufacturers claims that 0.1 pg DNA is detectable, our results showed that 25 pg 
of plasmid DNA was the lowest detectable signal (3.3 x 10
6
 plasmid copies). A rough 
estimate would suggest ~1.8 x 10
6
 genome copies in the 5g of genomic DNA 
suggested, placing our samples out of this range. Increases in DNA were not 
successful in capturing any signal, suggesting a possible limit to the capacity of the 
membrane or a reduction in capillary transfer efficiency. Ultimately, this technique 
was not successful, so an alternative method was devised. 
 
 
In order to quantify the frequency of total insertion events, including non-homologous 
off-target insertions, qPCR was performed on a number of correctly targeted DHFR 
clones. This technique was carried out as an alternative to the southern blot analysis 
described above, which was found to be not sensitive enough for this experiment. 
Each sample was assayed using a total of 50ng genomic DNA from each targeted cell 
line, with a primer set targeting the neo transgene within inserted cassettes used to 
indicate insertion event copy number.  
The vector plasmid containing this cassette was used to generate a standard curve for 
quantification. The samples used to generate this standard curve were also spiked with 
50ng of background CHO-K1 genomic DNA to reduce bias in amplification 
efficiency that may arise from using plasmid DNA alone. 
 
Due to a difficulty in obtaining precise dilutions of genomic DNA across a range of 
different samples, a β-actin reference gene was also measured to control for slight 
variances in genomic DNA concentration. Assuming 2 intact copies of this gene, this 
control could also then be used to calculate the number of CHO genomes in a given 




Samples assayed included 6 correctly targeted (5’/3’ arm HR events) clones, as well 
as a partially targeted (5’ arm HR event) clone and a randomly integrated (no HR) 
clone. Insertion numbers per genome were calculated based on a number of calculated 
factors including the number of insertion events measured via qPCR, sample 
concentration, genome copy number measured using a β-actin reference as well as an 






















Figure 3.1.12.1: The qPCR standard curve generated from the pAAV-DHFR plasmid 
using primers designed to target the neo resistance gene. These samples were also spiked 
with an appropriate concentration of genomic DNA to better mimic amplification 
conditions and efficiencies resulting from the use of genomic DNA alone. Samples were 
measured in triplicate within the linear range between 2.86 x 10
6
































Figure 3.1.12.2: Calculated insertion events from the individual clones assayed. qPCR 
was carried out on genomic DNA isolated from targeted clones, with the neo transgene 
used as the quantified target and a β-actin reference used to control for differences in 
DNA concentration. In order to factor in inaccuracy resulting from the nature of the 
experiment, error (denoted above as a minimum and maximum range of inserts) was 
also calculated by combining the highest and lowest estimated neo and β-actin 
replicate results to generate the range of possible calculated insert number values. 
 
From the clones assayed we see an average insert frequency of ~24 instances. This 
average result is increased by the high insert frequency clones 1H1 and 2F12, with a 
calculated 77 and 55 inserts respectively. A targeted clone (3H10) was also isolated 




A summary and further discussion of the results generated in this study is presented in 
section 4.1 of this thesis. 
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3.2 Mutagenesis and Directed Evolution Results 
 
3.2.1 Introduction  
 
This experiment was originally devised to investigate if mutagenesis and directed 
evolution techniques previously carried out to improve the properties of bacterial and 
yeast culture systems could also be successfully applied in CHO cells. These ‘whole 
cell evolution’ techniques have proven successful in lower order species, but have yet 
to be applied to mammalian cells. For this reason, this novel approach was attempted 
in CHO to investigate whether such techniques could be successful in eliciting an 
improved phenotype with regards to biopharmaceutical production.  
 
Two elements were combined with the goal of improving relevant phenotypic 
characteristics in a standard CHO-K1 cell line. Firstly, a gene was chosen for random 
mutagenesis to generate a mutant library with sufficient diversity. Tata binding 
protein (TBP) was chosen for this purpose. This choice was informed by similar 
studies using a technique described as ‘global transcription machinery engineering’ 
(gTME) in yeast (Alper 2006) and E. coli (Alper and Stephanopoulos 2007) in which 
high-level transcription factors directly or indirectly involved in the transcription of a 
wide range of genes was mutated and expressed to alter the cellular phenotype.  
TBP’s selection was supported by its role as a key mammalian transcriptional factor 
and essential component of the pre-initiation transcription complex that binds RNA 
polymerase II, the enzyme responsible for the transcription of a large portion of RNA 
in mammalian cells. It was theorised that any alteration to its sequence could modify 
this proteins binding affinities with its wide range of interactors (including DNA and 
a range of other transcription factors), therefore leading to a wide range of 
perturbations in the transcriptomic profile of a transfected cell. By producing a mixed 
population of transfected cells, we can hope to generate a wide heterogeneous pool of 
cells from which potentially advantageous mutants can be selected. 
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Once a heterogeneous population expressing various mutant TBP sequences is 
generated, the second element of this technique is the application of an environmental 
stress in order to select for cells that may have an improved phenotype resulting from 
their altered transcriptome. This element is based on a number of similar successful 
experiments in other mammalian cell lines in which a persistent environmental stress 
is used as a selective factor, for example the adaptation of CHO cells to grow in 
glutamine free medium (Bort, Stern and Borth 2010) or resistance to high ammonia 
concentrations in mouse hybridomas (Matsumura et al. 1991), as well as the gTME 
technique upon which this experiment was based. 
 
For the purposes of this study, two advantageous phenotypes were investigated; high 
speed growth and extended viability, with a suitable stress applied to a population of 
mutant library transfected cells in order to select for each particular phenotype. In 
order to select for high speed growers cells were passaged at a particularly low 
density, under the theory that faster growers would eventually overtake the remaining 
cell population after repeated passages and become the dominant phenotype. Cells 
with extended viability were selected for by allowing a standard culture to drop to a 
low viability before re-passaging, effectively selecting for cells that can better 
withstand the cumulative negative effects of late stage culture conditions such as 
nutrient depletion and waste build-up. 
 
Once the cell lines had undergone a number of passages under stress, both mixed 
populations and single cell clones were then isolated and their properties examined. 
This characterisation stage involved analysing properties such as growth and viability 
over the course of a standard culture and productivity levels. Analysis was also 
carried out on the mutant TBP sequences contained within successful clones, as well 
as a transcriptomic profiling carried out in order to determine the changes in gene 






3.2.2 Generation of a wild type TBP plasmid vector 
 
The first step taken in the generation of a mutant TBP library was to first clone the 
CHO TBP sequence into a suitable expression vector. For this purpose, the pcDNA3.1 
plasmid (Invitrogen, cat V860-20) utilising a selective marker conferring resistance to 
zeocin was chosen. 
 
First, PCR using a high fidelity enzyme (Merck, cat. 71085-3) was successfully 
carried out on a CHO cDNA library using primers to amplify the TBP cDNA, a 978 
bp fragment that was subsequently visualised and purified. 
 
Forward 5’ – catcggatccATGGACCAGAACAACAGC – 3’ 
Reverse 5’ – aatagcggcgcCTATGTGTCTTCCTGA – 3’ 
 
Figure 3.2.2.1: Details of the primers used to amplify the TBP cDNA sequence. Bases 
in uppercase denote those used in direct sequence binding, while lowercase italicised 
characters indicate overhangs containing restriction sites (BamHI/NotI) used for 
digestion and ligation of PCR fragments  
 
 
This was then cloned into the pcDNA3.1 multiple cloning site plasmid by digesting 
both PCR fragment and vector with BamHI and NotI, then ligating together to 
generate the wild type TBP plasmid. TBP expression is driven by a constitutive CMV 
promoter upstream of its position, with Zeocin (Invitrogen, cat. R250-01) used a 




3.2.3 Generation of the mutant TBP library 
 
In order to generate a mutant library of TBP sequences, a kit based mutagenesis 
protocol was followed utilising the GeneMorph II EZClone Mutagenesis system 
(Agilent Technologies, cat. 200552) as detailed in the materials and methods section 
2.5. The workflow follows the basic principles; 
 Low fidelity PCR is carried out on the TBP sequence under controlled conditions 
to generate a particular frequency of mutations 
 These mutant sequences are used to anneal to the original donor plasmid as 
‘megaprimers’ in a subsequent PCR step which extends and recreates the original 
plasmid, incorporating the mutant sequences. 
 DpnI is used to digest the original unmutated (methylated) donor plasmid, leaving 
a mixture of PCR-generated pcDNA plasmids incorporating the mutant TBP 
sequences. 
 
Following this protocol as detailed, 3 mutant libraries (low, medium and high 
frequency) were generated using reaction conditions specified by the kit to alter the 
levels of mutation within the target sequence. 
Once these libraries were generated and transformed, single cloned sequences were 
isolated and sent for sequencing. However, the first instance of this procedure 
revealed a lower than expected mutation rate. Mutagenesis was repeated with lower 
starting DNA concentrations in an attempt to increase these rates, however the 
resulting mutation rate was still lower than expected. 
 
To achieve the desired mutation rates, two elements were optimised for the 3
rd
 attempt 
at mutation. Firstly, the primers used in the mutagenesis reaction were extended to 
increase their annealing specificity and raise their melting temperature by 10°C. This 
brought the reaction into an optimal temperature range suggested by the kit, resulting 
in a greater amplification of mutant TBP. Secondly, the amount of template DNA was 
lowered to increase the rate of mutation in each reaction. After this 3rd round of 
mutation, 5 plasmid clones from each library were sent for sequence analysis in order 
to estimate mutation frequency (see figure 3.2.3.1.1). 
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Forward 5’ – ATTAATACGACTCACTATAGGGAGACCCA – 3’ 
Reverse 5’ – ACTAGAAGGCACAGTCGAGGCTG – 3’ 
 
Figure 3.2.3.1: This figure shows the final mutagenesis primers used, flanking the 
TBP sequence. Italicised letters indicate the extensions added to increase the Tm
 
and 





3.2.3.1 Mutant TBP library mutation rates 
 
 
Initial Target DNA (ng) 
Mutation rate Recommended Used 
Low 500-1000 100 
Medium 100-500 20 
High 0.1-100 0.1 
 
 
Mutation rates (per kb) 
Mutation rate Expected 
Average 
Achieved 
Average number of  
Base 
changes/insertions/deletions 
Low 0 - 4.5 6.2 4.5 / 0.5 / 1.2 
Medium 4.5 – 9 9.5 7.25 / 0 / 2.25 
High 9 - 16 13.5 9.75 / 1.75 / 2 
 
Figure 3.2.3.1.1: Details of the 3 final mutant libraries that were generated. Various 
concentrations of target plasmid DNA (noted above) were used in a low fidelity PCR 
reaction to achieve the measured mutation rates. A selection of 5 individual plasmids 
from each library was sequenced in order to estimate the average number of mutations 
in each library.  
 
 
Having generated libraries with acceptable mutation rates, it was decided that work 
would continue using the medium TBP mutant library with an average rate of ~9 
mutations per 957 bp gene sequence. This was chosen to avoid the likelihood of large 
amounts of deleterious or non-functional mutations associated with the highest 
mutation rate, while introducing a larger amount of heterogeneity than the low library 




3.2.4 Estimation of library complexity and large scale preparation 
 
In order to maximise the possible library complexity of a large scale mutant plasmid 
preparation, work was carried out to optimise the transformation efficiency of the 
library. 
To optimise this process varying volumes of the library were transformed in DH5 
competent bacterial cells, along with varying incubation times on ice. An optimum 
was found at 3μl volume of library plasmid, with an extended 30 min incubation time 
found to increase efficiency. In order to generate the large scale plasmid preparation, 
10 separate transformation reactions were pooled to increase overall complexity and 
subsequently grown in terrific broth medium (see section 2.5.4). This was then 
prepared using the plasmid maxi prep protocol (see section 2.3.4), producing a 




An efficiency of at least 10
4
 colony forming units was noted in single transformation 
tube. A combination of 10 individual transformations resulted in a large scale plasmid 
preparation containing an estimated complexity of ~10
5




3.2.5 Generation of stably transfected cells 
 
Stable cell lines were then generated using the protocol detailed in section 2.5.5. The 
following plasmids were transfected to generate individual cell lines; 
 Mutant TBP (Library) 
 Wild Type TBP (WT-TBP) 
 Empty vector control (pcDNA) 
 
Transfections were carried out using 2g plasmid DNA on 1 x 106 adherent cells 
(~70% confluent) using 4l Lipofectamine 2000 (Invitrogen, cat. 11668) according to 
the manufacturers instructions. A ‘cells only’ mock transfection was also carried out, 
as well as a GFP plasmid positive transfection control. After 72 hours, this GFP 
control was measured as ~55% of GFP positive cells, indicating a successful 
transfection. 
 
After 48 hours, cells were placed under selective pressure to select for stably 
transfected cells using the Zeocin selection marker contained on the pcDNA plasmid 
backbone. The concentration for effectively clearing the background of untransfected 
cells was previously determined to be 200μg/ml of Zeocin. This concentration was 
also used subsequently as a selective agent to maintain TBP expression. Once the 
background of untransfected cells was eliminated, these stable populations were 
adapted to suspension growth and serum free conditions in CHO-S-SFM II medium 




3 individually transfected mixed populations were generated for use in stress selection 
experiments.  
The mutant library transfected cells (designated ‘Library’) serve as an experimental 
population, while the wild-type TBP and control empty vector transfected cells 
(designated ‘TBP’ and ’pcDNA’ respectively) serve as controls to measure the impact 
our mutant TBP library may have on CHO compared to constitutive over expression 
or absence of recombinant TBP.
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3.2.6 Application of stress to select for advantageous phenotypes 
 
Once a stable population was generated that was adapted to typical culture conditions, 
an environmental stress was applied for a number of passages. This was carried out in 
order to allow cells with possibly beneficial or advantageous mutations to survive or 
otherwise outgrow their counterparts and eventually dominate the population. For the 
purposes of this experiment two selective pressures were applied in order to select for 
two distinct phenotypes; resistance to apoptotic conditions and high speed growth. 
 
 Extended Viability:  
This stress was applied in order to select for cells resistant to late stage (apoptotic) 
environmental culture conditions. Such a property would be advantageous in any 
industrial culture, increasing the possible productive cell time available. Cells were 
passaged at a standard concentration (2 x 10
5
 cells per ml) and left in culture for an 
extended period of time until viability began to drop below a given level. The 
remaining cells were then passaged, resuspended at a standard concentration of viable 
cells and re-stressed for a number of rounds in culture. Cell density and viability were 
the key metrics measured at the point of each passage. Initially, 50% viability was 
decided upon as a guideline level at which the cell lines would be passaged into fresh 
medium. 
 
 High speed growth:  
In order to investigate an alternative possible phenotype that may arise from the 
library transfected cells, an alternate contrasting stress was applied. While an 
extended viability phenotype would benefit cells in the later stages of culture, cells 
displaying an improved ability to grow to high density would reduce the time 
necessary to get a culture into a productive phase. Cells were passaged at a low 
concentration and allowed to grow back to high density. It was theorised that any cells 
with the ability to grow quickly would soon outgrow the population. Initially cells 
were passaged at 5 x 10
4
 cells per ml. After a number of rounds, this was then lowered 








In each case 3 replicate suspension culture tubes (5ml working volume) were seeded 
for each of the empty vector control (pcDNA), wild type TBP (TBP) and mutant TBP 
(Library) transfected populations. In between passages cells were monitored 
transiently by count on a haemocytometer.  
Viability and cell density measurements were then taken on the day of passage using 
the Guava Easycyte flow cytometer and Viacount reagent (Millipore, cat. 4000-0041), 




3.2.6.1 Results of ‘viability’ stressed cultures 
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Figure 3.2.6.1.1: Details of the total cell densities (including both living and dead 
populations) of each cell line as measured on the day of passage throughout the stress 
procedure designed to select for an extended viability phenotype. X axis values 
represent the passage number, with culture duration noted in parentheses. Each cell 
line was passaged in biological triplicate to a density of 2x10
5
 viable cells/ml, with 
each sample’s cell density and viability measured in triplicate. 
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Figure 3.2.6.1.2: Percentage viability of each cell line as measured on the day of 
passage throughout the stress procedure. X axis values represent the passage number, 
with culture duration noted in parentheses. Each cell line was passaged in biological 
triplicate to a density of 2x10
5
 viable cells/ml, with each sample’s cell density and 
viability measured in triplicate. 
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Figure 3.2.6.1.3: The data represented previously in 3.2.6.1.2, with values normalised to 
the pcDNA result. This representation allows us to examine the distinct effects the TBP 
and Library transfection procedures have in comparison to the control cell line.
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3.2.6.2 ‘Viability’ stressed cultures discussion 
This key experimental step was designed to function as a formative and selective 
stress. The effect of this stress on a mostly homogenous population would be seen in 
both control and TBP populations, with only the natural variation found in their 
populations contributing to any adaptation that may take place. This effect would 
perform in a similar manner to other experiments utilising directed evolution to 
generate cell lines with improved properties (as discussed in section 1.6.1).  
However, the experimental Library transfected cell line incorporates both natural 
cellular variation as well as the artificial heterogeneity generated by the different 
mutant TBP sequences expressed in each cell, and would hopefully have a greater 
ability to respond to this pressure due to this variation. This selective effect is more 
reminiscent of similar experiments involving mutagenesis as well as a selective 
pressure, such as the gTME experiments described in 1.6.3.3.  
By comparing these different populations, we hoped to gain an insight into the benefit 
of both TBP and Library overexpression compared to the technical control, as well as 
the differences between them that may arise as a result of the selective stress. 
 
The figures in this section display the total cell density and viability values measured 
on the day of passage for each of the control, TBP and Library transfected cell lines. 
Figure 3.2.6.1.3 also represents the normalised percentage viability data, displayed as 
a fold difference of the control pcDNA cell line.  
While 50% viability was initially decided upon as a guideline level at which the cell 
lines would be passaged into fresh medium, strict adherence to this limit was difficult 
to maintain due to the unpredictability of decline in viable cell numbers, and the 
differences in survival rates that arose between cell populations. A separate culture 
was seeded intermittently and preserved in liquid nitrogen as a precaution in case of a 
catastrophic loss in viability. 
 
In total 16 passages of selection were carried out. Passages 12 and 13 (not displayed in 
results) were carried out with no stress applied. Due to a fatal crash in viability in 
which the cultures were lost, these passages were used to revive frozen samples and 
re-continue the experiment from this point. 
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Due to the nature of the process and the resulting data, it is difficult to make any clear 
conclusions regarding the effectiveness of the stress whilst cells are continually within 
the stress process, as seen above. This is in part due to the changing nature of the cells 
being used to re-seed each passage, with differing results at each point making the 
identification of trends difficult.  
As a calculated volume of viable cells was used to re-seed the next culture, this 
invariably includes a large number of dead cells, possibly affecting both the 
environment of viable, reproducing cells, as well as the total cell counts of successive 
cultures. This approach is in contrast to a similar experiment in which cells are 
stressed and allowed to recover before re-seeding (Prentice, Ehrenfels and Sisk 2007), 
eliminating the large amount of dead cells forwarded in this process. Another 
beneficial modification to this procedure may be the use of FACS to allow for a strict 
selection of healthy cells, with this process being used successfully to sort for viable 
cells gradually adapted to grow in a glutamine free medium (Bort, Stern and Borth 
2010). However, FACS sorting was unavailable at the time of this experiment. 
 
Despite the inherent noise in this data, some features are notable or at least suggestive 
of the changes accumulating over the course of this experiment. Looking at total cell 
densities (figure 3.2.6.1.1) we see a trend of TBP and Library transfected cells 
possessing a maximum cell density generally higher than the pcDNA control, 
suggesting that the overexpression of this protein (or its mutant variations) has a 
beneficial effect on cell growth and maximum cell density. This is also suggested by 
overexpression of TBP in human disease tissue, with increased TBP concentrations 
linked to changes in cell growth and proliferation due to its associations with proto-
oncogenic cellular components such as p53 and Ras signalling proteins (Johnson et al. 
2003a; 2003b) 
Tracking the Library culture viability, the total and normalised percentage viability 
suggests that this stress is indeed selecting out an advantageous subpopulation, with 
many results from the halfway point (passage 8) demonstrating a proportion of viable 
cells greater or equal than the control equivalent, improving from an initial trend 
(passages 1-7) of only lower or equal viability. 
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This trend is somewhat reversed in the TBP culture. Persistently high total cell 
densities are measured on the passage days and, looking at the normalised data, an 
initial boost to late stage viability is apparent in early passages. These cultures soon 
appear to deteriorate at a faster pace (passage 9 onwards). The reason for this is not 
immediately obvious, with mycoplasma being eliminated as a possible factor through 
a standard detection procedure carried out on all in-house cell lines. Morphologically, 
TBP cells also began to clump on a macroscopic scale faster than their experimental 
and control counterparts, also affecting the accuracy of cell counts. 
 
As all cultures were measured and passaged at the same time to simplify the 
experiment and hopefully make comparisons easier, TBP cells’ premature 
deterioration also had the effect of reducing the possible incubation time length of 
cultures maintaining relatively high viability. For example, in the latter stage of the 
experiment rescue of TBP cultures, necessitated by viabilities of <20%, came at the 
expense of Library cells, whose viability suggested an ability to last longer and thus 
potentially have a greater stress placed on this population to further select for cells 
more resistant to later stage culture conditions. 
 
After this artificial stress procedure was carried out, these cultures were maintained 
under normal growth conditions with regular passaging at 3-4 days to allow for 
recovery, before single cell cloning and further characterisation was carried out on 
both mixed and clonally derived populations. 
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3.2.6.3 Results of ‘low density’ stressed cultures 
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Figure 3.2.6.3.1: Details of the viable cell densities of each cell line as measured on the 
day of passage throughout the stress procedure designed to select for an accelerated 
growth phenotype. X axis values represent the passage number, with culture duration 
noted in parentheses. Each cell line was initially passaged in biological triplicate to a 
density of 5x10
4
 cells/ml, further reduced to 1x10
4
 upon passage 10. 
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Figure 3.2.6.3.2: The data represented previously in 3.2.6.3.1, with values normalised 
to the pcDNA result. This representation allows us to examine the distinct effects the 
TBP and Library transfection procedures have in comparison to the control cell line.
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3.2.6.4 ‘Low density’ stressed culture discussion 
As with the ‘viability’ stress designed to select for a specific change in phenotype, the 
conditions of this experiment were designed to allow cells with a potential increase in 
growth rate to flourish and outgrow slower cells. Any improvement in exponential 
growth would allow for advantageous clones to quickly fill the available 
environmental space, with subsequent rounds of selection allowing the fastest growing 
cells to prevail. Initially cells were seeded at 5 x 10
4
 cells/ml, a four-fold lower 
concentration compared to a normal passage. Beginning at passage 10, this was 
reduced to 1 x 10
4
 cells/ml with 10% conditioned medium (a twenty-fold reduction in 
viable cells) as a further selective pressure. 
Figure 3.2.6.3.1 above represents the viable cell density values measured on the day of 
passage for each of the control, TBP and Library transfected cell lines. Figure 3.2.6.3.2 
also represents the normalised viable cell density data, displayed as a fold difference 
of the control pcDNA cell line. 
 
Most of the passages carried out on these cell lines were conducted once the cells had 
reached the stationary phase, and as such cannot tell us much about early stage growth 
patterns (this would be examined in subsequent single cell clones derived from these 
populations). However, the maximum viable cell concentrations of stationary phase 
cultures again hints at the growth benefit of TBP overexpression, with some data 
points indicating an increase in maximum cell density in both TBP and Library 
transfected lines. However, normalised to the control cell line, we can see this effect is 
not particularly strong. 
This is in contrast to a selection of passages carried out on lower density cells still in 
an exponential growth phase (i.e. passages 3, 6, 12 and 14). While the control cell line 
may not reach maximum densities as high as the experimental lines due to its lack of 
TBP overexpression, in these instances it appears to be able to grow at a faster 
exponential rate.  
 
This data would suggest no clear benefits gained from this stress procedure aside from 
the initial advantage gained in maximum cell density generated by TBP 
overexpression.  
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3.2.7 Pre-stress transfected clone analysis 
 
Prior to examining the characteristics of the stressed populations, a selection of pre-
stress clones were examined under standard culture conditions to assess the sole effect 
of TBP and Library transfection (and empty vector control transfection) on the 
parental CHO-K1 cells used in this experiment.  
 
Originally, the wild-type TBP gene was transfected alongside its mutant library 
counterpart as well as the empty vector control. By measuring a mixed population, this 
would return an average result of cell growth and viability made up of each 
population’s constituent single cells. However, as the mutant library transfected 
population introduces an increased level of heterogeneity due to the different mutant 
TBP sequences contained within each of the constituent cells, this ‘average’ result 
would be generated from cells expressing both advantageous and deleterious 
sequences. 
 
In order to look closer at the effects of each transfection a number of single cell clones 
from each population were compared to investigate, on a clonal level, the effect each 
transfection may have. By comparing a selection of clones, this allows us to see the 
range of possible phenotypic effects different mutant TBP sequences may have on 
individual cells, while an averaged result from this selection would also give an 
indication as to the cumulative effect that the expression of mutant and wild type TBP 
sequences would have in a mixed population 
 
In this experiment 12 clones from each of the empty vector, TBP and Library 
transfected cells were examined alongside clones isolated from a parental CHO-K1 
population. These were grown in serum free medium under standard suspension 
conditions using multi-well suspension culture plates (working volume of 1ml) 
agitated at 170 rpm. Each clone was seeded at 2 x 10
5
 viable cells in triplicate and 
measured using the Guava Easycyte flow cytometer. 
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3.2.7.1 Pre-stress transfected clone results 



























Figure 3.2.7.1.1: Average viable cell densities from groups of 12 clones isolated from 
each pre-stress mixed population, with error reported as the standard deviation of 
inter-clonal variability within each group. Clones were grown in triplicate (3x1ml), 
with single samples from each replicate analysed daily.  
 





















Figure 3.2.7.1.2: Average percentage viabilities from groups of 12 clones isolated 
from each pre-stress mixed population, with error reported as the standard deviation of 
inter-clonal variability within each group. Clones were grown in triplicate (3x1ml), 
with single samples from each replicate analysed daily.  
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Figure 3.2.7.1.3: Accumulated integrated viable cell density (AIVCD) of each group 
of 12 clones analysed, with error reported as the standard deviation of inter-clonal 
variability within each group. AIVCD describes the cumulative result of the integrated 
area below the cell curve (e.g. figure 3.2.7.1.), allowing us to compare the total ‘cell-
time’ of each cell curve when total cell density and viability varies between samples. 
 
3.2.7.2 Pre-stress transfected clone discussion 
The results detailed above are displayed as an average result from each group of 12 
clones, with error bars displaying the standard deviation arising from the clonal 
differences across each group. This data was presented in such a manner to allow us to 
assess the impact of each treatment (or lack thereof) in a general sense, while enabling 
us to investigate individual clones and the maximum potential of successful 
individuals from each population. 
 
Looking at each variable individually, we can begin to understand the differences 
between the groups and the impact each treatment has had. 
Examining the viable cell density graph, we first see the differences in maximum 
viable cell density reached on day 5. As predicted from the stress selection procedure, 
wild type TBP over expression appears to have a positive effect on cell growth, with a 
41.9% increase in maximum cell density reached over the untransfected K1 control. 
However, this average increase is only 13% over the more similar empty vector 
control. 
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Despite the apparent advantage in maximum growth gained from the transfection 
procedure, viable cell density remains similar in both control groups in the growth 
(days 2-4) and decline phases (days 6-8). Increased viable cell density is notable in the 
TBP group in the latter part of the growth curve, maintaining the highest levels from 
day 5 onwards.  
As expected, Library transfected cells display the highest amount of variability with 
almost a twofold range of densities on day 5 within its particular group (from 1.6 x 10
6
 
viable cells to 3.11 x 10
6
 viable cells per ml). This is likely due to their inherent 
heterogeneity stemming from the variety of mutant sequences expressed within, 
compared to the relatively heterogeneous TBP clones (3.38 x 10
6
 - 3.52 x 10
6
 viable 
cells per ml). Prior to the application of any stress or selection the overall effect of the 
TBP library seems to be deleterious, with Library clones exhibiting an average 37% 
decrease in maximum viable cell numbers reached compared to its wild type 
equivalent indicating that, in the absence of a selective pressure, mutant TBP 
sequences on average do not pose a benefit. 
 
When percentage viability (figure 3.2.7.1.2) is looked at independent of cell density, 
we see mostly similar results across all groups for the greatest proportion of the 
growth curve, with the only standout result being the actual increase in this percentage 
for Library viable cells on day 7. This may be a result of reduced waste and increased 
availability of nutrients due to lower cell densities throughout the culture, allowing for 
greater viability at this later stage. 
 
Figure 3.2.7.1.3 displays the accumulated integrated viable cell density (AIVCD) of 
each clonal group. This metric represents the accumulated hours of viable ‘cell time’ 
units existing in a culture up to a given point, with this figure increasing as cells persist 
(this figure may still grow as cells begin to become apoptotic, however then rate of 
growth will increase or decrease in relation to changes in cell density). 
This metric was chosen for use in this study due to the inherent difficulties in 
comparing cell lines and growth curves with varying levels of viability and cell 
density, and makes direct comparisons easier. For example, a temperature shifted 
CHO culture typically experiences a reduction in cell growth in tandem with delayed 
onset of apoptosis (Moore et al. 1997). This later stage cell survival brings an overall 
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benefit to the longevity of culture, with an improved AIVCD possible despite its lower 
cell density in comparison to an identical culture incubated at a higher temperature. 
 
This figure is calculated using the following formulae. Growth rate is first determined 
and then used in turn to calculate the daily integrated viable cell density (IVCD, i.e. 
the area encompassed by the growth curve). The cumulative sum of these IVCD 
figures is then used to calculate AIVCD, with units denoted as [cell-hours/ml]  
 
  Growth Rate  = [Ln.Density (b) – Ln.Density (a)] / [Hours elapsed] 
  Daily IVCD  = [Density (b) – Density (a)] / [Growth rate*24] 
     AIVCD  = Day 1 IVCD + Day 2 IVCD…. + Day (x) IVCD 
 
Looking at the AIVCD curve generated for the samples used in this experiment (fig 
3.2.7.1.3), we can see the overall potential of each cell line in terms of growth and 
sustained viability. Comparing the control populations (K1 and pcDNA), we see a 
difference of 8.5% in final day AIVCD for the control transfected population, with a 
similar co-efficient of variation (C.V.) for both (17.5% and 18.5% respectively). 
However, a students t-test comparing the day 8 AIVCD totals for each selection of 12 
clones indicates that despite the small increase in average performance there is no 
significant statistical difference between these groups (p=0.28) 
TBP overexpression does appear to provide a beneficial impact on overall 
performance, with a 25.9% and 16.1% increase in day 8 AIVCD over the K1 and 
pcDNA control populations respectively. TBP clones also display less variety in their 
overall performance, with a day 8 AIVCD clonal C.V. of 7.0%, with a notable 
statistical difference between the TBP population and the empty vector controls 
(p=0.01).  
Library transfected cells also behave as predicted, with a wide variety in performance 
in all metrics measured. However, despite a lack of selection, we can see the potential 
of individual clones even in the relatively small sample measured here. For example, 
while the day 8 AIVCD for TBP clones range from 1.0 - 1.25 x 10
7
 cells, Library 
clones present a more extreme range of values from 3.69 x 10
5
 for the poorest clone 
isolated up to 1.6 x 10
7
 for the highest performing clone. These ranges are visualised 






























Figure 3.2.7.2.1: Box-plot representation of the spread of resulting final day 
accumulated cell integrals (AIVCD) from the data displayed in fig 3.2.7.1.3. Median 
values are represented, flanked by coloured boxes representing upper and lower 
quartiles. A t-test comparing clonal groups indicates the consistent phenotypic benefit 
of TBP overexpression compared to the pcDNA control (p=0.01), while unselected 
Library expression provides a wide range of clonal behaviour, with  examples of both 
positive and negative extremes represented by asterisks. 
 
From the data generated above, we can conclude that TBP overexpression alone 
provides a consistent benefit to cell growth and the ultimate performance of a culture 
as measured by its accumulated IVCD in comparison to a similarly treated control cell 
line. We can also see that the mutant TBP library generates both positive and negative 
results, likely as a result of the different sequences expressed in each clone. This is in 
the absence of selection, and while clones with beneficial properties in excess of those 
provided by the wild type gene were isolated in this instance, we would expect the 
proportion of advantageous clones to increase once a selective pressure has been 
applied. 
p = 0.01 
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3.2.8 qPCR to determine TBP expression in mixed populations 
 
Prior to the examination or characterisation of post-stress clones, qRT-PCR was 
carried out on stressed TBP and Library mixed populations to investigate expression 
levels. 
To determine the levels of TBP expression within these populations, reverse 
transcription was first carried out on mRNA isolated from actively growing TBP and 
Library transfected cell cultures, as well as a pcDNA empty vector control to generate 
cDNA (see section 2.3.11). qRT-PCR was then carried out using primers designed to 
bind to the 3’ end of the cDNA molecule using the protocol detailed in section 2.3.12. 




Forward 5’ – TTCTCCTTATTTTTGTTTCTGG – 3’ 
Reverse 5’ – TATGTGGTCTTCCTGAATCC– 3’ 
 
Figure 3.2.8.1: Primer sequences used in the qPCR reaction. These were designed to 











Figure 3.2.8.1.1: Graph detailing relative gene expression levels of TBP within the 
stressed cell TBP and Library transfected populations. Each cell line was grown in 
biological triplicate, with technical triplicate cDNAs analysed via qPCR from each 
sample using the primers described in figure 3.2.8.1. Error is represented as the 
standard deviation of these multiple samples. TBP and Library samples are 
normalised to pcDNA (control) expression. 
 
 
Wild type and mutant library TBP were found to be over 5.7 and 9.6 times higher 
respectively in mixed populations than the empty vector transfected reference sample. 
This was carried out on post-stress mixed pools to ensure that possible improvements 
and variation were related to TBP and Library overexpression. If cells with TBP and 
Library expression were ultimately deleterious overall, we would expect 
overexpression to be selected out by an evolutionary pressure, with differences 
simply a result of natural clonal variation. This verification experiment was carried 
out before further investigative work into post-stress clones was considered. 
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3.2.9 Post-stress transfected clone analysis 
 
From the previous experiments carried out and the resulting data generated, we 
initially concluded that TBP overexpression bestowed a consistent benefit in terms of 
cell growth. This extra growth did not come at the cost of a drop in viability that one 
might expect from the increased consumption of nutrients etc. associated with a 
higher cell density, leading to an overall increase in useful cell-time as measured by 
an increase in the calculated AIVCD. This effect was also noted in a portion of high 
performing Library transfected clones, however the overall result from this clonal 
group was poor due to the contribution of deleterious clones to the average result. 
 
An experiment was carried out similar to that detailed above on a selection of TBP 
and Library clones isolated from both of the post-stress populations. This was done in 
order to investigate whether the stress procedure would, as hypothesised, select for 
Library cells with beneficial mutations as well as acting as a formative stress, causing 
changes in gene regulation and expression as a response to the unfavourable 
environmental conditions these cultures were challenged to grow in. By focusing on a 
selection of Library and TBP clones, this experiment would determine whether the 
selective process was capable of eliminating the large number of deleterious mutant 
TBP sequences from the Library transfected population and improve the overall 
fitness of this group.  
 
This experiment was carried out using the same conditions as those described 
previously in 3.2.7, with clones seeded at 2 x 10
5
 viable cells in triplicate and grown 
in a 1ml working volume of serum free medium. 12 clones were isolated from Library 
and TBP cultures resulting from both ‘viability’ and ‘low density’ stress procedures, 
and their relevant phenotypes examined. Each clone was measured daily using the 
Guava Easycyte flow cytometer.
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3.2.9.1 Post-stress clone results (‘Viability’ stress) 
























Figure 3.2.9.1.1: Average viable cell densities from groups of 12 clones isolated from 
each post-stress mixed population, with error reported as the standard deviation of 
inter-clonal variability within each group. Clones were grown in triplicate (3x1ml), 
with single samples from each replicate analysed daily. 
 



















Figure 3.2.9.1.2: Average percentage viabilities from groups of 12 clones isolated 
from each post-stress mixed population, with error reported as the standard deviation 
of inter-clonal variability within each group. Clones were grown in triplicate (3x1ml), 
with single samples from each replicate analysed daily. 
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Figure 3.2.9.1.3: Accumulated integrated viable cell density (AIVCD) of each group 
of clones analysed, with error reported as the standard deviation of inter-clonal 
variability within each group. The highest performing clones from each group are also 



























Figure 3.2.9.1.4: Box-plot representation of the spread of resulting final day accumulated 
cell integrals (AIVCD) from the data displayed in fig 3.2.9.1.3. Median values are 
represented, flanked by coloured boxes representing upper and lower quartiles. A t-test 
comparing the statistical difference between groups returns the value p=0.08.
p = 0.08 
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3.2.9.2 Post-stress clone discussion (‘Viability’ stress) 
The results detailed above are displayed as an average result from each group of 
clones, with error bars displaying the variability arising from the clonal differences 
across each group. It should be noted that while 12 clones from each group were 
assayed, due to persistent evaporation in a corner well of the suspension culture plates 
used leading to unreliable results, the results of 1 TBP clone was omitted from the 
final analysis. 
 
This experiment was carried out to examine the difference between the stressed TBP 
and Library populations on a clonal level. The previous experiment had established the 
beneficial effect of TBP overexpression, however prior to any selective pressure the 
Library transfected cells displayed a poor average performance. Despite the inclusion 
of a number of advantageous clones in the Library sample set, the median AIVCD 
result was found to be poorer than the empty vector control, indicating the negative 
effect that deleterious mutant TBP sequences were having on the unselected Library 
population as a whole. We would predict the stress procedure to remove these 
deleterious mutants an ultimately improve the overall fitness of the Library transfected 
pool. 
 
When we examine these results we see a marked increase in Library clone 
performance compared to its wild type TBP counterpart, suggesting the stress 
procedure was successful in eliminating a large proportion of Library cells expressing 
detrimental TBP mutants. In general, average Library clone results exceed those of 
TBP in terms of viability, while the viable cell concentrations suggest a difference 
between the growth curves, with Library cells continuing to grow until their maximum 
on day 6 (2.2 x 10
6
 viable cells per ml, see figure 3.2.9.1.1) compared to the day 5 
TBP maximum (2.07 x 10
6
 viable cells per ml), with a difference of 6.3%. This 
improvement in both maximum cell density and overall viability contribute to a 16.1% 
increase in final day AIVCD (figure 3.2.9.1.3). 
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In this experiment, both populations display a high degree of clonal variability in their 
overall performance. For TPB this is in contrast to its pre-stress performance, with an 
increase in final day AIVCD variance from 7.0% to 16.8% in this instance. However, 
this level of heterogeneity in Library clones is lower in comparison to their pre-stress 
counterparts, with AIVCD variance reduced from 55.2% to 21.4% in this experiment. 
A student’s t-test comparing the final day AIVCD values of both populations provides 
a p-value of 0.08, suggesting the differences between these populations is not wholly 
significant with only 2.7% difference in median values (compared to the 16.1% mean 
difference, see figure 3.2.9.1.4). However, the improvement of Library transfected 
cells from their unstressed counterparts in unmistakeable, and due to the inherent 
variance of this population a number of high performing clones worthy of further 
characterisation were isolated in the outlying portion of AIVCD performance (see 
clone A03 in figure 3.2.9.1.3) 
 
Notably, both TBP and Library populations drop below 40% viability between days 6 
and 7, while surviving at low percentages until day 10 (see figure 3.2.9.1.2). This in 
contrast to the pre-stressed populations, which did not drop below this level until day 
8. However this crash in viability was more pronounced, with no cells surviving 
beyond this day. This may be the result of an evolutionary response to the stress 
procedure, selecting for cells with a slower decline in the latter stages of culture. It 
also may be a result of nutrient depletion due to a higher maximum cell density 
reached by stressed cells, (suggested by the improvement in maximum Library viable 
cell density) causing an earlier decline below this threshold. 
 
Unfortunately, the comparison of inter-experimental absolute cell totals was hampered 
by the cell counting method used in the course of this study, and direct comparisons 
between the viable cell concentrations of different studies was unreliable. Due to a 
number of mechanical errors, part replacements and changes in operational procedures 
for the cytometer used throughout this thesis, drifts in calibration over time do not 
allow us to make accurate direct comparisons. While the data generated here indicates 
an improvement in Library cells resulting from the stress procedure compared to wild 
type TBP, further direct comparisons of clones from both pre- and post- stress 
populations allowed us to make more quantifiable conclusions regarding the benefit of 
the stress procedure overall, particularly with regard to cell density. 
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3.2.9.3 Post-stress clone results (‘Low density’ stress) 
This experiment was carried out as a follow up to the preliminary results gained 
throughout the course of the stress procedure designed to select for cells with an 
improved growth rate. While these initial results indicated no apparent benefit to the 
initial growth rate of TBP and Library transfected and selected cells (section 3.2.6.3), a 
selection of 12 clones from both Library and TBP cultures resulting the ‘low density’ 
stress procedure were isolated and grown under standard culture conditions. 
 
For this experiment, viable cell density was measured for the first 4 days of growth. In 
order to examine the exponential growth of these cultures both a basic growth rate 
calculation ([Ln.Density (b) – Ln.Density (a)] / [Hours elapsed]) was used as well as a 
more sophisticated online model using least square fit of exponential data (Roth 2006) 
to calculate the average days per doubling for this data. 
 






































Figure 3.2.9.3.1: Viable cell density from each group of 12 clones analysed, with error 
reported as the measure of clonal variability within each group. Cell lines were seeded 
in triplicate at 2 x 10
5
 viable cells in 5ml suspension culture, and sampled every 24 











Library 0.0258 7.1% 1.04 11.8% 
TBP 0.0278 6.3% 0.86 7.5% 
 
 
Figure 3.2.9.3.2: The average hourly growth rate and ‘days per doubling’ metrics as a 
measured average of the 12 clones isolated from the ‘low density’ stress mixed 
populations. Each clone was analysed separately using a basic growth rate calculation 
(growth rate/hour) and least square fit analysis tool (days per doubling), and the 
resulting figures analysed as a group to generate the results above. Differences 
between Library and TBP appear significant, with t-tests comparing both growth rate 





3.2.9.4 Post-stress clone discussion (‘Low density’ stress) 
The results detailed above are displayed as an average result from each group of 
clones, with error and CV detailing the levels of clonal variability within each group. 
Ideally, we would see an increased growth rate and reduction in days per doubling in 
the Library cells to indicate that the stress procedure had indeed selected for 
advantageous clones. However, the reverse was observed in the data generated.  
 
Looking at the growth curve generated (day 0-4), we see a slight reduction in viable 
cell density for TPB transfected cells for the first 48 hours compared to the stressed 
Library clones. This is similar to the initial dip in viability witnessed in unstressed 
TBP clones, suggesting a slight negative impact of TBP overexpression in early (i.e. 
24-48 hours post seeding) culture periods. This growth advantage in Library 
transfected cells is lost by day 3 however, and the average hourly growth rate across 
the four days is on average 7.3% less in Library clones (p<0.01 when comparing these 
two groups). The least square fit analysis of this data also confirms this difference, 
with an average doubling time of over 24 hours (1.04 days) for Library cells, 
compared to less than 22 hours (0.86 days) for TBP clones. 
 
From this data we can conclude that the transfection of the mutant library provides no 
additional benefit to initial cell growth speed after the application of the ‘low density’ 
stress procedure in comparison to the use of the wild type TBP gene. This may be 
indicative of the relative usefulness of the stress applied, with no strong negative 
selective pressure endured by these cultures (compared to the harsher conditions of the 
‘viability’ stress for instance). It may also indicate that TBP or its mutant derivatives 
may be of no use with regards to improving initial growth speed, with a previous study 
identifying TBP responsive genes as being traditionally linked to cellular stress 
responses, as opposed to basic metabolic functions that may have a greater impact on 
initial growth (Yang et al. 2007).  
 
Ultimately, due to the lack of any noticeable improvement in the Library transfected 
cells, these clones were discarded and further characterisation carried out on the more 
promising advantageous clones isolated from the ‘viability’ stressed cultures. 
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3.2.10 qRT-PCR to determine TBP expression in selected clones 
 
After the characterisation of the clones isolated from stressed mixed populations, 
qPCR was also carried out on selected clones using the same process as detailed in 
section 3.2.8. 
 
To determine the levels of TBP expression within these populations, reverse 
transcription was first carried out on mRNA isolated from actively growing TBP and 
Library transfected clones, using a previously isolated pcDNA control mRNA sample 
as a control. qRT-PCR was then carried out using primers designed to bind to the 3’ 
end of the cDNA molecule using the protocol detailed in . PabpnI was used a 
housekeeping control to normalise gene expression levels across these samples. 
 
 
Forward 5’ – TTCTCCTTATTTTTGTTTCTGG – 3’ 
Reverse 5’ – TATGTGGTCTTCCTGAATCC– 3’ 
 
Figure 3.2.10.1: Primer sequences used in the qPCR reaction. These were designed to 







3.2.10.1 TBP qRT-PCR (selected clone) results 





























































Figure 3.2.10.1.1: Graphs detailing relative gene expression levels of (a) TBP and (b) 
mutant library within the stressed cell TBP and Library transfected populations. The 
“2(-ΔΔCt)” method was used to calculate expression relative to the PabpnI housekeeping 
gene, with fold change normalised to an untransfected CHO control. RNA Samples 
were isolated from actively growing cultures, and analysed via qPCR using triplicate 









Figure 3.2.10.1.1 describes the relative expression of TBP in the 12 clones isolated 
from the ‘viability’ stress TBP and Library transfected populations analysed in the 
previous experiment. Interestingly, many of these clones, including some found to 
exhibit advantageous properties, did not express TBP (or its mutant derivatives) at the 
higher levels indicated by the mixed population results. This may be a result of each 
individual clone’s particular configuration, with gene copy number, position effects 
and associated epigenetic regulation affecting expression levels. 
 




















Figure 3.2.10.1.2: Scatter plot comparing relative TBP expression (data generated in 
this study) to final day AIVCD values generated in section 3.2.9. This data suggests no 
statistical correlation (R
2
=0.06) between these two variables, however the relatively 
small sample size (n=24) may inhibit the confidence of this conclusion. 
 
These figures were not found to correlate specifically to metrics such as maximum cell 
density or final day AIVCD (such as the example comparison displayed in figure 
3.2.10.1.2), suggesting that TBP and library expression levels are not the direct cause 
of any changes in phenotype and would not serve as a predictive marker for an 
improvement in performance. Rather, phenotype is likely a result of more complex 
changes in overall gene expression patterns mediated in some way by the 
overexpression of TBP and, in the case of Library transfected cells, the various effects 
of different mutant sequences, with the forced evolutionary stress selecting for 
advantageous differences. 
 190 
3.2.11 Pre-stress versus post-stress direct comparison 
 
At this point, the data generated with regard to the pre- and post-stress clones (selected 
under deleterious late stage culture conditions) indicated a benefit to overall cell 
performance (AIVCD) from TBP overexpression, as well as a likely additional benefit 
arising from selected Library expression after prolonged exposure to the stressed 
environment. However, in the absence of a direct comparison (made difficult due to 
disparities in inter-experimental absolute cell numbers arising from technical 
complications), it was impossible to rule out a number of potential explanations for 
these apparent differences. For instance, it could be argued that while Library clone 
performance is improved in comparison to the wild type TBP transfected clones, this 
apparent improvement may be due to an actual drop in post-stress TBP culture 
performance (this theory would be supported by the gradual drop in TBP culture 
viability over the course of the stress procedure, see figure 3.2.6.1.3). 
 
In order to verify that post-stress TBP and Library clones had in fact produced a 
superior phenotype to their pre-stress counterparts, an experiment was carried out in 
order to directly compare a number of pre- and post-stress TBP and library clones 
within the same experiment. This would eliminate experimental variation as a factor in 
comparative calculations and provide direct evidence of the impact provided by the 
applied stress. 
 
For this experiment the top 3 performing clones were chosen from previously isolated 
Library and TBP clone panels, both stressed and unstressed. Samples were assayed in 
triplicate in 1ml suspension format and seeded at 2 x 10
5
 viable cells per ml, with 
samples removed for analysis daily. Arising from the variability of clonal 
performance, we have demonstrated the ability to extract clones with phenotypic 
characteristics greater than the average performance of their original respective panels, 
with this effect being more pronounced in the heterogeneous Library populations as 
would be predicted. Comparing these ‘strong’ clones from each group would 
demonstrate that, with even a modest amount of screening, advantageous clones with 




3.2.11.1 Direct comparison results 



























Figure 3.2.11.1.1: Viable cell density curves from individual pre-stress clones 
characterised in this study. Each cell line was grown in triplicate (3x1ml), with single 
samples from each replicate analysed daily. Unstressed TBP clones denoted [T(U)1-3] 
are marked in red, with unstressed Library clones [L(U)1-3] are marked in red to 
highlight the differences between treatments.  
 



























Figure 3.2.11.1.2: Viable cell density curves from individual post-stress clones 
characterised in this study. Each cell line was grown in triplicate (3x1ml), with single 
samples from each replicate analysed daily. Stressed TBP clones denoted [T(S)1-3] 
are marked in red, with stressed Library clones [L(S)1-3] are marked in red to 
highlight the differences between treatments.  
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Figure 3.2.11.1.3: Percentage viability curves from individual pre-stress clones 
characterised in this study. Each cell line was grown in triplicate (3x1ml), with single 
samples from each replicate analysed daily. Unstressed TBP clones denoted [T(U)1-3] 
are marked in red, with unstressed Library clones [L(U)1-3] are marked in red to 
highlight the differences between treatments. 
 























Figure 3.2.11.1.4: Percentage viability curves from individual post-stress clones 
characterised in this study. Each cell line was grown in triplicate (3x1ml), with single 
samples from each replicate analysed daily. Stressed TBP clones denoted [T(S)1-3] 
are marked in red, with stressed Library clones [L(S)1-3] are marked in red to 
highlight the differences between treatments.  
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Figure 3.2.11.1.5: AIVCD results from individual pre-stress clones characterised in 
this study, an alternative method of analysis for the data presented in figure 3.2.11.1.1 
represented as cumulative “cell-hours”. Unstressed TBP clones [denoted T(U)1-3] are 
marked in red, with unstressed Library clones [L(U)1-3] are marked in red to highlight 
the differences between treatments. 
 

































Figure 3.2.11.1.6: AIVCD results from individual pre-stress clones characterised in 
this study, an alternative method of analysis for the data presented in figure 3.2.11.1.2 
represented as cumulative “cell-hours”. Stressed TBP clones [denoted T(S)1-3] are 
marked in red, with stressed Library clones [L(S)1-3] are marked in red to highlight 
the differences between treatments. 
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3.2.11.2 Direct comparison discussion 
The figures detailed above describe the viable cell densities, percentage viabilities and 
AIVCD values for individual clones as measured over the course of this study. While 
previous clonal results were usually grouped and discussed with respect to the average 
performance of a particular panel of clones, the reduced sample sizes of these groups 
and relative variation in performances for these clones make average comparisons 
difficult to interpret over the course of the majority of the graphs generated, and as 
such are displayed individually. 
 
Looking initially at the performance of the unstressed TBP group, we see a relatively 
homogenous set of results from the 3 clones analysed. Maximum cell density peaks on 
day 4 at ~2.4 x 10
6
 viable cells per ml, with viability steadily decreasing at this point 
till complete death on day 8. This homogeneity is reflected in their final day AIVCD, 
with the 3 clones clustering tightly around an average of 7.7 x 10
6
 viable cell hours per 
ml. 
As noted in the post-stress clone analysis carried out previously, the stress procedure 
appears to increase variability in the TBP transfected clones, and the 3 characterised in 
this instance provide 3 very different growth patterns; T(S)1  maintaining a steady 
pattern of growth and decline with a mid curve cell density peak between days 5 and 6, 
T(S)2 achieving a higher maximum viable cell density (4.8 x 10
6
) on day 4 with a 
sharper decline to below 30% viability by day 6, and T(S)3 managing to achieve 
steady growth until a day 7 maximum above 5.2 x 10
6
 viable cells on day 7, before a 
total crash in viability was measured 24 hours later. This peculiar growth pattern 
contributes to an impressive final AIVCD of 1.67 x 10
7
, greater than double the 
average of their unstressed counterparts, while T(S)1 & 2 average ~1.16 x 10
6
 viable 
cell hours per ml AIVCD.  
Despite the heterogeneity introduced into the TBP transfected population by the stress 
procedure as noted in both examinations of post-stress clones, this stress does indeed 
appear to benefit the overall performance of these clones, with the average 
performance increased from 7.69 x 10
6
 viable cell hours per ml (pre-stress) to 1.33 x 
10
7
 viable cell hours per ml (an increase of 73.3%). 
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An examination of the pre-stress Library transfected clones reveals two clones with 
almost identical behaviour (L(U)1&3), with another particularly potent clone (L(U)2). 
While 1&3 maintain a relatively flat curve once reaching a maximum of ~1.4 x 10
6
 
viable cells per ml, L(U)2 manages to reach over 4.3 x 10
6
 on day 5. Each clone 
maintains a similar steady drop in viability until day 8, although this is a less 
pronounced decline than the wild type TBP pre-stress clones with all 3 sustaining 
viability >60% by day 6. This could be related to the comparatively smaller maximum 
cell density reached for L(U)1&3, with a reduction in initial nutrient depletion 
permitting a longer survival. However the surprising maximum density of L(U)2 
suggests this clone has incorporated beneficial mutant TBP sequences allowing it to 
retain its later stage (days 5-7) viability percentages in combination with its high cell 
densities, and has likely been isolated by chance in this case in the absence of any 
selective pressure or selection.  
 
The post-stress Library clones exhibit more uniform behaviour than the post-stress 
TBP clones, all reaching a maximum cell density on day 4 and steadily dropping in 
percentage viability and viable cell numbers until day 8 or 9. The rate of change in 
viability does not appear to be significantly different in post-stress Library clones 
compared to their pre-stress counterparts. However the drastic increases in cell 
densities seen through out the stressed library clone growth curves contribute to the 
greater final overall results gained from the clones analysed here (a 60.6% 
improvement in average day 9 AIVCD from 9.52 x 10
6
 to 1.53 x 10
6
 viable cell hours 
per ml). 
 
The data generated here appears to confirm that the stress procedure has a positive 
effect on both TBP and Library transfected clones. This experiment was performed on 
a relatively small sample set of only 3 clones from each treatment. However, as these 
were the top performing clones from their original panels, any apparent improvements 
in performance when these groups are directly compared prove significant when 
considering the effect of both mutagenesis and stress as these clones represent the 




While the original stress was carried out to select for cells with resistance to apoptotic 
culture conditions, the comparative data generated here suggests increases in viable 
cell density rather than percentage viability to be more of a contributing factor to the 
overall improvements in performance noted previously. In this instance, no significant 
cell survival was demonstrated beyond day 9 in any cell line tested. However due to 
the average increased viable cell density in post-stress clones, the likelihood of an 
apoptotic environment and nutrient depletion affecting these clones at earlier time 
points may be suggestive of an actual resistance to such conditions. In any case, in a 
given industrial cell culture situation, an increased maximum cell density (reflected in 
useful AIVCD cell hours) is likely to be beneficial in generating a greater proportion 
of product and is ultimately a useful characteristic to improve upon.  
 
Environmental nutrients are finite, imposing a limit to the level of growth and survival 
possible in a given batch culture set up (for example, no clone assayed in this instance 
manages to overcome a limit of 1 x 10
7
 viable cell hours, while a number of successful 
clones converge on this limit). However, improvements to late stage culture viability 
could possibly be improved upon with the supplementation of additional nutrients. 
This would hopefully provide further noticeable performance gains in conjunction 
with the artificially engineered cell growth measured here, a theory that is explored in 
later experiments. 
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3.2.12 Scale-up phenotype investigation (selected clones) 
 
Previous experimentation up until this point had largely been carried out to determine 
the differences between the various treatments used in this study, and the advantages 
in growth and viability gained from each. These differences were determined through 
screening investigations of clones isolated from each group, with the effect of each 
treatment (i.e. TBP/Library overexpression and the application of a selective stress) 
measured by looking at the average difference between these groups of clones. For 
practical reasons these comparison were generally carried out in small scale 
suspension cultures using 1ml multiwell plates to allow the comparison of larger 
numbers of clones. Experiments carried out on these clones suggested benefits to 
cellular phenotype after the application of a suitable selective stress, as well as a 
heightened ability to isolate advantageous clones from a population expressing mutant 
copies of a beneficial gene due to the artificial heterogeneity contained within. 
 
Having isolated a number of seemingly advantageous clones with improved 
phenotypic growth and viability properties, this experiment was carried out in scaled 
up 50ml suspension cultures. While small scale cultures had proven useful for 
screening of larger numbers of individual clones, larger scale vessels were then used 
to ensure that these phenotypes could be replicated in environments more closely 
resembling those of large scale industrial reactors in which such cell lines might prove 
useful, as well as reducing some of the problems associated with multiwell plates such 
as evaporation. 
This comparison was carried out using the three best performing TBP and Library 
clones (used in the previous comparison to evaluate the effect of the stress procedure). 
As a controlled comparison, two common in-house cell lines were used; an 
untransfected CHO-K1 line derived from the original parental cells used in this study 
(representing basal cell line performance), as well as a SEAP expressing cell line 
shown to proliferate rapidly to high densities (CHO-SEAP, representing a known high 
performing cell line).
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3.2.12.1 Scale-up investigation (selected clones) results 































Figure 3.2.12.1.1: Viable cell densities of the 6 isolated advantageous clones over a 10 
day batch culture in 50ml volume seeded at 2x10
5
 viable cells per ml. Also included 
are 2 control CHO cell lines (K1 and SEAP). Cell lines were seeded in individual 
50ml suspension culture flasks, with triplicate samples taken daily for analysis. 
  

























Figure 3.2.12.1.2: Percentage viability of the 6 isolated advantageous clones over a 10 
day batch culture in 50ml volume seeded at 2x10
5
 viable cells per ml. Also included 
are 2 control CHO cell lines (K1 and SEAP). Cell lines were seeded in individual 









































Figure 3.2.12.1.3: AIVCD analysis of the data generated by the 6 isolated advantageous 
clones. Cell lines were seeded at 2x10
5
 viable cells per ml in 50ml volume and 
measured over a 10 day batch culture. Also included are 2 comparative control CHO 




























Figure 3.2.12.1.4: Day 10 AIVCD data of the 6 isolated advantageous clones and 2 
comparative control cell lines. To ensure reproducibility, this experiment was also 
repeated in both flask (50ml working volume) and triplicate suspension culture tube 
(5ml working volume) growth formats. Error bars in this figure represent standard 
deviation measured between all replicate experiments carried out in both formats.
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3.2.12.2 Scale-up investigation (selected clones) discussion 
 
This data illustrated in section 3.2.12.1 details the high growth potential of all the 
advantageous TBP and Library clones isolated in this study.  
All clones manage to reach peak densities >7 x 10
6
 viable cells per ml on day 5 (with 
the exception of T(S)3, measuring 6.56 x 10
6
 viable cells per ml peak density). These 
results compares favourably to CHO-SEAP with a 6.77 x 10
6
 viable cell maximum, 
considering this is one of the most proliferative cell lines commonly used in this 
institute. This also marks a 65% average increase in maximum density over the 
parental K1 cell line originally used to generate the transfected cell lines used in this 
study. 
 
Despite the high concentrations of cells reached by day 5, viability was maintained at 
higher levels in most experimental cell lines than both controls for the majority of 
culture. CHO-SEAP dropped to below 30% viability by day 6, with experimental 
clones averaging above 60% at this time point. K1 viability dropped precipitously after 
day 5 to complete death. 
 
These heightened levels of both cell density and viability allowed all experimental 
clones to outperform both controls in terms of day 10 AIVCD, with selected Library 
and TBP clones exhibiting an average of 2.48 x 10
7
 and 2.80 x 10
7
 viable cell hours 
per ml respectively. This relates to an average of 33.9% higher AIVCD for Library 
clones and 21.7% for TBP clones when compared to the high density SEAP cells.  
 
To ensure reproducibility, this experiment was also repeated in both flask (50ml 
working volume) and triplicate suspension culture tube (5ml working volume) growth 
formats. Similar results were returned in these experiments, and the data presented 
here in figures 3.2.12.1.1-3.2.12.1.3 displaying the results generated from the first 




3.2.13 Scale-up phenotype investigation (mixed populations) 
 
While the data from the previous section details the results gained from the selected 
clones isolated from mixed populations, this scale-up experiment was also repeated on 
TBP and pcDNA stressed and unstressed mixed populations. 
This was originally carried out to provide cell samples from which RNA could be 
extracted for future profiling experiments, however the results prove useful in their 
own right by demonstrating the growth patterns of these mixed populations as well as 
indicating the relative effects of the stress procedure and TBP overexpression in 
comparison to the control cell lines K1 and SEAP. 
 
In the resulting data, unstressed populations are denoted pcDNA-U and TBP-U, while 
stressed populations are denoted pcDNA-S and TBP-S. 
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3.2.13.1 Scale-up investigation (mixed populations) results 






































Figure 3.2.13.1.1: Viable cell densities of the pre-/post-stress TBP and pcDNA mixed 
populations in 50ml volume seeded at 2x10
5
 viable cells per ml. Also included are 2 
control CHO cell lines (K1 and SEAP). Cell lines were seeded in individual 50ml 
suspension culture flasks, with triplicate samples taken daily for analysis. 
 























Figure 3.2.13.1.2: Percentage viability of the pre-/post-stress TBP and pcDNA mixed 
populations in 50ml volume seeded at 2x10
5
 viable cells per ml. Also included are 2 
control CHO cell lines (K1 and SEAP). Cell lines were seeded in individual 50ml 


































Figure 3.2.13.1.3: AIVCD analysis of the data generated by pre-/post-stress TBP and 
pcDNA mixed populations. Cell lines were seeded at 2x10
5
 viable cells per ml in 50ml 
volume and measured over a 10 day batch culture. Also included are 2 comparative 


























Figure 3.2.13.1.4: Day 10 AIVCD data of the pre- and post-stress TBP and pcDNA 
mixed populations. Also included are the comparative control cell lines K1 and SEAP, 
as well as the performance of the highest performing clone (L(S)2) as measured in the 
previous set of results. Error bars represent the standard deviation of results between 
replicate experiments (carried out in both flask and tube formats). 
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3.2.13.2 Scale-up investigation (mixed populations) discussion 
 
The results gained from the mixed population growth curves are generally indicative 
of growth and viability patterns confirmed in previous clonal screen studies, but serve 
as a useful confirmation of the differences between treatments. Library transfected 
mixed populations were originally ruled out of any potential profiling experiment due 
to the likelihood of a noisy heterogeneous gene profile mixture, allowing us to focus 
on clones with proven advantageous phenotypes. As such, these samples were omitted 
from this study, whose original purpose was to provide samples for such a profiling 
experiment. 
 
Once again we see the benefit to growth potential of TBP overexpression compared to 
the empty vector control, with a 16.8% increase in maximum cell density between 
unstressed empty vector and TBP transfected populations, and a 38.2% increase 
between post-stress empty vector and TBP populations. These percentages are 
mirrored in the improvements for final day AIVCD, with TBP providing a 13.8% 
improvement (pre-stress) and a 30.2% improvement (post-stress) when compared to 
the empty vector control. 
 
In this instance the stress procedure appears to have had the least effect on empty 
vector control populations compared to its experimental gene-expressing counterparts. 
Post-stress pcDNA populations exhibit a benefit in viability in the later stages of 
culture, contributing to an increased AIVCD despite a slightly reduced maximum cell 
density. However, without the increased growth potential granted by TBP 
overexpression, the benefit to post-stress AIVCD is less pronounced. This result may 
also be contributed to by the lack of variation in gene expression in these cells, a factor 
demonstrated in this study as being advantageous for directed evolution by TBP and 
Library cells.  
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3.2.14 Investigation of selected clone productivity  
 
The data generated to this point has demonstrated the advantages gained from stressed 
Library and TBP cultures with respect to growth and viability, and the positive impact 
this treatment has in terms of overall viable cell time (AIVCD). However, such gains 
would ultimately be without merit if these clones were aversely affected in terms of 
their ability to produce and secret product, a key characteristic of any cell line utilised 
in a productive industrial cell culture environment. 
 
A series of experiments were carried out to investigate whether the genetic 
engineering and directed evolution techniques applied have affected these cells’ ability 
to remain productive. A series of transient transfections were carried out using 
plasmids encoding a variety of products commonly expressed in industrial mammalian 
cell lines. These products included; 
 
 SEAP (Secreted Alkaline Phosphatase) 
A commonly used reporter gene used to estimate productivity levels, measured in 
cellular supernatant using a standard colorimetric assay  
 EPO (Erythropoietin) 
Recombinant form of human EPO, a well known biopharmaceutical product. 
Intracellular levels of this protein were measured using a western blot. 
 IgG (Immunoglobulin) 
A recombinant mouse IgG, another common industrial product. Secreted levels were 
estimated using an ELISA assay on a sample of supernatant. 
 
In each case, 1 x 10
6
 suspension cells were transfected with 2.5µg plasmid DNA in 
2.5mls serum free medium in triplicate. This was done using 7.5µl TransIT-2020 
Transfection Reagent (Mirus, cat. MIR 5400) and carried out in accordance with the 
manufacturers instructions. Transfection efficiency was estimated using a separate 
GFP plasmid transfection, with the percentage of GFP positive cells measured after 24 
hours. Due to the high initial density of transfected cells, these samples were diluted in 
fresh medium 48 hours after transfection.
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Cell Line L(S)1 L(S)2 L(S)3 T(S)1 T(S)2 T(S)3 
% GFP 66.4 61.6 70.0 60.5 54.4 51.5 
 
Figure 3.2.14.1.1: Percentage of GFP positive cells in each cell line after transfection. 
One separate control sample of cells from each cell line was transfected with a plasmid 
expressing GFP in parallel to the experimental samples. GFP positive cells (indicating 
transfection efficiency) were then measured after 24 hours. 
 
 









































Figure 3.2.14.1.2: Specific productivity of each cell line as measured on day 3. SEAP 
productivity was estimated via kinetic assay in which the rate of change of SEAP 
product is measured. Units are reported as [change in OD/min], or mean velocity. 
Triplicate tubes were transfected, with technical triplicate samples from each tube 
analysed via SEAP assay (error bars represent the resulting standard deviation). A day 
3 sample was also removed from a standard culture of CHO-SEAP (constitutively 
expressing SEAP), and the result included here as a reference. 
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3.2.14.2 EPO productivity results 
 
 
Cell Line L(S)1 L(S)2 L(S)3 T(S)1 T(S)2 T(S)3 K1 
% GFP 49.7 57.1 53.9 41.4 45.0 44.5 53.9 
 
Figure 3.2.14.2.1: Percentage of GFP positive cells in each cell line after transfection. 
One separate control sample of cells from each cell line was transfected with a plasmid 
expressing GFP in parallel to the experimental samples. GFP positive cells (indicating 
transfection efficiency) were then measured after 24 hours. A parental K1 control was 








Figure 3.2.14.2.2: Western blot of intracellular EPO isolated from transfected TBP and 
Library clones alongside an EPO transfected K1 control. 10µg protein isolated from 
cell pellets was added per well, as measured by a Bradford assay. The α-tubulin 
housekeeping gene was used as a loading control.







3.2.14.3 IgG productivity results 
 
 
Cell Line L(S)1 L(S)2 L(S)3 T(S)1 T(S)2 T(S)3 K1 
% GFP 57.1 59.8 62.3 47.6 43.1 45.3 55.4 
 
Figure 3.2.14.3.1: Percentage of GFP positive cells in each cell line after transfection. 
One separate control sample of cells from each cell line was transfected with a plasmid 
expressing GFP in parallel to the experimental samples. GFP positive cells (indicating 
transfection efficiency) were then measured after 24 hours. A parental K1 control was 
also included in this experiment alongside the 6 selected clones. 
 


































Figure 3.2.14.3.2: Specific productivity of each IgG transfected cell line as measured 
on day 3. IgG productivity was estimated via ELISA assay (see 2.7.3). Triplicate tubes 
were transfected, with technical triplicate samples from each tube assayed for IgG 
content (error bars represent the resulting standard deviation between samples). 
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3.2.14.4 Discussion of productivity results 
 
Prior to the use of actual product encoding plasmids, a number of optimisation 
experiments were first carried out to determine the ideal concentrations of 
DNA/plasmid/cell numbers etc. to maximise transfection efficiency without adversely 
affecting cell viability. Experience has shown that some cell lines are naturally more 
resistant to transfection, demonstrated by the differences in transfection efficiency of 
some cell lines commonly used in-house and indeed by the differences noted in this 
study. The conditions described above were found to produce the highest percentage 
of GFP fluorescent cells without drastically impacting cell growth and viability after 
transfection, however the 3 selected Library clones exhibit generally higher average 
rates of efficiency under these conditions. 
 
The data generated from the SEAP transfection assay indicates some level of variation 
in productivity between clones, with almost a 2-fold difference in productivity 
between the highest and lowest producer. There appears to be little appreciable 
difference between Library and TBP clones, with 1.45 x 10
-3
 and 1.39 x 10
-3
 average 
changes in OD/min/cell respectively. While only a small number of clones from both 
Library and TBP populations are investigated in this instance, we cannot determine 
with any confidence whether either treatment has had a significant impact on 
productivity. However, no clone appears to exhibit any particular difficulty in 
producing and secreting SEAP, with variation likely to be a result of clonal differences 
(Pilbrough, Munro and Gray 2009) and factors such as transfection efficiency. The 
specific productivity of the CHO-SEAP sample included in this experiment does not 
appear as high, however this is expected considering the effect of high levels of 
transfected plasmid DNA producing transiently compared to a stable constitutive 
producer. 
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The EPO transient transfection produces results also indicating successful EPO 
productivity in all samples tested, including a parental CHO-K1 transfected population 
in this instance. While there is a measure of variability between samples (for instance, 
T(S)1-3 appear to have fainter EPO concentrations than the Library and K1 cell lines), 
once again this may be influenced by clonal variation and transfection efficiencies. We 
can infer from this result that the ability of all clones to produce an industrially 
relevant product (in this case an un-secreted recombinant product) has not been 
compromised by the genetic manipulation and directed evolution employed in this 
study, as evidenced by their similarity to the K1 control sample.  
 
The IgG transient transfection provides a similar result to previous transfections. 
Productivity compared to a wild type parental control does not appear to be 
significantly diminished. While variation in selected clones is present (including an 
apparent reduction in productivity in TBP selected clones) variation up and down 
appears to correlate with transfection efficiencies suggesting that this may be the cause 
of differences in overall IgG secretion.  
 
Without further in-depth analysis of a larger number of clones, we cannot conclude 
with certainty the relative impacts on productivity the TBP and Library transfections 
may have had in conjunction with the stress procedure. However, the data presented 
above does indicate that this impact is minimal (either positive or negative), with little 
observable difference between either treatments except with regard to transfection 
efficiencies, or when compared to a parental K1 control. 
 
An industrial processes’ total output is governed by both specific productivity (per 
cell) and volumetric productivity (per unit volume). While a simultaneous 
improvement in specific productivity would be ideal, the techniques applied in this 
study were designed to elicit improvements in growth and viability. Ultimately the 
valuable phenotypic improvements demonstrated by the selected clones isolated in this 
study do not appear to compromise the cells’ ability to produce a target product, and in 
most given industrial batch or fed batch processes this would in theory contribute to a 
greater total output of target product.
 211 
3.2.15 Nutrient feed and temperature shift 
 
Temperature shift is an established method of increasing overall productivity. After an 
initial growth period, a reduction in temperature causes a decrease in cell cycle 
activity. This channels cellular resources towards generation of the target product, 
leading to an increase in specific productivity as well as an associated reduction in 
waste products (Kaufmann et al. 1999). 
 
In order to investigate whether this technique could be applied to the clones isolated in 
this study to further prolong their productive culture time, a number of experiments 
were carried out in which temperature was shifted from 37°C to 31°C following an 
initial growth phase (typically after 72 hours of growth). Cells were also re-fed at 
selected time points in order to simulate a typical ‘fed batch’ culture. Initially this was 
crudely accomplished by replacing the total growth medium with fresh medium, 
however in subsequent iterations of this experiment a concentrated nutrient feed was 
used to provide more realistic results (Gibco CHO CD EfficientFeed A, cat. A10234-
01). 
 
Cells were seeded in 50ml shake flasks at 2 x 10
5
 cells as usual, and temperature 
shifted to 31°C on day 3 (72 hours). Feeding regimens varied, with an initial 
experiment fully replacing the medium once on day 3. Further experiments were 
carried out to maximise late stage cell survival, in which a concentrated nutrient feed 
was used instead at various time points. 
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Batch-1: 
Batch-1 was carried out initially to determine if viable cell densities could be 
preserved beyond the limits of a standard culture using temperature shifted method. A 
pair of 50ml shake flasks were seeded and grown for each selected Library and TBP 
cell line, with one remaining at 37°C for the entire culture and its ‘twin’ temperature-
shifted to 31°C at day 3 after exponential growth had begun. 
Prior to the use of a concentrated nutrient feed, a cruder system was used in this 
instance in which the entire serum free growth medium was replaced with fresh 
medium. This was only done after an initial phase of growth (day 3). 
 
Batch-2: 
Once the effect of temperature shift was established in the previous experiment, a 
commercial feed medium, supplemented at 10% of the total volume at each feed, was 
substituted for entire medium replacement. This was carried out to allow us to deduce 
if this more realistic method of fed-batch culture would provide similar results when 
applied to temperature shifted cells. In this experiment, each cell line was seeded in 
50mls, and temperature shifted at day 3. Feeding time points at day 3 (after 
exponential growth) and day 6 (maximum density) were used. A parental CHO-K1 
and high density SEAP control were also included in this instance. 
 
Batch-3: 
Having established the effects of both the temperature shift and a minimal number of 
re-feeds, a third experiment was carried out using a larger number of feed time-points 
to see if viable cells numbers could be sustained for a further length of time. This 
included a day 0 supplementation of feed medium (in accordance with the 
manufacturers recommendations, 10% of total volume), as well as subsequent days 3, 




3.2.15.1 Nutrient feed and temperature shift results 




























Figure 3.2.15.1.1: Viable cell densities of Library and TBP clones from experiment 
‘Batch-1’, grown persistently at 37°C. Cell lines were seeded at 2x105 cells per ml in a 
50ml culture, with all cells pelleted and resuspended in fresh medium on day 3. 
  




























Figure 3.2.15.1.2: Viable cell densities of Library and TBP clones from experiment 
‘Batch-1’, temperature shifted at day 3 to 31°C. Cell lines were seeded at 2x105 cells per 
ml in 50ml culture, with all cells pelleted and resuspended in fresh medium on day 3. 
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Figure 3.2.15.1.3: Percentage of viable cells of Library and TBP clones from experiment 
‘Batch-1’, grown persistently at 37°C. Cell lines were seeded at 2x105 viable cells per ml 
in a 50ml culture, with all cells pelleted and resuspended in fresh medium on day 3. 
 























Figure 3.2.15.1.4: Percentage of viable cells of Library and TBP clones from experiment 
‘Batch-1’, temperature shifted at day 3 to 31°C. Cell lines were seeded at 2x105 viable 
































Figure 3.2.15.1.5: AIVCD analysis of the data generated from the ‘Batch-1’ experiment. 
Each bar represents the average accumulated daily AIVCD figure for each group of 3 
clones (Library and TBP clones at both temperatures). With the addition of fresh nutrients 
in all cultures, performance between TBP and Library clones is minimal (*p=0.26), while 
the same conditions under temperature shift provide a more distinguished improvement to 




Final Day AIVCD (cell-hours/ml) 
Clone 37°C 31°C % Difference 
L(S)1 3.85 x 10
7
 5.43 x 10
7
 41% 
L(S)2 4.41 x 10
7
 5.07 x 10
7
 15% 
L(S)3 3.84 x 10
7
 4.77 x 10
7
 24% 
T(S)1 3.92 x 10
7
 4.28 x 10
7
 9% 
T(S)2 3.48 x 10
7
 3.13 x 10
7
 -10% 
T(S)3 3.77 x 10
7




Figure 3.2.15.1.6: Final day AIVCD figures for each selected clone for both 37°C and 
31°C cultures, and the percentage difference between them. 
  
 *      ** 
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Figure 3.2.15.1.7: Viable cell densities of Library and TBP clones (including K1 and 
SEAP control lines) from experiment ‘Batch-2’, temperature shifted at day 3 to 31°C. 
Cell lines were seeded at 2x10
5
 viable cells per ml in 50ml, with a concentrated 



























Figure 3.2.15.1.8: Percentage of viable cells of Library and TBP clones (including K1 
and SEAP control lines) from experiment ‘Batch-2’, temperature shifted at day 3 to 31°C. 
Cell lines were seeded at 2x10
5
 viable cells per ml in 50ml, with a concentrated nutrient 




































Figure 3.2.15.1.9: AIVCD data of Library and TBP clones (including K1 and SEAP 
control lines) from experiment ‘Batch-2’, temperature shifted at day 3 to 31°C. Cell lines 
were seeded at 2x10
5
 viable cells per ml in 50ml, with a concentrated nutrient feed added 
on days 3 and 6 (10% of total volume). 
 
 
Final Day AIVCD (cell-hours/ml) 
Clone AIVCD vs. K1 vs. SEAP 
L(S)1 3.77E+07 119% 20% 
L(S)2 3.63E+07 111% 15% 
L(S)3 3.58E+07 108% 14% 
T(S)1 3.17E+07 84% 1% 
T(S)2 2.61E+07 52% -17% 
T(S)3 2.75E+07 60% -13% 
K1 1.72E+07 - -45% 
SEAP 3.15E+07 83% - 
 
Figure 3.2.15.1.10: Final day AIVCD figures for each selected clone and control cell 
line from the Batch-2 experiment. Also included are the relative percentage 
differences between each sample line and the two control cell lines measured (K1 and 
SEAP). 
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Figure 3.2.15.1.11: Viable cell densities of Library and TBP clones (including K1 and 
SEAP control lines) from experiment ‘Batch-3’, temperature shifted at day 3 to 31°C. 
Cell lines were seeded at 2x10
5
 viable cells per ml in 50ml, with a concentrated 
nutrient feed added on days 0, 3, 5, 8 and 11 (10% of total volume). 
 

























Figure 3.2.15.1.12: Percentage of viable cells of Library and TBP clones (including K1 
and SEAP control lines) from experiment ‘Batch-3’, temperature shifted at day 3 to 31°C. 
Cell lines were seeded at 2x10
5
 viable cells per ml in 50ml, with a concentrated nutrient 
feed added on days 0, 3, 5, 8 and 11 (10% of total volume). 
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Figure 3.2.15.1.13: AIVCD data of Library and TBP clones (including K1 and SEAP 
control lines) from experiment ‘Batch-3’, temperature shifted at day 3 to 31°C. Cell lines 
were seeded at 2x10
5
 viable cells per ml in 50ml, with a concentrated nutrient feed added 
on days 0, 3, 5, 8 and 11 (10% of total volume). 
 
 
Final Day AIVCD (cell-hours/ml) 
Clone AIVCD vs. K1 vs. SEAP 
L(S)1 4.02E+07 291% 52% 
L(S)2 3.77E+07 267% 42% 
L(S)3 4.55E+07 343% 71% 
T(S)1 4.60E+07 347% 73% 
T(S)2 3.89E+07 278% 47% 
T(S)3 4.06E+07 295% 53% 
K1 1.03E+07 - -61% 
SEAP 2.65E+07 158% - 
 
Figure 3.2.15.1.14: Final day AIVCD figures for each selected clone and control cell 
line from the Batch-3 experiment. Also included are the relative percentage 
differences between each sample line and the two control cell lines measured (K1 and 
SEAP). 
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3.2.15.2 Nutrient feed and temperature shift discussion 
 
Batch 1: 
Batch 1 was originally intended to investigate the effect of temperature shift, with the 
only extra nutrients provided on day 3 in the form of a media change. This injection of 
extra nutrients has stimulated the 37°C cultures to continue exponential growth 
reaching densities above 1 x 10
7
 on day 5 (figure 3.2.15.1.1). This is in contrast with 
the temperature shifted cultures, reaching a lower average peak density (~8.3 x 10
6
, 
figure 3.2.15.1.2), generally at the later stage of day 7 (with the exception of L(S)3, 
peaking on day 4). The 31°C shifted growth cultures bear the hallmarks of a 
hypothermic temperature shifted culture, with flatter, wider growth curves, slower 
decline in viability coupled with survival of viable cells beyond day 9 (figure 
3.2.15.1.4), by which the 37°C culture has fully collapsed (figure 3.2.15.1.3).  
 
In figure 3.2.15.1.5 (AIVCD data), we see that this flatter growth curve permits the 
37°C Library clones on average to outperform their 37°C counterparts by overtaking 
their average number of viable cell-hours/ml by day 8 (with this 31°C AIVCD figure 
continuing to increase due to the continued presence of viable cells towards day 12). 
TBP clones do not perform as well under temperature shift, generally maintaining 
lower viable cell densities than the similarly treated Library clones, contributing to 
mixed final day AIVCD results. However, as with Library cells, viability is seen to 
decrease less drastically than 37°C cultures. 
 
While changes in AIVCD may provide an estimate to changes in overall productivity 
based on the cumulative number of viable cell-hours, this does not take into account 
the change in specific productivity (Qp) associated with temperature shifted cultures. 
Despite lower cell densities, a common characteristic of hypothermic CHO cultures is 
improved ‘per cell’ Qp contributing to an overall improvement in total productivity 
(for examples see Fox et al. 2006; Chen et al. 2004 etc). While productivity is not 
measured here due to the lack of a constitutively expressed product, we could 
speculate that the predictions regarding growth and viability demonstrated 
experimentally as holding true would also apply to the prediction regarding an 




Having witnessed the typical phenotypic effects of temperature shift in the first 
instance, the hypothermic cultures were once again seeded and grown under the same 
conditions, however in this instance the entire medium replacement at day 3 was 
substituted for a commercial nutrient feed, added at 10% of the total volume at days 3 
and 6. Both K1 and SEAP controls were also investigated in this instance. 
 
In this experiment we see more consistent growth patterns across all clones compared, 
with peaks in cell density coinciding on day 6 (figure 3.2.15.1.7). The varying growth 
rates in the previous 31°C batches may have been a reaction to the removal of 
conditioned medium and the cells re-adaption to entirely fresh nutrients on day 3. The 
feed regimen applied in this instance is more akin to that found in a true fed-batch 
culture, and the delayed decline in viability (figure 3.2.15.1.8) is similar to the 
previous hypothermic culture, with no significant decline in viability until day 8 
(compared to previous standard 37°C 50ml batch cultures in this and previous 
experiments (see figure 3.2.12.1), where this decline would tend to set in ~48 hours 
earlier, with no real viable cell presence beyond day 9 or 10).  
 
In this experiment we also see both low and high density controls (K1 and SEAP) 
leading to complete cell death day 9, highlighting the advantageous phenotype that has 
been isolated in the selected clones in this study. 
 
Due to the inclusion of only 2 feed points at relatively early time points, this batch did 
not generate late stage survival significantly different to that of the previous culture. In 
order to investigate if this viable culture length could be lengthened through the use of 
continual nutrient feeds in tandem with the temperature shift, this experiment was 
repeated a final time with an increased number of feeding time points. 
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Batch 3:  
Having established the beneficial effects of both temperature shift and supplementary 
nutrient feeds on overall viability in an extended batch culture, the final fed-batch 
experiment was carried out to investigate how long viable cell densities could be 
maintained with a further number of feed time points in order to prolong the time span 
of useful cell culture. Cells were seeded as usual at 2 x 10
5
 cells/ml in 50mls (45 
CHO-SFM serum free medium and 5mls concentrated feed, as per manufacturers 
recommendations) and supplemented on days 3, 5, 8 and 11. 
In general, maximum cell densities were reached on day 6 as previously (an exception 
to this is cell line L(S)3, whose early and high peak density may also be responsible 
for its apparent lower viable cell percentage due to an earlier build up of dead cells and 
debris, see figures 3.2.15.1.11-12). In this instance cell viability did not begin to drop 
substantially in any cell line till day 9, by which precipitous drops in culture health 
were seen in previous fed-batch experiments with fewer or no medium supplements. 
This is likely due to the additional nutrients and pH buffering provided by the media 
feeds, delaying the onset of apoptotic conditions. This also results in a slower decline 
in viability, with most selected clones maintaining viability >60% even by day 13. 
Despite the benefits of additional nutrients, both control lines’ viability drop sooner, 
with an average benefit of 15-20% to cell viability in selected clones. This 
demonstrates that, even with the feed medium mitigating negative environmental 
effects, stress selected cells maintain a benefit in viability as a result of their heritage.  
However, despite the relatively high percentage viabilities of the selected clone lines, 
suspended cell densities are seen to drop consistently from days 8-9 onwards. A 
number of physical factors are likely to have contributed to this, such as the 
macroscopic clumping of cells reducing the numbers of actual suspended cells 
(especially prevalent in control cell lines, however in a proper reactor environment this 
problem could be reduced with impeller mixing combined with the use of an anti-
clumping agents). This is combined with the gradual diluting effect of the nutrient 
feeds with total cell densities diluted almost 50% by day 12 after 4 x 10% total volume 
supplements. The increased osmolarity caused by the increased concentrations of 
nutrients may also have served to accelerate cell lysis, as evidenced by the increasing 
levels of cell debris detected by the flow cytometer when samples were measured in 
later culture stages, eventually limiting the effectiveness of continued feeds.  
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3.2.16 Determination of TBP copy number  
  
In order to fully characterise the advantageous TBP and Library clones isolated in this 
study, the qPCR technique originally used to quantify the numbers of viral inserts in 
section 3.1.12 of this thesis was applied to these cell lines to estimate the number of 
TBP gene copies within the genome following transfection.  
 
A protocol was followed identical to that carried out in section 3.1.12, utilising 
primers targeting the zeocin selection marker found beside transgenic TBP on the 
original pcDNA/TBP expression vector. These were chosen over primers directly 
binding TBP as to avoid interference from amplification of the wild type genomic 
sequence. 
 
As before, the original transfected plasmid was used to generate a standard curve for 
quantification, with the samples used to generate this curve spiked with control CHO-
K1 genomic DNA to reduce bias in amplification efficiency that may arise from using 
plasmid DNA alone. Measurement of a β-actin reference gene was also used to 
control for any variance in genomic DNA concentration. 
 
 
Forward 5’ – TTCTGGACCGACCGGCTCG– 3’ 
Reverse 5’ – ATCTCGGTCATGGCCGGCC– 3’ 
 
 
Figure 3.2.16.1: Primers used to target the zeocin sequence within the TBP expression 
vector, resulting in a 145 bp fragment suitable for qPCR. 
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3.2.16.1 Results of TBP copy number qPCR 
Standard Curve (pcDNA/TBP)






















Figure 3.2.16.1.1: The standard curve generated from the pcDNA/TBP plasmid. 
Samples were also spiked with an appropriate concentration of genomic DNA to better 
mimic amplification conditions and efficiencies resulting from the use of genomic 
DNA alone. Samples were measured in triplicate within the linear range between 8.4 x 
10
9
 and 8.4 x 10
3 
plasmid copies 




















Figure 3.2.16.1.2: Calculated TBP copy numbers from the transfected cell lines assayed. 
Genomic DNA isolated from each cell line was measured in triplicate for both TBP and 
β-actin concentrations .In order to factor in inaccuracy resulting from the nature of the 
experiment, error (minimum and maximum insert numbers) was also calculated by 
combining the highest and lowest estimated TBP and β-actin replicate results to 
generate a range of possible TBP copy numbers. 
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3.2.17 Estimation of intracellular TBP protein concentration  
 
A western blot to detect intracellular TBP concentrations was carried out on selected 
TPB clones along with a parental CHO-K1 control. This was done to further fully 
characterise the advantageous Library and TBP transfected clones isolated in this 
study and investigate as to whether the significant upregulation of TBP expression was 
correlated with a subsequent increase in TBP protein concentration. 
Cell pellets were harvested on day 3 from actively growing suspension cultures and 
lysed. Total protein was then purified and quantified using a Bradford assay (see 2.7.1) 
  









Figure 3.2.17.1: Western blot of intracellular TBP isolated from transfected TBP and 
Library clones alongside an untransfected K1 control. 10µg protein was added per 
well, as measured by a Bradford assay. The α-tubulin housekeeping gene was used as 
a loading control. Also noted below the figure are the corresponding mRNA 
expression levels (relative to the K1 control) as measured by qPCR in a previous 





Sample:    L(S)1        L(S)2         L(S)3         T(S)1          T(S)2        T(S)3          K1        
 
mRNA:      1.33            1.39            1.34           2.29           6.20            2.12            1        
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3.2.17.1 Discussion of intracellular TBP protein concentration  
 
From the results of the western blot carried out above (see figure 3.2.17.1), it would 
appear to indicate that TBP concentration did not vary considerably in the clones 
isolated when compared to the CHO-K1 control at this time point. This was to be 
expected based on mRNA expression levels measured in a previous qPCR experiment 
on selected post-stress clones. Originally wild-type and mutant library TBP mRNA 
were found to be 5.7 and 9.6 fold upregulated in mixed populations, however the 
selected advantageous clones generally exhibit more moderate TBP upregulation (with 
the exception of T(S)2, all other selected clones exhibit mRNA upregulation between 
1.3 and 2.3 fold). This may be indicative of selection for a more optimal range of 
expression, mediated by epigenetic, post-transcriptional and post-translational 
regulatory processes. 
 
Due to the nature of TBP and its close integration with cell-wide transcriptional 
activity, modest changes (less than two fold) in concentration are associated with 
marked changes in gene expression (Johnson et al. 2003b). Because of TBP’s ability to 
effect widespread metabolic changes, it is likely that this protein is also subject to tight 
post-transcriptional regulation, with expression and activity mediated by factors such 
as Ras-signalling and p53 binding (Johnson et al. 2003b, 2000). Increasing TBP 
concentration also promotes a form of autoregulation, with homodimerization 
preventing DNA binding and further transcriptional activation (Gokhale et al. 2010), 
however dimerized molecules were not detected by this assay. It is also possible that 
TBP molecules with sufficient mutations (in the first 100 amino acid residues to which 
the antibody used is reactive) may have been undetected by this assay. 
 
Auto-regulatory factors such as these may have contributed to these cell lines’ 
inability to stably maintain high TBP concentrations. While the TBP-linked zeocin 
resistance gene was used to estimate gene copy number, effective TBP expressing 
gene copies may have been silenced or removed during the stress selection process, in 
the same manner as recombinant gene silencing leading to production instability (Kim 
et al. 2011). However, as an evolutionary adaptation to this stress these mutations are 
likely to be advantageous, as suggested by the phenotypes generated. 
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3.2.18 Mutant TBP sequencing 
 
The post-stress clone data gathered with respect to both TBP and Library transfected 
clones demonstrated both populations as having an improved ability to adapt to the 
stress applied when compared to the empty vector control. While this data indicated a 
generally consistent change in phenotype with regard to the wild type gene, a wide 
range of performance was noted in the Library transfected cells. This result is in line 
with what one might predict; TBP overexpression producing a relatively similar 
phenotype in transfected cells while mutant library transfection results in a mixed 
heterogeneous pool of clones. As with any random mutagenesis technique, we are left 
with a resulting mixture of both positively and negatively acting sequences, with 
which we used a selective stress to try and eliminate deleterious mutants. This was 
successful in reducing the levels variation in performance, leaving us with a selection 
of advantageous clones. 
To examine the sequences present in these advantageous clones, and investigate if 
these beneficial mutants shared any common properties a series of samples were 
prepared from Library selected clones and sent for sequence analysis (carried out by 
Eurofins MWG Operon using chain-termination ‘Sanger’ sequencing).  
 
Initially a PCR was carried out to amplify the mutant sequences in each clone and sent 
for sequencing. However, due to the mixture of different sequences within each clone 
the result appeared as an ‘average’ of these combined sequences, essentially the wild 
type sequence. To overcome this, each PCR mixture was cloned into a plasmid vector 
and transformed into bacteria. This allowed us to select bacterial clones containing 
single plasmids, which were grown and purified for mutant TBP sequencing. 
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3.2.18.1 Mutant TBP sequencing results 
 
From each of L(S)1-3, five individual sequences were isolated (for a total of 15 
sequences) and analysed using both forward and reverse primers for separate 
sequencing reactions. A consensus sequence was generated from each pair, and 
analysed at the nucleotide and protein level. 
 
An average of 3.6 mutations per sequence was noted, a reduction from the original 9.5 
average mutations noted in the original mixed plasmid library. This was to be 
expected, as sequences with large numbers of deleterious mutations were likely to be 
eliminated from the population as a result of the stress selection procedure. The larger 
average mutation rate (‘medium’ mutant library) was originally chosen over a lower 
rate to generate a more diverse collection of sequences and distinguish the Library 
cells’ phenotypes from the effect of wild type TBP. This allowed us to demonstrate 
that, despite an initially negative effect on overall phenotype, the stress selection 
procedure could be successful in eliminating the majority of these deleterious mutants 
(or perhaps suppress their expression in selected clones) as well as providing sufficient 
diversity as to allow the selection and isolation of clones with the potential to 
outperform those isolated from a comparatively homogenous (WT-TBP) group.  
 
The following 3 tables (figures 3.2.18.1.1-3.2.18.1.3) detail the 5 mutant sequences 
isolated from each clone. Details noted include the residue number within the CHO 
TBP sequence, mutation type (base changes, deletions and frame shifts), amino acid 




L(S)1 Sequence Residue Change Mutation Notes 
 A 69 Base Stop Truncated N-terminal protein 
 
B 
33 Base P-L  
 96 Base Q-H  
 182 Base E-D  
 185 Base T-I B4 β-sheet 
 274 Base P-H  
 311 Deletion F-S  
 312 Frame shift 3 residues  




33 Base P-L  
 127 Base P-R  
 221 Base G-D  
 
D 
57 Base R-K  
 84 Base Q-H  
 144 Base I-M B1 β-sheet 
 E 9 Base P-L  
 
Figure 3.2.18.1.1: Details of the mutations found in the five (A-E) mutant sequences 
isolated from Library clone L(S)1. Details noted include the residue number within the 
CHO TBP sequence, mutation type (base changes, deletions and frame shifts), amino 
acid change as well as further details such as their location in particular structural 
domains (β-sheets and α-helices). Data above was generated from 5 mutant sequences 
isolated from cell line L(S)1, achieved by PCR amplification, subcloning and 
subsequent sequencing of individual mutant TBP sequences. 
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L(S)2 Sequence Residue Change Mutation Notes 
 
F 
33 Deletion P-L  
 34 Frame shift 37 residues Nonsense protein 
 71 - Stop Truncated N-terminal protein 
 
G 
7 Base L-P  
 8 Base P-S  
 9 Base P-T  
 120 Base T-S  
 205 Base Q-H A'2 α-helix 
 228 Base D-N  
 
H 
7 Base L-H  
 9 Base P-L  
 120 Base T-S  
 205 Base Q-H A'2 α-helix 
 299 Base E-A A'2 α-helix 
 300 Base A-R A'2 α-helix 
 
I 
120 Base T-S  
 299 Base E-A A'2 α-helix 
 300 Base A-P A'2 α-helix 
 
J 
60 Base Q-E  
 114 Base L-V  
 130 Base P-Q  
 149 Base N-T B1 β-sheet 
 164 Base R-P  
 174 Base A-D S1 stirrup loop 
 228 Base D-Y  
 263 Base L-I S2 stirrup loop 
 
Figure 3.2.18.1.2: Details of the mutations found in the five (F-J) mutant sequences 
isolated from Library clone L(S)2. Details noted include the residue number within the 
CHO TBP sequence, mutation type (base changes, deletions and frame shifts), amino 
acid change as well as further details such as their location in particular structural 
domains (β-sheets and α-helices). Data above was generated from 5 mutant sequences 
isolated from cell line L(S)2, achieved by PCR amplification, subcloning and 




L(S)3 Sequence Residue Change Mutation Notes 
 
K 
33 Deletion P-R  
 34 Frame shift 37 residues  
 71 Frame shift Stop Truncated N-terminal protein 
 
L 
46 Base T-A  
 85 Base Stop Truncated N-terminal protein 
 
M 
8 Base P-L  
 9 Base P-T  
 110 Base G-D  
 162 Base R-H A1 α-helix 
 174 Base A-T S1 stirrup loop 
 179 Base R-G B3 β-sheet 
 184 Base R-W  
 
N 
301 Frame shift 5 residues A'2 α-helix 
 308 - Stop A'2 α-helix 
 
O 
114 Base L-V  
 220 Base L-S  
 308 Deletion Stop A'2 α-helix 
 
Figure 3.2.18.1.3: Details of the mutations found in the five (K-O) mutant sequences 
isolated from Library clone L(S)3. Details noted include the residue number within the 
CHO TBP sequence, mutation type (base changes, deletions and frame shifts), amino 
acid change as well as further details such as their location in particular structural 
domains (β-sheets and α-helices). Data above was generated from 5 mutant sequences 
isolated from cell line L(S)3, achieved by PCR amplification, subcloning and 






             B1       A1         B2     S1      B3 
SGIVPQLQNIVSTVNLGCKLDLKTIALRARNAEYNPKRFAAVIMRI 
 
      B4(6/7)        B5 (6)             A2 




            B’1                  A’1         B’2     S2     B’3 
KFLDFKIQNMVGSCDVKFPIRLEGLVLTHQQFSSYEPELFPGLIYRM 
 




Figure 3.2.18.1.4: Protein sequence representing the conserved C-terminus of CHO 
TBP (amino acid residues 135-315) involved in DNA binding (adapted from Juo et al. 
1996). This terminus displays internal symmetry, consisting of two identically folded 
domains (i and ii) of 90 amino acids each. Each consists of 5 β-sheets (B1-5, 
highlighted in green) and 2 α-helices (A1/2, highlighted in blue). β-sheets form the 
main surface by which TBP interacts with DNA, with α-helices acting to form a 
strengthening scaffold. The stirrup loops (S1/2, highlighted in black) assist in bending 
DNA and compressing the major groove. 
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3.2.18.2 Mutant TBP Sequencing Discussion 
 
The first obvious characteristic of the sequences analysed is the diversity observed. 
TBP copy number qPCR estimates anywhere from 18 to 36 different mutant sequences 
in each clone, and the 5 sequences from each clone analysed above represent only a 
fraction of these. No sequence is represented twice in any clone, and with an original 
library complexity of 10
5
 individual mutant sequences it is possible that each 
transfected cell received an entirely different complement of mutants. 
 
To date, a number of mutagenesis studies have been carried out in human and yeast 
cells in order to elucidate the numerous functions and interactions that TBP is involved 
with. A wide range of non-functional and distinctly deleterious mutants have been 
discovered, usually for the purpose of further understanding of TBP’s constituent 
domains (Bryant et al. 1996; Hampsey 1998). However, using random mutagenesis or 
by targeting specific regions, researchers have also generated mutants with altered 
function; 
 
 Altered TATA sequence binding specificity (Arndt et al. 1992, 2004; Spencer and 
Arndt 2002) 
 Dimerisation impaired mutants, preventing autorepression of TBP activity and 
inducing heightened reporter gene activity (Jackson-Fisher et al. 1999) 
 Transcriptional de-repression (Kou et al. 2003) 
 Enhanced ability to overcome promoter repression of certain co-repressor 
complexes (Geisberg and Struhl 2000) 
 Bypassed transcriptional necessity for particular TBP associated factors, selectively 
altering gene expression  (Sprouse, Wells and Auble 2009, Blair and Cullen 1997) 
 
From these examples, we can see that TBP mutation can serve in generating a range of 
molecules with alternative functional capacity, with possible downstream implications 
for the expression of a large number of genes. While improved function is not 
guaranteed, this at least permits the creation of a more heterogeneous population with 
a mix of altered metabolic landscapes from which beneficial mutations can ultimately 
be selected.
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Initially TBP mutants in which altered function was generated as described in the 
literature were catalogued (mainly in human and yeast homologs), and their mutations 
were mapped onto the corresponding CHO TBP residues. However, of the thirty or so 
mutations with demonstrable changes in activity or specificity, none were found to 
correspond to the mutations noted in the mutant sequences isolated above. 
Unfortunately this does not allow us relate the sequences in the advantageous clones 
isolated to any previously characterised phenotypes or activities. 
 
As such we can only speculate as to the possible effects such mutations may have had 
on the structure or function of these sequences. As β-sheets are generally involved in 
the main DNA interacting domains, broadly speaking we can infer that mutations to 
these residues are more likely to affect the sequence specificity or DNA binding 
kinetics of TBP. These are also far less common in the clones sequenced in this 
experiment, with only 4 of these mutations appearing separately in isolated sequences, 
a possible indication that such mutations play a more active role in altering TBP 
function and thus are tolerated less by the cell’s metabolism and selected against.  
This is in contrast to mutations in α-helices that play a more structural role in TBP. 
These mutations appear more frequently in 7 of the sequences analysed above. This 
may suggest that these mutations are more tolerated by the structure itself and have 
less impact on overall function, or are actually beneficial in themselves through means 
of altering the protein’s interactions with other transcription factors. However, without 
experimental analysis of the effects of single sequences, this is impossible to verify. 
 
A SIFT (Sorting Intolerant From Tolerant) analysis of all mutations was carried out to 
predict changes most likely to result in functional changes (Ng and Henikoff 2006). 
This method compares a multiple sequence alignment of a database of similar 
sequences, and makes predictions based on residue conservation and the 
physiochemical properties of the substituted amino acid. However, low confidence in 
predictions relating to N-terminal mutations resulted due to its non-conserved nature 
across species, making sequence comparisons difficult. Of 44 non-synonymous base 
changes, 32 were predicted to affect function. However, only 12 of these (generally in 




While most of the sequences analysed appear to hold a different set of individual point 
mutations, present at least once in each clone (sequences ‘A’, ‘F’, ‘K’ and ‘L’) is a 
truncated N-terminal sequence encompassing between the first 69 and 85 residues of 
TBP. Frame shift deletions in both ‘F’ and ‘K’ ensure that the C-terminal portion of 
this code is nonsense. Mutation and deletion studies have found this N-terminus to be 
involved in modulating the effect of TBP, indicating interactions with other 
transcription factors as well as the core of the TBP protein itself, and removal of this 
portion is not lethal in yeast. Its sequence is also highly variable across species, and 
may have evolved a number of varying functions in different organisms (Friedman et 
al. 2007; Lee and Struhl 2001). It is difficult to predict if such a polypeptide solely 
made up of this portion could be successfully folded and possess any useful structure 
or function in isolation, but its occurrence in all 3 selected library clones may mark it 
as potentially interesting, or perhaps merely benign as to remain unremoved by the 
selection process. 
 
With each cell expressing a mix of different mutant sequences at different 
concentrations, it is impossible to ascribe the phenotype of each clone to a particular 
mutant. No sequence appears to be duplicated in each clone from the sample set 
analysed above, and from the insert copy number data we can see there may be 
between 18 to 36 individual different mutant sequences in each clone. TBP expression 
level data (along with TBP concentrations estimated by western blot) also 
demonstrates that these sequences are expressed at relatively low levels in selected 
clones. While we cannot be certain how many or which of these sequences are being 
expressed, we can hypothesise from this data that the beneficial phenotypes witnessed 
in these clones is a result of a number of different subtle interactions acting in tandem, 
rather than an obvious consequence of one single sequence. 
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3.2.19 Expression profiling in experimental CHO cell lines 
 
Having carried out the process of transfecting with both TBP and mutant library and 
subsequent selection for advantageous clones, a transcriptomic profiling experiment 
was carried out on a selection of cell lines including control, unstressed and stressed 
populations as well as a number of successful clonal cell lines isolated from stressed 
mixed population. This would permit an investigation into the changes in gene 
expression caused by the genetic and evolutionary pressures utilised over the course 
of this study and potentially allow us to identify the genes responsible for the 
advantageous phenotype we see in advantageous clones. 
 
For this experiment, the GeneChip 3’ IVT Express Kit (Affymetrix, 901229) was used 
for the processing of CHO RNA samples and generation of suitable antisense RNA 
(cRNA). The arrays used for this experiment were ‘Hamster 3a-520384’ chips (Lot 
no. 4115243, ref no. 520384), developed by Affymetrix. Based on more recent CHO-
specific transcriptome sequencing, these chips contain nucleotide probes with the 
ability to measure roughly 19,000 various gene transcripts and ~8,000 unique 
annotated genes. At this time not all genes measured are identified and annotated due 
in part to the historical lack of public CHO sequencing data. However identification 
of function based on similarities to human, mouse and rat orthologues is possible, 
allowing us to analyse this data and identify the factors that may contribute to a given 
change in phenotype. 
 
To generate samples for this experiment, a number of CHO cell lines were seeded at 2 
x 10
5
 cells/ml (using 50ml flasks) in a typical batch culture situation. Triplicate 
samples of 2 x 10
6
 viable cells were removed at day 5, and processed to isolate 
mRNA for transcriptional profiling. Day 5 was originally chosen as a suitable time 
point as this was often the point of maximum cell density or beginning of the decline 
phase, as well as the point when viability percentages in all cell lines appear to drop in 
batch culture. This would mark it as a suitable time to identify changes in gene 
expression related to any stress, the key phenotypic response we originally sought to 
investigate and characterise with this experiment. 
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3.2.19.1 Selection of profiling samples and comparisons 
 
The first step in this study was deciding on a number of representative samples from 
throughout the study to investigate. Due to the varied number of samples and 
experimental steps involved, such as the effect of TBP and Library (as well as a 
control) combined with the changes invoked by the stress procedure, we initially 
decided on a range of samples to cover this variety and hopefully allow us to describe 
the changes brought about by each sequential step. 
Ultimately being limited to 10 samples (carried out in triplicate for a total of 30 
arrays), the following samples were chosen for analysis: 
 
 pcDNA transfected mixed population (unstressed) 
 pcDNA transfected mixed population (stressed) 
 TBP transfected mixed population (unstressed) 
 TBP transfected mixed population (stressed) 
 Strong performing stress selected clones (T(S)1, T(S)2, L(S)2 and L(S)3) 
 Control cell lines (CHO-K1 and CHO-SEAP) 
 
The use of both stressed and unstressed versions of pcDNA and TBP mixed 
populations was initially decided upon to try and investigate the main genetic 
components responsible for the apparent benefits of transfection and selection. With 
pcDNA acting as a control the relative effects of TBP could be assessed, and pre- and 
post-stress mixed populations would allow for the identification of genes whose 
expression was affected by the stress procedure. The use of control cell lines would 
also provide a means of comparing successful cell lines to a relatively poor 
performing line (in the case of K1), or determine what the differences were that set 
apart the more successful selected clones from an known high density cell line, such 
as CHO-SEAP. Due to the limit of sample numbers Library transfected populations 
were not chosen for profiling. Due to the inherent heterogeneity of these populations, 
each cell is likely to contain transcriptomic profiles with variety exceeding that of 
more homogenous populations such as TBP transfected or clonal lines, thus 




Figure 3.2.19.1.1: Dendrogram representing the final clustering of profiling samples 
and cell lines analysed. Samples were generated from RNA extracted from standard 
batch cultures on day 5 and analysed in triplicate. Differential expression analysis was 
carried out to determine the transcriptomic differences between cell lines, with greater 
separation between samples in the diagram above indicating larger degrees of 
dissimilarity with regards to gene expression. In general triplicate samples cluster 
together tightly. With the exception of control CHO-K1, unstressed cell lines appear 
separated by less distance. The application of stress introduces greater changes in 
gene expression, with cell lines incorporating combined stress and genetic 
intervention appearing the most distant from the unstressed pcDNA control (i.e. TBP-
S and selected clones L(S)2, L(S)3, T(S)1 and T(S)2, noted in this diagram by their 
original designations B3, B4, C4 and D1)  
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3.2.19.2 Analysis of comparisons 
 
In order to begin to understand the effects of both the two main components, a 
number of binary comparisons were carried out in which profile pairs were compared. 
This allows us to see the differences in gene expression between pairs, and isolate 
interesting gene targets that may have contributed to any advantageous changes in 
phenotype. The original analysis of raw array data and identification of statistically 
relevant genes was carried out by resident bioinformatician Dr. Colin Clarke. Analysis 
of gene lists to identify enriched cellular pathways and bioprocesses was done with 




3.2.19.3 TBP(U) v pcDNA(U) – 104 genes (23 up, 81 down)  
Comparison examining the effect of TBP overexpression 
The first comparison carried out was that between the TBP transfected cell line and 
control (pcDNA) line, both unstressed. This allowed us to investigate the effects of 
TBP overexpression compared to an empty vector transfected control cell line. 
 
The most striking initial detail noticed about this comparison is the relatively short list 
of genes significantly dysregulated at this time point, despite the apparent difference 
in phenotype between these two cell lines (mainly in terms of cell density). Also of 
note is the range of differential expression noted in this comparison, with all genes 
expression changes falling within a range of 1.6 and -1.59 fold-change, suggesting 
that the overexpression of TBP does not appear to have a drastic effect on overall 
gene expression at this time point. 
Firstly, examining the individual genes differentially upregulated, we see no specific 
pattern or any biological pathways significantly affected. The majority display a fold 
change just above the significance limit (between 1.2 and 1.3). The most significantly 
upregulated genes with notable function are GAS1, a tumor suppressor known to 
suppress growth and metastasis (Del Sal et al. 1992; Wang et al. 2012) as well as a 
role in transcriptional silencing (Koch and Pillus 2009), and the PEDF gene, 
demonstrated to have apoptotic/anti-tumorigenic properties (Garcia et al. 2004) with 
the ability to facilitate G0 cell cycle quiescence (Tombran-Tink and Barnstable 2003).  
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When we examine the remaining list of downregulated genes we find that the most 
enriched processes are almost exclusively related to cell cycle progression and mitosis 
related categories such as chromosome segregation and nuclear division. Examples of 
genes with prominent negative fold changes that are representative of these categories 
include CCNB1 (promotion of mitosis), Nusap1 (mitotic spindle stabilisation), Spc25 
(chromosome segregation), CDC20 (chromatid separation), Ccna2 (transition of cell 
cycle phases) and Prc1 (cytokinesis). 
The downregulation of these genes (that, when active, are involved in cell cycle and 
cell division) as well as the upregulation of anti-tumorigenic proteins would suggest a 
slower growing culture. However, from our growth curve data we can see that higher 
density growth is achieved in these cells. An explanation for this may lie in temporal 
gene changes as the culture progresses. As stably transfected TBP cells (found to be 
overexpressed in actively growing cells) produce a higher density of viable cells, the 
gene profile measured here after a plateau in growth may reflect the cells’ changes in 
gene expression once growth has stopped. Instead of identifying genes associated with 
growth, this profile may be a cellular reaction to prevent overgrowth, thus we see a 
profile indicative of growth restriction. For this reason an earlier time point may 
provide a better indication of the affected genes involved in growth, rather than the 
pattern we see here.  
 
As this is the unstressed TBP culture, we do not see any significant stress responsive 
genes differentially regulated at this point. While phenotypically TBP has been 
demonstrated to perturb gene expression in early stages to benefit growth, the 
phenotypic differences between TBP and control cell lines in the later stage of culture 
would suggest that TBP does not play a significant role in the survival or viability 
aspect of these cells. For example, if we look at the percentage viability graph of the 
two cell lines compared here, we find that their profiles are mostly identical in the 
decline phase. From this profile we can see that, while TBP may be beneficial in early 
stage growth, its effects are mostly suppressed by day 5 in this culture, with an 
apparent shift to lower levels of mitotic proteins and a profile apparently geared 
towards growth suppression. 
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3.2.19.4 pcDNA(S) v pcDNA(U) – 351 genes (179 down, 172 up)  
Comparison examining the effect of the stress procedure (no genetic manipulation) 
The next comparison examined was between the control (empty vector transfected) 
population and its stressed counterpart. This comparison allowed us to investigate the 
differences in gene expression brought about by the stress procedure in isolation, 
without the added effects of TBP or Library overexpression. 
 
Initially we can see a greater number of genes affected by the stress procedure in 
isolation than by TBP overexpression alone, with small changes in a wide range of 
genes accounting for the change in phenotype we see here (less than 7% of genes are 
found with <±2-fold dysregulation). While TBP transfection was found to affect a 
positive change in maximum cell density, the stress procedure generally appears to 
help prolong later stage survival, especially in TBP and Library stressed populations. 
However, without any genetic intervention we only see modest improvements here in 
viability in later stages (see 3.2.13.1), compared to greater improvements to late stage 
viability gained in conjunction with stress and genetic manipulation combined (i.e. 
TBP and Library stressed cultures). This would suggest that the heterogeneous 
perturbations brought about by gene overexpression play a role in allowing a 
population to present cells more adapted to stress, with the phenotypic response from 
the genes dysregulated in this instance providing the most nominal improvements as a 
result of the stress procedure. 
 
A broad range of metabolic processes and pathways are found to be affected by the 
stress procedure at this time point, with no single areas appearing to be 
disproportionately affected in any greater proportion by the procedure. Dysregulated 
genes appear in highly enriched pathways affecting growth and apoptosis, ion 
homeostasis and the metabolism of various compounds (such as phosphorous, amines 
and glutathione). This broad range makes it difficult to attribute phenotype to any 
specific pathways. Phenotypically we see a reduction in the rate of loss of viable cells, 
however this reduction may possibly be contributed to by a wide range of targets such 
as antiapoptotic genes like BCL10 (Chen at al. 2012). This beneficial effect may also 
be inhibited by the reduction in oncogenic proteins such as BMI1 (known to promote 
growth in certain cancers; Wu et al. 2011). 
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An interesting area of dysregulated expression was noted consisting of 10 genes 
(found to be upregulated between 1.23- and 1.51-fold), all implicated in glutathione 
metabolism and reaction to oxidative stress. These are generally found to be 
upregulated as a response to reactive oxygen species such as peroxides (Cantoni et al. 
1993) and other toxic compounds (Dickinson and Forman 2002). Genes found 
upregulated in this instance include Catalase (prominent in the degradation of 
hydrogen peroxide and cellular pH maintenance), glutathione peroxidise (Gpx4) 
involved in the protection against oxidative damage, PSMB5 increasing proteasomal 
response to oxidative stress (Chondrogianni et al. 2005) and GCLM (involved in 
glutathione synthesis). In the context of the stressed population it seems possible that 
the pre-emptive upregulation of these genes was selected for by high concentrations 
of both intracellular and environmental waste products, with their increased activity 
playing a role in maintaining a healthy cell. A look at the transcriptional motifs found 
in these genes indicates no common factor, suggesting their upregulation together is a 
specific adaptation of the cell rather than a side effect of a related transcription factor. 
 
The most statistically enriched functional group of genes (with 20 targets falling 
under its definition) are those implicated in the cells response to organic substances. 
This definition lends itself to a broad range of receptors, kinases, transcription factors 
and other functional enzymes, and their dysregulation is possibly an adaptive response 
in stress selected cells to the build up of organic waste products that are characteristic 
of late stage culture. An example in this category with a known positive function is 
RNA stabilising protein RBM3 (upregulated in this instance) is a proto-oncogene 
shown to induce growth and proliferation (Sureban et al. 2008), a beneficial effect in 
CHO.  
 
However, while investigation into function allows us to pinpoint certain targets that 
may be beneficial to a viable phenotype, this functional category appeared to contain 
a number of genes with dysregulation that appears to be detrimental. While late stage 
viability in stressed CHO remains higher post day 5, until this time point viability is 
slightly lower (-8.2% on day 5) in stressed pcDNA culture. These apparently 
detrimental genes may be responsible for this reduced viability at this time point, 
however we can not know if their impact persists in the later stages of culture when 
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the stressed pcDNA culture phenotype retains a higher number of viable cells 
compared to the unstressed population. 
A number of these genes were noted. Examples of genes whose expression suggests a 
detrimental function in this instance include; HERPUD1 (function in ERAD protein 
degradation, however elevated levels are shown to induce apoptosis; Hendriksen et al. 
2006), Cyclin D1 (we see 1.7 fold downregulation in this comparison, while 
overexpression is known to be beneficial in CHO; Zhao et al. 2011), SGK1 (while 
downregulated here, promotes apoptotic resistance in various cancer types; Fagerli et 
al. 2011) and Growth Hormone Receptor (whose stimulation is shown to inhibit 
programmed cell death in CHO; Costoya et al. 1999). 
  
As with the investigation into the effects of TBP overexpression, it is suggested from 
the data that some of these changes may be temporal, reflecting the changes around 
this time point that begin to restrict growth as cells enter the stationary phase. We can 
correlate some genes with a function likely to be beneficial (such as those involved in 
the oxidative stress responses) while the negative viable cell density at this particular 
time point is possibly a result of the genes with detrimental effects such as those 
described above. 
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3.2.19.5 TBP(S) v TBP(U) – 576 genes (289 down, 287 up)  
Comparison examining the effect of the stress procedure with TBP overexpression 
The next key comparison to be investigated is a comparison between the stressed and 
unstressed versions of the TBP transfected population. Similarly to comparing 
pcDNA stressed and unstressed cultures, this comparison can direct us to the 
pathways and genes affected by the effect of the stress procedure   
 
Phenotypically, it is noted that of the beneficial changes from the stress procedure 
gained here (in conjunction with TBP) are greater than that of the stressed control 
(empty vector) culture. A greater number of genes are also found dysregulated than in 
the pcDNA(s) vs pcDNA(u) comparison, once again suggesting that the effect of TBP 
overexpression plays a role in facilitating a greater adaptive response to the effects of 
the stress environment. These two responses also appear to be divergent, with a 
comparison of gene expression from both stressed pcDNA and TBP populations 
identifying an even greater number (>700) of dysregulated genes, suggesting that the 
stress procedure has affected these two populations in fundamentally different ways, 
generating a different response in each. However, in this case the TBP stress response 
is certainly the most optimal as demonstrated by its phenotype. 
 
Again, a variety of pathways are found to be dysregulated. The most significantly 
affected areas in this case appear to be cell cycle related (mitosis, cell cycle, 
chromosome segregation etc), lipid metabolism (cholesterol, steroid and lipid 
biosynthetic bioprocesses) as well as translation related genes. Stress related genes 
affected by the pcDNA stress comparison (such as those involved in oxidative stress 
response and glutathione metabolism) also appear to be dysregulated in this case, 
implicating their role once again in the stress response. 
 
Previously it had been noted in TBP transfected cells that a range of genes involved in 
mitosis and the cell cycle were found to be down regulated, indicating the restriction 
of growth once maximum density was reached. When we look at the expression of 
these genes in the stressed population we find that a large proportion are again 
upregulated in comparison and restored to levels that would again suggest a 
population more involved in growth. However, day 5 is when the TBP-U population 
has begun to decline in cell number, while TBP-S population has reached peak 
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density. As with the earlier comparison between a day 5 peak density pcDNA and 
declining TBP culture, this may just be a temporal reflection of the cells metabolism 
in relation to mitotic and growth related processes. Examples of genes having 
apparently ‘restored’ levels of expression include AURKA (whose activity peaks in 
the G2/M phase; Bischoff and Plowman 1999), CCNA1 and CCNB2 (promotion of 
mitotic cell cycle transition), NCD80 and NUSAP1 (involved in spindle formation), 
SMC4 and Spc25 (chromosomal condensation and segregation).  
A number of genes involved cell cycle progression and mitotic pathways are found to 
be dysregulated that were not originally identified in TBP transfected cells alone, or 
dysregulated to a greater extent than originally found in unstressed TBP. Due to their 
appearance post-stress, they may suggest at their involvement in the increase in 
maximum cell density we see in stress selected TBP cells. For example, GAS1 (a 
tumor suppressor noted previously as 1.6-fold upregulated in TBP transfected cells) is 
found down regulated by over 2.4-fold. Downregulation of a tumor suppressor such as 
this is likely to promote growth to a greater extent. DUSP1 (originally unchanged by 
TBP and now downregulated 1.58-fold) is suggested to be involved in cell cycle due 
to its interactions with p53, however it is also shown to induce apoptosis when 
upregulated in response to oxidative stress, and its downregulation here may promote 
survival despite the environmental conditions (Liu et al. 2008). Tnfrsf21 (aka ‘Death 
Receptor 6’) is found downregulated 1.7-fold, and its reduced effect is likely to have a 
positive impact on apoptosis (Kasof et al. 2001). 
Other significantly upregulated genes identified with growth arrest and survival 
promoting characteristics are PLK2 and GADD45A. PLK2 is a stress responsive 
gene, and its upregulation in times of stress can mediate survival (for example in 
times of compromised respiration; Matsumoto et al. 2009). It was also found 
upregulated to the same degree in pcDNA stressed cells, suggesting it expression may 
be an authentically useful stress response. GADD45A is another stress responsive 
gene that is induced in conditions such as medium depletion to suppress growth (Zhan 
et al. 1994), and also confirmed to promote viability in tumor cells when 
overexpressed (Schneider et al. 2006). 
 
An area with a consistent level of increased activity is genes involved in protein 
translation. Of the 23 enriched for in this comparison, 18 are found with gentle 
increases (1.2-1.31 fold) in expression, with the remaining 5 similarly downregulated. 
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Of the upregulated genes, we see many eukaryotic initiation factor 2, 3 and 6 subunits 
(EIF2A, 3A, 3C, 3H, 3G and 6) overexpressed, many of which are directly and 
indirectly implicated in cell growth and tumorigenesis (Benelli et al. 2012; Hershey 
2010; Zhang, Pan and Hershey 2007). A selection of mitochondrial ribosomal 
proteins are also found upregulated alongside a downregulated ribosomal protein S5, 
an expression profile matching that of a prolific cancer line suggesting that these 
genes are involved in persistent growth and/or survival (Ma et al. 2009). While the 
remaining downregulated genes such as EIF4G2 and 3 are likely to mitigate this effect 
(such as the effects of EIF4G downregulation known to suppress translational 
efficiency; Park et al. 2011) it is possible from their implications in the growth and 
survival of cancerous cells that the majority of translational genes’ upregulation here 
may also have a beneficial impact on CHO growth and survival.  
 
A number of genes identified as playing a role in the regulation of cell death or 
survival were investigated, and was one of the principle categories of targets that were 
investigated in this study. Some were correlated for dysregulation in the same 
direction in both stressed pcDNA and TBP populations, implicating their change as 
beneficial. For example, the most downregulated gene (ERCC1, -1.95 fold regulated) 
is involved in DNA repair and its knockdown is associated with increased 
tumorigenesis in mice (although this may be a result of increased oncogenesis due to 
faulty DNA repair, and not necessarily related to an increase in antiapoptotic factors; 
Doig et al. 2006). A putative tumor suppressor protein SOD1 is also found 
downregulated, possibly a beneficial change as its upregulation is found to suppress 
growth in a number of tumors (Zhang et al. 2002; Weydert et al. 2006).  
The gene Plac8 (aka Onzin) was initially found to be substantially downregulated (4.4 
fold) in pcDNA stressed cells, while it is found as one of the more upregulated (2.3 
fold) in TBP stressed culture. The comparative increase in this genes expression may 
play a role in the improved phenotype of TBP selected cells compared to the control 
stressed culture, as its overexpression is shown to promote survival and growth while, 
conversely, its knockdown is shown to increase sensitivity to apoptotic stimuli (Li et 
al. 2006; Rogulski et al. 2005). The gene SPRR1A is found upregulated in increasing 
levels in TBP transfected, pcDNA stressed and TBP stressed populations. It 
expression is also demonstrated to correlate with the transformed phenotype of mouse 
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cells (Iacovoni et al. 2004), however it is unclear whether this is an effector molecule 
or merely a marker of growth initiated by other oncogenes such as c-jun.  
 
Not all genes investigated appeared beneficial, with a number of genes identified in 
both stressed populations suggesting a deleterious function at the levels expressed at 
this time point. For example, the transcription factor BMI1 is found to be upregulated 
in cancer, and its depletion (as seen in post-stress populations) is known to sensitize 
tumor cells to apoptosis (Alajez et al. 2009; Nowak et al. 2006). Similarly, receptor 
Fr2 (aka PAR1) is known to mediate antiapoptotic signals, yet is also found 
downregulated at day 5 (Yang et al. 2009; Guo et al. 2004). However, as both are 
found downregulated in stressed populations, it may be a result of this process or the 
side effect of a beneficial gene’s expression. 
 
Similarly to pcDNA stressed cells, genes responsive to oxidative stress and those 
involved in glutathione (a cellular anti-oxidant) metabolism. While this may be a 
similar reaction to this particular cellular stress, the genes involved vary to those 
dysregulated in pcDNA. Also, while pcDNA stressed cells produced a more definite 
pattern of upregulation in this area, the response here is a mixture of both up and 
downregulated genes. Genes upregulated include glutathione synthase (GSS), 
glutathione S-transferase omega 1 (GSTO1), GCLM (modulates the activity of 
another Glu anabolic enzyme) and heme oxygenase (HMOX1). Downregulated genes 
include glutathione peroxidise (Gpx1), glutathione S-transferases 1 & 7 (Gstm1/7) 
and IDH1 (demonstrated as having a protective effect with regards oxidative stress; 
Lee et al. 2002). The downregulation of genes such as these does not appear to be an 
optimal response, and is strange considering the more uniform response in this regard 
in pcDNA stressed cells. An interesting related gene involved in protein synthesis, 
QARS, was found to have an antiapoptotic role. Upregulated in this instance, it was 
determined to prevent the activity of the apoptotic signal ASK1 with increases in a 




A response unique to TBP stressed cells compared to the control stress is the 
downregulation of the majority (22 out of 24) of genes enriched for involvement in 
lipid, sterol and terpenoid (steroid precursor) metabolic and synthesis pathways. With 
the exception of upregulated CYB5R1 (involved in the desaturation of fatty acids) and 
CMAS (a transferase for a precursor of glycolipid production), the remainder are 
between 1.21 and 1.84 downregulated. Examples include HMGCS1, HMGCR, Insig1 
and FDPS (all involved in various stages or cholesterol biosynthesis and its 
regulation) and others involved in the synthesis of fatty acids such as Fasn, Cyb5r3 
and Cyb5r1. The sustained expression of these genes may be unnecessary for 
improved growth and survival, and this reduction in expression appears to be tolerated 
compared to the less successful unstressed population. This may also mark a shift 
from energy sources derived from fatty acid catabolism to leave more key substrates 
available for glycolysis and carbohydrate based forms of energy production, however 
we see no substantial changes in the regulation of respiratory genes. After an 
investigation into the function of these genes the phenotypic advantage in their 
reduction of expression for all these genes is not immediately obvious, making 
speculation difficult, with future metabolome analysis a possibly useful means to 
investigate this phenomenon. 
 
In these patterns of gene expression brought about by the stress procedure we find 
small changes in a wide variety of genes in order to affect phenotype, subtly shifting 
the metabolic landscape to better respond to the environmental stresses inflicted. 
Larger changes in gene expression are likely not tolerated and are generally not found 
in these comparisons. When investigated, many genes with significant fold change did 
not appear to hold important functions or appear likely to substantially affect 
phenotype in isolation, and were possibly a side effect or marker of the function of 
more important dysregulated gene targets (or in some cases expressed at a small 
enough level for dysregulation to produce a significant fold change). Examples 
include NCAM1 (a cell adhesion molecule and the most upregulated in this instance, 
6.5 fold), CD36 (a cell surface antigen, found here <9 fold downregulated), and 
WDFY4 (found downregulated 2-4 fold in stressed populations). These genes do not 
appear to hold substantial function outside of in vivo tissue situations. 
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3.2.19.6 Selected Clones v pcDNA(S)   
B3/L(S)2 comparison – 1440 genes (726 down, 714 up) 
B4/L(S)3 comparison – 998 genes (556 down, 442 up) 
C4/T(S)1 comparison – 1303 genes (640 down, 663 up) 
D1/T(S)2 comparison – 942 genes (461 down, 481 up) 
Comparisons examining the unique dysregulated genes of selected stressed clones 
compared to the stressed control 
The next comparison was carried out to investigate the changes in expression found in 
the four selected advantageous clones. Each was compared to the stressed pcDNA to 
control for the generic changes brought about by the stress procedure that have been 
identified, and allow us to isolate targets that are found in a number or indeed all of 
these more unique cell lines that may have contributed to their improvement.  
 
The most obvious characteristic of this comparison is the gross number of genes 
found dysregulated; between 942 and 1440 from the lowest and highest levels of gene 
changes. This appears appropriate for two reasons; first because they are the 
phenotypically the highest performing cell lines from this study and are likely to have 
undergone more changes in their transcriptome to alter their phenotype. Secondly is 
the fact that they are clonally derived cell lines. While the profile of the mixed 
populations represents the response from an entire heterogeneous mix of cells, these 
cell lines represent a more specific and distinct profile that is by definition more likely 
to vary from the average. 
 
The first step in analysing this data was to take a broad look at the bioprocesses 
affected in these clones compared to the stressed control. In general, the processes 
found affected resemble the functional groups most dysregulated in the stressed 
populations previously identified. Again, perturbed genes appear in a wide of 
metabolic processes in order to generate the improved phenotype we see in these 
cells. Cell cycle progress, transcription and translation, RNA metabolism and 
processing, lipid metabolism and glutathione/oxidative stress all appear as the most 
common areas of dysregulation across the four beneficial clones isolated. 
 
Similarly to TBP transfected cells, we see a reduction across the board in genes 
relating to mitotic and cell cycle processes such as spindle assembly, chromosome 
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alignment and Cyclins. As with the peak density reached in TBP cells, this relative 
downregulation is possibly a reaction to the previous high activity of these genes in 
the preceding days of exponential growth.  
 
A common feature noted in stressed populations is once again highlighted in the 
downregulation of a range of genes involved in lipid and sterol metabolism. Across 
the 4 cell lines a key group of 28 genes is found downregulated, most pertaining to 
specific enzymatic functions such as ACAT2 (aceyltransferase), SC4MOL (sterol 
monooxegenase), EBP (sterol isomerise) and SQLE (squalene monooxygenase). As 
noted in TBP selected mixed cells, determining any advantages related to the 
suppression of this area of metabolism is difficult. One paper describes a feedback 
loop in cholesterol production mediated by a number of genes in the mevalonate 
pathway that is known to affect growth (Brown and Goldstein 1980). A number of 
genes prominently downregulated are concentrated in this pathway, including the rate-
limiting HMG-CoA Reductase (average 2 fold down), HMG-CoA Synthase (average 
2 fold down), the LDL receptor (average 1.8 fold down) and thiolase subunits 
HADHA and HADHB. Ultimately, a reduction in the production of mevalonate is 
shown to induce G1 arrest and a reduction in DNA synthesis (Elson et al. 1999; 
Kawata et al. 1994). While we can infer from the data that these changes are somehow 
beneficial, the mechanism is unclear at this time. 
 
One likely downstream effect of reduced cholesterol synthesis is changes to the lipid 
membranes composing cellular structures. Changes in cholesterol and lipid 
concentrations affect membrane fluidity and the organisation of lipid rafts (Sinensky 
1978), and in selected cells this may be linked to changes in expression and activity in 
genes related to intracellular transport (Caliceti et al. 2012), protein localisation and 
signalling amongst others (Hao et al. 2001; Spector and Yorek 1985). In this case 
greater reductions in gene expression associated with cholesterol metabolism are also 
correlated with increased numbers of these dysregulated genes (for example the 
differences between samples L(S)2 and T(S)2, with the former maintaining the 
reduced levels of expression for genes such as ACAT2 and HMGCR etc, and more 
than twice the number of dysregulated genes involved in intracellular transport).   
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Another possible change in the cell resulting from decreased cholesterol is the 
increase in cellular oxygen concentration. A study was carried out demonstrating an 
increased oxygen gradient with the inclusion of higher levels of cholesterol in plasma 
membranes, with lower concentrations permitting an increase in oxygen diffusion into 
cells (Khan et al. 2003). This may be the case in the selected clones we have isolated 
in this instance, however an increase in cellular oxygen is contradicted by the 
hampered response in genes related to oxidative stress. In general, we would expect 
this response to increase. Similarly to TBP stressed cells we see a mixed response, 
with some increases in selected genes unique to each of the 4 lines tested (for 
example, DNA damage induced Ddit3 in T(S)1. However the trend is generally a 
reduction in these genes compared to the stressed pcDNA cell line in this comparison. 
This may suggest a reduced capacity to cope with oxidative damage (for example 
IDH1, previously demonstrated as providing a protective benefit, is consistently 
downregulated in all selected clones), or reduced need for such a response.  
However, elevated levels of reactive oxygen species (ROS) have also been shown to 
promote tumorigenesis and stimulate growth via activation of signalling pathways 
such as NF-KB (Hsu et al. 2000). Downregulation of genes such as Catalase and SOD 
(both found between 1.23 and 1.94 downregulated in all selected clones) have been 
demonstrated to induce such effects via the modulation of ROS concentrations 
(Reiners et al. 1991; Gupta et al. 2001), and may contribute the improved growth and 
survival we see here. Evidence of NF-KB over activity in promoting growth is also 
seen in the persistent downregulation of the NF-KB inhibitor NFKBIA, a putative 
tumor suppressor gene that is >2-fold downregulated in all selected clones (Cabannes 
et al. 1999). 
 
Another area of significant dysregulation is the processing and transport of mRNA. 
Across the four cell lines investigated, 3 have significant numbers of genes 
dysregulated in this area (>30) with the remaining clone (T(S)2) containing ~20 
affected genes. While the exact compliment of different dysregulated genes in this 
area are different in each cell line, on average two thirds of each group are found to be 
upregulated. In a subset of two clones, a group of Polymerase II related genes were 
also found to be upregulated, suggesting a possible increase in activity in the 
processes involved in mRNA generation and processing. While many genes did not 
provide compelling evidence to link them to a direct improvement in phenotype, some 
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examples were found that may impact in a positive way. For example, PRMT5 is 
implicated in the repression of genes involved in cell cycle progression and 
proliferation (Pal et al. 2004). Its downregulation in all clones tested may suggest the 
upregulation of these genes and related improvements in cell proliferation. The gene 
THOC7 is also upregulated in selected clones. Forming part of the TREX mRNA 
transport complex, it is found upregulated in certain aggressive breast cancers and 
may play a role in promoting growth (Guo et al. 2005). The expression of a number of 
genes known as ‘heterogeneous nuclear ribonucleoproteins’ (HNRNP’s) are also 
found to be perturbed, including HNRNPs-A,D,K and P (downregulated) and 
HNRNPs C, H and N (upregulated). They play a number of functional roles, including 
splicing, mRNA transport and inhibition of apoptosis (Choi et al. 1986). Upregulation 
of HNRNPC is also linked to expression of XIAP (noted in clone L(S)3), which is 
known to inhibit apoptosis. Conversely, HNRNPK expression is known to stimulate 
c-myc expression, and both are found ~1.2 downregulated in T(S)2 (Carpenter et al. 
2006). This may be detrimental, as c-myc is known to increase proliferation and is 
slightly upregulated in the other selected cell lines (Ifandi and Al-Rubeai 2003). 
Related to the area of mRNA processing are the genes related to Polymerase II 
transcription expressed in a subset (L(S)2 and C3) of the clones analysed. These are 
almost exclusively upregulated, and suggest at an increase in Pol II activity. These 
include subunits of RNA polymerase II (POLR2F, POLR2G, POLR2L), transcription 
factor TBP-like protein (TBPL1) and general transcription factors GTF2A (known to 
interact with TBP and TBPL1) and GFT2A2. These genes are correlated with the 
downregulation of SSU72 (found to be in 3 of the samples tested). As a phosphatase, 
it plays an apparent role in limiting the rate of polymerase II activity by functioning as 
a molecular ‘brake’ (Dichtl et al. 2002). Together with the pattern of gene expression 
we see here, its downregulation may play a role in increasing the expression of a 
number of Pol II transcribed genes. 
 
A number of genes previously associated with improved growth and survival in TBP 
and pcDNA selected cells were also found at levels likely to be advantageous in at 
least one or more selected clones. For example, the oncogenic protein BMI1 
(associated with high growth in certain tumors) is found upregulated between 1.4 and 
2.3 fold in all selected clones. The pro-apoptotic gene HERPUD1 is downregulated in 
selected cells, an effect likely to impact cell survival. Plac8 (aka Onzin), a gene found 
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whose expression is found to vary in to a large degree, is found between 1.6 and 17.3 
fold upregulated, and its overexpression may promote cell survival. CyclinD1 is 
found upregulated between 1.5 and 3.3 fold upregulated, and its activity in cell cycle 
progression may benefit or be indicative of growth. 
While these are the most common across all selected clones, other potentially 
beneficial targets are found in one or two of the advantageous cell lines such as PEDF 
(downregulated in L(S)2/T(S)1), DUSP1 (downregulated in L(S)3/T(S)1), GADD45A 
(upregulated in L(S)2/T(S)1) and AATF (upregulated in T(S)1 apoptotic protection; 
Xie and Guo 2006). 
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3.2.19.7 Stressed v Unstressed populations – 292 genes (203 down, 89 up)  
Comparison examining most prominent gene changes related to the stress procedure 
Previous comparisons were originally intended to examine the overall effects of 
discreet steps of the experiment by comparing single cultures to one another (such as 
the effect of TBP overexpression, or the effects of stress on both control and 
transfected cell lines). While the genetic interventions carried out were shown to elicit 
demonstrable phenotypic changes, benefits were mainly gained as a result of their 
combination with the stress procedure. To investigate the most common genetic 
changes underlying the benefits gained from the stress procedure a comparison was 
carried out that combined sample sets incorporating all stressed (pcDNA-S, TBP-S, 
selected clones) and unstressed (pcDNA-U, TBP-U, CHO-K1, CHO-SEAP) cultures. 
The average number of viable cells in each group was found to be significantly 
different at the day 5 time point and beyond (p=0.01) when the combined average was 
measured so, by comparing a larger combined number of different samples under this 
one common characteristic, this comparison was hoped to further elucidate the 
common differences in expression that were brought about by the effects of stress 
selection. 






















Figure 3.2.19.7.1: Graph displaying the average viable cell concentrations of the 
grouped stressed and unstressed populations when analysed together, with error 
representing the standard deviation of viable cells within each group. The most 
significant differences between stressed and unstressed populations appear from day 5 
onwards (when RNA sampling occurred, p=0.01), suggesting group analysis of these 
samples may expose the genetic elements most common to their phenotypes.  
*p = 0.01 
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Using this method of analysis we see a smaller cohort of genes significantly 
associated with the changes elicited by stress selection (203 down- and 89 up-
regulated). This is to be expected due to the wider range of phenotypically distinct 
samples contributing to each sample set. This variety of input also provides us with a 
greater level of statistical power in determining the more significant genes and 
pathways associated with improvements in phenotype.  
 
When the pathways affected were analysed, the only pathways highlighted for with 
significant adjusted p-values (<0.05, Benjamini Hochberg method) were those 
involved in lipid metabolism (sterol, steroid, lipid and cholesterol 
biosynthesis/metabolism). These categories encompassed a subgroup of 22 
downregulated genes. Once again, this was strongly indicative that the reduction in 
the expression and activity of this specific category of genes is related. A selection of 
these genes are involved in fatty acid synthesis (SCD1,) elongation (TECR) and 
desaturation (SCD3, DEGS1).  
At least 12 genes identified play a direct role in the synthesis and uptake of 
cholesterol;  
 
 Mevalonate pathway - HMG-CoA Synthase (HMGCS), HMG-CoA Reductase 
(HMGCR), isopentenyl-diphosphate delta isomerise (IDI1), farnesyl diphosphate 
synthase (FDPS),  farnesyl-diphosphate farnesyltransferase (FDFT1), squalene 
epoxidase (SQLE) 
 Post-squalene sterol modification - Emopamil binding protein (EBP), sterol 14 
alpha-demethylase (CYP51), sterol-C5-desaturase (SC5D), sterol-C4-methyl 
oxidase (SC4MOL), NADH-cytochrome b5 reductase 3 (CYB5R3) (Fukushima, 
Grinstead and Gaylor 1980; Herman 2003) 
 Cholesterol uptake - LDL receptor (LDLR), acyl-CoA:cholesterol 
acyltransferase (ACAT2, deficiency is shown to reduce cholesterol uptake; 
Buhman et al. 2000; Repa et al. 2004) 
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These proteins play key roles in pathways that ultimately lead to increases in the 
concentration of intracellular cholesterol. As speculated previously, a reduction in 
cholesterol and the activity of these pathways may affect a number of characteristics, 
such as membrane fluidity, oxygen permeability and intracellular transport rates.  
 
A study by Lee et al. (2011) measured the effects of cholesterol accumulation in 
CHO, and its effects on oxidative stress and related apoptotic pathways. This work 
followed from previous studies demonstrating the link between increased cholesterol 
concentrations and oxidative stress (Sanguigni et al. 2002). Experiments were carried 
out to show that mutants with naturally higher levels of free cholesterol were more 
susceptible to induced oxidative stress via menadione induced production of 
superoxide free radicals and nitric oxide. Dramatically increased levels of these 
reactive species then induced greater levels of apoptotic cell death, marking the 
downstream negative consequence of increased cholesterol accumulation. Free 
cholesterol is also found to aggravate this response by further inhibiting antioxidant 
enzyme activity, such as catalase, glutathione peroxidase and superoxide dismutase 
(Lu and Chiang 2001). Interestingly, these 3 genes are also marked as downregulated 
in the majority of stressed cells (between 1.2 and 1.36 fold down). However, with data 
suggesting the downregulation of cholesterol synthesis, this may be a reaction to a 
reduced level of intracellular oxidative stress. This idea is supported when we look at 
the pcDNA stressed population. As the only stressed population with no significant 
change in lipid metabolic enzymes, it also demonstrates a stress response in which the 
portion of genes related to oxidative stress are most upregulated. This is in contrast to 
other TBP and Library transfected cell lines which appear to make greater phenotypic 
gains with reductions in cholesterol metabolism, suggesting that this is a more optimal 
response in maintaining survival. 
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Of course, as we have seen previously the improvements to phenotype seen here are 
the result of a wide range of interacting genes generated by the transcriptomic shift 
(affected by both genetic modification and stress procedure). As this comparison is 
the result from a wider range of distinct cell lines than previous comparisons, fewer 
affected genes and pathways are identified with statistical significance (with the 
exception of those discussed above). Nevertheless, a number of single genes with 
more significant fold-changes that were noted previously are also present in this list, 
including SPRR1A and Apoptosis-antagonizing transcription factor (upregulated), as 
well as GAS1, DUSP1 and ERCC1 (downregulated). As well as being noted in 
previous binary comparisons, the presence of genes such as this in this comparison 
may signify a more significant relationship with the beneficial effects of stress, 
marking them as potential targets for future engineering work.
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3.2.19.8 Profiling conclusions 
 
Having generated a number of beneficial cell lines (both clonal and mixed 
populations), this experiment was carried out to give an oversight into the numbers 
and types of genes that were found to be affected by both the genetic intervention and 
stress procedure. From this data, we can make the following conclusions; 
 
 In almost all cases, changes in phenotype after the stress procedure were brought 
about by large numbers of small changes in expression. This method of reaching a 
complex phenotype is in contrast to single gene engineering approaches, in which 
a smaller number of genes have a more direct effect on a discreet selection of 
cellular processes (also seen here in the unstressed TBP population). 
 Phenotypically the effects of TBP transfection alone are minimal, as is the stress 
procedure. However, when combined we see a synergistic improvement in 
selected mixed populations and resulting clones. This synergy is reflected in the 
wider range of dysregulated genes in these cell lines. 
 Significantly affected areas of gene expression include cell cycle, regulation of 
growth and apoptosis, protein translation, mRNA processing, response to 
oxidative stress and lipid metabolism. Cholesterol synthesis proved to be a 
prominent area of dysregulation associated with improved phenotype, and is 
worthy of further investigation. 
 The selected day 5 time point provided a look at mid culture gene expression. 
However, further work would best incorporate samples in both exponential (day 
3) and decline (day 7) samples. This would give a more detailed look at the 
specific genes involved in growth to high density that are likely deactivated by 
day 5, while the later sample would give a better indication of the genes activated 
when environmental stresses are more prominent. 
 While previous experiments indicate a benefit to using a mutant library over the 
wild type expression of TBP, the data generated here from only 2 clones is not 
enough to determine the genetic mechanisms underlying this. Instead, all 
advantageous clones were analysed together to determine the common features 










& Future Work 
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4.1 Viral Targeting Discussion 
 
4.1.1 Summary of results  
This study was originally conceived as an investigation into the use of adeno-
associated viral vectors and their potential application for gene targeting in a CHO-K1 
cell line. For this study, a pair of model genes (DHFR and HPRT) was targeted using 
recombinant AAV vectors. These were generated to contain upwards of 1800 bp of 
DNA sequence homologous to a specific region in the genes targeted to promote the 
occurrence of homologous recombination. This, as demonstrated previously in other 
studies using AAV in mammalian cell lines, can be used effectively to introduce pre-
determined mutations, deletions and insertions at specific chromosomal loci, 
facilitating the precise modification of the CHO genome. This technique also permits 
targeting rates higher than those acquired using similar plasmid based vectors whilst 
also using considerably smaller homologous sequences.  
 
Initially, targeting vectors were constructed containing a selectable marker flanked by 
two homologous arm sequences. A 4.7 kb upper limit recommended for efficient 
packaging has been demonstrated (Dong, Fan and Frizzell 1996). In these instances, 
both DHFR (a 4186 bp constructed viral genome, including 2333 bp of homologous 
sequence) and HPRT (a 3710 bp constructed viral genome, including 1855 bp of 
homologous sequence) vector constructs were designed to remain under this limit and 
avoid the negative effects on viral propagation associated with oversized vectors. 
These constructs were used to successfully generate viral stocks, which were then 
concentrated and used to transduce CHO-K1 cells. These transduced cells were then 
placed under G418 selection to remove the untransduced cell population. 
 
A control GFP virus was used to estimate the number of viral particles produced using 
the method followed, resulting in a final estimated MOI of 2.08 x 10
5
 viral particles 
per cell applied in actual targeting experiments. The GFP virus was also used to verify 
the functional ability of AAV to successfully transduce CHO cells, with an MOI of 
less than 1000 particles per cell found to generate GFP fluorescence in 74.8% of cells. 
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A PCR screen was carried out on DHFR targeted clones in order to estimate the 
frequency of targeted homologous recombination events in comparison to the total 
number of recombinants. 195 clones were isolated with viral integration events, of 
these 5.6% had correctly integrated the 5’ arm, while 3.1% of the total fraction (6 
clones) were found to have integrated both 5’ and 3’ homologous arms, resulting a 
number of cell lines featuring a correctly targeted locus. 
 
Unfortunately, a screen in selective medium for both DHFR and HPRT targeted cells 
did not result in the discovery of homozygous knockout clones. qPCR and PCR 
screening of heterozygous DHFR (+/-) clones confirmed a functional allele of the gene 
existing within the cells characterised. A qPCR technique was also employed to 
estimate the frequency of off-target insertions in a number of correctly and incorrectly 
targeted clones. Of the 8 clones analysed, an average number of 24 integration events 
per clone was reported, with the highest insert number clone containing 77 inserts. 
This high frequency of random integration is likely due to the high MOI used in this 
study, with targeted as well as random integration known to increase in frequency with 
increases in MOI. This result may also have been augmented by the use of the drug 
based selective procedure used to enrich for cells having integrated viral genomes, 
skewing the population toward high insert copy numbers. Such high copy numbers 
may be a disadvantage in gene knockout experiments such as this, but may prove a 
useful method for delivering a product transgene or other situations where high copy 
numbers are beneficial. 
 
Alternative techniques were then explored in an attempt to generate null mutants. 
These included a protocol in which cells are subjected to a high concentration pulse of 
selective antibiotic to provoke a number of cellular mechanisms such as chromosomal 
duplication or gene conversion, potentially inducing cells to become homozygous at 
the targeted locus. A second protocol was also employed, in which a secondary 
targeting vector was constructed. This virus was generated and applied in the same 
manner as previous virus vectors in an attempt to target and disrupt the second allele. 
Unfortunately, neither of these further techniques was successful in isolating a true 
null (homozygous negative) mutant. 
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4.1.2 Improving targeting frequency 
 
The targeting efficiency for single correctly targeted alleles achieved in this study was 
found to be over 3% of cells with viral integration events. This compares favourably to 
the targeting frequency of up to 1% that was originally reported in early landmark 
targeting papers (Hirata et al. 2002; Russell and Hirata 1998), and would suggest that 
the protocol employed in this study is a good starting point for further experiments 
investigating the use of AAV for gene targeting in CHO cells. However, this result is 
from an unselected population, and represents 0.7% of all cells transfected. To 
examine this figure critically, we can compare it to a similar study in human 
fibroblasts (Hirata et al. 2002) in which G418 was used to enrich for targeted clones. 
Two separate attempts at this experiment yielded efficiencies of 1 in 8 and 1 in 23 
(12.5% and 4.3% respectively). While this initial instance of targeting in CHO did not 
reach these levels of efficiency, the use of a selectable marker successfully allowed us 
to reduce the population necessary for screening to a manageable level. 
As transduction conditions were generally kept consistent in this study, it is difficult to 
theorise how different factors, such as the relatively high MOI employed or the length 
of targeting arms used, may have affected the final outcome. However, a number of 
optimisations to the process of viral gene targeting have been performed, 
demonstrably improving targeting frequency using AAV in mammalian cell lines. 
These modifications could potentially be applied to further uses of AAV based gene 
targeting in CHO cells in order to improve targeting efficiency. 
 
Increasing MOI 
In this study, a relatively high MOI of 2.08 x 10
5
 was used to ultimately generate the 
DHFR targeted cell lines that were isolated. This compared favourably to the original 
study in human fibroblasts by Russell and Hirata (1998), in which a similarly high 
number of viral particles (3 x 10
5
) resulted in a 0.7% targeting rate.  
In this example, decreases in MOI directly resulted in reduced targeting rates. This 
dose dependency relating targeting rates to viral particles applied has been confirmed 
in other studies examining the effects of varying MOI rates (Vasileva, Linden and 
Jessberger 2006; Porteus et al. 2003) 
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These results would lead to the conclusion that an increased MOI is favourable for 
isolating clones with targeted genetic loci. However, generation and purification of 
such high levels of virus may not be feasible or even necessary for some studies, and 
successful targeting has been demonstrated at MOIs as low as 2000 (Hirata and 
Russell 2000). 
 
Increasing arm size 
The DHRF targeting vector used in this study on which targeting efficiency results are 
based contains 2333 bp worth of sequence homology to the target locus. From the 
results achieved, this would appear to be sufficient for correct targeting, and is 
comparable to previous successful studies utilising AAV targeting. Improved targeted 
rates have been demonstrated in studies evaluating the recombination potential of 
vectors containing different sized regions of homology. In one example, two to five-
fold increases in targeting are gained by increasing the region of locus homology used 
from 1693 bp to 2988 (Hirata and Russell 2000). Another study performed to 
introduce a single base pair gene correction found significant increases in targeting 
with the downstream (3’) arm size increasing from 205 to 435 bp, coupled with a 
1900 bp upstream (5’) region of homology (Liu et al. 2004). A similar gene repair 
study reported a 2-fold increase in 3′ homology resulting in a 23-fold increase in 
targeting at a high vector dose, with this improvement becoming more apparent (up to 
73-fold) at lower doses. 
 
Due to the packaging limit of AAV vectors, vector construction is ultimately a trade 
off between the size of expression cassette that is to be inserted within the vector and 
the remaining space available for homologous sequence. For small transgenes, such as 
the selection marker included in this study, this limit does not pose a problem and 
allows for large regions of homology to be used. For attempts at gene knockout a 
large inserted transgene is unnecessary. However for situations in which the locus is 
to be targeted for transgene expression, this can be mediated via RCME (recombinase 
mediated cassette exchange; Oumard et al. 2006). To achieve this, LoxP sites can be 
included in the vector. Once a suitably targeted clone is generated, Cre recombinase is 
then transfected along with a secondary plasmid vector containing the gene of interest. 
Cre-Lox recombination then promotes inclusion of the secondary vector at this target 
site, bypassing the need for an overly large transgene to be included on the original 
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targeting vector (Turan et al. 2011). An elegant method devised to overcome this size 
limit has also been successfully employed in which 2 separate vectors are co-
transduced, each encoding a separate element of the final cassette. Intracellular 
concatemerisation then links these viruses, allowing them to integrate as a single 
construct (Ghosh et al. 2008; Duan et al. 2000). This property of co-transduced 
viruses has not been explored yet with regard to gene targeting. 
  
Inducing double stranded DNA breaks 
Due to the nature of homologous recombination used by AAV vectors to generate 
targeted integrations, methods have been devised in order to exploit the cellular 
mechanisms used to induce homologous recombination and increase the proportion of 
correctly targeted cells. Protocols such as this generally seek to provoke the 
mechanisms involved in double stranded break (DSB) repair, one of the key apparatus 
by which cells maintain the integrity of their genomes. Prior to this technique being 
used in conjunction with viral targeting, this method was studied in yeast and mouse 
cells using a plasmid targeting vector. In one example, a homing endonuclease I-SceI 
is expressed on a co-transfected plasmid. By inducing a DSB at the HPRT locus, this 
was found to increase targeted recombination rate 5000 fold higher in mouse 
embryonic stem cells than a control line without the endonuclease cleavage site 
(Donoho, Jasin and Berg 1998). 
Utilising this strategy in combination with homologous AAV vectors has proved 
successful at improving targeting rates. In a study utilising a I-SceI cleavage site, AAV 
gene targeting was roughly 100-fold higher in human HT1080 cells (Miller, Petek and 
Russell 2003), with a similar substantial increase in defective GFP correction found in 
HEK cells (Hirsch et al. 2010) utilising a similar I-SceI expression system.  
The main drawback to this system however, is the need for a suitable endonuclease 
site at the target locus. However, the advent of zinc-finger nuclease technology has 
allowed us to generate DNA cleavage enzymes recognising almost any custom 
sequence. While this AAV and nuclease combination has proven useful in a clinical 
setting for introducing targeted insertions (Ellis et al. 2012), it seems likely that this 
approach could be successfully implemented for genome editing in cultured, 
industrially relevant cell lines. 
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Inhibition of NHEJ 
Induction of DSB repair mechanisms has been shown to increase targeting efficiency. 
Conversely it has also been found that by inhibiting the action of a competing DNA 
repair mechanism, non-homologous end joining (NHEJ), increases in gene targeting 
rates could also be achieved. In one study the protein Ku70, known to be involved in 
the NHEJ mechanism, was knocked down using siRNA interference in a human cell 
line. This resulted in a 5-10 fold increase in successful gene targeting for a variety of 
loci (Fattah et al. 2008). A similar study including knockdown of both Ku70 and 
Xrcc4 NHEJ proteins reported an 11-fold increase in targeted HR events, with a 
simultaneous 70% reduction in non-homologous random integration (Bertolini et al. 
2009). Methods such as this prove to be an attractive means of increasing gene 
targeting rates with the added benefit of reducing off-target integrations. 
 
Exploiting cell cycle sensitivity 
Two unrelated studies conducted in the 1980’s revealed an interesting property of viral 
transduction and homologous targeting rates, namely that both are found to be more 
efficient in cells in the S-phase portion of the cell cycle (Russell, Miller and Alexander 
1995; Wong and Capecchi 1987). This is suggested to relate to the competing DNA 
repair mechanisms of HR and NHEJ, with the HR machinery found to be 
preferentially active in proliferating mid cell-cycle populations.  
This property has since been exploited to demonstrate that AAV mediated gene 
targeting is indeed more efficient, with one study exhibiting a 1000-fold increase in 
dividing cells compared to their quiescent counterparts (Trobridge, Hirata and Russell 
2005). This effect was also noted in studies in which 2mM thymidine was used to 
enrich for cells in the G1/S cell cycle phase, resulting in between a 2 and 24 fold 
increase in successful gene targeting (Liu et al. 2004; Saleh-Gohari and Helleday 
2004). 
 
Enrichment methods such as this would prove useful due to their simple unintrusive 
nature requiring only a chemical addition to medium, and could easily be explored as a 
method of improving targeting rates in CHO cells. Methods such as those described 
above could also be implemented in tandem, hopefully in order to generate a 
synergistic response in which each factor contributes to increased gene targeting rates. 
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4.1.3 Generating a homozygous knockout cell line 
 
Unfortunately, a homozygous knockout cell line was not isolated in this study despite 
a number of alternative mechanisms explored in order to target or otherwise disrupt 
the second allele. Prior to further experimentation in CHO using AAV vectors, we can 
only speculate as to the potential reasons why this failure occurred based on 
observations in similar experiments and the mechanisms involved in homologous 
recombination. 
 
One experiment involved the use of a secondary targeting vector, identical in target 
locus homology to the original albeit with a different selectable marker. This was 
applied under identical conditions to those used for the initial targeting. However, 
subsequent analysis of the cell line used for this secondary targeting determined the 
presence of between 17 and 20 random neo insertions, possibly linked to the 
remaining homologous DHFR vector sequence. These ‘pseudo’ target insertions may 
have served to increase the number of possible recombination loci for the secondary 
vector due to their shared homology, diluting the possibility of targeting the true 
DHFR secondary allele. 
 
The protocol examining the use of a high pulse of selective drug to induce 
recombination at the targeted locus also failed to isolate null mutants. The surviving 
clone, 1H1, likely survived the high concentration of G418 due to the high number of 
neo insertions measured in its genome. Unfortunately data on the number of cassette 
insertions was unavailable when this technique was considered. With an estimated 
mutation rate of 1.3 x 10
-5
 per cell generation for this technique (Mortensen et al. 
1992), it is also possible that any successful mutants were not found due to an 
insufficient number of clones screened. A future repeat of this experiment would be 
best suited to a targeted clone with no extraneous insertions. Also, it is unknown at this 
time whether the peculiar chromosome structure and aneuploidy of CHO derived cell 
lines (Wurm and Hacker 2011) would possibly affect the likely hood of recombination 
between chromosomes necessary for this form of mutation. 
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Due to high incidence of non-homologous integrants, this may be indicative of the cell 
cycle phase in which the majority of cells were transduced at the time of 
experimentation. Non-dividing cells have been demonstrated to incorporate insertions 
preferentially using the NHEJ pathway (as opposed to the homologous recombination 
that is more prevalent in S-phase cells), and modifications to any future protocols 
followed could involve the use of techniques demonstrated previously to enrich for S-
phase cells. An examination of cell cycling in CHO to determine an optimum time 
post seeding to transduce the cells would also prove useful, as the 24 hours post-
seeding transduction used in this experiment may not be the optimum.  
 
From the data generated, the high incidence of off-target random insertions seems a 
likely factor in the inability to successfully isolate null CHO mutants in the 
experiments carried out. While a high MOI was initially used in this experiment as a 
means of increasing gene targeting rates, this variable should be carefully considered 
in future CHO gene targeting research. A more successful approach would likely 
combine a reduction in MOI with the use of techniques described above to both 
increase targeted recombination rates and reduce the occurrence of random NHEJ 
insertions. It is improbable that techniques successfully implemented in other 
mammalian cells could be found impossible to implement in CHO, and further work 
using optimised experimental protocols based on the knowledge gained in this attempt 
is likely to yield success. 
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4.1.4 Potential uses for targeted cell lines 
 
Gene knockout 
Gene targeting has two primary potential functions in industrially relevant cell lines. 
The first is gene knockout, in which both alleles are targeted to remove the effect of 
this gene on the cellular phenotype. This is applicable for any gene deemed to be 
detrimental to growth or productivity for example, and as expected total gene 
knockout provides superior results compared to techniques such as RNAi based gene 
knockdown (Li et al. 2010). In most cases, this would also require the use of 
sequential targeting methods in order to generate homozygous knockouts in order to 
completely ablate gene function. 
 
 
Targeted transgene insertions 
Another potential use for gene targeting is the insertion and expression of a target 
transgene (for example, a therapeutic protein product) at a predetermined genomic 
location. This would hold a number of benefits with regards to the creation of 
industrial producer cell lines, including eliminating the range of expression variability 
found with random insertions associated with common transfection methods.  
Position effects, such as the influences of nearby regulatory elements or the chromatin 
structure of that target site, can impact negatively on gene expression and stability 
over time. While targeted gene integration will not remove these effects, the discovery 
of a suitable genetic locus that is found to promote good levels of gene expression 
means that predictable, reproducible results can be achieved in successive 
experiments. Discovery of such a genomic locus could be mediated through methods 
such as random screens (Mielke et al. 1996), or via the use of in silico bioinformatic 
methods to predict positions with beneficial characteristics, such as the presence of 
S/MAR elements that may shield a transgene from inactivation (Frisch et al. 2002). 
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Correctly employing this technique could then be used to generate a correctly targeted 
‘master’ cell line, whose expression locus could be targeted with a number of different 
product genes. This would combine the benefit of predictably high levels of expression 
with a drastic reduction in the levels of screening necessary to select clones suitable 
for a bioprocess, as the phenotype of the master producer cell line could be 
characterised and preselected for advantageous properties. 
 
Figure 4.1.4.1 below demonstrates the process by which a correctly targeted cell line 
expressing a gene of interest is generated by first targeting a specific locus, generating 
a single targetable LoxP site and subsequent introduction of the gene of interest. This 
method has proven successful in CHO for generating targeted cell lines with 
predictable gene expression properties (Qiao et al. 2009; Fukushige and Sauer 1992), 
however the generation of the primary targeted site using traditional plasmid based 
recombination is a drawback due to the inherent difficulty of homologous targeting 
using plasmid vectors compared to AAV targeting. By combining this protocol with 
the advantages of AAV gene targeting with regards to efficiency, this could prove an 
interesting method for generating a useful, versatile system for protein production. 
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Figure 4.1.4.1: A brief description of the generation of a ‘master’ targeted expression 
system, and the introduction of a model gene of interest (GFP). 
(A) Singly targeted cell line is first generated. The cassette configuration in this 
example is identical to that used in this experiment. 
(B) Expression of Cre recombinase within the cell catalyses the excision of the 
sequence between the two artificial LoxP sites, leaving 1 remaining targetable 
‘Master’ LoxP integration site and simultaneously inactivating the neo resistance 
marker. 
(C) The re-addition of Cre recombinase in the presence of a vector constructed to 
contain a gene of interest (GFP), the Δneo exon (reactivating the neo selection marker) 
and an internal ribosome entry site (IRES) permitting the expression of GFP from the 
CMV promoter. 
(D) Cre-Lox recombination integrates this vector specifically within the target site, 
expressing the gene of interest in a predictable manner. G418 selection and a 
subsequent PCR screen at the highlighted position can also be used to determine 
successful recombination. 
  (A) 
  (B) 
  (D) 
  (C) 
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4.2 Directed Evolution Discussion 
 
4.2.1 Summary of results  
This study was originally carried out to investigate if a directed evolutionary technique 
known as ‘Global Transcriptional Machinery Engineering’ (gTME), demonstrated to 
generate beneficial phenotypes in E. coli and yeast, could be successfully applied in 
CHO cells. In this technique a gene is chosen for mutagenesis, ideally one involved at 
a high level in the cells’ transcriptional activity. This is then used to generate a mutant 
library that, when transfected, provides a heterogeneous pool of cells. Using a suitable 
environmental stress, advantageous clones can then be selected for. 
 
 
Mutation and Stress 
Initially, a gene was selected for mutagenesis. TBP was chosen based on its almost 
universal involvement in the transcription of the majority of genes, providing a likely 
means to alter the transcriptional profile by introducing mutant copies with functional 
variation. After cloning the CHO TBP mRNA sequence into a plasmid expression 
vector, this sequence was then subjected to a low fidelity polymerase under varying 
conditions to induce mutations. Libraries of different mutation rates were generated, 
with a library of 9.5 mutations per kb (or ~9 mutations per gene sequence) chosen for 
transfection. This would reduce the deleterious effects of an exceedingly high 
mutation rate, while providing sufficient heterogeneity of mutant sequences to 
distinguish this library from the effects of the wild type gene. This was transformed 
into bacterial cells to generate a plasmid library suitable for transfection, and a library 
complexity of ~10
5
 was measured. This library, along with an empty vector control 
plasmid and the wild type TBP gene were transfected separately into a CHO-K1 cell 
line and drug selected to generate stable cell lines. 
These stable cell lines were then subjected to two separate environmental pressures for 
18 passages each; one in which the culture was allowed to proceed until a low level of 
viability after which the remaining living cells were re-passaged, and a second in 
which cells were passaged at a low density to allow potentially faster growing cells to 
become the dominant subpopulation after exponential growth. 
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Clone analysis (pre- and post-stress) 
After the stress procedure, single cell cloning was carried out on both pre- and post-
stress mixed populations. Due to the nature of the mutant library, it was theorised that 
cells expressing different mutant sequences would provide a wide variety of 
phenotypes, with a mixed population only indicating the average performance of all its 
constituent cells. 12 single cell clones were isolated from each population and 
analysed in culture to assess the relative performance of both unstressed and stressed 
populations. 
Pre-stress clones from parental K1, pcDNA (empty vector), wild type TBP and 
Library transfected clones were analysed to assess the effect of transfection without 
the application of a selective stress. In this instance, TBP transfection alone was found 
to play a beneficial role in increasing maximum cell density, ultimately leading to a 
greater overall performance as measured by cumulative cell hours (AIVCD). This 
performance was also relatively consistent across the 12 clones isolated from this 
population, with the smallest variance in phenotype found in TBP clones.  
The Library transfected population on the other hand performed worse on average than 
all other comparative lines. However, this average was coupled with an extremely 
wide variance across the 12 clones analysed, including some potentially beneficial 
clones and despite the lack of any selective pressure. This is in contrast to the relative 
homogeneity of TBP transfected cells, confirming the hypothesis that a mutant library 
would produce a wider variety of phenotypes (both advantageous and deleterious).  
A similar analysis was carried out on 12 clones from both post-stress TBP and Library 
transfected cultures to investigate if the stress procedure had indeed selected for cells 
with a beneficial phenotype and reduced the numbers of Library transfected clones 
expressing deleterious mutant TBP sequences.  
In the instance of ‘viability’ stressed cultures, Library clones were found, on average, 
to outperform wild type TBP clones after the stress-selection procedure. A wider range 
of heterogeneity was still present, however a number of Library clones with AIVCD 
performance in the upper percentiles provided a phenotype apparently worthy of 
further investigation and characterisation. 
In the instance of ‘low density’ stressed cultures, no significant benefit to growth rate 
was found to be generated in Library clones post-stress, and further work was 
concentrated on the more successful ‘viability’ stressed cultures. 
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Due to difficulties in comparing the inter-experimental performances of particular cell 
lines, a final experiment was performed to confirm that stress selected cells were 
superior when directly compared to their pre-stress counterparts. The top 3 clones 
from each group were compared, representing the upper potential limits of 
performance from each group. Compared side by side, the benefit of the stress 
procedure was confirmed in both TBP and Library cells, however in general the 
selected top performing Library clones ultimately appeared to receive the greatest 
benefit to phenotype. This confirmed that, while the stress procedure was beneficial to 
both populations, the wide heterogeneity in phenotype provided by the mutant library 
allowed for the selection of clones with growth characteristics superior to those 
provided by wild type TBP alone. 
 
 
TBP concentrations (mRNA and protein)  
To investigate the levels of TBP expression in both mixed populations and clonal cell 
lines, qPCR was carried out. Initially, in post stress mixed populations, a relatively 
high level of TBP overexpression was measured, with upregulation of 5.7 and 9.6 fold 
in TBP and Library transfected populations respectively. However, when the selection 
of post-stress clones was isolated from this population, the average expression level 
was found to be considerably lower (2.5 and 3.34 fold in TBP and Library, 
respectively). The most successful clones, as determined previously by their growth 
curves and AIVCD performances, were mostly found in the range of 1.3-2.2. This 
may suggest that TBP overexpression is detrimental outside of this range, with 
smaller changes in expression levels able to bring about changes in global gene 
suitable for the advantageous phenotypes measured in these clones, a sentiment also 
suggested by the literature. A western blot for intracellular TBP concentrations also 
found expressed TBP concentrations to vary little compared to an untransfected 
control cell line. 
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Mutant TBP sequencing 
A selection of 15 mutant TBP sequences was isolated from 3 selected Library 
transfected clones. This was carried out to investigate the extent of variety in mutant 
sequences, and if particular mutations were more prevalent. A qPCR to determine the 
number of sequence inserts estimated between 18 and 36 individual sequences in the 
clones analysed, and of the 5 sequences isolated from each clone no mutant sequence 
was duplicated, suggesting a variety integrated into each different genome and 
expressed by each cell. A range of individual point mutations and deletions were 
characterised, however no definitive conclusions could be made as to their effects on 
structure or function. Any cumulative effect on phenotype caused by these mutant 
TBPs is likely the result of a range of more subtle interactions rather than the effect of 
one dominant mutant sequence. The limited level of overexpression measured in these 
cells also suggests that expression of any given single sequence is likely quite low, 
and a number may be epigenetically silenced by the cell or located in unexpressed 
regions of heterochromatin. 
 
 
Functional characterisation of selected clones 
Further experiments were then carried out a number of selected TBP and Library 
transfected clones to further characterise their phenotypic performances. Growth 
curves performed in 50ml disposable flasks confirmed that their advantageous 
phenotypes could be replicated in larger scale suspension culture vessels. A known 
high density control cell line (CHO-SEAP) and parental CHO-K1 cell line were also 
included, with the selected TBP and Library clones demonstrated to generally 
outperform both in terms of growth and survival.  
Productivity assays using transient plasmid transfection of 3 different products then 
demonstrated that the genetic and directed evolution interventions did not 
significantly affect these cell lines’ ability to generate and secrete a relevant protein 
product, a key characteristic of industrial bioprocess cell lines. A final study was then 
carried out to investigate the performance of these cell lines in a temperature shifted 
fed-batch situation, a common industrial bioprocess configuration. This was found to 
promote a longer period of viable cell time, with advantages in cell density in the 
early stages of culture and sustained viability in later stages promoting a greater 
overall performance in selected clones compared to K1 and SEAP controls. 
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4.2.2 gTME in a mammalian cell line 
In this study, the effects of two key experimental components were examined; the 
effect of a genetic intervention (in this case both a TBP mutant library and the wild 
type gene were examined), and the effect of a stress selective procedure. The use of 
the mutant gene library was inspired by its successful use in studies by Alper in lower 
organisms such as E. coli (Alper and Stephanopoulos 2007) and yeast (Alper et al. 
2006). The basic theory was applied in CHO, however the use of a mammalian cell 
line presents unique difficulties not encountered in the organisms previously 
examined. Generation time is one obvious factor, with sub-culturing times for E. coli 
of less than 20 hours providing a means of selecting for advantageous mutants with 
greater speed and efficiency.  
The overall complexity of mammalian cells when compared to simpler producer 
organisms also makes the determination of the unique effects of target sequences 
more difficult. For example, in previous gTME experiments single successful gene 
sequences could be isolated and subjected to subsequent rounds of mutation This 
sequence could also be re-transfected to elicit a similar phenotype, suggesting that the 
stress selection procedure did not induce changes in gene expression of itself (as 
opposed to the result seen in this experiment, and similar directed evolution 
experiments in mammalian cells detailed in section 1.6.1).  
In this instance, the integration of multiple mutant sequences in combination with 
position effects and variable expression levels makes attributing the benefits to one 
specific TBP mutant practically impossible. While the isolation of single copy 
transfectants is possible in theory, for the purposes of this study this method would 
have been impractical. The use of a low copy number would have also likely reduced 
the expression and phenotypic effect of the TBP transgenes, masking their effects and 
reducing the effectiveness of the treatment (Majors, Chiang and Betenbaugh 2009). 
Currently the use of the gTME technique in mammalian cells is relatively novel. 
While directed evolution experiments have proven successful in eliciting an improved 
phenotype, the results generated here suggest that directed evolution in conjunction 
with a suitable genetic intervention augments the selective process by providing a 
greater level of heterogeneity, and is a potentially useful tool in the generation of 




4.2.3 The effects of TBP/Library transfection 
While initially used as a control to measure the relative performance of the mutant 
library, wild-type TBP overexpression was found to be beneficial in its own right with 
regards to maximum cell density. The unselected mutant library was initially found to 
be detrimental, although this result was to be expected. After the stress procedure, 
both appeared to bestow additional benefits in terms of growth and survival compared 
to the use of the stress procedure alone in empty vector control cells. Immediately, 
this appears to confirm one of the original hypotheses that an increase in 
heterogeneity allows for a greater variety of potential responses to an environmental 
stress, a percentage of which are statistically likely to be beneficial and survive.  
 
However, the comparison between successful TBP clones and successful Library 
clones begs the question as to whether the added mutagenesis step is more beneficial 
compared to the use of the wild type gene. When we look at the selection of post 
stress clones isolated, the differences in final day AIVCD return a p value of 0.08, 
indicating the differences between groups is not strictly significant. However, a 
number of factors distinguish one group from the other; 
 The performance of Library selected clones is higher on average, with a 16.1% 
increase in AIVCD compared to the TBP group of clones. 
 Due to greater variability as a result of Library expression, clones at the highest 
percentile performance generally outperform their TBP counterparts. For example, 
when compared to the stressed pcDNA population, the top 3 TBP selected clones 
provided a benefit of 28% to final day AIVCD when scaled up to 50ml, while the 
top 3 Library clones provided an increase 44.5%. 
 Inequalities in the stress selection procedure may have reduced its effectiveness 
with regards to the Library transfected population. Individual populations were 
measured and passaged in parallel, and the results of section 3.2.6.1 show that in 
later rounds of selection Library cultures were relatively healthy (>40% viability) 
at the time of passage. This is compared to TBP cultures whose steep drop in 
viability prompted the passage of all cell lines. Had Library cultures been allowed 
to endure further selective pressure, this may have further enhanced the 
phenotypic change seen in selected Library clones, however this is speculation. 
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 Productivity is generally found to be higher in the 3 selected Library clones in all 
transient transfection experiments carried out above. However, transfection 
efficiencies were also found to be marginally lower in TBP clones, and this 
difference in apparent productivity may be a direct result. How these clones would 
function as stable producers (or if any differences would be observed) is as of yet 
unknown. 
 
While these differences are by no means definitive, in general the Library clones 
isolated in this experiment generally appear to outperform the TBP equivalents. It 
may also be inferred that, with an improved experimental process (such as an increase 
in library complexity or more equal application of stress to cell lines), the use of a 
genetic library could produce more definitive improvements in phenotype. 
 
TBP was chosen for its similarity to high-level transcription factors used in similar 
gTME experiments. Future work in the area of directed evolution and mutagenesis 
could investigate a number of similar various targets, while adhering to the basic 
theory behind this method. For example, a number of other high level transcription 
factors involved in stress and apoptotic responses that also interact with a range of 
similar proteins could be investigated, including c-Jun, c-Myc, p53 and NF-κB family 
proteins such as NFKB1 and NFKB2. As with TBP, the potential downstream effects 
of the mutagenesis of these genes cannot be predicted, however their involvement in a 
range of cellular stress responses and their interaction with a range of pathways and 
other transcription factors make them attractive prospects for further development of 
this method. 
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4.2.4 The effects of selective stress 
For the purposes of this experiment two selective stresses were originally 
investigated. Once stably transfected cell lines were generated, cells were placed at 
low density to promote selection of fast growing cells, while a second culture was 
allowed to grow until deleterious late stage conditions selected for cells with a greater 
resistance to the apoptotic environment. 
‘Viability’ stressed cultures provided the most beneficial changes to phenotype, while 
‘low density’ selected Library cultures were found to provide no benefit (or indeed a 
reduction in early growth rates) compared to the wild type control. This difference in 
results speaks of the need for the use of a well defined selective pressure that will 
promote the survival of cells with improved phenotypes. In the viability stress, we see 
the direct negative selection for cells that were more suited to survival under harsher 
conditions. This ensured that with each round of selection, the next seeded culture was 
enriched for resistant cells (as well as unexpected improvements in maximum cell 
densities). The failure of low density seeding to elicit a beneficial change in 
phenotype may be a result of its less stringent nature. While cells with potentially 
higher growth rates were originally intended to outgrow their competitors, no defined 
selective pressure can be applied to isolate these cells or fully eliminate slower 
growing cells from subsequent passages. This may also be a failure of the mutant 
library to affect growth rates in any significant way, preventing clones of this nature 
to become more prevalent. This could be overcome in a future experiment involving a 
gene more directly involved in the stimulation of growth and proliferation, however in 
this instance we found the combination of this stress and TBP mutagenesis to be 
ineffective. 
 
The effects of directed evolution and selective stress have been shown previously to 
be beneficial, for example in an experiment in which a culture was selected using a 
similar ‘late stage survival’ method before rescue (Prentice, Ehrenfels and Sisk 2007). 
In this experiment, the pcDNA control culture did gain a benefit to late stage survival, 
however this improvement was overshadowed by the far greater levels of overall 
growth and survival seen in TBP and Library selected cultures. The results of this 
study would suggest that the combination of a genetic intervention with the use of a 
selective stress is preferential to the use of a selection process alone. 
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Further work in this area could easily be carried out to investigate the use of similarly 
useful selective pressures. For the purposes of improving bioprocess relevant 
characteristics, future stress procedures could be tailored to select for cells with 
resistance to specific deleterious environmental factors commonly found in culture. In 
this instance, the overall negative effect of regular late stage culture conditions was 
used. However, through the controlled introduction or removal of particular 
compounds into the cell medium, resistance to adverse pH as well as increasing 
concentrations of waste products such as lactate and ammonia could be gradually 
selected for, as well as the induction of alternative metabolic pathways to cope with 








The experiments carried out to date using AAV in CHO were successful in 
demonstrating the use of a custom viral vector for introducing a targeted gene cassette 
to a defined genomic locus via homologous recombination.  
 
 A targeted integration rate of 3.1% of all cells having integrated the targeting 
cassette was achieved. While this is favourable compared to the figure of ~1% 
often reported in previous literature, this percentage is improved through the use of 
a selectable marker to eliminate untransduced cells. 
 This study was not successful in another of its original aims; that of generating a 
knockout cell line in which both alleles are targeted and disrupted. While a ‘one-
shot’ method using a single vector to generate null mutants is not generally 
reported in the literature, a number of alternative techniques (such as the use of a 
secondary viral targeting vector) unfortunately did not achieve this goal when 
attempted. 
 Further work with AAV using this protocol may benefit from refinements based on 
data gathered in this instance. For instance the use of a lower MOI as well as pre-
screening of insertion numbers in targeted clones prior to the use of an alternative 
vector for secondary allele targeting. This may help eliminate potential 
complications arising from high levels of off-target insertions.  
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The portion of this thesis in which mutagenesis and directed evolution was applied in 
CHO cells was successful in isolating a number of derivative clonal cell lines with 
improved phenotypic properties. 
 
 Initially, wild type TBP overexpression was found to be beneficial to growth, 
improving maximum cell density by 16.8%. 
 When compared to the wild type gene, the unselected mutant library was found to 
be deleterious in its overall effect, as was predicted.  
 The stress procedure was found to have a positive impact on the survival of 
pcDNA control cells. However, a more substantial benefit was gained in TBP 
selected cells, increasing maximum density by a further 9% and AIVCD by 39.9%. 
 After the elimination of deleterious mutants, a selection of Library clones with 
exceptional phenotypes was isolated, with characteristics of the highest performers 
exceeding those of the stressed control cell line (maximum cell density and 
AIVCD increased by 53% and 44.5% respectively). 
 While exceptional stressed TBP clones were also isolated, their relative increases 
in maximum cell density (49.8%) and AIVCD (28%) were not as great as the 
highest performing Library clones, suggesting that additional heterogeneity is 
beneficial to the selective process. 
 Transcriptional profiling of a selection of mixed populations and selected clones 
indicated a wide range of small changes in expression resulting from the effects of 
stress selection. Changes in the areas of lipid metabolism and regulation of growth 
appeared to have the most consistent impact in beneficial cell lines. 
 
Overall, this investigation suggests that global transcriptional machinery engineering 
is a useful technique for cell line engineering in CHO, with direct benefits gained 
from a combination of both the mutant library and stress selection procedures. This 
study also demonstrates the plasticity of CHO, and their innate ability to adapt to 
changes in their environment that can be successfully exploited to elicit an improved 
phenotype. 
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4.3.1 Future work (AAV) 
Future work on this topic would likely be focussed on efforts to generate a 
homozygous -/- knockout cell line. This would especially be true in experiments in 
which gene knockout is the primary concern, as opposed to targeted gene insertion.  
 
A number of modifications (suggested by the data generated to date as well as  
successful techniques demonstrated in the literature) could be applied in an effort to 
improve this protocol and increase the chances of generating a null mutant clone 
while reducing the numbers of off-target insertions; 
 
 Reduction in MOI to investigate the effect this may have on targeting rates 
compared to its effect on non-targeted insertions. 
 Enrichment for cells in the S-phase of the cell cycle to improve rates of 
homologous recombination (targeted) and reduce non-homologous end joining 
(non-targeted) insertion rates. 
 Further inhibition of NHEJ using simultaneous knockdown of genes such as Ku70 
and Xrcc4 prior to transfection. 
 Investigation of secondary allele targeting techniques in clones with reduced 
numbers of off-target insertions, as these may possibly provide a successful result. 
 
Using a successfully targeted cell line, utilising the loxP sites contained within this 
cassette to introduce a gene of interest would also be a logical follow up to this study. 
The cassette designed and used in this instance was created to allow the deactivation 
of the selectable marker and subsequent introduction of a target product gene using 
loxP recombination. Targeting a region of high transcriptional activity would act as a 
proof of concept study, and comparisons of the expression levels of similarly targeted 
clones would demonstrate the ability to generate cell lines with predictable gene 
expression patterns. This ability to generate a ‘master’ cell line would prove useful for 
future bioprocesses, reducing the levels of screening necessary by generating cell 
lines with a predictable phenotype and productivity characteristics. 
 
Also, the ability to target specific genomic loci would allow for the investigation of a 
selection of putative target expression sites prior to generating a master cell line, 
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possibly identified using in-silico methods or via random insertion screening. Once a 
sites or sites with potentially high transcriptional activity are identified, viral targeting 
vectors could be produced by simply swapping the homologous arm segments, and an 
experiment could be then carried out in an effort to experimentally determine the true 
transcriptional potential of a number of given loci. This could be carried out prior to 
the generation of a master cell line in order to identify the site most likely to provide 
the highest level of productivity while also remaining stably active, key characteristics 
for an industrial cell line. 
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4.3.2 Future work (Mutagenesis & Directed Evolution) 
The investigation carried out here into the use of mutagenesis and directed evolution 
was mostly successful in its aims of demonstrating the use of this technique in CHO 
cells, however future work could be carried out in a number of areas to both further 
characterise the clones generated in this study, and improve on this technique in 
further iterations to gain greater benefits if applied using other genes and 
environmental stresses. 
Based on the results of this experiment, a number of alterations could be made to this 
protocol in subsequent iterations in order to improve the results of any mutation and 
stress procedure, and maximise the potential gains in phenotypic improvement.  
 
 A further investigation into the mutation rates most likely to provide beneficial 
mutant clones. In this investigation the mutation rate measured in successful 
clones was substantially lower than that initially used in the original mutant 
library, suggesting that the optimal rate for generating non-deleterious sequences 
may be lower than our original target rate. 
 An optimisation of the transfection procedure could be employed to reduce the 
incidence of multiple mutant insertions per clone, isolating the effects of single 
sequences and making their analysis less complex. 
 An alternative method of mutagenesis may also be explored in CHO. As opposed 
to the low fidelity PCR method used in this study, gene shuffling or site saturation 
of key residues in a target gene could be employed, depending on knowledge of 
the gene selected and its key functional regions. 
 Only one of the two environmental stresses investigated in this study was found to 
be suitable in eliciting an improved phenotype. Further iterations of this study 
(including further work with mutant TBP) would be suited to investigating any 
number of defined, industrially relevant environmental stresses that could be 
replicated in a selective process such as resistance to the build-up of waste 
products such as ammonia or adaptation to lower nutrient concentration. 
 The use of alternative genes should also be considered for further work in this 
area. TBP was chosen in this experiment due to its high level involvement in the 
expression of a wide number of genes. However, a number of alternative genes 
with similar characteristics could be investigated (i.e. c-Jun, c-Myc, p53 etc.) 
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The clones isolated in this study were characterised based on properties such as 
growth, viability and productivity. However, further characterisation could be carried 
out to increase our understanding of these cells.  
 
 A cell cycle analysis of late stage cells could determine if new cell growth is 
responsible for the persistence of viable cells, or a halt to the cell cycle and 
prevention of apoptosis thereby maintaining current living cells as being the cause 
of this phenomenon. 
 Media analysis of metabolic products secreted (such as lactate and ammonia) 
would shed light on the environmental conditions created by these cells that may 
differentiate their ability to survive from that of less successful clones.  
 A larger volume culture (such as a 1 litre or greater bioreactor) could demonstrate 
if phenotypic advantages were still apparent at scales more typical of a real 
bioprocess.  
 Clonal stability was not addressed over the course of this study. While phenotypes 
did not appear to change significantly over the course of a small number of 
passages when clones were finally isolated and stocked, their ability to retain their 
unique pattern of gene expression over long periods of time (with and without the 
addition of zeocin selection) is currently unknown. 
 
A gene profiling experiment was carried out on selected clones and mixed cell 
populations as part of this investigation. The data generated and conclusions draw 
from this portion of this thesis could act as a prompt for further studies. 
 Genes consistently identified as deregulated in advantageous clones could be 
targeted for knockdown or overexpression in order to elicit a beneficial change. 
Counter to this, we may find that the interaction of a discreet combination of 
genes and/or mutants is necessary to unlock such a complex phenotype, with the 
process followed in this study a more attractive prospect than traditional single 
target engineering.  
 Due to economic constraints sample numbers in this study were limited. Analysis 
of the data suggested that an investigation of more time points would be useful. 
While day 5 was chosen as a compromise, further in depth investigation of both 
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the exponential and decline phases could further highlight genes involved in the 
two distinct states of growth and survival.  
 While a number of targets involving the regulation of growth and survival were 
noted as having a possible beneficial effect when dysregulated, downregulation of 
cholesterol and lipid biosynthesis appeared to have the most consistent impact on 
the survival of all stressed cell lines. Further work on the cell lines generated in 
this experiment could be useful in the study of the effects of lipid metabolism on 
producer cell lines, with measurements of cellular cholesterol concentrations in 
various cell lines and the artificial modulation of these genes providing useful 
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5.2.1 pAAV-DHFR sequence (7081 bp) 
 
Feature Region Size (bp) 
pAAV Backbone 1-149 149 
5’ HR Arm 150-1069 920 
CMV 1070-1645 576 
Neo 1646-2199 554 
Intron (including LoxP1) 2200-2345 146 
LoxP1 2276-2309 34 
Δneo 2346-2618 273 
PolyA signal 2619-2888 270 
LoxP2 2889-2922 34 
3’ HR Arm 2923-4335 1413 
pAAV Backbone 4336-7081 2746 
 
 
       1  CCTGCAGGCA GCTGCGCGCT CGCTCGCTCA CTGAGGCCGC CCGGGCAAAG CCCGGGCGTC 
      61  GGGCGACCTT TGGTCGCCCG GCCTCAGTGA GCGAGCGAGC GCGCAGAGAG GGAGTGGCCA 
     121  ACTCCATCAC TAGGGGTTCC TGCGGCCGCG CAGACGTGGA AGTGCGAAGT CTCCCGTGGG 
     181  AATCTGGGAA CTTTGCTTCT TGGCAGAAAT TTTTGTGCTG TTCCCAGAGT TTATTAAGCA 
     241  TCCTCTTTAA TATACAAATA TTTGAAATTT TGTTAGCAAG AGCAGTTAAC TGGACAGAAT 
     301  TCTCAGCAAA ATTTAGCGCT TTAAATATAA AGATCAGAGC CAGTATTTAG AATTGCCGCT 
     361  GGAAGACAGG AAACCTGAGT AAATAGAAAA GAATGCAGGG AGAATAGGCT AAAATACAAT 
     421  TAAACACTAA TGTGCGCTGT TGGAATTCTA GAGGCAGGAA GGCATGGTTG AAGGTATGAC 
     481  CTTCAGTGGG GCAGTCTGGG GGTCTGACTT GAAATAAAAG AATGGGGAGT GGTGTGCTAT 
     541  TATAAGGCAG TTTCCAGTTG CTTGTAGGAC ACTCATTGTA ATTTCTCTCT AACAGACATA 
     601  TTTGTTTATT CTAGTAGGAG AGGAATGGCT CTGTGGGTTT CAACCTCTTC GGGGGGTTGA 
     661  ATGACCCTTT CACAGGGGTG GCTGAAGACC ATTGGAAAAC AGTTATTTAC ATTTTGATTC 
     721  ATGACAGCAA AATTACATGT ATGAAGTAAC AACAAAAATA ATTTCACAGT TGGGGGGTCA 
     781  CCACAACATG AGGAACTATA TTAAAGGGTC ATAGCATTAG CATGCTTGAG AACCACTGGC 
     841  AAAGAGAATG GGGAAACAGG TCAGCAGAGC AGATGTTGAA CAGCATTCAT AGGACAGGTA 
     901  GAGAACATAG TAGGTCACTG GTAGACAAGT TGGTAAATGC CATTAACATG GTCTACTCTC 
     961  AAACTAAATA TCAGGATTGG GGAAATAGCT CAGTCAGTAA AGTTTTGAAG ACCTGAGTTA 
    1021  AAATCTCAGC ACCCAAATAA AAATGTGGGC CTGGTGGGAC ACAGCTAGCT AGTAATCAAT 
    1081  TACGGGGTCA TTAGTTCATA GCCCATATAT GGAGTTCCGC GTTACATAAC TTACGGTAAA 
    1141  TGGCCCGCCT GGCTGACCGC CCAACGACCC CCGCCCATTG ACGTCAATAA TGACGTATGT 
    1201  TCCCATAGTA ACGCCAATAG GGACTTTCCA TTGACGTCAA TGGGTGGAGT ATTTACGGTA 
    1261  AACTGCCCAC TTGGCAGTAC ATCAAGTGTA TCATATGCCA AGTACGCCCC CTATTGACGT 
    1321  CAATGACGGT AAATGGCCCG CCTGGCATTA TGCCCAGTAC ATGACCTTAT GGGACTTTCC 
    1381  TACTTGGCAG TACATCTACG TATTAGTCAT CGCTATTACC ATGGTGATGC GGTTTTGGCA 
    1441  GTACATCAAT GGGCGTGGAT AGCGGTTTGA CTCACGGGGA TTTCCAAGTC TCCACCCCAT 
    1501  TGACGTCAAT GGGAGTTTGT TTTGGCACCA AAATCAACGG GACTTTCCAA AATGTCGTAA 
    1561  CAACTCCGCC CCATTGACGC AAATGGGCGG TAGGCGTGTA CGGTGGGAGG TCTATATAAG 
    1621  CAGAGCTGGT TTAGTGAACC GTCAGGGATC CGCATGATTG AACAAGATGG ATTGCACGCA 
    1681  GGTTCTCCGG CCGCTTGGGT GGAGAGGCTA TTCGGCTATG ACTGGGCACA ACAGACAATC 
    1741  GGCTGCTCTG ATGCCGCCGT GTTCCGGCTG TCAGCGCAGG GGCGCCCGGT TCTTTTTGTC 
    1801  AAGACCGACC TGTCCGGTGC CCTGAATGAA CTGCAAGACG AGGCAGCGCG GCTATCGTGG 
    1861  CTGGCCACGA CGGGCGTTCC TTGCGCAGCT GTGCTCGACG TTGTCACTGA AGCGGGAAGG 
    1921  GACTGGCTGC TATTGGGCGA AGTGCCGGGG CAGGATCTCC TGTCATCTCA CCTTGCTCCT 
    1981  GCCGAGAAAG TATCCATCAT GGCTGATGCA ATGCGGCGGC TGCATACGCT TGATCCGGCT 
    2041  ACCTGCCCAT TCGACCACCA AGCGAAACAT CGCATCGAGC GAGCACGTAC TCGGATGGAA 
    2101  GCCGGTCTTG TCGATCAGGA TGATCTGGAC GAAGAGCATC AGGGGCTCGC GCCAGCCGAA 
    2161  CTGTTCGCCA GGCTCAAGGC GAGCATGCCC GACGGCGAGT AAGGAATGGA GGGAAATTAT 
    2221  CCTTATGCAT GGCAGAAATT TCCAGGGTTT CTATAGGGTT TTGTGGCACG TCGACTACCG 
 316 
    2281  TTCGTATAGC ATACATTATA CGAAGTTATA TCGATTTTTT AACTGCTAAT GCACTATGTC 
    2341  TTAGGGATCT CGTCGTGACA CATGGCGATG CCTGCTTGCC GAATATCATG GTGGAAAATG 
    2401  GCCGCTTTTC TGGATTCATC GACTGTGGCC GGCTGGGTGT GGCGGACCGC TATCAGGACA 
    2461  TAGCGTTGGC TACCCGTGAT ATTGCTGAAG AGCTTGGCGG CGAATGGGCT GACCGCTTCC 
    2521  TCGTGCTTTA CGGTATCGCC GCTCCCGATT CGCAGCGCAT CGCCTTCTAT CGCCTTCTTG 
    2581  ACGAGTTCTT CTGAATCAAG CTTATCGATA CCGTCGACGG GGGAGGCTAA CTGAAACACG 
    2641  GAAGGAGACA ATACCGGAAG GAACCCGCGC TATGACGGCA ATAAAAAGAC AGAATAAAAC 
    2701  GCACGGTGTT GGGTCGTTTG TTCATAAACG CGGGGTTCGG TCCCAGGGCT GGCACTCTGT 
    2761  CGATACCCCA CCGAGACCCC ATTGGGGCCA ATACGCCCGC GTTTCTTCCT TTTCCCCACC 
    2821  CCACCCCCCA AGTTCGGGTG AAGGCCCAGG GCTCGCAGCC AACGTCGGGG CGGCAGGCCC 
    2881  TGCCATAGAT AACTTCGTAT AGCATACATT ATACGAAGTT ATCTCGAGGG AGGCAGAGAC 
    2941  AGAAAGATCC CTGGGGCTTG TTCCTAGCCA AATTTGTGGG TTCCAGATTC AGTGAGAAAT 
    3001  CTTGTCTCAA AAAAATAAAG TGAAGACACT CATCTTCACT GTCTGGCCTG TGCAAACAGG 
    3061  TGCACAGTGC ATACAAAATA AAAATAATAA TTTTTTCAAG ATTATTTTTC TTTCTAATAT 
    3121  GTTTTGAGAA TGCCTATATA CATGTATGTA CAAAATATAT GTATGTGCCT GGTCCCCACA 
    3181  GAAGCAGAAG AAAATGTCAG TTCCCTAGAA CTGCCTCTAG ATGTGGGTGC TGAGAACCAA 
    3241  ACCCAGGTCC TCTACTATGC TTTTAACTGC TAAACCATCT CTCTAGCCCC CAAAGTCATT 
    3301  TTTCATTAAA GAATCCTAAG TATGACCTGG TAATTGTTAC TGTTCCTTTG ATCCAGATGT 
    3361  CTGACACTCA AGGTTTTTTC CCCAAGCAAT TAAATAAGAG ATGGAAGCTG CATGTCTAAA 
    3421  GTTTTCCTAA AAGTGCTTTT TAAATGTGTT TTCTATTCTT TGAAGTTTTT ATACATTTAT 
    3481  ACAGTGTTTA TAGAGCATAT CCATTTATCT TCTCACTCCT CCTTGTGCCC TCTTCTCCTT 
    3541  CCCTAATTCA TGTTGTAGTT GTTATCAATA ACCCTGTGTG GTGGTCAACT GGGGCATGAG 
    3601  CAATCTACAA CCAGCCCAAC CTAAGACTGA CTCTCCCTCT CTCAGCAGCC CCCAATAACC 
    3661  AATAGCTGTC TGATAGGGTG GGACCTCGGG AGCCCCTTCT GCATGCTGGA ATTTTGACTG 
    3721  ACTGTGAGTT GGTGCATACA GACATCAGCC ATGTCTCATC CTGTAGTCAG TTTTCACATC 
    3781  TCTCCCTCTT TCAGCAACTC TTATGTTCTA TCTGCCCCCT CTTCCTCAAT GGTCCCTTAA 
    3841  CCTTTGAATA GTGGGAGCTG GTATAGATGA CCCAGAGAAC AGTAGTTTTA GATGGTAAAT 
    3901  ACAAGTTATG AGTCTTTAAT CTTCTCAGAT TTCCAGGGGT AGGAGCATCT TTTCTCCATT 
    3961  TTAGAATTTA ATAAAGCATA TGGGGTTATC TAGTGGGACA AATCCTGTCA GCCTGAGCAC 
    4021  TTTGAACCAA AATTATGTGA GGTTGCAATT GACTAAAACC TAAGTAGAAG ATATAAATTG 
    4081  GATAAACCAA AAAGAAAAAT AAGTATTATA TCTAGTTAAT GAGTACTAAA TATCTGAAAT 
    4141  TTGGGTGAAG CTGTTGGTCT TAATTTTTCT AAAGGATATC CACTAGATGT CACTATGACA 
    4201  ATGGTATCTT GCCTGTGTAT GACACTAAAA ATGTGTGTTT TCAAAAATAT CCTTCCTGCT 
    4261  TAATTTTGTA GGTAAACAGA ACCTGGTGAT TATGGGCCGG AAAACCTGGT TCTCCATTCC 
    4321  TGAGAAGAAT CGACCGCGGC CGCAGGAACC CCTAGTGATG GAGTTGGCCA CTCCCTCTCT 
    4381  GCGCGCTCGC TCGCTCACTG AGGCCGGGCG ACCAAAGGTC GCCCGACGCC CGGGCTTTGC 
    4441  CCGGGCGGCC TCAGTGAGCG AGCGAGCGCG CAGCTGCCTG CAGGGGCGCC TGATGCGGTA 
    4501  TTTTCTCCTT ACGCATCTGT GCGGTATTTC ACACCGCATA CGTCAAAGCA ACCATAGTAC 
    4561  GCGCCCTGTA GCGGCGCATT AAGCGCGGCG GGTGTGGTGG TTACGCGCAG CGTGACCGCT 
    4621  ACACTTGCCA GCGCCCTAGC GCCCGCTCCT TTCGCTTTCT TCCCTTCCTT TCTCGCCACG 
    4681  TTCGCCGGCT TTCCCCGTCA AGCTCTAAAT CGGGGGCTCC CTTTAGGGTT CCGATTTAGT 
    4741  GCTTTACGGC ACCTCGACCC CAAAAAACTT GATTTGGGTG ATGGTTCACG TAGTGGGCCA 
    4801  TCGCCCTGAT AGACGGTTTT TCGCCCTTTG ACGTTGGAGT CCACGTTCTT TAATAGTGGA 
    4861  CTCTTGTTCC AAACTGGAAC AACACTCAAC CCTATCTCGG GCTATTCTTT TGATTTATAA 
    4921  GGGATTTTGC CGATTTCGGC CTATTGGTTA AAAAATGAGC TGATTTAACA AAAATTTAAC 
    4981  GCGAATTTTA ACAAAATATT AACGTTTACA ATTTTATGGT GCACTCTCAG TACAATCTGC 
    5041  TCTGATGCCG CATAGTTAAG CCAGCCCCGA CACCCGCCAA CACCCGCTGA CGCGCCCTGA 
    5101  CGGGCTTGTC TGCTCCCGGC ATCCGCTTAC AGACAAGCTG TGACCGTCTC CGGGAGCTGC 
    5161  ATGTGTCAGA GGTTTTCACC GTCATCACCG AAACGCGCGA GACGAAAGGG CCTCGTGATA 
    5221  CGCCTATTTT TATAGGTTAA TGTCATGATA ATAATGGTTT CTTAGACGTC AGGTGGCACT 
    5281  TTTCGGGGAA ATGTGCGCGG AACCCCTATT TGTTTATTTT TCTAAATACA TTCAAATATG 
    5341  TATCCGCTCA TGAGACAATA ACCCTGATAA ATGCTTCAAT AATATTGAAA AAGGAAGAGT 
    5401  ATGAGTATTC AACATTTCCG TGTCGCCCTT ATTCCCTTTT TTGCGGCATT TTGCCTTCCT 
    5461  GTTTTTGCTC ACCCAGAAAC GCTGGTGAAA GTAAAAGATG CTGAAGATCA GTTGGGTGCA 
    5521  CGAGTGGGTT ACATCGAACT GGATCTCAAC AGCGGTAAGA TCCTTGAGAG TTTTCGCCCC 
    5581  GAAGAACGTT TTCCAATGAT GAGCACTTTT AAAGTTCTGC TATGTGGCGC GGTATTATCC 
    5641  CGTATTGACG CCGGGCAAGA GCAACTCGGT CGCCGCATAC ACTATTCTCA GAATGACTTG 
    5701  GTTGAGTACT CACCAGTCAC AGAAAAGCAT CTTACGGATG GCATGACAGT AAGAGAATTA 
    5761  TGCAGTGCTG CCATAACCAT GAGTGATAAC ACTGCGGCCA ACTTACTTCT GACAACGATC 
    5821  GGAGGACCGA AGGAGCTAAC CGCTTTTTTG CACAACATGG GGGATCATGT AACTCGCCTT 
    5881  GATCGTTGGG AACCGGAGCT GAATGAAGCC ATACCAAACG ACGAGCGTGA CACCACGATG 
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    5941  CCTGTAGCAA TGGCAACAAC GTTGCGCAAA CTATTAACTG GCGAACTACT TACTCTAGCT 
    6001  TCCCGGCAAC AATTAATAGA CTGGATGGAG GCGGATAAAG TTGCAGGACC ACTTCTGCGC 
    6061  TCGGCCCTTC CGGCTGGCTG GTTTATTGCT GATAAATCTG GAGCCGGTGA GCGTGGGTCT 
    6121  CGCGGTATCA TTGCAGCACT GGGGCCAGAT GGTAAGCCCT CCCGTATCGT AGTTATCTAC 
    6181  ACGACGGGGA GTCAGGCAAC TATGGATGAA CGAAATAGAC AGATCGCTGA GATAGGTGCC 
    6241  TCACTGATTA AGCATTGGTA ACTGTCAGAC CAAGTTTACT CATATATACT TTAGATTGAT 
    6301  TTAAAACTTC ATTTTTAATT TAAAAGGATC TAGGTGAAGA TCCTTTTTGA TAATCTCATG 
    6361  ACCAAAATCC CTTAACGTGA GTTTTCGTTC CACTGAGCGT CAGACCCCGT AGAAAAGATC 
    6421  AAAGGATCTT CTTGAGATCC TTTTTTTCTG CGCGTAATCT GCTGCTTGCA AACAAAAAAA 
    6481  CCACCGCTAC CAGCGGTGGT TTGTTTGCCG GATCAAGAGC TACCAACTCT TTTTCCGAAG 
    6541  GTAACTGGCT TCAGCAGAGC GCAGATACCA AATACTGTCC TTCTAGTGTA GCCGTAGTTA 
    6601  GGCCACCACT TCAAGAACTC TGTAGCACCG CCTACATACC TCGCTCTGCT AATCCTGTTA 
    6661  CCAGTGGCTG CTGCCAGTGG CGATAAGTCG TGTCTTACCG GGTTGGACTC AAGACGATAG 
    6721  TTACCGGATA AGGCGCAGCG GTCGGGCTGA ACGGGGGGTT CGTGCACACA GCCCAGCTTG 
    6781  GAGCGAACGA CCTACACCGA ACTGAGATAC CTACAGCGTG AGCTATGAGA AAGCGCCACG 
    6841  CTTCCCGAAG GGAGAAAGGC GGACAGGTAT CCGGTAAGCG GCAGGGTCGG AACAGGAGAG 
    6901  CGCACGAGGG AGCTTCCAGG GGGAAACGCC TGGTATCTTT ATAGTCCTGT CGGGTTTCGC 
    6961  CACCTCTGAC TTGAGCGTCG ATTTTTGTGA TGCTCGTCAG GGGGGCGGAG CCTATGGAAA 
    7021  AACGCCAGCA ACGCGGCCTT TTTACGGTTC CTGGCCTTTT GCTGGCCTTT TGCTCACATG 
    7081  T 
 
 318 
5.2.2 pAAV-HPRT sequence (6605 bp) 
 
 
Feature Region Size (bp) 
pAAV Backbone 1-149 149 
5’ HR Arm 150-1084 935 
CMV 1085-1660 576 
Neo 1660-2214 554 
Intron (including LoxP1) 2215-2360 146 
LoxP1 2290-2324 34 
Δneo 2361-2633 273 
PolyA signal 2634-2903 270 
LoxP2 2904-2937 34 
3’ HR Arm 2938-3859 922 
pAAV Backbone 3860-6605 2746 
 
 
       1  CCTGCAGGCA GCTGCGCGCT CGCTCGCTCA CTGAGGCCGC CCGGGCAAAG CCCGGGCGTC 
      61  GGGCGACCTT TGGTCGCCCG GCCTCAGTGA GCGAGCGAGC GCGCAGAGAG GGAGTGGCCA 
     121  ACTCCATCAC TAGGGGTTCC TGCGGCCGCT TCCTCATGGA GTGATTATGG ACAGGTAAGT 
     181  AAGATCTTAA TTGAAGGGGC TGGAGAGATG GCTCAGCGGT TAAGAGCACT GACTGCTCTT 
     241  CCAGAGGTTC TGAGTTCAAT TCCCAGCAAC CACATGATGG CTCACAACCA TCCCTAATGA 
     301  GATCTGGTGC CCTCTTCTGG CCTGCAGGGA CACATGCAGA CAGAACAGAT CTTAATTGAA 
     361  GTTTTATGGG TTTATTTTAG ATGTGTCTGT GTGTATGTTT GTGATAGGCA TGTATTTGAT 
     421  ACATATGTAT AATGTATATA TTTATGTAAA AGCTAGAGAA GGACATTGGG TGCCATACTC 
     481  TGTTGCTCTC TGTCTTGCTC CCTTGAGTTG GTGTCTCTCA CTGAACCTGG GGACATGCTG 
     541  ATTCGGTTAG GCTCTGTCCC CTATTGCTGA AGTTTCAAGC AGATGCGGCC ACACCTGGTT 
     601  TTTATATGGG TATTAAGGAT CTGAATTTAG GTCCTGATGC TTGCACAAGT GCTCCCAATG 
     661  GCCTGCATGT ATGTGCAGCA TCTGCATTCC AGGAGACCAC AAAAGTGTGA TGGGTCCTCT 
     721  GGAACTGGAG TTGCAGGCCA TTGGGAGCTG CTGTGTGGCT GGGAACTGGA CTTAGGGCCT 
     781  CTGCCCAAAC AGCAAATGGG CTTAACTCTC TCCAGCCCCA ATATTTTCTA GTTTTAAAGT 
     841  TCTTTTTCAC AAAAAGAAAA ACACCAGGAA GTCCTACTAG TTATTCAGTT TGAGATATAA 
     901  ATAGTGGTAC TCCATAATGA GTCCAGCAAA TGTTGAAACG AGGTTGGAAG TCTGTAAATG 
     961  AGATTATGAT TCTGTTGGTT TGCTATACAC ATTTCTTTTA AAATTTTTTT ATAAATTTTA 
    1021  TTTAAATTAG AAACAATCTT ATTTTACATA TCAATCCCAG TTCACTCTCA CTCCCATCGC 
    1081  TAGCTAGTAA TCAATTACGG GGTCATTAGT TCATAGCCCA TATATGGAGT TCCGCGTTAC 
    1141  ATAACTTACG GTAAATGGCC CGCCTGGCTG ACCGCCCAAC GACCCCCGCC CATTGACGTC 
    1201  AATAATGACG TATGTTCCCA TAGTAACGCC AATAGGGACT TTCCATTGAC GTCAATGGGT 
    1261  GGAGTATTTA CGGTAAACTG CCCACTTGGC AGTACATCAA GTGTATCATA TGCCAAGTAC 
    1321  GCCCCCTATT GACGTCAATG ACGGTAAATG GCCCGCCTGG CATTATGCCC AGTACATGAC 
    1381  CTTATGGGAC TTTCCTACTT GGCAGTACAT CTACGTATTA GTCATCGCTA TTACCATGGT 
    1441  GATGCGGTTT TGGCAGTACA TCAATGGGCG TGGATAGCGG TTTGACTCAC GGGGATTTCC 
    1501  AAGTCTCCAC CCCATTGACG TCAATGGGAG TTTGTTTTGG CACCAAAATC AACGGGACTT 
    1561  TCCAAAATGT CGTAACAACT CCGCCCCATT GACGCAAATG GGCGGTAGGC GTGTACGGTG 
    1621  GGAGGTCTAT ATAAGCAGAG CTGGTTTAGT GAACCGTCAG GGATCCGCAT GATTGAACAA 
    1681  GATGGATTGC ACGCAGGTTC TCCGGCCGCT TGGGTGGAGA GGCTATTCGG CTATGACTGG 
    1741  GCACAACAGA CAATCGGCTG CTCTGATGCC GCCGTGTTCC GGCTGTCAGC GCAGGGGCGC 
    1801  CCGGTTCTTT TTGTCAAGAC CGACCTGTCC GGTGCCCTGA ATGAACTGCA AGACGAGGCA 
    1861  GCGCGGCTAT CGTGGCTGGC CACGACGGGC GTTCCTTGCG CAGCTGTGCT CGACGTTGTC 
    1921  ACTGAAGCGG GAAGGGACTG GCTGCTATTG GGCGAAGTGC CGGGGCAGGA TCTCCTGTCA 
    1981  TCTCACCTTG CTCCTGCCGA GAAAGTATCC ATCATGGCTG ATGCAATGCG GCGGCTGCAT 
    2041  ACGCTTGATC CGGCTACCTG CCCATTCGAC CACCAAGCGA AACATCGCAT CGAGCGAGCA 
    2101  CGTACTCGGA TGGAAGCCGG TCTTGTCGAT CAGGATGATC TGGACGAAGA GCATCAGGGG 
    2161  CTCGCGCCAG CCGAACTGTT CGCCAGGCTC AAGGCGAGCA TGCCCGACGG CGAGTAAGGA 
    2221  ATGGAGGGAA ATTATCCTTA TGCATGGCAG AAATTTCCAG GGTTTCTATA GGGTTTTGTG 
    2281  GCACGTCGAC TACCGTTCGT ATAGCATACA TTATACGAAG TTATATCGAT TTTTTAACTG 
    2341  CTAATGCACT ATGTCTTAGG GATCTCGTCG TGACACATGG CGATGCCTGC TTGCCGAATA 
    2401  TCATGGTGGA AAATGGCCGC TTTTCTGGAT TCATCGACTG TGGCCGGCTG GGTGTGGCGG 
    2461  ACCGCTATCA GGACATAGCG TTGGCTACCC GTGATATTGC TGAAGAGCTT GGCGGCGAAT 
    2521  GGGCTGACCG CTTCCTCGTG CTTTACGGTA TCGCCGCTCC CGATTCGCAG CGCATCGCCT 
 319 
    2581  TCTATCGCCT TCTTGACGAG TTCTTCTGAA TCAAGCTTAT CGATACCGTC GACGGGGGAG 
    2641  GCTAACTGAA ACACGGAAGG AGACAATACC GGAAGGAACC CGCGCTATGA CGGCAATAAA 
    2701  AAGACAGAAT AAAACGCACG GTGTTGGGTC GTTTGTTCAT AAACGCGGGG TTCGGTCCCA 
    2761  GGGCTGGCAC TCTGTCGATA CCCCACCGAG ACCCCATTGG GGCCAATACG CCCGCGTTTC 
    2821  TTCCTTTTCC CCACCCCACC CCCCAAGTTC GGGTGAAGGC CCAGGGCTCG CAGCCAACGT 
    2881  CGGGGCGGCA GGCCCTGCCA TAGATAACTT CGTATAGCAT ACATTATACG AAGTTATCTC 
    2941  GAGGTAGGGA CCATGCTTTA TATTTTTTCT CAAATGGATA AGTAATTGAC CAGATGCCAT 
    3001  TTGTTGAATA ATTCATCTTT TAATTACTGA CTCAAGATGC CATCTTTGTC ATATACTAAA 
    3061  TTGCCATATG TTTTTGGGTC TGTTTCTGGA TTTTACTTTG TTCCTTTAAC TTTTTGTCAA 
    3121  TCACTGTACT GATTGACACA AGGGAATTAC TGTAGCTTTA TGGTACTTGT CATTTTCCTA 
    3181  GTAGAGAAAG TCCAGGCTTT TTATTTATCT GCTTTCAATT CAGTTTTCTG TCTTCATTTC 
    3241  AGCACATCCA AATAACAGTT ATTCCCACCA ACTACAGTGA GTGTTAAGTG CTCTCTTTTG 
    3301  AAACCCCTAT AAGGGTTTCT GCTAATTTCT ATGAGAGCAG AGTGAAAACC TAAGAAGTGT 
    3361  GTTCTAACAG ACTGGTACTC AGACCTGGTT TCTCAGTTCT GAAGATGACT TGGGTATGGG 
    3421  CTGGACTTTG AGGGGGCATA TCCTCAGGGT TGGATGTGAT ACATACCAGC TCCTTCAACT 
    3481  TGTGACTCAC AGGAATGTTA CAGGGCCAGA AGCAGACACC TGCCATGCTA ATAAATTGTC 
    3541  CTTTGTGGTT GAGAACTGCC TGATTGATGA TGAGCAGCTA TATTATGCTC ACTCAGAAAT 
    3601  GGATGAACTC TATTTTTAGG ACTCTTCAGA ACATTAAAAA CCAGCAATGG CCAGTTATGA 
    3661  TTTTTAAATT TTACTAATCT CTATTTACCT AGTCATTAAT TTCTAGAAAC CTAATACTTA 
    3721  TAATACATGA TTTAGAATAC CATAATGTTG TAGCCATTAG ATAGCTAACT TCTTACATCT 
    3781  AATAATTTTT TGTGTGTATT CAAGAATATG CATGTAAATG ATGTTTTTTT TTAACTAGAA 
    3841  TGATCAGTCA ACAGGGGACG CGGCCGCAGG AACCCCTAGT GATGGAGTTG GCCACTCCCT 
    3901  CTCTGCGCGC TCGCTCGCTC ACTGAGGCCG GGCGACCAAA GGTCGCCCGA CGCCCGGGCT 
    3961  TTGCCCGGGC GGCCTCAGTG AGCGAGCGAG CGCGCAGCTG CCTGCAGGGG CGCCTGATGC 
    4021  GGTATTTTCT CCTTACGCAT CTGTGCGGTA TTTCACACCG CATACGTCAA AGCAACCATA 
    4081  GTACGCGCCC TGTAGCGGCG CATTAAGCGC GGCGGGTGTG GTGGTTACGC GCAGCGTGAC 
    4141  CGCTACACTT GCCAGCGCCC TAGCGCCCGC TCCTTTCGCT TTCTTCCCTT CCTTTCTCGC 
    4201  CACGTTCGCC GGCTTTCCCC GTCAAGCTCT AAATCGGGGG CTCCCTTTAG GGTTCCGATT 
    4261  TAGTGCTTTA CGGCACCTCG ACCCCAAAAA ACTTGATTTG GGTGATGGTT CACGTAGTGG 
    4321  GCCATCGCCC TGATAGACGG TTTTTCGCCC TTTGACGTTG GAGTCCACGT TCTTTAATAG 
    4381  TGGACTCTTG TTCCAAACTG GAACAACACT CAACCCTATC TCGGGCTATT CTTTTGATTT 
    4441  ATAAGGGATT TTGCCGATTT CGGCCTATTG GTTAAAAAAT GAGCTGATTT AACAAAAATT 
    4501  TAACGCGAAT TTTAACAAAA TATTAACGTT TACAATTTTA TGGTGCACTC TCAGTACAAT 
    4561  CTGCTCTGAT GCCGCATAGT TAAGCCAGCC CCGACACCCG CCAACACCCG CTGACGCGCC 
    4621  CTGACGGGCT TGTCTGCTCC CGGCATCCGC TTACAGACAA GCTGTGACCG TCTCCGGGAG 
    4681  CTGCATGTGT CAGAGGTTTT CACCGTCATC ACCGAAACGC GCGAGACGAA AGGGCCTCGT 
    4741  GATACGCCTA TTTTTATAGG TTAATGTCAT GATAATAATG GTTTCTTAGA CGTCAGGTGG 
    4801  CACTTTTCGG GGAAATGTGC GCGGAACCCC TATTTGTTTA TTTTTCTAAA TACATTCAAA 
    4861  TATGTATCCG CTCATGAGAC AATAACCCTG ATAAATGCTT CAATAATATT GAAAAAGGAA 
    4921  GAGTATGAGT ATTCAACATT TCCGTGTCGC CCTTATTCCC TTTTTTGCGG CATTTTGCCT 
    4981  TCCTGTTTTT GCTCACCCAG AAACGCTGGT GAAAGTAAAA GATGCTGAAG ATCAGTTGGG 
    5041  TGCACGAGTG GGTTACATCG AACTGGATCT CAACAGCGGT AAGATCCTTG AGAGTTTTCG 
    5101  CCCCGAAGAA CGTTTTCCAA TGATGAGCAC TTTTAAAGTT CTGCTATGTG GCGCGGTATT 
    5161  ATCCCGTATT GACGCCGGGC AAGAGCAACT CGGTCGCCGC ATACACTATT CTCAGAATGA 
    5221  CTTGGTTGAG TACTCACCAG TCACAGAAAA GCATCTTACG GATGGCATGA CAGTAAGAGA 
    5281  ATTATGCAGT GCTGCCATAA CCATGAGTGA TAACACTGCG GCCAACTTAC TTCTGACAAC 
    5341  GATCGGAGGA CCGAAGGAGC TAACCGCTTT TTTGCACAAC ATGGGGGATC ATGTAACTCG 
    5401  CCTTGATCGT TGGGAACCGG AGCTGAATGA AGCCATACCA AACGACGAGC GTGACACCAC 
    5461  GATGCCTGTA GCAATGGCAA CAACGTTGCG CAAACTATTA ACTGGCGAAC TACTTACTCT 
    5521  AGCTTCCCGG CAACAATTAA TAGACTGGAT GGAGGCGGAT AAAGTTGCAG GACCACTTCT 
    5581  GCGCTCGGCC CTTCCGGCTG GCTGGTTTAT TGCTGATAAA TCTGGAGCCG GTGAGCGTGG 
    5641  GTCTCGCGGT ATCATTGCAG CACTGGGGCC AGATGGTAAG CCCTCCCGTA TCGTAGTTAT 
    5701  CTACACGACG GGGAGTCAGG CAACTATGGA TGAACGAAAT AGACAGATCG CTGAGATAGG 
    5761  TGCCTCACTG ATTAAGCATT GGTAACTGTC AGACCAAGTT TACTCATATA TACTTTAGAT 
    5821  TGATTTAAAA CTTCATTTTT AATTTAAAAG GATCTAGGTG AAGATCCTTT TTGATAATCT 
    5881  CATGACCAAA ATCCCTTAAC GTGAGTTTTC GTTCCACTGA GCGTCAGACC CCGTAGAAAA 
    5941  GATCAAAGGA TCTTCTTGAG ATCCTTTTTT TCTGCGCGTA ATCTGCTGCT TGCAAACAAA 
    6001  AAAACCACCG CTACCAGCGG TGGTTTGTTT GCCGGATCAA GAGCTACCAA CTCTTTTTCC 
    6061  GAAGGTAACT GGCTTCAGCA GAGCGCAGAT ACCAAATACT GTCCTTCTAG TGTAGCCGTA 
    6121  GTTAGGCCAC CACTTCAAGA ACTCTGTAGC ACCGCCTACA TACCTCGCTC TGCTAATCCT 
    6181  GTTACCAGTG GCTGCTGCCA GTGGCGATAA GTCGTGTCTT ACCGGGTTGG ACTCAAGACG 
 320 
    6241  ATAGTTACCG GATAAGGCGC AGCGGTCGGG CTGAACGGGG GGTTCGTGCA CACAGCCCAG 
    6301  CTTGGAGCGA ACGACCTACA CCGAACTGAG ATACCTACAG CGTGAGCTAT GAGAAAGCGC 
    6361  CACGCTTCCC GAAGGGAGAA AGGCGGACAG GTATCCGGTA AGCGGCAGGG TCGGAACAGG 
    6421  AGAGCGCACG AGGGAGCTTC CAGGGGGAAA CGCCTGGTAT CTTTATAGTC CTGTCGGGTT 
    6481  TCGCCACCTC TGACTTGAGC GTCGATTTTT GTGATGCTCG TCAGGGGGGC GGAGCCTATG 
    6541  GAAAAACGCC AGCAACGCGG CCTTTTTACG GTTCCTGGCC TTTTGCTGGC CTTTTGCTCA 




5.2.3 pAAV-DHFR/Zeo Sequence (6479 bp) 
 
Feature Region Size (bp) 
pAAV Backbone 1-149 149 
5’ HR Arm 150-1069 920 
CMV 1070-1645 576 
Zeo (incl. polyA) 1646-2320 675 
3’ HR Arm 2321-3733 1413 
pAAV Backbone 3734-6479 2746 
 
       1  CCTGCAGGCA GCTGCGCGCT CGCTCGCTCA CTGAGGCCGC CCGGGCAAAG CCCGGGCGTC 
      61  GGGCGACCTT TGGTCGCCCG GCCTCAGTGA GCGAGCGAGC GCGCAGAGAG GGAGTGGCCA 
     121  ACTCCATCAC TAGGGGTTCC TGCGGCCGCG CAGACGTGGA AGTGCGAAGT CTCCCGTGGG 
     181  AATCTGGGAA CTTTGCTTCT TGGCAGAAAT TTTTGTGCTG TTCCCAGAGT TTATTAAGCA 
     241  TCCTCTTTAA TATACAAATA TTTGAAATTT TGTTAGCAAG AGCAGTTAAC TGGACAGAAT 
     301  TCTCAGCAAA ATTTAGCGCT TTAAATATAA AGATCAGAGC CAGTATTTAG AATTGCCGCT 
     361  GGAAGACAGG AAACCTGAGT AAATAGAAAA GAATGCAGGG AGAATAGGCT AAAATACAAT 
     421  TAAACACTAA TGTGCGCTGT TGGAATTCTA GAGGCAGGAA GGCATGGTTG AAGGTATGAC 
     481  CTTCAGTGGG GCAGTCTGGG GGTCTGACTT GAAATAAAAG AATGGGGAGT GGTGTGCTAT 
     541  TATAAGGCAG TTTCCAGTTG CTTGTAGGAC ACTCATTGTA ATTTCTCTCT AACAGACATA 
     601  TTTGTTTATT CTAGTAGGAG AGGAATGGCT CTGTGGGTTT CAACCTCTTC GGGGGGTTGA 
     661  ATGACCCTTT CACAGGGGTG GCTGAAGACC ATTGGAAAAC AGTTATTTAC ATTTTGATTC 
     721  ATGACAGCAA AATTACATGT ATGAAGTAAC AACAAAAATA ATTTCACAGT TGGGGGGTCA 
     781  CCACAACATG AGGAACTATA TTAAAGGGTC ATAGCATTAG CATGCTTGAG AACCACTGGC 
     841  AAAGAGAATG GGGAAACAGG TCAGCAGAGC AGATGTTGAA CAGCATTCAT AGGACAGGTA 
     901  GAGAACATAG TAGGTCACTG GTAGACAAGT TGGTAAATGC CATTAACATG GTCTACTCTC 
     961  AAACTAAATA TCAGGATTGG GGAAATAGCT CAGTCAGTAA AGTTTTGAAG ACCTGAGTTA 
    1021  AAATCTCAGC ACCCAAATAA AAATGTGGGC CTGGTGGGAC ACAGCTAGCT AGTAATCAAT 
    1081  TACGGGGTCA TTAGTTCATA GCCCATATAT GGAGTTCCGC GTTACATAAC TTACGGTAAA 
    1141  TGGCCCGCCT GGCTGACCGC CCAACGACCC CCGCCCATTG ACGTCAATAA TGACGTATGT 
    1201  TCCCATAGTA ACGCCAATAG GGACTTTCCA TTGACGTCAA TGGGTGGAGT ATTTACGGTA 
    1261  AACTGCCCAC TTGGCAGTAC ATCAAGTGTA TCATATGCCA AGTACGCCCC CTATTGACGT 
    1321  CAATGACGGT AAATGGCCCG CCTGGCATTA TGCCCAGTAC ATGACCTTAT GGGACTTTCC 
    1381  TACTTGGCAG TACATCTACG TATTAGTCAT CGCTATTACC ATGGTGATGC GGTTTTGGCA 
    1441  GTACATCAAT GGGCGTGGAT AGCGGTTTGA CTCACGGGGA TTTCCAAGTC TCCACCCCAT 
    1501  TGACGTCAAT GGGAGTTTGT TTTGGCACCA AAATCAACGG GACTTTCCAA AATGTCGTAA 
    1561  CAACTCCGCC CCATTGACGC AAATGGGCGG TAGGCGTGTA CGGTGGGAGG TCTATATAAG 
    1621  CAGAGCTGGT TTAGTGAACC GTCAGGGATC CCAAGGTGAG GAACTAAACC ATGGCCAAGT 
    1681  TGACCAGTGC CGTTCCGGTG CTCACCGCGC GCGACGTCGC CGGAGCGGTC GAGTTCTGGA 
    1741  CCGACCGGCT CGGGTTCTCC CGGGACTTCG TGGAGGACGA CTTCGCCGGT GTGGTCCGGG 
    1801  ACGACGTGAC CCTGTTCATC AGCGCGGTCC AGGACCAGGT GGTGCCGGAC AACACCCTGG 
    1861  CCTGGGTGTG GGTGCGCGGC CTGGACGAGC TGTACGCCGA GTGGTCGGAG GTCGTGTCCA 
    1921  CGAACTTCCG GGACGCCTCC GGGCCGGCCA TGACCGAGAT CGGCGAGCAG CCGTGGGGGC 
    1981  GGGAGTTCGC CCTGCGCGAC CCGGCCGGCA ACTGCGTGCA CTTCGTGGCC GAGGAGCAGG 
    2041  ACTGACACGT GCTACGAGAT TTCGATTCCA CCGCCGCCTT CTATGAAAGG TTGGGCTTCG 
    2101  GAATCGTTTT CCGGGACGCC GGCTGGATGA TCCTCCAGCG CGGGGATCTC ATGCTGGAGT 
    2161  TCTTCGCCCA CCCCAACTTG TTTATTGCAG CTTATAATGG TTACAAATAA AGCAATAGCA 
    2221  TCACAAATTT CACAAATAAA GCATTTTTTT CACTGCATTC TAGTTGTGGT TTGTCCAAAC 
    2281  TCATCAATGT ATCTTATCAT GTCTGTATAC CGTCGACCTC CTCGAGGGAG GCAGAGACAG 
    2341  AAAGATCCCT GGGGCTTGTT CCTAGCCAAA TTTGTGGGTT CCAGATTCAG TGAGAAATCT 
    2401  TGTCTCAAAA AAATAAAGTG AAGACACTCA TCTTCACTGT CTGGCCTGTG CAAACAGGTG 
    2461  CACAGTGCAT ACAAAATAAA AATAATAATT TTTTCAAGAT TATTTTTCTT TCTAATATGT 
    2521  TTTGAGAATG CCTATATACA TGTATGTACA AAATATATGT ATGTGCCTGG TCCCCACAGA 
    2581  AGCAGAAGAA AATGTCAGTT CCCTAGAACT GCCTCTAGAT GTGGGTGCTG AGAACCAAAC 
    2641  CCAGGTCCTC TACTATGCTT TTAACTGCTA AACCATCTCT CTAGCCCCCA AAGTCATTTT 
    2701  TCATTAAAGA ATCCTAAGTA TGACCTGGTA ATTGTTACTG TTCCTTTGAT CCAGATGTCT 
    2761  GACACTCAAG GTTTTTTCCC CAAGCAATTA AATAAGAGAT GGAAGCTGCA TGTCTAAAGT 
    2821  TTTCCTAAAA GTGCTTTTTA AATGTGTTTT CTATTCTTTG AAGTTTTTAT ACATTTATAC 
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    2881  AGTGTTTATA GAGCATATCC ATTTATCTTC TCACTCCTCC TTGTGCCCTC TTCTCCTTCC 
    2941  CTAATTCATG TTGTAGTTGT TATCAATAAC CCTGTGTGGT GGTCAACTGG GGCATGAGCA 
    3001  ATCTACAACC AGCCCAACCT AAGACTGACT CTCCCTCTCT CAGCAGCCCC CAATAACCAA 
    3061  TAGCTGTCTG ATAGGGTGGG ACCTCGGGAG CCCCTTCTGC ATGCTGGAAT TTTGACTGAC 
    3121  TGTGAGTTGG TGCATACAGA CATCAGCCAT GTCTCATCCT GTAGTCAGTT TTCACATCTC 
    3181  TCCCTCTTTC AGCAACTCTT ATGTTCTATC TGCCCCCTCT TCCTCAATGG TCCCTTAACC 
    3241  TTTGAATAGT GGGAGCTGGT ATAGATGACC CAGAGAACAG TAGTTTTAGA TGGTAAATAC 
    3301  AAGTTATGAG TCTTTAATCT TCTCAGATTT CCAGGGGTAG GAGCATCTTT TCTCCATTTT 
    3361  AGAATTTAAT AAAGCATATG GGGTTATCTA GTGGGACAAA TCCTGTCAGC CTGAGCACTT 
    3421  TGAACCAAAA TTATGTGAGG TTGCAATTGA CTAAAACCTA AGTAGAAGAT ATAAATTGGA 
    3481  TAAACCAAAA AGAAAAATAA GTATTATATC TAGTTAATGA GTACTAAATA TCTGAAATTT 
    3541  GGGTGAAGCT GTTGGTCTTA ATTTTTCTAA AGGATATCCA CTAGATGTCA CTATGACAAT 
    3601  GGTATCTTGC CTGTGTATGA CACTAAAAAT GTGTGTTTTC AAAAATATCC TTCCTGCTTA 
    3661  ATTTTGTAGG TAAACAGAAC CTGGTGATTA TGGGCCGGAA AACCTGGTTC TCCATTCCTG 
    3721  AGAAGAATCG ACCGCGGCCG CAGGAACCCC TAGTGATGGA GTTGGCCACT CCCTCTCTGC 
    3781  GCGCTCGCTC GCTCACTGAG GCCGGGCGAC CAAAGGTCGC CCGACGCCCG GGCTTTGCCC 
    3841  GGGCGGCCTC AGTGAGCGAG CGAGCGCGCA GCTGCCTGCA GGGGCGCCTG ATGCGGTATT 
    3901  TTCTCCTTAC GCATCTGTGC GGTATTTCAC ACCGCATACG TCAAAGCAAC CATAGTACGC 
    3961  GCCCTGTAGC GGCGCATTAA GCGCGGCGGG TGTGGTGGTT ACGCGCAGCG TGACCGCTAC 
    4021  ACTTGCCAGC GCCCTAGCGC CCGCTCCTTT CGCTTTCTTC CCTTCCTTTC TCGCCACGTT 
    4081  CGCCGGCTTT CCCCGTCAAG CTCTAAATCG GGGGCTCCCT TTAGGGTTCC GATTTAGTGC 
    4141  TTTACGGCAC CTCGACCCCA AAAAACTTGA TTTGGGTGAT GGTTCACGTA GTGGGCCATC 
    4201  GCCCTGATAG ACGGTTTTTC GCCCTTTGAC GTTGGAGTCC ACGTTCTTTA ATAGTGGACT 
    4261  CTTGTTCCAA ACTGGAACAA CACTCAACCC TATCTCGGGC TATTCTTTTG ATTTATAAGG 
    4321  GATTTTGCCG ATTTCGGCCT ATTGGTTAAA AAATGAGCTG ATTTAACAAA AATTTAACGC 
    4381  GAATTTTAAC AAAATATTAA CGTTTACAAT TTTATGGTGC ACTCTCAGTA CAATCTGCTC 
    4441  TGATGCCGCA TAGTTAAGCC AGCCCCGACA CCCGCCAACA CCCGCTGACG CGCCCTGACG 
    4501  GGCTTGTCTG CTCCCGGCAT CCGCTTACAG ACAAGCTGTG ACCGTCTCCG GGAGCTGCAT 
    4561  GTGTCAGAGG TTTTCACCGT CATCACCGAA ACGCGCGAGA CGAAAGGGCC TCGTGATACG 
    4621  CCTATTTTTA TAGGTTAATG TCATGATAAT AATGGTTTCT TAGACGTCAG GTGGCACTTT 
    4681  TCGGGGAAAT GTGCGCGGAA CCCCTATTTG TTTATTTTTC TAAATACATT CAAATATGTA 
    4741  TCCGCTCATG AGACAATAAC CCTGATAAAT GCTTCAATAA TATTGAAAAA GGAAGAGTAT 
    4801  GAGTATTCAA CATTTCCGTG TCGCCCTTAT TCCCTTTTTT GCGGCATTTT GCCTTCCTGT 
    4861  TTTTGCTCAC CCAGAAACGC TGGTGAAAGT AAAAGATGCT GAAGATCAGT TGGGTGCACG 
    4921  AGTGGGTTAC ATCGAACTGG ATCTCAACAG CGGTAAGATC CTTGAGAGTT TTCGCCCCGA 
    4981  AGAACGTTTT CCAATGATGA GCACTTTTAA AGTTCTGCTA TGTGGCGCGG TATTATCCCG 
    5041  TATTGACGCC GGGCAAGAGC AACTCGGTCG CCGCATACAC TATTCTCAGA ATGACTTGGT 
    5101  TGAGTACTCA CCAGTCACAG AAAAGCATCT TACGGATGGC ATGACAGTAA GAGAATTATG 
    5161  CAGTGCTGCC ATAACCATGA GTGATAACAC TGCGGCCAAC TTACTTCTGA CAACGATCGG 
    5221  AGGACCGAAG GAGCTAACCG CTTTTTTGCA CAACATGGGG GATCATGTAA CTCGCCTTGA 
    5281  TCGTTGGGAA CCGGAGCTGA ATGAAGCCAT ACCAAACGAC GAGCGTGACA CCACGATGCC 
    5341  TGTAGCAATG GCAACAACGT TGCGCAAACT ATTAACTGGC GAACTACTTA CTCTAGCTTC 
    5401  CCGGCAACAA TTAATAGACT GGATGGAGGC GGATAAAGTT GCAGGACCAC TTCTGCGCTC 
    5461  GGCCCTTCCG GCTGGCTGGT TTATTGCTGA TAAATCTGGA GCCGGTGAGC GTGGGTCTCG 
    5521  CGGTATCATT GCAGCACTGG GGCCAGATGG TAAGCCCTCC CGTATCGTAG TTATCTACAC 
    5581  GACGGGGAGT CAGGCAACTA TGGATGAACG AAATAGACAG ATCGCTGAGA TAGGTGCCTC 
    5641  ACTGATTAAG CATTGGTAAC TGTCAGACCA AGTTTACTCA TATATACTTT AGATTGATTT 
    5701  AAAACTTCAT TTTTAATTTA AAAGGATCTA GGTGAAGATC CTTTTTGATA ATCTCATGAC 
    5761  CAAAATCCCT TAACGTGAGT TTTCGTTCCA CTGAGCGTCA GACCCCGTAG AAAAGATCAA 
    5821  AGGATCTTCT TGAGATCCTT TTTTTCTGCG CGTAATCTGC TGCTTGCAAA CAAAAAAACC 
    5881  ACCGCTACCA GCGGTGGTTT GTTTGCCGGA TCAAGAGCTA CCAACTCTTT TTCCGAAGGT 
    5941  AACTGGCTTC AGCAGAGCGC AGATACCAAA TACTGTCCTT CTAGTGTAGC CGTAGTTAGG 
    6001  CCACCACTTC AAGAACTCTG TAGCACCGCC TACATACCTC GCTCTGCTAA TCCTGTTACC 
    6061  AGTGGCTGCT GCCAGTGGCG ATAAGTCGTG TCTTACCGGG TTGGACTCAA GACGATAGTT 
    6121  ACCGGATAAG GCGCAGCGGT CGGGCTGAAC GGGGGGTTCG TGCACACAGC CCAGCTTGGA 
    6181  GCGAACGACC TACACCGAAC TGAGATACCT ACAGCGTGAG CTATGAGAAA GCGCCACGCT 
    6241  TCCCGAAGGG AGAAAGGCGG ACAGGTATCC GGTAAGCGGC AGGGTCGGAA CAGGAGAGCG 
    6301  CACGAGGGAG CTTCCAGGGG GAAACGCCTG GTATCTTTAT AGTCCTGTCG GGTTTCGCCA 
    6361  CCTCTGACTT GAGCGTCGAT TTTTGTGATG CTCGTCAGGG GGGCGGAGCC TATGGAAAAA 
    6421  CGCCAGCAAC GCGGCCTTTT TACGGTTCCT GGCCTTTTGC TGGCCTTTTG CTCACATGT 
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5.2.4 pcDNA3.1/Zeo(+)-TBP sequence (5929 bp) 
 
Feature Region Size (bp) 
CMV promoter 236-852 617 
TBP 935-1891 957 
Zeocin resistance 3097-3472 375 
 
 
       1  GACGGATCGG GAGATCTCCC GATCCCCTAT GGTCGACTCT CAGTACAATC TGCTCTGATG 
      61  CCGCATAGTT AAGCCAGTAT CTGCTCCCTG CTTGTGTGTT GGAGGTCGCT GAGTAGTGCG 
     121  CGAGCAAAAT TTAAGCTACA ACAAGGCAAG GCTTGACCGA CAATTGCATG AAGAATCTGC 
     181  TTAGGGTTAG GCGTTTTGCG CTGCTTCGCG ATGTACGGGC CAGATATACG CGTTGACATT 
     241  GATTATTGAC TAGTTATTAA TAGTAATCAA TTACGGGGTC ATTAGTTCAT AGCCCATATA 
     301  TGGAGTTCCG CGTTACATAA CTTACGGTAA ATGGCCCGCC TGGCTGACCG CCCAACGACC 
     361  CCCGCCCATT GACGTCAATA ATGACGTATG TTCCCATAGT AACGCCAATA GGGACTTTCC 
     421  ATTGACGTCA ATGGGTGGAC TATTTACGGT AAACTGCCCA CTTGGCAGTA CATCAAGTGT 
     481  ATCATATGCC AAGTACGCCC CCTATTGACG TCAATGACGG TAAATGGCCC GCCTGGCATT 
     541  ATGCCCAGTA CATGACCTTA TGGGACTTTC CTACTTGGCA GTACATCTAC GTATTAGTCA 
     601  TCGCTATTAC CATGGTGATG CGGTTTTGGC AGTACATCAA TGGGCGTGGA TAGCGGTTTG 
     661  ACTCACGGGG ATTTCCAAGT CTCCACCCCA TTGACGTCAA TGGGAGTTTG TTTTGGCACC 
     721  AAAATCAACG GGACTTTCCA AAATGTCGTA ACAACTCCGC CCCATTGACG CAAATGGGCG 
     781  GTAGGCGTGT ACGGTGGGAG GTCTATATAA GCAGAGCTCT CTGGCTAACT AGAGAACCCA 
     841  CTGCTTACTG GCTTATCGAA ATTAATACGA CTCACTATAG GGAGACCCAA GCTGGCTAGC 
     901  GTTTAAACTT AAGCTTGGTA CCGAGCTCGG ATCCATGGAC CAGAACAACA GCCTTCCACC 
     961  TTATGCTCAG GGCTTGGCCT CCCCACAGGG TGCCATGACT CCTGGAATTC CCATCTTTAG 
    1021  TCCAATGATG CCTTATGGCA CAGGACTTAC TCCACAGCCT ATTCAGAACA CCAATAGTCT 
    1081  ATCTATTTTG GAAGAGCAGC AAAGAGAGCA GCAGCAGCAA CAGCAGCAGC AGCAACAGCA 
    1141  GCAGCAGCAA GCAGTAGCAA CTGCAGCAGC CTCAGTACAG CAATCGACAT CTCAGCAATC 
    1201  CACACAGGGT GCCTCAGGCC AGACTCCACA GCTCTTCCAT TCTCAGACTC TGACCACTGC 
    1261  ACCATTGCCA GGCACCACCC CCTTGTACCC TTCACCTATG ACCCCTATGA CCCCTATCAC 
    1321  TCCTGCCACA CCAGCCTCCG AGAGCTCTGG GATCGTACCC CAGCTGCAAA ATATTGTATC 
    1381  CACGGTGAAT CTTGGATGTA AACTTGACCT AAAGACCATT GCACTTCGTG CCCGAAATGC 
    1441  TGAATATAAT CCCAAGCGGT TTGCTGCTGT CATCATGAGA ATAAGAGAGC CTCGGACAAC 
    1501  TGCGCTGATT TTCAGTTCTG GGAAAATGGT GTGCACAGGA GCCAAGAGTG AAGAACAATC 
    1561  CAGGTTAGCA GCAAGAAAAT ACGCTAGAGT TGTGCAAAAG TTGGGCTTTC CAGCAAAGTT 
    1621  CTTAGACTTC AAGATCCAGA ACATGGTGGG GAGCTGTGAT GTGAAGTTCC CCATAAGGCT 
    1681  GGAAGGCCTT GTGCTGACCC ACCAGCAGTT CAGCAGCTAT GAGCCAGAGT TATTTCCTGG 
    1741  CTTAATCTAC AGAATGATCA AACCCAGGAT TGTTCTCCTT ATTTTTGTTT CTGGAAAAGT 
    1801  TGTATTAACA GGTGCTAAAG TTAGAGCAGA GATTTATGAA GCATTTGAAA ACATCTACCC 
    1861  CATCTTAAAG GGATTCAGGA AGACCACATA GGCGGCCGCT CGAGTCTAGA GGGCCCGTTT 
    1921  AAACCCGCTG ATCAGCCTCG ACTGTGCCTT CTAGTTGCCA GCCATCTGTT GTTTGCCCCT 
    1981  CCCCCGTGCC TTCCTTGACC CTGGAAGGTG CCACTCCCAC TGTCCTTTCC TAATAAAATG 
    2041  AGGAAATTGC ATCGCATTGT CTGAGTAGGT GTCATTCTAT TCTGGGGGGT GGGGTGGGGC 
    2101  AGGACAGCAA GGGGGAGGAT TGGGAAGACA ATAGCAGGCA TGCTGGGGAT GCGGTGGGCT 
    2161  CTATGGCTTC TGAGGCGGAA AGAACCAGCT GGGGCTCTAG GGGGTATCCC CACGCGCCCT 
    2221  GTAGCGGCGC ATTAAGCGCG GCGGGTGTGG TGGTTACGCG CAGCGTGACC GCTACACTTG 
    2281  CCAGCGCCCT AGCGCCCGCT CCTTTCGCTT TCTTCCCTTC CTTTCTCGCC ACGTTCGCCG 
    2341  GCTTTCCCCG TCAAGCTCTA AATCGGGGCA TCCCTTTAGG GTTCCGATTT AGTGCTTTAC 
    2401  GGCACCTCGA CCCCAAAAAA CTTGATTAGG GTGATGGTTC ACGTAGTGGG CCATCGCCCT 
    2461  GATAGACGGT TTTTCGCCCT TTGACGTTGG AGTCCACGTT CTTTAATAGT GGACTCTTGT 
    2521  TCCAAACTGG AACAACACTC AACCCTATCT CGGTCTATTC TTTTGATTTA TAAGGGATTT 
    2581  TGGGGATTTC GGCCTATTGG TTAAAAAATG AGCTGATTTA ACAAAAATTT AACGCGAATT 
    2641  AATTCTGTGG AATGTGTGTC AGTTAGGGTG TGGAAAGTCC CCAGGCTCCC CAGGCAGGCA 
    2701  GAAGTATGCA AAGCATGCAT CTCAATTAGT CAGCAACCAG GTGTGGAAAG TCCCCAGGCT 
    2761  CCCCAGCAGG CAGAAGTATG CAAAGCATGC ATCTCAATTA GTCAGCAACC ATAGTCCCGC 
    2821  CCCTAACTCC GCCCATCCCG CCCCTAACTC CGCCCAGTTC CGCCCATTCT CCGCCCCATG 
    2881  GCTGACTAAT TTTTTTTATT TATGCAGAGG CCGAGGCCGC CTCTGCCTCT GAGCTATTCC 
    2941  AGAAGTAGTG AGGAGGCTTT TTTGGAGGCC TAGGCTTTTG CAAAAAGCTC CCGGGAGCTT 
    3001  GTATATCCAT TTTCGGATCT GATCAGCACG TGTTGACAAT TAATCATCGG CATAGTATAT 
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    3061  CGGCATAGTA TAATACGACA AGGTGAGGAA CTAAACCATG GCCAAGTTGA CCAGTGCCGT 
    3121  TCCGGTGCTC ACCGCGCGCG ACGTCGCCGG AGCGGTCGAG TTCTGGACCG ACCGGCTCGG 
    3181  GTTCTCCCGG GACTTCGTGG AGGACGACTT CGCCGGTGTG GTCCGGGACG ACGTGACCCT 
    3241  GTTCATCAGC GCGGTCCAGG ACCAGGTGGT GCCGGACAAC ACCCTGGCCT GGGTGTGGGT 
    3301  GCGCGGCCTG GACGAGCTGT ACGCCGAGTG GTCGGAGGTC GTGTCCACGA ACTTCCGGGA 
    3361  CGCCTCCGGG CCGGCCATGA CCGAGATCGG CGAGCAGCCG TGGGGGCGGG AGTTCGCCCT 
    3421  GCGCGACCCG GCCGGCAACT GCGTGCACTT CGTGGCCGAG GAGCAGGACT GACACGTGCT 
    3481  ACGAGATTTC GATTCCACCG CCGCCTTCTA TGAAAGGTTG GGCTTCGGAA TCGTTTTCCG 
    3541  GGACGCCGGC TGGATGATCC TCCAGCGCGG GGATCTCATG CTGGAGTTCT TCGCCCACCC 
    3601  CAACTTGTTT ATTGCAGCTT ATAATGGTTA CAAATAAAGC AATAGCATCA CAAATTTCAC 
    3661  AAATAAAGCA TTTTTTTCAC TGCATTCTAG TTGTGGTTTG TCCAAACTCA TCAATGTATC 
    3721  TTATCATGTC TGTATACCGT CGACCTCTAG CTAGAGCTTG GCGTAATCAT GGTCATAGCT 
    3781  GTTTCCTGTG TGAAATTGTT ATCCGCTCAC AATTCCACAC AACATACGAG CCGGAAGCAT 
    3841  AAAGTGTAAA GCCTGGGGTG CCTAATGAGT GAGCTAACTC ACATTAATTG CGTTGCGCTC 
    3901  ACTGCCCGCT TTCCAGTCGG GAAACCTGTC GTGCCAGCTG CATTAATGAA TCGGCCAACG 
    3961  CGCGGGGAGA GGCGGTTTGC GTATTGGGCG CTCTTCCGCT TCCTCGCTCA CTGACTCGCT 
    4021  GCGCTCGGTC GTTCGGCTGC GGCGAGCGGT ATCAGCTCAC TCAAAGGCGG TAATACGGTT 
    4081  ATCCACAGAA TCAGGGGATA ACGCAGGAAA GAACATGTGA GCAAAAGGCC AGCAAAAGGC 
    4141  CAGGAACCGT AAAAAGGCCG CGTTGCTGGC GTTTTTCCAT AGGCTCCGCC CCCCTGACGA 
    4201  GCATCACAAA AATCGACGCT CAAGTCAGAG GTGGCGAAAC CCGACAGGAC TATAAAGATA 
    4261  CCAGGCGTTT CCCCCTGGAA GCTCCCTCGT GCGCTCTCCT GTTCCGACCC TGCCGCTTAC 
    4321  CGGATACCTG TCCGCCTTTC TCCCTTCGGG AAGCGTGGCG CTTTCTCAAT GCTCACGCTG 
    4381  TAGGTATCTC AGTTCGGTGT AGGTCGTTCG CTCCAAGCTG GGCTGTGTGC ACGAACCCCC 
    4441  CGTTCAGCCC GACCGCTGCG CCTTATCCGG TAACTATCGT CTTGAGTCCA ACCCGGTAAG 
    4501  ACACGACTTA TCGCCACTGG CAGCAGCCAC TGGTAACAGG ATTAGCAGAG CGAGGTATGT 
    4561  AGGCGGTGCT ACAGAGTTCT TGAAGTGGTG GCCTAACTAC GGCTACACTA GAAGGACAGT 
    4621  ATTTGGTATC TGCGCTCTGC TGAAGCCAGT TACCTTCGGA AAAAGAGTTG GTAGCTCTTG 
    4681  ATCCGGCAAA CAAACCACCG CTGGTAGCGG TGGTTTTTTT GTTTGCAAGC AGCAGATTAC 
    4741  GCGCAGAAAA AAAGGATCTC AAGAAGATCC TTTGATCTTT TCTACGGGGT CTGACGCTCA 
    4801  GTGGAACGAA AACTCACGTT AAGGGATTTT GGTCATGAGA TTATCAAAAA GGATCTTCAC 
    4861  CTAGATCCTT TTAAATTAAA AATGAAGTTT TAAATCAATC TAAAGTATAT ATGAGTAAAC 
    4921  TTGGTCTGAC AGTTACCAAT GCTTAATCAG TGAGGCACCT ATCTCAGCGA TCTGTCTATT 
    4981  TCGTTCATCC ATAGTTGCCT GACTCCCCGT CGTGTAGATA ACTACGATAC GGGAGGGCTT 
    5041  ACCATCTGGC CCCAGTGCTG CAATGATACC GCGAGACCCA CGCTCACCGG CTCCAGATTT 
    5101  ATCAGCAATA AACCAGCCAG CCGGAAGGGC CGAGCGCAGA AGTGGTCCTG CAACTTTATC 
    5161  CGCCTCCATC CAGTCTATTA ATTGTTGCCG GGAAGCTAGA GTAAGTAGTT CGCCAGTTAA 
    5221  TAGTTTGCGC AACGTTGTTG CCATTGCTAC AGGCATCGTG GTGTCACGCT CGTCGTTTGG 
    5281  TATGGCTTCA TTCAGCTCCG GTTCCCAACG ATCAAGGCGA GTTACATGAT CCCCCATGTT 
    5341  GTGCAAAAAA GCGGTTAGCT CCTTCGGTCC TCCGATCGTT GTCAGAAGTA AGTTGGCCGC 
    5401  AGTGTTATCA CTCATGGTTA TGGCAGCACT GCATAATTCT CTTACTGTCA TGCCATCCGT 
    5461  AAGATGCTTT TCTGTGACTG GTGAGTACTC AACCAAGTCA TTCTGAGAAT AGTGTATGCG 
    5521  GCGACCGAGT TGCTCTTGCC CGGCGTCAAT ACGGGATAAT ACCGCGCCAC ATAGCAGAAC 
    5581  TTTAAAAGTG CTCATCATTG GAAAACGTTC TTCGGGGCGA AAACTCTCAA GGATCTTACC 
    5641  GCTGTTGAGA TCCAGTTCGA TGTAACCCAC TCGTGCACCC AACTGATCTT CAGCATCTTT 
    5701  TACTTTCACC AGCGTTTCTG GGTGAGCAAA AACAGGAAGG CAAAATGCCG CAAAAAAGGG 
    5761  AATAAGGGCG ACACGGAAAT GTTGAATACT CATACTCTTC CTTTTTCAAT ATTATTGAAG 
    5821  CATTTATCAG GGTTATTGTC TCATGAGCGG ATACATATTT GAATGTATTT AGAAAAATAA 




5.2.5 TBP(U) v pcDNA(U) gene list 
 
Gene ID logFC AveExpr t P.Value adj.P.Val B Fold Change 
6430548M08Rik 0.360 5.381 5.130 3.05E-05 1.90E-03 2.465 1.28 
Acat2 -0.378 6.811 -5.724 6.91E-06 6.36E-04 3.883 -1.30 
Akap12 -0.292 7.889 -4.376 2.06E-04 6.96E-03 0.642 -1.22 
ANLN -0.502 6.950 -4.353 2.18E-04 7.12E-03 0.588 -1.42 
Asf1b -0.369 5.939 -4.405 1.91E-04 6.79E-03 0.712 -1.29 
ASPM -0.418 6.112 -6.381 1.39E-06 2.27E-04 5.414 -1.34 
Aurka -0.390 6.331 -4.964 4.63E-05 2.38E-03 2.065 -1.31 
C18orf49 0.279 6.640 3.377 2.51E-03 4.42E-02 -1.722 1.21 
C3 -0.331 7.330 -6.035 3.21E-06 3.72E-04 4.614 -1.26 
Ccl2 -0.586 7.806 -4.403 1.92E-04 6.79E-03 0.708 -1.50 
Ccna2 -0.433 6.788 -3.385 2.46E-03 4.42E-02 -1.703 -1.35 
CCNB1 -0.564 5.956 -3.961 5.87E-04 1.52E-02 -0.354 -1.48 
Ccnb1 -0.533 7.434 -6.346 1.51E-06 2.29E-04 5.332 -1.45 
CCNB2 -0.289 6.467 -4.356 2.16E-04 7.12E-03 0.594 -1.22 
CDC20 -0.467 7.231 -4.847 6.23E-05 2.90E-03 1.783 -1.38 
CDK1 -0.271 8.673 -4.239 2.91E-04 8.79E-03 0.312 -1.21 
CDKN3 -0.443 8.297 -5.123 3.10E-05 1.90E-03 2.449 -1.36 
Cenpa -0.497 7.615 -5.286 2.06E-05 1.43E-03 2.838 -1.41 
Cenpf -0.434 6.632 -5.278 2.10E-05 1.43E-03 2.820 -1.35 
CENPL -0.416 6.032 -5.999 3.51E-06 3.82E-04 4.529 -1.33 
Cep55 -0.332 6.066 -3.931 6.34E-04 1.60E-02 -0.426 -1.26 
CES1 0.420 3.649 4.192 3.28E-04 9.65E-03 0.200 1.34 
Cflar -0.271 7.205 -3.432 2.19E-03 4.03E-02 -1.595 -1.21 
CHMP2A 0.276 7.416 5.551 1.06E-05 9.08E-04 3.473 1.21 
CKAP2 -0.473 5.818 -7.734 5.97E-08 7.16E-05 8.390 -1.39 
CKAP5 -0.273 6.097 -3.505 1.83E-03 3.56E-02 -1.428 -1.21 
CKS2 -0.338 8.689 -4.324 2.35E-04 7.50E-03 0.517 -1.26 
Cpn2 0.445 6.648 5.624 8.85E-06 7.76E-04 3.646 1.36 
Creg1 0.326 6.806 3.465 2.02E-03 3.80E-02 -1.520 1.25 
Ctla2b -0.667 7.178 -7.798 5.18E-08 7.16E-05 8.523 -1.59 
Cxcl1 -0.329 6.634 -3.841 7.94E-04 1.88E-02 -0.639 -1.26 
D5Ertd579e 0.361 6.408 7.498 1.02E-07 7.50E-05 7.889 1.28 
DBF4 -0.334 6.260 -4.320 2.37E-04 7.50E-03 0.508 -1.26 
DCTPP1 -0.298 7.125 -4.877 5.78E-05 2.80E-03 1.853 -1.23 
DLGAP5 -0.428 6.521 -4.632 1.07E-04 4.42E-03 1.262 -1.35 
EBP -0.395 5.933 -6.555 9.14E-07 2.06E-04 5.810 -1.32 
ECT2 -0.477 7.232 -4.934 5.00E-05 2.53E-03 1.993 -1.39 
EFEMP1 -0.390 9.515 -6.411 1.29E-06 2.24E-04 5.482 -1.31 
EMP1 -0.374 7.772 -7.486 1.04E-07 7.50E-05 7.865 -1.30 
EPR1 -0.392 7.818 -4.861 6.01E-05 2.84E-03 1.817 -1.31 
EPS8 -0.335 8.261 -3.734 1.04E-03 2.36E-02 -0.892 -1.26 
EPS8 -0.315 7.562 -3.921 6.50E-04 1.61E-02 -0.449 -1.24 
ERAP1 -0.302 6.611 -6.404 1.31E-06 2.24E-04 5.467 -1.23 
ERCC1 0.315 6.529 4.130 3.83E-04 1.09E-02 0.051 1.24 
FDPS -0.299 8.124 -5.114 3.18E-05 1.90E-03 2.425 -1.23 
FOSL1 -0.438 7.032 -4.969 4.57E-05 2.38E-03 2.077 -1.35 
GAS1 0.674 6.643 7.132 2.35E-07 1.32E-04 7.098 1.60 
GPAM 0.271 7.859 6.504 1.03E-06 2.06E-04 5.694 1.21 
Gstm1 0.366 9.649 5.286 2.06E-05 1.43E-03 2.839 1.29 
Gstm7 0.329 8.876 4.727 8.44E-05 3.79E-03 1.493 1.26 
H2afx -0.296 6.799 -3.753 9.90E-04 2.26E-02 -0.847 -1.23 
KIF23 -0.417 6.746 -6.452 1.17E-06 2.21E-04 5.575 -1.34 
KIFC1 -0.452 6.589 -7.094 2.57E-07 1.32E-04 7.013 -1.37 
KPNA2 -0.318 7.512 -5.097 3.32E-05 1.92E-03 2.384 -1.25 
LOC685953 0.397 9.130 3.805 8.70E-04 2.03E-02 -0.725 1.32 
Mad2l1 -0.309 7.100 -4.719 8.62E-05 3.82E-03 1.472 -1.24 
MMD 0.336 6.497 4.140 3.74E-04 1.08E-02 0.074 1.26 
MRPL39 -0.292 6.894 -5.524 1.14E-05 9.49E-04 3.408 -1.22 
Mthfd2 -0.284 7.826 -6.316 1.62E-06 2.34E-04 5.263 -1.22 
Mthfd2l -0.340 6.000 -5.324 1.87E-05 1.41E-03 2.929 -1.27 
Ncam1 0.587 5.358 6.529 9.73E-07 2.06E-04 5.751 1.50 
Ncapd3 -0.309 5.993 -4.387 2.00E-04 6.95E-03 0.670 -1.24 
Ncaph -0.322 6.789 -4.872 5.85E-05 2.80E-03 1.843 -1.25 
NDC80 -0.437 6.736 -5.323 1.88E-05 1.41E-03 2.927 -1.35 
Nek2 -0.394 8.036 -5.978 3.69E-06 3.90E-04 4.481 -1.31 
NFKBIA -0.320 8.519 -4.550 1.32E-04 5.06E-03 1.064 -1.25 
NFKBIA -0.270 8.243 -4.354 2.18E-04 7.12E-03 0.589 -1.21 
Nusap1 -0.506 6.996 -6.341 1.53E-06 2.29E-04 5.322 -1.42 
Prc1 -0.488 7.462 -5.091 3.36E-05 1.92E-03 2.372 -1.40 
PRDX4 -0.292 8.079 -6.648 7.33E-07 1.88E-04 6.020 -1.22 
PTTG1 -0.339 6.979 -4.071 4.45E-04 1.20E-02 -0.091 -1.26 
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Pxdn 0.277 7.848 4.808 6.88E-05 3.17E-03 1.688 1.21 
Reep5 0.320 7.899 6.527 9.77E-07 2.06E-04 5.748 1.25 
RGD1560010 -0.274 6.651 -3.951 6.02E-04 1.53E-02 -0.377 -1.21 
RNASEH2C -0.430 6.445 -6.876 4.28E-07 1.54E-04 6.531 -1.35 
RPS5 0.276 11.111 6.112 2.66E-06 3.30E-04 4.794 1.21 
SBSN -0.275 9.801 -4.635 1.07E-04 4.42E-03 1.270 -1.21 
SEMA3C -0.335 6.612 -5.805 5.65E-06 5.49E-04 4.075 -1.26 
Serpinf1 0.447 8.278 5.178 2.70E-05 1.77E-03 2.580 1.36 
SGK1 -0.506 7.327 -8.133 2.48E-08 7.16E-05 9.215 -1.42 
SMC4 -0.450 6.591 -4.079 4.36E-04 1.20E-02 -0.072 -1.37 
SOD2 -0.387 6.599 -6.154 2.41E-06 3.09E-04 4.889 -1.31 
SOD2 -0.351 6.729 -5.181 2.68E-05 1.77E-03 2.587 -1.28 
Spc25 -0.469 6.631 -6.053 3.07E-06 3.68E-04 4.656 -1.38 
SPRR1A 0.334 8.643 3.880 7.21E-04 1.75E-02 -0.547 1.26 
STMN1 -0.319 7.260 -5.314 1.92E-05 1.41E-03 2.907 -1.25 
Tcf19 -0.307 5.912 -5.336 1.82E-05 1.41E-03 2.960 -1.24 
Tdgf1 0.291 6.194 4.317 2.39E-04 7.50E-03 0.501 1.22 
TFB1M -0.267 6.682 -3.827 8.22E-04 1.93E-02 -0.672 -1.20 
TMEM158 0.351 6.933 3.592 1.48E-03 3.07E-02 -1.226 1.28 
Tnfsf9 -0.386 6.765 -3.619 1.38E-03 2.97E-02 -1.161 -1.31 
Top2a -0.527 9.103 -6.684 6.72E-07 1.86E-04 6.102 -1.44 
Tpst1 -0.293 6.787 -6.932 3.75E-07 1.54E-04 6.656 -1.22 
TPX2 -0.429 6.219 -4.607 1.14E-04 4.54E-03 1.202 -1.35 
TUBA1C -0.299 9.068 -6.212 2.09E-06 2.89E-04 5.025 -1.23 
TUBB2C -0.309 8.450 -6.158 2.38E-06 3.09E-04 4.900 -1.24 
Tubb6 -0.270 7.128 -6.792 5.21E-07 1.56E-04 6.344 -1.21 
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5.2.6 pcDNA(S) v pcDNA(U) gene list 
 
Gene ID logFC AveExpr t P.Value adj.P.Val B Fold Change 
40790 -0.539 5.984 -6.104 2.72E-06 5.42E-05 4.013 -1.45 
1700052N19Rik 0.362 6.422 7.543 9.19E-08 3.24E-06 7.450 1.29 
1810037I17Rik -0.387 6.983 -7.248 1.80E-07 5.78E-06 6.765 -1.31 
2310001A20Rik 0.396 7.257 7.057 2.80E-07 8.25E-06 6.316 1.32 
2610002J02Rik -0.281 6.639 -5.302 1.98E-05 2.69E-04 2.008 -1.22 
4833417J20Rik -0.287 7.312 -4.094 4.20E-04 3.41E-03 -1.040 -1.22 
6430548M08Rik -1.301 5.381 -18.558 1.13E-15 2.89E-13 25.960 -2.46 
9530053H05Rik 1.406 10.002 24.358 2.36E-18 9.41E-16 32.088 2.65 
A330042M18Rik -0.793 7.205 -12.420 6.71E-12 8.61E-10 17.161 -1.73 
ABHD6 0.697 6.783 8.864 5.19E-09 2.78E-07 10.379 1.62 
Acp2 -0.317 6.448 -4.720 8.59E-05 9.26E-04 0.538 -1.25 
ADD3 -0.527 6.120 -4.466 1.64E-04 1.59E-03 -0.106 -1.44 
ADD3 -0.414 7.763 -8.646 8.21E-09 4.10E-07 9.912 -1.33 
AGAP1 -0.310 7.787 -3.202 3.84E-03 1.97E-02 -3.200 -1.24 
Agpat6 0.273 6.784 3.127 4.60E-03 2.27E-02 -3.374 1.21 
AI646531 -0.337 7.286 -4.206 3.16E-04 2.71E-03 -0.759 -1.26 
AI646531 -0.323 6.560 -5.427 1.45E-05 2.11E-04 2.325 -1.25 
Akap12 -0.805 7.889 -12.084 1.18E-11 1.33E-09 16.583 -1.75 
AMD1 -0.616 8.027 -7.175 2.13E-07 6.55E-06 6.594 -1.53 
AMD1 -0.596 7.422 -5.943 4.03E-06 7.47E-05 3.613 -1.51 
Amotl1 0.366 7.099 3.203 3.84E-03 1.97E-02 -3.199 1.29 
ANP32E -0.327 8.064 -4.700 9.05E-05 9.56E-04 0.485 -1.25 
AP1B1 -0.969 6.806 -18.368 1.42E-15 3.39E-13 25.729 -1.96 
APP -0.361 8.605 -3.729 1.05E-03 7.08E-03 -1.942 -1.28 
Arhgap25 0.428 6.665 5.144 2.94E-05 3.71E-04 1.610 1.35 
ASAP1 0.308 5.925 5.779 6.03E-06 1.03E-04 3.207 1.24 
Asf1b 0.316 5.939 3.769 9.50E-04 6.56E-03 -1.843 1.24 
Atp10a 0.328 7.352 7.689 6.61E-08 2.53E-06 7.785 1.26 
Atp5o -0.313 9.052 -6.584 8.53E-07 2.13E-05 5.185 -1.24 
AZIN1 -0.609 6.431 -8.401 1.38E-08 6.22E-07 9.378 -1.52 
Azin1 -0.477 6.442 -5.757 6.37E-06 1.07E-04 3.151 -1.39 
B230219D22Rik -0.547 8.128 -10.382 2.53E-10 2.07E-08 13.461 -1.46 
B230220B15Rik 2.634 7.506 55.056 1.22E-26 2.19E-23 49.455 6.21 
BAZ1A 0.271 6.516 3.161 4.24E-03 2.13E-02 -3.296 1.21 
BCL10 0.335 8.488 6.617 7.89E-07 2.01E-05 5.265 1.26 
BCLAF1 -0.387 6.690 -5.419 1.48E-05 2.13E-04 2.303 -1.31 
BCLAF1 -0.337 7.984 -5.407 1.52E-05 2.18E-04 2.273 -1.26 
BDNF 0.300 6.480 5.754 6.42E-06 1.08E-04 3.143 1.23 
BLVRB 0.280 8.858 2.921 7.51E-03 3.31E-02 -3.842 1.21 
BMI1 -0.925 6.386 -11.152 6.09E-11 5.91E-09 14.914 -1.90 
BRP44L -0.567 7.208 -3.552 1.63E-03 1.02E-02 -2.371 -1.48 
BRP44L -0.508 8.068 -11.357 4.21E-11 4.24E-09 15.290 -1.42 
Bsg -0.343 8.496 -3.879 7.22E-04 5.32E-03 -1.574 -1.27 
C12orf10 -0.279 6.223 -4.008 5.22E-04 4.11E-03 -1.254 -1.21 
C4orf27 -1.022 6.966 -20.607 1.07E-16 3.48E-14 28.316 -2.03 
CAMK2N1 -0.284 6.214 -3.786 9.12E-04 6.35E-03 -1.802 -1.22 
CANX 0.282 7.461 3.237 3.53E-03 1.85E-02 -3.120 1.22 
Cat 0.312 8.131 3.127 4.61E-03 2.27E-02 -3.375 1.24 
Ccl2 0.515 7.806 3.873 7.33E-04 5.36E-03 -1.588 1.43 
Ccnd1 -0.756 6.627 -8.905 4.77E-09 2.60E-07 10.465 -1.69 
CD36 -3.803 8.162 -19.069 6.12E-16 1.73E-13 26.571 -13.96 
CHMP2A -0.700 7.416 -14.088 4.71E-13 7.05E-11 19.864 -1.62 
CHPT1 0.282 8.437 5.060 3.64E-05 4.51E-04 1.398 1.22 
Cisd2 -0.332 6.498 -6.993 3.25E-07 9.35E-06 6.164 -1.26 
CITED2 0.532 6.419 5.636 8.60E-06 1.39E-04 2.848 1.45 
CKS1B 0.302 7.858 6.066 2.98E-06 5.88E-05 3.919 1.23 
Clstn1 -0.381 7.732 -5.532 1.11E-05 1.72E-04 2.589 -1.30 
Clu -0.291 10.477 -3.444 2.13E-03 1.27E-02 -2.631 -1.22 
Col5a1 -0.389 6.209 -6.254 1.89E-06 4.06E-05 4.380 -1.31 
COL5A2 0.455 7.606 6.256 1.88E-06 4.06E-05 4.387 1.37 
Commd3 -0.392 7.861 -9.346 1.93E-09 1.24E-07 11.388 -1.31 
CPD -0.372 7.815 -6.754 5.70E-07 1.52E-05 5.596 -1.29 
Cpn2 -0.287 6.648 -3.625 1.36E-03 8.87E-03 -2.194 -1.22 
Cr1l 0.264 8.857 6.210 2.10E-06 4.41E-05 4.273 1.20 
Cr1l 0.341 7.762 4.857 6.08E-05 6.96E-04 0.883 1.27 
CRELD2 0.347 7.396 4.828 6.54E-05 7.37E-04 0.810 1.27 
CROT 0.392 6.877 8.606 8.94E-09 4.32E-07 9.824 1.31 
CSE1L 0.334 7.389 6.342 1.52E-06 3.45E-05 4.597 1.26 
Csnk2a1 -0.486 6.763 -4.416 1.86E-04 1.76E-03 -0.230 -1.40 
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Cxcl1 0.569 6.634 6.649 7.31E-07 1.90E-05 5.342 1.48 
DAG1 0.269 8.711 4.153 3.61E-04 3.03E-03 -0.891 1.20 
DCTPP1 0.323 7.125 5.270 2.14E-05 2.84E-04 1.928 1.25 
Ddhd2 -0.285 7.529 -6.330 1.57E-06 3.52E-05 4.568 -1.22 
DDX3X -0.287 9.847 -3.311 2.95E-03 1.62E-02 -2.947 -1.22 
DNAJC3 0.283 6.786 5.523 1.14E-05 1.76E-04 2.564 1.22 
Dock9 0.493 6.569 7.624 7.65E-08 2.83E-06 7.637 1.41 
DST 0.289 6.933 4.109 4.05E-04 3.30E-03 -1.003 1.22 
DUSP1 -0.412 6.221 -6.382 1.38E-06 3.19E-05 4.694 -1.33 
Dusp3 -0.388 5.641 -4.219 3.06E-04 2.64E-03 -0.726 -1.31 
EBNA1BP2 -0.276 8.826 -4.836 6.40E-05 7.26E-04 0.831 -1.21 
EIF5 0.286 8.217 5.808 5.61E-06 9.64E-05 3.279 1.22 
EIF5 0.356 6.761 3.500 1.86E-03 1.13E-02 -2.497 1.28 
EPHX1 0.424 7.673 2.735 1.16E-02 4.57E-02 -4.252 1.34 
EPHX1 0.453 8.644 6.107 2.70E-06 5.41E-05 4.020 1.37 
ERAP1 0.297 6.611 6.284 1.75E-06 3.91E-05 4.456 1.23 
ERCC1 -0.628 6.529 -8.239 1.97E-08 8.51E-07 9.021 -1.55 
ERGIC2 -0.279 8.645 -5.980 3.67E-06 6.92E-05 3.707 -1.21 
Erp29 0.360 7.835 6.488 1.07E-06 2.61E-05 4.952 1.28 
ERP29 0.375 6.775 4.474 1.60E-04 1.56E-03 -0.084 1.30 
ESD 0.341 8.915 8.268 1.84E-08 8.07E-07 9.087 1.27 
ETHE1 -0.630 7.237 -9.019 3.77E-09 2.11E-07 10.706 -1.55 
EWSR1 -0.448 7.376 -12.214 9.50E-12 1.18E-09 16.807 -1.36 
Exosc1 -0.307 7.548 -4.126 3.87E-04 3.20E-03 -0.959 -1.24 
F2r -0.289 8.207 -3.200 3.86E-03 1.98E-02 -3.205 -1.22 
Fam100b -0.402 6.914 -5.643 8.45E-06 1.37E-04 2.866 -1.32 
FAM107B -0.470 6.765 -9.153 2.86E-09 1.66E-07 10.988 -1.38 
Fam125b -0.358 6.716 -6.934 3.73E-07 1.05E-05 6.025 -1.28 
FAM40B 0.322 6.679 5.483 1.26E-05 1.88E-04 2.465 1.25 
FBXO8 -1.223 6.542 -24.731 1.66E-18 7.75E-16 32.430 -2.33 
FCGRT -1.214 6.491 -17.744 3.06E-15 6.87E-13 24.955 -2.32 
Fhl1 -0.623 7.505 -14.259 3.64E-13 5.68E-11 20.126 -1.54 
Fkbp1a -0.313 9.533 -5.486 1.25E-05 1.88E-04 2.471 -1.24 
Fkbp9 0.310 7.631 6.013 3.39E-06 6.51E-05 3.788 1.24 
FMNL2 -0.399 7.362 -6.043 3.15E-06 6.15E-05 3.863 -1.32 
FOSL1 0.317 7.032 3.592 1.48E-03 9.49E-03 -2.276 1.25 
FOXJ3 -0.389 7.777 -7.035 2.95E-07 8.62E-06 6.264 -1.31 
Foxp2 -0.306 7.336 -4.848 6.22E-05 7.07E-04 0.860 -1.24 
G3BP2 -0.269 8.617 -5.032 3.91E-05 4.77E-04 1.326 -1.21 
GADD45B 0.460 6.746 6.776 5.41E-07 1.45E-05 5.648 1.38 
GALNT7 -0.997 7.466 -9.833 7.30E-10 5.38E-08 12.381 -2.00 
GAS1 -0.725 6.643 -7.667 6.94E-08 2.62E-06 7.736 -1.65 
GCLM 0.591 9.225 11.352 4.25E-11 4.24E-09 15.281 1.51 
GHR -0.421 6.655 -6.690 6.63E-07 1.75E-05 5.441 -1.34 
GJA1 -0.383 10.715 -5.221 2.43E-05 3.17E-04 1.804 -1.30 
Gm15104 0.278 6.022 4.934 5.01E-05 5.91E-04 1.077 1.21 
Gm6377 -0.332 8.134 -4.423 1.83E-04 1.74E-03 -0.215 -1.26 
Gmfb -0.375 8.592 -6.563 8.98E-07 2.21E-05 5.134 -1.30 
GNAI1 -0.478 7.278 -7.228 1.88E-07 5.94E-06 6.719 -1.39 
GOLGA7 -0.277 8.199 -5.500 1.21E-05 1.83E-04 2.508 -1.21 
GPC6 1.405 3.584 16.760 1.08E-14 2.29E-12 23.683 2.65 
Gpd2 0.348 6.879 4.567 1.27E-04 1.28E-03 0.150 1.27 
GPHN -0.270 6.426 -4.138 3.75E-04 3.14E-03 -0.928 -1.21 
Gpnmb -1.557 5.966 -24.691 1.73E-18 7.75E-16 32.393 -2.94 
Gpr56 -1.125 6.194 -14.319 3.32E-13 5.65E-11 20.217 -2.18 
Gpx4 0.445 10.579 8.509 1.10E-08 5.00E-07 9.614 1.36 
GSS 0.292 6.247 3.173 4.12E-03 2.08E-02 -3.268 1.22 
GSS 0.333 6.709 5.041 3.82E-05 4.68E-04 1.349 1.26 
Gss 0.402 8.655 8.590 9.25E-09 4.32E-07 9.789 1.32 
GSS 0.413 7.023 7.582 8.42E-08 2.99E-06 7.540 1.33 
GSTA5 0.381 9.606 7.147 2.28E-07 6.93E-06 6.528 1.30 
Gstm1 0.293 9.649 4.232 2.96E-04 2.58E-03 -0.694 1.23 
Gstm6 0.311 7.960 4.209 3.14E-04 2.70E-03 -0.752 1.24 
Gtf2h5 -0.264 6.911 -4.399 1.94E-04 1.82E-03 -0.273 -1.20 
GUSB 0.282 6.935 5.614 9.09E-06 1.44E-04 2.793 1.22 
HADHA 0.353 7.683 4.763 7.70E-05 8.44E-04 0.646 1.28 
HADHB 0.425 8.394 8.638 8.36E-09 4.11E-07 9.893 1.34 
Herpud1 0.395 6.811 8.909 4.73E-09 2.60E-07 10.474 1.32 
HEXIM1 -0.337 7.032 -4.871 5.86E-05 6.80E-04 0.919 -1.26 
HMGB1 -0.301 7.626 -5.234 2.35E-05 3.09E-04 1.837 -1.23 
HMGN2 -0.318 8.395 -7.443 1.15E-07 3.98E-06 7.221 -1.25 
HMOX1 0.383 7.105 4.435 1.77E-04 1.70E-03 -0.184 1.30 
Hnrnpa1 0.372 6.520 5.583 9.81E-06 1.54E-04 2.715 1.29 
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HSP90B1 0.421 10.245 6.599 8.24E-07 2.07E-05 5.221 1.34 
Hsp90b1 0.547 8.375 2.861 8.65E-03 3.69E-02 -3.976 1.46 
HSPA5 0.427 11.437 9.107 3.14E-09 1.79E-07 10.893 1.34 
HSPB1 0.340 9.142 5.224 2.40E-05 3.15E-04 1.813 1.27 
Hyou1 0.541 6.015 6.626 7.72E-07 1.98E-05 5.288 1.45 
IMMP1L -0.309 6.798 -4.651 1.02E-04 1.06E-03 0.362 -1.24 
Insig1 0.292 8.024 5.980 3.68E-06 6.92E-05 3.706 1.22 
Irak1 -0.287 6.508 -4.535 1.37E-04 1.37E-03 0.069 -1.22 
Irak2 0.379 6.582 5.322 1.88E-05 2.60E-04 2.059 1.30 
ITIH5 0.359 6.180 3.236 3.54E-03 1.85E-02 -3.121 1.28 
Jub 0.563 7.280 14.884 1.44E-13 2.59E-11 21.062 1.48 
LAMC1 0.274 7.195 5.602 9.35E-06 1.47E-04 2.763 1.21 
LAYN -0.449 6.973 -6.210 2.10E-06 4.41E-05 4.274 -1.37 
LOC100294264 0.405 6.932 4.858 6.05E-05 6.95E-04 0.887 1.32 
LOC685953 -3.528 9.130 -33.801 1.18E-21 1.06E-18 39.385 -11.53 
LOC732360 0.270 6.927 5.430 1.44E-05 2.11E-04 2.332 1.21 
LPP -0.270 7.853 -4.850 6.18E-05 7.05E-04 0.867 -1.21 
Lrp10 0.853 7.803 11.928 1.55E-11 1.68E-09 16.311 1.81 
LRRC8D 0.396 6.697 4.717 8.66E-05 9.29E-04 0.529 1.32 
MANF 0.439 8.744 7.953 3.67E-08 1.52E-06 8.385 1.36 
MAPK6 0.420 7.276 5.812 5.56E-06 9.64E-05 3.288 1.34 
MARK1 0.378 6.616 8.092 2.71E-08 1.16E-06 8.694 1.30 
MBNL2 -0.292 8.281 -6.841 4.64E-07 1.26E-05 5.804 -1.22 
MBNL2 -0.273 7.563 -4.764 7.69E-05 8.44E-04 0.648 -1.21 
ME1 0.342 7.376 7.333 1.48E-07 4.98E-06 6.964 1.27 
MGC112830 -0.264 6.352 -4.495 1.52E-04 1.49E-03 -0.031 -1.20 
MIR21 -0.291 6.244 -3.649 1.28E-03 8.45E-03 -2.136 -1.22 
Mknk2 -0.342 6.338 -4.872 5.84E-05 6.79E-04 0.923 -1.27 
Mknk2 -0.271 6.736 -3.039 5.68E-03 2.66E-02 -3.576 -1.21 
Mmp14 0.408 6.694 6.055 3.06E-06 6.01E-05 3.892 1.33 
MMP14 0.481 6.141 4.711 8.80E-05 9.42E-04 0.513 1.40 
MOBKL3 -0.298 6.352 -6.390 1.36E-06 3.17E-05 4.713 -1.23 
MRPS22 -0.278 6.359 -5.940 4.06E-06 7.47E-05 3.606 -1.21 
MTBP 0.302 6.107 5.722 6.95E-06 1.15E-04 3.064 1.23 
Mthfd2l 0.413 6.000 6.481 1.09E-06 2.63E-05 4.936 1.33 
Ncam1 0.678 5.358 7.535 9.35E-08 3.26E-06 7.433 1.60 
Ncapd3 0.351 5.993 4.980 4.45E-05 5.33E-04 1.195 1.28 
NCEH1 0.272 6.694 5.376 1.64E-05 2.33E-04 2.196 1.21 
NEIL3 0.384 7.798 5.431 1.43E-05 2.11E-04 2.335 1.31 
NFKBIA 0.499 8.519 7.083 2.64E-07 7.83E-06 6.379 1.41 
NFKBIA 0.540 8.243 8.716 7.09E-09 3.64E-07 10.061 1.45 
Nid1 0.304 8.249 4.215 3.10E-04 2.67E-03 -0.738 1.23 
NUCB2 0.519 7.514 9.817 7.54E-10 5.42E-08 12.347 1.43 
Nudt3 -0.276 6.423 -3.269 3.27E-03 1.75E-02 -3.045 -1.21 
OAZ1 0.439 7.602 8.015 3.20E-08 1.34E-06 8.523 1.36 
OAZ1 0.553 7.862 7.301 1.59E-07 5.16E-06 6.891 1.47 
OAZ2 0.446 6.880 7.707 6.34E-08 2.45E-06 7.827 1.36 
PALLD 0.583 7.134 11.895 1.64E-11 1.73E-09 16.252 1.50 
PCGF5 0.308 6.328 6.266 1.83E-06 4.04E-05 4.411 1.24 
PCK2 0.350 6.594 5.313 1.93E-05 2.63E-04 2.036 1.27 
PDIA3 0.334 9.730 5.375 1.65E-05 2.33E-04 2.194 1.26 
PDIA4 0.409 7.671 8.696 7.39E-09 3.74E-07 10.018 1.33 
PDIA5 0.349 7.082 5.420 1.47E-05 2.13E-04 2.307 1.27 
PDIA6 0.431 10.091 10.636 1.57E-10 1.38E-08 13.948 1.35 
PDLIM1 0.434 7.184 9.228 2.45E-09 1.47E-07 11.145 1.35 
Pdyn -0.321 7.034 -3.722 1.07E-03 7.19E-03 -1.960 -1.25 
Pex19 -0.311 6.163 -6.399 1.33E-06 3.14E-05 4.736 -1.24 
Pgs1 0.401 6.290 5.937 4.08E-06 7.47E-05 3.600 1.32 
Pir 0.538 6.603 7.899 4.14E-08 1.66E-06 8.262 1.45 
PJA1 -0.510 7.598 -12.142 1.07E-11 1.24E-09 16.683 -1.42 
PLAC8 -2.139 5.438 -21.416 4.45E-17 1.60E-14 29.185 -4.40 
PLK2 0.711 7.605 13.952 5.79E-13 8.33E-11 19.653 1.64 
PLTP -0.372 7.226 -2.834 9.22E-03 3.86E-02 -4.036 -1.29 
POLR2G -0.320 8.219 -7.897 4.15E-08 1.66E-06 8.258 -1.25 
Ppcs -0.297 7.062 -5.275 2.12E-05 2.82E-04 1.940 -1.23 
PPP1CB -0.283 9.069 -4.325 2.34E-04 2.13E-03 -0.460 -1.22 
PPP2R1A -0.771 6.065 -6.839 4.66E-07 1.26E-05 5.799 -1.71 
PRCP 0.274 7.535 6.572 8.78E-07 2.18E-05 5.156 1.21 
PRKCDBP 0.303 6.389 2.813 9.66E-03 4.00E-02 -4.080 1.23 
Prmt5 0.690 7.197 9.281 2.20E-09 1.37E-07 11.254 1.61 
Procr 0.571 6.220 8.555 9.96E-09 4.59E-07 9.714 1.49 
PSMB5 0.459 9.145 4.934 5.00E-05 5.91E-04 1.079 1.37 
PSMC4 -0.278 7.500 -3.967 5.78E-04 4.46E-03 -1.355 -1.21 
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PSMC5 -0.278 7.802 -6.967 3.46E-07 9.85E-06 6.103 -1.21 
PSMC5 -0.276 7.329 -3.127 4.61E-03 2.27E-02 -3.376 -1.21 
PSME4 0.552 7.404 9.278 2.21E-09 1.37E-07 11.248 1.47 
PTPRG 2.300 5.545 45.692 9.97E-25 1.19E-21 45.776 4.93 
PURB -0.330 7.313 -5.774 6.10E-06 1.04E-04 3.194 -1.26 
RAB11A 0.307 5.948 2.938 7.21E-03 3.21E-02 -3.804 1.24 
Rab31 -0.463 6.713 -5.725 6.90E-06 1.15E-04 3.071 -1.38 
Rapgef1 -0.264 9.228 -5.438 1.41E-05 2.09E-04 2.352 -1.20 
Rbck1 -0.504 6.528 -6.022 3.32E-06 6.43E-05 3.809 -1.42 
RBM3 0.315 7.415 3.133 4.54E-03 2.25E-02 -3.361 1.24 
Rere -0.400 6.955 -4.719 8.61E-05 9.26E-04 0.536 -1.32 
RFX7 -0.297 7.777 -4.113 4.01E-04 3.27E-03 -0.993 -1.23 
RGS17 -1.022 7.346 -10.533 1.90E-10 1.63E-08 13.752 -2.03 
RIOK3 -0.293 7.168 -4.106 4.07E-04 3.31E-03 -1.008 -1.23 
RNF10 -0.295 7.472 -5.339 1.80E-05 2.53E-04 2.103 -1.23 
RPP14 0.291 6.393 4.312 2.42E-04 2.18E-03 -0.492 1.22 
Rps28 0.311 8.402 3.260 3.34E-03 1.78E-02 -3.066 1.24 
RPS5 -0.414 11.111 -9.162 2.81E-09 1.65E-07 11.006 -1.33 
SAT1 0.427 6.704 8.816 5.75E-09 3.04E-07 10.275 1.34 
SBSN 0.350 9.801 5.918 4.28E-06 7.70E-05 3.552 1.27 
SBSN 0.452 6.788 5.059 3.65E-05 4.51E-04 1.394 1.37 
SCD -0.429 7.564 -4.585 1.21E-04 1.23E-03 0.195 -1.35 
Scd3 -0.417 8.588 -10.020 5.07E-10 3.88E-08 12.751 -1.34 
SEC24D 0.341 7.004 4.720 8.59E-05 9.26E-04 0.538 1.27 
SEL1L 0.580 7.016 6.135 2.52E-06 5.14E-05 4.089 1.49 
SELS 0.277 6.598 5.942 4.04E-06 7.47E-05 3.611 1.21 
SEMA3C -0.617 6.612 -10.704 1.38E-10 1.24E-08 14.078 -1.53 
Sepp1 -0.492 9.267 -7.592 8.23E-08 2.99E-06 7.562 -1.41 
Serpinh1 0.363 8.949 6.003 3.48E-06 6.61E-05 3.763 1.29 
SERPINH1 0.379 8.798 4.130 3.83E-04 3.18E-03 -0.949 1.30 
SERPINH1 0.395 9.252 12.158 1.04E-11 1.24E-09 16.712 1.32 
SF3B3 0.269 7.166 3.518 1.77E-03 1.09E-02 -2.452 1.20 
SGCE -0.729 6.005 -5.656 8.18E-06 1.33E-04 2.898 -1.66 
SGK1 -0.593 7.327 -9.533 1.32E-09 8.96E-08 11.774 -1.51 
SHMT2 0.310 6.208 3.041 5.65E-03 2.65E-02 -3.572 1.24 
SLC7A1 0.266 7.369 2.709 1.23E-02 4.78E-02 -4.308 1.20 
Slc7a11 0.362 7.310 4.303 2.47E-04 2.22E-03 -0.515 1.28 
SMPD1 0.311 6.885 5.172 2.75E-05 3.52E-04 1.680 1.24 
Smpd1 0.326 6.110 3.465 2.02E-03 1.22E-02 -2.580 1.25 
SNAP23 -0.350 7.105 -7.884 4.28E-08 1.69E-06 8.229 -1.27 
Snn 0.451 6.495 5.833 5.27E-06 9.24E-05 3.341 1.37 
SNRPA1 0.318 7.859 5.622 8.89E-06 1.42E-04 2.814 1.25 
SNRPD2 -0.423 8.788 -6.352 1.49E-06 3.39E-05 4.621 -1.34 
SPIN1 -0.263 7.093 -3.760 9.73E-04 6.69E-03 -1.866 -1.20 
SPRR1A 0.741 8.643 8.596 9.12E-09 4.32E-07 9.804 1.67 
Srpr -0.516 10.118 -3.101 4.90E-03 2.37E-02 -3.434 -1.43 
Srpr -0.460 10.831 -3.831 8.15E-04 5.78E-03 -1.692 -1.38 
Srpr 0.335 8.041 7.608 7.93E-08 2.91E-06 7.600 1.26 
SSU72 0.596 7.371 9.375 1.82E-09 1.19E-07 11.449 1.51 
STIM2 -0.293 6.458 -3.584 1.51E-03 9.61E-03 -2.293 -1.23 
STMN1 -0.590 7.260 -9.831 7.33E-10 5.38E-08 12.376 -1.51 
SUPT16H 0.274 10.402 3.780 9.24E-04 6.41E-03 -1.816 1.21 
SYNCRIP -1.013 6.547 -15.239 8.67E-14 1.64E-11 21.579 -2.02 
SYNCRIP -0.875 6.514 -4.587 1.21E-04 1.23E-03 0.200 -1.83 
Tbc1d1 -0.291 7.646 -5.143 2.95E-05 3.71E-04 1.608 -1.22 
Tcf19 -0.354 5.912 -6.157 2.39E-06 4.93E-05 4.142 -1.28 
TDP2 0.265 6.488 6.383 1.38E-06 3.19E-05 4.696 1.20 
Tes 0.417 6.550 8.595 9.15E-09 4.32E-07 9.801 1.34 
Tes 0.500 7.629 8.383 1.44E-08 6.39E-07 9.338 1.41 
TFPI 0.552 7.291 6.892 4.12E-07 1.14E-05 5.925 1.47 
Thbd -0.557 7.746 -6.436 1.22E-06 2.89E-05 4.826 -1.47 
TIMP2 -0.403 8.474 -5.828 5.35E-06 9.33E-05 3.327 -1.32 
Timp2 -0.381 7.474 -4.925 5.11E-05 5.98E-04 1.057 -1.30 
Tinagl1 0.442 6.534 3.906 6.75E-04 5.03E-03 -1.506 1.36 
TKT 0.281 6.994 6.210 2.10E-06 4.41E-05 4.272 1.21 
TM2D3 0.274 6.682 6.647 7.35E-07 1.90E-05 5.336 1.21 
Tm9sf3 -0.370 6.640 -7.198 2.02E-07 6.32E-06 6.648 -1.29 
Tmem138 -0.322 6.341 -3.197 3.89E-03 1.99E-02 -3.212 -1.25 
Tmem167b -0.309 6.863 -6.917 3.88E-07 1.08E-05 5.984 -1.24 
TMEM38B -0.359 6.934 -6.181 2.25E-06 4.68E-05 4.201 -1.28 
TMSB4X -0.386 10.469 -7.319 1.53E-07 4.99E-06 6.932 -1.31 
Tnfaip3 0.498 5.235 5.447 1.37E-05 2.05E-04 2.376 1.41 
Tnfsf9 1.035 6.765 9.703 9.43E-10 6.52E-08 12.119 2.05 
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TRIB1 -0.287 6.683 -4.125 3.88E-04 3.21E-03 -0.962 -1.22 
TSC22D3 -0.379 6.584 -7.319 1.53E-07 4.99E-06 6.933 -1.30 
TSPO -0.292 8.531 -3.891 6.99E-04 5.19E-03 -1.542 -1.22 
TUBA1A -0.579 8.193 -6.614 7.95E-07 2.01E-05 5.257 -1.49 
UAP1 0.320 6.881 5.192 2.61E-05 3.39E-04 1.732 1.25 
UAP1L1 -0.292 6.485 -3.264 3.31E-03 1.77E-02 -3.057 -1.22 
Ube2s -0.424 7.516 -5.147 2.92E-05 3.69E-04 1.618 -1.34 
USP46 -0.421 6.354 -6.256 1.88E-06 4.06E-05 4.387 -1.34 
UTP18 0.300 7.550 7.324 1.51E-07 4.99E-06 6.944 1.23 
VAMP7 -0.394 6.650 -4.882 5.70E-05 6.65E-04 0.948 -1.31 
VCAM1 -0.611 6.411 -7.178 2.12E-07 6.55E-06 6.601 -1.53 
VIM -0.321 8.032 -5.580 9.87E-06 1.54E-04 2.710 -1.25 
VMA21 -0.356 7.724 -5.511 1.17E-05 1.79E-04 2.535 -1.28 
VNN1 0.850 6.056 15.542 5.65E-14 1.13E-11 22.012 1.80 
Vps36 -0.304 6.947 -6.097 2.76E-06 5.49E-05 3.994 -1.23 
Wdfy4 -1.071 6.002 -10.082 4.49E-10 3.51E-08 12.875 -2.10 
WWC3 0.268 6.647 5.336 1.82E-05 2.53E-04 2.094 1.20 
Ybx1 -0.475 11.304 -10.367 2.60E-10 2.08E-08 13.431 -1.39 
YPEL3 0.264 7.458 5.100 3.29E-05 4.11E-04 1.498 1.20 
Ywhab -0.284 7.203 -4.457 1.68E-04 1.62E-03 -0.128 -1.22 
YWHAQ -0.306 7.581 -6.560 9.03E-07 2.21E-05 5.128 -1.24 
ZC3HAV1 -0.385 7.214 -7.139 2.32E-07 6.97E-06 6.510 -1.31 
Zfp110 -0.507 6.538 -12.599 4.98E-12 6.63E-10 17.464 -1.42 
ZFR -0.349 8.429 -4.435 1.77E-04 1.70E-03 -0.184 -1.27 
ZMYND11 -0.270 7.803 -7.583 8.40E-08 2.99E-06 7.542 -1.21 
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5.2.7 TBP(S) v TBP(U) gene list 
 
Gene ID logFC AveExpr t P.Value adj.P.Val B Fold Change 
40790 -0.920 5.984 -10.426 2.33E-10 1.09E-08 13.635 -1.89 
1810037I17Rik -0.284 6.983 -5.324 1.87E-05 1.74E-04 2.182 -1.22 
2310014D11Rik -0.417 6.536 -5.710 7.16E-06 7.91E-05 3.149 -1.33 
2610002J02Rik -0.369 6.639 -6.956 3.54E-07 6.43E-06 6.188 -1.29 
2810025M15Rik 0.388 6.900 7.035 2.95E-07 5.41E-06 6.375 1.31 
2810474O19Rik -0.317 7.272 -6.092 2.80E-06 3.71E-05 4.098 -1.25 
3110062M04Rik -0.317 7.493 -6.576 8.69E-07 1.36E-05 5.279 -1.25 
4833417J20Rik -0.643 7.312 -9.178 2.71E-09 9.41E-08 11.139 -1.56 
6430548M08Rik -1.508 5.381 -21.499 4.08E-17 1.63E-14 29.246 -2.84 
9530053H05Rik 0.650 10.002 11.267 4.95E-11 3.08E-09 15.209 1.57 
9530053H05Rik 0.675 9.988 13.204 2.85E-13 2.12E-11 20.257 1.60 
ABHD6 0.971 6.783 12.352 7.53E-12 6.06E-10 17.119 1.96 
ABHD6 0.985 6.770 14.034 6.74E-14 5.87E-12 21.715 1.98 
Acat2 -0.541 6.811 -8.186 2.20E-08 5.70E-07 9.009 -1.46 
ACLY -0.355 8.199 -6.349 1.50E-06 2.18E-05 4.727 -1.28 
ACO1 -0.466 6.759 -14.486 2.59E-13 3.88E-11 20.526 -1.38 
Acp2 -0.319 6.448 -4.751 7.95E-05 5.85E-04 0.734 -1.25 
ACTB -0.270 7.958 -3.245 3.46E-03 1.33E-02 -2.977 -1.21 
Adam10 -0.301 8.078 -4.640 1.05E-04 7.28E-04 0.454 -1.23 
ADD3 -0.595 7.763 -12.417 6.75E-12 5.77E-10 17.230 -1.51 
ADD3 -0.586 6.120 -4.971 4.55E-05 3.68E-04 1.291 -1.50 
ADH5 -0.406 8.532 -2.993 6.34E-03 2.14E-02 -3.556 -1.33 
ADH5 -0.348 9.619 -4.755 7.87E-05 5.80E-04 0.745 -1.27 
ADNP -0.277 7.851 -2.881 8.26E-03 2.64E-02 -3.808 -1.21 
AF085738 -0.334 10.908 -7.604 8.00E-08 1.71E-06 7.699 -1.26 
AFTPH 0.426 7.139 5.937 4.09E-06 4.98E-05 3.714 1.34 
AIMP1 0.274 8.513 6.637 7.52E-07 1.22E-05 5.425 1.21 
Akap12 -0.393 7.889 -5.893 4.55E-06 5.43E-05 3.607 -1.31 
AKIRIN2 0.448 6.069 5.886 4.63E-06 5.47E-05 3.588 1.36 
AKR1B10 0.349 9.869 10.843 1.07E-10 5.59E-09 14.426 1.27 
Akr7a5 -0.280 6.496 -3.228 3.61E-03 1.37E-02 -3.016 -1.21 
AMD1 0.502 7.422 5.004 4.19E-05 3.42E-04 1.376 1.42 
AMD1 0.538 8.027 6.257 1.87E-06 2.67E-05 4.501 1.45 
AMD1 0.570 7.999 7.163 1.08E-07 1.47E-06 7.222 1.48 
Amotl1 0.385 7.099 3.371 2.55E-03 1.04E-02 -2.680 1.31 
AMOTL2 -0.528 8.057 -5.126 3.08E-05 2.60E-04 1.683 -1.44 
Anxa4 -0.367 7.155 -6.401 1.32E-06 1.96E-05 4.854 -1.29 
ARHGAP24 -0.558 7.747 -7.440 1.16E-07 2.42E-06 7.321 -1.47 
ARHGEF6 -0.316 7.955 -4.923 5.14E-05 4.06E-04 1.170 -1.24 
Arl15 -0.458 6.329 -7.884 4.28E-08 9.92E-07 8.334 -1.37 
ARL6IP5 -0.277 7.904 -6.589 8.42E-07 1.33E-05 5.311 -1.21 
ARPC3 -0.275 7.652 -2.984 6.47E-03 2.17E-02 -3.576 -1.21 
Asf1b 0.326 5.939 3.888 7.06E-04 3.57E-03 -1.429 1.25 
ASNSD1 0.359 8.235 5.539 1.09E-05 1.13E-04 2.721 1.28 
ASRGL1 0.315 6.420 6.029 3.26E-06 4.18E-05 3.942 1.24 
Atf5 -0.343 9.270 -2.954 6.95E-03 2.29E-02 -3.644 -1.27 
Atf6 0.288 8.404 6.089 2.82E-06 3.72E-05 4.090 1.22 
Atp10a -0.264 7.352 -6.185 2.23E-06 3.06E-05 4.326 -1.20 
ATP5G2 0.301 8.724 2.880 8.26E-03 2.64E-02 -3.808 1.23 
Aurka 0.460 6.331 5.854 5.02E-06 5.85E-05 3.508 1.38 
B230220B15Rik 2.133 7.506 44.582 1.78E-24 6.40E-21 44.832 4.39 
B230220B15Rik 2.134 7.476 47.135 2.11E-27 7.54E-24 51.591 4.39 
B630006N21Rik 0.347 7.660 5.137 2.99E-05 2.54E-04 1.711 1.27 
BCL2L2 0.288 6.311 6.361 1.46E-06 2.15E-05 4.756 1.22 
BDNF 0.627 6.480 12.041 1.28E-11 9.60E-10 16.585 1.54 
BDNF 0.634 6.492 12.627 8.06E-13 5.53E-11 19.203 1.55 
BHLHE41 -0.423 6.897 -7.335 1.47E-07 2.96E-06 7.078 -1.34 
BMI1 -0.569 6.386 -6.861 4.43E-07 7.79E-06 5.963 -1.48 
Bnip2 0.337 6.652 4.333 2.29E-04 1.40E-03 -0.318 1.26 
BTG3 0.353 7.374 3.905 6.76E-04 3.45E-03 -1.386 1.28 
Bub3 0.268 7.159 5.989 3.60E-06 4.47E-05 3.844 1.20 
C11orf31 0.397 6.301 7.771 5.51E-08 1.23E-06 8.078 1.32 
C12orf10 0.432 6.223 6.205 2.12E-06 2.94E-05 4.375 1.35 
C18orf49 -0.889 6.640 -10.766 1.23E-10 6.24E-09 14.281 -1.85 
C1GALT1C1 -0.374 7.060 -7.542 9.21E-08 1.95E-06 7.555 -1.30 
C1R -0.434 9.482 -5.506 1.19E-05 1.20E-04 2.639 -1.35 
C3 -1.251 7.330 -22.795 1.08E-17 5.52E-15 30.548 -2.38 
C78376 -0.460 7.959 -7.350 1.42E-07 2.87E-06 7.113 -1.38 
C80142 0.673 6.839 6.075 2.91E-06 3.81E-05 4.056 1.59 
C80142 0.676 6.833 7.034 1.49E-07 1.96E-06 6.896 1.60 
CACHD1 0.301 6.534 5.869 4.83E-06 5.69E-05 3.546 1.23 
CALD1 -0.723 7.673 -5.660 8.10E-06 8.79E-05 3.025 -1.65 
CALD1 -0.643 7.225 -7.252 1.78E-07 3.45E-06 6.884 -1.56 
CAMK2N1 -0.392 6.214 -5.228 2.38E-05 2.13E-04 1.941 -1.31 
CAMLG 0.276 7.728 6.244 1.93E-06 2.71E-05 4.472 1.21 
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CAPZB -0.271 7.784 -4.947 4.84E-05 3.86E-04 1.231 -1.21 
CBX5 0.319 7.118 3.077 5.19E-03 1.81E-02 -3.365 1.25 
CCDC80 -0.468 8.173 -5.440 1.40E-05 1.37E-04 2.475 -1.38 
CCDC80 -0.282 7.753 -2.751 1.12E-02 3.40E-02 -4.092 -1.22 
Ccl2 0.664 7.826 5.410 1.03E-05 7.33E-05 2.631 1.58 
Ccl2 0.744 7.806 5.591 9.62E-06 1.00E-04 2.852 1.67 
Ccna2 0.393 6.788 3.073 5.23E-03 1.82E-02 -3.373 1.31 
CCNB1 0.506 5.956 3.556 1.61E-03 7.21E-03 -2.238 1.42 
Ccnb1 0.534 7.434 6.349 1.50E-06 2.18E-05 4.727 1.45 
CCNB1 0.585 5.963 4.418 1.46E-04 7.20E-04 -0.017 1.50 
Ccnb1 0.590 7.409 7.337 6.97E-08 1.04E-06 7.662 1.50 
Ccnd1 0.437 6.627 5.144 2.94E-05 2.51E-04 1.728 1.35 
CCNDBP1 0.331 7.359 5.210 2.49E-05 2.19E-04 1.895 1.26 
CD36 -3.316 8.162 -16.626 1.29E-14 2.73E-12 23.539 -9.96 
Cd81 -0.378 8.075 -7.328 1.50E-07 2.99E-06 7.061 -1.30 
CDC20 0.415 7.231 4.306 2.46E-04 1.48E-03 -0.388 1.33 
CDK1 0.323 8.673 5.037 3.86E-05 3.18E-04 1.458 1.25 
CDKN3 0.294 8.297 3.399 2.38E-03 9.88E-03 -2.614 1.23 
Cenpa 0.629 7.615 6.686 6.70E-07 1.10E-05 5.543 1.55 
Cenpa 0.699 7.609 7.657 3.17E-08 5.25E-07 8.463 1.62 
CES1 -0.737 3.649 -7.357 1.40E-07 2.85E-06 7.128 -1.67 
Chchd3 0.284 6.879 6.427 1.24E-06 1.87E-05 4.918 1.22 
CHMP2A -0.837 7.416 -16.841 9.72E-15 2.18E-12 23.822 -1.79 
Cidec 0.288 6.285 5.718 7.02E-06 7.80E-05 3.170 1.22 
CKS1B 0.415 7.858 8.337 1.59E-08 4.39E-07 9.342 1.33 
Clec2e -0.634 5.756 -6.004 3.47E-06 4.36E-05 3.880 -1.55 
Cmas 0.322 8.324 9.176 2.72E-09 9.41E-08 11.135 1.25 
COBLL1 -0.296 6.463 -5.541 1.09E-05 1.13E-04 2.728 -1.23 
Col12a1 -0.657 6.218 -13.697 8.58E-13 1.14E-10 19.317 -1.58 
COL16A1 -0.632 6.726 -8.919 4.63E-09 1.48E-07 10.596 -1.55 
Col5a1 -1.209 6.209 -19.447 3.94E-16 1.29E-13 27.012 -2.31 
COPG2 -0.341 6.694 -2.802 9.91E-03 3.08E-02 -3.980 -1.27 
CPD -0.420 7.815 -7.618 7.76E-08 1.68E-06 7.730 -1.34 
Cpn2 -2.253 6.648 -28.478 6.40E-20 4.60E-17 35.464 -4.77 
CRELD1 0.358 6.519 3.598 1.45E-03 6.60E-03 -2.136 1.28 
CRELD2 0.271 7.396 3.781 9.24E-04 4.47E-03 -1.693 1.21 
CSDA 0.269 7.938 3.813 8.51E-04 4.17E-03 -1.612 1.20 
Csf1 -0.702 7.153 -12.334 7.76E-12 6.06E-10 17.089 -1.63 
CSNK2A2 0.296 7.248 4.272 2.68E-04 1.58E-03 -0.472 1.23 
Ctla2b 0.293 7.178 3.424 2.24E-03 9.39E-03 -2.554 1.23 
CTNNB1 -0.275 7.234 -3.022 5.91E-03 2.02E-02 -3.489 -1.21 
CTSH -0.384 6.886 -6.392 1.35E-06 2.00E-05 4.831 -1.31 
Cxx1a -0.354 6.694 -5.511 1.17E-05 1.20E-04 2.651 -1.28 
CYB5R1 0.400 6.816 6.240 1.95E-06 2.72E-05 4.461 1.32 
Cyb5r3 -0.293 7.652 -4.679 9.53E-05 6.72E-04 0.553 -1.22 
Cyp51 -0.427 9.644 -7.939 3.78E-08 9.01E-07 8.459 -1.34 
D5Ertd579e -0.474 6.408 -9.845 7.12E-10 2.94E-08 12.499 -1.39 
D5Ertd579e -0.377 7.211 -9.375 1.82E-09 6.74E-08 11.546 -1.30 
DAG1 -0.408 7.183 -6.151 2.42E-06 3.28E-05 4.243 -1.33 
DAG1 -0.359 8.711 -5.541 1.09E-05 1.13E-04 2.726 -1.28 
DBF4 0.327 6.260 4.237 2.93E-04 1.70E-03 -0.561 1.25 
Dbi -0.424 8.412 -6.835 4.71E-07 8.22E-06 5.900 -1.34 
DCTPP1 0.294 7.125 4.810 6.84E-05 5.19E-04 0.884 1.23 
DDIT3 0.415 6.496 4.349 2.20E-04 1.35E-03 -0.278 1.33 
DDX1 0.265 6.903 5.858 4.97E-06 5.83E-05 3.518 1.20 
DDX39 0.303 7.395 4.745 8.07E-05 5.88E-04 0.719 1.23 
Dkc1 0.292 7.108 4.479 1.59E-04 1.03E-03 0.047 1.22 
DLGAP5 0.441 6.521 4.778 7.42E-05 5.52E-04 0.803 1.36 
Dmtf1 0.464 6.932 5.593 9.56E-06 1.00E-04 2.858 1.38 
DNAJA3 0.308 7.151 7.939 3.79E-08 9.01E-07 8.458 1.24 
DNAJA3 0.338 6.546 2.999 6.25E-03 2.11E-02 -3.543 1.26 
DNTTIP1 0.291 6.557 5.229 2.38E-05 2.13E-04 1.943 1.22 
Dpp3 -0.310 6.723 -4.331 2.31E-04 1.40E-03 -0.325 -1.24 
Dram1 -0.581 6.300 -9.574 1.22E-09 4.81E-08 11.953 -1.50 
DUSP1 -0.661 6.221 -10.244 3.29E-10 1.48E-08 13.284 -1.58 
E130203B14Rik -0.415 8.135 -5.084 3.43E-05 2.87E-04 1.576 -1.33 
ECT2 0.529 7.232 5.472 1.29E-05 1.29E-04 2.555 1.44 
ECT2 0.586 7.200 6.441 6.79E-07 7.23E-06 5.362 1.50 
EEF1E1 0.313 7.790 5.258 2.21E-05 2.01E-04 2.016 1.24 
EFEMP1 0.619 9.518 11.287 1.04E-11 4.52E-10 16.608 1.54 
EFEMP1 0.632 9.515 10.398 2.46E-10 1.13E-08 13.581 1.55 
EIF2A 0.349 7.926 7.036 2.94E-07 5.41E-06 6.376 1.27 
EIF2AK1 0.296 7.446 5.893 4.56E-06 5.43E-05 3.605 1.23 
EIF3A 0.272 6.909 4.815 6.75E-05 5.13E-04 0.898 1.21 
EIF3C 0.264 9.095 5.705 7.24E-06 7.98E-05 3.138 1.20 
EIF3G 0.313 9.161 6.125 2.58E-06 3.46E-05 4.178 1.24 
EIF3H 0.271 8.828 5.923 4.23E-06 5.08E-05 3.679 1.21 
EIF3H 0.297 8.385 2.569 1.69E-02 4.77E-02 -4.480 1.23 
Eif4a1 -0.554 8.429 -3.208 3.79E-03 1.42E-02 -3.064 -1.47 
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Eif4a1 -0.490 9.235 -11.418 3.78E-11 2.51E-09 15.483 -1.40 
Eif4ebp1 0.323 7.889 2.771 1.07E-02 3.27E-02 -4.049 1.25 
Eif4g2 -0.297 8.282 -5.531 1.12E-05 1.15E-04 2.703 -1.23 
EIF4G3 -0.317 7.477 -4.128 3.86E-04 2.15E-03 -0.833 -1.25 
EIF5 -0.491 8.217 -9.970 5.59E-10 2.39E-08 12.746 -1.41 
EIF5 -0.418 6.761 -4.113 4.01E-04 2.22E-03 -0.871 -1.34 
EIF6 0.268 8.152 3.205 3.81E-03 1.43E-02 -3.070 1.20 
EMP1 0.340 7.772 6.812 4.97E-07 8.59E-06 5.844 1.27 
EPR1 0.284 7.818 3.522 1.76E-03 7.73E-03 -2.320 1.22 
EPS8 0.396 8.261 4.412 1.88E-04 1.19E-03 -0.121 1.32 
ERCC1 -0.963 6.529 -12.634 4.71E-12 4.45E-10 17.595 -1.95 
Erlin1 0.367 6.942 7.325 1.51E-07 2.99E-06 7.055 1.29 
Ern1 0.338 6.120 5.424 1.46E-05 1.42E-04 2.434 1.26 
ETHE1 -0.926 7.237 -13.266 1.69E-12 1.96E-10 18.632 -1.90 
Exosc1 0.290 7.548 3.891 7.01E-04 3.56E-03 -1.422 1.22 
F2r -0.756 8.207 -8.373 1.47E-08 4.10E-07 9.420 -1.69 
Fam102b -0.430 7.655 -5.605 9.29E-06 9.88E-05 2.887 -1.35 
FAM107B -0.694 6.765 -13.525 1.12E-12 1.44E-10 19.046 -1.62 
Fasn -0.349 6.330 -3.496 1.87E-03 8.16E-03 -2.382 -1.27 
FCGRT -0.789 6.491 -11.527 3.11E-11 2.19E-09 15.680 -1.73 
FDPS -0.307 8.124 -5.243 2.30E-05 2.08E-04 1.977 -1.24 
Fez2 0.281 7.112 6.295 1.71E-06 2.45E-05 4.596 1.22 
Fhl1 -0.569 7.505 -13.027 2.48E-12 2.70E-10 18.245 -1.48 
Fhl2 0.775 6.253 18.283 1.06E-16 2.22E-14 28.220 1.71 
Fhl2 0.808 6.258 18.389 1.38E-15 3.82E-13 25.769 1.75 
FN1 -0.696 8.505 -13.910 6.18E-13 8.53E-11 19.649 -1.62 
FNIP2 -0.342 7.370 -5.206 2.52E-05 2.20E-04 1.885 -1.27 
FOSL1 0.704 7.029 8.555 3.71E-09 7.88E-08 10.637 1.63 
FOSL1 0.730 7.032 8.282 1.79E-08 4.83E-07 9.220 1.66 
FOXJ2 0.276 5.870 2.653 1.40E-02 4.06E-02 -4.302 1.21 
FSTL1 -0.409 8.751 -9.808 7.67E-10 3.13E-08 12.423 -1.33 
FUCA1 0.482 7.522 9.586 1.19E-09 4.75E-08 11.976 1.40 
GADD45A 0.703 8.855 10.536 1.89E-10 9.21E-09 13.846 1.63 
GADD45A 0.743 8.839 12.190 1.82E-12 1.01E-10 18.378 1.67 
GADD45B -0.389 6.746 -5.725 6.89E-06 7.68E-05 3.188 -1.31 
GALNT7 -0.395 7.466 -3.891 7.00E-04 3.56E-03 -1.421 -1.31 
GAMT -0.455 6.280 -5.665 7.99E-06 8.70E-05 3.038 -1.37 
GAS1 -1.275 6.643 -13.490 1.19E-12 1.47E-10 18.991 -2.42 
GCLM 0.579 9.225 11.125 6.39E-11 3.89E-09 14.949 1.49 
GCLM 0.614 9.205 12.496 1.03E-12 6.20E-11 18.958 1.53 
GGA2 -0.504 8.255 -13.270 1.68E-12 1.96E-10 18.639 -1.42 
GGA2 -0.391 6.153 -4.943 4.88E-05 3.88E-04 1.222 -1.31 
GHR -0.658 6.655 -10.451 2.22E-10 1.06E-08 13.683 -1.58 
Ghr 0.344 6.285 6.063 3.00E-06 3.88E-05 4.026 1.27 
GJA1 -0.319 10.715 -4.357 2.16E-04 1.33E-03 -0.258 -1.25 
Gm10397 -0.283 7.405 -5.431 1.43E-05 1.40E-04 2.452 -1.22 
Gm6377 -0.347 8.134 -4.621 1.10E-04 7.54E-04 0.407 -1.27 
GNAI1 -0.508 7.278 -7.690 6.60E-08 1.45E-06 7.894 -1.42 
GPAM -0.317 7.859 -7.605 7.99E-08 1.71E-06 7.699 -1.25 
GPC6 0.755 3.584 9.011 3.82E-09 1.27E-07 10.790 1.69 
GPC6 0.765 3.568 9.727 2.65E-10 7.57E-09 13.316 1.70 
Gpd2 0.341 6.879 4.485 1.56E-04 1.02E-03 0.062 1.27 
Gpnmb -0.960 5.966 -15.221 8.90E-14 1.68E-11 21.602 -1.94 
GPR176 -0.903 7.295 -20.666 1.00E-16 3.59E-14 28.366 -1.87 
Gpr56 0.904 6.210 12.539 9.48E-13 6.16E-11 19.038 1.87 
Gpr56 0.946 6.194 12.037 1.28E-11 9.60E-10 16.579 1.93 
Gpx1 -0.389 7.884 -5.595 9.52E-06 1.00E-04 2.863 -1.31 
GSS 0.319 6.709 4.834 6.44E-05 4.93E-04 0.945 1.25 
GSS 0.358 7.023 6.579 8.63E-07 1.35E-05 5.286 1.28 
GSS 0.411 6.247 4.459 1.67E-04 1.08E-03 -0.003 1.33 
Gss 0.419 8.655 8.964 4.21E-09 1.39E-07 10.691 1.34 
Gstm1 -0.404 9.649 -5.834 5.27E-06 6.11E-05 3.458 -1.32 
Gstm7 -0.378 8.876 -5.442 1.39E-05 1.37E-04 2.478 -1.30 
GSTO1 0.422 6.462 8.208 2.10E-08 5.58E-07 9.057 1.34 
Gt(ROSA)26Sor -0.326 6.526 -5.652 8.26E-06 8.91E-05 3.005 -1.25 
Gyg -0.464 8.497 -5.676 7.79E-06 8.51E-05 3.064 -1.38 
Gypc -0.439 7.466 -7.544 9.17E-08 1.95E-06 7.560 -1.36 
H6pd -0.628 6.439 -9.339 1.95E-09 7.09E-08 11.472 -1.55 
HBXIP 0.286 8.226 5.446 1.38E-05 1.36E-04 2.489 1.22 
HEG1 -0.548 8.653 -8.871 5.12E-09 1.63E-07 10.492 -1.46 
HEXA -0.347 6.609 -4.708 8.86E-05 6.35E-04 0.626 -1.27 
HEXB -0.361 7.769 -7.281 1.67E-07 3.25E-06 6.951 -1.28 
HEXIM1 -0.369 7.032 -5.339 1.80E-05 1.70E-04 2.220 -1.29 
HMGCR -0.442 6.572 -6.589 8.43E-07 1.33E-05 5.311 -1.36 
Hmgcs1 -0.877 6.887 -15.899 3.44E-14 6.87E-12 22.555 -1.84 
HMOX1 0.516 7.105 5.968 3.79E-06 4.66E-05 3.791 1.43 
Hnrnpa1 0.358 6.520 5.365 1.69E-05 1.61E-04 2.285 1.28 
Hsd17b12 -0.315 7.796 -6.601 8.20E-07 1.30E-05 5.338 -1.24 
HSP90B1 0.266 10.245 4.176 3.41E-04 1.95E-03 -0.713 1.20 
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HTRA1 -0.469 10.001 -7.911 4.03E-08 9.47E-07 8.394 -1.38 
Hyou1 0.502 6.015 6.155 2.40E-06 3.26E-05 4.253 1.42 
IDH1 -0.816 8.313 -10.840 1.07E-10 5.59E-09 14.422 -1.76 
IDH1 -0.813 6.178 -3.610 1.41E-03 6.43E-03 -2.107 -1.76 
Idi1 -0.610 6.124 -10.226 3.41E-10 1.51E-08 13.248 -1.53 
IFRD2 0.324 6.584 4.898 5.48E-05 4.29E-04 1.105 1.25 
Igf2bp2 -0.394 7.260 -5.508 1.18E-05 1.20E-04 2.644 -1.31 
ING1 0.283 6.587 6.000 3.50E-06 4.38E-05 3.870 1.22 
Ing1 0.367 7.161 10.250 3.25E-10 1.48E-08 13.296 1.29 
Insig1 -0.401 8.024 -8.191 2.18E-08 5.68E-07 9.020 -1.32 
IPO5 0.307 7.087 4.885 5.67E-05 4.42E-04 1.072 1.24 
IPO7 0.376 8.117 6.251 1.90E-06 2.69E-05 4.488 1.30 
IPO7 0.420 8.188 8.695 7.41E-09 2.24E-07 10.118 1.34 
Irak1 -0.345 6.508 -5.440 1.40E-05 1.37E-04 2.474 -1.27 
Irak2 -0.308 6.582 -4.317 2.39E-04 1.44E-03 -0.359 -1.24 
Itfg3 -0.305 6.192 -5.810 5.59E-06 6.44E-05 3.399 -1.24 
Jak2 -0.294 6.679 -4.109 4.05E-04 2.24E-03 -0.881 -1.23 
KARS 0.289 8.766 3.879 7.22E-04 3.63E-03 -1.451 1.22 
Kdelc2 0.291 7.107 3.235 3.55E-03 1.35E-02 -3.001 1.22 
Kdelr3 -0.345 6.846 -5.169 2.77E-05 2.39E-04 1.790 -1.27 
KIF23 0.332 6.746 5.131 3.04E-05 2.58E-04 1.696 1.26 
KLF6 0.403 6.300 5.208 2.51E-05 2.20E-04 1.889 1.32 
KLF6 0.407 8.141 8.193 2.17E-08 5.68E-07 9.025 1.33 
KLF6 0.455 7.705 7.793 5.24E-08 1.19E-06 8.128 1.37 
Kpna4 0.353 7.353 6.416 1.28E-06 1.91E-05 4.891 1.28 
KRR1 0.445 6.347 8.130 2.49E-08 6.30E-07 8.885 1.36 
LAMA5 0.281 6.977 4.126 3.87E-04 2.16E-03 -0.837 1.21 
LAMP2 -0.479 6.487 -7.410 1.24E-07 2.56E-06 7.252 -1.39 
LASS5 -0.320 6.341 -4.629 1.08E-04 7.42E-04 0.427 -1.25 
LAYN -0.517 6.973 -7.142 2.30E-07 4.39E-06 6.628 -1.43 
LOC100131463 0.296 10.883 8.681 7.63E-09 2.27E-07 10.087 1.23 
LOC100131826 -0.384 7.320 -4.515 1.45E-04 9.55E-04 0.139 -1.30 
LOC100288436 0.293 6.402 5.840 5.19E-06 6.04E-05 3.473 1.23 
LOC401387 -0.438 9.012 -7.715 6.23E-08 1.37E-06 7.952 -1.35 
LOC685953 -3.022 9.130 -28.957 4.35E-20 3.91E-17 35.828 -8.12 
LOC728758 0.267 6.767 5.335 1.82E-05 1.71E-04 2.210 1.20 
LPCAT3 -0.287 6.684 -3.111 4.78E-03 1.69E-02 -3.287 -1.22 
Lrig1 -0.423 8.856 -4.340 2.25E-04 1.38E-03 -0.301 -1.34 
Lrrc58 -0.331 8.100 -8.206 2.11E-08 5.58E-07 9.053 -1.26 
LRRC8D 0.369 6.697 4.404 1.92E-04 1.21E-03 -0.142 1.29 
LRRFIP1 0.437 6.403 5.140 2.97E-05 2.53E-04 1.718 1.35 
Ly6e -0.431 7.105 -5.790 5.87E-06 6.68E-05 3.349 -1.35 
LYSMD4 -0.381 7.687 -8.080 2.78E-08 6.93E-07 8.773 -1.30 
Mad2l1 0.341 7.100 5.200 2.55E-05 2.23E-04 1.870 1.27 
Mad2l1 0.463 6.292 3.767 9.56E-04 4.60E-03 -1.726 1.38 
MAGED1 -0.353 7.518 -5.783 5.97E-06 6.74E-05 3.333 -1.28 
MAMDC2 -0.763 7.429 -6.602 8.17E-07 1.30E-05 5.341 -1.70 
MAP4K4 0.305 6.730 4.950 4.80E-05 3.85E-04 1.238 1.24 
MAPK6 0.316 7.276 4.368 2.10E-04 1.30E-03 -0.231 1.24 
MBNL2 -0.337 7.563 -5.888 4.62E-06 5.47E-05 3.592 -1.26 
MCM7 0.276 7.318 3.894 6.95E-04 3.54E-03 -1.414 1.21 
MDP1 0.277 6.783 5.285 2.07E-05 1.90E-04 2.083 1.21 
MEF2A -0.424 7.229 -7.043 2.89E-07 5.38E-06 6.394 -1.34 
Met -0.643 9.659 -10.890 9.80E-11 5.42E-09 14.515 -1.56 
METTL9 -0.472 6.724 -7.789 5.28E-08 1.19E-06 8.121 -1.39 
MGST1 -0.361 11.519 -6.107 2.70E-06 3.59E-05 4.133 -1.28 
Mgst1 -0.333 11.656 -8.114 2.58E-08 6.48E-07 8.849 -1.26 
MIR21 -0.266 6.244 -3.340 2.75E-03 1.10E-02 -2.753 -1.20 
MITF -0.311 7.306 -4.347 2.21E-04 1.36E-03 -0.284 -1.24 
MMD -1.055 6.497 -12.988 2.64E-12 2.79E-10 18.180 -2.08 
MMP14 -0.611 6.141 -5.981 3.67E-06 4.53E-05 3.823 -1.53 
Mmp14 -0.539 6.694 -7.998 3.33E-08 8.19E-07 8.590 -1.45 
MMP9 -0.429 6.731 -6.794 5.18E-07 8.87E-06 5.802 -1.35 
MRPL24 0.355 7.227 6.890 4.14E-07 7.33E-06 6.030 1.28 
MRPL37 0.381 7.536 5.222 2.42E-05 2.15E-04 1.924 1.30 
MRPL37 0.438 6.243 3.147 4.39E-03 1.58E-02 -3.205 1.35 
MRPS18B 0.265 7.064 3.349 2.69E-03 1.08E-02 -2.732 1.20 
MRPS22 0.281 6.359 5.998 3.52E-06 4.39E-05 3.865 1.22 
MRPS30 0.350 6.293 5.927 4.19E-06 5.05E-05 3.690 1.27 
MRPS35 0.400 8.616 8.166 2.30E-08 5.87E-07 8.963 1.32 
MRPS9 0.364 6.453 7.785 5.34E-08 1.20E-06 8.110 1.29 
MTHFD1L 0.615 7.277 16.273 1.89E-15 3.06E-13 25.325 1.53 
MTHFD1L 0.623 7.267 14.601 2.19E-13 3.56E-11 20.697 1.54 
Mthfd2 0.459 7.826 10.195 3.61E-10 1.58E-08 13.189 1.37 
Mthfd2l 0.951 6.000 14.914 1.38E-13 2.37E-11 21.158 1.93 
Mthfd2l 0.970 5.991 17.297 4.20E-16 8.31E-14 26.837 1.96 
MYO1B 0.630 8.889 12.510 1.00E-12 6.16E-11 18.984 1.55 
MYO1B 0.631 8.879 11.265 4.97E-11 3.08E-09 15.205 1.55 
Nars 0.344 7.775 6.906 3.99E-07 7.09E-06 6.069 1.27 
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NARS 0.377 8.331 6.295 1.71E-06 2.45E-05 4.596 1.30 
NARS 0.381 6.984 3.330 2.81E-03 1.12E-02 -2.777 1.30 
Nbl1 -0.392 6.440 -4.544 1.34E-04 8.90E-04 0.212 -1.31 
Ncam1 2.710 5.415 35.704 3.32E-24 5.92E-21 44.999 6.54 
Ncam1 2.712 5.358 30.155 1.69E-20 3.04E-17 36.710 6.55 
Ncapd3 -0.441 5.993 -6.255 1.88E-06 2.67E-05 4.497 -1.36 
NCK2 -0.477 6.349 -6.019 3.35E-06 4.26E-05 3.916 -1.39 
NDC80 0.417 6.736 5.086 3.41E-05 2.86E-04 1.582 1.34 
Neat1 -0.614 8.207 -9.367 1.85E-09 6.77E-08 11.530 -1.53 
NEIL3 0.621 7.798 8.780 6.19E-09 1.92E-07 10.299 1.54 
NEIL3 0.629 7.792 10.051 1.32E-10 4.09E-09 14.026 1.55 
Nek2 0.554 8.036 8.422 1.32E-08 3.75E-07 9.526 1.47 
Nek2 0.610 8.014 9.624 3.32E-10 9.32E-09 13.089 1.53 
Nfib -0.700 6.638 -8.395 1.40E-08 3.94E-07 9.467 -1.62 
NGDN 0.430 7.269 8.687 7.53E-09 2.25E-07 10.100 1.35 
NINJ1 -0.383 6.177 -6.036 3.21E-06 4.13E-05 3.959 -1.30 
NOL7 0.286 8.228 4.734 8.30E-05 6.02E-04 0.691 1.22 
NR1D1 -0.330 6.614 -5.577 9.94E-06 1.03E-04 2.818 -1.26 
NR1H3 -0.461 6.661 -5.446 1.38E-05 1.36E-04 2.489 -1.38 
NUP54 0.265 6.875 3.961 5.88E-04 3.07E-03 -1.249 1.20 
Nusap1 0.392 6.996 4.913 5.27E-05 4.14E-04 1.145 1.31 
OAZ2 -0.303 6.880 -5.245 2.28E-05 2.07E-04 1.984 -1.23 
OBFC1 0.289 6.436 4.553 1.31E-04 8.73E-04 0.235 1.22 
Optn -0.480 7.088 -5.593 9.57E-06 1.00E-04 2.857 -1.39 
PALLD -0.487 7.134 -9.932 6.02E-10 2.51E-08 12.671 -1.40 
Parp3 -0.264 6.322 -4.370 2.09E-04 1.30E-03 -0.226 -1.20 
Pbk 0.272 6.261 3.101 4.90E-03 1.72E-02 -3.310 1.21 
PCGF5 0.283 6.328 5.762 6.29E-06 7.06E-05 3.279 1.22 
Pcolce -0.479 8.526 -6.358 1.47E-06 2.15E-05 4.749 -1.39 
Pcyox1 -0.305 6.602 -3.923 6.46E-04 3.33E-03 -1.342 -1.24 
PDIA6 0.353 10.091 8.710 7.17E-09 2.18E-07 10.150 1.28 
Pdyn -0.370 7.034 -4.294 2.53E-04 1.51E-03 -0.418 -1.29 
PECI -0.567 6.867 -10.881 9.96E-11 5.42E-09 14.498 -1.48 
PHGDH -0.305 7.601 -4.253 2.81E-04 1.64E-03 -0.519 -1.24 
Pir 0.313 6.603 4.598 1.17E-04 7.89E-04 0.349 1.24 
PJA1 -0.418 7.598 -9.951 5.80E-10 2.45E-08 12.708 -1.34 
PLAC8 1.171 5.487 12.097 2.16E-12 1.17E-10 18.201 2.25 
PLAC8 1.266 5.438 12.678 4.37E-12 4.25E-10 17.669 2.41 
Plekha5 0.440 7.039 10.850 1.06E-10 5.59E-09 14.439 1.36 
PLIN2 0.338 9.911 3.057 5.45E-03 1.89E-02 -3.412 1.26 
PLIN2 0.457 9.393 11.020 7.73E-11 4.55E-09 14.756 1.37 
PLK2 0.742 7.605 14.572 2.28E-13 3.56E-11 20.654 1.67 
PLK2 0.784 7.596 15.885 3.41E-15 4.86E-13 24.730 1.72 
PLS3 -0.331 8.295 -5.345 1.78E-05 1.68E-04 2.234 -1.26 
PLTP -0.566 7.226 -4.315 2.40E-04 1.45E-03 -0.364 -1.48 
PPAP2A -0.828 6.987 -10.968 8.50E-11 4.93E-09 14.660 -1.77 
Ppcs -0.303 7.062 -5.377 1.64E-05 1.57E-04 2.316 -1.23 
PPM1G 0.281 7.133 5.151 2.89E-05 2.48E-04 1.745 1.21 
PPP2R1A -0.620 6.065 -5.502 1.20E-05 1.21E-04 2.630 -1.54 
PPP2R5C 0.279 7.119 4.259 2.76E-04 1.62E-03 -0.504 1.21 
Prc1 0.502 7.462 5.233 2.35E-05 2.12E-04 1.953 1.42 
Prc1 0.557 7.457 6.231 1.17E-06 1.13E-05 4.812 1.47 
Procr 0.545 6.220 8.173 2.27E-08 5.82E-07 8.980 1.46 
Pros1 -0.760 7.149 -13.220 1.82E-12 2.04E-10 18.558 -1.69 
PRUNE2 -0.329 7.588 -5.934 4.12E-06 4.98E-05 3.706 -1.26 
PTPRM -0.269 7.071 -6.447 1.18E-06 1.80E-05 4.966 -1.20 
PTTG1 0.306 6.979 3.674 1.21E-03 5.62E-03 -1.954 1.24 
Pttg1ip -0.266 8.427 -6.530 9.71E-07 1.50E-05 5.167 -1.20 
PUM2 0.306 7.024 7.317 1.54E-07 3.03E-06 7.035 1.24 
PWP1 0.408 7.363 7.409 1.25E-07 2.56E-06 7.249 1.33 
Pxdn -0.515 7.848 -8.949 4.35E-09 1.42E-07 10.658 -1.43 
QARS 0.287 9.208 7.036 2.94E-07 5.41E-06 6.378 1.22 
RAB6A 0.270 6.620 4.089 4.25E-04 2.32E-03 -0.929 1.21 
RARRES2 -0.599 9.322 -8.434 1.29E-08 3.68E-07 9.552 -1.51 
Rbpj 0.786 7.011 10.931 9.10E-11 5.11E-09 14.591 1.72 
Rbpj 0.790 7.631 12.694 7.14E-13 4.99E-11 19.326 1.73 
Rbpj 0.795 7.019 12.515 9.90E-13 6.16E-11 18.993 1.73 
Rbpj 0.799 7.628 11.422 3.75E-11 2.51E-09 15.491 1.74 
RBPJ 0.836 7.585 14.977 1.26E-13 2.27E-11 21.249 1.79 
RBPJ 0.843 7.583 16.903 7.42E-16 1.26E-13 26.265 1.79 
RCBTB2 -0.738 7.042 -12.542 5.48E-12 5.05E-10 17.441 -1.67 
RCN2 -0.268 7.783 -6.292 1.72E-06 2.46E-05 4.588 -1.20 
Reep5 -0.578 7.899 -11.797 1.94E-11 1.42E-09 16.159 -1.49 
REEP5 -0.458 6.759 -4.690 9.29E-05 6.61E-04 0.580 -1.37 
Rere -0.456 6.955 -5.382 1.62E-05 1.56E-04 2.328 -1.37 
RETSAT -0.507 5.458 -5.402 1.54E-05 1.49E-04 2.377 -1.42 
REV3L -0.304 7.281 -4.631 1.08E-04 7.42E-04 0.433 -1.23 
RFX7 -0.594 7.777 -8.238 1.97E-08 5.28E-07 9.123 -1.51 
RGD1560010 0.316 6.651 4.560 1.29E-04 8.61E-04 0.253 1.25 
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RGS17 -0.469 7.346 -4.835 6.42E-05 4.93E-04 0.948 -1.38 
RNASET2 0.348 10.189 8.074 2.82E-08 6.98E-07 8.759 1.27 
RPF2 0.281 7.016 6.615 7.93E-07 1.28E-05 5.372 1.21 
RPS5 -0.426 11.111 -9.423 1.65E-09 6.31E-08 11.645 -1.34 
RYBP -0.482 8.342 -9.432 1.62E-09 6.26E-08 11.663 -1.40 
SC4MOL -0.444 8.194 -8.799 5.95E-09 1.86E-07 10.340 -1.36 
Sc5d -0.517 6.364 -5.482 1.26E-05 1.26E-04 2.579 -1.43 
Scarb1 -0.473 6.897 -6.834 4.71E-07 8.22E-06 5.899 -1.39 
SCD -0.674 7.564 -7.214 1.95E-07 3.74E-06 6.795 -1.60 
Scd3 -0.582 8.588 -13.985 5.50E-13 7.91E-11 19.765 -1.50 
Sdc4 0.300 8.779 5.944 4.01E-06 4.91E-05 3.733 1.23 
Sdc4 0.362 7.039 3.886 7.08E-04 3.57E-03 -1.432 1.28 
Sec22a 0.297 6.119 7.135 2.34E-07 4.44E-06 6.611 1.23 
SEC24D -0.266 7.004 -3.689 1.16E-03 5.44E-03 -1.917 -1.20 
SEMA3C -0.278 6.612 -4.830 6.51E-05 4.96E-04 0.935 -1.21 
Sepp1 -0.557 9.267 -8.600 9.06E-09 2.65E-07 9.913 -1.47 
SERPINH1 -0.265 8.798 -2.886 8.15E-03 2.61E-02 -3.795 -1.20 
SGCE -1.172 6.005 -9.091 3.24E-09 1.10E-07 10.957 -2.25 
Sh2b3 0.263 6.519 4.797 7.07E-05 5.32E-04 0.852 1.20 
Shc1 -0.312 8.134 -7.919 3.96E-08 9.35E-07 8.414 -1.24 
SLC25A20 -0.370 8.555 -5.199 2.56E-05 2.23E-04 1.867 -1.29 
Slc30a4 0.276 6.781 5.596 9.50E-06 1.00E-04 2.865 1.21 
Slc6a6 -0.268 8.040 -5.602 9.36E-06 9.92E-05 2.880 -1.20 
Slc7a11 0.300 7.310 3.570 1.56E-03 7.00E-03 -2.204 1.23 
SMC4 0.283 6.591 2.562 1.72E-02 4.83E-02 -4.494 1.22 
SMC6 0.301 6.823 4.898 5.48E-05 4.29E-04 1.107 1.23 
SNAI2 -0.434 6.399 -6.608 8.07E-07 1.29E-05 5.355 -1.35 
Snn -0.576 6.495 -7.453 1.13E-07 2.37E-06 7.350 -1.49 
Snora28 -0.481 7.421 -9.297 2.13E-09 7.58E-08 11.385 -1.40 
SNRPA1 0.298 7.859 5.257 2.22E-05 2.01E-04 2.013 1.23 
SNRPB2 0.280 7.682 4.572 1.25E-04 8.38E-04 0.283 1.21 
SNRPD2 -0.531 8.788 -7.977 3.49E-08 8.46E-07 8.543 -1.44 
SOD1 -0.500 8.506 -8.942 4.42E-09 1.43E-07 10.643 -1.41 
Spc25 0.444 6.631 5.726 6.88E-06 7.68E-05 3.189 1.36 
SPIN1 -0.633 7.093 -9.039 3.61E-09 1.21E-07 10.848 -1.55 
SPRR1A 2.022 8.643 23.454 5.61E-18 3.36E-15 31.182 4.06 
SPRR1A 2.087 8.682 26.345 9.48E-21 5.64E-18 37.430 4.25 
SPTBN1 -0.372 9.556 -6.630 7.64E-07 1.24E-05 5.410 -1.29 
Sqle -0.591 9.031 -9.379 1.80E-09 6.74E-08 11.554 -1.51 
SQLE -0.520 7.073 -7.818 4.96E-08 1.13E-06 8.185 -1.43 
SQLE -0.491 6.333 -3.192 3.94E-03 1.46E-02 -3.101 -1.41 
SSR2 0.324 9.195 6.016 3.36E-06 4.27E-05 3.911 1.25 
STMN1 -0.458 7.260 -7.638 7.42E-08 1.62E-06 7.775 -1.37 
STT3B -0.289 8.430 -4.842 6.30E-05 4.85E-04 0.966 -1.22 
Tapbpl 0.273 5.845 2.898 7.94E-03 2.57E-02 -3.770 1.21 
Tbc1d1 -0.734 7.646 -12.955 2.78E-12 2.86E-10 18.127 -1.66 
TBPL1 0.448 7.435 6.806 5.05E-07 8.68E-06 5.830 1.36 
Tcf19 -0.540 5.912 -9.408 1.70E-09 6.43E-08 11.614 -1.45 
TDP2 0.321 6.488 7.733 5.99E-08 1.33E-06 7.992 1.25 
Tes 0.513 6.550 10.572 1.77E-10 8.83E-09 13.914 1.43 
Tes 0.676 7.629 11.331 4.41E-11 2.83E-09 15.326 1.60 
Tes 0.693 7.604 12.981 4.24E-13 3.03E-11 19.853 1.62 
TFB1M 0.331 6.682 4.746 8.04E-05 5.88E-04 0.723 1.26 
Tgfbr2 -0.829 6.364 -10.535 1.90E-10 9.21E-09 13.844 -1.78 
Thbd -0.630 7.746 -7.279 1.68E-07 3.25E-06 6.948 -1.55 
THBS3 -0.277 6.147 -5.047 3.76E-05 3.11E-04 1.484 -1.21 
TIMM10 0.292 7.656 5.287 2.05E-05 1.90E-04 2.090 1.22 
TIMM16 0.324 8.011 6.186 2.22E-06 3.06E-05 4.329 1.25 
TIMM50 0.391 7.608 7.940 3.78E-08 9.01E-07 8.461 1.31 
TIMM9 0.316 7.636 6.460 1.15E-06 1.75E-05 4.998 1.24 
TIMP2 -0.465 8.474 -6.724 6.12E-07 1.02E-05 5.634 -1.38 
Timp2 -0.414 7.474 -5.362 1.70E-05 1.61E-04 2.278 -1.33 
TJP2 -0.446 6.785 -8.668 7.83E-09 2.31E-07 10.060 -1.36 
TMED3 -0.269 6.990 -5.617 9.01E-06 9.67E-05 2.917 -1.20 
TMEM101 0.593 6.466 7.113 2.46E-07 4.65E-06 6.558 1.51 
TMEM101 0.603 6.460 7.892 1.79E-08 3.19E-07 9.043 1.52 
Tmem109 -0.271 6.566 -5.208 2.50E-05 2.20E-04 1.890 -1.21 
TMEM156 0.476 7.139 8.308 1.69E-08 4.60E-07 9.279 1.39 
TMEM158 -1.079 6.933 -11.033 7.55E-11 4.52E-09 14.780 -2.11 
TMEM66 0.289 8.790 7.994 3.35E-08 8.20E-07 8.582 1.22 
TMSB10 -0.333 10.371 -5.367 1.68E-05 1.61E-04 2.290 -1.26 
Tnfaip3 -0.326 5.235 -3.559 1.60E-03 7.18E-03 -2.231 -1.25 
Tnfrsf21 -0.767 7.387 -10.824 1.11E-10 5.69E-09 14.390 -1.70 
Tnfsf9 0.992 6.765 9.300 2.12E-09 7.58E-08 11.391 1.99 
Tnfsf9 0.998 6.721 10.915 2.19E-11 8.77E-10 15.852 2.00 
TNIP1 -0.294 6.401 -3.976 5.65E-04 2.97E-03 -1.210 -1.23 
Top2a 0.480 9.103 6.083 2.86E-06 3.76E-05 4.076 1.39 
TPM1 -0.327 7.136 -7.309 1.57E-07 3.07E-06 7.017 -1.25 
Tpst1 -0.351 6.787 -8.318 1.66E-08 4.54E-07 9.299 -1.28 
 338 
TPX2 0.486 6.219 5.223 2.41E-05 2.15E-04 1.927 1.40 
TPX2 0.565 6.178 6.197 1.28E-06 1.21E-05 4.724 1.48 
TRAK2 -0.493 6.593 -6.162 2.36E-06 3.22E-05 4.269 -1.41 
Tram1 -0.290 6.401 -3.655 1.26E-03 5.85E-03 -1.998 -1.22 
TRAP1 0.283 6.783 3.462 2.04E-03 8.70E-03 -2.465 1.22 
TRAPPC4 0.304 7.791 5.483 1.26E-05 1.26E-04 2.582 1.23 
Trib3 0.441 8.754 9.455 1.55E-09 6.04E-08 11.710 1.36 
TRIB3 0.477 5.753 3.509 1.81E-03 7.93E-03 -2.351 1.39 
Trmt6 0.388 6.854 7.089 2.60E-07 4.89E-06 6.502 1.31 
TSC22D1 -0.534 10.051 -7.415 1.23E-07 2.55E-06 7.263 -1.45 
TSC22D3 -0.359 6.584 -6.940 3.68E-07 6.61E-06 6.150 -1.28 
TUBA1A -0.591 8.193 -6.741 5.88E-07 9.87E-06 5.675 -1.51 
UAP1 0.417 6.881 6.760 5.62E-07 9.52E-06 5.721 1.34 
UAP1L1 -0.434 6.485 -4.849 6.20E-05 4.78E-04 0.983 -1.35 
UBASH3B 0.361 8.046 8.819 5.70E-09 1.80E-07 10.383 1.28 
UBE2E3 -0.345 7.271 -5.258 2.21E-05 2.01E-04 2.015 -1.27 
Ube2s -0.277 7.516 -3.364 2.59E-03 1.05E-02 -2.698 -1.21 
UCK2 0.474 6.008 7.388 1.31E-07 2.67E-06 7.200 1.39 
VAMP7 -0.269 6.650 -3.329 2.82E-03 1.12E-02 -2.780 -1.20 
VCAM1 -1.064 6.411 -12.507 5.81E-12 5.22E-10 17.382 -2.09 
Vps36 -0.265 6.947 -5.324 1.87E-05 1.74E-04 2.182 -1.20 
VWA5A 0.314 7.095 6.132 2.54E-06 3.41E-05 4.196 1.24 
WBP5 -0.447 8.222 -8.516 1.08E-08 3.11E-07 9.732 -1.36 
Wdfy4 -1.984 6.002 -18.671 9.83E-16 2.94E-13 26.106 -3.96 
Wdr1 -0.282 8.251 -2.888 8.12E-03 2.61E-02 -3.792 -1.22 
WDR67 0.302 6.118 3.374 2.53E-03 1.04E-02 -2.674 1.23 
Wdyhv1 -0.303 7.392 -6.012 3.40E-06 4.30E-05 3.900 -1.23 
WHSC1 0.276 6.747 3.302 3.02E-03 1.18E-02 -2.844 1.21 
WWC2 -0.538 6.927 -9.196 2.61E-09 9.21E-08 11.177 -1.45 
XBP1 -0.372 7.896 -6.729 6.05E-07 1.01E-05 5.646 -1.29 
ZC3HAV1 0.277 7.214 5.126 3.08E-05 2.60E-04 1.684 1.21 
Zcchc24 -0.418 6.916 -6.827 4.80E-07 8.33E-06 5.881 -1.34 
ZEB1 -0.416 7.606 -11.366 4.14E-11 2.71E-09 15.389 -1.33 
Zfp110 -0.721 6.538 -17.923 2.45E-15 6.28E-13 25.199 -1.65 
ZFP36L1 -0.575 8.280 -9.671 1.01E-09 4.06E-08 12.148 -1.49 
ZFP36L2 -0.737 7.753 -12.386 7.10E-12 5.94E-10 17.178 -1.67 
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5.2.8 L(S)2 v pcDNA(S) gene list 
 
Gene ID logFC AveExpr t P.Value adj.P.Val B Fold Change 
40607 0.282 7.921 6.877 4.26E-07 1.95E-06 5.369 1.22 
40790 -0.340 5.984 -3.859 7.60E-04 1.70E-03 -2.170 -1.27 
0610039K10Rik 0.554 8.116 12.262 8.76E-12 1.39E-10 16.451 1.47 
1110003E01Rik -0.310 7.572 -2.988 6.42E-03 1.15E-02 -4.244 -1.24 
1110004F10Rik 0.327 6.588 5.956 3.90E-06 1.41E-05 3.117 1.25 
1700020I14Rik 0.427 8.162 10.034 4.93E-10 4.79E-09 12.302 1.34 
1700025O18Rik 0.507 7.116 8.284 1.78E-08 1.17E-07 8.617 1.42 
1700052N19Rik -0.837 6.422 -17.427 4.56E-15 2.06E-13 24.235 -1.79 
1810013D10Rik 0.356 7.076 6.673 6.90E-07 2.98E-06 4.878 1.28 
2310001A20Rik -0.500 7.257 -8.914 4.68E-09 3.56E-08 9.989 -1.41 
2310044H10Rik 0.361 6.864 4.908 5.34E-05 1.49E-04 0.472 1.28 
2810474O19Rik -0.385 7.272 -7.409 1.25E-07 6.55E-07 6.626 -1.31 
2810482I07Rik -0.412 6.348 -6.926 3.80E-07 1.76E-06 5.485 -1.33 
2900097C17Rik 0.602 9.676 12.386 7.11E-12 1.16E-10 16.666 1.52 
3010026O09Rik 0.381 6.003 2.582 1.64E-02 2.70E-02 -5.130 1.30 
3010026O09Rik 0.632 8.162 12.023 1.31E-11 1.99E-10 16.033 1.55 
4930535I16Rik 0.304 8.352 6.953 3.57E-07 1.66E-06 5.549 1.23 
4930539H15Rik 0.497 6.597 11.249 5.11E-11 6.45E-10 14.634 1.41 
5830485P09Rik -0.398 7.542 -7.659 7.08E-08 4.02E-07 7.204 -1.32 
5930416I19Rik 0.450 6.436 8.169 2.29E-08 1.46E-07 8.361 1.37 
6330406I15Rik -0.492 8.622 -7.733 5.98E-08 3.48E-07 7.376 -1.41 
6330578E17Rik 0.317 6.733 6.163 2.35E-06 8.96E-06 3.629 1.25 
6430548M08Rik 0.884 5.381 12.604 4.94E-12 8.54E-11 17.041 1.85 
9430072B17Rik -0.329 9.474 -7.458 1.11E-07 5.95E-07 6.740 -1.26 
9430083M05Rik 0.296 12.230 9.810 7.64E-10 7.09E-09 11.852 1.23 
9530053H05Rik -0.937 10.002 -16.234 2.18E-14 8.34E-13 22.625 -1.91 
A330042M18Rik 0.855 7.205 13.390 1.39E-12 3.04E-11 18.349 1.81 
A730071L15Rik 0.374 6.649 5.551 1.06E-05 3.43E-05 2.102 1.30 
Aars -0.316 7.664 -5.464 1.32E-05 4.19E-05 1.881 -1.24 
ABCC5 -0.507 7.507 -5.774 6.11E-06 2.09E-05 2.661 -1.42 
ABHD5 -0.744 6.637 -7.393 1.29E-07 6.78E-07 6.587 -1.68 
ABHD6 0.297 6.783 3.783 9.18E-04 2.01E-03 -2.357 1.23 
ACAT1 -0.799 8.170 -6.421 1.26E-06 5.07E-06 4.264 -1.74 
ACAT1 -0.562 8.742 -17.424 4.58E-15 2.06E-13 24.230 -1.48 
Acat2 -1.799 6.811 -27.215 1.83E-19 3.76E-17 34.593 -3.48 
ACLY -0.479 8.199 -8.560 9.85E-09 6.85E-08 9.225 -1.39 
ACO1 -0.576 6.759 -17.899 2.52E-15 1.22E-13 24.845 -1.49 
ACOT7 0.549 7.565 10.207 3.53E-10 3.64E-09 12.644 1.46 
ACTL6A -0.276 7.119 -4.484 1.56E-04 3.94E-04 -0.602 -1.21 
ACTR1A 0.290 7.024 3.677 1.20E-03 2.55E-03 -2.617 1.22 
ACTR3 -0.595 8.121 -3.563 1.59E-03 3.30E-03 -2.894 -1.51 
ACTR3 -0.385 8.697 -6.489 1.07E-06 4.40E-06 4.429 -1.31 
Actr3 -0.267 10.274 -4.645 1.04E-04 2.72E-04 -0.195 -1.20 
ADAM9 -0.527 8.339 -6.990 3.28E-07 1.54E-06 5.637 -1.44 
ADD3 0.400 6.120 3.395 2.40E-03 4.83E-03 -3.297 1.32 
ADH5 -0.699 8.532 -5.149 2.91E-05 8.57E-05 1.085 -1.62 
ADH5 -0.587 9.619 -8.035 3.07E-08 1.90E-07 8.060 -1.50 
ADNP -0.582 7.851 -6.047 3.12E-06 1.15E-05 3.343 -1.50 
Ado 0.331 7.572 8.225 2.03E-08 1.31E-07 8.486 1.26 
ADO 0.342 6.943 5.919 4.27E-06 1.52E-05 3.024 1.27 
ADSS -0.357 7.645 -7.041 2.91E-07 1.39E-06 5.759 -1.28 
AFF4 0.494 7.576 11.762 2.06E-11 2.94E-10 15.570 1.41 
AFTPH 0.306 7.139 4.265 2.73E-04 6.55E-04 -1.156 1.24 
Agrn 0.754 7.203 15.854 3.66E-14 1.28E-12 22.091 1.69 
AHNAK -0.835 8.479 -11.129 6.34E-11 7.76E-10 14.413 -1.78 
AIDA -0.519 6.309 -3.210 3.77E-03 7.17E-03 -3.733 -1.43 
AIFM1 -0.452 8.277 -9.786 8.01E-10 7.36E-09 11.803 -1.37 
AIMP1 0.452 8.513 10.963 8.59E-11 1.01E-09 14.100 1.37 
Ak2 0.523 9.209 9.695 9.59E-10 8.66E-09 11.618 1.44 
Akap12 -1.519 7.889 -22.796 1.08E-17 1.17E-15 30.440 -2.87 
AKIRIN2 0.661 6.069 8.689 7.49E-09 5.39E-08 9.506 1.58 
AKTIP -0.307 6.876 -4.969 4.57E-05 1.29E-04 0.629 -1.24 
ALDH2 -0.397 8.281 -6.384 1.38E-06 5.50E-06 4.172 -1.32 
Amacr -0.572 6.539 -8.486 1.15E-08 7.83E-08 9.062 -1.49 
AMD1 1.302 7.422 12.977 2.69E-12 5.06E-11 17.669 2.47 
AMD1 1.363 8.027 15.862 3.62E-14 1.28E-12 22.103 2.57 
ANKRD10 -0.316 6.403 -4.466 1.64E-04 4.12E-04 -0.649 -1.25 
ANLN -1.230 6.950 -10.665 1.49E-10 1.65E-09 13.535 -2.35 
ANP32E 0.310 8.064 4.456 1.68E-04 4.21E-04 -0.673 1.24 
ANXA2 -0.898 9.836 -5.882 4.67E-06 1.65E-05 2.933 -1.86 
ANXA2P3 -0.574 10.669 -8.209 2.10E-08 1.35E-07 8.450 -1.49 
AP1B1 0.704 6.806 13.356 1.46E-12 3.12E-11 18.293 1.63 
Ap3d1 0.485 7.148 4.942 4.90E-05 1.38E-04 0.559 1.40 
APEH -0.321 6.410 -5.104 3.26E-05 9.48E-05 0.970 -1.25 
APEX1 -0.342 7.431 -6.322 1.60E-06 6.28E-06 4.022 -1.27 
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API5 -0.338 6.606 -3.231 3.58E-03 6.87E-03 -3.683 -1.26 
APP 0.288 8.605 2.974 6.62E-03 1.18E-02 -4.275 1.22 
APP 0.345 10.319 8.056 2.93E-08 1.83E-07 8.107 1.27 
ARFGEF2 -0.298 6.640 -7.011 3.12E-07 1.48E-06 5.688 -1.23 
ARHGAP18 -0.821 6.699 -3.622 1.37E-03 2.89E-03 -2.751 -1.77 
ARHGAP18 -0.583 6.623 -5.822 5.43E-06 1.88E-05 2.781 -1.50 
ARHGAP18 -0.434 7.541 -4.988 4.36E-05 1.24E-04 0.677 -1.35 
ARHGAP18 -0.397 7.448 -5.117 3.15E-05 9.20E-05 1.004 -1.32 
ARHGAP24 -1.023 7.747 -13.630 9.52E-13 2.24E-11 18.737 -2.03 
Arhgap25 -0.298 6.665 -3.575 1.54E-03 3.21E-03 -2.864 -1.23 
Arhgap29 -0.342 7.970 -7.295 1.62E-07 8.24E-07 6.358 -1.27 
ARHGEF6 -0.606 7.955 -9.458 1.54E-09 1.32E-08 11.132 -1.52 
ARIH1 0.507 6.918 9.607 1.14E-09 1.00E-08 11.440 1.42 
Arl10 0.622 6.690 14.412 2.89E-13 7.99E-12 19.964 1.54 
Arl2bp 0.478 7.421 8.002 3.30E-08 2.03E-07 7.986 1.39 
ARL3 -0.280 8.358 -5.785 5.94E-06 2.04E-05 2.690 -1.21 
ARL6IP1 -0.423 8.692 -7.359 1.40E-07 7.24E-07 6.509 -1.34 
ARL6IP4 -0.297 6.141 -4.444 1.73E-04 4.33E-04 -0.703 -1.23 
ARL8B 0.364 7.987 7.885 4.27E-08 2.57E-07 7.721 1.29 
ARPC1B -0.384 9.617 -9.621 1.11E-09 9.83E-09 11.466 -1.30 
ARPC4 0.442 6.197 4.655 1.01E-04 2.66E-04 -0.169 1.36 
Arpp19 -0.263 6.929 -4.680 9.52E-05 2.51E-04 -0.106 -1.20 
Asf1b -1.183 5.939 -14.107 4.57E-13 1.22E-11 19.492 -2.27 
ASNS -0.580 9.701 -14.073 4.82E-13 1.25E-11 19.438 -1.49 
ASNS -0.444 9.296 -9.061 3.45E-09 2.73E-08 10.301 -1.36 
ASPM -0.803 6.112 -12.259 8.79E-12 1.39E-10 16.447 -1.75 
ATAD2 -0.363 6.552 -4.088 4.26E-04 9.88E-04 -1.599 -1.29 
Atf5 0.476 9.270 4.097 4.17E-04 9.69E-04 -1.578 1.39 
Atp10a -0.957 7.352 -22.398 1.61E-17 1.61E-15 30.029 -1.94 
ATP2A2 0.329 6.749 5.505 1.19E-05 3.82E-05 1.985 1.26 
ATP5A1 -0.620 7.427 -5.806 5.65E-06 1.95E-05 2.741 -1.54 
ATP5A1 -0.392 8.837 -9.370 1.84E-09 1.56E-08 10.950 -1.31 
ATP5B -0.680 9.171 -4.534 1.38E-04 3.52E-04 -0.476 -1.60 
Atp5b -0.327 10.066 -9.087 3.27E-09 2.60E-08 10.358 -1.25 
ATP5B -0.274 10.189 -5.526 1.13E-05 3.64E-05 2.040 -1.21 
ATP5G2 -0.288 8.724 -2.750 1.12E-02 1.90E-02 -4.772 -1.22 
ATP5H 0.320 9.664 7.123 2.40E-07 1.16E-06 5.954 1.25 
Atp5o 0.298 9.052 6.269 1.82E-06 7.07E-06 3.892 1.23 
ATP6V1B2 0.515 7.365 8.629 8.52E-09 6.01E-08 9.374 1.43 
ATP6V1D 0.428 9.487 12.699 4.23E-12 7.56E-11 17.201 1.35 
Atp6v1e1 0.312 8.150 6.454 1.17E-06 4.73E-06 4.344 1.24 
ATXN10 -0.477 6.608 -2.429 2.30E-02 3.68E-02 -5.446 -1.39 
ATXN7L3B 0.661 7.040 9.208 2.55E-09 2.09E-08 10.612 1.58 
ATXN7L3B 0.666 6.370 13.355 1.47E-12 3.12E-11 18.291 1.59 
AU015740 0.580 6.605 8.725 6.95E-09 5.05E-08 9.582 1.49 
Aurka -0.994 6.331 -12.649 4.59E-12 8.09E-11 17.116 -1.99 
AXL -0.526 7.254 -9.144 2.91E-09 2.35E-08 10.476 -1.44 
Azin1 0.928 6.442 11.188 5.71E-11 7.07E-10 14.521 1.90 
AZIN1 1.228 6.431 16.946 8.48E-15 3.42E-13 23.597 2.34 
B230219D22Rik 0.540 8.128 10.255 3.23E-10 3.37E-09 12.738 1.45 
B230220B15Rik -2.677 7.506 -55.955 8.31E-27 4.98E-24 51.314 -6.40 
B2m 0.354 7.614 7.366 1.37E-07 7.14E-07 6.527 1.28 
BAZ1A -0.367 6.516 -4.289 2.56E-04 6.18E-04 -1.095 -1.29 
BC013529 -0.304 7.343 -7.136 2.33E-07 1.13E-06 5.984 -1.23 
BC017643 0.287 6.869 6.798 5.14E-07 2.30E-06 5.178 1.22 
BC046331 0.366 6.418 5.406 1.53E-05 4.78E-05 1.735 1.29 
BCL2L2 0.451 6.311 9.953 5.77E-10 5.57E-09 12.141 1.37 
BCLAF1 0.294 7.984 4.718 8.63E-05 2.29E-04 -0.008 1.23 
BCLAF1 0.365 6.690 5.106 3.24E-05 9.43E-05 0.976 1.29 
Bloc1s2 0.746 6.230 9.802 7.76E-10 7.19E-09 11.836 1.68 
BMI1 0.848 6.386 10.225 3.41E-10 3.53E-09 12.681 1.80 
BNIP3L -0.430 7.109 -2.342 2.79E-02 4.37E-02 -5.621 -1.35 
BRE -0.274 6.906 -4.871 5.87E-05 1.62E-04 0.378 -1.21 
BRIX1 0.366 7.665 7.553 8.97E-08 4.94E-07 6.961 1.29 
BTBD1 0.371 8.357 5.901 4.46E-06 1.58E-05 2.979 1.29 
BTG3 0.274 7.374 3.029 5.82E-03 1.05E-02 -4.151 1.21 
BUD31 0.493 7.762 8.388 1.42E-08 9.46E-08 8.847 1.41 
BZW1 0.370 6.951 6.653 7.25E-07 3.12E-06 4.827 1.29 
C11orf73 -0.302 8.188 -4.589 1.20E-04 3.09E-04 -0.337 -1.23 
C12orf10 0.932 6.223 13.377 1.42E-12 3.08E-11 18.328 1.91 
C12orf11 -0.269 6.952 -3.176 4.10E-03 7.72E-03 -3.813 -1.20 
C12orf24 0.363 6.765 6.591 8.39E-07 3.55E-06 4.678 1.29 
C14orf166 -0.482 9.852 -12.634 4.70E-12 8.20E-11 17.092 -1.40 
C19orf62 0.374 6.759 5.868 4.85E-06 1.70E-05 2.895 1.30 
C1orf131 0.305 6.302 4.507 1.47E-04 3.74E-04 -0.544 1.24 
C1orf25 0.462 6.127 10.093 4.40E-10 4.41E-09 12.420 1.38 
C1orf77 0.274 7.460 8.006 3.27E-08 2.02E-07 7.996 1.21 
C1R -1.176 9.482 -14.913 1.38E-13 4.36E-12 20.723 -2.26 
C20orf111 0.652 6.588 13.069 2.32E-12 4.45E-11 17.821 1.57 
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C20orf24 0.394 9.165 11.159 6.01E-11 7.40E-10 14.468 1.31 
C20orf4 0.703 6.497 13.355 1.47E-12 3.12E-11 18.293 1.63 
C22orf32 -0.316 8.845 -5.503 1.20E-05 3.84E-05 1.980 -1.24 
C2orf24 0.789 6.408 6.929 3.78E-07 1.75E-06 5.493 1.73 
C2orf56 0.357 6.861 8.073 2.82E-08 1.78E-07 8.146 1.28 
C3 -3.164 7.330 -57.665 4.07E-27 2.93E-24 51.988 -8.97 
C3orf48 1.042 7.672 18.149 1.85E-15 9.36E-14 25.163 2.06 
C4orf27 1.252 6.966 25.249 1.03E-18 1.77E-16 32.832 2.38 
C4orf34 -0.459 6.275 -3.193 3.92E-03 7.43E-03 -3.772 -1.37 
C5orf51 0.461 6.308 5.973 3.74E-06 1.36E-05 3.159 1.38 
C78376 -0.953 7.959 -15.224 8.86E-14 2.95E-12 21.183 -1.94 
CAB39 0.305 7.933 5.890 4.59E-06 1.62E-05 2.951 1.24 
CAB39 0.368 7.377 6.140 2.49E-06 9.38E-06 3.571 1.29 
CACHD1 0.359 6.534 7.001 3.19E-07 1.50E-06 5.665 1.28 
CAD -0.337 6.534 -7.521 9.65E-08 5.23E-07 6.887 -1.26 
CALD1 -1.108 7.225 -12.508 5.80E-12 9.83E-11 16.876 -2.16 
CALD1 -0.925 7.673 -7.244 1.82E-07 9.16E-07 6.239 -1.90 
CAMK2D -0.317 9.232 -5.638 8.56E-06 2.82E-05 2.319 -1.25 
CAMK2N1 0.600 6.214 8.005 3.27E-08 2.02E-07 7.994 1.52 
CAMSAP1L1 0.312 6.300 7.355 1.41E-07 7.29E-07 6.500 1.24 
CAPG -0.905 7.250 -8.529 1.05E-08 7.23E-08 9.157 -1.87 
CAPG -0.593 7.270 -7.478 1.06E-07 5.71E-07 6.787 -1.51 
CAPN2 -0.827 6.868 -10.743 1.29E-10 1.44E-09 13.684 -1.77 
Capn7 0.273 6.641 4.593 1.19E-04 3.07E-04 -0.326 1.21 
Capns1 0.345 7.079 5.363 1.70E-05 5.30E-05 1.627 1.27 
CAPZA2 0.309 9.291 4.646 1.04E-04 2.72E-04 -0.192 1.24 
CAPZA2 0.357 10.363 8.059 2.91E-08 1.82E-07 8.115 1.28 
Cat -0.301 8.131 -3.020 5.95E-03 1.07E-02 -4.172 -1.23 
CAV2 -0.711 6.234 -9.834 7.29E-10 6.84E-09 11.900 -1.64 
CBX5 -0.571 7.118 -5.517 1.16E-05 3.72E-05 2.016 -1.49 
Cbx6-Nptxr 0.376 6.780 5.003 4.20E-05 1.20E-04 0.715 1.30 
CCDC132 0.419 7.485 7.574 8.55E-08 4.73E-07 7.010 1.34 
CCDC43 0.512 6.315 10.209 3.52E-10 3.63E-09 12.649 1.43 
CCDC50 0.316 7.337 5.568 1.02E-05 3.30E-05 2.143 1.25 
CCDC75 0.616 6.959 8.783 6.15E-09 4.49E-08 9.709 1.53 
CCDC85B -0.463 6.897 -6.305 1.67E-06 6.53E-06 3.979 -1.38 
Ccl2 -2.737 7.806 -20.572 1.11E-16 8.85E-15 28.051 -6.67 
Ccna2 -1.017 6.788 -7.959 3.63E-08 2.21E-07 7.888 -2.02 
CCNB1 -1.347 5.956 -9.460 1.53E-09 1.32E-08 11.137 -2.54 
Ccnb1 -1.155 7.434 -13.744 7.98E-13 1.91E-11 18.918 -2.23 
CCNB2 -0.409 6.467 -6.156 2.39E-06 9.07E-06 3.613 -1.33 
Ccnd1 0.612 6.627 7.202 2.00E-07 9.92E-07 6.142 1.53 
CCNL2 -0.348 7.749 -7.506 1.00E-07 5.40E-07 6.851 -1.27 
CCT2 -0.499 7.481 -2.491 2.01E-02 3.26E-02 -5.320 -1.41 
CCT8 -0.388 7.783 -3.560 1.60E-03 3.32E-03 -2.901 -1.31 
CD36 4.087 8.162 20.494 1.21E-16 9.23E-15 27.964 17.00 
CDC20 -1.127 7.231 -11.694 2.32E-11 3.23E-10 15.448 -2.18 
Cdca7 -0.647 7.256 -12.120 1.11E-11 1.70E-10 16.203 -1.57 
CDIPT 0.694 7.020 10.690 1.42E-10 1.58E-09 13.584 1.62 
CDK1 -0.441 8.673 -6.890 4.14E-07 1.90E-06 5.399 -1.36 
CDK11A 0.360 6.593 5.693 7.47E-06 2.49E-05 2.458 1.28 
Cdk5rap3 -0.326 7.163 -5.324 1.87E-05 5.76E-05 1.528 -1.25 
CDK6 0.408 6.642 3.668 1.22E-03 2.61E-03 -2.638 1.33 
Cdk6 0.559 8.613 8.823 5.65E-09 4.16E-08 9.795 1.47 
Cdk6 0.720 7.547 6.672 6.92E-07 2.99E-06 4.874 1.65 
CDKN3 -1.202 8.297 -13.900 6.27E-13 1.55E-11 19.167 -2.30 
Cdv3 0.500 8.233 8.619 8.70E-09 6.13E-08 9.352 1.41 
Cebpb -0.523 9.362 -13.001 2.58E-12 4.94E-11 17.709 -1.44 
CEBPZ 0.289 7.942 3.413 2.30E-03 4.63E-03 -3.254 1.22 
Cenpa -0.781 7.615 -8.303 1.71E-08 1.12E-07 8.659 -1.72 
Cenpf -0.915 6.632 -11.128 6.35E-11 7.76E-10 14.411 -1.89 
CENPL -0.417 6.032 -6.008 3.44E-06 1.26E-05 3.245 -1.34 
Cep55 -0.357 6.066 -4.226 3.01E-04 7.19E-04 -1.254 -1.28 
CETN3 -0.495 8.092 -6.606 8.09E-07 3.44E-06 4.716 -1.41 
Cfl1 0.376 5.881 2.632 1.47E-02 2.43E-02 -5.025 1.30 
Cflar -0.575 7.205 -7.298 1.61E-07 8.21E-07 6.366 -1.49 
CHD2 0.634 6.581 10.967 8.51E-11 1.00E-09 14.109 1.55 
CHD4 0.290 7.060 2.790 1.02E-02 1.75E-02 -4.685 1.22 
CHMP2A 0.481 7.416 9.677 9.92E-10 8.92E-09 11.583 1.40 
Chordc1 0.889 6.453 12.397 6.97E-12 1.15E-10 16.686 1.85 
Chpf 0.608 6.081 5.243 2.29E-05 6.92E-05 1.323 1.52 
CHPT1 -0.679 7.085 -6.232 1.99E-06 7.67E-06 3.799 -1.60 
CHPT1 -0.546 8.437 -9.786 8.00E-10 7.36E-09 11.804 -1.46 
CHUK 0.334 7.119 6.616 7.90E-07 3.37E-06 4.740 1.26 
Cidec -0.355 6.285 -7.057 2.80E-07 1.34E-06 5.798 -1.28 
CIRBP -0.835 7.470 -12.295 8.28E-12 1.33E-10 16.510 -1.78 
CISD3 -0.308 6.884 -4.948 4.83E-05 1.36E-04 0.575 -1.24 
CITED2 0.625 6.419 6.622 7.80E-07 3.33E-06 4.753 1.54 
CKAP2 -1.177 5.818 -19.230 5.07E-16 3.04E-14 26.492 -2.26 
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CKAP5 -0.583 6.097 -7.482 1.06E-07 5.67E-07 6.795 -1.50 
CKS1B -0.723 7.858 -14.503 2.53E-13 7.15E-12 20.103 -1.65 
CKS2 -0.405 8.689 -5.178 2.70E-05 8.03E-05 1.159 -1.32 
Clec2e -2.580 5.756 -24.439 2.19E-18 3.03E-16 32.068 -5.98 
Clic4 -0.534 8.809 -8.882 5.00E-09 3.77E-08 9.922 -1.45 
CLIP1 0.276 6.403 4.549 1.33E-04 3.40E-04 -0.439 1.21 
Clstn1 0.745 7.732 10.805 1.15E-10 1.31E-09 13.802 1.68 
CLTA 0.471 8.281 12.643 4.64E-12 8.13E-11 17.106 1.39 
CLTC 0.288 9.014 6.325 1.59E-06 6.25E-06 4.028 1.22 
Cmtm3 -0.348 6.630 -6.583 8.56E-07 3.62E-06 4.658 -1.27 
CNBP -0.342 9.436 -3.109 4.81E-03 8.91E-03 -3.967 -1.27 
CNOT7 0.280 7.521 6.151 2.42E-06 9.16E-06 3.601 1.21 
CNTD1 0.349 6.556 8.703 7.28E-09 5.26E-08 9.536 1.27 
COBLL1 -0.670 6.463 -12.531 5.58E-12 9.50E-11 16.915 -1.59 
COL5A2 -0.346 7.606 -4.756 7.84E-05 2.09E-04 0.088 -1.27 
Commd3 0.492 7.861 11.727 2.19E-11 3.08E-10 15.506 1.41 
COMMD7 0.748 6.618 15.867 3.60E-14 1.28E-12 22.110 1.68 
COMMD8 0.469 7.001 6.841 4.64E-07 2.10E-06 5.281 1.38 
COMTD1 -0.506 6.280 -7.520 9.68E-08 5.24E-07 6.883 -1.42 
COPE 0.442 8.277 8.158 2.34E-08 1.49E-07 8.337 1.36 
COPG2 -0.499 6.694 -4.104 4.09E-04 9.54E-04 -1.559 -1.41 
Cops8 0.568 7.245 11.485 3.35E-11 4.43E-10 15.069 1.48 
CORO1B -0.436 7.585 -6.044 3.14E-06 1.16E-05 3.335 -1.35 
Coro1b -0.408 8.179 -6.459 1.15E-06 4.68E-06 4.357 -1.33 
Cox4nb 0.738 7.112 13.419 1.33E-12 2.94E-11 18.396 1.67 
Cpn2 0.428 6.648 5.406 1.52E-05 4.78E-05 1.736 1.35 
Cpsf2 0.566 7.072 7.211 1.96E-07 9.82E-07 6.161 1.48 
CPT2 -0.412 6.454 -7.281 1.67E-07 8.48E-07 6.326 -1.33 
Creg1 -0.274 6.806 -2.909 7.74E-03 1.35E-02 -4.422 -1.21 
CRELD1 0.608 6.519 6.109 2.68E-06 1.01E-05 3.497 1.52 
CRELD2 0.415 7.396 5.782 5.99E-06 2.05E-05 2.681 1.33 
CRIPT 0.395 8.324 10.071 4.59E-10 4.54E-09 12.375 1.31 
Crkl 0.526 6.176 4.401 1.93E-04 4.77E-04 -0.812 1.44 
Crkl 0.556 6.976 13.208 1.85E-12 3.74E-11 18.051 1.47 
CROT -0.339 6.877 -7.450 1.14E-07 6.04E-07 6.720 -1.27 
CSDAP1 0.311 10.028 6.104 2.71E-06 1.02E-05 3.484 1.24 
CSDE1 -1.097 7.004 -2.842 9.03E-03 1.56E-02 -4.570 -2.14 
CSDE1 -0.307 7.867 -2.388 2.52E-02 3.99E-02 -5.529 -1.24 
CSE1L -1.052 7.389 -19.943 2.24E-16 1.46E-14 27.332 -2.07 
Csnk1d 0.586 7.166 10.087 4.45E-10 4.45E-09 12.408 1.50 
CSNK1E 0.368 6.379 7.207 1.98E-07 9.87E-07 6.153 1.29 
CSNK1E 0.500 6.600 7.736 5.95E-08 3.47E-07 7.382 1.41 
CSNK2A1 0.483 6.970 9.311 2.07E-09 1.73E-08 10.827 1.40 
Csnk2a1 0.700 6.763 6.363 1.45E-06 5.74E-06 4.122 1.62 
CSNK2A2 0.331 7.248 4.779 7.40E-05 1.99E-04 0.145 1.26 
CTAGE1 -0.368 8.036 -6.343 1.52E-06 6.00E-06 4.073 -1.29 
CTBP2 0.299 7.102 5.568 1.02E-05 3.30E-05 2.144 1.23 
Ctla2b -3.920 7.178 -45.815 9.36E-25 4.20E-22 46.768 -15.14 
Ctnnbl1 0.951 7.066 14.758 1.74E-13 5.38E-12 20.489 1.93 
Ctsb -0.390 9.036 -6.724 6.12E-07 2.68E-06 5.000 -1.31 
CTSF -0.364 6.525 -4.893 5.54E-05 1.54E-04 0.436 -1.29 
Ctsz -0.930 9.672 -20.294 1.51E-16 1.06E-14 27.736 -1.91 
CUL3 0.299 7.260 4.055 4.63E-04 1.07E-03 -1.681 1.23 
CUL3 0.306 8.127 6.576 8.70E-07 3.66E-06 4.642 1.24 
CUL4B -0.321 6.379 -6.047 3.12E-06 1.15E-05 3.343 -1.25 
Cul5 0.406 7.214 8.145 2.41E-08 1.53E-07 8.307 1.33 
Cxcl1 -1.357 6.634 -15.852 3.67E-14 1.28E-12 22.089 -2.56 
CYB5R1 0.430 6.816 6.707 6.37E-07 2.77E-06 4.960 1.35 
Cyb5r3 -0.422 7.652 -6.747 5.80E-07 2.55E-06 5.055 -1.34 
CYFIP1 -0.456 7.533 -8.325 1.63E-08 1.07E-07 8.708 -1.37 
CYP20A1 -0.464 7.126 -8.180 2.23E-08 1.43E-07 8.385 -1.38 
Cyp51 -0.943 9.644 -17.540 3.95E-15 1.86E-13 24.381 -1.92 
D10Jhu81e -0.722 6.385 -11.300 4.66E-11 5.98E-10 14.730 -1.65 
D15Ertd621e 0.569 7.356 13.496 1.17E-12 2.64E-11 18.522 1.48 
D17Wsu104e -0.445 6.741 -6.615 7.93E-07 3.38E-06 4.736 -1.36 
D5Ertd579e -0.359 7.211 -8.942 4.42E-09 3.38E-08 10.049 -1.28 
D5Ertd579e 0.573 6.408 11.903 1.62E-11 2.41E-10 15.820 1.49 
D830024F11Rik -0.422 7.236 -6.670 6.95E-07 3.00E-06 4.870 -1.34 
DAG1 -0.698 8.711 -10.782 1.20E-10 1.35E-09 13.758 -1.62 
DAG1 -0.509 7.183 -7.682 6.71E-08 3.85E-07 7.258 -1.42 
DARS -0.516 6.678 -2.291 3.11E-02 4.82E-02 -5.721 -1.43 
DARS -0.446 8.202 -2.554 1.75E-02 2.86E-02 -5.189 -1.36 
DBF4 -0.663 6.260 -8.582 9.41E-09 6.56E-08 9.272 -1.58 
Dbi -0.996 8.412 -16.056 2.78E-14 1.03E-12 22.376 -1.99 
DCAF13 0.401 7.411 9.518 1.36E-09 1.19E-08 11.257 1.32 
DCAF7 0.344 7.819 6.667 7.00E-07 3.01E-06 4.863 1.27 
DCN -0.505 10.903 -9.089 3.25E-09 2.60E-08 10.362 -1.42 
DCTN3 0.301 7.288 5.128 3.06E-05 8.97E-05 1.033 1.23 
DCTPP1 -0.504 7.125 -8.239 1.96E-08 1.27E-07 8.517 -1.42 
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Ddhd2 0.469 7.529 10.434 2.29E-10 2.46E-09 13.090 1.38 
DDHD2 0.595 9.554 2.535 1.82E-02 2.98E-02 -5.229 1.51 
DDIT3 0.667 6.496 6.993 3.25E-07 1.53E-06 5.645 1.59 
Ddx17 0.533 8.800 11.678 2.39E-11 3.29E-10 15.418 1.45 
DDX27 -0.292 6.735 -3.719 1.08E-03 2.33E-03 -2.515 -1.22 
Ddx54 -0.450 7.085 -6.392 1.35E-06 5.41E-06 4.193 -1.37 
DDX6 0.505 6.386 7.149 2.26E-07 1.11E-06 6.015 1.42 
Def8 0.365 6.413 7.211 1.96E-07 9.82E-07 6.161 1.29 
Dek -0.302 7.745 -4.889 5.60E-05 1.55E-04 0.426 -1.23 
Dennd4a 0.452 6.236 9.070 3.39E-09 2.69E-08 10.321 1.37 
DENND5A 0.286 6.500 3.986 5.51E-04 1.26E-03 -1.854 1.22 
DERL1 0.304 7.056 5.181 2.68E-05 7.99E-05 1.166 1.23 
DERL1 0.316 8.644 6.411 1.29E-06 5.18E-06 4.238 1.24 
Derl1 0.324 8.334 6.569 8.85E-07 3.71E-06 4.624 1.25 
Derl1 0.523 7.959 7.322 1.52E-07 7.81E-07 6.422 1.44 
DHRS7 -0.524 7.060 -12.694 4.26E-12 7.57E-11 17.193 -1.44 
DLAT 0.329 6.860 6.065 2.99E-06 1.11E-05 3.386 1.26 
DLGAP5 -0.959 6.521 -10.388 2.50E-10 2.67E-09 13.000 -1.94 
Dlst 0.443 6.415 6.582 8.58E-07 3.62E-06 4.655 1.36 
Dmtf1 0.307 6.932 3.693 1.15E-03 2.46E-03 -2.577 1.24 
DNAJA2 -0.335 6.750 -4.889 5.60E-05 1.55E-04 0.426 -1.26 
DNAJB2 0.500 6.280 4.712 8.76E-05 2.32E-04 -0.023 1.41 
Dnajb6 0.609 6.727 6.471 1.12E-06 4.57E-06 4.385 1.53 
DNAJC15 0.359 7.484 6.577 8.68E-07 3.66E-06 4.644 1.28 
DNAJC8 0.314 7.300 6.051 3.09E-06 1.14E-05 3.351 1.24 
DNTTIP1 0.707 6.557 12.692 4.28E-12 7.57E-11 17.189 1.63 
DNTTIP2 0.373 7.857 6.489 1.07E-06 4.40E-06 4.430 1.30 
DOCK7 -0.322 7.938 -6.473 1.11E-06 4.55E-06 4.390 -1.25 
Dock9 -0.789 6.569 -12.189 9.91E-12 1.54E-10 16.324 -1.73 
DPF2 0.353 6.623 5.707 7.20E-06 2.41E-05 2.494 1.28 
DPM1 -0.463 8.866 -10.727 1.33E-10 1.48E-09 13.653 -1.38 
Dpp3 -0.434 6.723 -6.069 2.96E-06 1.10E-05 3.398 -1.35 
DR1 0.362 8.097 4.172 3.45E-04 8.17E-04 -1.389 1.29 
Dram1 -1.132 6.300 -18.661 9.94E-16 5.33E-14 25.801 -2.19 
DUS1L -0.299 7.044 -5.809 5.59E-06 1.94E-05 2.750 -1.23 
Dusp3 1.266 5.641 13.772 7.64E-13 1.85E-11 18.964 2.41 
DYNC1H1 0.429 6.945 4.853 6.14E-05 1.69E-04 0.333 1.35 
DYNLRB1 0.608 9.137 11.766 2.05E-11 2.94E-10 15.576 1.52 
DYNLT3 0.299 6.979 6.802 5.09E-07 2.28E-06 5.187 1.23 
DYX1C1 -0.384 7.256 -7.449 1.14E-07 6.04E-07 6.720 -1.30 
E130203B14Rik -0.773 8.135 -9.475 1.49E-09 1.29E-08 11.167 -1.71 
EBNA1BP2 0.275 8.826 4.811 6.82E-05 1.85E-04 0.228 1.21 
EBP -1.345 5.933 -22.289 1.80E-17 1.74E-15 29.915 -2.54 
ECT2 -0.742 7.232 -7.677 6.78E-08 3.88E-07 7.247 -1.67 
EFEMP1 -1.230 9.515 -20.244 1.59E-16 1.08E-14 27.679 -2.35 
Ehd4 -0.692 6.254 -19.135 5.67E-16 3.23E-14 26.377 -1.62 
Eif1 0.278 9.538 5.987 3.61E-06 1.32E-05 3.194 1.21 
EIF1AX 0.387 7.613 7.140 2.31E-07 1.12E-06 5.995 1.31 
EIF2B4 0.291 6.151 3.291 3.09E-03 6.04E-03 -3.543 1.22 
EIF3B 0.377 7.197 2.726 1.18E-02 2.00E-02 -4.824 1.30 
EIF3D 0.396 7.558 3.389 2.44E-03 4.89E-03 -3.311 1.32 
EIF3D 0.563 9.026 8.985 4.03E-09 3.15E-08 10.141 1.48 
EIF3IP1 -0.297 10.139 -5.124 3.10E-05 9.06E-05 1.021 -1.23 
EIF3J 0.457 7.214 8.835 5.52E-09 4.12E-08 9.820 1.37 
EIF3J 0.492 6.961 4.780 7.39E-05 1.99E-04 0.148 1.41 
Eif4a1 -0.502 8.429 -2.905 7.81E-03 1.36E-02 -4.431 -1.42 
EIF4G1 0.328 7.266 2.875 8.36E-03 1.45E-02 -4.497 1.26 
EIF6 0.903 8.152 10.788 1.18E-10 1.34E-09 13.770 1.87 
ELAVL1 0.266 6.699 4.535 1.38E-04 3.52E-04 -0.474 1.20 
ELK3 -0.619 7.108 -7.715 6.24E-08 3.61E-07 7.333 -1.54 
ELOVL1 -0.472 6.439 -9.125 3.03E-09 2.43E-08 10.436 -1.39 
Elp2 0.474 5.950 4.481 1.58E-04 3.97E-04 -0.611 1.39 
EMP1 -1.234 7.772 -24.720 1.68E-18 2.63E-16 32.336 -2.35 
Enah 0.290 8.200 5.339 1.80E-05 5.57E-05 1.567 1.22 
Endod1 -0.403 6.475 -6.575 8.71E-07 3.67E-06 4.640 -1.32 
ENG 0.549 7.236 4.698 9.09E-05 2.40E-04 -0.061 1.46 
Ensa 0.292 6.811 7.419 1.22E-07 6.42E-07 6.650 1.22 
EPDR1 -0.344 7.424 -8.272 1.83E-08 1.19E-07 8.590 -1.27 
EPR1 -0.488 7.818 -6.045 3.14E-06 1.16E-05 3.336 -1.40 
EPRS -0.419 6.781 -3.375 2.53E-03 5.05E-03 -3.346 -1.34 
EPRS -0.290 8.814 -7.808 5.06E-08 3.00E-07 7.547 -1.22 
EPS8 -1.063 8.261 -11.829 1.84E-11 2.68E-10 15.690 -2.09 
EPS8 -0.913 7.562 -11.367 4.14E-11 5.38E-10 14.853 -1.88 
ERAP1 -0.498 6.611 -10.537 1.89E-10 2.07E-09 13.288 -1.41 
ERCC1 0.279 6.529 3.666 1.23E-03 2.62E-03 -2.644 1.21 
ERGIC3 0.297 7.529 3.153 4.32E-03 8.11E-03 -3.866 1.23 
ERGIC3 0.386 7.853 7.705 6.38E-08 3.68E-07 7.310 1.31 
Ermp1 -0.429 7.114 -6.899 4.05E-07 1.87E-06 5.421 -1.35 
Ern1 0.660 6.120 10.594 1.70E-10 1.87E-09 13.400 1.58 
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ERP29 -0.719 6.775 -8.580 9.45E-09 6.58E-08 9.268 -1.65 
Erp29 -0.536 7.835 -9.667 1.01E-09 9.08E-09 11.561 -1.45 
ERP44 -0.507 6.554 -3.447 2.11E-03 4.30E-03 -3.172 -1.42 
ESD -0.266 8.915 -6.453 1.17E-06 4.73E-06 4.343 -1.20 
ETFDH -0.347 7.133 -5.744 6.58E-06 2.23E-05 2.586 -1.27 
ETHE1 0.535 7.237 7.665 6.97E-08 3.97E-07 7.219 1.45 
ETNK1 0.472 8.465 8.190 2.18E-08 1.40E-07 8.408 1.39 
ETS1 -0.295 7.088 -5.850 5.06E-06 1.77E-05 2.852 -1.23 
EWSR1 0.277 7.376 7.547 9.10E-08 4.98E-07 6.947 1.21 
Exosc1 0.686 7.548 9.214 2.52E-09 2.08E-08 10.624 1.61 
EXOSC9 0.458 6.576 7.282 1.66E-07 8.47E-07 6.330 1.37 
EZH2 -0.379 6.593 -5.511 1.17E-05 3.77E-05 2.000 -1.30 
F2r -0.909 8.207 -10.070 4.60E-10 4.54E-09 12.373 -1.88 
FAF1 0.613 6.458 4.403 1.92E-04 4.75E-04 -0.808 1.53 
Fam102b -0.567 7.655 -7.388 1.30E-07 6.82E-07 6.578 -1.48 
FAM107B -1.009 6.765 -19.660 3.08E-16 1.94E-14 27.002 -2.01 
FAM113A -0.546 6.737 -8.499 1.12E-08 7.64E-08 9.091 -1.46 
FAM120A -0.377 9.029 -9.512 1.38E-09 1.20E-08 11.243 -1.30 
Fam125b 0.740 6.716 14.336 3.24E-13 8.89E-12 19.847 1.67 
FAM32A 0.346 6.710 6.329 1.57E-06 6.19E-06 4.038 1.27 
Fam32a 0.608 7.017 12.443 6.46E-12 1.08E-10 16.764 1.52 
FAM40B -0.494 6.679 -8.413 1.35E-08 9.02E-08 8.903 -1.41 
FAM49B -0.284 7.847 -5.838 5.22E-06 1.82E-05 2.821 -1.22 
FAM54B 0.347 6.657 5.020 4.03E-05 1.15E-04 0.757 1.27 
Fam82a2 0.410 6.323 9.832 7.31E-10 6.84E-09 11.896 1.33 
Fam92a 0.268 6.361 4.813 6.79E-05 1.85E-04 0.232 1.20 
FAM98A -0.399 6.939 -9.660 1.03E-09 9.15E-09 11.546 -1.32 
Farp2 0.276 6.968 5.070 3.55E-05 1.03E-04 0.884 1.21 
FARSB -0.311 7.344 -6.336 1.55E-06 6.10E-06 4.055 -1.24 
Farsb -0.295 7.210 -6.344 1.52E-06 6.00E-06 4.075 -1.23 
Fasn -0.794 6.330 -7.941 3.77E-08 2.29E-07 7.850 -1.73 
FAT1 -0.305 8.629 -6.031 3.25E-06 1.19E-05 3.302 -1.24 
FBXL5 -0.291 6.539 -4.382 2.03E-04 4.99E-04 -0.861 -1.22 
FBXO18 -0.271 6.618 -3.292 3.09E-03 6.03E-03 -3.541 -1.21 
FBXO28 0.458 7.050 8.916 4.66E-09 3.56E-08 9.993 1.37 
FBXO8 1.172 6.542 23.688 4.47E-18 5.18E-16 31.337 2.25 
FBXW11 0.345 7.396 6.494 1.06E-06 4.35E-06 4.443 1.27 
FCGRT 0.509 6.491 7.445 1.15E-07 6.08E-07 6.709 1.42 
FCHO2 -0.361 7.134 -6.238 1.96E-06 7.58E-06 3.814 -1.28 
FDFT1 -0.724 6.917 -16.287 2.03E-14 7.84E-13 22.700 -1.65 
FDPS -1.079 8.124 -18.441 1.30E-15 6.71E-14 25.528 -2.11 
Fem1b 0.617 7.723 12.247 8.98E-12 1.41E-10 16.426 1.53 
FERMT2 -0.281 8.924 -6.054 3.07E-06 1.13E-05 3.360 -1.21 
FH -0.269 8.282 -5.284 2.07E-05 6.31E-05 1.427 -1.21 
Fhl1 0.358 7.505 8.205 2.11E-08 1.36E-07 8.441 1.28 
Fhl2 -0.429 6.258 -9.755 8.51E-10 7.76E-09 11.740 -1.35 
Fkbp1a -0.293 9.533 -5.131 3.04E-05 8.91E-05 1.040 -1.23 
Fkbp9 -0.338 7.631 -6.561 9.02E-07 3.78E-06 4.605 -1.26 
FLJ44342 0.379 7.768 7.410 1.24E-07 6.54E-07 6.629 1.30 
FN1 -0.523 8.505 -10.464 2.17E-10 2.34E-09 13.148 -1.44 
FNTA 0.374 8.174 11.735 2.16E-11 3.05E-10 15.520 1.30 
FOXJ2 0.535 5.870 5.140 2.97E-05 8.75E-05 1.062 1.45 
FOXJ3 0.513 7.777 9.274 2.23E-09 1.86E-08 10.750 1.43 
FOXO3B 0.296 6.763 4.747 8.02E-05 2.14E-04 0.065 1.23 
Frmd6 -0.590 7.433 -10.826 1.10E-10 1.27E-09 13.843 -1.50 
FRMD6 -0.414 8.522 -7.816 4.97E-08 2.96E-07 7.566 -1.33 
FRY -1.023 7.685 -14.671 1.97E-13 5.83E-12 20.358 -2.03 
FTSJ3 0.314 7.362 4.779 7.40E-05 1.99E-04 0.146 1.24 
G3BP2 0.527 8.617 9.854 7.01E-10 6.62E-09 11.941 1.44 
Gaa 0.552 9.198 7.966 3.57E-08 2.17E-07 7.905 1.47 
GABARAP 0.537 9.365 11.600 2.74E-11 3.74E-10 15.278 1.45 
Gabarapl1 0.291 7.833 5.326 1.86E-05 5.74E-05 1.533 1.22 
GADD45A 0.499 8.855 7.474 1.08E-07 5.76E-07 6.776 1.41 
GADD45B -0.689 6.746 -10.136 4.05E-10 4.11E-09 12.505 -1.61 
GALNT7 0.522 7.466 5.151 2.89E-05 8.54E-05 1.090 1.44 
GAPDH -0.713 10.322 -4.693 9.19E-05 2.43E-04 -0.072 -1.64 
GAPDH -0.675 10.582 -4.948 4.83E-05 1.36E-04 0.575 -1.60 
GAPDH -0.664 8.290 -5.353 1.74E-05 5.40E-05 1.602 -1.58 
GAPDH -0.663 7.912 -5.278 2.10E-05 6.39E-05 1.411 -1.58 
GAPDH -0.588 7.234 -5.030 3.93E-05 1.13E-04 0.782 -1.50 
GAPDH -0.529 7.620 -5.957 3.89E-06 1.40E-05 3.119 -1.44 
Gapdh -0.437 9.031 -7.978 3.48E-08 2.13E-07 7.931 -1.35 
Gapdh -0.419 9.326 -8.507 1.10E-08 7.53E-08 9.109 -1.34 
GAPVD1 0.391 6.971 5.764 6.26E-06 2.13E-05 2.636 1.31 
GAS1 0.458 6.643 4.844 6.28E-05 1.72E-04 0.311 1.37 
GHITM 0.356 9.871 7.587 8.32E-08 4.64E-07 7.038 1.28 
GJA1 -0.267 10.715 -3.639 1.32E-03 2.78E-03 -2.710 -1.20 
GLG1 0.514 6.270 2.773 1.06E-02 1.81E-02 -4.722 1.43 
GLO1 -0.405 6.844 -2.534 1.83E-02 2.99E-02 -5.231 -1.32 
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GLOD4 -0.310 6.950 -3.536 1.70E-03 3.51E-03 -2.958 -1.24 
Glrx -0.272 7.177 -5.416 1.49E-05 4.68E-05 1.760 -1.21 
GLRX5 0.277 8.281 6.489 1.07E-06 4.40E-06 4.431 1.21 
GLUD1 -0.375 7.039 -4.437 1.76E-04 4.40E-04 -0.722 -1.30 
GLUL -0.448 6.564 -6.764 5.57E-07 2.47E-06 5.096 -1.36 
Gm10291 -0.411 10.903 -8.422 1.32E-08 8.87E-08 8.922 -1.33 
Gm10291 -0.360 10.446 -6.089 2.82E-06 1.05E-05 3.446 -1.28 
Gm10359 -0.545 10.886 -6.707 6.37E-07 2.77E-06 4.959 -1.46 
Gm12033 -0.573 8.805 -6.153 2.41E-06 9.14E-06 3.604 -1.49 
Gm12033 -0.559 9.387 -5.901 4.46E-06 1.58E-05 2.979 -1.47 
Gm14148 -0.461 9.820 -9.240 2.39E-09 1.98E-08 10.678 -1.38 
Gm15104 -0.374 6.022 -6.639 7.49E-07 3.21E-06 4.794 -1.30 
Gm2223 -0.280 7.713 -3.103 4.87E-03 9.00E-03 -3.980 -1.21 
Gm2260 -0.472 8.341 -7.552 9.00E-08 4.95E-07 6.958 -1.39 
Gm5069 -0.574 9.657 -10.339 2.75E-10 2.90E-09 12.904 -1.49 
Gm5578 0.353 6.726 6.603 8.16E-07 3.46E-06 4.707 1.28 
Gm70 -0.273 7.287 -2.476 2.08E-02 3.36E-02 -5.351 -1.21 
Gm9174 0.320 7.020 5.753 6.43E-06 2.18E-05 2.609 1.25 
GMFB 0.411 7.391 2.854 8.79E-03 1.52E-02 -4.544 1.33 
Gmfb 0.668 8.592 11.683 2.37E-11 3.27E-10 15.426 1.59 
GNAI1 0.324 7.278 4.908 5.34E-05 1.49E-04 0.473 1.25 
GNAI2 -0.373 6.846 -4.840 6.34E-05 1.74E-04 0.301 -1.29 
GNL2 0.281 6.688 4.623 1.10E-04 2.86E-04 -0.251 1.22 
GNPAT -0.723 6.582 -13.209 1.85E-12 3.74E-11 18.053 -1.65 
GNPTAB -0.738 7.124 -13.804 7.27E-13 1.78E-11 19.015 -1.67 
GPBP1L1 0.352 6.653 5.111 3.20E-05 9.34E-05 0.987 1.28 
GPC6 -1.701 3.584 -20.301 1.50E-16 1.06E-14 27.744 -3.25 
Gpd2 -0.465 6.879 -6.108 2.69E-06 1.01E-05 3.494 -1.38 
Gpnmb 1.397 5.966 22.165 2.04E-17 1.88E-15 29.786 2.63 
GPR176 -0.519 7.295 -11.879 1.68E-11 2.48E-10 15.779 -1.43 
Gpr56 1.920 6.194 24.439 2.18E-18 3.03E-16 32.069 3.78 
Gpsm2 -0.584 6.902 -8.827 5.61E-09 4.14E-08 9.802 -1.50 
Gpx1 -1.024 7.884 -14.715 1.85E-13 5.58E-12 20.425 -2.03 
Gpx4 -0.571 10.579 -10.933 9.07E-11 1.05E-09 14.045 -1.49 
GSK3B 0.449 6.314 4.927 5.09E-05 1.42E-04 0.521 1.36 
Gstm5 -0.436 10.418 -7.611 7.88E-08 4.43E-07 7.093 -1.35 
Gstm6 -0.318 7.960 -4.305 2.46E-04 5.95E-04 -1.054 -1.25 
Gstm7 -0.347 8.876 -4.996 4.27E-05 1.22E-04 0.697 -1.27 
GTF2A1 0.422 6.434 6.250 1.91E-06 7.39E-06 3.843 1.34 
Gtf2i 0.432 6.845 9.154 2.85E-09 2.30E-08 10.499 1.35 
GTPBP4 0.266 7.814 4.403 1.92E-04 4.75E-04 -0.808 1.20 
GUSB -0.954 6.935 -18.969 6.89E-16 3.83E-14 26.177 -1.94 
Gusb -0.775 7.029 -13.142 2.06E-12 4.00E-11 17.943 -1.71 
Gyg -0.485 8.497 -5.923 4.23E-06 1.51E-05 3.034 -1.40 
Gypc -0.567 7.466 -9.743 8.72E-10 7.93E-09 11.715 -1.48 
H1f0 0.948 8.525 15.035 1.16E-13 3.76E-12 20.905 1.93 
H2afx -0.329 6.799 -4.172 3.45E-04 8.17E-04 -1.390 -1.26 
H3F3B 0.425 9.428 10.045 4.83E-10 4.71E-09 12.324 1.34 
H3F3C 0.396 10.004 7.988 3.40E-08 2.09E-07 7.956 1.32 
H6pd -0.382 6.439 -5.680 7.70E-06 2.57E-05 2.426 -1.30 
HADHB -0.358 8.394 -7.277 1.69E-07 8.55E-07 6.317 -1.28 
HARS -0.322 6.414 -4.690 9.28E-05 2.45E-04 -0.081 -1.25 
HAT1 -0.305 6.594 -4.355 2.17E-04 5.31E-04 -0.928 -1.24 
HAX1 0.445 7.314 8.827 5.60E-09 4.14E-08 9.804 1.36 
HBP1 -0.273 6.407 -2.626 1.49E-02 2.46E-02 -5.038 -1.21 
HBS1L 0.533 6.390 11.362 4.18E-11 5.42E-10 14.842 1.45 
HBXIP 0.673 8.226 12.832 3.40E-12 6.20E-11 17.427 1.59 
HDDC3 -0.375 7.397 -10.352 2.68E-10 2.84E-09 12.929 -1.30 
HEG1 -0.299 8.653 -4.840 6.35E-05 1.74E-04 0.300 -1.23 
Hibadh -0.304 7.744 -5.601 9.38E-06 3.06E-05 2.226 -1.23 
HIP1 -0.618 6.987 -12.241 9.07E-12 1.42E-10 16.415 -1.53 
HIST1H2BN 0.315 7.314 3.695 1.14E-03 2.45E-03 -2.572 1.24 
HMBS -0.665 7.118 -14.228 3.81E-13 1.04E-11 19.680 -1.59 
HMGCR -1.175 6.572 -17.534 3.98E-15 1.86E-13 24.374 -2.26 
Hmgcs1 -1.236 6.887 -22.397 1.61E-17 1.61E-15 30.029 -2.35 
HMGN2 -0.313 8.395 -7.325 1.51E-07 7.76E-07 6.430 -1.24 
HMGN5 -0.519 8.999 -9.506 1.40E-09 1.21E-08 11.231 -1.43 
HMOX1 -0.519 7.105 -6.005 3.46E-06 1.26E-05 3.238 -1.43 
Hnrnpa3 -0.299 8.503 -3.234 3.56E-03 6.84E-03 -3.678 -1.23 
HNRNPC 0.310 9.033 6.523 9.88E-07 4.10E-06 4.512 1.24 
Hnrnpd -0.397 9.164 -7.158 2.22E-07 1.09E-06 6.036 -1.32 
HNRNPH1 0.312 8.470 5.630 8.73E-06 2.87E-05 2.299 1.24 
HNRNPR -0.344 8.226 -6.782 5.33E-07 2.38E-06 5.141 -1.27 
Hnrpdl -0.532 6.334 -8.336 1.59E-08 1.05E-07 8.733 -1.45 
HNRPDL -0.471 6.768 -7.209 1.97E-07 9.84E-07 6.158 -1.39 
Hoxd9 0.582 5.751 5.433 1.42E-05 4.50E-05 1.804 1.50 
HP1BP3 -0.312 8.095 -7.634 7.48E-08 4.21E-07 7.147 -1.24 
HPRT1 -0.671 9.127 -13.540 1.10E-12 2.51E-11 18.591 -1.59 
HSD17B10 -0.323 8.843 -6.268 1.82E-06 7.08E-06 3.889 -1.25 
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Hsd17b12 -0.309 7.796 -6.466 1.13E-06 4.61E-06 4.375 -1.24 
HSPH1 0.732 7.650 12.918 2.96E-12 5.50E-11 17.570 1.66 
HTRA1 -0.552 10.001 -9.318 2.04E-09 1.71E-08 10.841 -1.47 
HTRA2 -0.317 7.125 -6.119 2.62E-06 9.84E-06 3.519 -1.25 
IDH1 -1.534 6.178 -6.816 4.93E-07 2.22E-06 5.221 -2.90 
IDH1 -1.158 8.313 -15.379 7.11E-14 2.41E-12 21.410 -2.23 
IDH3B -0.272 7.689 -3.107 4.83E-03 8.95E-03 -3.973 -1.21 
Idi1 -1.320 6.124 -22.110 2.16E-17 1.94E-15 29.727 -2.50 
Ifitm2 -0.438 10.142 -5.710 7.15E-06 2.40E-05 2.502 -1.35 
Ifitm3 -0.761 9.676 -11.241 5.18E-11 6.49E-10 14.620 -1.69 
Ifngr2 -0.516 6.377 -11.301 4.66E-11 5.98E-10 14.730 -1.43 
IFRD1 0.638 6.993 3.314 2.93E-03 5.74E-03 -3.489 1.56 
IFRD1 0.752 9.381 11.029 7.60E-11 9.02E-10 14.226 1.68 
IFRD2 0.311 6.584 4.700 9.04E-05 2.39E-04 -0.055 1.24 
Ift52 0.620 7.441 17.286 5.47E-15 2.39E-13 24.049 1.54 
IGFBP4 -0.571 6.718 -5.450 1.37E-05 4.33E-05 1.847 -1.49 
IK 0.268 6.681 4.620 1.11E-04 2.88E-04 -0.258 1.20 
Ildr2 0.406 6.552 7.912 4.02E-08 2.43E-07 7.782 1.32 
Impad1 0.327 6.929 3.941 6.18E-04 1.40E-03 -1.966 1.25 
IMPDH2 -0.387 9.639 -9.677 9.93E-10 8.92E-09 11.582 -1.31 
Insig1 -0.878 8.024 -17.964 2.32E-15 1.14E-13 24.928 -1.84 
IP6K1 0.406 6.552 2.527 1.86E-02 3.03E-02 -5.246 1.33 
IPO7 0.404 8.117 6.724 6.12E-07 2.68E-06 5.000 1.32 
IPO7 0.487 8.188 10.073 4.57E-10 4.54E-09 12.380 1.40 
Irak2 -0.925 6.582 -12.975 2.69E-12 5.06E-11 17.666 -1.90 
IRS1 0.583 6.303 8.828 5.60E-09 4.14E-08 9.804 1.50 
Isca1 -0.336 8.849 -7.967 3.56E-08 2.17E-07 7.907 -1.26 
ITCH 0.474 7.087 9.780 8.11E-10 7.43E-09 11.791 1.39 
ITIH5 -1.171 6.180 -10.550 1.84E-10 2.02E-09 13.313 -2.25 
Jak2 -0.555 6.679 -7.741 5.89E-08 3.45E-07 7.392 -1.47 
Jub -0.305 7.280 -8.057 2.92E-08 1.83E-07 8.111 -1.24 
JUN 0.745 7.869 10.484 2.09E-10 2.26E-09 13.186 1.68 
KCMF1 0.279 8.700 6.456 1.16E-06 4.70E-06 4.350 1.21 
Kctd10 0.333 6.615 6.733 5.99E-07 2.63E-06 5.022 1.26 
KIAA0174 0.504 7.533 11.722 2.21E-11 3.09E-10 15.497 1.42 
KIF23 -0.542 6.746 -8.379 1.45E-08 9.63E-08 8.827 -1.46 
KIF5B 0.372 8.303 5.790 5.87E-06 2.02E-05 2.701 1.29 
KIF5B 0.432 6.853 3.549 1.65E-03 3.41E-03 -2.928 1.35 
KIFC1 -0.647 6.589 -10.149 3.95E-10 4.02E-09 12.529 -1.57 
KLF4 -0.274 6.396 -3.147 4.39E-03 8.20E-03 -3.879 -1.21 
KLF6 0.399 6.300 5.157 2.85E-05 8.44E-05 1.105 1.32 
KLF6 0.414 7.705 7.095 2.56E-07 1.23E-06 5.889 1.33 
KLF6 0.417 8.141 8.404 1.38E-08 9.18E-08 8.882 1.34 
KPNA2 -0.684 7.512 -10.954 8.73E-11 1.02E-09 14.084 -1.61 
Kpna4 0.637 7.353 11.554 2.97E-11 4.01E-10 15.193 1.55 
KPNA6 0.453 6.350 6.547 9.32E-07 3.89E-06 4.572 1.37 
Kpnb1 0.288 8.159 5.213 2.48E-05 7.42E-05 1.247 1.22 
KPNB1 0.312 7.476 3.086 5.08E-03 9.33E-03 -4.020 1.24 
KRIT1 0.288 7.004 5.185 2.66E-05 7.92E-05 1.176 1.22 
KRR1 0.540 6.347 9.870 6.80E-10 6.44E-09 11.972 1.45 
LAMA5 -0.351 6.977 -5.154 2.87E-05 8.50E-05 1.097 -1.28 
LAMC1 -0.400 7.195 -8.183 2.22E-08 1.42E-07 8.393 -1.32 
LAMP2 0.282 6.487 4.369 2.09E-04 5.14E-04 -0.894 1.22 
LAP3 -0.472 6.693 -3.581 1.52E-03 3.17E-03 -2.850 -1.39 
LAP3 -0.400 7.918 -10.099 4.35E-10 4.38E-09 12.431 -1.32 
LAPTM4A -0.653 7.312 -3.534 1.70E-03 3.52E-03 -2.963 -1.57 
LAPTM4A -0.531 7.522 -7.071 2.71E-07 1.30E-06 5.830 -1.45 
LARP1 0.311 7.726 5.120 3.12E-05 9.13E-05 1.013 1.24 
LAYN -0.619 6.973 -8.554 9.99E-09 6.91E-08 9.211 -1.54 
LDHA -0.530 9.533 -5.232 2.36E-05 7.12E-05 1.295 -1.44 
Ldlr -1.380 6.729 -22.030 2.34E-17 2.05E-15 29.643 -2.60 
Lemd2 0.280 6.690 4.651 1.02E-04 2.69E-04 -0.179 1.21 
LEMD3 0.296 7.077 3.121 4.68E-03 8.69E-03 -3.941 1.23 
Leprotl1 0.464 7.192 11.440 3.63E-11 4.76E-10 14.986 1.38 
LGALS1 -1.120 10.053 -13.340 1.50E-12 3.16E-11 18.267 -2.17 
LGALS3 -0.736 10.366 -11.687 2.35E-11 3.26E-10 15.435 -1.67 
Lman2 -0.351 7.930 -4.259 2.77E-04 6.64E-04 -1.172 -1.28 
LOC100043810 -0.557 7.540 -6.713 6.27E-07 2.74E-06 4.975 -1.47 
LOC100130746 0.501 7.013 10.380 2.54E-10 2.71E-09 12.983 1.42 
LOC100131826 -0.706 7.320 -8.307 1.70E-08 1.12E-07 8.667 -1.63 
LOC100133593 0.363 6.201 3.306 2.98E-03 5.84E-03 -3.508 1.29 
LOC100287146 -0.440 7.745 -6.867 4.37E-07 1.99E-06 5.344 -1.36 
LOC100287239 -0.310 9.812 -2.496 1.99E-02 3.23E-02 -5.310 -1.24 
LOC100287552 0.806 5.617 5.987 3.61E-06 1.32E-05 3.193 1.75 
LOC100287653 0.294 7.806 5.036 3.86E-05 1.11E-04 0.799 1.23 
LOC100287764 1.098 6.206 5.813 5.54E-06 1.92E-05 2.760 2.14 
LOC100288436 0.363 6.402 7.229 1.88E-07 9.44E-07 6.205 1.29 
LOC100294264 -0.625 6.932 -7.497 1.02E-07 5.50E-07 6.831 -1.54 
LOC100294264 0.461 7.669 5.870 4.82E-06 1.70E-05 2.902 1.38 
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LOC294154 0.542 5.851 4.355 2.17E-04 5.31E-04 -0.928 1.46 
LOC401387 -0.851 9.012 -15.001 1.22E-13 3.91E-12 20.854 -1.80 
LOC547349 0.445 9.208 6.476 1.10E-06 4.52E-06 4.398 1.36 
LOC553150 0.435 8.437 7.205 1.99E-07 9.90E-07 6.148 1.35 
LOC642969 -0.896 6.690 -3.819 8.39E-04 1.86E-03 -2.268 -1.86 
LOC685953 3.997 9.130 38.295 6.36E-23 1.90E-20 42.609 15.96 
LOC728758 0.662 6.767 13.233 1.78E-12 3.66E-11 18.092 1.58 
LOC728776 0.359 9.135 5.335 1.82E-05 5.63E-05 1.555 1.28 
LOC732229 0.455 7.725 8.457 1.23E-08 8.28E-08 9.000 1.37 
LOC732229 0.502 7.558 10.039 4.89E-10 4.76E-09 12.311 1.42 
LPCAT3 -0.869 6.684 -9.414 1.68E-09 1.43E-08 11.041 -1.83 
LPCAT3 -0.638 6.785 -11.039 7.47E-11 8.91E-10 14.245 -1.56 
LPL 0.316 10.528 5.807 5.62E-06 1.94E-05 2.745 1.24 
LPP 0.500 6.385 5.646 8.38E-06 2.77E-05 2.341 1.41 
LPP 0.644 7.853 11.570 2.89E-11 3.93E-10 15.222 1.56 
Lrig1 -1.924 8.856 -19.737 2.82E-16 1.81E-14 27.092 -3.79 
Lrp10 -0.655 7.803 -9.166 2.78E-09 2.25E-08 10.523 -1.57 
LRPPRC 0.436 7.197 5.414 1.50E-05 4.70E-05 1.755 1.35 
LRRC33 0.464 8.703 12.770 3.76E-12 6.83E-11 17.322 1.38 
LRRC59 0.474 8.298 10.046 4.82E-10 4.71E-09 12.325 1.39 
LRRC8D -0.484 6.697 -5.766 6.22E-06 2.12E-05 2.642 -1.40 
Lsg1 0.391 7.593 5.567 1.02E-05 3.31E-05 2.141 1.31 
LSG1 0.474 7.417 9.070 3.39E-09 2.69E-08 10.321 1.39 
LSM14A 0.282 6.661 5.873 4.79E-06 1.69E-05 2.908 1.22 
LSM3 -0.545 7.307 -9.828 7.38E-10 6.89E-09 11.888 -1.46 
LUZP6 0.311 7.299 6.868 4.36E-07 1.99E-06 5.347 1.24 
LUZP6 0.381 6.513 6.654 7.23E-07 3.11E-06 4.831 1.30 
Ly6e -0.987 7.105 -13.246 1.74E-12 3.60E-11 18.114 -1.98 
LYAR -0.296 7.006 -5.254 2.23E-05 6.75E-05 1.352 -1.23 
MACROD1 0.354 6.433 5.420 1.47E-05 4.64E-05 1.771 1.28 
Mad2l1 -0.731 6.292 -5.938 4.07E-06 1.46E-05 3.072 -1.66 
Mad2l1 -0.575 7.100 -8.764 6.40E-09 4.67E-08 9.667 -1.49 
MAFG 0.598 6.127 6.278 1.78E-06 6.94E-06 3.913 1.51 
MAFG 0.660 6.400 6.703 6.43E-07 2.80E-06 4.949 1.58 
MAFG 0.755 5.986 5.850 5.07E-06 1.77E-05 2.851 1.69 
MAGOH 0.366 7.716 7.365 1.38E-07 7.15E-07 6.523 1.29 
MAMDC2 -1.020 7.429 -8.828 5.59E-09 4.14E-08 9.806 -2.03 
MAN2A1 -0.509 6.683 -6.916 3.89E-07 1.80E-06 5.461 -1.42 
Man2a1 -0.473 6.504 -6.540 9.47E-07 3.95E-06 4.555 -1.39 
MAN2C1 -0.564 6.482 -7.606 7.97E-08 4.47E-07 7.083 -1.48 
Manbal 0.625 6.723 10.763 1.24E-10 1.40E-09 13.722 1.54 
Map1lc3b 0.301 8.856 4.166 3.50E-04 8.26E-04 -1.403 1.23 
Map1lc3b 0.433 8.566 13.201 1.87E-12 3.74E-11 18.040 1.35 
MAP2K1 0.313 8.294 6.088 2.82E-06 1.05E-05 3.444 1.24 
MAPK1 -0.387 6.595 -7.378 1.34E-07 6.98E-07 6.553 -1.31 
MAPKAPK5 0.475 6.646 7.716 6.22E-08 3.60E-07 7.337 1.39 
MAPRE1 0.554 7.902 9.271 2.25E-09 1.87E-08 10.743 1.47 
MARK1 -0.960 6.616 -20.525 1.17E-16 9.12E-15 27.998 -1.95 
MAX 0.296 5.929 2.578 1.66E-02 2.72E-02 -5.139 1.23 
MBNL1 0.360 9.159 8.792 6.03E-09 4.42E-08 9.728 1.28 
Mbp -0.968 6.692 -14.604 2.17E-13 6.30E-12 20.258 -1.96 
MCL1 0.284 7.354 6.762 5.59E-07 2.48E-06 5.092 1.22 
Mcm2 -0.345 6.936 -5.935 4.11E-06 1.47E-05 3.062 -1.27 
MDH1 -0.440 8.427 -3.478 1.96E-03 4.01E-03 -3.099 -1.36 
MDH1 -0.275 9.418 -6.427 1.24E-06 5.01E-06 4.279 -1.21 
Med29 0.467 7.001 7.846 4.66E-08 2.79E-07 7.633 1.38 
Mesdc2 -0.306 9.074 -9.463 1.52E-09 1.31E-08 11.143 -1.24 
METTL6 0.629 6.319 13.267 1.69E-12 3.50E-11 18.148 1.55 
METTL9 -0.697 6.724 -11.510 3.21E-11 4.27E-10 15.114 -1.62 
MFN2 0.383 7.176 8.613 8.81E-09 6.19E-08 9.339 1.30 
Mia3 -0.311 8.330 -5.703 7.27E-06 2.43E-05 2.484 -1.24 
MIB1 0.454 7.443 7.115 2.45E-07 1.18E-06 5.935 1.37 
MIF -0.462 9.040 -6.535 9.59E-07 3.99E-06 4.542 -1.38 
MIF -0.342 9.635 -5.475 1.28E-05 4.08E-05 1.910 -1.27 
MIR21 -0.456 6.244 -5.717 7.04E-06 2.37E-05 2.518 -1.37 
MITF -1.221 7.306 -17.062 7.29E-15 3.08E-13 23.753 -2.33 
Mknk2 -0.356 6.736 -3.989 5.48E-04 1.25E-03 -1.847 -1.28 
MLF2 0.275 6.161 2.365 2.65E-02 4.17E-02 -5.575 1.21 
MLL 0.347 6.439 4.541 1.35E-04 3.46E-04 -0.457 1.27 
MMD -0.333 6.497 -4.101 4.13E-04 9.60E-04 -1.568 -1.26 
MMP24 0.582 6.162 8.942 4.42E-09 3.38E-08 10.049 1.50 
MMP9 0.618 6.731 9.796 7.86E-10 7.26E-09 11.823 1.54 
Mobkl1b 0.271 8.120 5.323 1.88E-05 5.77E-05 1.526 1.21 
MOBKL3 0.553 6.352 11.846 1.78E-11 2.62E-10 15.718 1.47 
MPHOSPH10 0.375 6.627 7.189 2.06E-07 1.02E-06 6.110 1.30 
MPP6 -0.473 7.328 -8.534 1.04E-08 7.16E-08 9.169 -1.39 
MPST -0.402 6.645 -6.976 3.38E-07 1.58E-06 5.605 -1.32 
MRPL1 0.363 7.634 7.261 1.75E-07 8.83E-07 6.280 1.29 
Mrpl18 -0.302 7.610 -6.800 5.11E-07 2.29E-06 5.184 -1.23 
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MRPL24 0.511 7.227 9.914 6.22E-10 5.96E-09 12.062 1.42 
MRPL30 0.318 8.776 5.090 3.37E-05 9.78E-05 0.936 1.25 
MRPL37 0.645 7.536 8.831 5.56E-09 4.14E-08 9.811 1.56 
MRPL43 0.332 7.341 5.229 2.38E-05 7.16E-05 1.287 1.26 
Mrpl50 -0.394 7.408 -5.441 1.40E-05 4.42E-05 1.824 -1.31 
Mrpl53 0.313 6.945 4.637 1.06E-04 2.77E-04 -0.214 1.24 
Mrpl9 0.343 6.152 3.467 2.01E-03 4.11E-03 -3.124 1.27 
MRPS10 0.315 6.973 3.844 7.88E-04 1.75E-03 -2.206 1.24 
MRPS15 0.268 7.120 4.423 1.83E-04 4.55E-04 -0.758 1.20 
MRPS18A 0.265 9.934 4.216 3.08E-04 7.36E-04 -1.279 1.20 
MRPS18B 0.391 7.064 4.937 4.96E-05 1.39E-04 0.547 1.31 
MRPS18C 0.321 8.020 8.045 3.00E-08 1.87E-07 8.084 1.25 
MRPS22 0.638 6.359 13.625 9.60E-13 2.24E-11 18.728 1.56 
Mrps23 0.434 6.974 9.252 2.33E-09 1.94E-08 10.704 1.35 
MRPS35 0.382 8.616 7.799 5.17E-08 3.06E-07 7.525 1.30 
MSL1 0.354 6.484 5.034 3.88E-05 1.12E-04 0.794 1.28 
MSN 0.456 7.535 3.103 4.88E-03 9.00E-03 -3.981 1.37 
Msrb2 -0.372 6.378 -5.605 9.28E-06 3.03E-05 2.237 -1.29 
MT1A -0.328 7.750 -3.132 4.55E-03 8.47E-03 -3.915 -1.26 
Mtap4 0.377 6.079 4.386 2.00E-04 4.94E-04 -0.849 1.30 
MTBP -0.362 6.107 -6.854 4.50E-07 2.05E-06 5.314 -1.29 
MTDH 0.299 7.693 5.834 5.26E-06 1.83E-05 2.813 1.23 
MTHFD1 -0.481 7.372 -12.115 1.12E-11 1.71E-10 16.195 -1.40 
MTHFD1L -0.508 7.267 -11.895 1.64E-11 2.43E-10 15.806 -1.42 
Mthfd2 -0.480 7.826 -10.660 1.50E-10 1.66E-09 13.526 -1.39 
Mthfd2l -0.672 6.000 -10.534 1.90E-10 2.07E-09 13.284 -1.59 
MTX1 0.635 7.183 10.082 4.49E-10 4.48E-09 12.398 1.55 
MTX2 -0.339 7.973 -5.795 5.79E-06 2.00E-05 2.715 -1.27 
Myc 0.302 9.167 6.977 3.38E-07 1.58E-06 5.606 1.23 
Myd88 -0.310 6.590 -7.484 1.05E-07 5.64E-07 6.801 -1.24 
MYL12B -0.337 10.684 -4.203 3.19E-04 7.60E-04 -1.312 -1.26 
MYO1B -0.378 8.879 -6.758 5.65E-07 2.50E-06 5.082 -1.30 
N6AMT2 -0.517 6.228 -8.654 8.07E-09 5.73E-08 9.430 -1.43 
NAP1L1 0.269 6.670 5.942 4.04E-06 1.45E-05 3.080 1.21 
Nap1l4 0.488 6.668 7.831 4.81E-08 2.87E-07 7.599 1.40 
NARS 0.292 8.331 4.873 5.83E-05 1.61E-04 0.385 1.22 
Nars 0.345 7.775 6.931 3.76E-07 1.75E-06 5.497 1.27 
Nbl1 -0.655 6.440 -7.584 8.37E-08 4.65E-07 7.032 -1.57 
Ncam1 0.453 5.358 5.041 3.82E-05 1.10E-04 0.811 1.37 
Ncapd3 -0.845 5.993 -11.988 1.40E-11 2.11E-10 15.971 -1.80 
Ncaph -0.870 6.789 -13.151 2.03E-12 3.98E-11 17.958 -1.83 
NCEH1 -0.654 6.694 -12.909 3.00E-12 5.55E-11 17.556 -1.57 
NCK2 -0.434 6.349 -5.478 1.27E-05 4.06E-05 1.918 -1.35 
NCL -0.347 8.619 -6.451 1.17E-06 4.75E-06 4.337 -1.27 
NCOA6 0.670 5.976 12.555 5.36E-12 9.22E-11 16.957 1.59 
NDC80 -0.344 6.736 -4.186 3.33E-04 7.90E-04 -1.354 -1.27 
Ndufaf2 0.496 7.178 9.118 3.07E-09 2.46E-08 10.422 1.41 
Ndufb5 -0.546 9.033 -8.599 9.07E-09 6.35E-08 9.310 -1.46 
Ndufb9 0.285 10.546 8.134 2.47E-08 1.57E-07 8.282 1.22 
NDUFS7 0.328 9.159 4.532 1.38E-04 3.54E-04 -0.481 1.25 
Neat1 -0.771 8.207 -11.765 2.05E-11 2.94E-10 15.574 -1.71 
NEDD8 0.331 8.511 6.852 4.53E-07 2.06E-06 5.307 1.26 
Nek2 -0.727 8.036 -11.039 7.47E-11 8.91E-10 14.245 -1.65 
Neu1 0.303 6.374 5.530 1.12E-05 3.61E-05 2.048 1.23 
NEURL3 0.420 6.003 3.080 5.16E-03 9.46E-03 -4.035 1.34 
Neurl3 0.650 6.664 9.350 1.91E-09 1.62E-08 10.908 1.57 
NFKBIA -1.215 8.519 -17.262 5.63E-15 2.44E-13 24.018 -2.32 
NFKBIA -1.161 8.243 -18.751 8.92E-16 4.86E-14 25.912 -2.24 
NFU1 0.397 6.920 11.169 5.90E-11 7.29E-10 14.486 1.32 
NGDN 0.651 7.269 13.144 2.05E-12 4.00E-11 17.946 1.57 
NGRN 0.355 7.748 9.449 1.57E-09 1.34E-08 11.113 1.28 
NHP2L1 -0.439 8.019 -7.454 1.12E-07 5.99E-07 6.731 -1.36 
Nid1 -0.645 8.249 -8.943 4.41E-09 3.38E-08 10.050 -1.56 
Nid1 -0.290 8.359 -2.987 6.43E-03 1.15E-02 -4.246 -1.22 
NINJ1 -0.362 6.177 -5.710 7.15E-06 2.40E-05 2.502 -1.29 
NIT1 -0.493 6.656 -6.231 1.99E-06 7.67E-06 3.797 -1.41 
NOL7 0.556 8.228 9.190 2.65E-09 2.16E-08 10.575 1.47 
NOP56 -0.335 7.327 -3.981 5.58E-04 1.27E-03 -1.866 -1.26 
NOP58 0.459 8.700 5.660 8.10E-06 2.69E-05 2.375 1.37 
Nox1 -0.293 7.107 -3.706 1.11E-03 2.40E-03 -2.547 -1.23 
NPC2 -0.350 9.515 -7.689 6.62E-08 3.80E-07 7.273 -1.27 
Nploc4 0.520 6.036 6.028 3.27E-06 1.20E-05 3.294 1.43 
NR1H3 -0.724 6.661 -8.545 1.02E-08 7.01E-08 9.193 -1.65 
Nr2c1 0.285 6.434 5.598 9.44E-06 3.07E-05 2.220 1.22 
NRAS 0.521 7.871 10.334 2.77E-10 2.92E-09 12.895 1.43 
NRD1 0.323 6.675 2.628 1.48E-02 2.45E-02 -5.034 1.25 
NRP1 -0.545 7.277 -9.181 2.70E-09 2.19E-08 10.556 -1.46 
NSMCE2 0.332 8.368 5.006 4.17E-05 1.19E-04 0.723 1.26 
NSMCE4A -0.306 6.768 -6.734 5.97E-07 2.62E-06 5.024 -1.24 
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NTAN1 -0.380 7.177 -5.094 3.34E-05 9.71E-05 0.945 -1.30 
Nucb1 0.288 6.716 5.214 2.47E-05 7.41E-05 1.249 1.22 
Nucks1 -0.365 6.595 -4.935 4.99E-05 1.40E-04 0.541 -1.29 
NUDC 0.630 8.891 9.938 5.94E-10 5.71E-09 12.110 1.55 
Nudt3 0.277 6.423 3.282 3.16E-03 6.14E-03 -3.564 1.21 
NUMB 0.380 6.379 5.783 5.98E-06 2.05E-05 2.683 1.30 
NUP205 -0.278 6.845 -6.292 1.72E-06 6.71E-06 3.948 -1.21 
NUP93 -0.350 6.264 -5.830 5.32E-06 1.85E-05 2.801 -1.27 
Nusap1 -0.968 6.996 -12.131 1.09E-11 1.68E-10 16.223 -1.96 
NVL 0.862 6.210 16.059 2.77E-14 1.03E-12 22.380 1.82 
Oaf -0.433 7.439 -9.327 2.00E-09 1.69E-08 10.860 -1.35 
OAZ1 -0.641 7.862 -8.460 1.22E-08 8.25E-08 9.006 -1.56 
OAZ1 -0.475 7.602 -8.675 7.72E-09 5.51E-08 9.475 -1.39 
OAZ2 -0.279 6.880 -4.823 6.62E-05 1.80E-04 0.258 -1.21 
OBFC1 -0.504 6.436 -7.934 3.83E-08 2.32E-07 7.832 -1.42 
ORC4L 0.507 6.941 10.793 1.17E-10 1.33E-09 13.780 1.42 
Ormdl1 0.609 6.318 13.758 7.80E-13 1.88E-11 18.942 1.53 
Ormdl3 0.321 7.280 6.613 7.96E-07 3.39E-06 4.732 1.25 
OSBPL9 -0.571 6.512 -5.605 9.27E-06 3.03E-05 2.238 -1.49 
Osmr -0.865 7.659 -13.521 1.13E-12 2.55E-11 18.562 -1.82 
OXR1 -0.420 6.713 -6.010 3.41E-06 1.25E-05 3.251 -1.34 
OXSR1 -0.381 8.386 -6.697 6.52E-07 2.83E-06 4.935 -1.30 
Pabpc4 0.405 7.915 5.478 1.28E-05 4.06E-05 1.916 1.32 
PABPN1 -0.532 8.440 -10.806 1.15E-10 1.31E-09 13.804 -1.45 
Paics -0.325 9.258 -5.356 1.73E-05 5.38E-05 1.608 -1.25 
PALLD -0.953 7.134 -19.459 3.89E-16 2.37E-14 26.764 -1.94 
PAM -0.443 7.027 -6.465 1.13E-06 4.62E-06 4.371 -1.36 
PAPSS1 -0.669 6.702 -10.256 3.21E-10 3.37E-09 12.742 -1.59 
Parp3 -0.786 6.322 -12.995 2.61E-12 4.96E-11 17.699 -1.72 
Pbk -0.634 6.261 -7.233 1.86E-07 9.38E-07 6.214 -1.55 
PCBP1 -0.345 9.084 -3.336 2.77E-03 5.47E-03 -3.436 -1.27 
PCK2 -1.148 6.594 -17.427 4.56E-15 2.06E-13 24.235 -2.22 
Pcolce -0.953 8.526 -12.631 4.73E-12 8.21E-11 17.086 -1.94 
PDE6D -0.425 6.781 -3.424 2.24E-03 4.52E-03 -3.228 -1.34 
PDIA3 -0.299 9.730 -4.807 6.89E-05 1.87E-04 0.218 -1.23 
PDIA4 -0.798 6.027 -4.004 5.27E-04 1.21E-03 -1.810 -1.74 
PDIA4 -0.266 7.671 -5.664 8.03E-06 2.67E-05 2.385 -1.20 
PDIA5 -0.857 7.082 -13.298 1.60E-12 3.35E-11 18.199 -1.81 
PDLIM1 -1.045 7.184 -22.198 1.97E-17 1.86E-15 29.820 -2.06 
Pdrg1 2.158 7.434 38.856 4.52E-23 1.48E-20 42.949 4.46 
Pdyn -0.429 7.034 -4.977 4.48E-05 1.27E-04 0.650 -1.35 
Pebp1 -0.277 9.686 -7.354 1.41E-07 7.30E-07 6.498 -1.21 
PECI -0.395 6.867 -7.572 8.60E-08 4.74E-07 7.005 -1.31 
Pes1 0.602 7.542 8.114 2.58E-08 1.63E-07 8.237 1.52 
Pex19 0.422 6.163 8.692 7.45E-09 5.37E-08 9.511 1.34 
PGAM4 -0.443 6.574 -8.303 1.71E-08 1.12E-07 8.660 -1.36 
PGK1 -0.725 9.403 -20.434 1.29E-16 9.66E-15 27.895 -1.65 
Pgs1 -0.428 6.290 -6.334 1.56E-06 6.13E-06 4.050 -1.34 
PHF20 0.385 6.211 5.733 6.76E-06 2.28E-05 2.559 1.31 
PHF20 0.479 6.196 10.252 3.24E-10 3.37E-09 12.734 1.39 
PHF5A 0.838 7.050 15.905 3.42E-14 1.24E-12 22.164 1.79 
PHGDH -0.829 7.601 -11.567 2.90E-11 3.94E-10 15.217 -1.78 
PI4KA -0.269 7.162 -4.542 1.35E-04 3.46E-04 -0.456 -1.20 
PIGT 0.584 6.318 5.824 5.40E-06 1.87E-05 2.786 1.50 
Pir -0.398 6.603 -5.837 5.22E-06 1.82E-05 2.820 -1.32 
PJA2 0.285 7.115 5.371 1.67E-05 5.21E-05 1.646 1.22 
PJA2 0.298 7.451 6.366 1.44E-06 5.72E-06 4.128 1.23 
PKN2 0.362 7.422 8.692 7.44E-09 5.37E-08 9.513 1.29 
PLAA -0.356 6.833 -7.273 1.70E-07 8.61E-07 6.309 -1.28 
PLAC8 2.290 5.438 22.929 9.42E-18 1.06E-15 30.576 4.89 
Plbd2 0.459 7.151 6.723 6.13E-07 2.68E-06 4.997 1.37 
Plekha5 -0.694 7.039 -17.130 6.68E-15 2.86E-13 23.843 -1.62 
PLK2 0.585 7.605 11.481 3.38E-11 4.45E-10 15.060 1.50 
Plp2 -0.289 7.148 -3.985 5.53E-04 1.26E-03 -1.856 -1.22 
PLS3 -0.277 8.295 -4.475 1.60E-04 4.03E-04 -0.626 -1.21 
PLTP 1.268 7.226 9.659 1.03E-09 9.15E-09 11.546 2.41 
Plxna1 -0.499 6.084 -9.873 6.76E-10 6.42E-09 11.978 -1.41 
PMPCA 0.378 7.183 6.163 2.35E-06 8.96E-06 3.630 1.30 
Pnn 0.348 7.266 6.545 9.37E-07 3.91E-06 4.566 1.27 
Pnp2 -0.277 6.523 -4.142 3.72E-04 8.75E-04 -1.465 -1.21 
POLR1C 0.297 7.898 6.091 2.80E-06 1.04E-05 3.452 1.23 
POLR1D -0.567 8.762 -7.352 1.42E-07 7.32E-07 6.493 -1.48 
POLR2F 0.525 8.788 9.661 1.03E-09 9.15E-09 11.549 1.44 
POLR2G 0.573 8.219 14.121 4.48E-13 1.20E-11 19.514 1.49 
POLR2L 0.287 7.536 5.771 6.15E-06 2.10E-05 2.654 1.22 
POM121C 0.377 6.545 4.338 2.26E-04 5.52E-04 -0.970 1.30 
PPAP2A -1.221 6.987 -16.179 2.35E-14 8.88E-13 22.549 -2.33 
Ppia -0.432 10.987 -7.445 1.15E-07 6.08E-07 6.709 -1.35 
PPP1CB 0.398 9.069 6.077 2.90E-06 1.08E-05 3.417 1.32 
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PPP1R11 0.466 6.328 3.532 1.71E-03 3.54E-03 -2.968 1.38 
PPP1R12A 0.402 6.479 4.795 7.10E-05 1.92E-04 0.187 1.32 
PPP2CB 0.269 9.586 6.137 2.51E-06 9.43E-06 3.565 1.21 
PPP2R1A 0.428 6.065 3.792 8.97E-04 1.97E-03 -2.334 1.34 
PPP2R2A 0.291 7.150 6.440 1.21E-06 4.87E-06 4.310 1.22 
Ppp2r2a 0.407 7.954 6.267 1.83E-06 7.10E-06 3.886 1.33 
PPP2R5A 0.520 6.010 8.547 1.01E-08 7.00E-08 9.197 1.43 
PPP3CB 0.316 6.496 5.267 2.16E-05 6.55E-05 1.385 1.24 
PPPDE1 0.313 6.277 3.259 3.34E-03 6.48E-03 -3.618 1.24 
Pqlc3 -0.621 6.550 -5.351 1.75E-05 5.43E-05 1.596 -1.54 
Prc1 -1.257 7.462 -13.108 2.18E-12 4.20E-11 17.886 -2.39 
PRCP -0.439 7.535 -10.518 1.96E-10 2.13E-09 13.251 -1.36 
Prdx3 -0.437 8.036 -6.502 1.04E-06 4.28E-06 4.462 -1.35 
PRKACB 0.370 8.518 7.007 3.15E-07 1.49E-06 5.678 1.29 
PRKCA -0.419 5.864 -5.590 9.64E-06 3.13E-05 2.200 -1.34 
PRKCDBP -0.584 6.389 -5.425 1.45E-05 4.59E-05 1.784 -1.50 
PRKCSH -0.336 6.754 -3.018 5.97E-03 1.08E-02 -4.175 -1.26 
Prkrir 0.442 7.275 10.154 3.91E-10 3.99E-09 12.541 1.36 
Prmt5 -0.464 7.197 -6.238 1.96E-06 7.58E-06 3.815 -1.38 
Procr 0.911 6.220 13.654 9.18E-13 2.18E-11 18.775 1.88 
Pros1 -0.976 7.149 -16.984 8.07E-15 3.33E-13 23.648 -1.97 
Prps2 -0.476 7.860 -6.222 2.04E-06 7.83E-06 3.775 -1.39 
PRPS2 -0.362 9.468 -6.522 9.89E-07 4.10E-06 4.510 -1.29 
PRUNE2 -0.511 7.588 -9.210 2.54E-09 2.09E-08 10.617 -1.42 
Psap 0.483 8.656 8.946 4.37E-09 3.37E-08 10.058 1.40 
Psat1 -0.811 8.652 -12.376 7.23E-12 1.18E-10 16.648 -1.75 
Psat1 -0.683 9.538 -14.953 1.31E-13 4.16E-12 20.782 -1.61 
PSIMCT-1 0.731 7.013 8.874 5.08E-09 3.81E-08 9.904 1.66 
PSMA7 -0.617 10.089 -18.433 1.31E-15 6.71E-14 25.519 -1.53 
PSMB3 0.442 8.872 5.626 8.81E-06 2.89E-05 2.290 1.36 
PSMB3 0.617 6.534 12.261 8.77E-12 1.39E-10 16.450 1.53 
PSMB5 -0.952 9.145 -10.230 3.38E-10 3.51E-09 12.690 -1.93 
PSMB6 0.484 8.403 8.331 1.61E-08 1.06E-07 8.721 1.40 
PSMB8 -0.366 7.695 -7.373 1.35E-07 7.05E-07 6.541 -1.29 
Psmc1 0.341 8.262 6.780 5.36E-07 2.39E-06 5.135 1.27 
PSMC4 0.411 7.500 5.855 5.01E-06 1.75E-05 2.863 1.33 
PSMC5 0.426 7.329 4.824 6.61E-05 1.80E-04 0.259 1.34 
PSMC5 0.629 7.802 15.757 4.19E-14 1.45E-12 21.954 1.55 
Psmd12 0.524 7.739 5.918 4.28E-06 1.53E-05 3.021 1.44 
PSMD12 0.584 8.257 12.390 7.06E-12 1.16E-10 16.673 1.50 
PSMD4 0.479 8.426 8.683 7.60E-09 5.45E-08 9.492 1.39 
PSMD4 0.573 8.639 10.585 1.73E-10 1.90E-09 13.381 1.49 
Psmd8 -0.327 7.549 -5.794 5.81E-06 2.00E-05 2.712 -1.25 
Ptdss1 -0.349 6.929 -6.245 1.93E-06 7.46E-06 3.833 -1.27 
PTGR1 -0.676 7.564 -5.908 4.38E-06 1.56E-05 2.997 -1.60 
PTGR1 -0.550 8.581 -11.284 4.80E-11 6.09E-10 14.700 -1.46 
Ptgr2 0.343 6.491 8.446 1.26E-08 8.45E-08 8.976 1.27 
PTMA -0.267 11.781 -2.771 1.07E-02 1.82E-02 -4.726 -1.20 
PTP4A2 0.420 9.890 5.616 9.04E-06 2.96E-05 2.264 1.34 
Ptp4a2 0.490 9.223 3.647 1.29E-03 2.73E-03 -2.690 1.40 
PTPRG -2.656 5.545 -52.750 3.35E-26 1.72E-23 49.986 -6.30 
PTS -0.288 7.243 -3.479 1.95E-03 4.00E-03 -3.095 -1.22 
PTTG1 -0.585 6.979 -7.026 3.01E-07 1.43E-06 5.724 -1.50 
PUM1 0.296 6.424 5.178 2.70E-05 8.03E-05 1.159 1.23 
PUM1 0.426 6.710 4.928 5.08E-05 1.42E-04 0.524 1.34 
PURB 0.575 7.313 10.057 4.72E-10 4.63E-09 12.347 1.49 
PWP1 0.350 7.363 6.364 1.45E-06 5.74E-06 4.124 1.27 
Pxdn -0.292 7.848 -5.077 3.49E-05 1.01E-04 0.901 -1.22 
PXK -0.626 6.721 -13.561 1.06E-12 2.44E-11 18.625 -1.54 
QARS -0.544 9.208 -13.339 1.50E-12 3.16E-11 18.266 -1.46 
Qsox1 -0.371 7.440 -4.792 7.16E-05 1.93E-04 0.179 -1.29 
RAB10 -0.406 6.225 -2.407 2.42E-02 3.84E-02 -5.491 -1.33 
RAB11A -0.792 5.948 -7.577 8.51E-08 4.72E-07 7.016 -1.73 
RAB24 -0.282 6.607 -5.362 1.70E-05 5.30E-05 1.625 -1.22 
Rab32 -0.696 6.424 -8.955 4.30E-09 3.33E-08 10.076 -1.62 
RAB34 0.378 8.642 7.915 4.00E-08 2.42E-07 7.789 1.30 
RAB5C 0.409 6.092 4.823 6.62E-05 1.80E-04 0.257 1.33 
RAB6A 0.686 6.620 10.368 2.60E-10 2.76E-09 12.960 1.61 
RAB7A 0.299 8.931 5.779 6.03E-06 2.06E-05 2.675 1.23 
RAB7A 0.305 7.737 4.978 4.47E-05 1.27E-04 0.652 1.24 
Rad17 0.324 6.445 6.190 2.20E-06 8.43E-06 3.697 1.25 
RALGAPB 0.624 6.409 14.570 2.29E-13 6.57E-12 20.206 1.54 
RALY 0.707 6.393 7.549 9.06E-08 4.97E-07 6.951 1.63 
RANGRF -0.526 7.413 -8.264 1.86E-08 1.21E-07 8.572 -1.44 
Rapgef1 0.266 9.228 5.492 1.23E-05 3.93E-05 1.953 1.20 
RARRES2 -1.140 9.322 -16.048 2.81E-14 1.03E-12 22.365 -2.20 
Rbck1 0.625 6.528 7.464 1.10E-07 5.87E-07 6.755 1.54 
RBM3 -1.411 7.415 -14.020 5.22E-13 1.33E-11 19.355 -2.66 
RBM39 0.688 8.443 13.648 9.26E-13 2.19E-11 18.766 1.61 
 351 
RBM5 0.289 7.044 6.447 1.18E-06 4.78E-06 4.328 1.22 
RBM7 -0.278 7.727 -4.976 4.50E-05 1.28E-04 0.645 -1.21 
RBMXL1 -0.879 5.851 -9.816 7.56E-10 7.03E-09 11.863 -1.84 
Rbpms -0.637 6.521 -11.046 7.38E-11 8.86E-10 14.257 -1.56 
Rcan1 0.388 6.276 6.548 9.29E-07 3.89E-06 4.575 1.31 
RCBTB2 -0.488 7.042 -8.283 1.79E-08 1.17E-07 8.615 -1.40 
RCL1 -0.290 7.522 -7.647 7.26E-08 4.11E-07 7.178 -1.22 
REEP5 1.022 6.759 10.460 2.18E-10 2.35E-09 13.140 2.03 
Reep5 1.184 7.899 24.155 2.86E-18 3.66E-16 31.795 2.27 
RELA 0.375 6.829 3.364 2.59E-03 5.16E-03 -3.370 1.30 
Rere 0.304 6.955 3.582 1.52E-03 3.17E-03 -2.848 1.23 
RETSAT -0.933 5.458 -9.951 5.80E-10 5.59E-09 12.135 -1.91 
REV3L -0.404 7.281 -6.141 2.48E-06 9.35E-06 3.576 -1.32 
Rfx5 -0.505 6.821 -8.993 3.97E-09 3.11E-08 10.158 -1.42 
RFX7 -0.405 7.777 -5.609 9.18E-06 3.00E-05 2.248 -1.32 
RGD1561797 -0.336 7.190 -4.318 2.38E-04 5.79E-04 -1.022 -1.26 
RGS17 0.697 7.346 7.188 2.07E-07 1.02E-06 6.107 1.62 
Riok1 0.384 6.689 7.573 8.58E-08 4.74E-07 7.007 1.30 
RIOK3 0.521 7.168 7.311 1.56E-07 7.99E-07 6.396 1.44 
RNASEH2C -1.522 6.445 -24.323 2.44E-18 3.24E-16 31.957 -2.87 
RNASET2 0.346 10.189 8.038 3.05E-08 1.89E-07 8.068 1.27 
RNF10 0.319 7.472 5.783 5.97E-06 2.05E-05 2.685 1.25 
RNF11 0.448 7.884 9.652 1.04E-09 9.26E-09 11.531 1.36 
RNF111 0.840 6.483 12.504 5.83E-12 9.84E-11 16.870 1.79 
RNF139 -0.375 7.550 -8.405 1.37E-08 9.17E-08 8.884 -1.30 
RNFT1 -0.452 6.370 -7.967 3.56E-08 2.17E-07 7.907 -1.37 
RNH1 -0.382 6.472 -3.050 5.54E-03 1.01E-02 -4.104 -1.30 
RNH1 -0.280 7.269 -4.425 1.81E-04 4.52E-04 -0.751 -1.21 
ROCK2 0.559 7.129 6.002 3.49E-06 1.27E-05 3.230 1.47 
ROMO1 0.610 9.948 12.186 9.96E-12 1.54E-10 16.319 1.53 
Rpia -0.606 7.906 -10.253 3.23E-10 3.37E-09 12.736 -1.52 
RPL10 -0.835 6.263 -10.699 1.40E-10 1.56E-09 13.601 -1.78 
RPL11 -0.415 11.456 -14.006 5.33E-13 1.34E-11 19.334 -1.33 
Rpl14 0.299 11.184 6.180 2.26E-06 8.63E-06 3.672 1.23 
RPL7 -0.387 11.044 -7.447 1.14E-07 6.06E-07 6.715 -1.31 
RPP14 -0.463 6.393 -6.868 4.36E-07 1.99E-06 5.345 -1.38 
RPP21 0.533 8.060 8.640 8.31E-09 5.88E-08 9.399 1.45 
RPS25 -0.268 11.745 -6.092 2.80E-06 1.04E-05 3.453 -1.20 
Rps28 -0.321 8.402 -3.364 2.59E-03 5.16E-03 -3.372 -1.25 
RPS5 0.459 11.111 10.154 3.91E-10 3.99E-09 12.541 1.37 
RRAS -0.421 6.545 -5.978 3.70E-06 1.34E-05 3.170 -1.34 
Rrp1 0.712 6.040 7.221 1.91E-07 9.61E-07 6.186 1.64 
RSL1D1 0.396 7.841 3.257 3.36E-03 6.50E-03 -3.623 1.32 
Rsl24d1 0.397 7.715 6.928 3.78E-07 1.75E-06 5.490 1.32 
RSRC1 0.335 6.889 7.706 6.37E-08 3.68E-07 7.312 1.26 
RSU1 -0.449 8.196 -5.350 1.76E-05 5.44E-05 1.594 -1.37 
RTN3 -0.446 7.053 -3.392 2.42E-03 4.87E-03 -3.305 -1.36 
RTN3 -0.268 8.012 -5.205 2.52E-05 7.54E-05 1.228 -1.20 
RTN4 0.310 7.824 7.740 5.90E-08 3.45E-07 7.390 1.24 
RUVBL1 -0.311 6.682 -5.495 1.22E-05 3.91E-05 1.960 -1.24 
RYBP 0.315 8.342 6.159 2.38E-06 9.03E-06 3.618 1.24 
RYK 0.297 6.736 7.203 2.00E-07 9.92E-07 6.143 1.23 
S100A11 -0.477 7.784 -7.096 2.56E-07 1.23E-06 5.889 -1.39 
SAMD4B 0.437 8.703 9.052 3.51E-09 2.76E-08 10.284 1.35 
SAMM50 -0.343 7.616 -7.698 6.48E-08 3.73E-07 7.294 -1.27 
SAP18 0.272 8.656 4.782 7.34E-05 1.98E-04 0.154 1.21 
SASH1 -0.468 7.769 -8.133 2.47E-08 1.57E-07 8.280 -1.38 
SAT1 -0.559 6.704 -11.539 3.05E-11 4.10E-10 15.167 -1.47 
SBSN -4.003 9.801 -67.587 9.46E-29 1.17E-25 55.474 -16.03 
SBSN -3.754 6.788 -42.023 7.16E-24 2.86E-21 44.771 -13.49 
SC4MOL -1.746 6.368 -8.209 2.10E-08 1.35E-07 8.450 -3.35 
SC4MOL -1.352 8.194 -26.799 2.61E-19 4.94E-17 34.231 -2.55 
Sc5d -0.649 6.364 -6.879 4.24E-07 1.95E-06 5.373 -1.57 
Scamp2 0.264 6.915 4.956 4.73E-05 1.34E-04 0.595 1.20 
Scamp2 0.281 8.543 6.978 3.36E-07 1.58E-06 5.610 1.21 
SCAP -0.424 7.413 -8.253 1.91E-08 1.23E-07 8.548 -1.34 
Scarb1 -0.503 6.897 -7.271 1.71E-07 8.65E-07 6.302 -1.42 
SCD -0.853 7.257 -8.023 3.14E-08 1.94E-07 8.035 -1.81 
SCD -0.703 7.564 -7.526 9.55E-08 5.18E-07 6.898 -1.63 
SCD -0.694 9.542 -16.365 1.83E-14 7.14E-13 22.807 -1.62 
Scd1 -0.581 9.240 -11.025 7.66E-11 9.05E-10 14.218 -1.50 
Scd3 -0.466 8.588 -11.201 5.57E-11 6.93E-10 14.546 -1.38 
Scyl3 1.525 5.993 24.436 2.19E-18 3.03E-16 32.066 2.88 
Sdc1 -0.419 5.513 -6.841 4.65E-07 2.10E-06 5.281 -1.34 
SDHA -0.273 7.108 -5.292 2.03E-05 6.20E-05 1.448 -1.21 
Sdhd -0.436 9.423 -6.835 4.71E-07 2.13E-06 5.266 -1.35 
SEC22B 0.605 6.590 11.069 7.07E-11 8.53E-10 14.300 1.52 
SEC24D -0.311 7.004 -4.311 2.42E-04 5.88E-04 -1.039 -1.24 
SELK 0.416 7.749 8.682 7.62E-09 5.45E-08 9.489 1.33 
 352 
SEMA3C 0.981 6.612 17.014 7.76E-15 3.24E-13 23.688 1.97 
SENP5 0.363 6.817 5.174 2.73E-05 8.10E-05 1.149 1.29 
SENP6 0.451 7.501 5.153 2.87E-05 8.50E-05 1.096 1.37 
SEPHS2 -0.318 8.261 -6.423 1.25E-06 5.05E-06 4.269 -1.25 
SERBP1 -0.274 8.550 -3.431 2.20E-03 4.46E-03 -3.211 -1.21 
SERINC3 0.309 9.592 7.089 2.60E-07 1.25E-06 5.873 1.24 
Serp1 0.481 7.644 11.295 4.71E-11 6.02E-10 14.720 1.40 
SERPINB1 -1.299 8.041 -18.081 2.01E-15 1.00E-13 25.076 -2.46 
Serpinf1 -0.762 8.278 -8.832 5.55E-09 4.14E-08 9.814 -1.70 
SERPINH1 -0.660 8.798 -7.182 2.10E-07 1.03E-06 6.093 -1.58 
SERPINH1 -0.490 9.252 -15.081 1.09E-13 3.58E-12 20.971 -1.40 
Serpinh1 -0.472 8.949 -7.808 5.06E-08 3.00E-07 7.547 -1.39 
SERTAD2 -0.275 7.311 -4.071 4.45E-04 1.03E-03 -1.642 -1.21 
SET 0.498 8.500 13.163 1.99E-12 3.93E-11 17.977 1.41 
SF3A3 0.398 8.084 8.559 9.87E-09 6.85E-08 9.223 1.32 
SFRS2 -0.495 6.996 -6.852 4.53E-07 2.06E-06 5.307 -1.41 
SFRS2 -0.465 8.647 -13.525 1.12E-12 2.55E-11 18.567 -1.38 
SFRS7 -0.508 8.831 -5.182 2.67E-05 7.96E-05 1.170 -1.42 
SGCE -0.310 6.005 -2.407 2.42E-02 3.85E-02 -5.492 -1.24 
Sh2b3 -0.508 6.519 -9.252 2.33E-09 1.94E-08 10.704 -1.42 
SH3BGRL -0.692 7.329 -2.930 7.35E-03 1.29E-02 -4.374 -1.62 
Shc1 0.282 8.134 7.138 2.32E-07 1.13E-06 5.990 1.22 
SHMT2 -0.780 6.208 -7.642 7.35E-08 4.14E-07 7.166 -1.72 
Sik3 -0.334 7.041 -7.025 3.02E-07 1.43E-06 5.721 -1.26 
Sin3b 0.430 6.811 5.022 4.01E-05 1.15E-04 0.762 1.35 
Slc1a5 -0.703 6.945 -14.021 5.22E-13 1.33E-11 19.357 -1.63 
SLC25A1 -0.658 6.910 -7.196 2.03E-07 1.00E-06 6.126 -1.58 
SLC25A13 -0.285 6.821 -5.964 3.83E-06 1.38E-05 3.135 -1.22 
SLC25A17 0.265 6.764 5.937 4.08E-06 1.47E-05 3.070 1.20 
SLC25A20 -0.626 6.724 -3.636 1.32E-03 2.80E-03 -2.717 -1.54 
SLC25A20 -0.481 8.555 -6.758 5.64E-07 2.50E-06 5.082 -1.40 
SLC25A5 -0.598 10.477 -14.014 5.27E-13 1.33E-11 19.346 -1.51 
Slc35a1 -0.299 6.412 -6.099 2.75E-06 1.03E-05 3.470 -1.23 
Slc35c2 0.599 6.171 8.915 4.67E-09 3.56E-08 9.992 1.51 
SLC39A1 -0.287 8.219 -5.732 6.77E-06 2.28E-05 2.557 -1.22 
SLC44A1 0.395 7.158 5.979 3.68E-06 1.34E-05 3.174 1.31 
SLC4A7 -0.391 6.315 -3.974 5.68E-04 1.29E-03 -1.884 -1.31 
Slc4a7 -0.374 6.815 -5.356 1.73E-05 5.38E-05 1.609 -1.30 
Slc6a6 -0.917 8.040 -19.167 5.46E-16 3.21E-14 26.417 -1.89 
Slc7a11 0.413 7.310 4.911 5.30E-05 1.48E-04 0.482 1.33 
Slc7a5 -0.436 7.632 -7.809 5.05E-08 3.00E-07 7.549 -1.35 
Slmo2 -0.362 7.294 -8.876 5.06E-09 3.81E-08 9.908 -1.29 
SLTM 0.265 6.758 5.505 1.19E-05 3.82E-05 1.986 1.20 
SMARCA5 0.317 9.386 5.623 8.88E-06 2.91E-05 2.282 1.25 
SMARCC1 0.431 6.216 2.641 1.44E-02 2.38E-02 -5.006 1.35 
SMC4 -0.491 6.591 -4.448 1.71E-04 4.29E-04 -0.693 -1.41 
Smg1 0.458 6.069 7.371 1.36E-07 7.07E-07 6.538 1.37 
SNAI2 -0.961 6.399 -14.622 2.12E-13 6.19E-12 20.284 -1.95 
Snn -1.034 6.495 -13.371 1.43E-12 3.09E-11 18.318 -2.05 
SNRNP27 0.303 7.046 2.782 1.04E-02 1.77E-02 -4.701 1.23 
SNRPB2 0.360 7.682 5.867 4.85E-06 1.70E-05 2.895 1.28 
SNRPC 0.504 7.891 10.075 4.56E-10 4.54E-09 12.383 1.42 
SNRPD2 0.478 8.788 7.176 2.13E-07 1.05E-06 6.078 1.39 
SNRPF -0.451 7.914 -9.420 1.66E-09 1.41E-08 11.054 -1.37 
SNX12 0.283 6.594 5.280 2.09E-05 6.36E-05 1.418 1.22 
SNX14 -0.544 6.583 -9.239 2.40E-09 1.98E-08 10.677 -1.46 
Snx18 0.514 6.521 9.765 8.35E-10 7.63E-09 11.760 1.43 
SNX2 -0.352 6.773 -8.667 7.85E-09 5.60E-08 9.458 -1.28 
Snx5 -0.450 7.211 -6.918 3.88E-07 1.79E-06 5.465 -1.37 
SOD1 -0.348 8.506 -6.221 2.04E-06 7.83E-06 3.773 -1.27 
SOD2 -1.163 6.599 -18.495 1.21E-15 6.41E-14 25.596 -2.24 
SOD2 -0.954 6.729 -14.086 4.72E-13 1.23E-11 19.459 -1.94 
SOX12 1.495 5.451 11.085 6.86E-11 8.30E-10 14.331 2.82 
SPATA2 -0.429 6.823 -8.497 1.13E-08 7.65E-08 9.087 -1.35 
Spc25 -0.526 6.631 -6.787 5.28E-07 2.36E-06 5.151 -1.44 
SPIN1 0.414 7.093 5.921 4.25E-06 1.52E-05 3.029 1.33 
SPPL2A -0.526 7.487 -2.356 2.70E-02 4.25E-02 -5.593 -1.44 
SPRR1A 1.635 8.643 18.963 6.94E-16 3.83E-14 26.170 3.10 
SQLE -1.414 6.333 -9.197 2.61E-09 2.13E-08 10.588 -2.67 
SQLE -1.297 7.073 -19.491 3.75E-16 2.32E-14 26.802 -2.46 
Sqle -1.107 9.031 -17.577 3.77E-15 1.81E-13 24.430 -2.15 
SQSTM1 0.691 7.962 14.725 1.82E-13 5.55E-12 20.440 1.61 
SRP68 0.655 6.373 6.816 4.93E-07 2.22E-06 5.221 1.57 
SRP72 -0.597 6.670 -2.823 9.46E-03 1.63E-02 -4.613 -1.51 
Srpr 0.585 10.118 3.518 1.77E-03 3.65E-03 -3.001 1.50 
Srpr 0.633 10.831 5.274 2.12E-05 6.44E-05 1.402 1.55 
SSR4 -0.542 9.057 -6.298 1.70E-06 6.64E-06 3.961 -1.46 
SSU72 -0.809 7.371 -12.722 4.07E-12 7.32E-11 17.240 -1.75 
STIM2 0.743 6.458 9.088 3.26E-09 2.60E-08 10.359 1.67 
 353 
STK39 0.421 6.315 4.627 1.09E-04 2.84E-04 -0.241 1.34 
STK4 0.608 6.572 14.098 4.64E-13 1.23E-11 19.478 1.52 
STMN1 -0.338 7.260 -5.631 8.71E-06 2.86E-05 2.302 -1.26 
STT3A -0.972 6.388 -4.370 2.09E-04 5.13E-04 -0.891 -1.96 
STT3A -0.566 7.885 -10.102 4.33E-10 4.37E-09 12.436 -1.48 
Stx12 0.367 7.514 7.002 3.19E-07 1.50E-06 5.666 1.29 
SUCLG2 -0.286 8.679 -7.143 2.29E-07 1.12E-06 6.002 -1.22 
Sumf2 0.328 7.010 5.999 3.51E-06 1.28E-05 3.223 1.26 
SUPT16H -0.895 10.402 -12.364 7.38E-12 1.19E-10 16.628 -1.86 
SUPT4H1 0.652 7.223 12.205 9.65E-12 1.51E-10 16.352 1.57 
SUPT6H 0.707 6.509 6.829 4.78E-07 2.16E-06 5.253 1.63 
Syf2 0.622 7.090 9.892 6.51E-10 6.22E-09 12.017 1.54 
SYNCRIP 0.540 6.547 8.123 2.53E-08 1.60E-07 8.257 1.45 
SYPL1 -0.340 7.000 -3.710 1.10E-03 2.37E-03 -2.536 -1.27 
SYS1 0.911 6.956 16.605 1.33E-14 5.30E-13 23.136 1.88 
Taf2 0.361 8.441 7.672 6.86E-08 3.91E-07 7.236 1.28 
TAGLN2 -0.476 8.340 -6.571 8.80E-07 3.70E-06 4.630 -1.39 
TAGLN2 -0.368 7.238 -6.146 2.45E-06 9.25E-06 3.588 -1.29 
TALDO1 -0.294 8.276 -5.485 1.25E-05 3.99E-05 1.935 -1.23 
Tapbpl 0.557 5.845 5.904 4.43E-06 1.57E-05 2.987 1.47 
Tardbp -0.443 6.769 -3.286 3.14E-03 6.11E-03 -3.555 -1.36 
TARDBP -0.301 6.505 -3.832 8.13E-04 1.81E-03 -2.237 -1.23 
TAX1BP1 0.353 8.337 6.414 1.28E-06 5.14E-06 4.247 1.28 
Tbc1d13 0.542 6.269 8.806 5.86E-09 4.30E-08 9.759 1.46 
Tbc1d20 0.664 7.320 11.787 1.97E-11 2.85E-10 15.614 1.58 
TBCE 0.550 6.484 11.747 2.12E-11 3.00E-10 15.541 1.46 
TBPL1 1.089 7.435 16.524 1.48E-14 5.83E-13 23.026 2.13 
TBRG1 0.486 6.867 7.547 9.10E-08 4.98E-07 6.947 1.40 
TCEA1 0.394 8.260 8.969 4.17E-09 3.25E-08 10.107 1.31 
Tcf19 -0.655 5.912 -11.408 3.84E-11 5.02E-10 14.928 -1.58 
TECR -0.560 8.225 -7.981 3.46E-08 2.12E-07 7.938 -1.47 
TFB1M -0.524 6.682 -7.527 9.52E-08 5.18E-07 6.900 -1.44 
Tfb2m 0.366 7.005 7.199 2.02E-07 9.99E-07 6.133 1.29 
TFPI -1.079 7.291 -13.471 1.22E-12 2.73E-11 18.481 -2.11 
Tgfbr2 -0.613 6.364 -7.789 5.29E-08 3.10E-07 7.503 -1.53 
Tgm2 0.537 7.080 8.876 5.07E-09 3.81E-08 9.907 1.45 
Tgoln2 -0.284 6.450 -3.398 2.38E-03 4.80E-03 -3.290 -1.22 
Thbd -2.274 7.746 -26.259 4.18E-19 7.51E-17 33.754 -4.84 
THBS3 0.476 6.147 8.663 7.92E-09 5.64E-08 9.449 1.39 
THOC7 0.454 7.681 8.582 9.40E-09 6.56E-08 9.273 1.37 
TIMM10 0.508 7.656 9.182 2.69E-09 2.19E-08 10.557 1.42 
TIMM17B -0.568 6.995 -6.373 1.42E-06 5.64E-06 4.145 -1.48 
TIMM23 -0.402 7.920 -2.879 8.30E-03 1.44E-02 -4.489 -1.32 
TIMM50 0.359 7.608 7.299 1.60E-07 8.20E-07 6.368 1.28 
TIMM9 0.319 7.636 6.531 9.69E-07 4.03E-06 4.531 1.25 
TIMP1 -0.911 6.932 -13.406 1.35E-12 2.98E-11 18.376 -1.88 
Timp2 0.280 7.474 3.625 1.36E-03 2.88E-03 -2.744 1.21 
TIMP2 0.288 8.474 4.169 3.47E-04 8.20E-04 -1.396 1.22 
Tinagl1 -1.639 6.534 -14.492 2.57E-13 7.20E-12 20.087 -3.11 
TIPARP 0.342 7.024 2.990 6.38E-03 1.14E-02 -4.238 1.27 
TIPARP 0.363 8.475 8.854 5.30E-09 3.97E-08 9.861 1.29 
TJP2 -0.699 6.785 -13.597 1.00E-12 2.33E-11 18.683 -1.62 
TKT -0.745 6.373 -5.333 1.83E-05 5.65E-05 1.550 -1.68 
TKT -0.510 6.994 -11.292 4.73E-11 6.03E-10 14.714 -1.42 
TM9SF4 1.389 5.793 24.004 3.30E-18 4.09E-16 31.648 2.62 
TMBIM6 0.276 8.964 5.368 1.68E-05 5.24E-05 1.639 1.21 
TMED3 -0.595 6.990 -12.434 6.56E-12 1.09E-10 16.749 -1.51 
TMEM101 0.382 6.466 4.589 1.20E-04 3.09E-04 -0.337 1.30 
Tmem109 -0.669 6.566 -12.839 3.36E-12 6.16E-11 17.437 -1.59 
Tmem111 0.502 7.013 9.062 3.45E-09 2.73E-08 10.303 1.42 
Tmem14c -0.269 9.909 -6.160 2.37E-06 9.00E-06 3.623 -1.20 
Tmem150a -0.436 6.896 -6.306 1.66E-06 6.52E-06 3.982 -1.35 
TMEM156 -3.624 7.139 -63.314 4.45E-28 4.00E-25 54.053 -12.33 
Tmem161b 0.280 6.598 4.127 3.87E-04 9.06E-04 -1.503 1.21 
Tmem167 0.493 7.216 7.585 8.36E-08 4.65E-07 7.034 1.41 
Tmem167b 0.659 6.863 14.771 1.70E-13 5.32E-12 20.510 1.58 
TMEM183A 0.374 6.182 7.144 2.29E-07 1.12E-06 6.003 1.30 
Tmem189 -0.572 6.827 -7.870 4.41E-08 2.66E-07 7.687 -1.49 
TMEM223 -0.499 7.260 -7.327 1.50E-07 7.74E-07 6.435 -1.41 
TMEM30A -0.470 6.995 -4.510 1.46E-04 3.71E-04 -0.536 -1.39 
TMEM5 -0.360 6.602 -8.956 4.29E-09 3.33E-08 10.080 -1.28 
TMEM66 0.327 8.790 9.055 3.49E-09 2.75E-08 10.290 1.25 
TMSB10 -0.610 10.371 -9.841 7.19E-10 6.77E-09 11.914 -1.53 
Tmx1 0.417 8.098 7.575 8.54E-08 4.73E-07 7.012 1.34 
Tnfaip3 -0.864 5.235 -9.439 1.60E-09 1.36E-08 11.094 -1.82 
Tnfrsf21 -1.358 7.387 -19.155 5.54E-16 3.21E-14 26.402 -2.56 
Tnfsf9 -1.268 6.765 -11.884 1.67E-11 2.47E-10 15.786 -2.41 
TNIP1 -0.392 6.401 -5.316 1.91E-05 5.87E-05 1.508 -1.31 
Tnks2 0.324 6.639 6.409 1.30E-06 5.20E-06 4.234 1.25 
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Tollip 0.413 6.477 6.227 2.01E-06 7.74E-06 3.787 1.33 
TOMM34 0.869 7.388 14.669 1.98E-13 5.83E-12 20.355 1.83 
TOP1 0.380 7.654 5.547 1.07E-05 3.47E-05 2.091 1.30 
Top2a -0.930 9.103 -11.795 1.95E-11 2.82E-10 15.627 -1.91 
TOP2B 0.282 7.259 4.440 1.75E-04 4.37E-04 -0.714 1.22 
TPD52L2 -0.358 6.534 -3.762 9.68E-04 2.11E-03 -2.409 -1.28 
TPI1 -0.313 9.171 -6.171 2.31E-06 8.80E-06 3.650 -1.24 
Tprgl -0.477 6.781 -7.869 4.43E-08 2.66E-07 7.685 -1.39 
Tpst1 -0.528 6.787 -12.496 5.92E-12 9.93E-11 16.856 -1.44 
TPX2 0.828 6.219 8.891 4.91E-09 3.71E-08 9.940 1.78 
TRAK2 -0.471 6.593 -5.887 4.62E-06 1.63E-05 2.945 -1.39 
Tram1 -0.303 6.401 -3.812 8.53E-04 1.89E-03 -2.285 -1.23 
TRAP1 0.461 6.783 5.639 8.52E-06 2.81E-05 2.324 1.38 
TRAPPC4 0.657 7.791 11.827 1.84E-11 2.68E-10 15.685 1.58 
TRIAP1 0.377 6.780 8.905 4.77E-09 3.62E-08 9.969 1.30 
TRIB3 1.107 5.604 7.793 5.24E-08 3.08E-07 7.512 2.15 
TRIB3 1.523 5.753 11.208 5.50E-11 6.86E-10 14.559 2.87 
Trib3 1.752 8.754 37.549 1.01E-22 2.79E-20 42.150 3.37 
Trim44 0.365 6.505 8.029 3.11E-08 1.92E-07 8.047 1.29 
Trmt6 0.477 6.854 8.722 7.00E-09 5.07E-08 9.576 1.39 
TSC22D3 0.723 6.584 13.954 5.78E-13 1.44E-11 19.252 1.65 
TSEN15 0.372 7.360 10.166 3.83E-10 3.93E-09 12.563 1.29 
Tspan4 -0.431 6.391 -7.596 8.15E-08 4.56E-07 7.059 -1.35 
TSPO 0.406 8.531 5.405 1.53E-05 4.79E-05 1.733 1.32 
Ttc13 -0.275 7.694 -4.974 4.52E-05 1.28E-04 0.640 -1.21 
Ttc3 0.387 7.465 6.173 2.30E-06 8.77E-06 3.654 1.31 
TTC33 0.365 6.573 5.218 2.44E-05 7.34E-05 1.260 1.29 
TUBA1C -0.981 9.068 -20.362 1.40E-16 1.03E-14 27.813 -1.97 
TUBB2C -0.755 8.450 -15.057 1.13E-13 3.68E-12 20.936 -1.69 
Tubb6 -0.805 7.128 -20.264 1.56E-16 1.08E-14 27.702 -1.75 
Twistnb 0.363 7.652 4.488 1.55E-04 3.91E-04 -0.591 1.29 
TXNDC15 0.450 6.914 11.636 2.57E-11 3.53E-10 15.342 1.37 
TXNIP 1.000 8.976 14.208 3.93E-13 1.06E-11 19.649 2.00 
TXNRD1 0.469 7.365 3.218 3.70E-03 7.06E-03 -3.715 1.38 
TXNRD1 0.581 9.549 14.670 1.98E-13 5.83E-12 20.357 1.50 
Tyms -1.008 8.010 -12.872 3.18E-12 5.87E-11 17.494 -2.01 
UAP1 -0.525 6.881 -8.508 1.10E-08 7.53E-08 9.110 -1.44 
UAP1L1 -0.426 6.485 -4.759 7.78E-05 2.08E-04 0.096 -1.34 
UBASH3B -1.112 8.046 -27.180 1.89E-19 3.76E-17 34.563 -2.16 
UBE2D4 0.415 6.665 6.821 4.86E-07 2.19E-06 5.234 1.33 
Ube2h 0.330 6.554 2.977 6.58E-03 1.18E-02 -4.268 1.26 
UBE2J2 0.272 7.348 6.062 3.01E-06 1.12E-05 3.379 1.21 
UBE2Q1 -0.331 7.359 -4.258 2.77E-04 6.64E-04 -1.172 -1.26 
UBE2R2 0.280 6.750 3.931 6.33E-04 1.43E-03 -1.991 1.21 
Ube2s 0.681 7.516 8.271 1.83E-08 1.19E-07 8.589 1.60 
Ubiad1 0.417 6.641 7.646 7.28E-08 4.12E-07 7.176 1.33 
UBL3 0.398 6.206 7.527 9.51E-08 5.18E-07 6.901 1.32 
UBL3 0.417 7.629 5.793 5.82E-06 2.00E-05 2.710 1.34 
UBQLN1 0.520 7.255 13.229 1.79E-12 3.66E-11 18.086 1.43 
UBQLN2 0.325 8.467 4.596 1.18E-04 3.05E-04 -0.318 1.25 
UBQLN4 0.275 6.593 2.920 7.52E-03 1.32E-02 -4.396 1.21 
UBR4 0.500 6.320 5.247 2.27E-05 6.85E-05 1.334 1.41 
UCHL5 -0.370 6.364 -3.954 5.97E-04 1.36E-03 -1.933 -1.29 
UCK2 -0.266 6.008 -4.139 3.75E-04 8.82E-04 -1.473 -1.20 
Uck2 0.515 6.716 4.814 6.77E-05 1.84E-04 0.235 1.43 
Ufd1l 0.562 6.294 11.936 1.53E-11 2.29E-10 15.879 1.48 
UFD1L 0.782 8.108 17.353 5.02E-15 2.22E-13 24.137 1.72 
UGCG -0.610 6.257 -7.002 3.19E-07 1.50E-06 5.666 -1.53 
UGCG -0.429 6.614 -4.288 2.57E-04 6.20E-04 -1.099 -1.35 
UGP2 -0.297 8.371 -7.098 2.55E-07 1.23E-06 5.894 -1.23 
Ugt1a1 -0.356 10.340 -8.042 3.02E-08 1.88E-07 8.076 -1.28 
UQCC 0.629 7.071 13.826 7.03E-13 1.73E-11 19.050 1.55 
UQCC 0.639 6.686 12.945 2.83E-12 5.29E-11 17.616 1.56 
USP1 -0.471 7.729 -7.591 8.24E-08 4.60E-07 7.048 -1.39 
USP19 0.389 6.555 7.644 7.32E-08 4.13E-07 7.170 1.31 
USP46 0.514 6.354 7.640 7.38E-08 4.15E-07 7.162 1.43 
UTP18 -0.293 7.550 -7.164 2.19E-07 1.07E-06 6.050 -1.23 
UTP3 0.515 6.703 11.097 6.73E-11 8.19E-10 14.352 1.43 
VAMP8 -0.443 7.162 -7.780 5.40E-08 3.16E-07 7.481 -1.36 
VAPA 0.268 8.901 7.597 8.13E-08 4.55E-07 7.062 1.20 
Vapb -0.472 8.100 -5.600 9.40E-06 3.06E-05 2.225 -1.39 
VAT1 0.494 7.192 2.990 6.38E-03 1.14E-02 -4.239 1.41 
VCAM1 -0.805 6.411 -9.470 1.50E-09 1.30E-08 11.157 -1.75 
VDAC2 -0.322 8.821 -7.485 1.05E-07 5.64E-07 6.803 -1.25 
VEGFB 0.374 6.878 6.951 3.59E-07 1.67E-06 5.545 1.30 
VMA21 0.744 7.724 11.534 3.07E-11 4.12E-10 15.158 1.68 
VNN1 -1.373 6.056 -25.098 1.19E-18 1.94E-16 32.692 -2.59 
VPS33B -0.286 6.639 -6.748 5.78E-07 2.55E-06 5.058 -1.22 
VWA5A -0.460 7.095 -8.966 4.20E-09 3.27E-08 10.100 -1.38 
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WAC 0.406 8.157 7.842 4.70E-08 2.81E-07 7.623 1.33 
WAC 0.426 7.633 5.901 4.46E-06 1.58E-05 2.979 1.34 
WAPAL 0.302 6.875 6.506 1.03E-06 4.24E-06 4.472 1.23 
WBP5 0.323 8.222 6.151 2.42E-06 9.17E-06 3.599 1.25 
Wdfy4 0.394 6.002 3.708 1.11E-03 2.38E-03 -2.541 1.31 
Wdr1 -0.290 8.251 -2.962 6.82E-03 1.21E-02 -4.302 -1.22 
WDR26 0.425 6.370 6.932 3.75E-07 1.74E-06 5.500 1.34 
Wdr5 0.361 6.168 5.292 2.03E-05 6.20E-05 1.448 1.28 
WDR67 -0.345 6.118 -3.859 7.59E-04 1.70E-03 -2.170 -1.27 
WDR74 0.487 6.571 8.911 4.71E-09 3.58E-08 9.983 1.40 
Wdr77 0.396 6.647 7.534 9.38E-08 5.12E-07 6.916 1.32 
WDYHV1 -0.588 6.805 -5.943 4.03E-06 1.45E-05 3.083 -1.50 
Wdyhv1 -0.504 7.392 -10.018 5.09E-10 4.93E-09 12.269 -1.42 
WSB1 0.819 6.023 12.411 6.82E-12 1.13E-10 16.710 1.76 
WWC3 -0.433 6.647 -8.613 8.81E-09 6.19E-08 9.340 -1.35 
XBP1 -0.681 7.896 -12.340 7.68E-12 1.24E-10 16.586 -1.60 
XPOT -0.355 7.326 -3.319 2.89E-03 5.68E-03 -3.478 -1.28 
Xrcc5 -0.369 6.430 -7.390 1.30E-07 6.81E-07 6.582 -1.29 
YIPF1 0.498 6.174 8.954 4.30E-09 3.33E-08 10.075 1.41 
Ykt6 0.337 6.652 7.395 1.29E-07 6.76E-07 6.593 1.26 
YPEL5 0.623 6.204 9.035 3.64E-09 2.85E-08 10.248 1.54 
YWHAB 0.377 6.224 2.735 1.16E-02 1.96E-02 -4.805 1.30 
Ywhab 0.497 7.203 7.797 5.19E-08 3.07E-07 7.521 1.41 
YWHAG 0.370 7.313 4.418 1.85E-04 4.60E-04 -0.770 1.29 
YWHAQ 0.294 7.581 6.305 1.67E-06 6.53E-06 3.978 1.23 
Ywhaz 0.463 7.652 6.361 1.46E-06 5.76E-06 4.117 1.38 
ZC3HAV1 0.533 7.214 9.878 6.68E-10 6.37E-09 11.990 1.45 
ZEB1 -0.275 7.606 -7.527 9.52E-08 5.18E-07 6.900 -1.21 
ZFAND5 0.652 7.866 11.510 3.21E-11 4.27E-10 15.114 1.57 
Zfp110 0.355 6.538 8.813 5.77E-09 4.24E-08 9.774 1.28 
ZFP36L1 -0.491 8.280 -8.253 1.91E-08 1.23E-07 8.549 -1.41 
ZFR 0.867 8.429 11.033 7.55E-11 8.99E-10 14.233 1.82 
ZMYND11 0.403 7.803 11.320 4.50E-11 5.82E-10 14.765 1.32 
ZNF664 0.330 6.480 6.613 7.96E-07 3.39E-06 4.732 1.26 
ZSWIM3 0.708 6.905 14.091 4.68E-13 1.23E-11 19.468 1.63 
Zyx -0.304 7.962 -4.746 8.05E-05 2.14E-04 0.062 -1.23 
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Gene ID logFC AveExpr t P.Value adj.P.Val B Fold Change 
40788 -0.278 8.571 -2.637 1.45E-02 2.93E-02 -4.623 -1.21 
40790 0.566 5.984 6.418 1.27E-06 7.84E-06 4.632 1.48 
1700020I14Rik 0.478 8.162 11.243 5.16E-11 1.08E-09 14.961 1.39 
1700052N19Rik -0.750 6.422 -15.626 5.02E-14 3.11E-12 22.048 -1.68 
2310001A20Rik -0.717 7.257 -12.785 3.67E-12 1.16E-10 17.666 -1.64 
2310014D11Rik -0.908 6.536 -12.442 6.47E-12 1.91E-10 17.086 -1.88 
2310044H10Rik 0.291 6.864 3.953 5.99E-04 1.78E-03 -1.547 1.22 
2610002M06Rik -0.309 6.504 -5.273 2.13E-05 9.49E-05 1.781 -1.24 
2810025M15Rik -0.360 6.900 -6.529 9.74E-07 6.21E-06 4.902 -1.28 
2810474O19Rik -1.132 7.272 -21.770 3.07E-17 6.13E-15 29.544 -2.19 
2810482I07Rik -0.454 6.348 -7.636 7.45E-08 6.66E-07 7.520 -1.37 
3010026O09Rik -0.298 8.162 -5.674 7.83E-06 3.91E-05 2.790 -1.23 
3110062M04Rik -0.537 7.493 -11.137 6.26E-11 1.27E-09 14.764 -1.45 
4833417J20Rik 0.384 7.312 5.482 1.26E-05 5.94E-05 2.309 1.31 
6330578E17Rik 0.321 6.733 6.232 1.99E-06 1.17E-05 4.178 1.25 
6430548M08Rik 0.649 5.381 9.253 2.33E-09 3.13E-08 11.062 1.57 
9430072B17Rik -0.271 9.474 -6.133 2.53E-06 1.43E-05 3.934 -1.21 
9530053H05Rik -1.151 10.002 -19.943 2.24E-16 2.77E-14 27.543 -2.22 
A330042M18Rik 0.733 7.205 11.486 3.35E-11 7.52E-10 15.404 1.66 
A430103D13Rik 0.299 6.913 4.182 3.36E-04 1.08E-03 -0.978 1.23 
A730071L15Rik 0.376 6.649 5.584 9.77E-06 4.78E-05 2.567 1.30 
Abcf1 0.326 7.651 3.728 1.05E-03 2.97E-03 -2.103 1.25 
ABHD6 -0.324 6.783 -4.120 3.94E-04 1.23E-03 -1.133 -1.25 
Acat2 -1.292 6.811 -19.544 3.52E-16 3.96E-14 27.083 -2.45 
ACLY -0.431 8.199 -7.704 6.40E-08 5.75E-07 7.675 -1.35 
ACO1 -0.659 6.759 -20.467 1.25E-16 1.79E-14 28.134 -1.58 
ACOT7 0.298 7.565 5.548 1.07E-05 5.18E-05 2.474 1.23 
Acp2 0.290 6.448 4.325 2.34E-04 7.82E-04 -0.617 1.22 
ACTB 0.299 7.958 3.593 1.47E-03 3.94E-03 -2.431 1.23 
ACTB 0.321 7.918 3.732 1.04E-03 2.94E-03 -2.092 1.25 
Adam23 -0.373 7.575 -5.864 4.89E-06 2.57E-05 3.266 -1.29 
Adam23 -0.372 7.260 -5.984 3.64E-06 1.96E-05 3.563 -1.29 
ADAM9 -0.328 8.339 -4.355 2.17E-04 7.33E-04 -0.542 -1.26 
ADD3 -0.307 7.763 -6.400 1.32E-06 8.14E-06 4.590 -1.24 
ADO 0.522 6.943 9.028 3.69E-09 4.69E-08 10.589 1.44 
Ado 0.616 7.572 15.325 7.67E-14 4.31E-12 21.617 1.53 
ADSS 0.343 7.645 6.764 5.56E-07 3.79E-06 5.472 1.27 
ADSS 0.393 8.642 6.071 2.94E-06 1.64E-05 3.780 1.31 
AFAP1 -0.421 6.434 -6.362 1.45E-06 8.82E-06 4.496 -1.34 
AGAP1 0.320 7.787 3.298 3.05E-03 7.39E-03 -3.137 1.25 
Agap1 0.330 7.472 6.582 8.58E-07 5.48E-06 5.031 1.26 
Agrn 0.334 7.203 7.032 2.97E-07 2.22E-06 6.110 1.26 
AHCYL1 -0.590 7.942 -14.231 3.79E-13 1.66E-11 19.986 -1.51 
AI646531 0.637 6.560 10.695 1.41E-10 2.53E-09 13.935 1.55 
AI646531 0.686 7.286 8.553 1.00E-08 1.11E-07 9.570 1.61 
AIG1 -0.356 6.487 -4.691 9.25E-05 3.42E-04 0.308 -1.28 
Akap12 -0.808 7.889 -12.120 1.11E-11 2.88E-10 16.531 -1.75 
Amacr -0.479 6.539 -7.109 2.48E-07 1.91E-06 6.293 -1.39 
AMD1 0.804 7.422 8.010 3.24E-08 3.17E-07 8.369 1.75 
AMD1 0.812 8.027 9.455 1.55E-09 2.20E-08 11.480 1.76 
AMOTL2 -0.370 8.057 -3.594 1.47E-03 3.94E-03 -2.429 -1.29 
ANLN -0.772 6.950 -6.691 6.61E-07 4.36E-06 5.296 -1.71 
ANO6 -0.414 7.837 -10.263 3.17E-10 5.25E-09 13.102 -1.33 
ANXA1 -0.291 10.378 -4.032 4.91E-04 1.49E-03 -1.350 -1.22 
Anxa4 -0.316 7.155 -5.520 1.15E-05 5.49E-05 2.406 -1.25 
AP1B1 0.736 6.806 13.963 5.69E-13 2.30E-11 19.571 1.67 
APP 0.572 10.319 13.337 1.51E-12 5.42E-11 18.574 1.49 
APP 0.777 8.605 8.036 3.06E-08 3.03E-07 8.428 1.71 
APP 0.812 6.325 3.551 1.63E-03 4.31E-03 -2.532 1.76 
Arf2 -0.484 6.235 -6.791 5.22E-07 3.60E-06 5.536 -1.40 
ARHGAP24 -0.427 7.747 -5.685 7.61E-06 3.82E-05 2.819 -1.34 
Arhgap25 -0.478 6.665 -5.743 6.59E-06 3.35E-05 2.965 -1.39 
Arhgap29 -0.284 7.970 -6.066 2.98E-06 1.65E-05 3.768 -1.22 
Arl2bp 0.359 7.421 6.017 3.36E-06 1.83E-05 3.646 1.28 
ARL6IP1 -0.288 8.692 -5.014 4.09E-05 1.68E-04 1.126 -1.22 
ARL6IP4 -0.315 6.141 -4.716 8.68E-05 3.24E-04 0.371 -1.24 
ARPC1A 0.412 8.147 7.031 2.98E-07 2.22E-06 6.107 1.33 
ARPC5 0.325 8.452 4.807 6.89E-05 2.65E-04 0.602 1.25 
ASAP1 0.610 5.925 11.437 3.65E-11 8.01E-10 15.314 1.53 
Asf1b -0.821 5.939 -9.795 7.87E-10 1.18E-08 12.172 -1.77 
ASPM -0.852 6.112 -12.999 2.59E-12 8.54E-11 18.022 -1.80 
ATAD2 0.302 6.552 3.403 2.36E-03 5.94E-03 -2.888 1.23 
Atf5 0.417 9.270 3.590 1.49E-03 3.97E-03 -2.439 1.34 
ATG3 -0.297 6.477 -4.782 7.35E-05 2.79E-04 0.538 -1.23 
Atp10a -0.629 7.352 -14.727 1.82E-13 9.06E-12 20.738 -1.55 
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ATP2A2 -0.282 6.749 -4.726 8.47E-05 3.17E-04 0.396 -1.22 
ATXN7L3B 0.362 7.040 5.038 3.84E-05 1.59E-04 1.188 1.29 
ATXN7L3B 0.458 6.370 9.177 2.72E-09 3.59E-08 10.904 1.37 
Aurka -0.530 6.331 -6.739 5.91E-07 3.98E-06 5.411 -1.44 
AW742525 -0.293 7.372 -7.545 9.14E-08 7.98E-07 7.311 -1.23 
Azin1 0.556 6.442 6.705 6.40E-07 4.27E-06 5.329 1.47 
AZIN1 0.785 6.431 10.839 1.08E-10 2.03E-09 14.207 1.72 
B230219D22Rik 0.804 8.128 15.270 8.30E-14 4.53E-12 21.536 1.75 
B230220B15Rik -1.771 7.506 -37.012 1.42E-22 1.02E-19 41.602 -3.41 
B2M -0.356 10.904 -8.359 1.52E-08 1.63E-07 9.145 -1.28 
B4GALT3 0.389 6.562 6.507 1.03E-06 6.47E-06 4.850 1.31 
BAZ1A -0.513 6.516 -5.989 3.59E-06 1.94E-05 3.578 -1.43 
BAZ1A -0.366 6.586 -7.433 1.18E-07 9.88E-07 7.051 -1.29 
BC013529 -0.320 7.343 -7.499 1.02E-07 8.72E-07 7.204 -1.25 
BCL10 -0.575 8.488 -11.344 4.31E-11 9.27E-10 15.146 -1.49 
BCLAF1 0.320 6.690 4.480 1.58E-04 5.53E-04 -0.226 1.25 
BCLAF1 0.331 7.984 5.308 1.95E-05 8.81E-05 1.870 1.26 
BEST1 -0.373 11.907 -7.466 1.09E-07 9.34E-07 7.128 -1.29 
BLVRB -0.694 8.858 -7.234 1.86E-07 1.48E-06 6.586 -1.62 
BMI1 0.563 6.386 6.781 5.35E-07 3.66E-06 5.511 1.48 
Bod1 -0.293 7.775 -6.077 2.90E-06 1.62E-05 3.796 -1.23 
BRD7 -0.339 7.096 -6.061 3.01E-06 1.67E-05 3.756 -1.27 
BRP44L 0.326 8.068 7.287 1.65E-07 1.33E-06 6.710 1.25 
BRP44L 0.380 7.208 2.382 2.55E-02 4.78E-02 -5.148 1.30 
BTBD1 0.286 7.455 2.509 1.93E-02 3.76E-02 -4.890 1.22 
BTBD1 0.322 8.357 5.117 3.15E-05 1.34E-04 1.386 1.25 
BTBD1 0.397 8.023 3.669 1.22E-03 3.37E-03 -2.248 1.32 
BUD31 0.303 7.762 5.154 2.87E-05 1.23E-04 1.480 1.23 
C11orf17 -0.272 6.469 -4.826 6.57E-05 2.54E-04 0.650 -1.21 
C12orf10 0.308 6.223 4.418 1.85E-04 6.38E-04 -0.384 1.24 
C14orf50 -0.264 7.750 -5.716 7.04E-06 3.56E-05 2.897 -1.20 
C19orf62 0.280 6.759 4.385 2.01E-04 6.87E-04 -0.465 1.21 
C1R -0.971 9.482 -12.310 8.07E-12 2.26E-10 16.860 -1.96 
C22orf28 -0.267 8.171 -7.184 2.09E-07 1.65E-06 6.470 -1.20 
C2orf24 0.298 6.408 2.616 1.52E-02 3.05E-02 -4.666 1.23 
C3 -1.960 7.330 -35.720 3.25E-22 1.95E-19 40.810 -3.89 
C4orf27 1.279 6.966 25.781 6.38E-19 2.09E-16 33.414 2.43 
C5orf51 0.278 6.308 3.604 1.43E-03 3.84E-03 -2.404 1.21 
C78376 -0.371 7.959 -5.924 4.22E-06 2.25E-05 3.415 -1.29 
C7orf55 0.293 9.383 3.983 5.56E-04 1.67E-03 -1.474 1.23 
CACHD1 0.355 6.534 6.913 3.92E-07 2.80E-06 5.827 1.28 
CALD1 -0.477 7.225 -5.384 1.61E-05 7.37E-05 2.062 -1.39 
CALD1 -0.426 7.673 -3.335 2.78E-03 6.86E-03 -3.049 -1.34 
CAMK2N1 0.348 6.214 4.646 1.04E-04 3.78E-04 0.193 1.27 
CANX -0.548 7.461 -6.284 1.75E-06 1.05E-05 4.306 -1.46 
CANX -0.392 8.370 -9.495 1.43E-09 2.05E-08 11.562 -1.31 
CAPG -0.385 7.270 -4.862 5.99E-05 2.34E-04 0.742 -1.31 
CAPG -0.352 7.250 -3.320 2.88E-03 7.06E-03 -3.083 -1.28 
Capns1 0.449 7.079 6.964 3.48E-07 2.56E-06 5.950 1.36 
Cat -0.589 8.131 -5.906 4.40E-06 2.33E-05 3.372 -1.50 
CAT -0.527 6.892 -2.649 1.41E-02 2.86E-02 -4.596 -1.44 
CAV2 -0.377 6.234 -5.216 2.46E-05 1.07E-04 1.637 -1.30 
CBFB 0.299 7.994 5.209 2.50E-05 1.08E-04 1.620 1.23 
Cbx1 0.305 6.452 4.766 7.65E-05 2.89E-04 0.498 1.24 
Cbx6-Nptxr 0.365 6.780 4.862 6.00E-05 2.34E-04 0.742 1.29 
CCDC132 0.300 7.485 5.432 1.43E-05 6.61E-05 2.183 1.23 
CCDC50 0.534 7.337 9.404 1.71E-09 2.40E-08 11.375 1.45 
CCDC53 -0.436 7.195 -8.903 4.79E-09 5.88E-08 10.323 -1.35 
CCDC80 -0.264 7.753 -2.577 1.66E-02 3.30E-02 -4.749 -1.20 
Ccna2 -0.610 6.788 -4.773 7.51E-05 2.84E-04 0.516 -1.53 
CCNB1 -1.171 5.956 -8.223 2.03E-08 2.13E-07 8.846 -2.25 
Ccnb1 -0.927 7.434 -11.028 7.62E-11 1.50E-09 14.563 -1.90 
CCNB2 -1.093 6.467 -16.455 1.62E-14 1.19E-12 23.201 -2.13 
Ccnd1 1.744 6.627 20.529 1.16E-16 1.74E-14 28.204 3.35 
Cd151 0.268 6.994 3.154 4.31E-03 1.01E-02 -3.472 1.20 
CD36 3.337 8.162 16.730 1.12E-14 8.98E-13 23.572 10.10 
CDC20 -0.938 7.231 -9.739 8.78E-10 1.31E-08 12.059 -1.92 
CDC37 0.406 7.553 6.451 1.17E-06 7.33E-06 4.713 1.32 
Cdc42se1 -0.353 6.268 -6.227 2.02E-06 1.19E-05 4.164 -1.28 
CDIPT 0.326 7.020 5.018 4.04E-05 1.67E-04 1.138 1.25 
CDK1 -0.435 8.673 -6.787 5.27E-07 3.63E-06 5.527 -1.35 
Cdk5rap3 -0.330 7.163 -5.397 1.56E-05 7.16E-05 2.095 -1.26 
CDKN3 -1.362 8.297 -15.752 4.22E-14 2.70E-12 22.227 -2.57 
Cenpa -0.866 7.615 -9.199 2.60E-09 3.46E-08 10.949 -1.82 
Cenpf -0.955 6.632 -11.607 2.70E-11 6.31E-10 15.623 -1.94 
CENPL -0.717 6.032 -10.335 2.77E-10 4.66E-09 13.242 -1.64 
Cep55 -0.470 6.066 -5.569 1.01E-05 4.95E-05 2.528 -1.39 
Cflar -0.587 7.205 -7.451 1.13E-07 9.57E-07 7.093 -1.50 
CHD2 0.412 6.581 7.126 2.38E-07 1.85E-06 6.334 1.33 
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Chordc1 0.343 6.453 4.789 7.22E-05 2.75E-04 0.555 1.27 
Chpf 0.639 6.081 5.504 1.19E-05 5.69E-05 2.364 1.56 
CHPT1 -0.277 8.437 -4.971 4.55E-05 1.84E-04 1.018 -1.21 
Cisd2 0.491 6.498 10.337 2.76E-10 4.66E-09 13.245 1.41 
CISD3 0.269 6.884 4.323 2.35E-04 7.86E-04 -0.623 1.21 
CKAP2 -1.046 5.818 -17.098 6.96E-15 5.82E-13 24.059 -2.07 
CKAP5 -0.569 6.097 -7.307 1.57E-07 1.29E-06 6.757 -1.48 
CKS1B -0.384 7.858 -7.703 6.40E-08 5.75E-07 7.674 -1.30 
CKS2 -0.622 8.689 -7.960 3.62E-08 3.48E-07 8.257 -1.54 
Clec2e -0.468 5.756 -4.433 1.78E-04 6.16E-04 -0.346 -1.38 
CLIC1 -0.356 8.811 -7.549 9.06E-08 7.94E-07 7.320 -1.28 
Clstn1 0.580 7.732 8.412 1.35E-08 1.46E-07 9.263 1.49 
Clu 0.295 10.477 3.488 1.91E-03 4.96E-03 -2.684 1.23 
Cmas -0.300 8.324 -8.549 1.01E-08 1.12E-07 9.562 -1.23 
CMTM1 -0.494 8.581 -12.635 4.69E-12 1.45E-10 17.415 -1.41 
Cnn2 0.421 7.200 4.150 3.64E-04 1.15E-03 -1.056 1.34 
COBLL1 -0.757 6.463 -14.148 4.30E-13 1.84E-11 19.858 -1.69 
Col12a1 -0.745 6.218 -15.548 5.60E-14 3.25E-12 21.937 -1.68 
COL4A3BP -0.330 6.224 -8.314 1.67E-08 1.78E-07 9.047 -1.26 
COL5A2 -0.857 7.606 -11.767 2.05E-11 4.90E-10 15.908 -1.81 
COMTD1 -0.276 6.280 -4.110 4.03E-04 1.26E-03 -1.157 -1.21 
COPB2 -0.289 7.048 -5.086 3.40E-05 1.43E-04 1.309 -1.22 
CORO1B -0.376 7.585 -5.204 2.53E-05 1.10E-04 1.606 -1.30 
Coro1b -0.335 8.179 -5.305 1.97E-05 8.86E-05 1.862 -1.26 
Cox4nb 0.388 7.112 7.045 2.88E-07 2.17E-06 6.142 1.31 
COX7A2L 0.268 7.153 2.815 9.63E-03 2.05E-02 -4.238 1.20 
CPD 0.425 7.815 7.714 6.25E-08 5.64E-07 7.699 1.34 
Cpn2 -0.579 6.648 -7.312 1.55E-07 1.28E-06 6.769 -1.49 
Cpsf2 0.298 7.072 3.793 8.96E-04 2.56E-03 -1.944 1.23 
CPT2 -0.559 6.454 -9.877 6.69E-10 1.02E-08 12.338 -1.47 
Cr1l -0.708 8.857 -16.675 1.21E-14 9.25E-13 23.497 -1.63 
Cr1l -0.530 7.762 -7.561 8.81E-08 7.76E-07 7.349 -1.44 
CRELD1 -0.300 6.519 -3.011 6.08E-03 1.37E-02 -3.801 -1.23 
CRELD2 -0.659 7.396 -9.176 2.73E-09 3.59E-08 10.900 -1.58 
Crk -0.567 7.733 -6.192 2.19E-06 1.27E-05 4.078 -1.48 
CROT -0.402 6.877 -8.820 5.69E-09 6.73E-08 10.147 -1.32 
CSDAP1 0.297 10.028 5.819 5.46E-06 2.84E-05 3.154 1.23 
CSE1L -0.385 7.389 -7.293 1.62E-07 1.32E-06 6.726 -1.31 
CSNK2A1 0.323 6.970 6.231 1.99E-06 1.17E-05 4.175 1.25 
Csnk2a1 0.518 6.763 4.707 8.89E-05 3.30E-04 0.348 1.43 
Ctla2b -3.209 7.178 -37.496 1.04E-22 9.37E-20 41.891 -9.24 
Ctsb 0.325 9.036 5.599 9.41E-06 4.62E-05 2.604 1.25 
CTSH -0.713 6.886 -11.846 1.78E-11 4.30E-10 16.049 -1.64 
Ctsz -0.284 9.672 -6.204 2.13E-06 1.24E-05 4.108 -1.22 
Cxcl1 -1.338 6.634 -15.631 4.99E-14 3.11E-12 22.055 -2.53 
Cxx1a 0.303 6.694 4.714 8.73E-05 3.25E-04 0.366 1.23 
CYFIP1 -0.348 7.533 -6.346 1.51E-06 9.14E-06 4.457 -1.27 
Cyp51 -0.668 9.644 -12.426 6.65E-12 1.94E-10 17.058 -1.59 
D15Ertd621e 0.569 7.356 13.500 1.17E-12 4.42E-11 18.837 1.48 
D17Wsu104e -0.417 6.741 -6.211 2.09E-06 1.22E-05 4.126 -1.34 
D5Ertd579e -0.351 7.211 -8.750 6.60E-09 7.70E-08 9.996 -1.28 
D830024F11Rik -0.390 7.236 -6.168 2.33E-06 1.33E-05 4.018 -1.31 
DAG1 -0.302 8.711 -4.666 9.86E-05 3.61E-04 0.244 -1.23 
DBF4 -0.705 6.260 -9.125 3.03E-09 3.94E-08 10.793 -1.63 
Dcaf12l1 0.450 6.572 5.279 2.10E-05 9.35E-05 1.796 1.37 
DCAF13 0.269 7.411 6.380 1.39E-06 8.51E-06 4.541 1.20 
DCN -0.328 10.903 -5.906 4.41E-06 2.33E-05 3.372 -1.26 
Ddhd2 0.483 7.529 10.749 1.27E-10 2.32E-09 14.037 1.40 
DDHD2 1.681 9.554 7.159 2.21E-07 1.74E-06 6.410 3.21 
DDIT3 -0.802 6.496 -8.398 1.39E-08 1.50E-07 9.232 -1.74 
DDOST -0.302 8.414 -6.694 6.57E-07 4.35E-06 5.302 -1.23 
DDOST -0.266 6.514 -2.713 1.22E-02 2.51E-02 -4.460 -1.20 
DDX21 0.280 7.918 5.366 1.69E-05 7.69E-05 2.016 1.21 
DDX41 0.344 6.481 3.928 6.37E-04 1.88E-03 -1.609 1.27 
Degs1 -0.345 6.778 -7.800 5.15E-08 4.77E-07 7.896 -1.27 
DERL1 0.333 7.056 5.674 7.81E-06 3.91E-05 2.792 1.26 
DERL1 0.366 8.644 7.430 1.19E-07 9.91E-07 7.045 1.29 
Derl1 0.442 8.334 8.960 4.25E-09 5.30E-08 10.446 1.36 
Derl1 0.607 7.959 8.491 1.14E-08 1.26E-07 9.435 1.52 
DHRS7 -0.277 7.060 -6.713 6.29E-07 4.21E-06 5.347 -1.21 
DLAT -0.309 7.289 -5.767 6.21E-06 3.19E-05 3.025 -1.24 
DLGAP5 -0.751 6.521 -8.131 2.48E-08 2.53E-07 8.641 -1.68 
Dmtf1 0.276 6.932 3.325 2.85E-03 7.00E-03 -3.072 1.21 
DNAJA3 0.282 7.151 7.270 1.71E-07 1.38E-06 6.672 1.22 
DNAJB2 -0.300 6.280 -2.828 9.35E-03 1.99E-02 -4.210 -1.23 
Dnajb6 0.299 6.727 3.179 4.06E-03 9.56E-03 -3.414 1.23 
DNAJC3 -0.827 6.788 -10.809 1.14E-10 2.11E-09 14.151 -1.77 
DNAJC3 -0.720 6.786 -14.033 5.12E-13 2.11E-11 19.680 -1.65 
DNPEP -0.273 7.288 -3.473 1.98E-03 5.12E-03 -2.721 -1.21 
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Dock9 -0.269 6.569 -4.153 3.62E-04 1.15E-03 -1.051 -1.20 
Dram1 -0.871 6.300 -14.358 3.13E-13 1.43E-11 20.181 -1.83 
DTYMK 0.328 7.027 6.022 3.32E-06 1.81E-05 3.658 1.26 
DUSP1 -0.740 6.221 -11.474 3.42E-11 7.64E-10 15.381 -1.67 
DYNC2LI1 0.299 8.006 5.770 6.17E-06 3.17E-05 3.031 1.23 
DYNC2LI1 0.334 7.258 2.510 1.93E-02 3.75E-02 -4.888 1.26 
E130203B14Rik -0.290 8.135 -3.561 1.59E-03 4.21E-03 -2.508 -1.22 
EBNA1BP2 0.285 7.513 5.539 1.09E-05 5.28E-05 2.453 1.22 
EBNA1BP2 0.294 8.826 5.145 2.93E-05 1.26E-04 1.459 1.23 
EBP -1.246 5.933 -20.648 1.02E-16 1.67E-14 28.335 -2.37 
ECT2 -0.646 7.232 -6.681 6.78E-07 4.46E-06 5.270 -1.56 
EEF1B2 0.268 10.413 8.186 2.21E-08 2.28E-07 8.762 1.20 
Eef2 0.401 6.433 7.537 9.32E-08 8.07E-07 7.291 1.32 
EFEMP1 -0.335 9.515 -5.509 1.18E-05 5.63E-05 2.378 -1.26 
EFEMP2 -0.323 6.616 -3.868 7.41E-04 2.16E-03 -1.758 -1.25 
Efr3a 0.340 8.691 6.935 3.72E-07 2.69E-06 5.880 1.27 
EIF2A 0.337 7.926 6.780 5.36E-07 3.66E-06 5.510 1.26 
EIF2S3 0.350 6.968 5.650 8.31E-06 4.11E-05 2.731 1.27 
EIF3C 0.322 9.095 6.974 3.40E-07 2.51E-06 5.973 1.25 
EIF3C 0.333 9.693 6.725 6.10E-07 4.11E-06 5.377 1.26 
EIF3H 0.353 8.828 7.731 6.02E-08 5.45E-07 7.737 1.28 
EIF3H 0.381 8.385 3.294 3.08E-03 7.46E-03 -3.147 1.30 
EIF3K 0.459 9.323 8.209 2.10E-08 2.18E-07 8.814 1.37 
EIF3M 0.394 9.726 7.087 2.61E-07 2.00E-06 6.241 1.31 
Eif4a1 -0.626 8.429 -3.625 1.36E-03 3.70E-03 -2.355 -1.54 
Eif4a1 -0.529 9.235 -12.338 7.71E-12 2.21E-10 16.907 -1.44 
EIF5 -0.915 6.761 -9.002 3.89E-09 4.93E-08 10.535 -1.89 
EIF5 -0.898 8.217 -18.239 1.66E-15 1.53E-13 25.516 -1.86 
EIF5A 0.304 6.847 6.288 1.74E-06 1.04E-05 4.315 1.23 
EIF5A 0.399 9.394 3.232 3.57E-03 8.52E-03 -3.291 1.32 
Elp2 0.342 5.950 3.231 3.58E-03 8.54E-03 -3.294 1.27 
EMP1 -0.657 7.772 -13.153 2.02E-12 6.92E-11 18.275 -1.58 
ENAH -0.271 7.328 -7.113 2.46E-07 1.90E-06 6.301 -1.21 
Ensa 0.353 6.811 8.970 4.16E-09 5.21E-08 10.467 1.28 
EPHX1 -0.301 8.644 -4.051 4.68E-04 1.43E-03 -1.303 -1.23 
EPR1 -0.684 7.818 -8.473 1.19E-08 1.30E-07 9.396 -1.61 
EPS8 -0.462 7.562 -5.754 6.42E-06 3.28E-05 2.990 -1.38 
EPS8 -0.428 8.261 -4.759 7.79E-05 2.94E-04 0.480 -1.34 
ERAP1 -0.703 6.611 -14.888 1.44E-13 7.37E-12 20.977 -1.63 
ERCC1 0.267 6.529 3.503 1.84E-03 4.80E-03 -2.649 1.20 
Ern1 0.514 6.120 8.249 1.92E-08 2.03E-07 8.902 1.43 
Erp29 -0.784 7.835 -14.131 4.41E-13 1.87E-11 19.831 -1.72 
ERP29 -0.779 6.775 -9.293 2.15E-09 2.91E-08 11.145 -1.72 
ERP44 -0.465 7.100 -9.719 9.14E-10 1.35E-08 12.018 -1.38 
ERP44 -0.459 6.554 -3.122 4.66E-03 1.08E-02 -3.545 -1.37 
ESD -0.902 8.915 -21.901 2.68E-17 6.02E-15 29.680 -1.87 
Esyt2 0.378 7.084 8.030 3.10E-08 3.06E-07 8.414 1.30 
EWSR1 0.460 7.376 12.542 5.48E-12 1.64E-10 17.257 1.38 
EXOSC9 0.280 6.576 4.453 1.69E-04 5.88E-04 -0.294 1.21 
F2r -0.547 8.207 -6.052 3.08E-06 1.71E-05 3.734 -1.46 
Fam100b 0.375 6.914 5.269 2.15E-05 9.55E-05 1.772 1.30 
Fam102b -0.351 7.655 -4.571 1.26E-04 4.48E-04 0.003 -1.28 
FAM107B -0.329 6.765 -6.416 1.28E-06 7.86E-06 4.628 -1.26 
Fam108b -0.383 6.803 -5.224 2.41E-05 1.05E-04 1.658 -1.30 
FAM108B1 -0.344 7.357 -6.367 1.44E-06 8.74E-06 4.508 -1.27 
Fam125b 0.274 6.716 5.302 1.98E-05 8.90E-05 1.855 1.21 
FAM40A -0.287 6.463 -6.009 3.43E-06 1.86E-05 3.627 -1.22 
FAM40B -0.367 6.679 -6.259 1.86E-06 1.11E-05 4.243 -1.29 
FAM49B 0.468 7.847 9.638 1.07E-09 1.57E-08 11.855 1.38 
Fam92a 0.268 6.361 4.808 6.88E-05 2.64E-04 0.604 1.20 
Fasn -0.662 6.330 -6.620 7.84E-07 5.05E-06 5.123 -1.58 
FAT1 -0.517 8.629 -10.219 3.45E-10 5.64E-09 13.015 -1.43 
FBL -0.688 9.015 -12.775 3.73E-12 1.17E-10 17.650 -1.61 
FBXO6 0.302 7.635 3.623 1.37E-03 3.71E-03 -2.358 1.23 
FBXO8 1.053 6.542 21.279 5.16E-17 9.75E-15 29.022 2.07 
FCGRT 0.516 6.491 7.545 9.15E-08 7.98E-07 7.310 1.43 
FDPS -1.070 8.124 -18.294 1.55E-15 1.50E-13 25.584 -2.10 
FERMT2 -0.368 9.646 -5.466 1.31E-05 6.15E-05 2.269 -1.29 
FERMT2 -0.331 8.924 -7.129 2.37E-07 1.85E-06 6.340 -1.26 
Fez2 -0.311 7.112 -6.959 3.52E-07 2.57E-06 5.938 -1.24 
Fhl1 0.293 7.505 6.699 6.49E-07 4.31E-06 5.314 1.22 
Fkbp9 -0.346 7.631 -6.708 6.36E-07 4.25E-06 5.336 -1.27 
FMNL2 0.663 7.362 10.041 4.87E-10 7.70E-09 12.663 1.58 
FOSL1 -0.266 7.032 -3.016 6.00E-03 1.35E-02 -3.789 -1.20 
Foxp2 0.325 7.336 5.145 2.93E-05 1.26E-04 1.459 1.25 
Frmd6 -0.311 7.433 -5.712 7.11E-06 3.59E-05 2.887 -1.24 
Fth1 -0.350 11.320 -7.242 1.83E-07 1.46E-06 6.606 -1.27 
FUBP3 0.348 6.446 6.441 1.20E-06 7.47E-06 4.689 1.27 
FUCA1 0.496 7.522 9.854 7.01E-10 1.06E-08 12.290 1.41 
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G3BP1 0.314 7.821 6.202 2.14E-06 1.24E-05 4.104 1.24 
G3BP2 0.480 8.617 8.978 4.10E-09 5.15E-08 10.483 1.40 
GABARAP 0.555 9.365 11.980 1.42E-11 3.53E-10 16.285 1.47 
Gabarapl1 -0.269 7.833 -4.914 5.26E-05 2.09E-04 0.873 -1.20 
GABARAPL2 0.263 8.308 4.789 7.22E-05 2.75E-04 0.556 1.20 
GADD45A -0.304 8.855 -4.551 1.32E-04 4.67E-04 -0.046 -1.23 
GADD45B -0.951 6.746 -13.992 5.45E-13 2.23E-11 19.616 -1.93 
GALNT7 0.971 7.466 9.580 1.20E-09 1.75E-08 11.737 1.96 
Gapdh -0.271 9.031 -4.947 4.84E-05 1.94E-04 0.956 -1.21 
Gatad2a -0.369 6.422 -5.261 2.19E-05 9.69E-05 1.751 -1.29 
Gatad2a -0.363 6.502 -6.932 3.75E-07 2.70E-06 5.874 -1.29 
GCLM -0.843 9.225 -16.193 2.31E-14 1.62E-12 22.841 -1.79 
GFM1 -0.433 7.517 -11.055 7.25E-11 1.44E-09 14.613 -1.35 
GHR 0.292 6.655 4.646 1.04E-04 3.78E-04 0.193 1.22 
Gm10159 0.412 10.114 11.707 2.27E-11 5.40E-10 15.801 1.33 
Gm10291 -0.289 10.903 -5.920 4.26E-06 2.26E-05 3.405 -1.22 
Gm10397 0.310 7.405 5.955 3.91E-06 2.09E-05 3.493 1.24 
Gm14148 -0.276 9.820 -5.530 1.12E-05 5.38E-05 2.429 -1.21 
Gm2260 0.276 8.341 4.416 1.86E-04 6.40E-04 -0.388 1.21 
Gm3811 0.343 7.340 6.362 1.45E-06 8.82E-06 4.496 1.27 
Gm5069 -0.320 9.657 -5.777 6.06E-06 3.13E-05 3.049 -1.25 
Gm5512 -0.371 6.531 -6.183 2.24E-06 1.30E-05 4.056 -1.29 
GMCL1 0.452 6.620 6.858 4.46E-07 3.16E-06 5.696 1.37 
Gmfb 0.431 8.592 7.541 9.22E-08 8.02E-07 7.302 1.35 
GNAI2 -0.336 6.846 -4.366 2.11E-04 7.16E-04 -0.514 -1.26 
GNB2L1 0.289 10.808 8.535 1.04E-08 1.15E-07 9.531 1.22 
GNPAT -0.484 6.582 -8.844 5.41E-09 6.48E-08 10.199 -1.40 
GPC6 -1.031 3.584 -12.301 8.19E-12 2.28E-10 16.845 -2.04 
Gpd2 -0.315 6.879 -4.135 3.79E-04 1.19E-03 -1.095 -1.24 
Gpnmb 1.322 5.966 20.966 7.21E-17 1.23E-14 28.684 2.50 
Gpr124 0.628 7.400 13.216 1.83E-12 6.32E-11 18.379 1.55 
GPR176 -1.233 7.295 -28.225 7.88E-20 3.14E-17 35.483 -2.35 
Gpr56 1.447 6.194 18.419 1.33E-15 1.37E-13 25.739 2.73 
Gpsm2 -0.363 6.902 -5.483 1.26E-05 5.93E-05 2.312 -1.29 
Gpx1 -0.847 7.884 -12.171 1.02E-11 2.72E-10 16.620 -1.80 
Gpx4 -0.366 10.579 -6.994 3.24E-07 2.40E-06 6.021 -1.29 
GRINA -0.300 7.072 -3.369 2.56E-03 6.40E-03 -2.969 -1.23 
GSS -1.023 7.023 -18.801 8.41E-16 8.89E-14 26.203 -2.03 
Gss -0.942 8.655 -20.147 1.78E-16 2.39E-14 27.776 -1.92 
GSS -0.832 6.247 -9.038 3.62E-09 4.63E-08 10.609 -1.78 
GSS -0.678 6.709 -10.268 3.15E-10 5.23E-09 13.110 -1.60 
GSTA5 -0.711 9.606 -13.338 1.51E-12 5.42E-11 18.576 -1.64 
Gstm6 -0.357 7.960 -4.836 6.40E-05 2.48E-04 0.676 -1.28 
Gt(ROSA)26Sor -0.512 6.526 -8.855 5.29E-09 6.40E-08 10.222 -1.43 
Gtf2h5 0.368 6.911 6.142 2.48E-06 1.41E-05 3.955 1.29 
GULP1 0.304 6.746 3.512 1.80E-03 4.71E-03 -2.628 1.23 
GUSB -0.748 6.935 -14.878 1.46E-13 7.37E-12 20.963 -1.68 
Gusb -0.604 7.029 -10.253 3.23E-10 5.33E-09 13.082 -1.52 
H1f0 0.444 8.525 7.038 2.93E-07 2.19E-06 6.125 1.36 
H3F3B 0.417 9.428 9.869 6.80E-10 1.03E-08 12.322 1.34 
H3F3C 0.400 10.004 8.080 2.78E-08 2.79E-07 8.527 1.32 
HADHB -0.285 8.394 -5.797 5.76E-06 2.99E-05 3.100 -1.22 
HBXIP 0.354 8.226 6.740 5.89E-07 3.98E-06 5.413 1.28 
HEATR3 -0.292 6.574 -6.023 3.31E-06 1.81E-05 3.660 -1.22 
Herpud1 -0.477 6.811 -10.765 1.23E-10 2.26E-09 14.068 -1.39 
HEXA -0.470 6.609 -6.372 1.42E-06 8.66E-06 4.521 -1.38 
HEXIM1 0.602 7.032 8.717 7.07E-09 8.20E-08 9.925 1.52 
Hibadh -0.310 7.744 -5.727 6.85E-06 3.48E-05 2.925 -1.24 
Hint1 0.325 9.534 7.525 9.56E-08 8.26E-07 7.265 1.25 
HMGCR -1.060 6.572 -15.810 3.89E-14 2.59E-12 22.308 -2.08 
Hmgcs1 -1.111 6.887 -20.138 1.80E-16 2.39E-14 27.764 -2.16 
HMOX1 -1.041 7.105 -12.040 1.28E-11 3.25E-10 16.390 -2.06 
Hnrnpa3 -0.381 8.503 -4.117 3.96E-04 1.24E-03 -1.140 -1.30 
Hnrnpa3 -0.287 9.119 -5.898 4.50E-06 2.37E-05 3.350 -1.22 
HNRNPC 0.286 9.033 6.004 3.47E-06 1.88E-05 3.615 1.22 
HNRNPH1 0.449 8.470 8.095 2.69E-08 2.72E-07 8.559 1.36 
HNRNPM 0.300 8.319 5.291 2.03E-05 9.11E-05 1.828 1.23 
HNRPDL -0.401 6.768 -6.128 2.56E-06 1.45E-05 3.921 -1.32 
Hnrpdl -0.323 6.334 -5.060 3.63E-05 1.51E-04 1.244 -1.25 
HPRT1 -0.499 9.127 -10.077 4.54E-10 7.25E-09 12.735 -1.41 
Hsd17b12 -0.512 7.796 -10.719 1.34E-10 2.43E-09 13.981 -1.43 
Hsp90b1 -1.188 8.375 -6.209 2.10E-06 1.23E-05 4.122 -2.28 
Hsp90b1 -1.118 7.905 -5.055 3.69E-05 1.53E-04 1.229 -2.17 
HSP90B1 -1.037 10.245 -16.248 2.14E-14 1.54E-12 22.917 -2.05 
HSPA5 -1.162 11.437 -24.785 1.58E-18 4.73E-16 32.512 -2.24 
HSPA8 0.271 10.561 5.648 8.34E-06 4.12E-05 2.726 1.21 
HSPB1 -0.334 9.142 -5.128 3.06E-05 1.30E-04 1.416 -1.26 
Hspb8 -0.340 7.970 -6.913 3.92E-07 2.80E-06 5.827 -1.27 
Hyou1 -0.825 6.015 -10.106 4.29E-10 6.94E-09 12.792 -1.77 
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IBTK -0.478 6.329 -6.822 4.86E-07 3.38E-06 5.609 -1.39 
IDH1 -0.321 8.313 -4.266 2.71E-04 8.90E-04 -0.765 -1.25 
Idi1 -1.266 6.124 -21.204 5.58E-17 1.00E-14 28.942 -2.40 
Ifngr2 -0.333 6.377 -7.291 1.63E-07 1.32E-06 6.721 -1.26 
IL1R1 0.700 6.416 10.063 4.66E-10 7.41E-09 12.708 1.63 
Ildr2 0.559 6.552 10.907 9.50E-11 1.83E-09 14.336 1.47 
Impad1 0.395 6.929 4.756 7.84E-05 2.95E-04 0.472 1.31 
Insig1 -0.582 8.024 -11.905 1.61E-11 3.91E-10 16.154 -1.50 
INSIG2 0.357 6.483 7.270 1.71E-07 1.38E-06 6.671 1.28 
IPO7 0.301 8.117 5.006 4.17E-05 1.71E-04 1.105 1.23 
IPO7 0.523 8.188 10.827 1.10E-10 2.06E-09 14.184 1.44 
Irak2 -0.337 6.582 -4.727 8.44E-05 3.16E-04 0.400 -1.26 
Isca1 -0.281 8.849 -6.674 6.89E-07 4.53E-06 5.253 -1.22 
ITGB5 0.365 7.557 4.090 4.24E-04 1.31E-03 -1.207 1.29 
ITIH5 -0.533 6.180 -4.799 7.03E-05 2.69E-04 0.582 -1.45 
Jak2 -0.415 6.679 -5.795 5.80E-06 3.01E-05 3.094 -1.33 
Jub -0.633 7.280 -16.710 1.16E-14 9.02E-13 23.545 -1.55 
JUN -0.282 7.869 -3.970 5.74E-04 1.72E-03 -1.506 -1.22 
KARS 0.277 8.766 3.715 1.09E-03 3.05E-03 -2.135 1.21 
Kdelr3 -0.448 6.846 -6.714 6.26E-07 4.20E-06 5.352 -1.36 
Kdm1a -0.275 7.988 -6.670 6.95E-07 4.56E-06 5.244 -1.21 
KIAA0196 0.510 7.763 8.326 1.63E-08 1.74E-07 9.074 1.42 
KIAA0494 0.367 6.477 9.361 1.87E-09 2.58E-08 11.285 1.29 
KIF23 -0.529 6.746 -8.180 2.23E-08 2.30E-07 8.751 -1.44 
KIF5B -0.264 8.303 -4.109 4.04E-04 1.26E-03 -1.159 -1.20 
KIFAP3 0.287 6.899 4.456 1.68E-04 5.85E-04 -0.287 1.22 
KIFC1 -0.347 6.589 -5.444 1.39E-05 6.46E-05 2.214 -1.27 
KLC1 -0.356 7.277 -6.457 1.16E-06 7.28E-06 4.729 -1.28 
KLF6 0.328 7.705 5.622 8.89E-06 4.38E-05 2.661 1.26 
KLF6 0.340 8.141 6.849 4.55E-07 3.21E-06 5.675 1.27 
KLF6 0.380 6.300 4.905 5.38E-05 2.13E-04 0.849 1.30 
KPNA1 -0.304 6.808 -4.581 1.22E-04 4.40E-04 0.029 -1.23 
KPNA2 -0.663 7.512 -10.619 1.62E-10 2.87E-09 13.789 -1.58 
Krcc1 -0.895 6.207 -14.647 2.04E-13 9.65E-12 20.618 -1.86 
LAMC1 -0.481 7.195 -9.842 7.18E-10 1.08E-08 12.266 -1.40 
LAMP2 0.431 6.487 6.669 6.97E-07 4.56E-06 5.242 1.35 
LAP3 -0.277 7.918 -6.998 3.21E-07 2.38E-06 6.031 -1.21 
LAPTM4A -0.380 7.522 -5.058 3.65E-05 1.52E-04 1.238 -1.30 
LAYN 0.327 6.973 4.516 1.44E-04 5.07E-04 -0.137 1.25 
Ldlr -0.767 6.729 -12.250 8.93E-12 2.45E-10 16.756 -1.70 
LEMD3 0.422 7.077 4.445 1.73E-04 6.00E-04 -0.314 1.34 
Leprotl1 0.326 7.192 8.037 3.05E-08 3.03E-07 8.430 1.25 
LETM1 -0.476 6.495 -9.555 1.27E-09 1.84E-08 11.684 -1.39 
Lgals8 -0.384 7.619 -5.921 4.25E-06 2.26E-05 3.408 -1.30 
LOC100043810 0.283 7.540 3.410 2.32E-03 5.86E-03 -2.871 1.22 
LOC100129096 0.281 9.294 4.022 5.04E-04 1.53E-03 -1.377 1.21 
LOC100130003 0.288 8.698 5.291 2.04E-05 9.11E-05 1.827 1.22 
LOC100130746 0.359 7.013 7.449 1.14E-07 9.58E-07 7.088 1.28 
LOC100131826 -0.459 7.320 -5.400 1.55E-05 7.12E-05 2.102 -1.37 
LOC100287803 0.325 10.185 5.448 1.37E-05 6.41E-05 2.224 1.25 
LOC100288550 0.325 11.286 3.739 1.02E-03 2.90E-03 -2.074 1.25 
LOC144017 -0.291 9.492 -3.375 2.52E-03 6.32E-03 -2.955 -1.22 
LOC401387 -0.629 9.012 -11.082 6.91E-11 1.38E-09 14.663 -1.55 
LOC624853 0.365 9.491 2.748 1.12E-02 2.35E-02 -4.383 1.29 
LOC685953 3.176 9.130 30.430 1.37E-20 6.17E-18 37.195 9.04 
LOC728066 -0.321 7.550 -7.481 1.06E-07 9.05E-07 7.162 -1.25 
LOC732360 -0.324 6.927 -6.521 9.92E-07 6.27E-06 4.884 -1.25 
LPL 0.296 10.528 5.434 1.42E-05 6.59E-05 2.187 1.23 
LPP 0.319 6.385 3.605 1.43E-03 3.84E-03 -2.403 1.25 
LPP 0.394 7.853 7.080 2.65E-07 2.02E-06 6.225 1.31 
Lrig1 -0.449 8.856 -4.608 1.14E-04 4.14E-04 0.096 -1.37 
Lrp10 -0.767 7.803 -10.737 1.30E-10 2.36E-09 14.014 -1.70 
LRRFIP1 0.758 6.403 8.923 4.59E-09 5.67E-08 10.367 1.69 
Ly6e -0.410 7.105 -5.498 1.21E-05 5.75E-05 2.350 -1.33 
MAFG -0.339 6.127 -3.559 1.60E-03 4.23E-03 -2.512 -1.26 
MAFG -0.330 6.400 -3.345 2.72E-03 6.72E-03 -3.026 -1.26 
MAFG -0.326 5.986 -2.530 1.84E-02 3.62E-02 -4.847 -1.25 
MAMDC2 -0.960 7.429 -8.312 1.68E-08 1.78E-07 9.043 -1.95 
Man2a1 -0.355 6.504 -4.908 5.34E-05 2.12E-04 0.857 -1.28 
MAN2A1 -0.307 6.683 -4.171 3.45E-04 1.10E-03 -1.004 -1.24 
MAN2C1 -0.497 6.482 -6.700 6.47E-07 4.30E-06 5.318 -1.41 
MANF -1.203 8.744 -21.808 2.95E-17 6.13E-15 29.583 -2.30 
Map1lc3b 0.430 8.856 5.960 3.86E-06 2.07E-05 3.504 1.35 
Map1lc3b 0.585 8.566 17.852 2.67E-15 2.34E-13 25.031 1.50 
MAPK14 0.290 7.353 8.161 2.33E-08 2.39E-07 8.708 1.22 
MAPK6 -0.333 7.276 -4.604 1.15E-04 4.17E-04 0.087 -1.26 
MARK1 -0.444 6.616 -9.491 1.44E-09 2.06E-08 11.554 -1.36 
Mcm2 0.530 6.936 9.132 2.98E-09 3.90E-08 10.808 1.44 
MCM6 0.487 7.043 7.332 1.48E-07 1.22E-06 6.817 1.40 
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MCM7 0.427 7.318 6.025 3.29E-06 1.81E-05 3.667 1.34 
ME1 -0.438 7.376 -9.384 1.79E-09 2.48E-08 11.333 -1.35 
Me1 -0.374 7.716 -5.692 7.48E-06 3.77E-05 2.836 -1.30 
Med29 -0.617 7.001 -10.354 2.67E-10 4.57E-09 13.278 -1.53 
Mesdc2 -0.288 9.074 -8.906 4.76E-09 5.86E-08 10.329 -1.22 
Met -0.381 9.659 -6.453 1.17E-06 7.32E-06 4.718 -1.30 
METTL9 -0.447 6.724 -7.386 1.31E-07 1.09E-06 6.943 -1.36 
MGC112830 0.585 6.352 9.977 5.51E-10 8.57E-09 12.537 1.50 
Mgst1 -0.464 11.656 -11.314 4.54E-11 9.72E-10 15.091 -1.38 
MGST1 -0.422 11.519 -7.124 2.40E-07 1.86E-06 6.329 -1.34 
Mia3 -0.361 8.330 -6.614 7.95E-07 5.12E-06 5.108 -1.28 
MMD -0.329 6.497 -4.050 4.70E-04 1.43E-03 -1.308 -1.26 
MMP14 -0.391 6.141 -3.826 8.23E-04 2.38E-03 -1.861 -1.31 
MMP9 -0.708 6.731 -11.218 5.40E-11 1.13E-09 14.914 -1.63 
MOBKL3 0.331 6.352 7.076 2.68E-07 2.03E-06 6.215 1.26 
MPHOSPH8 -0.271 7.252 -3.905 6.75E-04 1.99E-03 -1.666 -1.21 
MRPL13 0.339 9.065 9.038 3.62E-09 4.63E-08 10.610 1.26 
Mrpl18 -0.317 7.610 -7.143 2.30E-07 1.80E-06 6.372 -1.25 
MRPL20 0.391 8.473 8.034 3.07E-08 3.03E-07 8.424 1.31 
MRPL30 0.376 8.776 6.019 3.34E-06 1.82E-05 3.651 1.30 
MRPL37 0.266 7.536 3.642 1.31E-03 3.57E-03 -2.313 1.20 
MRPL37 0.333 6.243 2.390 2.51E-02 4.72E-02 -5.132 1.26 
MRPL39 -0.369 6.894 -6.961 3.50E-07 2.57E-06 5.943 -1.29 
Mrpl50 -0.269 7.408 -3.715 1.09E-03 3.05E-03 -2.134 -1.21 
MRPS18A 0.415 9.934 6.599 8.23E-07 5.29E-06 5.073 1.33 
MRPS18B 0.498 7.064 6.291 1.72E-06 1.04E-05 4.322 1.41 
Msrb2 0.283 6.378 4.263 2.74E-04 8.97E-04 -0.774 1.22 
MTCH2 -0.268 8.629 -4.788 7.24E-05 2.76E-04 0.553 -1.20 
MTERFD1 -0.293 6.708 -4.869 5.89E-05 2.31E-04 0.759 -1.23 
Mthfd2l -0.856 6.000 -13.416 1.33E-12 4.93E-11 18.703 -1.81 
MYO1C -0.528 7.651 -7.802 5.14E-08 4.77E-07 7.899 -1.44 
MYO1C -0.320 7.577 -6.743 5.85E-07 3.96E-06 5.420 -1.25 
NAA20 0.479 8.064 9.055 3.49E-09 4.50E-08 10.647 1.39 
NACA 0.280 10.388 5.663 8.05E-06 4.00E-05 2.763 1.21 
NAGA -0.264 6.853 -4.574 1.24E-04 4.46E-04 0.011 -1.20 
NANS -0.492 6.959 -10.104 4.31E-10 6.94E-09 12.789 -1.41 
Nap1l1 0.380 6.621 6.843 4.62E-07 3.25E-06 5.660 1.30 
NAP1L1 0.402 6.670 8.867 5.16E-09 6.26E-08 10.247 1.32 
Nap1l4 0.284 6.668 4.565 1.27E-04 4.53E-04 -0.011 1.22 
Nars 0.266 7.775 5.332 1.83E-05 8.31E-05 1.932 1.20 
NARS 0.291 6.984 2.547 1.77E-02 3.49E-02 -4.811 1.22 
Ncam1 1.993 5.358 22.157 2.06E-17 4.93E-15 29.946 3.98 
Ncapd3 -1.286 5.993 -18.243 1.65E-15 1.53E-13 25.521 -2.44 
Ncaph -0.350 6.789 -5.292 2.03E-05 9.10E-05 1.830 -1.27 
NCEH1 -0.555 6.694 -10.963 8.59E-11 1.67E-09 14.440 -1.47 
NDC80 -0.371 6.736 -4.521 1.43E-04 5.02E-04 -0.124 -1.29 
Ndufb9 0.516 10.546 14.715 1.85E-13 9.10E-12 20.720 1.43 
NDUFV1 -0.279 7.817 -5.306 1.96E-05 8.85E-05 1.864 -1.21 
Neat1 -0.607 8.207 -9.260 2.30E-09 3.10E-08 11.076 -1.52 
Nek2 -0.711 8.036 -10.807 1.14E-10 2.11E-09 14.147 -1.64 
Nek6 0.338 7.298 5.594 9.54E-06 4.68E-05 2.591 1.26 
Neu1 -0.661 6.374 -12.086 1.18E-11 3.03E-10 16.471 -1.58 
Neurl3 -0.545 6.664 -7.838 4.74E-08 4.43E-07 7.980 -1.46 
NEURL3 -0.364 6.003 -2.670 1.34E-02 2.75E-02 -4.552 -1.29 
NFE2L2 -0.273 9.200 -5.004 4.19E-05 1.72E-04 1.100 -1.21 
Nfib 0.297 6.638 3.556 1.62E-03 4.27E-03 -2.521 1.23 
Nfic -0.359 6.666 -5.063 3.61E-05 1.51E-04 1.251 -1.28 
NFKB2 -0.330 6.057 -3.033 5.77E-03 1.31E-02 -3.751 -1.26 
NFKBIA -1.096 8.519 -15.579 5.36E-14 3.24E-12 21.981 -2.14 
NFKBIA -1.054 8.243 -17.030 7.60E-15 6.20E-13 23.970 -2.08 
NGDN 0.576 7.269 11.624 2.63E-11 6.17E-10 15.652 1.49 
Nhlrc3 -0.264 6.385 -5.951 3.95E-06 2.11E-05 3.483 -1.20 
NHP2L1 -0.351 8.019 -5.962 3.85E-06 2.07E-05 3.509 -1.28 
NIT1 -0.386 6.656 -4.876 5.80E-05 2.28E-04 0.776 -1.31 
NME1-NME2 0.269 9.016 6.038 3.19E-06 1.76E-05 3.699 1.20 
NOL7 0.289 8.228 4.776 7.46E-05 2.83E-04 0.522 1.22 
NONO 0.396 8.710 7.134 2.34E-07 1.83E-06 6.351 1.32 
NOP58 0.331 8.700 4.081 4.34E-04 1.34E-03 -1.230 1.26 
Nox1 0.338 7.107 4.281 2.62E-04 8.62E-04 -0.728 1.26 
NPC2 -0.454 9.515 -9.990 5.38E-10 8.45E-09 12.562 -1.37 
NPM1 0.319 7.805 4.360 2.14E-04 7.25E-04 -0.529 1.25 
Nr2c1 0.579 6.434 11.389 3.98E-11 8.66E-10 15.228 1.49 
NSA2 0.318 9.381 8.068 2.86E-08 2.86E-07 8.499 1.25 
NSMCE2 0.819 8.368 12.334 7.76E-12 2.21E-10 16.900 1.76 
NUCB2 -0.527 7.514 -9.972 5.56E-10 8.61E-09 12.527 -1.44 
Nudt3 0.456 6.423 5.395 1.57E-05 7.18E-05 2.090 1.37 
NUP98 -1.079 7.281 -16.655 1.24E-14 9.30E-13 23.470 -2.11 
Nusap1 -0.692 6.996 -8.664 7.90E-09 8.98E-08 9.812 -1.62 
NVL 0.292 6.210 5.442 1.39E-05 6.49E-05 2.208 1.22 
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OAZ1 -0.267 7.862 -3.520 1.77E-03 4.63E-03 -2.608 -1.20 
OGT 0.411 7.673 7.103 2.52E-07 1.93E-06 6.279 1.33 
OSBPL3 -0.471 6.826 -10.590 1.71E-10 3.00E-09 13.734 -1.39 
Osmr -0.391 7.659 -6.110 2.68E-06 1.51E-05 3.875 -1.31 
OSTC -0.461 8.595 -6.836 4.70E-07 3.29E-06 5.643 -1.38 
OSTC -0.460 9.604 -9.988 5.39E-10 8.45E-09 12.559 -1.38 
OXR1 -0.506 6.713 -7.246 1.81E-07 1.45E-06 6.616 -1.42 
OXSR1 -0.284 8.386 -4.990 4.34E-05 1.77E-04 1.065 -1.22 
P4hb -0.291 7.388 -4.787 7.26E-05 2.76E-04 0.550 -1.22 
Pabpc4 0.475 7.915 6.428 1.24E-06 7.67E-06 4.657 1.39 
PALLD -1.502 7.134 -30.647 1.16E-20 5.97E-18 37.357 -2.83 
PAPSS1 -0.470 6.702 -7.206 1.98E-07 1.57E-06 6.522 -1.39 
Parp3 -0.535 6.322 -8.836 5.51E-09 6.55E-08 10.181 -1.45 
PCGF5 -0.335 6.328 -6.821 4.86E-07 3.38E-06 5.608 -1.26 
PCNA 0.512 8.681 11.356 4.22E-11 9.14E-10 15.167 1.43 
Pcolce -0.586 8.526 -7.768 5.54E-08 5.05E-07 7.822 -1.50 
PDIA3 -0.892 9.730 -14.344 3.20E-13 1.44E-11 20.158 -1.86 
PDIA4 -1.411 6.027 -7.080 2.65E-07 2.02E-06 6.225 -2.66 
PDIA4 -1.236 7.671 -26.312 3.99E-19 1.43E-16 33.879 -2.36 
PDIA5 -0.530 7.082 -8.215 2.07E-08 2.16E-07 8.827 -1.44 
PDIA6 -0.723 10.091 -17.853 2.67E-15 2.34E-13 25.033 -1.65 
PDLIM1 -0.524 7.184 -11.138 6.24E-11 1.27E-09 14.767 -1.44 
Pdrg1 0.429 7.434 7.731 6.01E-08 5.45E-07 7.738 1.35 
Pebp1 0.388 9.686 10.311 2.90E-10 4.87E-09 13.194 1.31 
PECI -0.359 6.867 -6.894 4.10E-07 2.91E-06 5.782 -1.28 
Pex19 0.425 6.163 8.759 6.47E-09 7.57E-08 10.016 1.34 
Pgs1 -0.495 6.290 -7.326 1.51E-07 1.24E-06 6.801 -1.41 
PHF5A 0.303 7.050 5.745 6.57E-06 3.35E-05 2.968 1.23 
PHOSPHO2 -0.428 7.478 -11.244 5.16E-11 1.08E-09 14.962 -1.35 
Pir -0.906 6.603 -13.298 1.60E-12 5.65E-11 18.512 -1.87 
PITPNA -0.308 7.555 -6.641 7.44E-07 4.83E-06 5.176 -1.24 
PLAA -0.587 6.833 -11.992 1.39E-11 3.51E-10 16.307 -1.50 
PLAC8 4.114 5.438 41.191 1.15E-23 1.37E-20 43.963 17.32 
Plbd2 0.303 7.151 4.442 1.74E-04 6.03E-04 -0.321 1.23 
PLIN2 0.436 9.911 3.950 6.04E-04 1.79E-03 -1.556 1.35 
PLIN2 0.660 9.393 15.896 3.46E-14 2.34E-12 22.429 1.58 
PLK2 -0.665 7.605 -13.062 2.34E-12 7.86E-11 18.126 -1.59 
PLTP 1.178 7.226 8.980 4.08E-09 5.15E-08 10.487 2.26 
POLR2G 0.306 8.219 7.536 9.33E-08 8.07E-07 7.291 1.24 
PPAP2A -1.141 6.987 -15.121 1.03E-13 5.50E-12 21.320 -2.21 
Ppap2c -0.265 6.713 -4.331 2.30E-04 7.72E-04 -0.602 -1.20 
Ppcs -0.278 7.062 -4.937 4.96E-05 1.98E-04 0.932 -1.21 
PPP3R1 0.284 7.691 3.827 8.22E-04 2.37E-03 -1.859 1.22 
Prc1 -0.668 7.462 -6.962 3.50E-07 2.57E-06 5.944 -1.59 
Prdx1 -0.264 11.449 -5.309 1.94E-05 8.80E-05 1.872 -1.20 
PRKACB 0.412 8.518 7.793 5.23E-08 4.82E-07 7.880 1.33 
PRKCDBP -0.794 6.389 -7.379 1.33E-07 1.10E-06 6.927 -1.73 
PRKCSH -0.369 6.754 -3.318 2.90E-03 7.10E-03 -3.089 -1.29 
Prkrir 0.399 7.275 9.177 2.72E-09 3.59E-08 10.902 1.32 
Prmt5 -0.702 7.197 -9.447 1.57E-09 2.22E-08 11.464 -1.63 
Procr -0.411 6.220 -6.162 2.36E-06 1.35E-05 4.006 -1.33 
Pros1 -0.632 7.149 -10.997 8.07E-11 1.57E-09 14.504 -1.55 
PRPF38B -0.357 7.449 -5.906 4.41E-06 2.33E-05 3.371 -1.28 
PRPF8 -0.612 8.561 -10.241 3.31E-10 5.43E-09 13.058 -1.53 
PRUNE2 -0.299 7.588 -5.398 1.55E-05 7.14E-05 2.099 -1.23 
Psap 0.434 8.656 8.051 2.96E-08 2.95E-07 8.462 1.35 
PSMB5 -0.506 9.145 -5.439 1.40E-05 6.52E-05 2.202 -1.42 
PSMC4 -0.317 7.500 -4.517 1.44E-04 5.05E-04 -0.132 -1.25 
PSMC5 0.315 7.329 3.567 1.57E-03 4.17E-03 -2.495 1.24 
PSMC5 0.327 7.802 8.201 2.13E-08 2.22E-07 8.796 1.25 
PSME4 -0.326 7.404 -5.472 1.29E-05 6.07E-05 2.284 -1.25 
Ptdss1 -0.349 6.929 -6.258 1.87E-06 1.11E-05 4.242 -1.27 
PTGR1 -0.386 7.564 -3.375 2.52E-03 6.32E-03 -2.954 -1.31 
PTGR1 -0.380 8.581 -7.780 5.39E-08 4.95E-07 7.851 -1.30 
Ptplad1 -0.464 7.781 -11.923 1.56E-11 3.86E-10 16.186 -1.38 
Ptpmt1 -0.377 6.973 -7.772 5.49E-08 5.02E-07 7.831 -1.30 
PTPRG -2.282 5.545 -45.330 1.20E-24 2.16E-21 46.037 -4.86 
PTPRM -0.599 7.071 -14.383 3.02E-13 1.39E-11 20.219 -1.52 
PTTG1 -1.023 6.979 -12.278 8.52E-12 2.35E-10 16.805 -2.03 
PURB 0.873 7.313 15.267 8.33E-14 4.53E-12 21.533 1.83 
QKI -0.680 5.943 -4.981 4.44E-05 1.80E-04 1.042 -1.60 
QKI -0.571 7.862 -7.517 9.74E-08 8.39E-07 7.247 -1.49 
RAB11A -0.491 5.948 -4.699 9.07E-05 3.36E-04 0.328 -1.41 
RAB22A 0.371 7.574 3.324 2.85E-03 7.01E-03 -3.074 1.29 
RAB24 -0.465 6.607 -8.850 5.35E-09 6.43E-08 10.210 -1.38 
Rab31 0.357 6.713 4.416 1.86E-04 6.40E-04 -0.388 1.28 
Rab32 -0.632 6.424 -8.126 2.51E-08 2.55E-07 8.629 -1.55 
RANBP9 -0.348 7.016 -7.648 7.25E-08 6.50E-07 7.548 -1.27 
RANGRF -0.322 7.413 -5.063 3.61E-05 1.51E-04 1.251 -1.25 
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RARRES2 -1.376 9.322 -19.375 4.29E-16 4.67E-14 26.886 -2.60 
Rbck1 0.664 6.528 7.935 3.82E-08 3.63E-07 8.202 1.58 
RBM3 -0.348 7.415 -3.459 2.05E-03 5.28E-03 -2.755 -1.27 
RBPJ 0.381 7.585 6.832 4.75E-07 3.32E-06 5.633 1.30 
Rbpj 0.463 7.011 6.434 1.22E-06 7.56E-06 4.673 1.38 
Rbpj 0.560 7.628 8.004 3.28E-08 3.21E-07 8.356 1.47 
Rcan1 -0.466 6.276 -7.863 4.48E-08 4.24E-07 8.039 -1.38 
RCBTB2 -0.702 7.042 -11.920 1.57E-11 3.86E-10 16.180 -1.63 
RCL1 -0.462 7.522 -12.171 1.02E-11 2.72E-10 16.619 -1.38 
Rere 0.469 6.955 5.529 1.12E-05 5.39E-05 2.428 1.38 
RETSAT 0.501 5.458 5.343 1.78E-05 8.12E-05 1.959 1.42 
REV3L -0.418 7.281 -6.369 1.43E-06 8.71E-06 4.513 -1.34 
Rfx5 -0.297 6.821 -5.293 2.02E-05 9.08E-05 1.833 -1.23 
RFX7 0.331 7.777 4.586 1.21E-04 4.35E-04 0.041 1.26 
RGD1561797 -0.290 7.190 -3.728 1.05E-03 2.97E-03 -2.103 -1.22 
RGD1565775 0.268 6.526 5.698 7.37E-06 3.72E-05 2.851 1.20 
RGS17 1.049 7.346 10.807 1.14E-10 2.11E-09 14.147 2.07 
RHOQ -0.413 7.966 -6.842 4.63E-07 3.25E-06 5.658 -1.33 
RIOK3 0.533 7.168 7.482 1.06E-07 9.05E-07 7.164 1.45 
RNASEH2C -1.005 6.445 -16.058 2.77E-14 1.91E-12 22.655 -2.01 
RNASET2 0.605 10.189 14.034 5.11E-13 2.11E-11 19.681 1.52 
Rnf114 0.268 6.909 4.288 2.57E-04 8.49E-04 -0.710 1.20 
RNF139 0.288 7.550 6.453 1.17E-06 7.32E-06 4.717 1.22 
RNFT1 -0.632 6.370 -11.123 6.41E-11 1.29E-09 14.739 -1.55 
ROMO1 0.380 9.948 7.605 7.98E-08 7.06E-07 7.449 1.30 
RPL10 -0.286 6.263 -3.660 1.25E-03 3.44E-03 -2.268 -1.22 
Rpl14 0.307 11.088 6.748 5.78E-07 3.93E-06 5.432 1.24 
Rpl14 0.361 11.184 7.458 1.11E-07 9.45E-07 7.111 1.28 
RPL17 0.321 11.062 6.743 5.86E-07 3.96E-06 5.419 1.25 
RPL31 0.313 7.816 3.450 2.10E-03 5.37E-03 -2.776 1.24 
RPL34 0.276 9.992 5.401 1.54E-05 7.11E-05 2.105 1.21 
RPL38 0.407 9.372 7.089 2.60E-07 1.99E-06 6.246 1.33 
Rpn1 -0.581 9.350 -12.930 2.90E-12 9.47E-11 17.907 -1.50 
RPN1 -0.528 7.818 -3.608 1.42E-03 3.82E-03 -2.394 -1.44 
RPN2 -0.377 10.428 -8.665 7.88E-09 8.98E-08 9.814 -1.30 
RPN2 -0.365 9.821 -4.164 3.52E-04 1.12E-03 -1.022 -1.29 
RPP14 -0.568 6.393 -8.418 1.34E-08 1.45E-07 9.275 -1.48 
RPS19 0.292 11.192 6.780 5.36E-07 3.66E-06 5.510 1.22 
RPS5 0.401 11.111 8.875 5.08E-09 6.18E-08 10.264 1.32 
RPS6 0.293 9.161 3.892 6.99E-04 2.05E-03 -1.699 1.22 
Rrp1 0.349 6.040 3.541 1.68E-03 4.42E-03 -2.558 1.27 
RSL1D1 0.314 7.841 2.588 1.62E-02 3.23E-02 -4.726 1.24 
Rsl24d1 0.344 7.715 5.994 3.55E-06 1.92E-05 3.590 1.27 
RTN3 -0.393 8.012 -7.630 7.54E-08 6.73E-07 7.507 -1.31 
RYK 0.420 6.736 10.187 3.67E-10 5.97E-09 12.952 1.34 
S100A11 -0.278 7.784 -4.132 3.81E-04 1.20E-03 -1.101 -1.21 
SAT1 -0.513 6.704 -10.591 1.71E-10 3.00E-09 13.736 -1.43 
SBSN -0.553 9.801 -9.344 1.94E-09 2.65E-08 11.250 -1.47 
SBSN -0.491 6.788 -5.497 1.21E-05 5.76E-05 2.348 -1.41 
SC4MOL -0.999 8.194 -19.803 2.62E-16 3.06E-14 27.383 -2.00 
SC4MOL -0.900 6.368 -4.229 2.98E-04 9.68E-04 -0.858 -1.87 
Sc5d -0.492 6.364 -5.214 2.47E-05 1.07E-04 1.633 -1.41 
Scarb1 -0.620 6.897 -8.954 4.31E-09 5.36E-08 10.432 -1.54 
SCCPDH -0.279 7.895 -5.868 4.84E-06 2.55E-05 3.276 -1.21 
SCD -0.636 9.542 -15.010 1.20E-13 6.27E-12 21.157 -1.55 
SCD -0.485 7.257 -4.564 1.28E-04 4.54E-04 -0.014 -1.40 
Scd1 -0.631 9.240 -11.988 1.40E-11 3.51E-10 16.300 -1.55 
Scyl2 -0.266 6.432 -6.384 1.38E-06 8.45E-06 4.550 -1.20 
Scyl3 -1.095 5.993 -17.548 3.91E-15 3.35E-13 24.645 -2.14 
Sdc1 -0.633 5.513 -10.340 2.74E-10 4.66E-09 13.252 -1.55 
Sdc4 0.272 7.039 2.926 7.42E-03 1.63E-02 -3.991 1.21 
Sec13 -0.392 7.937 -11.561 2.93E-11 6.80E-10 15.540 -1.31 
Sec13 -0.343 6.597 -2.557 1.73E-02 3.43E-02 -4.790 -1.27 
SEC23B -0.688 6.844 -9.242 2.38E-09 3.18E-08 11.038 -1.61 
SEC24D -0.717 7.004 -9.932 6.02E-10 9.28E-09 12.446 -1.64 
SEC62 -0.320 7.883 -7.941 3.78E-08 3.61E-07 8.213 -1.25 
SEL1L -0.566 7.016 -5.989 3.60E-06 1.94E-05 3.576 -1.48 
SELK 0.376 7.749 7.850 4.61E-08 4.34E-07 8.009 1.30 
SELS -0.566 6.598 -12.151 1.06E-11 2.79E-10 16.585 -1.48 
SERPINB1 -0.766 8.041 -10.654 1.52E-10 2.71E-09 13.857 -1.70 
SERPINB6 -0.301 8.276 -5.666 7.97E-06 3.98E-05 2.772 -1.23 
SERPINH1 -0.787 9.252 -24.211 2.71E-18 7.49E-16 31.975 -1.73 
SERPINH1 -0.736 8.798 -8.019 3.17E-08 3.12E-07 8.391 -1.67 
Serpinh1 -0.721 8.949 -11.908 1.60E-11 3.91E-10 16.159 -1.65 
SET 0.268 8.500 7.080 2.66E-07 2.02E-06 6.224 1.20 
SF3A3 0.323 8.084 6.940 3.68E-07 2.66E-06 5.893 1.25 
SF3B2 0.314 7.337 3.883 7.14E-04 2.09E-03 -1.721 1.24 
SFRS2 -0.394 8.647 -11.465 3.48E-11 7.67E-10 15.365 -1.31 
SFRS2 -0.314 6.996 -4.347 2.21E-04 7.46E-04 -0.562 -1.24 
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SFRS7 -0.315 8.831 -3.207 3.80E-03 9.00E-03 -3.349 -1.24 
SGCE -1.037 6.005 -8.045 3.00E-08 2.99E-07 8.448 -2.05 
Sh2b3 0.289 6.519 5.261 2.19E-05 9.69E-05 1.751 1.22 
SHMT2 -0.353 6.208 -3.453 2.08E-03 5.34E-03 -2.768 -1.28 
SLBP 0.725 6.124 12.449 6.39E-12 1.90E-10 17.099 1.65 
Slc12a7 -0.273 6.801 -4.949 4.82E-05 1.93E-04 0.961 -1.21 
Slc1a5 -0.409 6.945 -8.148 2.40E-08 2.46E-07 8.678 -1.33 
SLC25A1 -0.417 6.910 -4.561 1.29E-04 4.57E-04 -0.022 -1.34 
SLC25A12 0.305 7.062 6.805 5.05E-07 3.50E-06 5.570 1.24 
SLC25A13 -0.478 6.821 -9.986 5.42E-10 8.47E-09 12.554 -1.39 
SLC25A17 0.549 6.764 12.315 8.00E-12 2.26E-10 16.869 1.46 
SLC25A28 -0.287 6.288 -6.091 2.81E-06 1.57E-05 3.829 -1.22 
Slc25a39 0.325 8.449 3.998 5.35E-04 1.61E-03 -1.437 1.25 
SLC35B1 -0.617 7.240 -12.561 5.30E-12 1.60E-10 17.289 -1.53 
SLC39A1 -0.353 8.219 -7.041 2.91E-07 2.18E-06 6.132 -1.28 
SLC44A1 0.364 7.158 5.514 1.16E-05 5.57E-05 2.390 1.29 
Slc4a7 -0.364 6.815 -5.216 2.45E-05 1.07E-04 1.639 -1.29 
Slc7a11 -0.539 7.310 -6.407 1.30E-06 8.02E-06 4.607 -1.45 
SMC1A 0.272 6.532 5.649 8.32E-06 4.11E-05 2.729 1.21 
SMC4 -0.538 6.591 -4.870 5.87E-05 2.30E-04 0.762 -1.45 
Smpd1 -0.674 6.110 -7.155 2.23E-07 1.75E-06 6.401 -1.59 
SMPD1 -0.664 6.885 -11.036 7.51E-11 1.48E-09 14.577 -1.58 
SMS 0.284 7.609 6.546 9.34E-07 5.96E-06 4.945 1.22 
SNAP23 0.384 7.105 8.657 8.03E-09 9.10E-08 9.796 1.31 
Snn -1.202 6.495 -15.553 5.56E-14 3.25E-12 21.944 -2.30 
Snora28 -0.663 7.421 -12.809 3.53E-12 1.12E-10 17.707 -1.58 
SNRPC 0.351 7.891 7.006 3.15E-07 2.35E-06 6.049 1.28 
SNRPD3 0.325 8.958 6.983 3.33E-07 2.46E-06 5.995 1.25 
SNX12 0.369 6.594 6.893 4.10E-07 2.91E-06 5.781 1.29 
SNX2 -0.281 6.773 -6.929 3.77E-07 2.71E-06 5.866 -1.22 
SNX21 0.325 6.347 3.882 7.16E-04 2.09E-03 -1.724 1.25 
SNX9 0.275 7.033 6.320 1.61E-06 9.68E-06 4.394 1.21 
SOD2 -0.499 6.599 -7.935 3.82E-08 3.63E-07 8.202 -1.41 
SOD2 -0.330 6.729 -4.867 5.93E-05 2.32E-04 0.753 -1.26 
SPATA2 0.583 6.823 11.555 2.97E-11 6.83E-10 15.528 1.50 
Spats2 -0.358 6.500 -6.045 3.14E-06 1.73E-05 3.716 -1.28 
Spc25 -0.515 6.631 -6.635 7.55E-07 4.89E-06 5.161 -1.43 
SPRR1A 0.962 8.643 11.158 6.02E-11 1.24E-09 14.803 1.95 
Sptlc1 -0.349 6.938 -3.628 1.35E-03 3.67E-03 -2.345 -1.27 
SQLE -0.621 7.073 -9.322 2.02E-09 2.75E-08 11.205 -1.54 
SQLE -0.435 6.333 -2.828 9.34E-03 1.99E-02 -4.209 -1.35 
Srgn 0.542 7.415 6.284 1.75E-06 1.05E-05 4.305 1.46 
Srpr -0.426 8.041 -9.689 9.69E-10 1.43E-08 11.958 -1.34 
SRPR -0.266 6.329 -2.892 8.04E-03 1.76E-02 -4.067 -1.20 
Srpr 0.942 10.831 7.841 4.70E-08 4.40E-07 7.989 1.92 
Srpr 1.237 10.118 7.439 1.16E-07 9.75E-07 7.066 2.36 
SSR4 -0.373 9.057 -4.331 2.31E-04 7.73E-04 -0.603 -1.29 
SSU72 -0.732 7.371 -11.519 3.16E-11 7.18E-10 15.463 -1.66 
STIM2 0.301 6.458 3.682 1.18E-03 3.29E-03 -2.215 1.23 
STK10 -0.289 6.417 -5.046 3.77E-05 1.56E-04 1.207 -1.22 
STK39 0.550 6.315 6.050 3.10E-06 1.71E-05 3.727 1.46 
STT3A -0.389 7.885 -6.942 3.67E-07 2.66E-06 5.896 -1.31 
SUPT16H -0.411 10.402 -5.683 7.66E-06 3.84E-05 2.813 -1.33 
SUPT4H1 0.465 7.223 8.697 7.37E-09 8.46E-08 9.883 1.38 
SUPT6H 0.263 6.509 2.542 1.79E-02 3.53E-02 -4.822 1.20 
Surf4 -0.345 7.067 -7.624 7.64E-08 6.80E-07 7.494 -1.27 
Syf2 0.317 7.090 5.041 3.82E-05 1.58E-04 1.194 1.25 
SYN2 0.356 10.923 9.248 2.35E-09 3.15E-08 11.051 1.28 
SYNCRIP 0.965 6.514 5.057 3.66E-05 1.52E-04 1.236 1.95 
SYNCRIP 1.221 6.547 18.363 1.42E-15 1.42E-13 25.670 2.33 
TAB2 -0.542 7.349 -9.888 6.56E-10 1.01E-08 12.358 -1.46 
TACC2 -0.327 6.631 -7.803 5.12E-08 4.77E-07 7.903 -1.25 
Taf2 0.431 8.441 9.149 2.88E-09 3.78E-08 10.844 1.35 
TAGLN2 -0.287 8.340 -3.959 5.90E-04 1.76E-03 -1.533 -1.22 
TARDBP 0.334 7.735 6.712 6.30E-07 4.22E-06 5.345 1.26 
Tbc1d20 0.364 7.320 6.456 1.16E-06 7.29E-06 4.726 1.29 
Tbl1xr1 0.284 7.703 5.008 4.15E-05 1.70E-04 1.111 1.22 
TBPL1 0.361 7.435 5.486 1.25E-05 5.90E-05 2.320 1.28 
TCEA1 0.357 8.260 8.146 2.41E-08 2.46E-07 8.673 1.28 
Tcf19 0.725 5.912 12.621 4.80E-12 1.48E-10 17.391 1.65 
Tdgf1 0.449 6.194 6.658 7.16E-07 4.68E-06 5.215 1.36 
TECR -0.530 8.225 -7.557 8.90E-08 7.82E-07 7.338 -1.44 
Tes -0.873 7.629 -14.629 2.10E-13 9.78E-12 20.591 -1.83 
Tes -0.766 6.550 -15.788 4.01E-14 2.62E-12 22.277 -1.70 
TFPI -0.752 7.291 -9.387 1.78E-09 2.47E-08 11.339 -1.68 
Tgfbr2 -0.562 6.364 -7.141 2.30E-07 1.80E-06 6.369 -1.48 
Thbd -1.059 7.746 -12.233 9.19E-12 2.50E-10 16.727 -2.08 
THOC4 0.270 8.085 3.353 2.66E-03 6.61E-03 -3.007 1.21 
THOC7 0.272 7.681 5.142 2.96E-05 1.27E-04 1.449 1.21 
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Thumpd3 0.265 6.634 4.927 5.09E-05 2.02E-04 0.906 1.20 
TIMM17B -0.381 6.995 -4.274 2.67E-04 8.76E-04 -0.747 -1.30 
TIMM50 -0.601 7.608 -12.204 9.66E-12 2.61E-10 16.676 -1.52 
TIMP1 -0.741 6.932 -10.906 9.52E-11 1.83E-09 14.334 -1.67 
Timp2 0.389 7.474 5.030 3.92E-05 1.62E-04 1.167 1.31 
TIMP2 0.466 8.474 6.749 5.76E-07 3.92E-06 5.435 1.38 
TJP2 -0.326 6.785 -6.336 1.55E-06 9.36E-06 4.432 -1.25 
TKT -0.612 6.994 -13.547 1.08E-12 4.19E-11 18.914 -1.53 
TKT -0.552 6.373 -3.948 6.07E-04 1.80E-03 -1.561 -1.47 
TMED3 -0.638 6.990 -13.331 1.52E-12 5.42E-11 18.566 -1.56 
TMEM101 0.589 6.466 7.074 2.69E-07 2.04E-06 6.210 1.50 
Tmem109 -0.373 6.566 -7.167 2.17E-07 1.72E-06 6.429 -1.30 
Tmem150a -0.360 6.896 -5.212 2.48E-05 1.08E-04 1.627 -1.28 
TMEM156 0.449 7.139 7.845 4.67E-08 4.38E-07 7.997 1.37 
TMEM158 0.398 6.933 4.067 4.50E-04 1.38E-03 -1.264 1.32 
Tmem167 0.357 7.216 5.496 1.22E-05 5.77E-05 2.345 1.28 
Tmem167b 0.465 6.863 10.418 2.36E-10 4.10E-09 13.403 1.38 
TMEM5 -0.332 6.602 -8.256 1.89E-08 2.01E-07 8.919 -1.26 
TMSB10 -0.335 10.371 -5.409 1.51E-05 6.98E-05 2.125 -1.26 
Tmx1 0.354 8.098 6.437 1.21E-06 7.52E-06 4.680 1.28 
Tnfaip3 -1.295 5.235 -14.151 4.28E-13 1.84E-11 19.862 -2.45 
Tnfrsf21 -0.627 7.387 -8.841 5.44E-09 6.50E-08 10.193 -1.54 
Tnfsf9 -1.105 6.765 -10.354 2.67E-10 4.57E-09 13.278 -2.15 
TNIP1 -0.513 6.401 -6.951 3.59E-07 2.62E-06 5.917 -1.43 
TNKS2 0.294 6.486 4.934 5.00E-05 1.99E-04 0.924 1.23 
TOMM34 0.412 7.388 6.956 3.54E-07 2.59E-06 5.930 1.33 
Top2a -0.451 9.103 -5.717 7.03E-06 3.56E-05 2.899 -1.37 
Tpst1 -0.658 6.787 -15.572 5.42E-14 3.24E-12 21.971 -1.58 
TPX2 -0.726 6.219 -7.798 5.18E-08 4.78E-07 7.891 -1.65 
TRAK2 -0.460 6.593 -5.753 6.43E-06 3.28E-05 2.990 -1.38 
TRAP1 0.271 6.783 3.316 2.92E-03 7.13E-03 -3.094 1.21 
TRIB1 0.685 6.683 9.848 7.09E-10 1.07E-08 12.279 1.61 
TRIM44 0.362 6.784 3.024 5.89E-03 1.33E-02 -3.771 1.29 
Trmt6 0.576 6.854 10.530 1.91E-10 3.34E-09 13.619 1.49 
Trub1 0.382 7.328 9.472 1.50E-09 2.13E-08 11.514 1.30 
TSC22D1 -0.407 10.051 -5.655 8.20E-06 4.07E-05 2.743 -1.33 
TSEN15 0.323 7.360 8.824 5.65E-09 6.70E-08 10.155 1.25 
TTC33 0.267 6.573 3.817 8.44E-04 2.42E-03 -1.884 1.20 
TUBA1A -0.290 8.193 -3.315 2.92E-03 7.13E-03 -3.097 -1.22 
TUBA1C -0.539 9.068 -11.182 5.76E-11 1.20E-09 14.849 -1.45 
TUBB2C -0.579 8.450 -11.544 3.02E-11 6.91E-10 15.510 -1.49 
Tubb6 -0.525 7.128 -13.221 1.82E-12 6.32E-11 18.386 -1.44 
Twf1 -0.282 6.551 -2.531 1.84E-02 3.61E-02 -4.844 -1.22 
TXNRD1 -0.649 7.365 -4.455 1.68E-04 5.86E-04 -0.289 -1.57 
TXNRD1 -0.608 9.549 -15.345 7.45E-14 4.25E-12 21.646 -1.52 
Tyms -0.348 8.010 -4.442 1.74E-04 6.03E-04 -0.322 -1.27 
UAP1 -0.413 6.881 -6.693 6.59E-07 4.35E-06 5.300 -1.33 
UBA5 -0.374 7.149 -7.986 3.42E-08 3.32E-07 8.315 -1.30 
UBASH3B 0.280 8.046 6.855 4.50E-07 3.17E-06 5.688 1.21 
UBE2D4 0.524 6.665 8.601 9.03E-09 1.01E-07 9.676 1.44 
UBE2E3 -0.288 7.271 -4.393 1.97E-04 6.75E-04 -0.447 -1.22 
Ube2h -0.325 6.554 -2.936 7.25E-03 1.60E-02 -3.969 -1.25 
UBL3 0.268 7.629 3.719 1.08E-03 3.02E-03 -2.125 1.20 
UBL3 0.359 6.206 6.780 5.36E-07 3.66E-06 5.510 1.28 
UBQLN1 0.319 7.255 8.099 2.66E-08 2.70E-07 8.570 1.25 
UFD1L 0.294 8.108 6.527 9.77E-07 6.21E-06 4.898 1.23 
Ufd1l 0.326 6.294 6.930 3.76E-07 2.71E-06 5.869 1.25 
UGCG 0.272 6.614 2.721 1.20E-02 2.47E-02 -4.443 1.21 
Uggt1 0.288 7.043 6.326 1.58E-06 9.57E-06 4.408 1.22 
Ugt1a1 -0.380 10.340 -8.570 9.64E-09 1.08E-07 9.608 -1.30 
Uqcr10 0.264 9.233 6.262 1.85E-06 1.11E-05 4.250 1.20 
Uqcr10 0.298 8.893 4.257 2.78E-04 9.08E-04 -0.789 1.23 
USO1 -0.573 6.539 -8.477 1.18E-08 1.29E-07 9.404 -1.49 
USO1 -0.421 7.181 -8.852 5.33E-09 6.42E-08 10.215 -1.34 
USP46 0.406 6.354 6.033 3.23E-06 1.77E-05 3.687 1.32 
USP47 -0.276 6.270 -3.381 2.49E-03 6.24E-03 -2.940 -1.21 
USP9X -0.514 7.078 -8.501 1.12E-08 1.23E-07 9.457 -1.43 
UTP18 -0.279 7.550 -6.803 5.08E-07 3.51E-06 5.563 -1.21 
UTP3 0.370 6.703 7.978 3.48E-08 3.37E-07 8.297 1.29 
VAMP8 -0.593 7.162 -10.404 2.43E-10 4.20E-09 13.375 -1.51 
Vapb 0.274 8.100 3.246 3.45E-03 8.28E-03 -3.258 1.21 
VEGFC -0.333 6.894 -6.941 3.67E-07 2.66E-06 5.895 -1.26 
VIM 0.350 8.032 6.075 2.92E-06 1.63E-05 3.789 1.27 
VMA21 0.841 7.724 13.029 2.47E-12 8.21E-11 18.072 1.79 
VNN1 -1.124 6.056 -20.540 1.15E-16 1.74E-14 28.215 -2.18 
VOPP1 -0.442 6.712 -7.929 3.87E-08 3.67E-07 8.188 -1.36 
VWA5A 0.320 7.095 6.251 1.90E-06 1.12E-05 4.225 1.25 
Wdfy4 0.776 6.002 7.304 1.58E-07 1.29E-06 6.751 1.71 
WDR1 -0.297 6.551 -6.279 1.78E-06 1.06E-05 4.292 -1.23 
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Wsb2 0.732 6.048 14.700 1.89E-13 9.17E-12 20.697 1.66 
WWC2 -0.547 6.927 -9.346 1.93E-09 2.64E-08 11.255 -1.46 
WWC3 -0.375 6.647 -7.461 1.11E-07 9.42E-07 7.116 -1.30 
XBP1 -1.093 7.896 -19.797 2.64E-16 3.06E-14 27.377 -2.13 
Xiap 0.430 6.328 7.115 2.45E-07 1.90E-06 6.306 1.35 
Xpot -0.288 8.618 -4.913 5.27E-05 2.09E-04 0.870 -1.22 
YIF1A -0.517 6.830 -8.090 2.72E-08 2.74E-07 8.548 -1.43 
YPEL5 -0.284 6.204 -4.122 3.91E-04 1.22E-03 -1.126 -1.22 
Ywhab 0.263 7.203 4.134 3.80E-04 1.20E-03 -1.098 1.20 
Ywhae -0.309 10.471 -2.888 8.12E-03 1.77E-02 -4.077 -1.24 
ZC3HAV1 0.729 7.214 13.502 1.16E-12 4.42E-11 18.841 1.66 
Zcchc24 0.330 6.916 5.383 1.62E-05 7.37E-05 2.060 1.26 
ZFP36L1 -0.645 8.280 -10.842 1.07E-10 2.03E-09 14.213 -1.56 
ZMYND11 0.397 7.803 11.170 5.89E-11 1.22E-09 14.826 1.32 
ZNF639 -0.267 6.621 -6.199 2.16E-06 1.25E-05 4.095 -1.20 
 
 368 
5.2.10 T(S)1 v pcDNA(S) gene list 
 
Gene ID logFC AveExpr t P.Value adj.P.Val B Fold Change 
40607 0.404 7.921 9.875 6.72E-10 7.60E-09 12.303 1.32 
40790 -0.641 5.984 -7.270 1.71E-07 9.88E-07 6.640 -1.56 
0610031J06Rik -0.355 7.340 -7.947 3.73E-08 2.53E-07 8.195 -1.28 
0610039K10Rik -0.400 8.116 -8.855 5.29E-09 4.71E-08 10.192 -1.32 
1110003E01Rik -0.396 7.572 -3.812 8.55E-04 2.08E-03 -1.932 -1.32 
1110004F10Rik 0.317 6.588 5.781 5.99E-06 2.42E-05 3.026 1.25 
1110008F13Rik -0.268 9.165 -7.595 8.17E-08 5.13E-07 7.394 -1.20 
1190005F20Rik 0.811 6.127 17.720 3.15E-15 1.95E-13 24.847 1.75 
1500011H22Rik 0.431 6.765 7.838 4.73E-08 3.10E-07 7.950 1.35 
1700025O18Rik 0.485 7.116 7.914 4.00E-08 2.68E-07 8.123 1.40 
1700052N19Rik -0.614 6.422 -12.793 3.62E-12 7.84E-11 17.654 -1.53 
1700123N01Rik 0.328 8.426 5.948 3.98E-06 1.67E-05 3.441 1.26 
1700123N01Rik 0.357 8.639 6.590 8.42E-07 4.07E-06 5.017 1.28 
1810022C23Rik -0.314 6.867 -6.030 3.25E-06 1.39E-05 3.645 -1.24 
1810031K17Rik 0.524 6.408 4.597 1.17E-04 3.49E-04 0.035 1.44 
1810037I17Rik -0.425 6.983 -7.950 3.70E-08 2.52E-07 8.204 -1.34 
2010107E04Rik -0.895 9.453 -18.104 1.95E-15 1.35E-13 25.332 -1.86 
2310001A20Rik -0.361 7.257 -6.437 1.21E-06 5.70E-06 4.647 -1.28 
2310003F16Rik -0.354 7.742 -9.142 2.92E-09 2.75E-08 10.799 -1.28 
2310014H01Rik 0.373 7.462 6.912 3.93E-07 2.07E-06 5.792 1.29 
2310035C23Rik 0.567 6.446 11.312 4.56E-11 7.07E-10 15.059 1.48 
2410015M20Rik -0.627 8.054 -10.551 1.84E-10 2.41E-09 13.630 -1.54 
2410017P09Rik 0.279 6.838 6.962 3.49E-07 1.87E-06 5.912 1.21 
2410129H14Rik 0.435 6.698 6.481 1.09E-06 5.18E-06 4.753 1.35 
2610002M06Rik -0.289 6.504 -4.939 4.94E-05 1.59E-04 0.901 -1.22 
2610030H06Rik 0.435 7.724 6.738 5.91E-07 2.98E-06 5.376 1.35 
2700029M09Rik 1.144 6.966 23.071 8.17E-18 1.63E-15 30.866 2.21 
2810025M15Rik 0.520 6.900 9.413 1.68E-09 1.70E-08 11.364 1.43 
2810482I07Rik -0.478 6.348 -8.031 3.09E-08 2.16E-07 8.386 -1.39 
2900097C17Rik -0.341 9.676 -7.006 3.15E-07 1.71E-06 6.017 -1.27 
3110062M04Rik -0.382 7.493 -7.924 3.91E-08 2.63E-07 8.145 -1.30 
4833417J20Rik -0.592 7.312 -8.447 1.25E-08 1.01E-07 9.309 -1.51 
4930404A10Rik -0.506 6.588 -10.151 3.94E-10 4.58E-09 12.852 -1.42 
4930535I16Rik 0.353 8.352 8.061 2.89E-08 2.05E-07 8.454 1.28 
4930539H15Rik 0.422 6.597 9.543 1.30E-09 1.35E-08 11.630 1.34 
4932427H20Rik -0.396 6.583 -6.723 6.14E-07 3.08E-06 5.339 -1.32 
4932441K18Rik -0.318 8.460 -8.166 2.30E-08 1.70E-07 8.687 -1.25 
4932703K07Rik -0.292 9.835 -6.411 1.29E-06 6.05E-06 4.582 -1.22 
4933424B01Rik -0.333 6.952 -3.934 6.29E-04 1.58E-03 -1.631 -1.26 
5830485P09Rik 0.297 7.290 3.709 1.11E-03 2.60E-03 -2.184 1.23 
5930416I19Rik 0.398 6.436 7.227 1.89E-07 1.08E-06 6.538 1.32 
6330406I15Rik -0.309 8.024 -5.730 6.81E-06 2.71E-05 2.897 -1.24 
6430548M08Rik 0.585 5.381 8.347 1.55E-08 1.21E-07 9.089 1.50 
9030411K21Rik 0.272 6.758 5.654 8.22E-06 3.20E-05 2.707 1.21 
9330115C17Rik 0.525 8.429 6.680 6.78E-07 3.35E-06 5.237 1.44 
9430034N14Rik 0.413 6.625 8.144 2.41E-08 1.77E-07 8.639 1.33 
9530053H05Rik -1.117 10.002 -19.356 4.38E-16 4.14E-14 26.850 -2.17 
A330042M18Rik 0.753 7.205 11.802 1.92E-11 3.34E-10 15.944 1.69 
A330042M18Rik 0.885 6.806 16.790 1.04E-14 5.26E-13 23.632 1.85 
A730085K08Rik -0.460 6.637 -4.573 1.25E-04 3.68E-04 -0.026 -1.38 
A930005N03Rik -0.346 6.933 -4.914 5.25E-05 1.68E-04 0.840 -1.27 
Abcc5 -0.331 7.507 -3.774 9.39E-04 2.26E-03 -2.025 -1.26 
Abce1 0.273 7.808 5.227 2.39E-05 8.27E-05 1.632 1.21 
ABHD2 -0.315 6.655 -6.743 5.85E-07 2.96E-06 5.387 -1.24 
Abhd6 -0.402 6.783 -5.121 3.12E-05 1.05E-04 1.363 -1.32 
Acadl -0.272 7.741 -5.428 1.44E-05 5.29E-05 2.139 -1.21 
Acat2 -1.308 6.811 -19.781 2.69E-16 2.93E-14 27.345 -2.48 
Acbd6 0.625 6.747 11.178 5.80E-11 8.80E-10 14.813 1.54 
ACLY -0.557 8.199 -9.953 5.78E-10 6.57E-09 12.458 -1.47 
Aco1 -0.533 6.759 -16.555 1.42E-14 6.80E-13 23.316 -1.45 
Acot9 -0.357 6.777 -7.999 3.32E-08 2.31E-07 8.313 -1.28 
Acp2 -0.564 6.448 -8.418 1.34E-08 1.07E-07 9.243 -1.48 
Actr3 0.316 10.274 5.494 1.23E-05 4.57E-05 2.304 1.25 
Actr3 0.398 8.697 6.720 6.17E-07 3.10E-06 5.333 1.32 
Actr3 0.427 8.121 2.558 1.73E-02 3.03E-02 -4.823 1.34 
Adam10 -0.574 8.078 -8.850 5.34E-09 4.75E-08 10.181 -1.49 
Adam9 -0.298 8.339 -3.949 6.05E-04 1.52E-03 -1.592 -1.23 
ADD3 0.730 7.763 15.232 8.76E-14 3.24E-12 21.459 1.66 
Add3 0.733 6.120 6.214 2.08E-06 9.31E-06 4.100 1.66 
Adh5 -0.382 9.619 -5.230 2.37E-05 8.23E-05 1.638 -1.30 
Adh5 -0.351 8.532 -2.589 1.62E-02 2.85E-02 -4.759 -1.28 
Adipor1 0.494 7.755 10.694 1.41E-10 1.93E-09 13.903 1.41 
Adss 0.485 7.645 9.554 1.27E-09 1.33E-08 11.653 1.40 
Adss 0.574 8.642 8.860 5.24E-09 4.68E-08 10.201 1.49 
AF085738 -0.448 10.908 -10.180 3.72E-10 4.39E-09 12.908 -1.36 
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Aftph 0.599 7.139 8.346 1.56E-08 1.21E-07 9.085 1.52 
Aga -0.296 9.240 -2.738 1.15E-02 2.10E-02 -4.440 -1.23 
Aga -0.296 10.321 -5.413 1.50E-05 5.46E-05 2.103 -1.23 
Agap1 0.302 7.787 3.112 4.77E-03 9.61E-03 -3.604 1.23 
Agap1 0.377 7.472 7.519 9.71E-08 5.92E-07 7.218 1.30 
Agbl5 -0.325 8.349 -2.793 1.01E-02 1.88E-02 -4.321 -1.25 
Ahctf1 0.604 6.293 7.224 1.90E-07 1.09E-06 6.530 1.52 
Ahcy -0.394 6.717 -8.130 2.49E-08 1.82E-07 8.608 -1.31 
Ahnak -1.036 8.479 -13.810 7.21E-13 1.92E-11 19.306 -2.05 
Ahsa1 0.268 7.553 4.755 7.86E-05 2.43E-04 0.436 1.20 
AI428898 -0.551 7.749 -11.880 1.68E-11 2.96E-10 16.082 -1.47 
Aida 0.444 6.309 2.745 1.13E-02 2.07E-02 -4.425 1.36 
Aig1 -0.427 6.487 -5.631 8.69E-06 3.37E-05 2.651 -1.34 
Aimp1 0.491 8.513 11.904 1.61E-11 2.85E-10 16.125 1.41 
Airn 0.343 6.764 6.118 2.62E-06 1.14E-05 3.864 1.27 
Ak2 0.357 7.391 2.727 1.18E-02 2.15E-02 -4.465 1.28 
Ak2 0.635 9.209 11.773 2.02E-11 3.44E-10 15.892 1.55 
Akap12 0.442 7.889 6.628 7.69E-07 3.76E-06 5.109 1.36 
Akirin2 0.446 6.069 5.857 4.98E-06 2.06E-05 3.215 1.36 
Akr1b8 -0.604 9.869 -18.780 8.62E-16 6.59E-14 26.164 -1.52 
Akr7a5 -0.350 6.496 -4.037 4.85E-04 1.25E-03 -1.374 -1.27 
Akt3 1.023 5.980 17.058 7.33E-15 3.93E-13 23.989 2.03 
Aktip 0.383 7.013 7.946 3.73E-08 2.53E-07 8.193 1.30 
AL024054 0.646 6.117 10.976 8.38E-11 1.22E-09 14.436 1.57 
Aldh2 -0.426 8.281 -6.858 4.46E-07 2.32E-06 5.663 -1.34 
Amacr -0.333 6.539 -4.940 4.93E-05 1.59E-04 0.904 -1.26 
Amd1 1.444 7.422 14.391 2.98E-13 9.09E-12 20.207 2.72 
Amd2 1.629 8.027 18.955 7.01E-16 5.85E-14 26.374 3.09 
Anapc11 -0.297 7.726 -3.005 6.16E-03 1.20E-02 -3.849 -1.23 
Ankrd13c 0.362 7.255 8.726 6.93E-09 5.97E-08 9.914 1.28 
Anp32e 0.361 8.064 5.187 2.64E-05 9.02E-05 1.531 1.28 
Anp32e 0.440 7.906 9.716 9.20E-10 1.00E-08 11.982 1.36 
Anxa2 -0.475 9.836 -3.114 4.75E-03 9.58E-03 -3.599 -1.39 
Anxa2 -0.393 10.669 -5.622 8.89E-06 3.42E-05 2.628 -1.31 
Ap1ar 0.300 7.345 6.351 1.49E-06 6.93E-06 4.436 1.23 
Ap2a2 0.338 7.233 6.984 3.32E-07 1.79E-06 5.964 1.26 
Ap2m1 0.267 9.164 3.096 4.96E-03 9.95E-03 -3.641 1.20 
Apeh -0.425 6.410 -6.773 5.44E-07 2.79E-06 5.461 -1.34 
Arhgap18 -0.289 6.623 -2.880 8.26E-03 1.57E-02 -4.128 -1.22 
Arhgap24 -0.378 7.747 -5.039 3.84E-05 1.27E-04 1.156 -1.30 
Arhgap25 -0.469 6.665 -5.630 8.72E-06 3.37E-05 2.648 -1.38 
Arhgef6 -0.342 7.955 -5.334 1.83E-05 6.54E-05 1.902 -1.27 
Arl10 0.272 6.690 6.310 1.65E-06 7.59E-06 4.337 1.21 
Arl15 -0.331 6.329 -5.704 7.27E-06 2.86E-05 2.832 -1.26 
Arl2bp 0.292 7.421 4.888 5.62E-05 1.79E-04 0.772 1.22 
Arpc3 -0.280 7.652 -3.043 5.63E-03 1.11E-02 -3.762 -1.21 
Arpc5 0.750 8.452 11.101 6.67E-11 9.91E-10 14.670 1.68 
Arpc5 0.775 8.740 16.633 1.28E-14 6.25E-13 23.422 1.71 
Asap1 -0.324 5.925 -6.069 2.96E-06 1.28E-05 3.742 -1.25 
Asf1b -0.407 5.939 -4.860 6.04E-05 1.90E-04 0.701 -1.33 
Asns -0.618 9.296 -12.616 4.85E-12 1.01E-10 17.355 -1.53 
Asns -0.610 9.701 -14.811 1.61E-13 5.43E-12 20.840 -1.53 
Asnsd1 0.450 8.235 6.950 3.59E-07 1.91E-06 5.883 1.37 
Aspm 0.509 6.112 7.773 5.48E-08 3.56E-07 7.801 1.42 
Atf6 0.853 8.404 18.056 2.08E-15 1.38E-13 25.272 1.81 
Atg3 0.320 6.477 5.140 2.98E-05 1.01E-04 1.411 1.25 
Atp10a -0.599 7.352 -14.024 5.19E-13 1.49E-11 19.641 -1.51 
Atp13a3 -0.491 6.608 -2.534 1.82E-02 3.18E-02 -4.873 -1.41 
Atp2a2 0.413 6.749 6.911 3.94E-07 2.07E-06 5.791 1.33 
Atp5a1 -0.359 7.427 -3.360 2.62E-03 5.69E-03 -3.025 -1.28 
Atp5a1 -0.314 8.837 -7.487 1.04E-07 6.33E-07 7.145 -1.24 
Atp5h 0.266 9.664 5.911 4.35E-06 1.82E-05 3.350 1.20 
Atp5o 0.480 9.052 10.113 4.24E-10 4.89E-09 12.776 1.39 
ATP6V1B2 0.435 7.365 7.290 1.63E-07 9.51E-07 6.687 1.35 
Atpif1 -0.436 9.759 -10.180 3.72E-10 4.39E-09 12.909 -1.35 
ATXN7L3B 0.419 6.370 8.399 1.39E-08 1.10E-07 9.204 1.34 
AU015740 0.383 6.605 5.772 6.14E-06 2.47E-05 3.002 1.30 
AU019300 0.456 7.174 9.118 3.07E-09 2.86E-08 10.749 1.37 
AW549877 0.317 6.308 4.117 3.97E-04 1.04E-03 -1.175 1.25 
AW742525 -0.325 7.372 -8.370 1.48E-08 1.17E-07 9.140 -1.25 
AW743318 0.305 8.635 5.711 7.14E-06 2.82E-05 2.850 1.24 
Azin1 0.889 6.442 10.722 1.34E-10 1.85E-09 13.957 1.85 
Azin1 1.187 6.431 16.392 1.76E-14 8.13E-13 23.094 2.28 
B230219D22Rik 0.419 8.128 7.951 3.69E-08 2.52E-07 8.205 1.34 
B230220B15Rik -2.249 7.506 -47.005 5.11E-25 6.39E-22 46.890 -4.75 
B3galnt2 0.273 6.763 3.637 1.32E-03 3.05E-03 -2.359 1.21 
B4galt3 0.762 6.562 12.727 4.04E-12 8.69E-11 17.543 1.70 
Bat2 0.320 6.201 2.916 7.60E-03 1.46E-02 -4.049 1.25 
BC029722 -0.603 6.162 -9.257 2.31E-09 2.24E-08 11.040 -1.52 
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BC046331 0.443 6.418 6.542 9.43E-07 4.52E-06 4.902 1.36 
Bcap31 -0.317 7.616 -7.953 3.67E-08 2.51E-07 8.211 -1.25 
Bcl2l2 0.469 6.311 10.337 2.76E-10 3.32E-09 13.216 1.38 
Bclaf1 0.340 6.690 4.761 7.75E-05 2.40E-04 0.451 1.27 
Bclaf1 0.411 7.984 6.598 8.25E-07 4.00E-06 5.038 1.33 
Birc5 0.350 7.818 4.335 2.28E-04 6.40E-04 -0.627 1.27 
Bloc1s2 0.515 6.230 6.766 5.53E-07 2.83E-06 5.444 1.43 
Bmi1 1.229 6.386 14.811 1.61E-13 5.43E-12 20.841 2.34 
Bms1 -0.407 6.641 -6.832 4.74E-07 2.46E-06 5.601 -1.33 
Bre -0.323 6.906 -5.739 6.65E-06 2.66E-05 2.921 -1.25 
Brp44 0.901 7.735 18.592 1.08E-15 7.92E-14 25.935 1.87 
Brp44l 0.416 7.208 2.604 1.56E-02 2.77E-02 -4.727 1.33 
Btbd1 0.299 7.455 2.620 1.51E-02 2.68E-02 -4.694 1.23 
Btbd1 0.388 8.023 3.588 1.49E-03 3.41E-03 -2.479 1.31 
Btg1 -0.300 7.972 -7.899 4.14E-08 2.76E-07 8.087 -1.23 
Btg3 0.309 7.374 3.426 2.23E-03 4.91E-03 -2.867 1.24 
Bzw1 0.317 6.951 5.688 7.55E-06 2.95E-05 2.794 1.25 
C130057N11Rik 0.413 6.393 4.406 1.91E-04 5.44E-04 -0.448 1.33 
C1qbp 0.304 7.278 3.730 1.05E-03 2.48E-03 -2.132 1.23 
C1rb -0.527 9.482 -6.676 6.86E-07 3.38E-06 5.225 -1.44 
C630016N16Rik -0.669 9.801 -11.292 4.73E-11 7.29E-10 15.023 -1.59 
C630016N16Rik -0.616 6.788 -6.900 4.04E-07 2.12E-06 5.765 -1.53 
C78376 -0.654 7.959 -10.457 2.20E-10 2.78E-09 13.450 -1.57 
C79646 -0.385 7.168 -7.972 3.53E-08 2.43E-07 8.252 -1.31 
Cab39 0.362 7.933 6.983 3.33E-07 1.79E-06 5.962 1.29 
Cab39 0.386 6.216 3.375 2.52E-03 5.52E-03 -2.988 1.31 
Cab39 0.418 7.377 6.970 3.43E-07 1.83E-06 5.930 1.34 
Cacybp 0.489 8.731 5.534 1.11E-05 4.16E-05 2.406 1.40 
Cacybp 0.590 9.038 14.520 2.46E-13 7.83E-12 20.404 1.51 
Cald1 -0.507 7.225 -5.721 6.96E-06 2.76E-05 2.875 -1.42 
Cald1 -0.494 7.673 -3.868 7.42E-04 1.83E-03 -1.793 -1.41 
Calm1 0.458 6.188 4.087 4.27E-04 1.11E-03 -1.248 1.37 
Camsap1l1 0.807 6.300 19.029 6.42E-16 5.65E-14 26.463 1.75 
Cap1 -0.353 6.658 -3.186 4.00E-03 8.24E-03 -3.434 -1.28 
Capg -0.437 7.250 -4.115 3.98E-04 1.05E-03 -1.179 -1.35 
Capg -0.433 7.270 -5.458 1.34E-05 4.93E-05 2.215 -1.35 
Capn2 -0.280 6.868 -3.630 1.34E-03 3.10E-03 -2.375 -1.21 
Capn7 0.279 6.641 4.708 8.86E-05 2.70E-04 0.316 1.21 
Capns1 0.321 7.079 4.983 4.42E-05 1.44E-04 1.014 1.25 
Capza2 0.342 8.594 2.840 9.08E-03 1.70E-02 -4.218 1.27 
Capza2 0.358 9.291 5.371 1.66E-05 6.03E-05 1.996 1.28 
Capza2 0.385 10.363 8.708 7.21E-09 6.18E-08 9.874 1.31 
Cat -0.788 8.131 -7.906 4.08E-08 2.72E-07 8.103 -1.73 
Cat -0.709 6.892 -3.563 1.59E-03 3.60E-03 -2.538 -1.63 
Cav2 -0.668 6.234 -9.228 2.45E-09 2.36E-08 10.978 -1.59 
Cbara1 0.267 6.904 3.701 1.13E-03 2.64E-03 -2.204 1.20 
Cbfb 0.356 7.994 6.217 2.06E-06 9.30E-06 4.106 1.28 
Cbl 0.295 6.841 2.817 9.58E-03 1.79E-02 -4.268 1.23 
Ccdc43 0.585 6.315 11.675 2.40E-11 4.03E-10 15.717 1.50 
Ccdc50 0.292 7.337 5.139 2.98E-05 1.01E-04 1.410 1.22 
Ccdc53 -0.514 7.195 -10.492 2.05E-10 2.64E-09 13.517 -1.43 
Ccdc85b -1.080 7.032 -12.245 9.01E-12 1.75E-10 16.721 -2.11 
Ccdc85b -1.016 6.897 -13.826 7.03E-13 1.89E-11 19.331 -2.02 
Ccdc90b -0.365 7.006 -4.792 7.17E-05 2.24E-04 0.528 -1.29 
Ccl2 -2.891 7.806 -21.727 3.21E-17 5.45E-15 29.490 -7.42 
Ccl25 0.480 6.699 8.179 2.24E-08 1.66E-07 8.717 1.39 
Ccndbp1 0.308 7.359 4.842 6.31E-05 1.99E-04 0.656 1.24 
Cct8 -0.264 7.783 -2.420 2.35E-02 4.02E-02 -5.108 -1.20 
Cd109 -0.270 6.836 -2.945 7.10E-03 1.37E-02 -3.984 -1.21 
Cd151 -0.268 7.704 -4.187 3.32E-04 8.91E-04 -0.998 -1.20 
Cd36 1.954 8.162 9.796 7.85E-10 8.76E-09 12.145 3.87 
Cdc16 -0.432 7.096 -6.205 2.12E-06 9.50E-06 4.077 -1.35 
Cdc42se1 0.283 6.268 4.992 4.32E-05 1.41E-04 1.037 1.22 
Cdipt 0.460 7.020 7.088 2.61E-07 1.45E-06 6.210 1.38 
Cdk1 0.342 8.673 5.342 1.79E-05 6.42E-05 1.924 1.27 
Cdk6 0.522 8.613 8.249 1.92E-08 1.47E-07 8.872 1.44 
Cdk6 0.575 6.642 5.170 2.76E-05 9.39E-05 1.487 1.49 
Cdk6 0.593 7.547 5.492 1.23E-05 4.57E-05 2.302 1.51 
Cdv3 0.530 8.233 9.126 3.02E-09 2.83E-08 10.766 1.44 
Cebpb -0.493 9.362 -12.241 9.07E-12 1.75E-10 16.714 -1.41 
Cenpl 0.644 6.032 9.275 2.23E-09 2.18E-08 11.077 1.56 
Cetn3 -0.486 8.092 -6.481 1.09E-06 5.18E-06 4.753 -1.40 
Cfdp1 -0.273 8.313 -5.434 1.42E-05 5.21E-05 2.155 -1.21 
Cflar -0.355 7.205 -4.507 1.48E-04 4.30E-04 -0.193 -1.28 
Chchd3 0.268 6.879 6.055 3.06E-06 1.31E-05 3.706 1.20 
Chd2 0.466 6.581 8.070 2.84E-08 2.02E-07 8.472 1.38 
Chordc1 0.463 6.453 6.460 1.15E-06 5.44E-06 4.701 1.38 
Chpf 0.357 6.081 3.080 5.15E-03 1.03E-02 -3.678 1.28 
CHUK 0.348 7.119 6.882 4.21E-07 2.21E-06 5.722 1.27 
 371 
Cirbp -0.680 7.470 -10.022 5.05E-10 5.82E-09 12.596 -1.60 
Cisd3 -0.659 6.884 -10.583 1.73E-10 2.30E-09 13.692 -1.58 
Cited2 -0.471 6.419 -4.991 4.33E-05 1.41E-04 1.033 -1.39 
Clec2e -0.854 5.756 -8.093 2.70E-08 1.95E-07 8.524 -1.81 
Clic4 -0.586 8.809 -9.743 8.72E-10 9.61E-09 12.037 -1.50 
Clns1a 0.453 7.669 10.907 9.50E-11 1.37E-09 14.307 1.37 
Clstn1 0.700 7.732 10.160 3.87E-10 4.51E-09 12.869 1.62 
Cltc -0.298 7.897 -3.335 2.78E-03 6.00E-03 -3.084 -1.23 
Cnbp -0.342 9.436 -3.109 4.81E-03 9.67E-03 -3.611 -1.27 
Cnbp -0.272 10.434 -5.710 7.15E-06 2.82E-05 2.848 -1.21 
Cnn2 -0.405 7.200 -3.988 5.48E-04 1.40E-03 -1.495 -1.32 
Cnot7 0.283 7.521 6.235 1.98E-06 8.93E-06 4.150 1.22 
Cobll1 -0.384 6.463 -7.172 2.15E-07 1.21E-06 6.408 -1.30 
Col5a2 0.462 7.606 6.343 1.52E-06 7.05E-06 4.417 1.38 
Commd3 0.730 7.861 17.407 4.68E-15 2.67E-13 24.444 1.66 
Commd7 0.579 6.618 12.272 8.60E-12 1.69E-10 16.768 1.49 
Copa 0.284 6.314 5.782 5.99E-06 2.42E-05 3.027 1.22 
Copa 0.285 7.525 3.072 5.25E-03 1.05E-02 -3.696 1.22 
Copb2 -0.281 7.048 -4.951 4.79E-05 1.55E-04 0.931 -1.22 
Copg -0.465 6.669 -7.562 8.80E-08 5.43E-07 7.318 -1.38 
Copg2 -0.405 6.694 -3.331 2.81E-03 6.04E-03 -3.093 -1.32 
Cops4 0.304 7.810 5.201 2.55E-05 8.74E-05 1.567 1.23 
Cops8 0.306 7.245 6.186 2.22E-06 9.84E-06 4.031 1.24 
Coro1b -0.529 8.179 -8.369 1.48E-08 1.17E-07 9.137 -1.44 
Coro1b -0.474 7.585 -6.557 9.09E-07 4.37E-06 4.939 -1.39 
Cox18 0.323 6.621 8.995 3.95E-09 3.62E-08 10.490 1.25 
Cox4i1 0.285 10.414 6.991 3.26E-07 1.76E-06 5.982 1.22 
Cox4nb 0.730 7.112 13.267 1.69E-12 3.93E-11 18.436 1.66 
Cox7a2l 0.543 8.364 13.253 1.72E-12 4.00E-11 18.413 1.46 
Cpn2 -0.300 6.648 -3.796 8.88E-04 2.15E-03 -1.969 -1.23 
Cpsf2 0.367 7.072 4.667 9.83E-05 2.97E-04 0.212 1.29 
Cpt2 -0.428 6.454 -7.565 8.73E-08 5.42E-07 7.326 -1.35 
Crkl 0.455 6.976 10.801 1.15E-10 1.63E-09 14.108 1.37 
Crot -0.373 6.877 -8.193 2.17E-08 1.62E-07 8.748 -1.30 
Csda 0.344 7.938 4.875 5.81E-05 1.84E-04 0.739 1.27 
Csda 0.420 10.028 8.225 2.02E-08 1.53E-07 8.818 1.34 
Cse1l -0.794 7.389 -15.049 1.14E-13 4.12E-12 21.192 -1.73 
Csnk1d 0.429 7.166 7.376 1.34E-07 7.94E-07 6.887 1.35 
Csnk1e 0.347 6.379 6.807 5.03E-07 2.59E-06 5.540 1.27 
Csnk1e 0.472 6.600 7.302 1.59E-07 9.27E-07 6.714 1.39 
Csnk2a1 1.151 6.763 10.459 2.19E-10 2.78E-09 13.453 2.22 
Csnk2a2 0.425 7.248 6.140 2.49E-06 1.09E-05 3.918 1.34 
Ctage5 -0.311 8.036 -5.354 1.74E-05 6.29E-05 1.952 -1.24 
Ctla2b -1.054 7.178 -12.318 7.96E-12 1.60E-10 16.848 -2.08 
Ctsf -0.364 6.525 -4.893 5.55E-05 1.77E-04 0.785 -1.29 
Ctsh -0.372 6.886 -6.186 2.22E-06 9.84E-06 4.031 -1.29 
Ctsz -0.669 9.672 -14.595 2.21E-13 7.14E-12 20.516 -1.59 
Cul5 0.346 7.214 6.938 3.70E-07 1.96E-06 5.854 1.27 
Cxcl1 -1.818 6.634 -21.246 5.34E-17 7.99E-15 28.978 -3.53 
Cyb5r1 0.700 6.816 10.911 9.44E-11 1.37E-09 14.314 1.62 
Cyp51 -0.432 9.012 -7.613 7.84E-08 4.94E-07 7.435 -1.35 
Cyp51 -0.379 9.644 -7.049 2.85E-07 1.56E-06 6.119 -1.30 
D10Jhu81e -0.497 6.385 -7.783 5.36E-08 3.49E-07 7.824 -1.41 
D15Ertd621e 0.403 7.356 9.568 1.23E-09 1.29E-08 11.681 1.32 
D17Wsu104e -0.553 6.741 -8.226 2.02E-08 1.53E-07 8.821 -1.47 
D230049E03Rik 0.290 7.384 5.416 1.49E-05 5.43E-05 2.109 1.22 
D2Ertd63e -0.372 8.866 -8.609 8.88E-09 7.51E-08 9.661 -1.29 
D2Ertd93e -0.321 7.851 -3.340 2.75E-03 5.93E-03 -3.071 -1.25 
D2Wsu85e -0.310 6.977 -4.552 1.32E-04 3.86E-04 -0.078 -1.24 
D4Ucla1 0.515 9.740 15.043 1.15E-13 4.12E-12 21.183 1.43 
D4Ucla1 0.537 8.647 13.528 1.12E-12 2.77E-11 18.858 1.45 
D5Ertd579e -0.374 7.211 -9.309 2.08E-09 2.06E-08 11.147 -1.30 
D6Wsu116e -0.278 6.601 -5.225 2.40E-05 8.28E-05 1.628 -1.21 
D830024F11Rik -0.336 7.236 -5.314 1.92E-05 6.80E-05 1.852 -1.26 
D9Ertd815e 0.490 6.918 9.292 2.15E-09 2.11E-08 11.112 1.40 
Dag1 -0.467 7.183 -7.052 2.83E-07 1.55E-06 6.126 -1.38 
Dag1 -0.429 8.711 -6.620 7.84E-07 3.81E-06 5.090 -1.35 
Dars 0.374 9.109 6.198 2.16E-06 9.62E-06 4.061 1.30 
Dcaf13 0.344 7.411 8.156 2.35E-08 1.73E-07 8.664 1.27 
Dcakd -0.299 6.772 -3.840 7.96E-04 1.95E-03 -1.862 -1.23 
Dctpp1 -0.339 7.125 -5.532 1.11E-05 4.17E-05 2.402 -1.26 
Ddhd2 0.554 7.529 12.308 8.11E-12 1.62E-10 16.829 1.47 
Ddit3 0.722 6.496 7.564 8.75E-08 5.42E-07 7.323 1.65 
Ddr2 0.601 6.558 2.654 1.39E-02 2.50E-02 -4.621 1.52 
Ddx18 0.459 7.916 10.782 1.20E-10 1.67E-09 14.072 1.37 
Ddx27 -0.431 6.735 -5.485 1.25E-05 4.64E-05 2.284 -1.35 
Ddx39 0.467 7.395 7.303 1.59E-07 9.26E-07 6.717 1.38 
Ddx5 -0.267 9.635 -3.259 3.35E-03 7.06E-03 -3.263 -1.20 
Ddx54 -0.522 7.085 -7.410 1.24E-07 7.44E-07 6.965 -1.44 
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Degs1 0.437 8.459 5.857 4.98E-06 2.06E-05 3.215 1.35 
Degs1 0.527 6.778 11.928 1.55E-11 2.75E-10 16.166 1.44 
Dennd4a 0.841 6.236 16.863 9.45E-15 4.85E-13 23.730 1.79 
Derl1 0.549 7.959 7.676 6.81E-08 4.35E-07 7.580 1.46 
Dhrs7 -0.609 7.060 -14.760 1.73E-13 5.75E-12 20.765 -1.53 
Dlst 0.393 6.415 5.843 5.15E-06 2.11E-05 3.180 1.31 
Dnaja2 -0.315 6.750 -4.598 1.17E-04 3.48E-04 0.038 -1.24 
Dnajb2 0.437 6.280 4.121 3.93E-04 1.04E-03 -1.165 1.35 
Dnajb6 0.447 6.727 4.743 8.11E-05 2.50E-04 0.405 1.36 
Dnajc15 0.308 7.484 5.637 8.57E-06 3.32E-05 2.665 1.24 
DNAJC8 0.322 7.300 6.204 2.13E-06 9.50E-06 4.075 1.25 
Dock9 -0.576 6.569 -8.898 4.84E-09 4.37E-08 10.283 -1.49 
Dpf2 0.358 6.623 5.778 6.04E-06 2.43E-05 3.018 1.28 
Dpp3 -0.618 6.723 -8.644 8.24E-09 6.99E-08 9.737 -1.53 
Dr1 0.286 8.097 3.291 3.10E-03 6.57E-03 -3.187 1.22 
Drg1 0.594 6.182 3.459 2.05E-03 4.57E-03 -2.788 1.51 
Dus1l -0.428 7.044 -8.329 1.62E-08 1.25E-07 9.049 -1.35 
Dusp1 -0.526 6.221 -8.148 2.39E-08 1.76E-07 8.647 -1.44 
Dusp12 0.520 6.981 14.474 2.64E-13 8.25E-12 20.333 1.43 
Dusp3 0.399 5.641 4.336 2.28E-04 6.39E-04 -0.624 1.32 
Dync1h1 -0.506 6.945 -5.722 6.95E-06 2.76E-05 2.878 -1.42 
E130203B14Rik -0.717 8.135 -8.789 6.08E-09 5.33E-08 10.048 -1.64 
E330037I15Rik 0.308 8.259 4.703 8.98E-05 2.74E-04 0.303 1.24 
Ebp -1.112 5.933 -18.438 1.30E-15 9.34E-14 25.746 -2.16 
Ect2 0.346 7.232 3.578 1.53E-03 3.48E-03 -2.503 1.27 
Edem3 0.881 7.296 14.507 2.51E-13 7.92E-12 20.383 1.84 
Efemp2 -0.553 6.616 -6.619 7.84E-07 3.81E-06 5.089 -1.47 
Ehd4 -0.627 6.254 -17.336 5.12E-15 2.88E-13 24.353 -1.54 
Eif1 0.375 9.538 8.092 2.71E-08 1.95E-07 8.521 1.30 
Eif1ad -0.382 7.437 -9.820 7.49E-10 8.43E-09 12.193 -1.30 
Eif3d 0.394 9.026 6.291 1.73E-06 7.92E-06 4.288 1.31 
Eif3d 0.438 7.558 3.748 1.00E-03 2.39E-03 -2.088 1.36 
Eif3g 0.264 9.161 5.164 2.80E-05 9.51E-05 1.473 1.20 
Eif4a1 -0.747 8.429 -4.323 2.35E-04 6.56E-04 -0.656 -1.68 
Eif4a1 -0.699 9.235 -16.305 1.98E-14 8.90E-13 22.975 -1.62 
Eif4b -0.301 6.944 -2.614 1.53E-02 2.72E-02 -4.707 -1.23 
Eif4b -0.274 7.807 -5.588 9.69E-06 3.70E-05 2.541 -1.21 
Eif4e2 -0.315 7.044 -8.402 1.38E-08 1.10E-07 9.209 -1.24 
Eif4g2 -0.344 8.282 -6.406 1.31E-06 6.12E-06 4.570 -1.27 
Eif5a 0.503 6.847 10.387 2.51E-10 3.09E-09 13.314 1.42 
Eif5a 0.677 9.394 5.480 1.27E-05 4.69E-05 2.271 1.60 
Eif6 0.528 8.152 6.300 1.69E-06 7.77E-06 4.311 1.44 
Elk3 -0.494 7.108 -6.155 2.40E-06 1.05E-05 3.954 -1.41 
Elovl1 -0.337 6.439 -6.501 1.04E-06 4.96E-06 4.802 -1.26 
Emb 0.474 8.004 13.229 1.79E-12 4.13E-11 18.375 1.39 
Enah 0.687 8.200 12.642 4.64E-12 9.85E-11 17.400 1.61 
Enah 0.700 7.328 18.392 1.38E-15 9.69E-14 25.689 1.62 
Endod1 -0.341 6.475 -5.572 1.01E-05 3.83E-05 2.501 -1.27 
Eng 0.320 7.236 2.738 1.15E-02 2.10E-02 -4.441 1.25 
Eprs 0.328 8.814 8.827 5.61E-09 4.94E-08 10.131 1.26 
Eprs 0.348 6.781 2.807 9.80E-03 1.82E-02 -4.290 1.27 
Erap1 -0.406 6.611 -8.598 9.10E-09 7.67E-08 9.637 -1.32 
Ercc1 -0.325 6.529 -4.257 2.78E-04 7.63E-04 -0.824 -1.25 
Ergic3 -0.565 7.853 -11.269 4.93E-11 7.53E-10 14.981 -1.48 
Ergic3 -0.555 7.529 -5.882 4.67E-06 1.94E-05 3.278 -1.47 
Erlin1 0.524 6.942 10.455 2.20E-10 2.78E-09 13.446 1.44 
Ermp1 -0.301 7.114 -4.832 6.47E-05 2.03E-04 0.631 -1.23 
Ern1 0.498 6.120 7.995 3.35E-08 2.32E-07 8.303 1.41 
Erp29 -0.795 7.835 -14.334 3.25E-13 9.73E-12 20.120 -1.74 
Erp29 -0.675 6.775 -8.054 2.94E-08 2.08E-07 8.437 -1.60 
Esd -0.710 8.915 -17.231 5.87E-15 3.19E-13 24.215 -1.64 
Esyt2 -0.493 7.084 -10.458 2.19E-10 2.78E-09 13.451 -1.41 
Ethe1 0.411 7.237 5.892 4.57E-06 1.90E-05 3.302 1.33 
EWSR1 0.446 7.376 12.138 1.08E-11 2.02E-10 16.534 1.36 
Exosc1 0.657 7.548 8.823 5.65E-09 4.97E-08 10.123 1.58 
F2r -0.316 8.207 -3.501 1.85E-03 4.16E-03 -2.689 -1.24 
Faf1 0.518 6.458 3.724 1.06E-03 2.51E-03 -2.148 1.43 
Fam100b 0.586 6.914 8.231 2.00E-08 1.52E-07 8.831 1.50 
Fam107b 0.563 6.765 10.975 8.40E-11 1.22E-09 14.434 1.48 
Fam113a -0.539 6.737 -8.394 1.40E-08 1.11E-07 9.192 -1.45 
Fam125b 0.737 6.716 14.275 3.55E-13 1.05E-11 20.029 1.67 
Fam129c 0.323 7.400 4.050 4.70E-04 1.22E-03 -1.342 1.25 
Fam20b 0.550 6.715 11.701 2.30E-11 3.87E-10 15.763 1.46 
Fam32a 0.271 7.017 5.543 1.08E-05 4.08E-05 2.429 1.21 
Fam40a 0.282 6.463 5.904 4.43E-06 1.85E-05 3.333 1.22 
Fam54b 0.328 6.657 4.743 8.12E-05 2.50E-04 0.404 1.25 
Fam82a2 0.423 6.323 10.138 4.03E-10 4.68E-09 12.826 1.34 
Fam92a 0.348 6.361 6.244 1.93E-06 8.76E-06 4.173 1.27 
Fam98a -0.502 6.939 -12.132 1.09E-11 2.03E-10 16.525 -1.42 
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Fasn -0.755 6.330 -7.557 8.89E-08 5.47E-07 7.307 -1.69 
Fbxo28 0.998 7.050 19.415 4.09E-16 3.97E-14 26.919 2.00 
Fbxo6 0.332 7.635 3.991 5.45E-04 1.39E-03 -1.489 1.26 
Fbxo8 1.334 6.542 26.968 2.26E-19 8.21E-17 34.448 2.52 
Fbxw11 0.306 7.396 5.756 6.38E-06 2.56E-05 2.964 1.24 
Fcgrt 0.549 6.491 8.030 3.10E-08 2.16E-07 8.382 1.46 
Fdft1 -0.710 6.917 -15.959 3.17E-14 1.32E-12 22.496 -1.64 
Fdps -0.670 8.124 -11.443 3.61E-11 5.72E-10 15.299 -1.59 
Fem1b 0.585 7.723 11.615 2.67E-11 4.43E-10 15.610 1.50 
Fh1 0.618 8.282 12.126 1.10E-11 2.04E-10 16.515 1.54 
Fhl1 1.129 7.505 25.861 5.94E-19 1.94E-16 33.487 2.19 
Fhl2 -0.290 6.258 -6.595 8.30E-07 4.02E-06 5.031 -1.22 
Fkbp3 -0.371 9.016 -11.461 3.50E-11 5.59E-10 15.330 -1.29 
Flnb -0.398 6.896 -7.393 1.29E-07 7.72E-07 6.925 -1.32 
Fmc1 0.439 9.383 5.963 3.83E-06 1.61E-05 3.479 1.36 
FMNL2 0.363 7.362 5.504 1.19E-05 4.46E-05 2.330 1.29 
Foxj2 0.608 5.870 5.841 5.18E-06 2.12E-05 3.175 1.52 
Foxj3 0.504 7.777 9.109 3.13E-09 2.91E-08 10.729 1.42 
Fry -0.561 7.685 -8.043 3.01E-08 2.12E-07 8.412 -1.48 
Gabarap 0.427 9.365 9.214 2.52E-09 2.42E-08 10.950 1.34 
Gadd45a 0.420 8.855 6.291 1.73E-06 7.92E-06 4.288 1.34 
Gadd45b -1.067 6.746 -15.699 4.54E-14 1.81E-12 22.131 -2.09 
Galnt7 0.867 7.466 8.547 1.01E-08 8.32E-08 9.525 1.82 
Gamt -0.397 6.280 -4.942 4.90E-05 1.58E-04 0.910 -1.32 
Gapvd1 0.341 6.971 5.037 3.86E-05 1.28E-04 1.150 1.27 
Gas1 -0.415 6.643 -4.388 1.99E-04 5.66E-04 -0.492 -1.33 
Gclm -0.437 9.225 -8.395 1.40E-08 1.11E-07 9.194 -1.35 
Gemin4 -0.326 6.950 -3.715 1.09E-03 2.56E-03 -2.169 -1.25 
Gga2 -0.394 8.255 -10.366 2.61E-10 3.20E-09 13.273 -1.31 
Gga2 -0.345 6.153 -4.355 2.17E-04 6.12E-04 -0.577 -1.27 
Gla -0.283 6.688 -5.193 2.60E-05 8.90E-05 1.545 -1.22 
Glrx -0.336 7.177 -6.706 6.39E-07 3.18E-06 5.298 -1.26 
Glul 0.481 6.564 7.258 1.76E-07 1.01E-06 6.612 1.40 
Gm10031 1.031 6.970 19.898 2.35E-16 2.64E-14 27.479 2.04 
Gm10079 0.282 11.797 7.944 3.75E-08 2.53E-07 8.189 1.22 
Gm10094 0.333 8.656 5.845 5.12E-06 2.11E-05 3.185 1.26 
Gm10725 -0.385 6.956 -7.014 3.10E-07 1.68E-06 6.034 -1.31 
Gm10845 -0.413 8.522 -4.235 2.94E-04 7.99E-04 -0.878 -1.33 
Gm12231 0.294 8.659 4.404 1.91E-04 5.45E-04 -0.452 1.23 
Gm13552 0.289 7.064 3.654 1.27E-03 2.94E-03 -2.318 1.22 
Gm13910 -1.033 8.394 -20.981 7.10E-17 9.81E-15 28.690 -2.05 
Gm14121 0.485 8.357 7.709 6.32E-08 4.05E-07 7.656 1.40 
Gm2260 -0.634 8.341 -10.161 3.86E-10 4.51E-09 12.871 -1.55 
Gm3650 0.386 6.961 3.747 1.01E-03 2.40E-03 -2.091 1.31 
Gm3650 0.543 7.214 10.503 2.02E-10 2.60E-09 13.537 1.46 
Gm5578 0.809 6.726 15.109 1.04E-13 3.83E-12 21.279 1.75 
Gm6206 0.667 7.911 11.854 1.76E-11 3.08E-10 16.036 1.59 
Gm6304 -0.285 6.832 -4.472 1.61E-04 4.66E-04 -0.282 -1.22 
Gm6969 0.555 7.153 5.832 5.30E-06 2.16E-05 3.152 1.47 
Gm70 -0.416 7.750 -9.005 3.88E-09 3.57E-08 10.509 -1.33 
Gm70 -0.294 7.287 -2.673 1.33E-02 2.40E-02 -4.580 -1.23 
Gm7859 0.449 6.920 12.640 4.66E-12 9.85E-11 17.396 1.37 
Gm8730 0.269 11.286 3.093 5.00E-03 1.00E-02 -3.648 1.20 
Gm9178 0.381 6.970 6.402 1.32E-06 6.17E-06 4.560 1.30 
Gm9905 -0.517 6.724 -8.536 1.04E-08 8.48E-08 9.503 -1.43 
Gm9993 0.391 8.157 7.551 9.02E-08 5.54E-07 7.292 1.31 
Gmfb 0.491 7.391 3.411 2.31E-03 5.09E-03 -2.904 1.41 
Gmfb 0.604 8.592 10.559 1.81E-10 2.38E-09 13.646 1.52 
Gnai1 0.537 7.278 8.125 2.52E-08 1.84E-07 8.596 1.45 
Gnai2 -0.433 6.846 -5.619 8.96E-06 3.45E-05 2.620 -1.35 
Gnpat -0.414 6.582 -7.558 8.89E-08 5.47E-07 7.308 -1.33 
GNPTAB -0.355 7.124 -6.647 7.34E-07 3.60E-06 5.157 -1.28 
Gpc6 -1.331 3.584 -15.888 3.49E-14 1.44E-12 22.398 -2.52 
Gpd2 -0.536 6.879 -7.037 2.94E-07 1.61E-06 6.089 -1.45 
Gpnmb 1.955 5.966 31.010 8.85E-21 4.54E-18 37.642 3.88 
Gpr124 0.327 7.400 6.876 4.28E-07 2.24E-06 5.705 1.25 
Gpr56 1.280 6.194 16.295 2.01E-14 8.91E-13 22.961 2.43 
Gpsm2 -0.400 6.902 -6.057 3.05E-06 1.31E-05 3.712 -1.32 
Gpx1 -0.549 7.884 -7.896 4.16E-08 2.77E-07 8.082 -1.46 
Gpx4 -0.994 10.579 -19.026 6.45E-16 5.65E-14 26.458 -1.99 
Grsf1 0.274 7.133 5.342 1.79E-05 6.42E-05 1.923 1.21 
Gsr -0.303 6.891 -3.373 2.54E-03 5.53E-03 -2.994 -1.23 
Gss -0.412 7.023 -7.579 8.47E-08 5.27E-07 7.357 -1.33 
Gss -0.390 8.655 -8.348 1.55E-08 1.21E-07 9.091 -1.31 
Gss -0.360 6.247 -3.904 6.77E-04 1.69E-03 -1.703 -1.28 
Gss -0.293 6.709 -4.429 1.80E-04 5.15E-04 -0.389 -1.22 
Gsta4 0.395 8.552 7.832 4.80E-08 3.14E-07 7.937 1.31 
Gstm1 -0.271 9.649 -3.918 6.55E-04 1.64E-03 -1.670 -1.21 
Gstm5 -0.410 10.418 -7.161 2.20E-07 1.24E-06 6.384 -1.33 
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Gstm6 -0.418 7.960 -5.670 7.90E-06 3.08E-05 2.747 -1.34 
Gstm7 -0.773 8.876 -11.124 6.40E-11 9.54E-10 14.713 -1.71 
Gt(ROSA)26Sor 0.458 6.526 7.921 3.94E-08 2.65E-07 8.138 1.37 
GTF2A1 0.320 6.434 4.731 8.37E-05 2.56E-04 0.374 1.25 
Gtf2a2 0.308 8.193 8.562 9.82E-09 8.14E-08 9.559 1.24 
Gtf2i 0.370 6.845 7.854 4.57E-08 3.00E-07 7.986 1.29 
Gtl3 0.290 7.631 3.066 5.33E-03 1.06E-02 -3.710 1.22 
Gtl3 0.382 7.181 2.851 8.85E-03 1.67E-02 -4.193 1.30 
Guk1 0.302 7.485 6.033 3.23E-06 1.38E-05 3.654 1.23 
Gulp1 0.468 6.746 5.402 1.54E-05 5.62E-05 2.073 1.38 
Gusb -0.533 6.935 -10.604 1.67E-10 2.22E-09 13.733 -1.45 
Gusb -0.516 7.029 -8.760 6.45E-09 5.62E-08 9.988 -1.43 
Gypc -0.409 7.466 -7.032 2.97E-07 1.62E-06 6.078 -1.33 
H1f0 0.566 8.525 8.983 4.05E-09 3.70E-08 10.464 1.48 
H2-T23 -0.582 6.932 -6.978 3.37E-07 1.81E-06 5.949 -1.50 
H3f3a 0.441 10.382 10.815 1.13E-10 1.59E-09 14.134 1.36 
H3f3a 0.631 10.194 8.322 1.64E-08 1.27E-07 9.034 1.55 
H3f3b 0.288 10.004 5.808 5.62E-06 2.28E-05 3.092 1.22 
H3f3b 0.350 9.428 8.269 1.84E-08 1.41E-07 8.916 1.27 
Hadh -0.286 7.777 -3.960 5.89E-04 1.49E-03 -1.565 -1.22 
Hadha -0.681 7.157 -5.608 9.22E-06 3.54E-05 2.592 -1.60 
Hadha -0.602 7.683 -8.110 2.60E-08 1.88E-07 8.562 -1.52 
Hars -0.411 6.414 -5.984 3.64E-06 1.54E-05 3.532 -1.33 
Hat1 -0.359 6.594 -5.135 3.01E-05 1.01E-04 1.398 -1.28 
Hax1 0.268 7.314 5.326 1.86E-05 6.65E-05 1.882 1.20 
Hbp1 -0.298 6.407 -2.870 8.46E-03 1.60E-02 -4.151 -1.23 
Hbs1l 0.280 6.390 5.966 3.81E-06 1.61E-05 3.485 1.21 
Hbxip 0.480 8.226 9.138 2.95E-09 2.77E-08 10.791 1.39 
Hdgf 0.281 6.281 3.472 1.99E-03 4.45E-03 -2.758 1.21 
Heg1 -0.469 8.653 -7.584 8.37E-08 5.24E-07 7.369 -1.38 
Herpud1 -0.509 6.811 -11.480 3.38E-11 5.45E-10 15.366 -1.42 
Hint1 0.379 9.534 8.785 6.13E-09 5.36E-08 10.040 1.30 
Hip1 -0.415 6.987 -8.227 2.02E-08 1.53E-07 8.822 -1.33 
Hirip3 -0.351 6.715 -7.379 1.33E-07 7.91E-07 6.893 -1.28 
Hmbs -0.442 7.118 -9.456 1.54E-09 1.57E-08 11.452 -1.36 
HMGCR -1.004 6.572 -14.971 1.27E-13 4.48E-12 21.078 -2.00 
Hmgcs1 -0.988 6.887 -17.916 2.47E-15 1.58E-13 25.096 -1.98 
Hmox1 -0.788 7.105 -9.121 3.05E-09 2.85E-08 10.756 -1.73 
Hnrpdl 0.297 6.768 4.536 1.37E-04 4.01E-04 -0.120 1.23 
Hoxd9 0.284 5.751 2.653 1.40E-02 2.50E-02 -4.623 1.22 
Hsd17b12 -0.296 7.796 -6.196 2.17E-06 9.67E-06 4.055 -1.23 
Hsp90b1 -0.481 8.375 -2.514 1.91E-02 3.31E-02 -4.915 -1.40 
Hspb1 -0.419 9.142 -6.437 1.21E-06 5.70E-06 4.647 -1.34 
Iars2 0.269 7.066 6.795 5.17E-07 2.65E-06 5.513 1.20 
Iars2 0.347 7.976 9.291 2.15E-09 2.11E-08 11.111 1.27 
Idh1 -1.066 6.178 -4.738 8.21E-05 2.52E-04 0.392 -2.09 
IDH1 -1.038 8.313 -13.790 7.43E-13 1.95E-11 19.275 -2.05 
Idi1 -1.160 6.124 -19.434 4.00E-16 3.97E-14 26.941 -2.23 
Ifngr2 -0.266 6.377 -5.826 5.37E-06 2.19E-05 3.137 -1.20 
Ifrd1 0.761 9.381 11.162 5.97E-11 9.02E-10 14.783 1.69 
Ifrd1 1.074 6.993 5.575 9.99E-06 3.81E-05 2.510 2.11 
Ifrd2 0.267 6.584 4.036 4.86E-04 1.26E-03 -1.377 1.20 
Ift52 -0.440 7.441 -12.257 8.83E-12 1.72E-10 16.741 -1.36 
IGFBP4 -0.585 6.718 -5.589 9.65E-06 3.69E-05 2.545 -1.50 
Ildr2 1.057 6.552 20.616 1.06E-16 1.35E-14 28.288 2.08 
IMMP1L 0.515 6.798 7.767 5.55E-08 3.60E-07 7.789 1.43 
Insig1 -1.033 8.024 -21.127 6.07E-17 8.72E-15 28.848 -2.05 
Insig2 0.592 6.483 12.058 1.24E-11 2.22E-10 16.395 1.51 
Irak2 -1.429 6.582 -20.053 1.98E-16 2.29E-14 27.656 -2.69 
Irs1 0.500 6.303 7.571 8.62E-08 5.36E-07 7.339 1.41 
Itgb1bp1 0.276 7.656 7.002 3.19E-07 1.72E-06 6.006 1.21 
Itgb5 -0.587 8.275 -5.980 3.68E-06 1.56E-05 3.520 -1.50 
Itgb5 -0.539 7.557 -6.041 3.17E-06 1.36E-05 3.671 -1.45 
Itih5 -0.695 6.180 -6.261 1.85E-06 8.45E-06 4.215 -1.62 
Jak2 0.427 6.679 5.957 3.89E-06 1.64E-05 3.465 1.34 
Jun 0.371 7.869 5.225 2.40E-05 8.28E-05 1.628 1.29 
Kcmf1 0.507 8.700 11.745 2.12E-11 3.60E-10 15.842 1.42 
Kdelr3 -0.266 6.846 -3.982 5.57E-04 1.42E-03 -1.510 -1.20 
KIAA0174 0.376 7.533 8.739 6.74E-09 5.83E-08 9.943 1.30 
Kifap3 0.518 6.899 8.057 2.92E-08 2.07E-07 8.444 1.43 
Klc1 -0.692 7.277 -12.544 5.46E-12 1.13E-10 17.233 -1.62 
Klf6 0.373 6.300 4.811 6.82E-05 2.14E-04 0.578 1.29 
Klhdc10 0.523 5.617 3.879 7.22E-04 1.79E-03 -1.766 1.44 
Kpna4 0.996 7.353 18.079 2.02E-15 1.37E-13 25.301 1.99 
Kpna6 0.300 6.350 4.333 2.29E-04 6.42E-04 -0.631 1.23 
Kpnb1 0.322 8.159 5.828 5.34E-06 2.18E-05 3.144 1.25 
Krr1 0.293 6.347 5.349 1.76E-05 6.34E-05 1.941 1.22 
Lamp2 -0.306 6.487 -4.731 8.36E-05 2.56E-04 0.375 -1.24 
Lamp3 -0.651 7.710 -12.222 9.36E-12 1.80E-10 16.681 -1.57 
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Larp1 0.462 7.726 7.588 8.29E-08 5.20E-07 7.379 1.38 
Lasp1 -0.326 6.790 -7.459 1.11E-07 6.71E-07 7.080 -1.25 
Layn -1.261 6.973 -17.419 4.61E-15 2.67E-13 24.461 -2.40 
LBR 0.642 7.626 14.926 1.36E-13 4.74E-12 21.011 1.56 
Ldlr -0.603 6.729 -9.623 1.11E-09 1.17E-08 11.793 -1.52 
Lemd2 0.305 6.690 5.063 3.61E-05 1.20E-04 1.216 1.24 
Lemd3 0.313 7.077 3.292 3.09E-03 6.57E-03 -3.186 1.24 
Leprotl1 0.332 7.192 8.183 2.22E-08 1.65E-07 8.724 1.26 
Lgals1 -0.656 10.053 -7.820 4.93E-08 3.22E-07 7.908 -1.58 
Lgals3 -0.452 10.366 -7.174 2.14E-07 1.21E-06 6.413 -1.37 
Lgtn 0.531 7.503 13.198 1.88E-12 4.28E-11 18.324 1.44 
Lims1 0.317 7.351 2.473 2.09E-02 3.61E-02 -5.000 1.25 
LOC100043810 -0.659 7.540 -7.946 3.73E-08 2.53E-07 8.193 -1.58 
LOC100131826 -0.711 7.320 -8.358 1.52E-08 1.19E-07 9.112 -1.64 
LOC294154 0.503 5.851 4.043 4.78E-04 1.24E-03 -1.359 1.42 
LOC434391 -0.327 7.088 -6.489 1.07E-06 5.09E-06 4.774 -1.25 
LOC544737 0.571 7.040 7.958 3.63E-08 2.49E-07 8.221 1.49 
LOC547349 0.290 7.669 3.697 1.14E-03 2.66E-03 -2.213 1.22 
LOC553150 0.289 8.437 4.791 7.18E-05 2.24E-04 0.527 1.22 
LOC624853 -0.468 9.491 -3.524 1.75E-03 3.94E-03 -2.634 -1.38 
LOC624853 -0.367 10.561 -7.649 7.24E-08 4.60E-07 7.518 -1.29 
LOC684894 0.359 8.353 6.345 1.51E-06 7.02E-06 4.422 1.28 
LOC685953 1.972 9.130 18.899 7.48E-16 6.11E-14 26.307 3.92 
LOC75771 0.283 6.778 6.692 6.60E-07 3.27E-06 5.265 1.22 
LOC768253 0.288 6.480 5.784 5.96E-06 2.41E-05 3.033 1.22 
Lpcat3 -0.902 6.684 -9.763 8.38E-10 9.30E-09 12.077 -1.87 
Lpcat3 -0.803 6.785 -13.883 6.44E-13 1.75E-11 19.422 -1.74 
Lpp 0.298 6.385 3.368 2.57E-03 5.60E-03 -3.007 1.23 
Lpp 0.399 7.853 7.173 2.14E-07 1.21E-06 6.412 1.32 
Lrig1 -1.035 8.856 -10.614 1.63E-10 2.19E-09 13.752 -2.05 
Lrp10 -0.977 7.803 -13.668 8.98E-13 2.29E-11 19.081 -1.97 
Lrpap1 -0.324 7.109 -5.063 3.61E-05 1.20E-04 1.216 -1.25 
Lrrc59 0.459 8.298 9.717 9.17E-10 1.00E-08 11.985 1.37 
Lrrc8d -0.632 6.697 -7.539 9.26E-08 5.68E-07 7.265 -1.55 
Lrrfip1 0.714 6.403 8.408 1.36E-08 1.09E-07 9.223 1.64 
Lsm3 -0.379 7.307 -6.844 4.61E-07 2.40E-06 5.629 -1.30 
Lta4h -0.267 7.861 -5.663 8.03E-06 3.13E-05 2.730 -1.20 
Ly6e -1.055 7.105 -14.154 4.26E-13 1.25E-11 19.843 -2.08 
Lyplal1 0.635 7.767 11.605 2.72E-11 4.50E-10 15.591 1.55 
Maged1 -0.264 7.518 -4.335 2.28E-04 6.40E-04 -0.627 -1.20 
Magoh 0.374 7.716 7.512 9.85E-08 6.00E-07 7.202 1.30 
MAMDC2 -0.767 7.429 -6.639 7.48E-07 3.66E-06 5.138 -1.70 
Man2a1 -0.439 6.504 -6.075 2.91E-06 1.26E-05 3.757 -1.36 
Man2a1 -0.263 6.683 -3.576 1.54E-03 3.49E-03 -2.506 -1.20 
Man2c1 -0.648 6.482 -8.739 6.75E-09 5.83E-08 9.941 -1.57 
MAP2K1 0.273 8.294 5.315 1.92E-05 6.80E-05 1.854 1.21 
Map4k3 0.498 7.727 9.386 1.78E-09 1.79E-08 11.306 1.41 
MAPK1 -0.281 6.595 -5.353 1.74E-05 6.30E-05 1.950 -1.21 
Mapkapk2 0.931 6.739 10.365 2.61E-10 3.20E-09 13.272 1.91 
Mapkapk5 0.466 6.646 7.564 8.76E-08 5.42E-07 7.322 1.38 
Mark3 -0.889 6.635 -19.494 3.73E-16 3.83E-14 27.011 -1.85 
Mbnl2 0.290 8.281 6.810 5.00E-07 2.58E-06 5.548 1.22 
Mcm6 0.285 7.043 4.285 2.59E-04 7.14E-04 -0.751 1.22 
Mdh1 -0.354 9.418 -8.272 1.83E-08 1.40E-07 8.923 -1.28 
Mdh1 -0.301 8.427 -2.379 2.57E-02 4.35E-02 -5.190 -1.23 
Med24 -0.360 6.772 -5.221 2.43E-05 8.35E-05 1.616 -1.28 
Memo1 0.289 7.534 7.052 2.83E-07 1.55E-06 6.126 1.22 
METTL10 -0.273 8.998 -4.431 1.79E-04 5.13E-04 -0.385 -1.21 
Mettl6 0.344 6.319 7.251 1.79E-07 1.03E-06 6.595 1.27 
Mfn2 0.343 7.176 7.708 6.33E-08 4.06E-07 7.653 1.27 
Mgst1 -0.365 11.519 -6.173 2.29E-06 1.01E-05 3.999 -1.29 
Mgst1 -0.277 11.656 -6.743 5.85E-07 2.96E-06 5.388 -1.21 
Mitf -0.936 7.306 -13.083 2.26E-12 5.02E-11 18.135 -1.91 
Mki67ip 0.606 7.731 15.682 4.65E-14 1.84E-12 22.106 1.52 
Mmd -1.180 6.497 -14.530 2.43E-13 7.79E-12 20.418 -2.27 
Mmp9 -0.498 6.731 -7.881 4.31E-08 2.85E-07 8.047 -1.41 
Mobkl1b 0.269 7.614 4.365 2.11E-04 5.97E-04 -0.551 1.20 
Mobkl3 0.400 6.352 8.559 9.88E-09 8.18E-08 9.552 1.32 
Mosc2 0.702 7.334 16.886 9.17E-15 4.77E-13 23.760 1.63 
Mosc2 0.713 8.107 11.492 3.31E-11 5.36E-10 15.387 1.64 
Mpst -0.293 6.645 -5.089 3.38E-05 1.13E-04 1.281 -1.23 
Mrpl1 0.268 7.634 5.360 1.71E-05 6.20E-05 1.967 1.20 
Mrpl18 -0.334 7.610 -7.536 9.34E-08 5.72E-07 7.257 -1.26 
Mrpl20 0.328 8.473 6.747 5.80E-07 2.95E-06 5.397 1.26 
Mrpl34 -0.316 6.826 -4.302 2.48E-04 6.89E-04 -0.710 -1.24 
Mrpl37 0.556 7.536 7.614 7.83E-08 4.94E-07 7.437 1.47 
Mrpl37 0.582 6.243 4.175 3.42E-04 9.16E-04 -1.028 1.50 
Mrpl41 -0.359 7.421 -6.938 3.70E-07 1.96E-06 5.854 -1.28 
Mrpl53 0.395 6.945 5.851 5.05E-06 2.08E-05 3.199 1.31 
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Mrps10 0.481 6.973 5.868 4.84E-06 2.00E-05 3.243 1.40 
Mrps14 0.780 7.595 21.807 2.95E-17 5.31E-15 29.574 1.72 
Mrps18a 0.362 9.934 5.754 6.42E-06 2.57E-05 2.957 1.29 
Mrps22 0.498 6.359 10.624 1.61E-10 2.16E-09 13.770 1.41 
Mrps35 0.556 8.616 11.335 4.38E-11 6.81E-10 15.101 1.47 
MSL1 0.337 6.484 4.789 7.21E-05 2.25E-04 0.522 1.26 
Mta3 0.451 6.286 8.083 2.76E-08 1.97E-07 8.502 1.37 
Mtdh 0.311 7.693 6.076 2.90E-06 1.26E-05 3.760 1.24 
Mthfd1l -0.346 7.267 -8.109 2.61E-08 1.89E-07 8.560 -1.27 
Mthfd2l -0.876 6.000 -13.727 8.19E-13 2.10E-11 19.175 -1.83 
Myc 0.300 9.167 6.939 3.69E-07 1.96E-06 5.856 1.23 
Myg1 0.808 6.223 11.589 2.79E-11 4.60E-10 15.562 1.75 
Myof 0.358 9.190 6.174 2.29E-06 1.01E-05 4.001 1.28 
N6amt2 -0.327 6.228 -5.482 1.26E-05 4.67E-05 2.276 -1.25 
Nadk 0.268 7.568 6.090 2.81E-06 1.22E-05 3.793 1.20 
Nap1l4 0.571 6.668 9.169 2.77E-09 2.63E-08 10.855 1.49 
Ncam1 1.186 5.358 13.187 1.92E-12 4.33E-11 18.305 2.28 
Ncapd3 -0.854 5.993 -12.109 1.13E-11 2.09E-10 16.485 -1.81 
Nck2 -0.738 6.349 -9.323 2.02E-09 2.01E-08 11.176 -1.67 
Ndc80 0.369 6.736 4.494 1.53E-04 4.42E-04 -0.226 1.29 
Ndfip2 0.512 6.868 3.787 9.09E-04 2.19E-03 -1.992 1.43 
Ndufa6 0.442 7.661 6.264 1.84E-06 8.41E-06 4.222 1.36 
Ndufab1 0.635 6.612 10.977 8.36E-11 1.22E-09 14.439 1.55 
Ndufaf2 0.423 7.178 7.775 5.45E-08 3.55E-07 7.806 1.34 
Ndufb8 0.317 7.719 3.589 1.49E-03 3.40E-03 -2.476 1.25 
Ndufb9 0.379 10.546 10.820 1.12E-10 1.59E-09 14.143 1.30 
Ndufs2 0.789 7.740 18.776 8.66E-16 6.59E-14 26.159 1.73 
Ndufs7 0.485 9.159 6.716 6.24E-07 3.12E-06 5.321 1.40 
Ndufv1 -0.443 7.817 -8.440 1.27E-08 1.03E-07 9.293 -1.36 
Neat1 -0.681 8.207 -10.395 2.47E-10 3.06E-09 13.330 -1.60 
Neil3 0.292 7.798 4.130 3.83E-04 1.02E-03 -1.141 1.22 
Nek2 0.775 8.036 11.777 2.01E-11 3.44E-10 15.898 1.71 
Nek7 0.517 9.354 9.574 1.22E-09 1.29E-08 11.693 1.43 
Neu1 -0.367 6.374 -6.711 6.30E-07 3.15E-06 5.311 -1.29 
Neurl3 0.357 6.664 5.139 2.98E-05 1.01E-04 1.408 1.28 
Neurl3 0.487 6.003 3.570 1.56E-03 3.54E-03 -2.522 1.40 
Nfib -0.440 6.638 -5.274 2.12E-05 7.41E-05 1.752 -1.36 
Nfic -0.269 6.666 -3.790 9.03E-04 2.18E-03 -1.986 -1.20 
Nfkbia -1.086 8.243 -17.539 3.96E-15 2.37E-13 24.615 -2.12 
Nfkbia -1.015 8.519 -14.423 2.84E-13 8.74E-12 20.256 -2.02 
Nfs1 -0.752 7.421 -17.256 5.67E-15 3.14E-13 24.249 -1.68 
Ngdn 0.513 7.269 10.363 2.62E-10 3.21E-09 13.267 1.43 
Ngfrap1 -0.492 8.673 -12.510 5.78E-12 1.19E-10 17.176 -1.41 
Ngrn 0.392 7.748 10.421 2.35E-10 2.93E-09 13.379 1.31 
Nid1 -0.531 8.249 -7.359 1.40E-07 8.25E-07 6.847 -1.44 
Nid1 -0.372 8.359 -3.828 8.20E-04 2.00E-03 -1.892 -1.29 
Ninj1 -0.446 6.177 -7.023 3.03E-07 1.65E-06 6.057 -1.36 
Nit1 -0.350 6.656 -4.428 1.80E-04 5.17E-04 -0.393 -1.27 
Nme7 0.471 7.081 8.223 2.04E-08 1.53E-07 8.813 1.39 
Nop58 0.352 8.700 4.348 2.21E-04 6.21E-04 -0.594 1.28 
Nploc4 0.272 6.036 3.150 4.36E-03 8.89E-03 -3.518 1.21 
Nr1h3 -1.088 6.661 -12.853 3.28E-12 7.15E-11 17.754 -2.13 
Nr2c1 0.547 6.434 10.753 1.26E-10 1.75E-09 14.016 1.46 
Nsmce2 0.442 8.368 6.658 7.16E-07 3.52E-06 5.182 1.36 
Nucb2 -0.808 7.514 -15.295 8.01E-14 3.03E-12 21.551 -1.75 
Nucks1 0.528 6.595 7.136 2.33E-07 1.31E-06 6.325 1.44 
Nudc 0.346 8.891 5.458 1.34E-05 4.93E-05 2.215 1.27 
Nudt3 0.500 6.423 5.914 4.33E-06 1.81E-05 3.357 1.41 
Nudt5 0.335 7.630 6.220 2.05E-06 9.23E-06 4.114 1.26 
NUP205 -0.264 6.845 -5.985 3.64E-06 1.54E-05 3.533 -1.20 
Nusap1 0.390 6.996 4.891 5.57E-05 1.78E-04 0.781 1.31 
Nvl 0.873 6.210 16.258 2.11E-14 9.24E-13 22.912 1.83 
Oaf -0.268 7.439 -5.785 5.94E-06 2.40E-05 3.035 -1.20 
Oaz1 -0.918 7.862 -12.108 1.14E-11 2.09E-10 16.482 -1.89 
Oaz1 -0.811 7.602 -14.807 1.62E-13 5.43E-12 20.834 -1.75 
Oaz2 -0.772 6.880 -13.345 1.49E-12 3.59E-11 18.563 -1.71 
Ormdl1 0.343 6.318 7.746 5.82E-08 3.76E-07 7.739 1.27 
Osbpl9 -0.403 6.512 -3.952 6.01E-04 1.51E-03 -1.586 -1.32 
Osmr -0.722 7.659 -11.273 4.89E-11 7.51E-10 14.987 -1.65 
Ostf1 -0.269 9.588 -7.485 1.05E-07 6.34E-07 7.141 -1.20 
Oxr1 -0.349 6.713 -5.004 4.19E-05 1.37E-04 1.066 -1.27 
Pabpc4 0.372 7.915 5.027 3.95E-05 1.30E-04 1.126 1.29 
Pabpn1 -0.306 8.440 -6.214 2.08E-06 9.31E-06 4.101 -1.24 
Pacsin2 0.282 6.564 4.880 5.73E-05 1.82E-04 0.753 1.22 
Palld -0.931 7.134 -18.998 6.66E-16 5.70E-14 26.425 -1.91 
Papd7 0.500 6.772 6.825 4.82E-07 2.49E-06 5.584 1.41 
Papola -0.965 8.682 -9.460 1.53E-09 1.57E-08 11.460 -1.95 
Papola -0.850 8.026 -18.014 2.19E-15 1.43E-13 25.219 -1.80 
Papola -0.812 6.381 -6.740 5.90E-07 2.98E-06 5.379 -1.76 
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PAPSS1 -0.457 6.702 -7.005 3.16E-07 1.71E-06 6.015 -1.37 
Paqr3 0.330 6.379 5.012 4.11E-05 1.35E-04 1.086 1.26 
Parp1 0.644 6.304 10.561 1.81E-10 2.38E-09 13.650 1.56 
Parp3 -0.929 6.322 -15.347 7.43E-14 2.87E-12 21.627 -1.90 
Pbk 0.286 6.261 3.267 3.28E-03 6.93E-03 -3.244 1.22 
Pck2 -0.711 6.594 -10.796 1.17E-10 1.64E-09 14.098 -1.64 
Pcolce -0.595 8.526 -7.890 4.22E-08 2.80E-07 8.067 -1.51 
Pcp4l1 0.429 8.567 12.697 4.24E-12 9.07E-11 17.493 1.35 
Pdap1 0.291 7.806 4.981 4.45E-05 1.45E-04 1.007 1.22 
Pdia3 -0.285 9.730 -4.586 1.21E-04 3.58E-04 0.007 -1.22 
Pdlim1 -0.469 7.184 -9.961 5.68E-10 6.50E-09 12.476 -1.38 
Pdrg1 0.907 7.434 16.327 1.92E-14 8.75E-13 23.006 1.87 
Pebp1 -0.353 9.686 -9.378 1.81E-09 1.81E-08 11.290 -1.28 
Pes1 0.275 7.542 3.700 1.13E-03 2.65E-03 -2.207 1.21 
Pex19 0.911 6.163 18.763 8.80E-16 6.59E-14 26.142 1.88 
Pfdn5 -0.358 8.087 -7.456 1.12E-07 6.74E-07 7.073 -1.28 
Pgk1 -0.466 9.403 -13.138 2.07E-12 4.65E-11 18.226 -1.38 
Pgrmc2 -0.264 7.361 -7.976 3.49E-08 2.41E-07 8.261 -1.20 
Pgs1 -0.353 6.290 -5.223 2.41E-05 8.32E-05 1.621 -1.28 
Phf20 -0.499 6.196 -10.696 1.40E-10 1.93E-09 13.907 -1.41 
Phf20 -0.494 6.211 -7.355 1.41E-07 8.32E-07 6.837 -1.41 
PHF5A 0.504 7.050 9.572 1.22E-09 1.29E-08 11.689 1.42 
PHGDH -0.649 7.601 -9.060 3.46E-09 3.20E-08 10.626 -1.57 
PIGT -0.607 6.318 -6.055 3.06E-06 1.31E-05 3.707 -1.52 
Pigx 0.443 8.703 12.207 9.62E-12 1.84E-10 16.654 1.36 
Pin4 0.270 6.767 5.399 1.55E-05 5.65E-05 2.066 1.21 
Pir -0.780 6.603 -11.436 3.66E-11 5.74E-10 15.286 -1.72 
Pja2 0.275 7.451 5.874 4.77E-06 1.98E-05 3.258 1.21 
Pkn2 0.310 6.309 3.831 8.14E-04 1.99E-03 -1.884 1.24 
Pkn2 0.382 7.422 9.174 2.74E-09 2.62E-08 10.865 1.30 
Plaa -0.394 6.833 -8.044 3.01E-08 2.12E-07 8.415 -1.31 
Plac8 0.738 5.438 7.386 1.31E-07 7.81E-07 6.910 1.67 
Plbd2 0.423 7.151 6.193 2.19E-06 9.71E-06 4.047 1.34 
Plcg1 -0.609 7.243 -13.309 1.58E-12 3.75E-11 18.505 -1.53 
Plekha5 -0.325 7.039 -8.021 3.16E-08 2.20E-07 8.363 -1.25 
Plin2 -0.392 9.393 -9.437 1.60E-09 1.62E-08 11.413 -1.31 
Plin2 -0.297 9.911 -2.693 1.28E-02 2.31E-02 -4.539 -1.23 
PLK2 -0.470 7.605 -9.227 2.45E-09 2.36E-08 10.977 -1.39 
Pltp -2.846 7.226 -21.691 3.34E-17 5.45E-15 29.451 -7.19 
Plxna1 -0.450 6.084 -8.906 4.76E-09 4.31E-08 10.300 -1.37 
Pnn 0.393 7.266 7.387 1.31E-07 7.80E-07 6.913 1.31 
Pnp2 -0.452 6.523 -6.761 5.61E-07 2.86E-06 5.430 -1.37 
Polr1c 0.267 7.898 5.477 1.28E-05 4.72E-05 2.263 1.20 
Polr1c 0.291 6.856 2.590 1.61E-02 2.84E-02 -4.756 1.22 
Polr2b -0.380 8.094 -7.666 6.96E-08 4.44E-07 7.556 -1.30 
Polr2g 0.437 8.219 10.778 1.21E-10 1.68E-09 14.064 1.35 
Polr3e 0.762 5.962 13.885 6.42E-13 1.75E-11 19.424 1.70 
Pomt2 -0.324 7.750 -3.093 5.00E-03 1.00E-02 -3.648 -1.25 
Pop7 -0.283 6.953 -4.613 1.13E-04 3.36E-04 0.075 -1.22 
Ppap2a -0.654 6.987 -8.662 7.93E-09 6.77E-08 9.777 -1.57 
Ppcs -0.300 7.062 -5.322 1.88E-05 6.70E-05 1.872 -1.23 
Ppif 0.316 7.174 6.255 1.88E-06 8.56E-06 4.200 1.24 
Ppp1cb 0.554 9.069 8.462 1.21E-08 9.84E-08 9.342 1.47 
Ppp2cb 0.311 9.586 7.092 2.58E-07 1.43E-06 6.220 1.24 
PPP2R5A 0.847 6.010 13.904 6.23E-13 1.75E-11 19.454 1.80 
Ppp2r5c -1.004 7.119 -15.309 7.85E-14 3.00E-12 21.571 -2.01 
Ppp2r5c -0.483 7.078 -10.190 3.65E-10 4.33E-09 12.928 -1.40 
Ppp3cb 0.390 6.496 6.504 1.03E-06 4.94E-06 4.809 1.31 
Pppde1 0.761 6.727 15.976 3.10E-14 1.31E-12 22.520 1.69 
Pppde1 1.189 6.277 12.392 7.04E-12 1.42E-10 16.974 2.28 
Pqlc3 -0.527 6.550 -4.541 1.35E-04 3.97E-04 -0.105 -1.44 
Prc1 0.393 7.462 4.100 4.14E-04 1.08E-03 -1.217 1.31 
Prcp -0.394 7.535 -9.447 1.57E-09 1.60E-08 11.433 -1.31 
Prdx6 0.529 9.310 8.322 1.64E-08 1.27E-07 9.033 1.44 
Prdx6 0.625 7.805 16.445 1.64E-14 7.77E-13 23.167 1.54 
Prkacb 0.318 8.518 6.023 3.31E-06 1.41E-05 3.628 1.25 
Prkcdbp -0.824 6.389 -7.662 7.02E-08 4.47E-07 7.548 -1.77 
Prkcsh -0.310 6.754 -2.790 1.02E-02 1.89E-02 -4.329 -1.24 
Prkrir 0.498 7.275 11.464 3.48E-11 5.58E-10 15.337 1.41 
Prmt3 0.340 7.986 10.171 3.78E-10 4.44E-09 12.892 1.27 
Prmt5 -0.635 7.197 -8.547 1.01E-08 8.32E-08 9.526 -1.55 
Procr -0.316 6.220 -4.738 8.22E-05 2.52E-04 0.392 -1.24 
Prpf6 -0.302 7.446 -5.299 2.00E-05 7.03E-05 1.813 -1.23 
Prps2 -0.326 7.860 -4.266 2.72E-04 7.46E-04 -0.800 -1.25 
Prps2 -0.284 9.468 -5.119 3.13E-05 1.05E-04 1.359 -1.22 
Prune2 -0.654 7.588 -11.790 1.97E-11 3.40E-10 15.922 -1.57 
Psat1 -0.691 8.652 -10.547 1.85E-10 2.41E-09 13.623 -1.61 
Psat1 -0.668 9.538 -14.615 2.14E-13 7.00E-12 20.546 -1.59 
Psma7 -0.376 10.089 -11.233 5.26E-11 8.01E-10 14.913 -1.30 
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PSMB5 -0.484 9.145 -5.196 2.58E-05 8.83E-05 1.554 -1.40 
Psmb6 0.367 8.403 6.330 1.57E-06 7.26E-06 4.385 1.29 
Psmc2 0.283 9.287 8.118 2.56E-08 1.85E-07 8.580 1.22 
Psmc4 0.422 7.500 6.019 3.35E-06 1.42E-05 3.617 1.34 
Psmc4 0.465 6.706 4.125 3.88E-04 1.03E-03 -1.153 1.38 
Psmc5 0.516 7.329 5.845 5.13E-06 2.11E-05 3.185 1.43 
Psmc5 0.542 7.802 13.587 1.02E-12 2.56E-11 18.953 1.46 
Psmd1 -0.339 6.492 -5.225 2.40E-05 8.28E-05 1.627 -1.26 
Psmd14 0.280 8.374 8.403 1.38E-08 1.10E-07 9.211 1.21 
Psme4 -0.388 7.404 -6.524 9.85E-07 4.71E-06 4.858 -1.31 
Psmg1 0.389 7.725 9.966 5.63E-10 6.46E-09 12.485 1.31 
Ptdss1 -0.341 6.929 -6.102 2.73E-06 1.18E-05 3.824 -1.27 
Ptgr1 -0.483 8.581 -9.910 6.28E-10 7.12E-09 12.373 -1.40 
Ptgr1 -0.431 7.564 -3.773 9.41E-04 2.26E-03 -2.027 -1.35 
Ptp4a2 0.291 9.890 3.884 7.13E-04 1.76E-03 -1.753 1.22 
Ptp4a2 0.424 9.223 3.155 4.31E-03 8.79E-03 -3.506 1.34 
Ptpn11 0.270 8.669 5.795 5.79E-06 2.35E-05 3.062 1.21 
Ptprg -2.362 5.545 -46.919 5.34E-25 6.39E-22 46.851 -5.14 
Ptrf -0.365 7.830 -4.639 1.06E-04 3.17E-04 0.142 -1.29 
Pum2 0.338 7.024 8.093 2.70E-08 1.95E-07 8.524 1.26 
Pwp1 0.314 7.363 5.699 7.35E-06 2.89E-05 2.821 1.24 
Pxdn -0.338 7.848 -5.876 4.75E-06 1.97E-05 3.262 -1.26 
Qars -0.514 9.208 -12.618 4.83E-12 1.01E-10 17.358 -1.43 
Qsox1 0.334 7.440 4.310 2.43E-04 6.77E-04 -0.691 1.26 
R3hdm1 0.312 6.525 6.162 2.36E-06 1.04E-05 3.972 1.24 
Rab1 -0.368 9.110 -8.898 4.84E-09 4.37E-08 10.283 -1.29 
Rab11a -0.309 5.948 -2.953 6.97E-03 1.35E-02 -3.966 -1.24 
Rab11a -0.268 7.923 -5.349 1.76E-05 6.34E-05 1.940 -1.20 
Rab14 0.358 8.540 8.553 1.00E-08 8.25E-08 9.538 1.28 
Rab24 -0.578 6.607 -11.001 8.00E-11 1.18E-09 14.484 -1.49 
Rab28 0.333 7.987 4.865 5.95E-05 1.88E-04 0.715 1.26 
Rab31 0.308 6.713 3.807 8.64E-04 2.10E-03 -1.943 1.24 
Rab32 -0.314 6.424 -4.034 4.89E-04 1.26E-03 -1.382 -1.24 
Rab5a 0.303 7.672 5.278 2.10E-05 7.36E-05 1.761 1.23 
Rab6 0.501 6.620 7.582 8.41E-08 5.25E-07 7.364 1.42 
Rab7 0.323 7.596 5.093 3.35E-05 1.12E-04 1.293 1.25 
Ralb 0.314 6.456 6.128 2.56E-06 1.12E-05 3.888 1.24 
Ralgapb -0.589 6.409 -13.734 8.10E-13 2.09E-11 19.186 -1.50 
Rapgef1 0.469 9.228 9.674 9.99E-10 1.07E-08 11.898 1.38 
Rarres2 -0.812 9.322 -11.439 3.64E-11 5.74E-10 15.290 -1.76 
Rbck1 0.812 6.528 9.698 9.53E-10 1.03E-08 11.945 1.76 
RBM3 -0.646 7.415 -6.420 1.27E-06 5.94E-06 4.603 -1.56 
Rbm39 -0.418 8.443 -8.292 1.75E-08 1.35E-07 8.968 -1.34 
Rbm8a -0.294 8.097 -7.614 7.82E-08 4.94E-07 7.439 -1.23 
Rcbtb2 -0.516 7.042 -8.760 6.46E-09 5.62E-08 9.987 -1.43 
Rcc2 0.295 7.768 5.666 7.98E-06 3.11E-05 2.738 1.23 
Rcn3 0.355 8.011 5.375 1.65E-05 5.98E-05 2.007 1.28 
Rdx 0.264 8.988 5.149 2.91E-05 9.85E-05 1.435 1.20 
Rer1 0.451 7.708 9.798 7.82E-10 8.75E-09 12.149 1.37 
Rer1 0.457 8.619 7.396 1.28E-07 7.67E-07 6.933 1.37 
Retsat -0.960 5.458 -10.234 3.36E-10 4.01E-09 13.014 -1.94 
Rev3l -0.360 7.281 -5.473 1.29E-05 4.77E-05 2.251 -1.28 
Rexo2 0.308 9.534 8.042 3.02E-08 2.12E-07 8.409 1.24 
Rfc1 -0.297 7.032 -5.345 1.78E-05 6.39E-05 1.930 -1.23 
Rfx5 -0.354 6.821 -6.310 1.65E-06 7.60E-06 4.334 -1.28 
RGD1560010 0.466 6.651 6.719 6.19E-07 3.10E-06 5.330 1.38 
RGD1561797 -0.407 7.190 -5.239 2.32E-05 8.06E-05 1.661 -1.33 
Rgs17 0.784 7.346 8.084 2.76E-08 1.97E-07 8.503 1.72 
Riok3 0.583 7.168 8.179 2.24E-08 1.66E-07 8.716 1.50 
Rnaseh2c -1.175 6.445 -18.782 8.60E-16 6.59E-14 26.165 -2.26 
Rnaset2a 0.570 10.189 13.225 1.80E-12 4.13E-11 18.367 1.48 
Rnf10 0.316 7.472 5.733 6.76E-06 2.70E-05 2.904 1.25 
Rnf11 0.281 7.884 6.059 3.03E-06 1.30E-05 3.717 1.22 
Rnft1 -0.348 6.370 -6.124 2.59E-06 1.13E-05 3.877 -1.27 
ROCK2 0.292 7.129 3.139 4.47E-03 9.08E-03 -3.542 1.22 
Romo1 -0.381 9.948 -7.619 7.74E-08 4.90E-07 7.449 -1.30 
rp9 0.444 6.933 7.385 1.32E-07 7.82E-07 6.907 1.36 
Rpia -0.273 7.906 -4.619 1.11E-04 3.31E-04 0.091 -1.21 
Rpn2 -0.458 9.821 -5.217 2.45E-05 8.43E-05 1.606 -1.37 
Rpn2 -0.291 10.428 -6.702 6.44E-07 3.20E-06 5.289 -1.22 
Rpp21 0.327 8.060 5.300 1.99E-05 7.02E-05 1.815 1.25 
Rpp30 0.309 7.292 5.056 3.68E-05 1.22E-04 1.198 1.24 
Rps28 -0.819 8.402 -8.579 9.47E-09 7.93E-08 9.596 -1.76 
Rps5 0.284 11.111 6.288 1.74E-06 7.97E-06 4.281 1.22 
Rps6kb1 0.325 6.763 5.698 7.38E-06 2.90E-05 2.817 1.25 
Rqcd1 0.308 6.141 4.628 1.09E-04 3.25E-04 0.113 1.24 
Rras -0.353 6.545 -5.018 4.05E-05 1.33E-04 1.102 -1.28 
Rrp1 0.460 6.040 4.666 9.85E-05 2.98E-04 0.211 1.38 
Rrp15 0.682 7.873 20.847 8.21E-17 1.09E-14 28.543 1.60 
 379 
Rsl24d1 0.429 7.715 7.483 1.05E-07 6.37E-07 7.134 1.35 
Rsrc1 0.347 6.889 7.985 3.42E-08 2.36E-07 8.282 1.27 
Rsu1 -0.290 8.196 -3.449 2.10E-03 4.67E-03 -2.813 -1.22 
Ryk 0.342 6.736 8.298 1.73E-08 1.33E-07 8.980 1.27 
S100a11 -0.290 7.784 -4.316 2.40E-04 6.68E-04 -0.676 -1.22 
SAMD4B 0.460 8.703 9.524 1.35E-09 1.39E-08 11.592 1.38 
Samhd1 -0.472 6.716 -9.811 7.63E-10 8.56E-09 12.174 -1.39 
Samm50 -0.288 7.616 -6.465 1.13E-06 5.37E-06 4.715 -1.22 
Sars -0.272 7.477 -2.797 1.00E-02 1.87E-02 -4.313 -1.21 
Sat1 -1.197 6.704 -24.727 1.67E-18 4.28E-16 32.457 -2.29 
SC4MOL -1.137 8.194 -22.532 1.40E-17 2.65E-15 30.324 -2.20 
Sc4mol -1.056 6.368 -4.963 4.64E-05 1.50E-04 0.964 -2.08 
Sc5d -0.921 6.364 -9.758 8.46E-10 9.35E-09 12.068 -1.89 
Scarb1 0.277 6.897 4.001 5.31E-04 1.36E-03 -1.463 1.21 
Sccpdh 0.339 7.895 7.122 2.41E-07 1.34E-06 6.292 1.26 
Sccpdh 0.477 7.248 13.569 1.05E-12 2.61E-11 18.924 1.39 
SCD -0.528 9.542 -12.449 6.39E-12 1.30E-10 17.072 -1.44 
Scd1 -0.541 7.257 -5.086 3.41E-05 1.14E-04 1.274 -1.45 
Scd1 -0.472 9.240 -8.957 4.28E-09 3.89E-08 10.409 -1.39 
Scd3 -0.537 7.564 -5.749 6.50E-06 2.60E-05 2.945 -1.45 
Scd3 -0.401 8.588 -9.629 1.09E-09 1.16E-08 11.807 -1.32 
Scfd1 0.323 6.868 5.991 3.58E-06 1.52E-05 3.549 1.25 
Scoc 0.300 7.007 4.642 1.05E-04 3.15E-04 0.149 1.23 
Sdc1 -0.433 5.513 -7.079 2.66E-07 1.47E-06 6.190 -1.35 
Sdc4 -0.491 8.779 -9.741 8.75E-10 9.62E-09 12.033 -1.41 
Sdc4 -0.416 7.039 -4.467 1.63E-04 4.72E-04 -0.294 -1.33 
Sdf2 -0.333 6.838 -8.192 2.17E-08 1.62E-07 8.746 -1.26 
Sdhb 0.341 8.786 3.190 3.96E-03 8.18E-03 -3.425 1.27 
Sdhd -0.303 9.423 -4.752 7.92E-05 2.44E-04 0.429 -1.23 
Sec13 -0.319 7.937 -9.412 1.69E-09 1.70E-08 11.361 -1.25 
Sec23b -0.500 6.844 -6.708 6.35E-07 3.17E-06 5.304 -1.41 
Sec24d -0.418 7.004 -5.794 5.81E-06 2.36E-05 3.058 -1.34 
Sec63 0.271 6.781 5.565 1.02E-05 3.89E-05 2.485 1.21 
Sel1l -0.355 7.016 -3.751 9.95E-04 2.38E-03 -2.081 -1.28 
Selk 0.344 7.749 7.189 2.06E-07 1.17E-06 6.449 1.27 
Sema3c 1.004 6.612 17.408 4.67E-15 2.67E-13 24.446 2.01 
Senp6 0.293 7.501 3.349 2.69E-03 5.81E-03 -3.051 1.23 
SERINC3 -0.583 9.592 -13.387 1.40E-12 3.41E-11 18.630 -1.50 
Serpinb1a -0.663 8.041 -9.229 2.45E-09 2.36E-08 10.981 -1.58 
Serpinb6a -0.291 8.276 -5.493 1.23E-05 4.57E-05 2.302 -1.22 
Serpinf1 -1.188 8.278 -13.766 7.71E-13 2.01E-11 19.237 -2.28 
Serpinh1 -0.431 8.949 -7.130 2.37E-07 1.32E-06 6.309 -1.35 
Serpinh1 -0.389 9.252 -11.963 1.46E-11 2.60E-10 16.229 -1.31 
Serpinh1 -0.376 8.798 -4.095 4.19E-04 1.10E-03 -1.228 -1.30 
SET 0.522 8.500 13.792 7.40E-13 1.95E-11 19.278 1.44 
Sf3b3 -0.688 7.166 -9.003 3.89E-09 3.57E-08 10.506 -1.61 
Sfrs1 0.406 7.768 7.944 3.74E-08 2.53E-07 8.190 1.32 
Sfrs7 0.265 8.831 2.703 1.25E-02 2.25E-02 -4.516 1.20 
Sgce 0.642 6.005 4.977 4.48E-05 1.45E-04 1.000 1.56 
Sgk1 0.665 7.327 10.698 1.40E-10 1.93E-09 13.911 1.59 
Sh2b3 -0.503 6.519 -9.170 2.76E-09 2.63E-08 10.858 -1.42 
Shmt2 -0.835 6.208 -8.173 2.26E-08 1.67E-07 8.704 -1.78 
Sin3b 0.475 6.811 5.540 1.09E-05 4.11E-05 2.421 1.39 
Slain2 0.344 7.905 6.262 1.85E-06 8.43E-06 4.219 1.27 
Slc1a5 -0.465 6.945 -9.273 2.24E-09 2.18E-08 11.073 -1.38 
Slc25a1 -0.886 6.910 -9.685 9.78E-10 1.05E-08 11.920 -1.85 
Slc25a17 0.317 6.764 7.103 2.52E-07 1.40E-06 6.246 1.25 
Slc25a20 -0.354 8.555 -4.978 4.47E-05 1.45E-04 1.002 -1.28 
Slc35b1 -0.287 7.240 -5.844 5.14E-06 2.11E-05 3.182 -1.22 
Slc44a1 0.287 7.158 4.356 2.16E-04 6.09E-04 -0.573 1.22 
Slc6a6 -0.637 8.040 -13.317 1.56E-12 3.73E-11 18.518 -1.56 
Slc7a11 -1.284 7.310 -15.281 8.17E-14 3.06E-12 21.531 -2.44 
Smpd1 -0.475 6.885 -7.897 4.16E-08 2.77E-07 8.082 -1.39 
Smpd1 -0.428 6.110 -4.543 1.35E-04 3.95E-04 -0.100 -1.35 
Smyd2 0.949 6.489 17.733 3.10E-15 1.95E-13 24.864 1.93 
Snai2 -0.758 6.399 -11.536 3.07E-11 5.01E-10 15.466 -1.69 
Snn -0.814 6.495 -10.534 1.90E-10 2.47E-09 13.597 -1.76 
Snora28 -1.612 6.761 -15.853 3.67E-14 1.50E-12 22.347 -3.06 
Snora28 -1.327 8.217 -26.955 2.29E-19 8.21E-17 34.437 -2.51 
Snora28 -1.268 7.421 -24.486 2.09E-18 5.01E-16 32.232 -2.41 
Snora75 -0.307 8.619 -5.712 7.11E-06 2.81E-05 2.853 -1.24 
Snrnp27 0.366 7.046 3.364 2.59E-03 5.64E-03 -3.015 1.29 
Snrpc 0.522 7.891 10.439 2.27E-10 2.84E-09 13.414 1.44 
Snrpe 0.274 9.000 4.695 9.15E-05 2.78E-04 0.284 1.21 
SNX21 -0.605 6.347 -7.234 1.86E-07 1.07E-06 6.556 -1.52 
Snx4 0.324 8.191 6.679 6.80E-07 3.36E-06 5.234 1.25 
Sod1 -0.363 8.506 -6.489 1.07E-06 5.09E-06 4.773 -1.29 
Sod2 -0.743 6.599 -11.810 1.90E-11 3.31E-10 15.958 -1.67 
SOD2 -0.620 6.729 -9.144 2.91E-09 2.75E-08 10.804 -1.54 
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Sox12 0.576 5.451 4.274 2.66E-04 7.34E-04 -0.780 1.49 
Sprr1a 1.051 8.643 12.199 9.74E-12 1.85E-10 16.641 2.07 
Sptlc1 -0.344 6.938 -3.586 1.50E-03 3.42E-03 -2.483 -1.27 
Sqle -0.829 7.073 -12.459 6.29E-12 1.28E-10 17.088 -1.78 
Sqle -0.775 9.031 -12.296 8.27E-12 1.63E-10 16.809 -1.71 
Sqle -0.717 6.333 -4.660 1.00E-04 3.02E-04 0.194 -1.64 
Srgn -0.375 7.415 -4.349 2.20E-04 6.20E-04 -0.592 -1.30 
Srp54c -0.307 6.551 -6.383 1.38E-06 6.44E-06 4.514 -1.24 
Srp68 0.303 6.373 3.157 4.28E-03 8.75E-03 -3.500 1.23 
Srpr -0.430 8.041 -9.768 8.29E-10 9.23E-09 12.088 -1.35 
Srpr -0.366 6.329 -3.986 5.51E-04 1.40E-03 -1.500 -1.29 
Ssu72 -1.080 7.371 -16.992 7.98E-15 4.22E-13 23.902 -2.11 
Stim2 0.434 6.458 5.311 1.94E-05 6.85E-05 1.844 1.35 
Stk39 0.387 6.315 4.253 2.81E-04 7.67E-04 -0.833 1.31 
Stk4 -0.445 6.572 -10.312 2.89E-10 3.48E-09 13.167 -1.36 
Stt3a -0.624 6.388 -2.803 9.90E-03 1.84E-02 -4.300 -1.54 
STT3A -0.482 7.885 -8.596 9.13E-09 7.68E-08 9.633 -1.40 
Stx12 0.384 7.584 7.621 7.70E-08 4.89E-07 7.454 1.30 
Stx12 0.399 7.514 7.605 7.99E-08 5.03E-07 7.416 1.32 
Stx6 0.471 6.481 7.964 3.59E-08 2.47E-07 8.233 1.39 
Sumf2 0.401 7.010 7.324 1.51E-07 8.91E-07 6.766 1.32 
SUPT16H -0.973 10.402 -13.447 1.27E-12 3.12E-11 18.727 -1.96 
Supt4h1 0.338 7.223 6.323 1.60E-06 7.38E-06 4.367 1.26 
Supt6h 0.492 6.509 4.750 7.97E-05 2.46E-04 0.423 1.41 
Syf2 0.420 7.090 6.686 6.69E-07 3.31E-06 5.251 1.34 
Syncrip 0.570 6.547 8.564 9.77E-09 8.13E-08 9.563 1.48 
Syncrip 0.576 6.514 3.016 6.00E-03 1.17E-02 -3.823 1.49 
Sypl -0.267 7.000 -2.909 7.73E-03 1.48E-02 -4.065 -1.20 
Taldo1 -0.282 8.276 -5.254 2.23E-05 7.76E-05 1.701 -1.22 
Tbc1d13 0.426 6.269 6.912 3.93E-07 2.07E-06 5.793 1.34 
Tbc1d20 1.103 7.320 19.587 3.36E-16 3.55E-14 27.120 2.15 
Tbpl1 0.951 7.435 14.437 2.79E-13 8.63E-12 20.278 1.93 
Tcea1 0.530 8.260 12.080 1.19E-11 2.16E-10 16.433 1.44 
Tceal8 -0.419 6.586 -9.549 1.28E-09 1.33E-08 11.643 -1.34 
Tcf19 -0.464 5.912 -8.070 2.84E-08 2.02E-07 8.473 -1.38 
Tecr -0.435 8.225 -6.194 2.18E-06 9.71E-06 4.049 -1.35 
Tes -0.323 7.629 -5.424 1.46E-05 5.34E-05 2.128 -1.25 
Tes -0.276 6.550 -5.693 7.46E-06 2.93E-05 2.805 -1.21 
Tfb2m 0.844 7.005 16.628 1.29E-14 6.25E-13 23.415 1.80 
TFPI -0.453 7.291 -5.650 8.31E-06 3.23E-05 2.697 -1.37 
Tgm2 -0.565 7.080 -9.326 2.01E-09 2.00E-08 11.182 -1.48 
Tgoln2 -0.532 6.450 -6.375 1.41E-06 6.55E-06 4.496 -1.45 
Tgoln2 -0.493 7.676 -7.228 1.88E-07 1.08E-06 6.542 -1.41 
Thbd -0.988 7.746 -11.413 3.81E-11 5.95E-10 15.243 -1.98 
Thoc7 0.287 7.681 5.420 1.47E-05 5.39E-05 2.118 1.22 
Timm10 0.600 7.656 10.848 1.06E-10 1.52E-09 14.195 1.52 
Timm17a 0.868 7.349 19.160 5.50E-16 5.07E-14 26.618 1.82 
Timm50 0.431 7.608 8.751 6.57E-09 5.70E-08 9.969 1.35 
Timp1 -0.438 6.932 -6.440 1.20E-06 5.68E-06 4.654 -1.35 
Timp2 0.320 8.474 4.629 1.08E-04 3.24E-04 0.117 1.25 
Timp2 0.399 7.474 5.164 2.80E-05 9.51E-05 1.472 1.32 
Tinagl1 -1.504 6.534 -13.304 1.59E-12 3.76E-11 18.496 -2.84 
Tiprl 0.983 7.485 14.908 1.40E-13 4.82E-12 20.984 1.98 
Tjp2 -0.448 6.785 -8.720 7.03E-09 6.04E-08 9.900 -1.36 
Tkt -0.737 6.373 -5.275 2.12E-05 7.41E-05 1.753 -1.67 
Tkt -0.725 6.994 -16.050 2.80E-14 1.21E-12 22.623 -1.65 
Tm9sf4 0.394 5.793 6.807 5.03E-07 2.59E-06 5.542 1.31 
Tmbim6 -0.344 8.960 -3.078 5.17E-03 1.03E-02 -3.681 -1.27 
Tmco1 0.900 7.160 20.586 1.09E-16 1.35E-14 28.256 1.87 
Tmed3 -0.621 6.990 -12.967 2.73E-12 5.98E-11 17.943 -1.54 
Tmed5 0.341 9.161 8.367 1.49E-08 1.17E-07 9.131 1.27 
Tmem101 0.737 6.466 8.848 5.36E-09 4.75E-08 10.177 1.67 
Tmem109 -0.502 6.566 -9.636 1.08E-09 1.15E-08 11.819 -1.42 
Tmem111 0.312 7.013 5.628 8.76E-06 3.38E-05 2.643 1.24 
Tmem14c -0.289 9.909 -6.625 7.74E-07 3.77E-06 5.103 -1.22 
Tmem150a -0.585 6.896 -8.471 1.19E-08 9.68E-08 9.361 -1.50 
Tmem156 0.661 7.139 11.548 3.00E-11 4.93E-10 15.488 1.58 
Tmem158 -0.673 6.933 -6.880 4.24E-07 2.22E-06 5.716 -1.59 
Tmem167 0.419 7.216 6.438 1.21E-06 5.70E-06 4.649 1.34 
Tmem167b 0.382 6.863 8.553 1.00E-08 8.25E-08 9.540 1.30 
Tmem183a 0.503 6.350 8.888 4.94E-09 4.42E-08 10.262 1.42 
Tmem183a 0.701 6.182 13.378 1.41E-12 3.43E-11 18.616 1.63 
Tmem189 -0.405 6.827 -5.572 1.01E-05 3.83E-05 2.501 -1.32 
Tmem223 -0.411 7.260 -6.039 3.18E-06 1.36E-05 3.668 -1.33 
Tmem30a -0.336 6.995 -3.224 3.64E-03 7.61E-03 -3.345 -1.26 
Tmem38b 0.391 6.934 6.744 5.83E-07 2.96E-06 5.390 1.31 
Tmem49 -0.325 6.244 -4.073 4.42E-04 1.15E-03 -1.283 -1.25 
Tmem55b -0.364 7.431 -6.726 6.09E-07 3.06E-06 5.347 -1.29 
Tmem60 0.465 6.952 8.059 2.91E-08 2.06E-07 8.448 1.38 
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TMEM66 0.391 8.790 10.826 1.10E-10 1.57E-09 14.155 1.31 
Tnfaip3 -0.814 5.235 -8.895 4.87E-09 4.38E-08 10.276 -1.76 
Tnfrsf21 -1.115 7.387 -15.724 4.38E-14 1.77E-12 22.166 -2.17 
Tnfsf14 -0.880 7.330 -16.040 2.84E-14 1.21E-12 22.609 -1.84 
Tnip1 -0.622 6.401 -8.427 1.31E-08 1.05E-07 9.265 -1.54 
Tnks2 0.320 6.639 6.319 1.61E-06 7.44E-06 4.359 1.25 
Tollip 0.323 6.477 4.865 5.96E-05 1.88E-04 0.714 1.25 
Tomm20l 0.520 7.636 10.638 1.56E-10 2.11E-09 13.797 1.43 
Top1 -0.303 7.654 -4.434 1.78E-04 5.11E-04 -0.378 -1.23 
Tpm1 -0.296 7.136 -6.606 8.09E-07 3.93E-06 5.058 -1.23 
Tpp1 -0.481 7.300 -10.559 1.81E-10 2.38E-09 13.647 -1.40 
Tpr 0.565 6.127 8.208 2.10E-08 1.57E-07 8.780 1.48 
Tprgl -0.353 6.781 -5.823 5.41E-06 2.20E-05 3.131 -1.28 
Tpst1 -0.470 6.787 -11.131 6.32E-11 9.46E-10 14.726 -1.39 
Tpx2 0.732 6.219 7.859 4.53E-08 2.98E-07 7.997 1.66 
Tram1 -0.342 6.401 -4.314 2.41E-04 6.70E-04 -0.679 -1.27 
Tram1 -0.293 7.603 -7.064 2.76E-07 1.52E-06 6.154 -1.23 
Trap1 0.335 6.783 4.095 4.19E-04 1.10E-03 -1.229 1.26 
Trappc4 0.566 7.791 10.196 3.61E-10 4.30E-09 12.940 1.48 
Trib3 0.847 5.604 5.968 3.79E-06 1.60E-05 3.491 1.80 
Trib3 1.125 8.754 24.110 2.98E-18 6.70E-16 31.877 2.18 
Trib3 1.202 5.753 8.844 5.42E-09 4.78E-08 10.167 2.30 
Trim44 0.368 6.784 3.070 5.27E-03 1.05E-02 -3.700 1.29 
Trim44 0.390 6.505 8.570 9.64E-09 8.04E-08 9.577 1.31 
Trmt6 0.773 6.854 14.144 4.33E-13 1.25E-11 19.828 1.71 
Trub1 0.662 7.328 16.419 1.70E-14 7.94E-13 23.131 1.58 
Tsc22d1 -0.317 10.051 -4.409 1.89E-04 5.40E-04 -0.440 -1.25 
Tsc22d3 0.490 6.584 9.457 1.54E-09 1.57E-08 11.454 1.40 
Tsen15 0.926 7.360 25.323 9.65E-19 2.89E-16 33.004 1.90 
Tspan31 -0.416 7.093 -4.213 3.11E-04 8.41E-04 -0.934 -1.33 
Tspan4 -0.413 6.391 -7.281 1.67E-07 9.70E-07 6.665 -1.33 
TSPYL1 -0.270 8.138 -4.104 4.09E-04 1.07E-03 -1.205 -1.21 
Tuba1c -0.511 9.068 -10.598 1.68E-10 2.24E-09 13.721 -1.42 
Tubb2c -0.610 8.450 -12.177 1.01E-11 1.90E-10 16.602 -1.53 
Tubb5 -0.713 7.745 -11.131 6.32E-11 9.46E-10 14.726 -1.64 
Tubb6 -0.570 7.128 -14.343 3.21E-13 9.68E-12 20.134 -1.48 
Twistnb 0.266 7.652 3.291 3.10E-03 6.57E-03 -3.188 1.20 
Txndc15 0.329 6.914 8.509 1.10E-08 8.98E-08 9.443 1.26 
Txnip 0.558 8.976 7.926 3.90E-08 2.63E-07 8.148 1.47 
Txnl4a 0.266 8.328 6.247 1.92E-06 8.71E-06 4.180 1.20 
Tyms -0.910 8.010 -11.629 2.60E-11 4.35E-10 15.634 -1.88 
Uap1 0.280 6.881 4.536 1.37E-04 4.01E-04 -0.118 1.21 
Uap1l1 -1.163 6.485 -12.979 2.68E-12 5.90E-11 17.964 -2.24 
Uba5 -0.334 7.149 -7.140 2.31E-07 1.30E-06 6.334 -1.26 
Ubash3b -0.544 8.046 -13.292 1.62E-12 3.81E-11 18.476 -1.46 
Ube2a 0.316 7.184 2.917 7.58E-03 1.46E-02 -4.046 1.24 
UBE2D4 0.316 6.665 5.181 2.68E-05 9.15E-05 1.516 1.24 
Ube2f 0.276 6.835 6.701 6.47E-07 3.21E-06 5.285 1.21 
Ube2i 0.313 7.595 6.764 5.57E-07 2.84E-06 5.438 1.24 
Ube2j2 0.320 7.348 7.134 2.34E-07 1.31E-06 6.320 1.25 
Ube2s 0.499 7.516 6.063 3.00E-06 1.29E-05 3.726 1.41 
Ube4a -0.365 7.131 -6.957 3.54E-07 1.89E-06 5.900 -1.29 
Ubiad1 0.568 6.641 10.423 2.34E-10 2.92E-09 13.384 1.48 
Ubl3 0.526 7.629 7.303 1.59E-07 9.26E-07 6.717 1.44 
Ubl3 0.623 6.206 11.780 2.00E-11 3.44E-10 15.905 1.54 
Ubqln4 0.267 6.593 2.840 9.08E-03 1.70E-02 -4.218 1.20 
UBXN4 0.442 7.191 6.648 7.32E-07 3.59E-06 5.159 1.36 
Ubxn4 0.700 7.247 12.587 5.09E-12 1.06E-10 17.306 1.62 
Uchl5 0.695 6.364 7.417 1.22E-07 7.33E-07 6.982 1.62 
Uck2 0.892 6.008 13.899 6.28E-13 1.75E-11 19.447 1.86 
Uck2 1.034 6.716 9.662 1.02E-09 1.10E-08 11.873 2.05 
Ufd1l 0.318 8.108 7.057 2.80E-07 1.54E-06 6.138 1.25 
Ugcg -0.598 6.257 -6.860 4.44E-07 2.32E-06 5.667 -1.51 
Uggt1 0.265 7.043 5.832 5.29E-06 2.16E-05 3.153 1.20 
Ugt1a1 -0.364 10.340 -8.226 2.02E-08 1.53E-07 8.821 -1.29 
Unc13a 0.329 8.035 3.923 6.46E-04 1.62E-03 -1.656 1.26 
Uqcc -0.300 7.071 -6.586 8.49E-07 4.10E-06 5.009 -1.23 
Uso1 -0.399 6.539 -5.910 4.36E-06 1.82E-05 3.348 -1.32 
Usp19 0.291 6.555 5.715 7.06E-06 2.79E-05 2.861 1.22 
Usp24 0.379 6.789 8.042 3.02E-08 2.12E-07 8.410 1.30 
Usp4 -0.389 6.466 -5.628 8.77E-06 3.38E-05 2.642 -1.31 
Usp46 0.362 6.354 5.387 1.60E-05 5.82E-05 2.037 1.29 
Vamp3 0.321 8.124 8.438 1.28E-08 1.03E-07 9.287 1.25 
Vamp3 0.373 7.446 7.131 2.36E-07 1.32E-06 6.313 1.30 
Vamp8 -0.313 7.162 -5.490 1.23E-05 4.59E-05 2.296 -1.24 
VAPA 0.366 8.901 10.361 2.63E-10 3.21E-09 13.264 1.29 
Vapb -0.321 8.100 -3.811 8.56E-04 2.08E-03 -1.934 -1.25 
Vasn 0.310 6.546 2.744 1.13E-02 2.08E-02 -4.427 1.24 
Vasn 0.567 7.151 14.651 2.03E-13 6.69E-12 20.601 1.48 
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Vdac2 -0.282 8.821 -6.549 9.28E-07 4.45E-06 4.918 -1.22 
Vldlr -0.441 6.836 -6.411 1.29E-06 6.05E-06 4.582 -1.36 
Vnn1 -1.275 6.056 -23.297 6.54E-18 1.38E-15 31.090 -2.42 
VPS4B 0.514 7.605 10.985 8.25E-11 1.21E-09 14.453 1.43 
Vwa5a -0.531 7.095 -10.359 2.65E-10 3.21E-09 13.259 -1.44 
Wasl 0.300 6.738 5.018 4.05E-05 1.33E-04 1.102 1.23 
Wdr1 -0.702 8.251 -7.181 2.10E-07 1.19E-06 6.431 -1.63 
Wdr1 -0.620 6.551 -13.091 2.23E-12 4.98E-11 18.149 -1.54 
Wdr26 0.918 6.370 14.980 1.26E-13 4.47E-12 21.090 1.89 
Wdr74 0.273 6.571 4.999 4.25E-05 1.39E-04 1.053 1.21 
Wdyhv1 -0.490 7.392 -9.733 8.90E-10 9.75E-09 12.016 -1.40 
Wdyhv1 -0.369 6.805 -3.728 1.05E-03 2.50E-03 -2.138 -1.29 
Whsc1 0.597 6.747 7.150 2.26E-07 1.27E-06 6.357 1.51 
Wnk1 0.307 7.241 2.390 2.51E-02 4.26E-02 -5.168 1.24 
Wsb1 0.349 6.023 5.282 2.08E-05 7.30E-05 1.771 1.27 
Xbp1 -0.383 7.896 -6.930 3.77E-07 1.99E-06 5.835 -1.30 
Xiap -0.293 6.328 -4.841 6.32E-05 1.99E-04 0.655 -1.23 
Xpo6 0.422 6.739 5.349 1.76E-05 6.34E-05 1.941 1.34 
Xpot -0.453 8.618 -7.732 6.00E-08 3.87E-07 7.708 -1.37 
Xrcc5 -0.263 6.430 -5.278 2.10E-05 7.36E-05 1.760 -1.20 
Ybx1 0.287 11.304 6.253 1.89E-06 8.58E-06 4.196 1.22 
Yif1a -0.396 6.830 -6.204 2.13E-06 9.50E-06 4.075 -1.32 
Yipf1 0.445 6.174 7.988 3.40E-08 2.36E-07 8.288 1.36 
Ykt6 0.419 6.652 9.199 2.60E-09 2.49E-08 10.918 1.34 
Yme1l1 -0.431 8.144 -4.925 5.12E-05 1.64E-04 0.867 -1.35 
Ypel5 0.288 6.204 4.176 3.41E-04 9.16E-04 -1.027 1.22 
Ywhab -0.429 6.224 -3.111 4.79E-03 9.64E-03 -3.607 -1.35 
Zc3hav1 0.511 7.214 9.468 1.51E-09 1.55E-08 11.477 1.43 
Zfand5 0.337 7.866 5.946 3.99E-06 1.67E-05 3.437 1.26 
Zfp207 -0.464 7.869 -5.172 2.74E-05 9.33E-05 1.493 -1.38 
Zfp207 -0.364 7.955 -8.123 2.53E-08 1.84E-07 8.591 -1.29 
Zfp259 0.467 6.408 7.750 5.77E-08 3.74E-07 7.748 1.38 
ZFP36L1 -0.276 8.280 -4.644 1.04E-04 3.14E-04 0.154 -1.21 
Zfp36l2 -0.497 7.753 -8.363 1.50E-08 1.18E-07 9.124 -1.41 
ZMYND11 0.494 7.803 13.883 6.44E-13 1.75E-11 19.420 1.41 
Zmynd19 0.264 7.078 6.583 8.55E-07 4.12E-06 5.001 1.20 
Zranb1 0.334 7.102 6.207 2.12E-06 9.48E-06 4.082 1.26 
Zyx -0.435 7.962 -6.799 5.13E-07 2.63E-06 5.521 -1.35 
 
 383 
5.2.11 T(S)2 v pcDNA(S) gene list 
 
Gene ID logFC AveExpr t P.Value adj.P.Val B Fold Change 
40788 -0.739 8.571 -7.012 3.11E-07 2.30E-06 6.074 -1.67 
40790 0.537 5.984 6.086 2.84E-06 1.67E-05 3.828 1.45 
0610037P05Rik 0.268 6.611 5.629 8.75E-06 4.68E-05 2.689 1.20 
0610039K10Rik 0.372 8.116 8.228 2.01E-08 1.97E-07 8.868 1.29 
1110005A03Rik 0.339 6.854 5.607 9.24E-06 4.88E-05 2.634 1.26 
1700020I14Rik 0.281 8.162 6.601 8.19E-07 5.59E-06 5.089 1.21 
1810022C23Rik 0.415 6.867 7.963 3.59E-08 3.20E-07 8.275 1.33 
1810031K17Rik -0.650 6.408 -5.704 7.27E-06 3.97E-05 2.877 -1.57 
2010106G01Rik 0.574 8.362 6.690 6.63E-07 4.61E-06 5.305 1.49 
2010106G01Rik 0.655 7.487 2.937 7.24E-03 1.71E-02 -3.955 1.58 
2310001A20Rik -0.360 7.257 -6.422 1.26E-06 8.19E-06 4.653 -1.28 
2310035C23Rik -0.266 6.446 -5.309 1.95E-05 9.41E-05 1.883 -1.20 
2610030H06Rik 0.487 7.724 7.547 9.11E-08 7.47E-07 7.325 1.40 
2700029M09Rik 1.042 6.966 21.010 6.88E-17 1.03E-14 28.735 2.06 
2700060E02Rik 0.472 9.852 12.365 7.36E-12 1.77E-10 16.964 1.39 
2700094K13Rik -0.395 6.301 -7.734 5.98E-08 5.11E-07 7.755 -1.31 
2810004N23Rik 0.273 6.302 4.029 4.95E-04 1.64E-03 -1.347 1.21 
2810025M15Rik -0.804 6.900 -14.566 2.30E-13 7.95E-12 20.503 -1.75 
2810482I07Rik -0.558 6.348 -9.379 1.80E-09 2.26E-08 11.334 -1.47 
2900064A13Rik 0.404 8.255 9.464 1.52E-09 1.95E-08 11.508 1.32 
2900097C17Rik 0.327 9.676 6.726 6.08E-07 4.25E-06 5.391 1.25 
4930539H15Rik 0.284 6.597 6.419 1.27E-06 8.21E-06 4.647 1.22 
5430437P03Rik 0.272 6.759 4.263 2.74E-04 9.82E-04 -0.763 1.21 
5830485P09Rik -0.290 7.542 -5.583 9.82E-06 5.13E-05 2.573 -1.22 
5930416I19Rik 0.268 6.436 4.860 6.03E-05 2.54E-04 0.747 1.20 
6330406I15Rik 0.299 8.622 4.707 8.88E-05 3.61E-04 0.359 1.23 
6430548M08Rik 2.243 5.381 31.992 4.28E-21 2.56E-18 38.322 4.73 
9130221J17Rik -0.374 9.549 -9.432 1.62E-09 2.06E-08 11.443 -1.30 
9530053H05Rik -1.185 10.002 -20.524 1.17E-16 1.50E-14 28.201 -2.27 
A330042M18Rik 0.833 7.205 13.045 2.41E-12 6.60E-11 18.107 1.78 
A330042M18Rik 0.945 6.806 17.922 2.45E-15 1.69E-13 25.126 1.93 
A430057M04Rik 0.307 6.280 4.568 1.26E-04 4.91E-04 0.007 1.24 
A830039H05Rik -0.350 8.012 -6.800 5.12E-07 3.62E-06 5.567 -1.27 
Abhd6 -0.878 6.783 -11.178 5.80E-11 1.11E-09 14.850 -1.84 
Acadl -0.741 7.741 -14.817 1.59E-13 5.72E-12 20.879 -1.67 
Acat2 -0.990 6.811 -14.983 1.25E-13 4.59E-12 21.125 -1.99 
Aco1 -0.349 6.759 -10.839 1.08E-10 1.92E-09 14.217 -1.27 
Acot9 -0.416 6.777 -9.313 2.06E-09 2.55E-08 11.197 -1.33 
Adam23 -0.810 7.260 -13.033 2.45E-12 6.67E-11 18.087 -1.75 
Adam23 -0.771 7.575 -12.121 1.11E-11 2.51E-10 16.540 -1.71 
Adh5 0.360 9.619 4.923 5.14E-05 2.20E-04 0.908 1.28 
Adh5 0.464 8.532 3.417 2.28E-03 6.28E-03 -2.844 1.38 
Adi1 0.356 6.996 5.108 3.22E-05 1.47E-04 1.377 1.28 
Ado 0.431 6.943 7.455 1.12E-07 9.08E-07 7.113 1.35 
Ado 0.519 7.572 12.920 2.94E-12 7.84E-11 17.900 1.43 
Adss 0.825 8.642 12.739 3.96E-12 1.02E-10 17.597 1.77 
Adss 0.851 7.645 16.783 1.05E-14 5.10E-13 23.648 1.80 
Aftph 0.293 7.139 4.079 4.37E-04 1.48E-03 -1.224 1.23 
Agrn -0.574 7.203 -12.067 1.22E-11 2.72E-10 16.447 -1.49 
Ahctf1 0.455 6.293 5.444 1.39E-05 6.93E-05 2.225 1.37 
Ahnak -0.479 8.479 -6.384 1.38E-06 8.86E-06 4.561 -1.39 
Aida 0.498 6.309 3.083 5.12E-03 1.27E-02 -3.625 1.41 
Aig1 -0.673 6.487 -8.862 5.22E-09 5.91E-08 10.246 -1.59 
Airn 0.533 6.764 9.512 1.38E-09 1.78E-08 11.607 1.45 
Ak2 0.424 7.391 3.241 3.49E-03 9.11E-03 -3.257 1.34 
Ak2 0.452 9.209 8.387 1.43E-08 1.45E-07 9.218 1.37 
Akap12 0.548 7.889 8.218 2.06E-08 2.00E-07 8.845 1.46 
Akt3 0.352 5.980 5.867 4.86E-06 2.74E-05 3.284 1.28 
Amd1 0.977 7.422 9.738 8.81E-10 1.20E-08 12.066 1.97 
Amd2 0.910 8.027 10.592 1.70E-10 2.92E-09 13.748 1.88 
Anapc11 -0.666 7.726 -6.744 5.83E-07 4.09E-06 5.434 -1.59 
Ankrd10 0.405 6.403 5.717 7.03E-06 3.86E-05 2.910 1.32 
Ankrd13c 0.390 7.255 9.402 1.72E-09 2.18E-08 11.381 1.31 
Anln -1.184 6.950 -10.261 3.19E-10 4.94E-09 13.106 -2.27 
Anxa1 -0.365 10.378 -5.063 3.61E-05 1.61E-04 1.262 -1.29 
Anxa2 -0.810 9.836 -5.305 1.96E-05 9.47E-05 1.874 -1.75 
Anxa2 -0.793 10.669 -11.332 4.40E-11 8.69E-10 15.133 -1.73 
Anxa4 -0.306 7.155 -5.337 1.81E-05 8.80E-05 1.954 -1.24 
Apeh 0.271 6.410 4.317 2.39E-04 8.65E-04 -0.626 1.21 
App 0.384 10.319 8.945 4.39E-09 5.09E-08 10.424 1.30 
App 0.493 8.605 5.099 3.30E-05 1.50E-04 1.353 1.41 
App 0.553 6.325 2.420 2.35E-02 4.75E-02 -5.060 1.47 
Arf2 -0.594 6.235 -8.331 1.61E-08 1.61E-07 9.094 -1.51 
Arhgap18 0.504 6.623 5.029 3.93E-05 1.73E-04 1.176 1.42 
Arhgap18 0.508 7.448 6.550 9.27E-07 6.25E-06 4.964 1.42 
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Arhgap18 0.667 7.541 7.666 6.96E-08 5.83E-07 7.600 1.59 
Arhgap18 0.703 6.699 3.102 4.88E-03 1.22E-02 -3.580 1.63 
Arhgap21 -0.757 7.070 -11.983 1.41E-11 3.10E-10 16.300 -1.69 
Arhgap25 -1.459 6.665 -17.528 4.01E-15 2.40E-13 24.625 -2.75 
Arhgdia -0.617 7.280 -4.309 2.44E-04 8.81E-04 -0.647 -1.53 
Arl2bp 0.298 7.421 5.000 4.23E-05 1.85E-04 1.102 1.23 
Arl6ip1 -0.423 8.692 -7.364 1.38E-07 1.10E-06 6.903 -1.34 
Arl6ip4 0.364 6.141 5.449 1.37E-05 6.86E-05 2.237 1.29 
Arl6ip5 0.289 7.904 6.874 4.30E-07 3.09E-06 5.745 1.22 
Arpc2 -0.852 10.069 -18.651 1.01E-15 8.21E-14 26.027 -1.81 
Arpp19 -0.443 6.929 -7.887 4.25E-08 3.71E-07 8.103 -1.36 
Asf1b -0.782 5.939 -9.324 2.02E-09 2.51E-08 11.218 -1.72 
Aspm -1.165 6.112 -17.770 2.96E-15 1.85E-13 24.934 -2.24 
Atad2 -0.347 6.552 -3.903 6.79E-04 2.19E-03 -1.659 -1.27 
Atf5 0.325 9.270 2.795 1.01E-02 2.27E-02 -4.269 1.25 
Atic -0.838 6.808 -14.512 2.49E-13 8.43E-12 20.422 -1.79 
Atp1a1 0.270 6.924 3.116 4.72E-03 1.18E-02 -3.547 1.21 
Atp5o 0.289 9.052 6.082 2.86E-06 1.68E-05 3.819 1.22 
Atp6v0e 0.288 6.614 2.764 1.08E-02 2.42E-02 -4.338 1.22 
ATXN7L3B 0.342 6.370 6.852 4.52E-07 3.24E-06 5.694 1.27 
AU014716 0.450 7.565 8.360 1.51E-08 1.53E-07 9.158 1.37 
AU022840 0.339 8.064 6.413 1.28E-06 8.30E-06 4.633 1.27 
Aurka -0.678 6.331 -8.626 8.57E-09 9.25E-08 9.739 -1.60 
Aurkaip1 0.419 8.159 5.637 8.57E-06 4.60E-05 2.710 1.34 
Azin1 0.453 6.442 5.460 1.33E-05 6.69E-05 2.266 1.37 
Azin1 0.543 6.431 7.496 1.02E-07 8.31E-07 7.208 1.46 
B230220B15Rik 0.983 7.506 20.553 1.13E-16 1.50E-14 28.234 1.98 
B3galnt2 0.330 6.763 4.394 1.96E-04 7.28E-04 -0.432 1.26 
B4galt3 0.269 6.562 4.499 1.50E-04 5.74E-04 -0.166 1.21 
Baz1a -0.270 6.516 -3.150 4.35E-03 1.10E-02 -3.470 -1.21 
BC005624 0.336 6.428 3.769 9.50E-04 2.93E-03 -1.990 1.26 
BC017643 -0.691 6.869 -16.368 1.82E-14 8.39E-13 23.088 -1.61 
BCL10 -0.451 8.488 -8.909 4.72E-09 5.44E-08 10.348 -1.37 
Bdnf -0.826 6.480 -15.868 3.59E-14 1.52E-12 22.397 -1.77 
Birc5 -0.932 7.818 -11.548 3.00E-11 6.20E-10 15.525 -1.91 
Bmi1 1.014 6.386 12.226 9.31E-12 2.19E-10 16.723 2.02 
Brp44l 0.531 8.068 11.867 1.72E-11 3.68E-10 16.095 1.45 
Brp44l 0.750 7.208 4.700 9.04E-05 3.66E-04 0.342 1.68 
Btbd1 0.322 7.455 2.827 9.36E-03 2.13E-02 -4.199 1.25 
BTF3L4 0.308 6.571 5.519 1.15E-05 5.92E-05 2.414 1.24 
Bud31 0.277 7.762 4.709 8.85E-05 3.60E-04 0.364 1.21 
C78226 -0.359 7.237 -7.984 3.43E-08 3.08E-07 8.322 -1.28 
C78997 -0.961 6.861 -18.085 2.00E-15 1.47E-13 25.329 -1.95 
Cab39 -0.891 7.933 -17.186 6.21E-15 3.49E-13 24.181 -1.85 
Cab39 -0.778 6.216 -6.797 5.15E-07 3.63E-06 5.562 -1.71 
Cab39 -0.761 7.377 -12.686 4.32E-12 1.08E-10 17.509 -1.69 
Cald1 0.363 7.225 4.093 4.21E-04 1.43E-03 -1.187 1.29 
CAMK2N1 0.539 6.214 7.194 2.04E-07 1.55E-06 6.503 1.45 
Capns1 0.301 7.079 4.671 9.74E-05 3.89E-04 0.267 1.23 
Cat -0.343 8.131 -3.443 2.14E-03 5.92E-03 -2.781 -1.27 
Cav1 -0.581 9.812 -4.686 9.37E-05 3.77E-04 0.307 -1.50 
Cav2 -0.862 7.077 -11.180 5.79E-11 1.11E-09 14.853 -1.82 
Cav2 -0.600 6.234 -8.296 1.74E-08 1.73E-07 9.018 -1.52 
Cbfb 0.340 7.994 5.931 4.14E-06 2.36E-05 3.445 1.27 
Cbx5 -0.441 7.118 -4.261 2.75E-04 9.84E-04 -0.766 -1.36 
Cbx6-Nptxr 0.325 6.780 4.333 2.29E-04 8.33E-04 -0.586 1.25 
Ccdc75 0.336 6.959 4.787 7.24E-05 2.98E-04 0.563 1.26 
Ccl2 -1.741 7.806 -13.088 2.25E-12 6.21E-11 18.177 -3.34 
Ccl25 0.465 6.699 7.925 3.90E-08 3.44E-07 8.190 1.38 
Ccna2 -0.937 6.788 -7.328 1.50E-07 1.18E-06 6.817 -1.91 
Ccnb1 -1.272 7.434 -15.136 1.01E-13 3.84E-12 21.348 -2.41 
Ccnb2 -0.827 6.467 -12.452 6.36E-12 1.57E-10 17.112 -1.77 
Ccnd1 1.098 6.627 12.924 2.92E-12 7.84E-11 17.907 2.14 
Cd109 -0.815 6.836 -8.902 4.80E-09 5.51E-08 10.332 -1.76 
Cd36 2.789 8.162 13.982 5.53E-13 1.71E-11 19.609 6.91 
Cdc20 -0.696 7.231 -7.222 1.91E-07 1.46E-06 6.570 -1.62 
Cdipt 0.412 7.020 6.349 1.50E-06 9.53E-06 4.476 1.33 
Cdk1 -0.275 8.673 -4.292 2.54E-04 9.15E-04 -0.689 -1.21 
Cdk17 -0.367 7.214 -6.004 3.47E-06 1.99E-05 3.625 -1.29 
Cdkn3 -1.109 8.297 -12.828 3.42E-12 8.90E-11 17.747 -2.16 
Cenpa -1.251 7.615 -13.299 1.60E-12 4.61E-11 18.522 -2.38 
Cenpf -0.751 6.632 -9.134 2.97E-09 3.59E-08 10.823 -1.68 
Cenpl -1.161 6.032 -16.722 1.14E-14 5.45E-13 23.567 -2.24 
Cep55 -0.901 6.066 -10.668 1.48E-10 2.59E-09 13.893 -1.87 
Cfl2 0.304 6.863 6.420 1.26E-06 8.20E-06 4.650 1.23 
Cflar -0.404 7.205 -5.128 3.06E-05 1.40E-04 1.427 -1.32 
Chordc1 0.314 6.453 4.386 2.00E-04 7.40E-04 -0.451 1.24 
Cidec 0.457 6.285 9.075 3.36E-09 3.98E-08 10.698 1.37 
Cited2 -0.428 6.419 -4.531 1.39E-04 5.35E-04 -0.087 -1.34 
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Ckap2 -1.028 5.818 -16.800 1.03E-14 5.05E-13 23.671 -2.04 
Ckap5 -0.681 6.097 -8.733 6.84E-09 7.56E-08 9.970 -1.60 
Cks1b -0.489 7.858 -9.806 7.70E-10 1.08E-08 12.204 -1.40 
Clec2e 0.479 5.756 4.540 1.36E-04 5.24E-04 -0.064 1.39 
Clic1 -0.385 8.811 -8.171 2.28E-08 2.19E-07 8.740 -1.31 
Clstn1 0.555 7.732 8.050 2.97E-08 2.71E-07 8.469 1.47 
Clu 0.365 10.477 4.318 2.38E-04 8.63E-04 -0.623 1.29 
Cnn3 -0.450 8.306 -7.989 3.39E-08 3.05E-07 8.333 -1.37 
Cnn3 -0.359 8.547 -9.444 1.58E-09 2.02E-08 11.467 -1.28 
Col12a1 -1.221 6.218 -25.471 8.44E-19 2.76E-16 33.135 -2.33 
Col16a1 0.368 6.726 5.192 2.61E-05 1.22E-04 1.587 1.29 
Col4a3bp -0.329 6.224 -8.273 1.83E-08 1.81E-07 8.966 -1.26 
Col5a1 -0.678 6.209 -10.906 9.52E-11 1.71E-09 14.343 -1.60 
Col5a2 -0.999 7.606 -13.722 8.25E-13 2.49E-11 19.200 -2.00 
Commd3 0.532 7.861 12.690 4.29E-12 1.08E-10 17.514 1.45 
Commd7 0.363 6.618 7.686 6.66E-08 5.60E-07 7.645 1.29 
Copa 0.306 7.525 3.306 2.99E-03 7.97E-03 -3.107 1.24 
Copa 0.398 6.314 8.105 2.63E-08 2.45E-07 8.594 1.32 
Copg -0.282 6.669 -4.586 1.21E-04 4.70E-04 0.053 -1.22 
Cops2 0.370 8.102 5.385 1.61E-05 7.90E-05 2.077 1.29 
Cops8 -0.541 7.245 -10.952 8.75E-11 1.60E-09 14.430 -1.46 
Cpd 0.572 7.815 10.374 2.57E-10 4.16E-09 13.326 1.49 
Creg1 0.471 6.806 4.999 4.24E-05 1.85E-04 1.100 1.39 
Creld2 -0.684 7.396 -9.528 1.34E-09 1.73E-08 11.639 -1.61 
Csda 0.291 10.028 5.700 7.34E-06 3.99E-05 2.867 1.22 
Cse1l -0.676 7.389 -12.816 3.49E-12 9.02E-11 17.727 -1.60 
Csf1 0.376 7.153 6.610 8.01E-07 5.47E-06 5.111 1.30 
Csnk1d -0.355 7.166 -6.118 2.62E-06 1.56E-05 3.908 -1.28 
Csnk2a1 0.387 6.763 3.518 1.78E-03 5.06E-03 -2.601 1.31 
Ctage5 -0.329 8.036 -5.664 8.01E-06 4.33E-05 2.779 -1.26 
Ctbp1 0.351 8.025 6.999 3.21E-07 2.35E-06 6.042 1.28 
Cuedc2 0.412 6.975 6.574 8.74E-07 5.95E-06 5.023 1.33 
Cul3 -0.841 8.127 -18.093 1.98E-15 1.47E-13 25.339 -1.79 
Cul3 -0.829 7.260 -11.250 5.10E-11 9.96E-10 14.982 -1.78 
Cul3 -0.781 6.424 -4.255 2.80E-04 1.00E-03 -0.782 -1.72 
Cxcl1 -1.236 6.634 -14.442 2.77E-13 9.03E-12 20.316 -2.36 
Cyp51 -0.564 9.644 -10.491 2.06E-10 3.46E-09 13.553 -1.48 
Cyp51 -0.518 9.012 -9.125 3.03E-09 3.64E-08 10.803 -1.43 
D5Ertd579e 0.426 6.408 8.853 5.31E-09 6.00E-08 10.228 1.34 
D6Ertd439e -0.524 6.821 -10.951 8.77E-11 1.60E-09 14.428 -1.44 
D830024F11Rik -0.618 7.236 -9.779 8.12E-10 1.13E-08 12.150 -1.54 
Dazap2 0.400 7.914 7.659 7.07E-08 5.88E-07 7.583 1.32 
Dbf4 -0.795 6.260 -10.290 3.02E-10 4.73E-09 13.163 -1.74 
Dbi -0.316 8.412 -5.088 3.39E-05 1.53E-04 1.326 -1.24 
Dcaf13 0.313 7.411 7.426 1.20E-07 9.67E-07 7.046 1.24 
Dctpp1 -0.468 7.125 -7.651 7.20E-08 5.98E-07 7.565 -1.38 
Ddhd2 0.399 7.529 8.875 5.08E-09 5.77E-08 10.275 1.32 
DDHD2 1.084 9.554 4.615 1.12E-04 4.41E-04 0.126 2.12 
Ddit3 -0.616 6.496 -6.457 1.16E-06 7.60E-06 4.738 -1.53 
Ddx3x 0.375 6.627 2.562 1.72E-02 3.62E-02 -4.769 1.30 
Ddx41 0.377 6.481 4.308 2.45E-04 8.83E-04 -0.650 1.30 
Ddx50 -0.361 7.623 -8.250 1.92E-08 1.89E-07 8.916 -1.28 
Ddx6 0.291 6.386 4.113 4.00E-04 1.38E-03 -1.137 1.22 
Degs1 -0.372 6.778 -8.425 1.32E-08 1.36E-07 9.301 -1.29 
Degs1 0.417 8.459 5.589 9.66E-06 5.06E-05 2.590 1.33 
Dek -0.292 7.745 -4.717 8.65E-05 3.53E-04 0.386 -1.22 
DLGAP5 -1.225 6.521 -13.266 1.69E-12 4.82E-11 18.467 -2.34 
Dnajb2 -1.036 6.280 -9.761 8.41E-10 1.16E-08 12.114 -2.05 
Dnajc15 0.298 7.484 5.459 1.33E-05 6.70E-05 2.263 1.23 
Dnajc3 -0.423 6.786 -8.243 1.95E-08 1.92E-07 8.901 -1.34 
Dnajc3 -0.398 6.788 -5.198 2.57E-05 1.20E-04 1.602 -1.32 
Dnpep -0.997 7.288 -12.685 4.33E-12 1.08E-10 17.506 -2.00 
Dnpep -0.891 6.145 -10.651 1.53E-10 2.65E-09 13.861 -1.85 
Dtymk -0.319 7.027 -5.846 5.12E-06 2.88E-05 3.232 -1.25 
Dus1l -0.334 7.044 -6.500 1.04E-06 6.95E-06 4.843 -1.26 
Dusp1 0.587 6.221 9.101 3.18E-09 3.78E-08 10.754 1.50 
Ebna1bp2 0.296 7.513 5.765 6.24E-06 3.45E-05 3.031 1.23 
Ebna1bp2 0.303 8.826 5.292 2.03E-05 9.75E-05 1.840 1.23 
Ebp -0.875 5.933 -14.507 2.51E-13 8.43E-12 20.415 -1.83 
Ect2 -1.076 7.232 -11.133 6.30E-11 1.19E-09 14.766 -2.11 
Edf1 0.306 8.060 5.133 3.02E-05 1.39E-04 1.440 1.24 
Efnb2 0.342 6.492 5.623 8.87E-06 4.72E-05 2.675 1.27 
Eif4a1 -0.442 9.235 -10.317 2.87E-10 4.58E-09 13.215 -1.36 
Eif4a1 -0.434 8.429 -2.509 1.93E-02 4.02E-02 -4.878 -1.35 
Eif4e2 -0.829 7.044 -22.093 2.20E-17 3.95E-15 29.882 -1.78 
Eif4ebp2 0.365 6.811 5.115 3.17E-05 1.45E-04 1.392 1.29 
Eif4g3 0.399 7.477 5.195 2.59E-05 1.21E-04 1.596 1.32 
Eif5a 0.419 6.847 8.655 8.05E-09 8.74E-08 9.803 1.34 
Eif5a 0.547 9.394 4.432 1.79E-04 6.69E-04 -0.337 1.46 
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Emb 0.331 8.004 9.241 2.39E-09 2.94E-08 11.047 1.26 
Emp1 -0.928 7.772 -18.586 1.09E-15 8.69E-14 25.948 -1.90 
Eng 0.380 7.236 3.254 3.39E-03 8.87E-03 -3.228 1.30 
Ephx1 0.624 8.644 8.401 1.38E-08 1.42E-07 9.249 1.54 
Ephx1 0.783 7.673 5.051 3.72E-05 1.65E-04 1.232 1.72 
Eprs 0.401 8.814 10.770 1.22E-10 2.16E-09 14.087 1.32 
Eprs 0.552 6.781 4.453 1.69E-04 6.40E-04 -0.282 1.47 
Eps8 -0.359 7.562 -4.466 1.64E-04 6.21E-04 -0.250 -1.28 
Ercc1 0.588 6.529 7.709 6.32E-08 5.35E-07 7.698 1.50 
Erlec1 -0.304 6.948 -7.789 5.28E-08 4.54E-07 7.881 -1.23 
Erp44 -0.294 7.100 -6.131 2.54E-06 1.52E-05 3.939 -1.23 
Esd -0.599 8.915 -14.548 2.36E-13 8.08E-12 20.477 -1.51 
Ethe1 0.359 7.237 5.141 2.96E-05 1.37E-04 1.460 1.28 
EWSR1 0.526 7.376 14.325 3.30E-13 1.05E-11 20.137 1.44 
Ext2 0.468 6.990 9.064 3.43E-09 4.05E-08 10.676 1.38 
Fam100b 0.345 6.914 4.836 6.41E-05 2.68E-04 0.686 1.27 
Fam107b 0.456 6.765 8.889 4.93E-09 5.63E-08 10.304 1.37 
Fam125a 0.390 6.719 6.087 2.83E-06 1.67E-05 3.830 1.31 
Fam125b 0.435 6.716 8.428 1.31E-08 1.36E-07 9.308 1.35 
Fam129c 0.366 7.400 4.584 1.21E-04 4.72E-04 0.048 1.29 
Fam134a -0.967 7.086 -10.162 3.86E-10 5.85E-09 12.912 -1.96 
Fam32a 0.297 6.710 5.446 1.38E-05 6.91E-05 2.229 1.23 
Fam32a 0.300 7.017 6.151 2.42E-06 1.46E-05 3.988 1.23 
Farp2 -0.647 6.968 -11.914 1.59E-11 3.43E-10 16.178 -1.57 
Farsb -0.991 7.210 -21.287 5.11E-17 7.98E-15 29.034 -1.99 
Farsb -0.938 7.344 -19.105 5.87E-16 5.02E-14 26.571 -1.92 
Fasn -1.002 6.330 -10.031 4.96E-10 7.36E-09 12.654 -2.00 
Fat1 -0.476 8.629 -9.397 1.74E-09 2.19E-08 11.369 -1.39 
Fbxo28 0.598 7.050 11.624 2.62E-11 5.55E-10 15.662 1.51 
Fbxo6 0.485 7.635 5.822 5.42E-06 3.04E-05 3.173 1.40 
Fbxo8 1.093 6.542 22.105 2.17E-17 3.95E-15 29.894 2.13 
Fcgrt 0.818 6.491 11.962 1.46E-11 3.20E-10 16.263 1.76 
Fdps -0.802 8.124 -13.705 8.48E-13 2.54E-11 19.172 -1.74 
Fez2 -0.464 7.112 -10.382 2.53E-10 4.14E-09 13.342 -1.38 
Fh1 0.292 8.282 5.721 6.96E-06 3.83E-05 2.921 1.22 
Fhl2 -0.288 6.258 -6.555 9.15E-07 6.19E-06 4.977 -1.22 
Fkbp9 -0.369 7.631 -7.151 2.25E-07 1.71E-06 6.403 -1.29 
Flnb -0.295 6.896 -5.473 1.29E-05 6.53E-05 2.296 -1.23 
Fmc1 0.545 9.383 7.416 1.22E-07 9.84E-07 7.024 1.46 
FMNL2 0.478 7.362 7.237 1.85E-07 1.42E-06 6.606 1.39 
Fnip2 0.504 7.370 7.667 6.94E-08 5.82E-07 7.603 1.42 
Foxj3 0.437 7.777 7.897 4.16E-08 3.63E-07 8.126 1.35 
Fry 0.468 7.685 6.712 6.30E-07 4.40E-06 5.356 1.38 
FSTL1 -0.376 8.751 -9.009 3.84E-09 4.48E-08 10.560 -1.30 
Fubp3 0.360 6.446 6.671 6.93E-07 4.80E-06 5.258 1.28 
Fundc1 0.346 6.478 4.070 4.46E-04 1.50E-03 -1.244 1.27 
G3bp2 0.301 8.617 5.633 8.67E-06 4.64E-05 2.699 1.23 
Gaa 0.313 9.198 4.522 1.42E-04 5.46E-04 -0.109 1.24 
Gabarap 0.450 9.365 9.717 9.18E-10 1.24E-08 12.024 1.37 
Gadd45a -0.307 8.855 -4.600 1.16E-04 4.56E-04 0.089 -1.24 
Gadd45b -0.666 6.746 -9.795 7.87E-10 1.10E-08 12.182 -1.59 
Galnt7 0.846 7.466 8.342 1.57E-08 1.58E-07 9.118 1.80 
Gas1 1.367 6.643 14.464 2.68E-13 8.82E-12 20.349 2.58 
Gclm -0.302 9.225 -5.800 5.73E-06 3.19E-05 3.117 -1.23 
Gga2 0.503 8.255 13.232 1.78E-12 5.05E-11 18.412 1.42 
Gga2 0.564 6.153 7.122 2.41E-07 1.82E-06 6.333 1.48 
Ghr 0.551 6.655 8.752 6.57E-09 7.29E-08 10.011 1.46 
Gipc1 0.330 6.525 5.376 1.65E-05 8.05E-05 2.052 1.26 
Glud1 0.297 8.163 5.900 4.48E-06 2.54E-05 3.367 1.23 
Gm10154 -0.283 12.036 -7.704 6.39E-08 5.41E-07 7.686 -1.22 
Gm10259 -0.777 7.512 -12.441 6.49E-12 1.59E-10 17.093 -1.71 
Gm10397 0.633 7.405 12.150 1.06E-11 2.42E-10 16.591 1.55 
Gm11602 -0.961 7.611 -14.384 3.02E-13 9.67E-12 20.228 -1.95 
Gm11602 -0.916 6.581 -6.518 1.00E-06 6.71E-06 4.887 -1.89 
Gm15452 -0.798 8.689 -10.204 3.55E-10 5.45E-09 12.996 -1.74 
Gm3650 0.295 7.214 5.698 7.36E-06 4.00E-05 2.864 1.23 
Gm5506 0.269 9.306 4.847 6.23E-05 2.60E-04 0.715 1.20 
Gm5578 0.617 6.726 11.522 3.14E-11 6.45E-10 15.479 1.53 
Gm5593 -1.134 5.956 -7.965 3.58E-08 3.20E-07 8.278 -2.19 
Gm6158 -0.263 7.472 -5.069 3.56E-05 1.59E-04 1.277 -1.20 
Gm6644 -0.268 9.438 -5.299 1.99E-05 9.59E-05 1.860 -1.20 
Gm6829 0.327 8.199 6.476 1.10E-06 7.32E-06 4.786 1.25 
Gm7859 0.300 6.920 8.440 1.27E-08 1.32E-07 9.335 1.23 
Gm9178 0.362 6.970 6.084 2.85E-06 1.68E-05 3.824 1.29 
Gm9803 0.331 8.011 6.314 1.63E-06 1.02E-05 4.391 1.26 
Gm9816 -0.535 7.596 -7.039 2.92E-07 2.17E-06 6.138 -1.45 
Gmcl1 0.292 6.620 4.427 1.81E-04 6.76E-04 -0.350 1.22 
Gnpat -0.435 6.582 -7.942 3.76E-08 3.34E-07 8.228 -1.35 
Gpc6 -1.653 3.584 -19.724 2.87E-16 2.64E-14 27.296 -3.14 
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Gpd2 -0.302 6.879 -3.975 5.67E-04 1.85E-03 -1.483 -1.23 
Gpnmb 1.279 5.966 20.289 1.52E-16 1.88E-14 27.938 2.43 
Gpr56 1.706 6.194 21.723 3.23E-17 5.27E-15 29.496 3.26 
Gstm1 0.685 9.649 9.898 6.43E-10 9.31E-09 12.389 1.61 
Gstm6 0.321 7.960 4.344 2.23E-04 8.14E-04 -0.558 1.25 
Gstm7 0.316 8.876 4.553 1.31E-04 5.08E-04 -0.030 1.25 
Gt(ROSA)26Sor -0.404 6.526 -6.987 3.30E-07 2.41E-06 6.013 -1.32 
Gtf2a2 0.296 8.193 8.237 1.97E-08 1.94E-07 8.888 1.23 
Gtf2h5 0.312 6.911 5.206 2.52E-05 1.18E-04 1.625 1.24 
Gtf2i 0.296 6.845 6.275 1.79E-06 1.12E-05 4.293 1.23 
Guk1 0.393 7.485 7.844 4.67E-08 4.06E-07 8.007 1.31 
Gusb -0.391 6.935 -7.772 5.49E-08 4.71E-07 7.842 -1.31 
Gusb -0.360 7.029 -6.113 2.65E-06 1.58E-05 3.896 -1.28 
Gyg 0.796 8.497 9.732 8.91E-10 1.21E-08 12.054 1.74 
Gypc 0.316 7.466 5.425 1.45E-05 7.25E-05 2.176 1.24 
H2afx -0.638 6.799 -8.080 2.78E-08 2.56E-07 8.538 -1.56 
H2afy 0.479 8.313 11.893 1.64E-11 3.53E-10 16.142 1.39 
H3f3a 0.397 10.382 9.740 8.77E-10 1.20E-08 12.070 1.32 
H3f3a 0.616 10.194 8.114 2.58E-08 2.43E-07 8.613 1.53 
H47 -0.304 6.598 -6.528 9.75E-07 6.56E-06 4.912 -1.23 
Hat1 -0.540 6.594 -7.722 6.14E-08 5.23E-07 7.728 -1.45 
Hbxip 0.383 8.226 7.298 1.60E-07 1.25E-06 6.748 1.30 
Hdac5 0.387 6.214 5.268 2.16E-05 1.03E-04 1.780 1.31 
Hdlbp -0.990 7.276 -21.967 2.50E-17 4.28E-15 29.751 -1.99 
Hdlbp -0.568 6.583 -5.828 5.35E-06 3.01E-05 3.187 -1.48 
Hdlbp -0.464 6.619 -6.914 3.91E-07 2.83E-06 5.840 -1.38 
Heg1 0.309 8.653 5.000 4.24E-05 1.85E-04 1.101 1.24 
Herc2 -0.360 6.883 -6.660 7.13E-07 4.92E-06 5.230 -1.28 
Herpud1 -0.334 6.811 -7.538 9.28E-08 7.60E-07 7.306 -1.26 
Hexim1 0.684 7.032 9.899 6.41E-10 9.31E-09 12.391 1.61 
Hint1 0.279 9.534 6.454 1.16E-06 7.64E-06 4.731 1.21 
Hip1 0.509 6.987 10.089 4.44E-10 6.67E-09 12.768 1.42 
Hist1h2bc 0.318 7.314 3.731 1.05E-03 3.19E-03 -2.084 1.25 
HMGCR -0.886 6.572 -13.215 1.83E-12 5.14E-11 18.385 -1.85 
Hmgcs1 -0.858 6.887 -15.549 5.60E-14 2.23E-12 21.945 -1.81 
Hmgn5 -0.473 8.999 -8.666 7.88E-09 8.60E-08 9.825 -1.39 
Hmox1 -0.342 7.105 -3.958 5.91E-04 1.92E-03 -1.523 -1.27 
Hnrnpa1 -0.447 6.520 -6.694 6.56E-07 4.57E-06 5.314 -1.36 
Hnrnpa3 -0.431 8.503 -4.663 9.94E-05 3.96E-04 0.247 -1.35 
Hnrnpa3 -0.421 9.119 -8.659 8.00E-09 8.71E-08 9.810 -1.34 
Hnrnpk -0.273 9.607 -4.993 4.30E-05 1.87E-04 1.085 -1.21 
Hnrpdl -0.352 6.768 -5.377 1.64E-05 8.04E-05 2.056 -1.28 
Hnrpdl -0.273 6.334 -4.277 2.64E-04 9.48E-04 -0.726 -1.21 
Hprt 0.541 9.127 10.916 9.35E-11 1.69E-09 14.363 1.45 
Hsd17b12 -0.500 7.796 -10.455 2.20E-10 3.65E-09 13.485 -1.41 
Hsp90b1 -0.937 8.375 -4.896 5.51E-05 2.34E-04 0.838 -1.91 
Hsp90b1 -0.847 7.905 -3.830 8.16E-04 2.58E-03 -1.841 -1.80 
Hsp90b1 -0.837 10.245 -13.115 2.15E-12 5.99E-11 18.222 -1.79 
Hspa4 0.295 8.370 5.724 6.92E-06 3.81E-05 2.927 1.23 
Hspa5 -0.808 11.437 -17.244 5.77E-15 3.34E-13 24.256 -1.75 
Hspb8 0.344 7.970 6.999 3.20E-07 2.35E-06 6.044 1.27 
Hyou1 -0.678 6.015 -8.306 1.70E-08 1.70E-07 9.040 -1.60 
Iars 0.484 6.251 2.467 2.12E-02 4.34E-02 -4.964 1.40 
Iars2 0.352 7.066 8.900 4.82E-09 5.51E-08 10.328 1.28 
Iars2 0.384 7.976 10.294 2.99E-10 4.71E-09 13.171 1.31 
IDH1 -0.487 8.313 -6.473 1.11E-06 7.34E-06 4.777 -1.40 
Idi1 -1.011 6.124 -16.937 8.58E-15 4.47E-13 23.853 -2.02 
Ifngr2 -0.304 6.377 -6.655 7.20E-07 4.95E-06 5.220 -1.23 
Il1r1 0.351 6.416 5.049 3.74E-05 1.66E-04 1.227 1.28 
Ildr2 0.315 6.552 6.153 2.41E-06 1.45E-05 3.993 1.24 
IMMP1L 0.295 6.798 4.446 1.72E-04 6.49E-04 -0.301 1.23 
ING1 -0.396 6.587 -8.394 1.40E-08 1.44E-07 9.234 -1.32 
Ing1 -0.329 7.161 -9.195 2.62E-09 3.20E-08 10.950 -1.26 
Irs1 -1.267 6.303 -19.195 5.28E-16 4.63E-14 26.678 -2.41 
Isy1 0.328 7.407 6.941 3.67E-07 2.66E-06 5.906 1.26 
Itgb5 0.339 7.557 3.795 8.91E-04 2.78E-03 -1.927 1.26 
Itih5 0.425 6.180 3.827 8.22E-04 2.60E-03 -1.848 1.34 
Itm2c -0.871 8.920 -16.651 1.25E-14 5.90E-13 23.471 -1.83 
Jak2 -0.489 6.679 -6.825 4.83E-07 3.44E-06 5.627 -1.40 
Jun -0.848 7.869 -11.943 1.51E-11 3.29E-10 16.229 -1.80 
Kif23 -1.123 6.746 -17.364 4.94E-15 2.91E-13 24.413 -2.18 
Kifc1 -0.626 6.589 -9.829 7.36E-10 1.04E-08 12.251 -1.54 
Klc1 -0.310 7.277 -5.619 8.98E-06 4.76E-05 2.663 -1.24 
Klhl5 0.308 7.361 5.771 6.16E-06 3.41E-05 3.044 1.24 
Kpnb1 -0.444 8.159 -8.035 3.06E-08 2.79E-07 8.438 -1.36 
KPNB1 -0.295 7.476 -2.919 7.54E-03 1.76E-02 -3.995 -1.23 
Ktn1 -0.343 7.099 -8.477 1.18E-08 1.23E-07 9.416 -1.27 
Lamp2 0.740 6.487 11.450 3.57E-11 7.21E-10 15.347 1.67 
Lamp3 -0.401 7.710 -7.522 9.64E-08 7.87E-07 7.268 -1.32 
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Lass5 0.424 6.341 6.128 2.56E-06 1.53E-05 3.931 1.34 
Lats2 0.363 7.475 6.022 3.32E-06 1.92E-05 3.670 1.29 
LBR 0.641 7.626 14.911 1.39E-13 5.04E-12 21.018 1.56 
Ldlr -0.661 6.729 -10.559 1.81E-10 3.06E-09 13.684 -1.58 
Lgmn -0.352 9.298 -6.793 5.19E-07 3.66E-06 5.552 -1.28 
LOC100043810 0.375 7.540 4.521 1.42E-04 5.46E-04 -0.110 1.30 
LOC100131826 -0.477 7.320 -5.615 9.05E-06 4.79E-05 2.655 -1.39 
LOC100270747 -0.264 6.813 -4.383 2.02E-04 7.46E-04 -0.460 -1.20 
LOC294154 0.300 5.851 2.411 2.40E-02 4.84E-02 -5.079 1.23 
LOC544737 0.348 7.040 4.848 6.22E-05 2.60E-04 0.716 1.27 
LOC624853 0.330 9.491 2.484 2.04E-02 4.22E-02 -4.931 1.26 
LOC684894 0.288 8.353 5.078 3.48E-05 1.56E-04 1.299 1.22 
LOC685953 2.644 9.130 25.337 9.53E-19 2.85E-16 33.015 6.25 
Lpp 0.274 6.385 3.091 5.01E-03 1.25E-02 -3.605 1.21 
Lpp 0.292 7.853 5.247 2.27E-05 1.08E-04 1.726 1.22 
Lrp10 -0.568 7.803 -7.954 3.67E-08 3.26E-07 8.254 -1.48 
Lrpap1 0.269 7.109 4.215 3.09E-04 1.09E-03 -0.882 1.21 
Lrrc8d -0.355 6.697 -4.236 2.93E-04 1.05E-03 -0.830 -1.28 
Lsm3 -0.421 7.307 -7.601 8.06E-08 6.65E-07 7.451 -1.34 
Lsmd1 0.346 6.667 6.077 2.90E-06 1.70E-05 3.806 1.27 
Ly6e -0.540 7.105 -7.243 1.82E-07 1.40E-06 6.619 -1.45 
Lypla1 0.423 6.729 6.004 3.46E-06 1.99E-05 3.626 1.34 
Lyplal1 0.528 7.767 9.657 1.03E-09 1.37E-08 11.902 1.44 
Macrod1 0.518 6.433 7.933 3.84E-08 3.40E-07 8.206 1.43 
Mad2l1 -0.790 7.100 -12.044 1.27E-11 2.81E-10 16.407 -1.73 
Mad2l1 -0.694 6.292 -5.638 8.54E-06 4.59E-05 2.713 -1.62 
Mafg -0.771 6.127 -8.097 2.67E-08 2.48E-07 8.576 -1.71 
MAMDC2 0.428 7.429 3.707 1.11E-03 3.34E-03 -2.142 1.35 
Man2a1 -0.737 6.504 -10.202 3.57E-10 5.46E-09 12.991 -1.67 
Man2a1 -0.601 6.683 -8.155 2.36E-08 2.24E-07 8.705 -1.52 
Manf -0.947 8.744 -17.171 6.34E-15 3.50E-13 24.161 -1.93 
Map1lc3b 0.275 8.566 8.380 1.45E-08 1.47E-07 9.203 1.21 
Map1lc3b 0.408 8.856 5.660 8.10E-06 4.36E-05 2.767 1.33 
Mapk14 0.372 7.353 10.470 2.14E-10 3.57E-09 13.513 1.29 
Mapk6 -0.347 7.276 -4.799 7.05E-05 2.91E-04 0.591 -1.27 
Mark1 0.941 6.616 20.121 1.83E-16 2.05E-14 27.750 1.92 
Mark3 -0.288 6.635 -6.321 1.60E-06 1.01E-05 4.407 -1.22 
Mat2a 0.266 7.126 3.925 6.43E-04 2.07E-03 -1.605 1.20 
Mbnl2 0.432 8.281 10.127 4.12E-10 6.22E-09 12.844 1.35 
Mbnl2 0.470 7.563 8.213 2.08E-08 2.01E-07 8.833 1.39 
Mbp 0.804 6.692 12.122 1.11E-11 2.51E-10 16.543 1.75 
Mcl1 0.322 7.354 7.660 7.05E-08 5.88E-07 7.587 1.25 
MCM7 0.273 7.318 3.863 7.52E-04 2.40E-03 -1.760 1.21 
Mdfic 0.310 9.142 5.251 2.25E-05 1.07E-04 1.737 1.24 
Mdp1 0.340 6.783 6.482 1.09E-06 7.24E-06 4.799 1.27 
Me1 -0.293 7.376 -6.290 1.73E-06 1.08E-05 4.331 -1.23 
Me1 -0.291 7.716 -4.428 1.80E-04 6.74E-04 -0.346 -1.22 
Mesdc2 -0.398 9.074 -12.293 8.31E-12 1.98E-10 16.839 -1.32 
METTL10 -0.327 8.998 -5.307 1.95E-05 9.43E-05 1.880 -1.25 
Mettl11a 0.289 6.539 4.554 1.31E-04 5.06E-04 -0.027 1.22 
MGC112830 0.530 6.352 9.036 3.64E-09 4.27E-08 10.616 1.44 
Mia3 0.362 8.330 6.643 7.42E-07 5.09E-06 5.190 1.29 
Mitf 0.450 7.306 6.281 1.77E-06 1.10E-05 4.309 1.37 
Mknk2 0.390 6.736 4.373 2.07E-04 7.62E-04 -0.484 1.31 
Mknk2 0.457 6.338 6.507 1.02E-06 6.84E-06 4.862 1.37 
Mll1 -0.268 6.439 -3.503 1.84E-03 5.23E-03 -2.638 -1.20 
Mlycd 0.427 6.291 7.914 4.00E-08 3.52E-07 8.165 1.34 
Mmp14 -0.347 6.141 -3.397 2.39E-03 6.54E-03 -2.889 -1.27 
Mmp9 -0.708 6.731 -11.211 5.47E-11 1.06E-09 14.910 -1.63 
Mosc2 0.814 7.334 19.588 3.35E-16 3.01E-14 27.139 1.76 
Mosc2 1.108 8.107 17.873 2.60E-15 1.73E-13 25.063 2.16 
Mpv17 0.370 7.533 4.030 4.93E-04 1.64E-03 -1.344 1.29 
Mrpl12 -0.291 8.284 -5.907 4.40E-06 2.50E-05 3.384 -1.22 
Mrpl53 0.269 6.945 3.988 5.49E-04 1.81E-03 -1.450 1.21 
Mrps10 0.327 6.973 3.984 5.54E-04 1.82E-03 -1.460 1.25 
Mrps23 0.268 6.974 5.709 7.18E-06 3.92E-05 2.889 1.20 
Msrb2 0.548 6.378 8.262 1.87E-08 1.85E-07 8.942 1.46 
Mta3 0.405 6.286 7.259 1.76E-07 1.36E-06 6.656 1.32 
Mtap1b -0.321 6.862 -6.218 2.06E-06 1.26E-05 4.154 -1.25 
Mtap4 -0.378 6.079 -4.401 1.93E-04 7.17E-04 -0.414 -1.30 
Mtbp -0.335 6.107 -6.346 1.51E-06 9.57E-06 4.468 -1.26 
Mtdh 0.392 7.693 7.644 7.31E-08 6.05E-07 7.550 1.31 
Mthfd2l -0.335 6.000 -5.254 2.23E-05 1.06E-04 1.744 -1.26 
Myc -0.319 9.167 -7.368 1.37E-07 1.09E-06 6.912 -1.25 
Myd88 0.360 6.590 8.712 7.14E-09 7.87E-08 9.926 1.28 
Myl12b -0.589 10.684 -7.341 1.45E-07 1.15E-06 6.849 -1.50 
MYL12B -0.406 11.165 -12.182 1.00E-11 2.34E-10 16.647 -1.33 
Myof -0.580 9.190 -9.996 5.31E-10 7.86E-09 12.584 -1.49 
N6amt2 0.438 6.228 7.339 1.46E-07 1.15E-06 6.844 1.35 
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Ncam1 0.311 5.358 3.453 2.08E-03 5.80E-03 -2.756 1.24 
Ncapd3 -1.396 5.993 -19.804 2.62E-16 2.47E-14 27.388 -2.63 
Ncaph -0.400 6.789 -6.051 3.09E-06 1.80E-05 3.742 -1.32 
Nck2 0.404 6.349 5.105 3.25E-05 1.48E-04 1.368 1.32 
Ndc80 -1.470 6.736 -17.909 2.49E-15 1.69E-13 25.109 -2.77 
Ndufa10 -0.487 6.714 -5.932 4.14E-06 2.36E-05 3.446 -1.40 
Ndufa7 0.283 8.951 7.305 1.58E-07 1.24E-06 6.763 1.22 
Ndufab1 -0.315 6.612 -5.443 1.39E-05 6.93E-05 2.223 -1.24 
Ndufaf2 0.306 7.178 5.619 8.97E-06 4.76E-05 2.664 1.24 
Ndufb9 0.401 10.546 11.456 3.53E-11 7.16E-10 15.359 1.32 
Ndufv2 -0.813 9.165 -15.286 8.11E-14 3.13E-12 21.566 -1.76 
Neat1 -0.531 8.207 -8.099 2.66E-08 2.48E-07 8.580 -1.44 
Neil3 -0.582 7.798 -8.220 2.05E-08 1.99E-07 8.849 -1.50 
Nek2 -0.332 8.036 -5.049 3.74E-05 1.66E-04 1.225 -1.26 
Nfic -0.349 6.666 -4.919 5.20E-05 2.22E-04 0.896 -1.27 
Nfkb2 -0.375 6.057 -3.454 2.08E-03 5.79E-03 -2.755 -1.30 
Nfkbia -1.116 8.243 -18.021 2.17E-15 1.56E-13 25.250 -2.17 
Nfkbia -1.061 8.519 -15.074 1.10E-13 4.15E-12 21.259 -2.09 
Nhp2 0.379 7.341 9.107 3.14E-09 3.76E-08 10.767 1.30 
Nit1 0.432 6.656 5.462 1.32E-05 6.67E-05 2.271 1.35 
Nit2 0.353 7.294 5.238 2.32E-05 1.10E-04 1.706 1.28 
Nme1 0.307 9.016 6.881 4.23E-07 3.04E-06 5.762 1.24 
Nmt1 0.292 8.067 4.691 9.25E-05 3.73E-04 0.320 1.22 
Npc2 -0.276 9.515 -6.056 3.05E-06 1.78E-05 3.754 -1.21 
Nr1h3 0.314 6.661 3.706 1.11E-03 3.35E-03 -2.145 1.24 
Nr2c1 0.525 6.434 10.325 2.82E-10 4.52E-09 13.232 1.44 
Nras -0.273 7.871 -5.414 1.49E-05 7.39E-05 2.149 -1.21 
Nsun5 0.311 6.545 3.578 1.53E-03 4.43E-03 -2.456 1.24 
Nucb2 -0.331 7.514 -6.262 1.85E-06 1.15E-05 4.261 -1.26 
Nudt3 0.408 6.423 4.834 6.43E-05 2.68E-04 0.682 1.33 
Nudt5 0.304 7.630 5.649 8.31E-06 4.47E-05 2.741 1.23 
Nusap1 -1.179 6.996 -14.774 1.70E-13 5.97E-12 20.815 -2.26 
Nvl 0.947 6.210 17.643 3.47E-15 2.12E-13 24.771 1.93 
Oaz1 -0.303 7.862 -4.000 5.32E-04 1.76E-03 -1.419 -1.23 
Oaz1 -0.293 7.602 -5.344 1.78E-05 8.68E-05 1.972 -1.22 
Oaz2 -0.418 6.880 -7.226 1.89E-07 1.45E-06 6.579 -1.34 
Osgep 0.389 6.568 11.245 5.14E-11 9.99E-10 14.974 1.31 
Osmr -0.378 7.659 -5.902 4.45E-06 2.52E-05 3.373 -1.30 
Ostc -0.789 9.604 -17.122 6.75E-15 3.66E-13 24.097 -1.73 
Ostc -0.719 8.595 -10.649 1.53E-10 2.65E-09 13.857 -1.65 
Otub1 0.263 6.529 3.964 5.83E-04 1.90E-03 -1.509 1.20 
Oxr1 -1.437 6.713 -20.580 1.10E-16 1.50E-14 28.263 -2.71 
P4hb -0.559 8.556 -9.159 2.82E-09 3.43E-08 10.876 -1.47 
P4hb -0.517 7.388 -8.489 1.15E-08 1.20E-07 9.441 -1.43 
Palld -0.991 7.134 -20.224 1.63E-16 1.95E-14 27.866 -1.99 
Pam -0.881 7.027 -12.865 3.22E-12 8.45E-11 17.808 -1.84 
PAPSS1 -0.342 6.702 -5.235 2.34E-05 1.11E-04 1.696 -1.27 
Parp1 0.688 6.304 11.287 4.77E-11 9.37E-10 15.050 1.61 
Parva 0.356 8.144 4.776 7.46E-05 3.07E-04 0.534 1.28 
Parva 0.367 6.308 5.627 8.78E-06 4.69E-05 2.685 1.29 
Pbk -0.974 6.261 -11.112 6.55E-11 1.23E-09 14.727 -1.96 
Pcgf5 -0.335 6.328 -6.820 4.88E-07 3.47E-06 5.616 -1.26 
Pde6d -1.093 6.781 -8.804 5.89E-09 6.59E-08 10.123 -2.13 
Pdia3 -0.640 9.730 -10.295 2.99E-10 4.71E-09 13.173 -1.56 
Pdia4 -0.803 7.671 -17.093 7.00E-15 3.70E-13 24.059 -1.74 
Pdia4 -0.788 6.027 -3.953 5.99E-04 1.94E-03 -1.535 -1.73 
Pdia6 -0.587 10.091 -14.486 2.59E-13 8.63E-12 20.382 -1.50 
Pex19 1.237 6.163 25.476 8.40E-19 2.76E-16 33.140 2.36 
Pfdn5 -0.326 8.087 -6.789 5.25E-07 3.69E-06 5.542 -1.25 
Pgs1 -0.538 6.290 -7.963 3.59E-08 3.20E-07 8.276 -1.45 
Phf20 -0.289 6.196 -6.192 2.19E-06 1.33E-05 4.089 -1.22 
Phf20 -0.277 6.211 -4.120 3.94E-04 1.37E-03 -1.121 -1.21 
Picalm -0.321 8.359 -5.955 3.91E-06 2.24E-05 3.504 -1.25 
PIGT -0.535 6.318 -5.329 1.85E-05 8.96E-05 1.933 -1.45 
Pin4 0.313 6.767 6.251 1.90E-06 1.18E-05 4.236 1.24 
Pir -0.349 6.603 -5.126 3.08E-05 1.41E-04 1.421 -1.27 
Pja1 0.488 7.598 11.618 2.65E-11 5.57E-10 15.651 1.40 
Pja2 -0.983 7.115 -18.552 1.13E-15 8.85E-14 25.906 -1.98 
Pja2 -0.931 7.451 -19.874 2.42E-16 2.47E-14 27.469 -1.91 
Plaa -0.340 6.833 -6.944 3.64E-07 2.65E-06 5.913 -1.27 
Plac8 1.246 5.438 12.473 6.15E-12 1.52E-10 17.147 2.37 
Pldn 0.409 6.610 9.681 9.86E-10 1.31E-08 11.950 1.33 
Plekha1 0.319 6.363 6.370 1.43E-06 9.13E-06 4.526 1.25 
Plekhm1 0.352 5.234 3.536 1.70E-03 4.84E-03 -2.557 1.28 
Plin2 0.594 8.507 3.089 5.04E-03 1.25E-02 -3.611 1.51 
Plin2 0.617 9.911 5.585 9.74E-06 5.10E-05 2.580 1.53 
Plin2 0.656 9.393 15.796 3.97E-14 1.66E-12 22.296 1.58 
PLK2 -1.419 7.605 -27.860 1.06E-19 4.78E-17 35.182 -2.67 
Plp2 -0.413 7.148 -5.699 7.35E-06 4.00E-05 2.865 -1.33 
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Pls3 0.341 8.295 5.510 1.18E-05 6.02E-05 2.391 1.27 
Pltp 0.528 7.226 4.026 4.98E-04 1.65E-03 -1.355 1.44 
Pmpca 0.280 7.183 4.568 1.27E-04 4.91E-04 0.006 1.21 
Pnn -0.416 7.266 -7.813 5.01E-08 4.33E-07 7.935 -1.33 
Pnn -0.312 7.913 -4.567 1.27E-04 4.92E-04 0.004 -1.24 
Poldip2 0.272 7.267 5.379 1.63E-05 8.00E-05 2.061 1.21 
Polr2g 0.400 8.219 9.859 6.94E-10 9.86E-09 12.310 1.32 
Ppcs 0.913 7.062 16.209 2.26E-14 1.00E-12 22.870 1.88 
Ppic 0.552 7.196 8.550 1.01E-08 1.07E-07 9.575 1.47 
Ppip5k2 -0.691 7.088 -10.073 4.57E-10 6.85E-09 12.737 -1.61 
Ppp1cb 0.331 9.069 5.048 3.75E-05 1.66E-04 1.225 1.26 
Ppp1r7 -0.363 6.619 -6.205 2.12E-06 1.30E-05 4.121 -1.29 
Ppp1r7 -0.341 7.153 -4.798 7.06E-05 2.91E-04 0.589 -1.27 
Ppp1r7 -0.325 6.514 -2.870 8.47E-03 1.96E-02 -4.105 -1.25 
PPP2R5A 1.027 6.010 16.871 9.35E-15 4.75E-13 23.766 2.04 
Ppp2r5c -0.776 7.078 -16.355 1.85E-14 8.43E-13 23.070 -1.71 
Ppp2r5c 0.381 7.119 5.805 5.65E-06 3.15E-05 3.130 1.30 
Ppp4r1 -1.449 7.146 -22.856 1.01E-17 2.27E-15 30.658 -2.73 
Pppde1 0.530 6.727 11.136 6.26E-11 1.18E-09 14.772 1.44 
Pppde1 0.695 6.277 7.249 1.80E-07 1.39E-06 6.633 1.62 
Prc1 -0.999 7.462 -10.417 2.37E-10 3.90E-09 13.410 -2.00 
Prcp -0.556 7.535 -13.317 1.56E-12 4.51E-11 18.550 -1.47 
Prdx3 0.270 8.036 4.017 5.10E-04 1.69E-03 -1.378 1.21 
Prdx4 -0.539 8.079 -12.256 8.85E-12 2.09E-10 16.775 -1.45 
Prkca -0.439 5.864 -5.848 5.09E-06 2.87E-05 3.237 -1.36 
Prkcdbp -0.316 6.389 -2.934 7.28E-03 1.72E-02 -3.961 -1.24 
Prkcsh -0.373 6.754 -3.359 2.63E-03 7.13E-03 -2.982 -1.30 
Prkrir 0.425 7.275 9.764 8.36E-10 1.16E-08 12.119 1.34 
Prmt5 -0.669 7.197 -8.995 3.96E-09 4.60E-08 10.529 -1.59 
Pros1 -0.348 7.149 -6.062 3.01E-06 1.76E-05 3.768 -1.27 
Prpf38b -0.448 7.449 -7.402 1.27E-07 1.01E-06 6.990 -1.36 
Prune2 -0.454 7.588 -8.187 2.20E-08 2.12E-07 8.776 -1.37 
Psap 0.460 8.656 8.521 1.07E-08 1.13E-07 9.511 1.38 
Psat1 -0.265 9.538 -5.812 5.56E-06 3.11E-05 3.148 -1.20 
Psmb3 0.288 8.872 3.663 1.24E-03 3.67E-03 -2.249 1.22 
PSMB5 -0.334 9.145 -3.583 1.51E-03 4.39E-03 -2.444 -1.26 
Psmb6 0.285 8.403 4.914 5.26E-05 2.25E-04 0.884 1.22 
Psmc4 0.421 7.500 5.995 3.55E-06 2.04E-05 3.602 1.34 
Psmc4 0.496 6.706 4.401 1.93E-04 7.17E-04 -0.415 1.41 
Psmc5 0.361 7.802 9.048 3.54E-09 4.18E-08 10.642 1.28 
Psmc5 0.375 7.329 4.249 2.83E-04 1.01E-03 -0.796 1.30 
Psmd1 -0.679 7.960 -10.270 3.13E-10 4.88E-09 13.125 -1.60 
Psmd1 -0.647 6.492 -9.971 5.57E-10 8.20E-09 12.535 -1.57 
Psmd8 0.311 7.549 5.518 1.15E-05 5.93E-05 2.410 1.24 
Psmg1 0.287 7.725 7.363 1.38E-07 1.10E-06 6.899 1.22 
Psmg4 0.342 6.705 6.981 3.34E-07 2.44E-06 6.001 1.27 
Ptma -0.721 7.975 -8.114 2.58E-08 2.43E-07 8.613 -1.65 
Ptma -0.464 11.781 -4.817 6.73E-05 2.79E-04 0.637 -1.38 
Ptpmt1 -0.292 6.973 -6.016 3.36E-06 1.94E-05 3.656 -1.22 
Ptpn12 -0.325 6.870 -6.407 1.30E-06 8.41E-06 4.618 -1.25 
Ptprg -1.752 5.545 -34.805 5.98E-22 5.37E-19 40.217 -3.37 
Ptprm -0.839 7.071 -20.125 1.82E-16 2.05E-14 27.754 -1.79 
Ptrf -0.491 7.830 -6.244 1.93E-06 1.20E-05 4.217 -1.41 
Pts 0.515 7.243 6.219 2.05E-06 1.26E-05 4.157 1.43 
Pttg1 -0.947 6.979 -11.370 4.11E-11 8.21E-10 15.203 -1.93 
Purb 0.447 7.313 7.817 4.97E-08 4.30E-07 7.944 1.36 
Pxdn 0.290 7.848 5.043 3.80E-05 1.68E-04 1.211 1.22 
Qk -2.513 5.943 -18.401 1.36E-15 1.04E-13 25.721 -5.71 
Qk -2.382 7.862 -31.366 6.78E-21 3.48E-18 37.875 -5.21 
Qsox1 0.764 7.440 9.873 6.75E-10 9.62E-09 12.339 1.70 
Rab10 0.288 8.081 3.337 2.77E-03 7.46E-03 -3.032 1.22 
Rab11a -0.387 5.948 -3.699 1.13E-03 3.39E-03 -2.162 -1.31 
Rab12 -1.011 7.313 -10.301 2.95E-10 4.69E-09 13.186 -2.02 
Rab31 -0.306 6.713 -3.789 9.05E-04 2.81E-03 -1.942 -1.24 
Rad21 -0.398 8.291 -5.040 3.83E-05 1.69E-04 1.203 -1.32 
Rapgef1 0.618 9.228 12.735 3.98E-12 1.02E-10 17.591 1.53 
Rbck1 0.781 6.528 9.334 1.97E-09 2.46E-08 11.241 1.72 
Rbm39 -0.323 8.443 -6.406 1.31E-06 8.41E-06 4.615 -1.25 
Rbpms 0.329 6.521 5.700 7.34E-06 3.99E-05 2.867 1.26 
Rcan1 -0.276 6.276 -4.655 1.01E-04 4.02E-04 0.229 -1.21 
Rcc2 0.288 7.768 5.531 1.12E-05 5.76E-05 2.444 1.22 
Rcc2 0.452 6.920 9.538 1.31E-09 1.70E-08 11.661 1.37 
Rcl1 -0.375 7.522 -9.885 6.59E-10 9.47E-09 12.364 -1.30 
Rell1 -0.306 6.441 -7.998 3.33E-08 3.02E-07 8.353 -1.24 
Rere 0.470 6.955 5.549 1.07E-05 5.53E-05 2.488 1.39 
Retsat 1.665 5.458 17.761 2.99E-15 1.85E-13 24.922 3.17 
Rexo2 0.331 9.534 8.630 8.50E-09 9.20E-08 9.748 1.26 
Rfx5 -0.295 6.821 -5.259 2.21E-05 1.05E-04 1.757 -1.23 
RGD1304567 0.278 6.998 5.272 2.13E-05 1.02E-04 1.792 1.21 
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RGD1311072 0.267 6.926 6.550 9.26E-07 6.25E-06 4.964 1.20 
RGD1560010 -0.357 6.651 -5.139 2.98E-05 1.37E-04 1.454 -1.28 
RGD1561797 -0.828 7.190 -10.644 1.55E-10 2.66E-09 13.847 -1.77 
Rgs17 0.928 7.346 9.564 1.24E-09 1.62E-08 11.714 1.90 
Rnaseh2c -0.969 6.445 -15.483 6.14E-14 2.40E-12 21.851 -1.96 
Rnaset2a 0.677 10.189 15.715 4.44E-14 1.79E-12 22.180 1.60 
Rnf10 0.480 7.472 8.692 7.46E-09 8.17E-08 9.881 1.39 
Rnf111 -0.341 6.483 -5.085 3.42E-05 1.54E-04 1.317 -1.27 
Rnf149 0.276 8.048 3.675 1.20E-03 3.57E-03 -2.221 1.21 
Rnft1 -0.279 6.370 -4.913 5.27E-05 2.25E-04 0.883 -1.21 
Romo1 0.278 9.948 5.560 1.04E-05 5.41E-05 2.517 1.21 
Rpia 0.464 7.906 7.844 4.68E-08 4.06E-07 8.006 1.38 
Rpl10 0.401 6.263 5.140 2.97E-05 1.37E-04 1.456 1.32 
Rpl34 -0.333 9.992 -6.515 1.01E-06 6.74E-06 4.880 -1.26 
Rpl37a -0.462 12.328 -13.961 5.71E-13 1.75E-11 19.575 -1.38 
Rpn1 -0.279 9.350 -6.207 2.11E-06 1.29E-05 4.127 -1.21 
Rpn2 -0.281 9.821 -3.206 3.81E-03 9.80E-03 -3.340 -1.22 
Rps28 -0.414 8.402 -4.338 2.26E-04 8.26E-04 -0.573 -1.33 
Rqcd1 -0.807 6.141 -12.119 1.12E-11 2.51E-10 16.537 -1.75 
Rras -0.294 6.545 -4.173 3.43E-04 1.21E-03 -0.986 -1.23 
Rrp15 0.743 7.873 22.714 1.17E-17 2.47E-15 30.516 1.67 
Ryk 0.319 6.736 7.732 6.01E-08 5.13E-07 7.750 1.25 
S100a11 -0.471 7.784 -7.006 3.15E-07 2.33E-06 6.060 -1.39 
SAMD4B 0.416 8.703 8.604 8.98E-09 9.66E-08 9.691 1.33 
Sash1 0.303 7.769 5.258 2.21E-05 1.05E-04 1.756 1.23 
Sat1 -0.656 6.704 -13.557 1.07E-12 3.17E-11 18.937 -1.58 
SC4MOL -0.947 8.194 -18.761 8.82E-16 7.37E-14 26.160 -1.93 
Sc4mol -0.809 6.368 -3.803 8.74E-04 2.73E-03 -1.907 -1.75 
Sc5d -0.448 6.364 -4.747 8.03E-05 3.28E-04 0.460 -1.36 
Scarb1 -0.339 6.897 -4.895 5.52E-05 2.34E-04 0.836 -1.26 
Sccpdh 0.525 7.895 11.027 7.63E-11 1.41E-09 14.570 1.44 
Sccpdh 0.554 7.248 15.766 4.13E-14 1.71E-12 22.254 1.47 
SCD -0.715 9.542 -16.869 9.38E-15 4.75E-13 23.763 -1.64 
Scd1 -0.710 9.240 -13.475 1.21E-12 3.57E-11 18.806 -1.64 
Scd1 -0.301 7.257 -2.829 9.33E-03 2.13E-02 -4.196 -1.23 
Scd3 -0.351 8.588 -8.420 1.33E-08 1.37E-07 9.291 -1.28 
Scd3 -0.319 7.564 -3.416 2.28E-03 6.29E-03 -2.846 -1.25 
Scoc 0.265 7.007 4.101 4.12E-04 1.41E-03 -1.167 1.20 
Scpep1 0.478 7.152 3.526 1.74E-03 4.96E-03 -2.582 1.39 
Scyl2 -0.270 6.432 -6.491 1.07E-06 7.09E-06 4.822 -1.21 
Scyl3 -1.051 5.993 -16.836 9.78E-15 4.88E-13 23.720 -2.07 
Sec22a -0.337 6.119 -8.107 2.62E-08 2.45E-07 8.598 -1.26 
Sec22b -0.389 6.590 -7.122 2.41E-07 1.82E-06 6.334 -1.31 
Sec23b -0.470 6.844 -6.317 1.62E-06 1.02E-05 4.397 -1.39 
Sec24d -0.361 7.004 -5.008 4.15E-05 1.82E-04 1.122 -1.28 
Sel1l -0.522 7.016 -5.519 1.15E-05 5.92E-05 2.414 -1.44 
Serpinf1 0.389 8.278 4.504 1.49E-04 5.69E-04 -0.155 1.31 
Sf3a3 0.454 8.084 9.761 8.42E-10 1.16E-08 12.113 1.37 
Sfrs6 0.299 8.208 6.111 2.67E-06 1.58E-05 3.890 1.23 
Sfxn1 0.493 7.684 13.871 6.56E-13 2.00E-11 19.434 1.41 
Sgce -1.342 6.005 -10.407 2.42E-10 3.96E-09 13.390 -2.53 
Shisa5 -0.379 7.375 -6.325 1.59E-06 1.00E-05 4.417 -1.30 
Shmt2 -0.273 6.208 -2.678 1.32E-02 2.88E-02 -4.522 -1.21 
Sirt7 -0.845 6.400 -8.575 9.55E-09 1.02E-07 9.628 -1.80 
Sirt7 -0.671 5.986 -5.199 2.57E-05 1.20E-04 1.605 -1.59 
Slc17a5 -0.375 6.797 -8.193 2.17E-08 2.10E-07 8.789 -1.30 
Slc25a17 0.402 6.764 9.015 3.79E-09 4.44E-08 10.572 1.32 
Slc25a20 0.314 8.555 4.415 1.87E-04 6.95E-04 -0.380 1.24 
Slc30a4 0.350 6.781 7.101 2.53E-07 1.89E-06 6.285 1.27 
Slc35b1 -0.311 7.240 -6.323 1.60E-06 1.01E-05 4.410 -1.24 
Slc35c2 0.412 6.171 6.131 2.54E-06 1.52E-05 3.939 1.33 
Slc4a7 -0.931 6.815 -13.345 1.49E-12 4.35E-11 18.597 -1.91 
Slc4a7 -0.747 6.315 -7.595 8.17E-08 6.72E-07 7.437 -1.68 
Slc6a6 0.466 8.040 9.727 9.00E-10 1.22E-08 12.044 1.38 
Slc7a11 -0.844 7.310 -10.039 4.88E-10 7.28E-09 12.671 -1.79 
Smc4 -1.066 6.591 -9.652 1.04E-09 1.38E-08 11.892 -2.09 
Smchd1 -0.741 6.819 -4.536 1.37E-04 5.28E-04 -0.073 -1.67 
Smpd1 -0.346 6.110 -3.676 1.20E-03 3.57E-03 -2.218 -1.27 
Smpd1 -0.289 6.885 -4.811 6.83E-05 2.83E-04 0.623 -1.22 
Smyd2 0.920 6.489 17.186 6.21E-15 3.49E-13 24.180 1.89 
Snap23 -0.342 7.105 -7.716 6.22E-08 5.29E-07 7.714 -1.27 
Snn -1.113 6.495 -14.400 2.94E-13 9.53E-12 20.252 -2.16 
Snora28 -0.618 6.761 -6.078 2.89E-06 1.70E-05 3.808 -1.53 
Snora28 -0.539 8.217 -10.946 8.85E-11 1.61E-09 14.419 -1.45 
Snora28 -0.442 7.421 -8.540 1.03E-08 1.09E-07 9.553 -1.36 
Snora41 -0.589 10.413 -17.985 2.26E-15 1.60E-13 25.205 -1.50 
Snora75 -0.521 8.619 -9.684 9.80E-10 1.31E-08 11.957 -1.44 
Snrnp200 0.418 7.905 8.400 1.39E-08 1.42E-07 9.247 1.34 
Snrpc 0.286 7.891 5.725 6.89E-06 3.80E-05 2.930 1.22 
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Snrpe -0.263 9.000 -4.515 1.45E-04 5.54E-04 -0.127 -1.20 
Snx12 0.412 6.594 7.689 6.62E-08 5.58E-07 7.651 1.33 
Snx4 0.313 8.191 6.437 1.21E-06 7.93E-06 4.689 1.24 
Snx9 0.305 7.033 7.005 3.16E-07 2.33E-06 6.058 1.24 
Sod1 0.374 8.506 6.678 6.82E-07 4.73E-06 5.275 1.30 
SOD2 -0.394 6.729 -5.811 5.57E-06 3.11E-05 3.146 -1.31 
Spc25 -1.144 6.631 -14.744 1.77E-13 6.18E-12 20.770 -2.21 
Sprr1a 0.797 8.643 9.242 2.38E-09 2.94E-08 11.048 1.74 
Sqle -0.548 9.031 -8.701 7.31E-09 8.03E-08 9.901 -1.46 
Sqle -0.444 7.073 -6.667 7.00E-07 4.83E-06 5.249 -1.36 
Srpr 0.711 10.831 5.923 4.23E-06 2.41E-05 3.423 1.64 
Srpr 0.901 10.118 5.417 1.48E-05 7.37E-05 2.155 1.87 
Ssr4 -0.344 9.057 -3.992 5.43E-04 1.79E-03 -1.439 -1.27 
Stim2 0.345 6.458 4.223 3.03E-04 1.08E-03 -0.863 1.27 
Stmn1 -0.330 7.260 -5.500 1.21E-05 6.16E-05 2.366 -1.26 
Strap -0.269 6.933 -6.175 2.28E-06 1.38E-05 4.048 -1.21 
Sumo3 0.383 7.605 9.703 9.43E-10 1.27E-08 11.996 1.30 
SUPT16H -0.537 10.402 -7.420 1.22E-07 9.79E-07 7.031 -1.45 
Supt4h1 0.472 7.223 8.838 5.49E-09 6.18E-08 10.195 1.39 
Syncrip 0.933 6.514 4.888 5.61E-05 2.38E-04 0.819 1.91 
Syncrip 1.061 6.547 15.958 3.18E-14 1.38E-12 22.522 2.09 
Tagln2 0.296 7.238 4.943 4.89E-05 2.11E-04 0.958 1.23 
Tagln2 0.342 8.340 4.719 8.61E-05 3.52E-04 0.390 1.27 
Tbc1d1 0.658 7.646 11.607 2.70E-11 5.62E-10 15.632 1.58 
Tbc1d13 0.304 6.269 4.939 4.94E-05 2.12E-04 0.948 1.23 
Tbc1d20 0.460 7.320 8.162 2.32E-08 2.22E-07 8.720 1.38 
Tbl1xr1 0.448 7.703 7.898 4.15E-08 3.63E-07 8.128 1.36 
Tcea1 0.282 8.260 6.425 1.25E-06 8.15E-06 4.660 1.22 
Tdgf1 0.546 6.194 8.097 2.68E-08 2.48E-07 8.575 1.46 
Tecr -0.572 8.225 -8.154 2.36E-08 2.24E-07 8.702 -1.49 
Tes -1.241 7.629 -20.812 8.53E-17 1.23E-14 28.518 -2.36 
Tes -1.145 6.550 -23.610 4.82E-18 1.33E-15 31.400 -2.21 
Tfb2m 0.654 7.005 12.889 3.10E-12 8.18E-11 17.848 1.57 
TFPI -0.308 7.291 -3.843 7.90E-04 2.51E-03 -1.808 -1.24 
Tgfbr2 0.719 6.364 9.134 2.97E-09 3.59E-08 10.822 1.65 
Tgm2 0.341 7.080 5.626 8.81E-06 4.70E-05 2.682 1.27 
Tgoln2 0.280 7.676 4.110 4.03E-04 1.39E-03 -1.145 1.21 
Thoc4 -0.572 8.085 -7.109 2.48E-07 1.87E-06 6.304 -1.49 
Thoc7 0.308 7.681 5.813 5.55E-06 3.10E-05 3.150 1.24 
Tial1 -0.329 7.699 -9.129 3.00E-09 3.61E-08 10.813 -1.26 
Timm8b 0.406 7.727 7.355 1.41E-07 1.11E-06 6.882 1.33 
Timp1 -0.495 6.932 -7.275 1.69E-07 1.32E-06 6.694 -1.41 
Timp2 0.383 8.376 6.816 4.93E-07 3.50E-06 5.606 1.30 
Tinagl1 -0.695 6.534 -6.145 2.45E-06 1.47E-05 3.975 -1.62 
Tkt -0.426 6.994 -9.431 1.62E-09 2.06E-08 11.441 -1.34 
Tmbim6 -0.426 8.960 -3.810 8.59E-04 2.70E-03 -1.891 -1.34 
Tmed10 0.264 6.968 6.475 1.11E-06 7.33E-06 4.783 1.20 
Tmed3 -0.405 6.990 -8.453 1.24E-08 1.29E-07 9.363 -1.32 
Tmem101 0.451 6.466 5.417 1.48E-05 7.37E-05 2.156 1.37 
Tmem109 -0.379 6.566 -7.278 1.68E-07 1.31E-06 6.701 -1.30 
Tmem147 0.447 8.457 8.565 9.74E-09 1.04E-07 9.608 1.36 
Tmem150a -0.563 6.896 -8.159 2.34E-08 2.23E-07 8.713 -1.48 
Tmem156 0.405 7.139 7.083 2.64E-07 1.97E-06 6.242 1.32 
Tmem158 0.695 6.933 7.112 2.46E-07 1.86E-06 6.312 1.62 
Tmem219 0.321 6.567 5.161 2.82E-05 1.31E-04 1.509 1.25 
Tmem223 0.317 7.260 4.659 1.00E-04 3.99E-04 0.238 1.25 
Tmsb10 0.373 10.371 6.018 3.35E-06 1.94E-05 3.660 1.30 
Tnfaip3 -1.282 5.235 -14.012 5.29E-13 1.65E-11 19.655 -2.43 
Tnfsf14 -0.875 7.330 -15.943 3.24E-14 1.39E-12 22.502 -1.83 
Tnfsf9 -0.731 6.765 -6.850 4.55E-07 3.25E-06 5.688 -1.66 
Tnks2 0.573 6.486 9.619 1.11E-09 1.47E-08 11.825 1.49 
Top2a -1.182 9.103 -14.984 1.25E-13 4.59E-12 21.126 -2.27 
Tpd52l2 0.300 6.534 3.157 4.28E-03 1.09E-02 -3.454 1.23 
Tpx2 -0.903 6.219 -9.699 9.51E-10 1.28E-08 11.988 -1.87 
Tram1 0.654 7.603 15.756 4.20E-14 1.71E-12 22.238 1.57 
Tram1 0.701 6.401 8.833 5.54E-09 6.22E-08 10.185 1.63 
Trap1 0.386 6.783 4.717 8.65E-05 3.53E-04 0.386 1.31 
Triap1 0.348 6.780 8.223 2.03E-08 1.99E-07 8.856 1.27 
Trib1 0.280 6.683 4.030 4.93E-04 1.64E-03 -1.345 1.21 
Trim44 0.395 6.784 3.299 3.04E-03 8.10E-03 -3.123 1.31 
Trub1 0.597 7.328 14.802 1.63E-13 5.79E-12 20.856 1.51 
Tspo 0.297 8.531 3.961 5.87E-04 1.91E-03 -1.516 1.23 
Ttc33 0.357 6.573 5.112 3.19E-05 1.46E-04 1.385 1.28 
Ttrap -0.482 6.488 -11.612 2.68E-11 5.60E-10 15.640 -1.40 
Tuba1c -0.505 9.068 -10.477 2.12E-10 3.54E-09 13.525 -1.42 
Tubb2c -0.276 8.450 -5.498 1.21E-05 6.16E-05 2.362 -1.21 
Tubb5 -0.696 7.745 -10.861 1.03E-10 1.85E-09 14.258 -1.62 
Tubb6 -0.454 7.128 -11.434 3.67E-11 7.37E-10 15.318 -1.37 
Twistnb 0.283 7.652 3.502 1.85E-03 5.23E-03 -2.640 1.22 
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Txndc15 0.296 6.914 7.664 7.00E-08 5.85E-07 7.594 1.23 
TXNDC5 0.400 7.407 7.025 3.02E-07 2.24E-06 6.104 1.32 
Tyms -0.964 8.010 -12.308 8.10E-12 1.94E-10 16.865 -1.95 
Uap1 -0.529 6.881 -8.576 9.52E-09 1.02E-07 9.631 -1.44 
Uap1l1 0.355 6.485 3.966 5.80E-04 1.89E-03 -1.504 1.28 
Uba5 -0.377 7.149 -8.065 2.87E-08 2.64E-07 8.504 -1.30 
Ubash3b 0.436 8.046 10.651 1.53E-10 2.65E-09 13.860 1.35 
Ube2d3 -0.446 6.574 -11.017 7.78E-11 1.43E-09 14.550 -1.36 
UBE2D4 0.599 6.665 9.828 7.37E-10 1.04E-08 12.248 1.51 
Ube2f -0.473 6.835 -11.472 3.43E-11 7.01E-10 15.387 -1.39 
Ube2q1 0.321 7.359 4.126 3.87E-04 1.35E-03 -1.106 1.25 
Ubl3 0.339 6.206 6.414 1.28E-06 8.29E-06 4.635 1.27 
Ugcg -0.291 6.257 -3.340 2.75E-03 7.41E-03 -3.025 -1.22 
Uggt1 0.317 7.043 6.974 3.40E-07 2.47E-06 5.983 1.25 
Ugt1a1 -0.362 10.340 -8.166 2.30E-08 2.21E-07 8.730 -1.29 
Uqcr10 0.287 8.893 4.106 4.08E-04 1.40E-03 -1.156 1.22 
Usp1 -0.304 7.729 -4.901 5.44E-05 2.32E-04 0.851 -1.23 
Usp19 0.364 6.555 7.151 2.25E-07 1.71E-06 6.403 1.29 
Usp46 0.689 6.354 10.235 3.35E-10 5.16E-09 13.057 1.61 
Usp8 0.465 7.823 11.149 6.12E-11 1.16E-09 14.795 1.38 
Usp9x -0.300 7.078 -4.968 4.59E-05 1.99E-04 1.021 -1.23 
Vamp7 0.479 6.650 5.934 4.12E-06 2.36E-05 3.450 1.39 
VAPA -0.700 8.901 -19.809 2.60E-16 2.47E-14 27.394 -1.62 
Vapb 0.427 8.100 5.067 3.57E-05 1.60E-04 1.272 1.34 
Vasn 0.361 6.546 3.201 3.86E-03 9.90E-03 -3.353 1.28 
Vasn 0.384 7.151 9.914 6.23E-10 9.10E-09 12.420 1.30 
Vcam1 -1.055 6.411 -12.399 6.96E-12 1.69E-10 17.021 -2.08 
Vldlr 0.296 6.836 4.303 2.47E-04 8.92E-04 -0.661 1.23 
Vnn1 -0.823 6.056 -15.045 1.14E-13 4.28E-12 21.216 -1.77 
Vopp1 -0.352 6.712 -6.317 1.62E-06 1.02E-05 4.397 -1.28 
Vps25 0.505 7.885 7.925 3.91E-08 3.44E-07 8.188 1.42 
Vps29 0.310 8.817 4.295 2.52E-04 9.09E-04 -0.681 1.24 
Vps36 0.417 6.947 8.372 1.47E-08 1.49E-07 9.184 1.34 
Vwa5a -0.542 7.095 -10.572 1.77E-10 3.01E-09 13.709 -1.46 
Wdfy4 1.501 6.002 14.128 4.43E-13 1.40E-11 19.835 2.83 
Wdr26 0.391 6.370 6.379 1.40E-06 8.96E-06 4.548 1.31 
Wdr77 -0.271 6.647 -5.163 2.81E-05 1.30E-04 1.514 -1.21 
Wdyhv1 0.325 6.805 3.281 3.17E-03 8.38E-03 -3.164 1.25 
Whsc1 -0.390 6.747 -4.666 9.86E-05 3.94E-04 0.255 -1.31 
Wsb1 0.374 6.023 5.666 7.98E-06 4.32E-05 2.782 1.30 
Xbp1 -0.292 7.896 -5.294 2.02E-05 9.71E-05 1.846 -1.22 
Xpot -0.326 8.618 -5.567 1.02E-05 5.32E-05 2.535 -1.25 
Xrcc5 -0.890 6.430 -17.835 2.73E-15 1.78E-13 25.015 -1.85 
Ybx1 0.348 11.304 7.598 8.11E-08 6.68E-07 7.444 1.27 
ZC3H11A -0.373 9.226 -6.803 5.07E-07 3.60E-06 5.576 -1.29 
Zcchc2 0.534 6.640 6.473 1.11E-06 7.34E-06 4.778 1.45 
Zcchc24 0.512 6.916 8.358 1.52E-08 1.53E-07 9.154 1.43 
Zfp110 0.290 6.538 7.198 2.02E-07 1.54E-06 6.512 1.22 
Zfp259 0.354 6.408 5.877 4.74E-06 2.68E-05 3.309 1.28 
ZFP36L1 -0.419 8.280 -7.047 2.87E-07 2.13E-06 6.157 -1.34 
Zyx -0.319 7.962 -4.986 4.38E-05 1.90E-04 1.067 -1.25 
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5.2.12 Stressed v Unstressed gene list 
 
Gene ID logFC AveExpr t P.Value adj.P.Val B Fold Change 
38231 -0.886 5.984 -5.895 1.66E-06 1.53E-04 5.148 -1.85 
1810037I17Rik -0.386 6.983 -6.314 5.04E-07 9.54E-05 6.282 -1.31 
2810482I07Rik -0.274 6.348 -4.338 1.42E-04 2.86E-03 0.917 -1.21 
4833417J20Rik -0.466 7.312 -5.105 1.59E-05 6.73E-04 2.994 -1.38 
9530053H05Rik 0.454 10.002 3.729 7.72E-04 7.96E-03 -0.681 1.37 
A330042M18Rik -0.298 6.806 -3.125 3.85E-03 2.22E-02 -2.173 -1.23 
Abhd6 0.428 6.783 3.267 2.66E-03 1.77E-02 -1.833 1.34 
Acat2 -0.723 6.811 -4.478 9.53E-05 2.18E-03 1.292 -1.65 
Actn1 -0.285 8.286 -5.985 1.28E-06 1.52E-04 5.394 -1.22 
Add3 -0.281 6.120 -2.801 8.70E-03 3.89E-02 -2.919 -1.22 
Adh5 -0.391 9.619 -4.171 2.27E-04 3.80E-03 0.473 -1.31 
Aftph 0.284 7.139 4.248 1.83E-04 3.35E-03 0.676 1.22 
Ahctf1 0.390 6.293 4.451 1.03E-04 2.28E-03 1.220 1.31 
AI646531 -0.430 6.560 -4.352 1.36E-04 2.79E-03 0.955 -1.35 
AI646531 -0.299 7.286 -3.499 1.44E-03 1.18E-02 -1.261 -1.23 
Aig1 -0.316 6.487 -3.883 5.06E-04 6.20E-03 -0.284 -1.24 
Akap12 -0.745 7.889 -3.454 1.62E-03 1.26E-02 -1.373 -1.68 
Akirin2 0.349 6.069 3.687 8.66E-04 8.57E-03 -0.788 1.27 
Amd1 0.467 7.422 3.240 2.85E-03 1.85E-02 -1.898 1.38 
Amd2 0.528 8.027 3.252 2.77E-03 1.81E-02 -1.869 1.44 
Anxa4 -0.326 7.155 -5.992 1.25E-06 1.52E-04 5.414 -1.25 
Arhgef6 -0.313 7.955 -4.130 2.54E-04 4.06E-03 0.364 -1.24 
Arl15 -0.270 6.329 -3.673 8.99E-04 8.74E-03 -0.823 -1.21 
Atf6 0.354 8.404 3.979 3.87E-04 5.17E-03 -0.033 1.28 
Atp6v0c-ps2 -0.290 7.644 -3.426 1.75E-03 1.33E-02 -1.443 -1.22 
AU015740 0.315 6.605 4.377 1.27E-04 2.70E-03 1.021 1.24 
AU018778 -1.447 3.649 -4.461 9.99E-05 2.23E-03 1.248 -2.73 
AU019300 0.315 7.174 4.517 8.54E-05 2.06E-03 1.396 1.24 
B630006N21Rik 0.264 7.660 5.897 1.65E-06 1.53E-04 5.154 1.20 
Bdnf 0.331 6.480 3.222 2.99E-03 1.90E-02 -1.940 1.26 
BHLHE41 -0.297 6.897 -6.973 7.99E-08 4.63E-05 8.033 -1.23 
Bsg -0.273 8.496 -4.627 6.25E-05 1.68E-03 1.693 -1.21 
C1rb -0.419 9.482 -3.394 1.90E-03 1.41E-02 -1.523 -1.34 
C80142 0.358 6.839 5.025 2.00E-05 7.87E-04 2.776 1.28 
Cald1 -0.342 7.673 -2.739 1.01E-02 4.32E-02 -3.057 -1.27 
Cat -0.304 8.131 -3.376 2.00E-03 1.46E-02 -1.567 -1.23 
Cav1 -0.301 9.812 -2.981 5.54E-03 2.90E-02 -2.509 -1.23 
Cav2 -0.282 6.234 -3.342 2.18E-03 1.55E-02 -1.651 -1.22 
Chd2 0.273 6.581 3.743 7.43E-04 7.79E-03 -0.645 1.21 
Chmp2a -0.496 7.416 -4.864 3.18E-05 1.04E-03 2.336 -1.41 
Chordc1 0.271 6.453 3.124 3.85E-03 2.22E-02 -2.175 1.21 
Cidec 0.280 6.285 3.641 9.81E-04 9.14E-03 -0.905 1.21 
Cited2 0.506 6.419 3.938 4.34E-04 5.63E-03 -0.140 1.42 
Clic4 -0.267 8.809 -3.849 5.55E-04 6.47E-03 -0.371 -1.20 
Col5a1 -1.053 6.209 -5.300 9.08E-06 4.59E-04 3.528 -2.07 
Commd7 0.269 6.618 2.785 9.04E-03 4.01E-02 -2.955 1.21 
Cox4nb 0.270 7.112 3.389 1.93E-03 1.42E-02 -1.535 1.21 
Cpn2 -0.600 6.648 -3.074 4.38E-03 2.41E-02 -2.292 -1.52 
Csda 0.283 7.938 4.255 1.79E-04 3.32E-03 0.695 1.22 
Csnk1e 0.317 6.600 3.664 9.21E-04 8.83E-03 -0.846 1.25 
CTBS -0.270 6.573 -5.212 1.17E-05 5.30E-04 3.288 -1.21 
Ctsh -0.321 6.886 -4.483 9.41E-05 2.17E-03 1.305 -1.25 
Ctsz -0.374 9.672 -3.789 6.55E-04 7.15E-03 -0.526 -1.30 
Cyb5r3 -0.310 7.652 -5.587 3.99E-06 2.56E-04 4.310 -1.24 
Cyp51 -0.402 9.644 -4.587 6.99E-05 1.76E-03 1.587 -1.32 
Cyp51 -0.388 9.012 -4.729 4.66E-05 1.36E-03 1.971 -1.31 
D10Jhu81e -0.287 6.385 -3.195 3.21E-03 1.99E-02 -2.006 -1.22 
D17Wsu104e -0.346 6.741 -4.901 2.86E-05 9.78E-04 2.437 -1.27 
Dag1 -0.299 7.183 -3.323 2.30E-03 1.59E-02 -1.697 -1.23 
Dag1 -0.294 8.711 -2.898 6.84E-03 3.29E-02 -2.701 -1.23 
Dbi -0.283 8.412 -2.886 7.04E-03 3.34E-02 -2.727 -1.22 
Dcaf13 0.270 7.411 5.302 9.03E-06 4.59E-04 3.533 1.21 
Ddx39 0.288 7.395 4.011 3.54E-04 4.84E-03 0.052 1.22 
Degs1 -0.287 6.778 -2.829 8.12E-03 3.70E-02 -2.857 -1.22 
Dram1 -0.359 6.300 -2.681 1.17E-02 4.71E-02 -3.185 -1.28 
Drg1 0.320 6.182 3.316 2.33E-03 1.61E-02 -1.712 1.25 
Dusp1 -0.470 6.221 -3.587 1.13E-03 1.00E-02 -1.040 -1.38 
E130203B14Rik -0.692 8.135 -5.700 2.89E-06 2.04E-04 4.618 -1.62 
Ebp -0.535 5.933 -3.751 7.25E-04 7.66E-03 -0.622 -1.45 
 395 
Ehd4 -0.296 6.254 -2.983 5.52E-03 2.89E-02 -2.505 -1.23 
Eif4a1 -0.556 8.429 -5.492 5.25E-06 3.20E-04 4.051 -1.47 
Eif4a1 -0.456 9.235 -5.706 2.84E-06 2.04E-04 4.635 -1.37 
Eif4ebp2 0.290 6.811 6.266 5.77E-07 1.04E-04 6.153 1.22 
Eif6 0.306 8.152 3.176 3.37E-03 2.04E-02 -2.052 1.24 
Ercc1 -0.421 6.529 -3.354 2.12E-03 1.52E-02 -1.621 -1.34 
Erp29 -0.281 7.835 -2.685 1.15E-02 4.68E-02 -3.176 -1.21 
Ethe1 -0.340 7.237 -3.496 1.45E-03 1.18E-02 -1.268 -1.27 
F2r -0.445 8.207 -3.524 1.34E-03 1.13E-02 -1.198 -1.36 
Faf1 0.398 6.458 4.073 2.98E-04 4.38E-03 0.213 1.32 
Fam102b -0.486 7.655 -5.944 1.44E-06 1.52E-04 5.283 -1.40 
Fam40b 0.423 6.679 4.871 3.11E-05 1.04E-03 2.357 1.34 
Fasn -0.511 6.330 -4.364 1.31E-04 2.75E-03 0.988 -1.42 
Fcgrt -0.899 6.491 -10.521 9.41E-12 3.38E-08 16.481 -1.86 
Fdft1 -0.331 6.917 -3.842 5.66E-04 6.52E-03 -0.390 -1.26 
Fdps -0.510 8.124 -4.670 5.53E-05 1.54E-03 1.810 -1.42 
Foxj2 0.378 5.870 4.712 4.90E-05 1.41E-03 1.924 1.30 
FSTL1 -0.376 8.751 -5.864 1.81E-06 1.61E-04 5.064 -1.30 
Galnt7 -0.344 7.466 -3.128 3.81E-03 2.21E-02 -2.165 -1.27 
Gas1 -0.691 6.643 -3.867 5.27E-04 6.27E-03 -0.323 -1.61 
Glul -0.298 6.564 -3.449 1.64E-03 1.26E-02 -1.386 -1.23 
Gm15104 1.096 6.022 2.815 8.41E-03 3.79E-02 -2.889 2.14 
Gm5578 0.374 6.726 4.029 3.37E-04 4.71E-03 0.098 1.30 
Gm6377 -0.333 8.134 -6.527 2.76E-07 6.64E-05 6.854 -1.26 
Gm7859 0.293 6.920 3.960 4.08E-04 5.43E-03 -0.081 1.22 
Gm9905 -0.318 6.724 -3.619 1.04E-03 9.45E-03 -0.958 -1.25 
Gnpat -0.286 6.582 -3.559 1.22E-03 1.06E-02 -1.110 -1.22 
Gpx1 -0.439 7.884 -3.388 1.93E-03 1.42E-02 -1.537 -1.36 
H6pd -0.307 6.439 -4.588 6.97E-05 1.76E-03 1.590 -1.24 
Hadh -0.294 7.777 -3.175 3.38E-03 2.04E-02 -2.053 -1.23 
Hbxip 0.294 8.226 4.293 1.61E-04 3.12E-03 0.797 1.23 
HMGCR -0.622 6.572 -4.923 2.68E-05 9.44E-04 2.498 -1.54 
Hmgcs1 -0.863 6.887 -7.209 4.16E-08 3.74E-05 8.651 -1.82 
Hnrnpa3 -0.309 8.503 -4.467 9.84E-05 2.21E-03 1.263 -1.24 
Hnrnpa3 -0.266 9.119 -3.925 4.50E-04 5.77E-03 -0.173 -1.20 
Hnrpdl -0.264 6.334 -3.250 2.78E-03 1.82E-02 -1.874 -1.20 
Hoxd9 0.288 5.751 3.614 1.05E-03 9.52E-03 -0.973 1.22 
Hsd17b12 -0.301 7.796 -5.234 1.10E-05 5.13E-04 3.346 -1.23 
Htra1 -0.286 10.001 -4.339 1.41E-04 2.86E-03 0.919 -1.22 
Idh1 -0.755 6.178 -4.260 1.77E-04 3.30E-03 0.708 -1.69 
IDH1 -0.683 8.313 -5.405 6.74E-06 3.78E-04 3.812 -1.61 
Idi1 -0.717 6.124 -5.339 8.14E-06 4.30E-04 3.633 -1.64 
Ifitm3 -0.408 9.676 -3.261 2.70E-03 1.78E-02 -1.848 -1.33 
Ildr2 0.479 6.552 3.275 2.61E-03 1.75E-02 -1.814 1.39 
Insig1 -0.394 8.024 -3.337 2.21E-03 1.55E-02 -1.661 -1.31 
Itfg3 -0.439 6.192 -4.507 8.78E-05 2.07E-03 1.371 -1.36 
Jub 0.516 7.280 4.122 2.60E-04 4.08E-03 0.344 1.43 
Kpna4 0.362 7.353 2.832 8.05E-03 3.68E-02 -2.849 1.29 
Lamb1-1 -0.284 9.576 -4.224 1.95E-04 3.49E-03 0.614 -1.22 
Laptm4a -0.545 7.312 -3.177 3.36E-03 2.04E-02 -2.049 -1.46 
Laptm4a -0.509 7.522 -3.857 5.42E-04 6.38E-03 -0.349 -1.42 
Layn -0.735 6.973 -4.728 4.68E-05 1.36E-03 1.967 -1.66 
Ldlr -0.346 6.729 -2.844 7.82E-03 3.61E-02 -2.823 -1.27 
Lgals1 -0.423 10.053 -3.468 1.56E-03 1.23E-02 -1.338 -1.34 
Lrig1 -0.526 8.856 -2.710 1.09E-02 4.49E-02 -3.120 -1.44 
Lrrfip1 0.331 6.403 3.216 3.04E-03 1.92E-02 -1.955 1.26 
MAMDC2 -0.539 7.429 -3.340 2.19E-03 1.55E-02 -1.654 -1.45 
Man2a1 -0.443 6.504 -4.141 2.46E-04 3.99E-03 0.394 -1.36 
Man2a1 -0.423 6.683 -4.370 1.29E-04 2.73E-03 1.004 -1.34 
Mef2a -0.264 7.229 -5.919 1.55E-06 1.52E-04 5.214 -1.20 
Mgst1 -0.269 11.519 -4.688 5.25E-05 1.47E-03 1.859 -1.20 
Mknk2 -0.273 6.736 -3.290 2.50E-03 1.70E-02 -1.777 -1.21 
Mmd -0.543 6.497 -3.747 7.35E-04 7.72E-03 -0.635 -1.46 
Mrpl20 0.288 8.473 3.554 1.24E-03 1.07E-02 -1.125 1.22 
Mrpl24 0.306 7.227 3.776 6.79E-04 7.32E-03 -0.560 1.24 
Mrps35 0.326 8.616 4.926 2.66E-05 9.44E-04 2.506 1.25 
Myo1b 0.293 8.879 4.056 3.13E-04 4.52E-03 0.169 1.23 
Ncam1 1.141 5.358 3.790 6.53E-04 7.15E-03 -0.524 2.21 
Ncapd3 -0.529 5.993 -3.472 1.54E-03 1.22E-02 -1.328 -1.44 
Nck2 -0.295 6.349 -2.658 1.23E-02 4.88E-02 -3.234 -1.23 
Ndufaf2 0.303 7.178 4.804 3.76E-05 1.17E-03 2.175 1.23 
Neil3 0.293 7.798 3.226 2.96E-03 1.89E-02 -1.931 1.23 
Ninj1 -0.366 6.177 -4.113 2.67E-04 4.16E-03 0.320 -1.29 
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Nvl 0.460 6.210 4.071 3.00E-04 4.38E-03 0.208 1.38 
Palld -0.476 7.134 -2.920 6.47E-03 3.17E-02 -2.651 -1.39 
Pam -0.375 7.027 -3.721 7.88E-04 8.00E-03 -0.700 -1.30 
Parp1 0.318 6.304 2.773 9.32E-03 4.08E-02 -2.981 1.25 
Pcolce -0.412 8.526 -3.580 1.16E-03 1.02E-02 -1.058 -1.33 
Pin4 0.291 6.767 3.661 9.28E-04 8.84E-03 -0.853 1.22 
Pja1 -0.379 7.598 -6.154 7.93E-07 1.30E-04 5.851 -1.30 
Plxna1 -0.320 6.084 -3.129 3.81E-03 2.21E-02 -2.164 -1.25 
Polr3e 0.296 5.962 3.114 3.95E-03 2.26E-02 -2.199 1.23 
Ppap2a -0.571 6.987 -3.872 5.21E-04 6.26E-03 -0.312 -1.49 
Ppcs -0.358 7.062 -2.944 6.09E-03 3.07E-02 -2.595 -1.28 
Ppp2r1a -0.282 6.065 -2.671 1.19E-02 4.78E-02 -3.206 -1.22 
PPP2R5A 0.324 6.010 2.671 1.19E-02 4.78E-02 -3.205 1.25 
Prkca -0.410 5.864 -4.607 6.60E-05 1.74E-03 1.641 -1.33 
Prkrir 0.263 7.275 3.924 4.51E-04 5.77E-03 -0.176 1.20 
Pros1 -0.551 7.149 -4.824 3.55E-05 1.12E-03 2.230 -1.46 
Prune2 -0.386 7.588 -5.640 3.43E-06 2.32E-04 4.456 -1.31 
Psme4 0.306 7.404 4.824 3.56E-05 1.12E-03 2.228 1.24 
Ptma -0.269 7.975 -2.757 9.68E-03 4.18E-02 -3.016 -1.21 
Pxdn -0.476 7.848 -5.095 1.64E-05 6.83E-04 2.968 -1.39 
Rab11a -0.307 5.948 -2.678 1.17E-02 4.73E-02 -3.190 -1.24 
Rab31 -0.426 6.713 -4.727 4.69E-05 1.36E-03 1.966 -1.34 
Rarres2 -0.596 9.322 -4.092 2.82E-04 4.27E-03 0.265 -1.51 
Rcbtb2 -0.365 7.042 -3.514 1.38E-03 1.15E-02 -1.225 -1.29 
Rgs17 -0.288 7.346 -2.682 1.16E-02 4.70E-02 -3.182 -1.22 
Rnaseh2c -0.393 6.445 -2.700 1.11E-02 4.56E-02 -3.142 -1.31 
Rnaset2a 0.444 10.189 4.731 4.64E-05 1.36E-03 1.976 1.36 
ROCK2 0.273 7.129 3.213 3.06E-03 1.93E-02 -1.964 1.21 
Rpf1 0.385 9.587 3.457 1.61E-03 1.25E-02 -1.367 1.31 
Rrp15 0.344 7.873 3.832 5.82E-04 6.66E-03 -0.415 1.27 
Rsu1 -0.278 8.196 -4.171 2.27E-04 3.80E-03 0.473 -1.21 
Sc4mol -0.709 6.368 -4.067 3.03E-04 4.40E-03 0.199 -1.64 
SC4MOL -0.628 8.194 -4.862 3.19E-05 1.04E-03 2.331 -1.54 
Sc5d -0.604 6.364 -6.525 2.78E-07 6.64E-05 6.847 -1.52 
Sccpdh 0.264 7.895 2.891 6.96E-03 3.33E-02 -2.717 1.20 
Sccpdh 0.316 7.248 3.872 5.21E-04 6.26E-03 -0.311 1.24 
SCD -1.042 9.542 -3.871 5.22E-04 6.26E-03 -0.314 -2.06 
Scd1 -1.110 7.257 -3.628 1.01E-03 9.33E-03 -0.936 -2.16 
Scd1 -1.040 9.240 -3.725 7.79E-04 7.96E-03 -0.690 -2.06 
Scd3 -0.547 7.564 -5.630 3.53E-06 2.35E-04 4.428 -1.46 
Scd3 -0.467 8.588 -6.433 3.60E-07 7.61E-05 6.603 -1.38 
Scp2 -0.306 8.021 -6.705 1.68E-07 6.26E-05 7.327 -1.24 
Sdc1 -0.724 5.513 -4.759 4.28E-05 1.30E-03 2.053 -1.65 
Sepp1 -0.429 9.267 -6.503 2.96E-07 6.64E-05 6.790 -1.35 
Serbp1 -0.410 10.563 -4.906 2.82E-05 9.73E-04 2.450 -1.33 
Serpinb1a -0.368 8.041 -2.824 8.23E-03 3.73E-02 -2.869 -1.29 
Sf3b1 -0.332 5.926 -4.468 9.82E-05 2.21E-03 1.265 -1.26 
Sgce -1.097 6.005 -5.479 5.43E-06 3.25E-04 4.017 -2.14 
Slc25a20 -0.329 8.555 -4.138 2.49E-04 3.99E-03 0.384 -1.26 
Slc4a7 -0.363 6.315 -3.194 3.22E-03 1.99E-02 -2.009 -1.29 
Slc4a7 -0.358 6.815 -2.734 1.02E-02 4.34E-02 -3.067 -1.28 
Smyd2 0.340 6.489 2.826 8.18E-03 3.72E-02 -2.864 1.27 
Snhg11 -0.458 6.593 -5.949 1.42E-06 1.52E-04 5.297 -1.37 
Snn -0.627 6.495 -4.640 6.01E-05 1.65E-03 1.731 -1.54 
Snx18 0.283 6.521 4.172 2.26E-04 3.80E-03 0.475 1.22 
Snx5 -0.276 7.211 -4.506 8.81E-05 2.07E-03 1.367 -1.21 
Sod1 -0.289 8.506 -3.639 9.84E-04 9.14E-03 -0.908 -1.22 
Sprr1a 1.582 8.643 9.140 2.63E-10 4.72E-07 13.412 2.99 
Sqle -0.498 6.333 -3.540 1.29E-03 1.10E-02 -1.158 -1.41 
Sqle -0.465 7.073 -3.946 4.25E-04 5.55E-03 -0.120 -1.38 
Sqle -0.411 9.031 -3.301 2.43E-03 1.67E-02 -1.749 -1.33 
Stk39 0.283 6.315 3.047 4.69E-03 2.53E-02 -2.356 1.22 
Stmn1 -0.506 7.260 -6.627 2.09E-07 6.26E-05 7.120 -1.42 
SUPT16H -0.454 10.402 -3.671 9.04E-04 8.74E-03 -0.829 -1.37 
Supt4h1 0.282 7.223 4.052 3.16E-04 4.53E-03 0.159 1.22 
Tbc1d20 0.277 7.320 2.665 1.21E-02 4.82E-02 -3.218 1.21 
Tbpl1 0.380 7.435 3.282 2.56E-03 1.73E-02 -1.797 1.30 
Tcf19 -0.382 5.912 -2.787 8.99E-03 4.00E-02 -2.949 -1.30 
Tecr -0.290 8.225 -4.397 1.20E-04 2.58E-03 1.076 -1.22 
Tfb2m 0.505 7.005 5.346 7.97E-06 4.30E-04 3.653 1.42 
Tgfbr2 -0.368 6.364 -2.640 1.29E-02 5.00E-02 -3.272 -1.29 
Tgm2 -0.408 7.080 -2.887 7.02E-03 3.34E-02 -2.725 -1.33 
Thbd -0.876 7.746 -3.476 1.53E-03 1.22E-02 -1.319 -1.84 
 397 
Thra -0.282 6.614 -5.818 2.06E-06 1.76E-04 4.941 -1.22 
Timm10 0.332 7.656 4.242 1.86E-04 3.37E-03 0.660 1.26 
Timp1 -0.489 6.932 -4.698 5.10E-05 1.44E-03 1.886 -1.40 
Tinagl1 -0.785 6.534 -3.342 2.18E-03 1.55E-02 -1.650 -1.72 
Tkt -0.333 6.373 -3.095 4.16E-03 2.34E-02 -2.245 -1.26 
Tkt -0.272 6.994 -3.425 1.75E-03 1.33E-02 -1.445 -1.21 
Tm9sf3 -0.318 6.640 -6.191 7.14E-07 1.22E-04 5.951 -1.25 
Tmed3 -0.388 6.990 -5.354 7.78E-06 4.30E-04 3.675 -1.31 
Tmem101 0.378 6.466 4.240 1.87E-04 3.37E-03 0.655 1.30 
Tmem109 -0.406 6.566 -5.041 1.91E-05 7.81E-04 2.819 -1.32 
Tmem150a -0.384 6.896 -4.635 6.09E-05 1.65E-03 1.717 -1.31 
Tnfrsf21 -0.985 7.387 -5.859 1.84E-06 1.61E-04 5.051 -1.98 
Tpm1 -0.323 7.136 -6.087 9.58E-07 1.50E-04 5.671 -1.25 
Trappc4 0.329 7.791 4.044 3.24E-04 4.61E-03 0.137 1.26 
Trub1 0.304 7.328 3.868 5.26E-04 6.27E-03 -0.321 1.23 
Tsc22d1 -0.370 6.481 -3.164 3.47E-03 2.08E-02 -2.079 -1.29 
Tsc22d1 -0.307 10.051 -3.929 4.45E-04 5.74E-03 -0.163 -1.24 
Ttc13 -0.324 7.694 -6.010 1.19E-06 1.52E-04 5.462 -1.25 
Ttll3 -0.343 11.009 -5.010 2.09E-05 7.87E-04 2.734 -1.27 
Ttll3 -0.342 11.241 -5.008 2.10E-05 7.87E-04 2.728 -1.27 
Ttll3 -0.338 11.078 -4.804 3.77E-05 1.17E-03 2.174 -1.26 
Tuba1a -0.593 8.193 -8.929 4.47E-10 5.35E-07 12.917 -1.51 
Tuba1c -0.351 9.068 -2.845 7.81E-03 3.61E-02 -2.821 -1.28 
Tubb2c -0.529 8.450 -5.434 6.19E-06 3.53E-04 3.893 -1.44 
Tubb5 -0.344 7.745 -3.111 3.99E-03 2.27E-02 -2.206 -1.27 
Tubb6 -0.302 7.128 -3.504 1.42E-03 1.17E-02 -1.248 -1.23 
Tyms -0.336 8.010 -2.974 5.65E-03 2.93E-02 -2.527 -1.26 
Uap1l1 -0.506 6.485 -3.534 1.31E-03 1.11E-02 -1.175 -1.42 
Uba52 -0.322 8.310 -2.872 7.29E-03 3.42E-02 -2.759 -1.25 
Uba52 -0.303 10.676 -3.201 3.16E-03 1.97E-02 -1.991 -1.23 
Uba52 -0.296 10.694 -3.250 2.78E-03 1.82E-02 -1.874 -1.23 
Uba52 -0.288 10.442 -3.059 4.55E-03 2.48E-02 -2.328 -1.22 
Ubqln4 0.299 6.593 5.999 1.23E-06 1.52E-04 5.431 1.23 
Uck2 0.379 6.716 3.053 4.62E-03 2.51E-02 -2.342 1.30 
Vcam1 -0.599 6.411 -3.697 8.41E-04 8.42E-03 -0.761 -1.52 
Wdr26 0.320 6.370 3.049 4.67E-03 2.52E-02 -2.351 1.25 
Wsb1 0.341 6.023 4.081 2.91E-04 4.30E-03 0.236 1.27 
Xbp1 -0.432 7.896 -3.784 6.64E-04 7.23E-03 -0.539 -1.35 
Ybx1 -0.296 11.304 -5.132 1.47E-05 6.29E-04 3.068 -1.23 
Zfp110 -0.294 6.538 -4.174 2.25E-04 3.80E-03 0.480 -1.23 
ZFP36L1 -0.473 8.280 -5.059 1.82E-05 7.50E-04 2.868 -1.39 
Zfp36l2 -0.481 7.753 -5.946 1.43E-06 1.52E-04 5.288 -1.40 
 
 
